

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection



Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the NIH Office of AIDS Research Advisory Council (OARAC)

How to Cite the Pediatric Antiretroviral Guidelines:

Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/pediatric-ary>. Accessed (insert date) [include page numbers, table number, etc., if applicable].

It is emphasized that concepts relevant to HIV management evolve rapidly. The Panels have a mechanism to update recommendations on a regular basis, and the most recent information is available on the Clinicalinfo website (<https://clinicalinfo.hiv.gov/>).

Table of Contents

| | |
|--|-------------|
| What's New in the Guidelines..... | vii |
| Guidelines Panel Members | xi |
| Financial Disclosure..... | xiii |
| Introduction..... | A-1 |
| Table 1. Outline of the Guidelines Development Process | A-3 |
| Table 2. Rating Scheme for Recommendations..... | A-6 |
| Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure | B-1 |
| Overview | B-2 |
| HIV Testing During Labor in People with Unknown HIV Status | B-6 |
| HIV Testing During the Postpartum Period | B-7 |
| Preventing HIV Transmission During Infant Feeding | C-1 |
| Overview of Counseling and Management | C-3 |
| Factors Affecting Decisions About Infant Feeding | C-8 |
| Safety of Antiretroviral Drugs During Breastfeeding..... | C-11 |
| Diagnosis of HIV Infection in Infants and Children..... | C-21 |
| Diagnosis of HIV in Infants and Children..... | C-22 |
| Timing of Diagnostic Testing in Infants with Perinatal HIV Exposure | C-23 |
| Table 3: Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV | C-26 |
| Diagnostic Testing in Children with Postnatal HIV Exposure | C-28 |
| Diagnostic Testing in Children with Non-perinatal HIV Exposure or Children with Perinatal HIV Exposure Aged >24 Months | C-30 |
| Virologic Assays to Diagnose HIV Infection in Infants Younger Than 18 Months with Perinatal HIV-1 Exposure | C-31 |
| Other Issues..... | C-32 |
| Clinical and Laboratory Monitoring of Pediatric HIV Infection | D-1 |
| Clinical and Laboratory Monitoring of Children with HIV | D-2 |
| Table 4. Characteristics and Requirements for In-Person Clinic Visits vs. Telemedicine Visits | D-4 |
| Immunologic Monitoring in Children: General Considerations | D-6 |
| Table 5. CD4 Cell Counts and Percentages in Healthy Children: Distribution by Age..... | D-6 |
| HIV RNA Monitoring in Children: General Considerations | D-7 |
| Genetic Testing for Management of HIV | D-8 |

| | |
|--|-------------|
| Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy | D-9 |
| Table 7. Primary U.S. Food and Drug Administration–Approved Assays for Monitoring Viral Load..... | D-11 |
| When to Initiate Antiretroviral Treatment in Children with HIV Infection..... | E-1 |
| What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV | F-1 |
| Criteria Used for Recommendations | F-1 |
| Factors to Consider When Selecting an Initial Regimen | F-2 |
| Table A. Factors to Consider When Selecting an Antiretroviral Treatment Regimen for Children..... | F-3 |
| Panel Recommendations for Initial ART Regimens in Infants and Children | F-5 |
| Planning for Transitions in ART Regimens | F-5 |
| Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Antiretroviral Therapy Regimens..... | F-6 |
| Recommended Initial ART Regimens for Infants from Birth to <30 Days of Age | F-7 |
| Table B. Advantages and Disadvantages of Anchor Drugs Recommended for Initial Antiretroviral Therapy Regimens in Infants From Birth to <30 Days of Age..... | F-9 |
| Recommended Initial ART Regimens for Infants and Children Aged ≥30 Days to <2 Years..... | F-11 |
| Recommended Initial ART Regimens for Children Aged ≥2 Years to <12 Years | F-14 |
| Recommended Regimens for Children and Adolescents Aged ≥12 Years..... | F-17 |
| Table 8. Antiretroviral Treatment Regimens Recommended for Initial Therapy for HIV Infection in Infants and Children: Birth to <12 Years of Age | F-20 |
| Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Antiretroviral Therapy in Infants and Children | F-25 |
| What Not to Start: Regimens Not Recommended for Initial Antiretroviral Therapy in Infants and Children..... | F-37 |
| Antiretroviral Drugs and Drug Combinations Not Recommended for Initial Therapy in Children | F-37 |
| Antiretroviral Drugs and Combinations with Insufficient Data to Recommend for Initial Therapy in Children..... | F-40 |
| Table 10. Antiretroviral Regimens or Components That Are Not Recommended for Initial Treatment of HIV Infection in Children and Adolescents | F-42 |
| Table 11. Antiretroviral Regimens or Components That Are Never Recommended for Treating HIV in Children and Adolescents | F-43 |
| Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV..... | G-1 |
| Table 12. Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period | G-4 |
| Table 13. Antiretroviral Management for Infants With <i>In Utero</i> or Intrapartum Exposure to HIV..... | G-7 |
| Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With <i>In Utero</i> or Intrapartum Exposure to HIV..... | G-10 |
| Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding..... | G-19 |

| | |
|---|------------|
| Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed..... | G-21 |
| Figure 1. Algorithm for Antiretroviral Management of Infants With <i>In Utero</i> or Intrapartum HIV Exposure by Risk of HIV Transmission..... | G-6 |
| Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV | H-1 |
| Background | H-1 |
| Timing and Selection of Antiretroviral Therapy | H-2 |
| Dosing of Antiretroviral Therapy for Adolescents with HIV..... | H-2 |
| Adherence Concerns in Adolescents | H-2 |
| Mental Health and Substance Use Concerns in Adolescents | H-3 |
| Sexually Transmitted Infections in Adolescents | H-4 |
| Contraception, Pregnancy, and Antiretroviral Therapy | H-5 |
| Special Considerations for Adolescents with HIV Who Are Sexual and Gender Minorities | H-6 |
| Transitioning Adolescents Into Adult HIV Care Settings | H-6 |
| Adherence to Antiretroviral Therapy in Children and Adolescents with HIV | I-1 |
| Background | I-1 |
| Specific Adherence Issues in Children..... | I-2 |
| Adherence Assessment and Monitoring..... | I-3 |
| Strategies to Improve and Support Adherence | I-3 |
| Regimen-Related Strategies | I-4 |
| Family-Related Adherence Strategies..... | I-4 |
| Health Care Provider–Related Strategies | I-6 |
| Table 15. Approaches for Monitoring Medication Adherence | I-8 |
| Table 16. Strategies to Improve Adherence to Antiretroviral Medications | I-9 |
| Management of Medication Toxicity or Intolerance..... | J-1 |
| Medication Toxicity or Intolerance..... | J-1 |
| Management | J-2 |
| Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity..... | J-8 |
| Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia | J-21 |
| Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects..... | J-28 |
| Table 17d. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hematologic Effects | J-33 |
| Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events..... | J-39 |
| Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus | J-46 |

| | |
|---|-------------|
| Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis | J-51 |
| Table 17h. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain | J-55 |
| Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects | J-64 |
| Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis | J-70 |
| Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions | J-77 |
| Management of Children Receiving Antiretroviral Therapy..... | K-1 |
| Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy | K-1 |
| Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression | K-6 |
| Recognizing and Managing Antiretroviral Treatment Failure | K-22 |
| Categories of Treatment Failure..... | K-22 |
| Table 19. Discordance Among Virologic, Immunologic, and Clinical Responses | K-25 |
| Management of Virologic Failure..... | K-26 |
| Therapeutic Options to Achieve Complete Virologic Suppression After Virologic Failure | K-27 |
| Management Options When Two Fully Active Agents Cannot Be Identified or Administered | K-30 |
| Table 20. Options for Regimens with at Least Two Fully Active Agents to Achieve Virologic Suppression in Patients with Virologic Failure and Evidence of Viral Resistance | K-31 |
| Antiretroviral Treatment Interruption in Children with HIV | K-40 |
| Unplanned Treatment Interruptions..... | K-40 |
| Structured Treatment Interruptions | K-41 |
| Short-Cycle Therapy Strategies | K-42 |
| Conclusion | K-43 |
| Appendix A: Pediatric Antiretroviral Drug Information | L-1 |
| Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors | L-3 |
| Abacavir..... | L-4 |
| Emtricitabine | L-17 |
| Lamivudine | L-25 |
| Tenofovir Alafenamide | L-36 |
| Tenofovir Disoproxil Fumarate | L-58 |
| Zidovudine | L-72 |
| Non-Nucleoside Analogue Reverse Transcriptase Inhibitors | L-82 |
| Doravirine | L-83 |

| | |
|---|-------|
| Efavirenz..... | L-90 |
| Etravirine | L-105 |
| Nevirapine | L-111 |
| Rilpivirine | L-122 |
| Protease Inhibitors | L-133 |
| Atazanavir..... | L-134 |
| Darunavir | L-146 |
| Lopinavir/Ritonavir | L-159 |
| Entry and Fusion Inhibitors..... | L-175 |
| Fostemsavir..... | L-176 |
| Ibalizumab | L-182 |
| Maraviroc | L-186 |
| Capsid Inhibitor | L-191 |
| Lenacapavir | L-192 |
| Integrase Inhibitors..... | L-197 |
| Bictegravir..... | L-198 |
| Cabotegravir | L-209 |
| Dolutegravir | L-217 |
| Elvitegravir | L-236 |
| Raltegravir | L-249 |
| Pharmacokinetic Enhancers..... | L-264 |
| Cobicistat..... | L-265 |
| Ritonavir | L-271 |
| Fixed-Dose Combinations | L-277 |
| Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class | L-278 |
| Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents | L-281 |
| Archived Drugs..... | L-287 |
| Didanosine..... | L-288 |
| Enfuvirtide..... | L-293 |
| Fosamprenavir..... | L-297 |
| Indinavir | L-302 |
| Nelfinavir..... | L-307 |
| Saquechinavir..... | L-313 |
| Stavudine..... | L-318 |

| | |
|---|------------|
| Tipranavir..... | L-327 |
| Appendix B: Acronyms | M-1 |
| Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization..... | N-1 |
| Table A. HIV Infection Stage Based on Age-Specific CD4 Count or Percentage..... | N-1 |
| Table B. HIV-Related Symptoms and Conditions | N-1 |
| Appendix D: Supplemental Information | O-1 |
| Table A. Likelihood of Developing AIDS or Death Within 12 Months, by Age and CD4 T-Cell Percentage or Log ₁₀ HIV-1 RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy | O-1 |
| Table B. Death and AIDS/Death Rate per 100 Person-Years by Current Absolute CD4 Cell Count and Age in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy (HIV Paediatric Prognostic Markers Collaborative Study) and Adult Seroconverters (CASCADE Study) | O-1 |
| Table C. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4 T-Cell Percentage With Long-Term Risk of Death in HIV-Infected Children..... | O-3 |
| Figure A. Estimated Probability of AIDS Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy | O-3 |
| Figure B. Estimated Probability of Death Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy | O-4 |
| Figure C. Death Rate per 100 Person-Years in HIV-Infected Children Aged 5 Years or Older in the HIV Paediatric Prognostic Marker Collaborative Study and HIV-Infected Seroconverting Adults From the CASCADE Study..... | O-4 |
| Figure D. Estimated Probability of AIDS Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy | O-5 |
| Figure E. Estimated Probability of Death Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy | O-5 |

What's New in the Guidelines

Updated: December 19, 2024

Reviewed: December 19, 2024

December 19, 2024

The Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV has reviewed and updated three sections of the *Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection* that are developed in collaboration with the Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission (the Panels). These sections have been revised to include new data and publications where relevant. Key updates are summarized below.

Preventing HIV Transmission During Infant Feeding

- Bulleted recommendations now include information from the text on counseling about the infant feeding options of formula feeding, use of banked donor milk, or breastfeeding. Recommendations also address clinical management if viremia is identified.
 - In the case of a detectable viral load during breastfeeding, the Panels recommend breastfeeding be stopped temporarily or discontinued and replacement feeding initiated while the viral load is rechecked; causes for the viremia are assessed, and, when applicable, adherence counseling is reinforced (AII). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥ 200 copies/mL (CIII).
 - Depending on the level and persistence of viremia during breastfeeding, next steps may include initiating or modifying infant antiretroviral (ARV) prophylaxis, permanently stopping breastfeeding, and considering the need for additional infant HIV testing.
 - If the repeat viral load is undetectable, a joint decision should be made by the parent and providers about whether breastfeeding may resume (AIII).

Diagnosis of HIV Infection in Infants and Children

- Section text and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) have been revised to align with changes in [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#).
- The Panels recommend virologic diagnostic testing at birth using an HIV nucleic acid test, which should generally be performed for all infants with perinatal HIV exposure but is not necessary for infants at low risk of HIV acquisition (HIV RNA levels <50 copies/mL from 20 weeks of gestation through delivery put infants at low risk of HIV acquisition). Birth testing should be performed in infants at low risk of HIV acquisition if there is a plan to breastfeed or there are concerns about loss to follow-up (BIII).

Antiretroviral Management of Infants With In Utero, Intrapartum or Breastfeeding Exposure or HIV Infection

- This section has been extensively revised, and the title has been updated to reflect changes in recommendations, associated content about infant ARV management according to risk from *in*

utero and intrapartum HIV exposure, and guidance for infant ARV prophylaxis during breastfeeding.

- The Panels have added [Table 12. Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period](#), which summarizes risk of transmission from exposure during three antenatal time periods. Because robust data are not available to define thresholds of risk across pregnancy, the Panels have selected time points balancing available data with implications for clinical management. Transmission risk categories inform ARV choice and management of prophylaxis and presumptive HIV therapy for infants with HIV exposure.
- Revised criteria for infant risk of HIV infection from *in utero* or intrapartum exposure and recommended ARV management are summarized in [Figure 1. Algorithm for Antiretroviral Management of Infants With In Utero or Intrapartum HIV Exposure by Risk of HIV Transmission](#) and [Table 13. Antiretroviral Management for Infants With In Utero or Intrapartum Exposure to HIV](#). The Panels recommend the following:
 - Viremia (HIV RNA ≥ 50 copies/mL) in the 4 weeks prior to delivery puts infants at higher risk of HIV infection from *in utero* or intrapartum exposure. Infants in this category should be provided a three-drug ARV regimen, administered from birth for 2 to 6 weeks, that serves as presumptive HIV therapy or enhanced prophylaxis. If the duration of the three-drug regimen is shorter than 6 weeks, zidovudine (ZDV) should be continued alone to complete a total of 6 weeks of prophylaxis (**AII**).
 - HIV RNA levels < 50 copies/ml from 20 weeks of gestation through delivery put infants at low risk of *in utero* and intrapartum HIV acquisition. These infants should receive ZDV alone for a duration of 2 weeks (**AII**).
 - Infants not meeting the criteria for high or low risk should have ARV regimens and durations based on case-specific factors related to the level and timing of viremia during the pregnancy (**AII**).
- The section now includes updated recommendations and expanded content about ARV prophylaxis for infants who are being breastfed. Recommendations of the Panels are summarized in a new table, [Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding](#).
 - For infants with low risk of HIV acquisition during breastfeeding, some Panel members do not recommend extended ARV prophylaxis; however, other Panel members do recommend extended ARV prophylaxis with either nevirapine or lamivudine (**CIII**). The Panels did not reach consensus.
 - Infants are considered at low risk of transmission during breastfeeding when (1) the breastfeeding woman is receiving antiretroviral therapy and has had sustained virologic suppression (HIV RNA < 50 copies/mL) for at least 3 months prior to delivery and (2) the provider and parent are confident that the breastfeeding woman will maintain ART adherence during breastfeeding (**AII**).
 - Bulleted recommendations and associated content have been added to provide guidance about infant ARV prophylaxis or use of presumptive HIV therapy when the breastfeeding woman experiences new viremia or there are concerns about future risk of viremia.
 - [Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#) has been revised to provide updated dosing information and to address infant ARV management for scenarios when a breastfeeding woman develops viremia or is diagnosed with HIV during

breastfeeding.

June 27, 2024

Clinical and Laboratory Monitoring of Pediatric HIV Infection

- The section has been updated to address recommended baseline screening tests for coinfections and opportunistic infections (e.g., tuberculosis, hepatitis B virus, hepatitis C virus, cytomegalovirus). See [Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy](#) and the [Pediatric Opportunistic Infection Guidelines](#).

When to Initiate Antiretroviral Treatment in Children with HIV Infection

- If a child with HIV has not initiated antiretroviral treatment (ART), the Panel recommends that ART initiation be discussed and strongly encouraged at every visit.
- When there are concerns about optimal timing of ART initiation relative to treatment of opportunistic infections (e.g., cryptococcal meningitis, tuberculous meningitis, disseminated *Mycobacterium avium* complex disease), timing should be discussed with a pediatric HIV specialist.
- New data provide additional evidence supporting the neurodevelopmental and immune benefits associated with early initiation of ART.

What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV

- The section has been revised to present and discuss Panel recommendations for initial ART regimens by age group (i.e., birth to <30 days, ≥30 days to <2 years, ≥2 to <12 years, and ≥12 years) rather than by antiretroviral (ARV) drug class. Content has been added within new subsections to address practical considerations in ARV drug and regimen selection and implementation of initial ART. Some content is deliberately repeated across the age groups.
- Two new tables have been added to the section: [Table A. Factors to Consider When Selecting an Antiretroviral Treatment Regimen for Children](#) and [Table B. Advantages and Disadvantages of Anchor Drugs Recommended for Initial Antiretroviral Therapy Regimens in Infants from Birth to <30 days of Age](#). [Table 8. Antiretroviral Treatment Regimens Recommended for Initial Therapy for HIV Infection in Infants and Children: Birth to <12 Years of Age](#) has been reorganized to present *Preferred* and *Alternative* regimens and ARV drugs by age group to follow the revised structure of the section.
- Nevirapine- and raltegravir-based regimens continue to be recommended as *Preferred* ART for infants aged <30 days. Lopinavir/ritonavir (LPV/r)-based ART is now recommended as an *Alternative* regimen for infants in this age group if they have reached a postmenstrual age of 42 weeks and a postnatal age of at least 14 days; LPV/r was previously a *Preferred* ARV for infants.
- To avoid delays in initiating treatment in neonates, abacavir (ABC) is now recommended as an *Alternative* rather than a *Preferred* nucleoside reverse transcriptase inhibitor for infants aged <30 days.

days who test negative for the HLA-B*5701 allele.

- The Panel now recommends second-generation integrase strand transfer inhibitor (INSTI)-based regimens with dolutegravir (DTG) or bictegravir (BIC) as the *Preferred* anchor drugs for initial ART in infants and children aged ≥ 30 days and weighing ≥ 3 kg whenever possible. DTG is approved for children aged ≥ 30 days and weighing ≥ 3 kg, and BIC is approved for children aged ≥ 2 years and weighing ≥ 14 kg. Protease inhibitor (PI)-based regimens are recommended as *Alternative* options. Non-nucleoside reverse transcriptase inhibitor-based regimens are recommended as *Alternative* options only if needed for resistance or intolerance to INSTIs and PIs.

What Not to Start: Regimens Not Recommended for Initial Antiretroviral Therapy in Infants and Children

- Because elvitegravir (EVG) has a lower genetic barrier to the development of resistance compared to second-generation INSTIs (i.e., DTG, BIC), the Panel no longer recommends EVG as an *Alternative* ARV for initial ART regimens in children.
- Lenacapavir (LEN), a capsid inhibitor, has been added to this section. LEN is U.S. Food and Drug Administration (FDA) approved for use in heavily treatment-experienced adults with multidrug-resistant HIV-1; it is not approved for initial ART or for use in children.

Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV

- Trauma experience is high among people with HIV generally and among youth with perinatally acquired HIV. Interest in the adoption of trauma-informed care (TIC) practices for people with HIV is emerging; however, research evaluating TIC interventions is limited, and efficacy is mixed. Providers may consider utilizing TIC principles for youth who have experienced trauma.

Adherence to Antiretroviral Therapy in Children and Adolescents with HIV

- The Panel recommends discussing the option of long-acting injectable ART to facilitate and support adherence with eligible patients and their caregivers.

Management of Children Receiving Antiretroviral Therapy

- Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy and Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression have been updated to incorporate the most recent switch options in line with pediatric ARV drug approvals and Panel recommendations.
- Recognizing and Managing Antiretroviral Treatment Failure and Table 20. Options for Regimens with at Least Two Fully Active Agents to Achieve Virologic Suppression in Patients with Virologic Failure and Evidence of Viral Resistance have been updated to incorporate new data and recommendations for ARV options in the context of treatment failure.
- Boxed recommendations in Antiretroviral Treatment Interruption in Children with HIV have been updated to underscore that treatment interruption is not recommended as a strategy to confirm diagnosis or to assess remission or cure in clinical settings.

- The section has been updated to expand content about mitigating unplanned interruptions in treatment (e.g., by clinicians working closely with families and providing anticipatory guidance around potential short-term interruptions from such events as vacation, travel, or summer camps).
- [Guidance for Non-HIV-Specialized Providers Caring for People with HIV Who Have Been Displaced by Disasters \(Such as a Hurricane\)](#) addresses the care of children when unforeseeable events, such as natural disasters, displace them from their primary HIV care programs.

Appendix A: Pediatric Antiretroviral Drug Information

Drug sections and fixed-dose combination (FDC) tables, [Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and [Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#), in this appendix were reviewed and updated to include recent pediatric data, dosing and safety information, and FDA approvals of new formulations and FDCs. Significant changes are summarized below:

- The dispersible FDC ABC/DTG/emtricitabine (Triumeq PD) now has FDA-approved dosing for use in infants and children aged ≥ 3 months and weighing ≥ 6 kg to <25 kg (see [Dolutegravir](#), [Abacavir](#), and [Emtricitabine](#)).
- Information about DTG dispersible tablet (Tivicay) dosing for infants and children with first-generation INSTI resistance has been added to the [Dolutegravir](#) section.
- Based on available data, cautions about the use of DTG in pregnancy due to concerns about neural defects have been removed from the [package inserts](#) for products containing DTG.
- Ritonavir (RTV) oral solution has been discontinued, but the pediatric formulation of 100-mg powder packets is still available for children who are not able to swallow pills (see [Ritonavir](#)).
- Because the minimum dose of the powdered formulation of RTV is now 100 mg, doses of RTV-boosted atazanavir (ATV/r) and RTV-boosted darunavir (DRV/r) requiring <100 mg RTV have been removed or updated. Dosing for ATV/r is available for children weighing ≥ 15 kg. Dosing for DRV/r is available for children weighing ≥ 20 kg. See [Atazanavir](#) and [Darunavir](#).
- A new drug section has been added for the capsid inhibitor [lenacapavir](#). LEN is FDA approved for use in adults with multidrug-resistant HIV infection who are heavily treatment experienced.
- The recent FDA approval of rilpivirine tablets for oral suspension (Edurant PED) will be addressed in the next update of the [Rilpivirine](#) section.

Members of the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel Executive Secretary | |
|---------------------------|---|
| Rohan Hazra, MD | National Institutes of Health, Bethesda, MD |

| Panel Co-chairs | |
|------------------------|--|
| Ann J. Melvin, MD, MPH | Seattle Children's Hospital, University of Washington, Seattle, WA |
| Mary E. Paul, MD | Baylor College of Medicine, Houston, TX |
| Theodore D. Ruel, MD | University of California, San Francisco, San Francisco, CA |

| Members of the Panel | |
|--------------------------------------|--|
| Elaine J. Abrams, MD | Columbia University, New York, NY |
| Lisa Abuogi, MD, MS | University of Colorado Denver, Denver, CO |
| Ben Banks, MPH, BSW | Ashland, VA |
| Kristina M. Brooks, PharmD | University of Colorado Anschutz Medical Campus, Aurora, CO |
| Megan Brundrett, MD, MPH, FACP, FAAP | The Ohio State University College of Medicine, Columbus, OH |
| Ellen G. Chadwick, MD | Northwestern University Feinberg School of Medicine, Chicago, IL |
| Rana Chakraborty, MD, PhD, MS | University of Miami Miller School of Medicine, Miami, FL |
| Diana F. Clarke, PharmD | Boston Medical Center, Boston, MA |
| Summer Drake, DO | Los Angeles, CA |
| Alka Khaitan, MD | Indiana University School of Medicine, Indianapolis, IN |
| James B. McAuley, MD, MPH, DTM&H | Rush University Medical Center, Chicago, IL |
| Jeremiah Momper, PharmD, PhD | University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA |
| Anne Neilan, MD, MPH | Harvard Medical School, Boston, MA |
| Kathleen (Kate) Powis, MD, MPH, MBA | Massachusetts General Hospital, Boston, MA |
| Murli Purwani, MD | BronxCare Health System, Bronx, NY |

| | |
|-----------------------------|---|
| Natella Rakhmanina, MD, PhD | Children's National Medical Center, Washington, DC |
| George K. Siberry, MD, MPH | United States Agency for International Development, Washington, DC |
| Nicole H. Tobin, MD | University of California, Los Angeles, Los Angeles, CA |
| Geoffrey A. Weinberg, MD | University of Rochester School of Medicine and Dentistry, Rochester, NY |

| Members from the U.S. Department of Health and Human Services | |
|---|---|
| Nickolas Agathis, MD, MPH | U.S. Food and Drug Administration, Silver Spring, MD |
| Mindy Golatt, MPH, MA, RN, CPNP | Health Resources and Services Administration, Rockville, MD |
| Katrina Byrd, MD, MS | Centers for Disease Control and Prevention, Atlanta, GA |
| Dwight E. Yin, MD, PhD | National Institutes of Health, Rockville, MD |

| Non-voting Observers | |
|--|--|
| Adam Bartlett, MBBS, MPHTM, PhD, FRACP | Sydney Children's Hospital, Randwick, New South Wales, Australia Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine, Sydney, Australia |
| Jason Brophy, MD, MSc, DTM&H | Children's Hospital of Eastern Ontario, Ottawa, Ontario |
| Deborah Storm, MSN, PhD | Fairfield, CA. Formerly, François-Xavier Bagnoud Center, Rutgers School of Nursing, Rutgers, The State University of New Jersey, Newark, NJ |

HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV Financial Disclosure

Updated: June 27, 2024

Reviewed: June 27, 2024

| Name | Panel Status | Company | Relationship |
|------------------------|--------------|----------------------------|---------------------------|
| Abrams, Elaine J. | M | Merck | Data Monitoring Committee |
| Abuogi, Lisa | M | Gilead Sciences | Research Support |
| Banks, Ben | M | None | N/A |
| Bartlett, Adam | NVO | Gilead Sciences | Research Support |
| Brooks, Kristina M. | M | None | N/A |
| Brophy, Jason | NVO | Abbott Laboratories | Research Support |
| Brundrett, Megan | M | None | N/A |
| Chadwick, Ellen G. | M | AbbVie/Abbott Laboratories | Stockholder |
| Chakraborty, Rana | M | None | N/A |
| Clarke, Diana F. | M | ViiV Healthcare | Research Support |
| Drake, Summer | M | None | N/A |
| Golatt, Mindy | HHS | None | N/A |
| Hazra, Rohan | ES | None | N/A |
| Khaitan, Alka | M | None | N/A |
| McAuley, James B. | M | None | N/A |
| Melvin, Ann J. | CC | None | N/A |
| Momper, Jeremiah | M | None | N/A |
| Neilan, Anne | M | None | N/A |
| Paul, Mary E. | CC | None | N/A |
| Powis, Kathleen (Kate) | M | None | N/A |
| Purwani, Murli | M | None | N/A |
| Rakhmanina, Natella | M | 1. ViiV/GSK | 1. Research Support |

| Name | Panel Status | Company | Relationship |
|-----------------------|--------------|--|--|
| | | 2. Gilead Sciences | 2. Research Support |
| Ruel, Theodore D. | CC | None | N/A |
| Siberry, George K. | M | None | N/A |
| Storm, Deborah | NVO | 1. Eli Lilly and Company 2. Merck 3. Roche | 1. Stockholder 2. Stockholder 3. Stockholder |
| Tobin, Nicole H. | M | None | NA |
| Weinberg, Geoffrey A. | M | Merck | Honoraria |
| Yin, Dwight E. | M | None | N/A |

Key: C = Chair; CC = Co-chair; ES = Executive Secretary; HHS = Member from the U.S. Department of Health and Human Services; M = Member; N/A = Not Applicable; NVO = Non-voting Observer

Introduction

Updated: June 27, 2024

Reviewed: June 27, 2024

The *Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection* (Pediatric Guidelines) address the diagnosis of HIV infection in infants and children and the use of antiretroviral therapy (ART) in children with HIV, including adolescents with sexual maturity ratings (SMRs; formerly Tanner Staging) 1 to 3. Note that the [*Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV*](#), developed by the Panel on Antiretroviral Guidelines for Adults and Adolescents, are suitable for the [care and management of adolescents in late puberty \(SMRs 4–5\)](#).

The Pediatric Guidelines also include recommendations for managing adverse events that are associated with the use of antiretroviral (ARV) drugs in children and a detailed review of information about the safety, efficacy, and pharmacokinetics (PK) of ARV agents in children. The U.S. Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel), a working group of the Office of AIDS Research Advisory Council (OARAC), reviews new data on an ongoing basis and regularly updates the guidelines. The guidelines are available on the [Clinicalinfo](#) website. These guidelines are developed for the United States and may not be applicable in other countries. The World Health Organization provides [guidelines for resource-limited settings](#).

The Pediatric Guidelines and the Perinatal Guidelines contain some closely related content that can overlap. To ensure that information is consistent across the guidelines and that users can easily find the information they need, the Panels that publish these two sets of guidelines have developed a process to jointly produce sections for shared content areas. The development of these sections is led by a group composed of members from both Panels; the sections are discussed separately and voted on by each full Panel. Jointly produced sections include—

- [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#)
- [Diagnosis of HIV Infection in Infants and Children](#)
- [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)
- [Preventing HIV Transmission During Infant Feeding](#)

Since the guidelines were first developed in 1993 (with the support of the François-Xavier Bagnoud Center, Rutgers School of Nursing, The State University of New Jersey), advances in medical management have dramatically reduced both the number of new pediatric HIV infections and the morbidity and mortality in children with HIV in the United States. The widespread use of ARV drugs in people with HIV during pregnancy and the use of ARV prophylaxis in infants who have been exposed to HIV have reduced the annual rate of perinatally acquired HIV infection^{1,2} from a peak of 43.1 per 100,000 births in 1992 to 1.0 per 100,000 births in 2020. Racial and ethnic disparities are evident in annual rates of new perinatal infection; in 2020, perinatal infections occurred in Black or African American infants (3.8 per 100,000 births) at annual rates of 4 and 13 times those of Hispanic/Latinx (0.9 per 100,000 births) and White infants (0.3 per 100,000 births), respectively.¹ Since the introduction of ART, mortality in children with perinatal HIV infection has decreased by about 90%, and the incidence of opportunistic infections and other infections in these children has significantly declined.^{3,4} ARV drug-resistance testing has made it easier for clinicians to choose

effective initial and subsequent regimens. Treatment strategies focus on early initiation of potent ARV regimens that are capable of maximally suppressing viral replication, which can prevent disease progression, preserve or restore immunologic function, reduce the size of viral reservoirs, and prevent the development of drug resistance.^{5,6} In addition, the availability of new drugs and drug formulations has led to more potent regimens with lower toxicity, lower pill burden, and less frequent medication administration—all factors that can improve adherence and outcomes. However, delays in the development and testing of pediatric formulations continue to limit the availability of optimal ARV regimens for children, especially infants.⁷

Children with HIV in the United States are increasingly born outside the United States⁸; they may be members of immigrant families or they may have been adopted by U.S. residents. These children may have non-B subtypes of HIV, incomplete medical and treatment histories, an increased risk of tuberculosis and other infections that are endemic in their countries of origin, and legal and psychosocial needs related to immigration.^{9,10}

Finally, as children with HIV grow older, new challenges arise related to adherence, drug resistance, reproductive health planning, transition to adult medical care, and the potential for long-term complications from HIV and its treatments.¹¹⁻¹³

The pathogenesis of HIV infection and the virologic and immunologic principles underlying the use of ART are generally similar for all individuals with HIV. However, unique considerations exist for infants, children, and adolescents with HIV, including—

- Acquisition of infection through perinatal exposure for most children with HIV;
- *In utero* and neonatal exposure to ARV drugs in most children with perinatal HIV infection¹⁴;
- The need to use HIV virologic tests to diagnose perinatal HIV infection in infants younger than 18 months;
- Age-specific interpretations of CD4 T lymphocyte (CD4) cell counts;
- Higher plasma viral loads in infants with perinatal HIV infection than in adolescents and adults with non-perinatal HIV infection;
- Age-related changes in PK parameters that are caused by the continuing development and maturation of organ systems involved in drug absorption, distribution, metabolism, and clearance¹⁵;
- Differences in the clinical manifestations and treatment of HIV in growing, immunologically immature individuals; *and*
- Special considerations associated with adherence to ART in infants, children, and adolescents.

The care of children with HIV is complex and evolves as results of new research are reported, new ARV drugs are approved, and new approaches to treatment are recommended. As new drugs become available, a critical need exists for clinical trials that define appropriate drug doses and identify possible toxicities in infants, children, and adolescents. As additional ARV drugs are approved and optimal strategies for the use of these drugs in children become better understood, the Panel will modify these guidelines.

The recommendations in these guidelines are based on the current state of knowledge regarding the use of ARV drugs in children. Evidence is drawn primarily from published data regarding the treatment of HIV in infants, children, adolescents, and adults; however, when no such data are available, unpublished data and the clinical expertise of Panel members are also considered. These

guidelines are only a starting point for medical decision-making and are not meant to supersede the judgment of clinicians who are experienced in the care of children with HIV. Because of the complexity of caring for children with HIV, health care providers with limited experience in the care of these patients should consult a pediatric HIV specialist. The [HIV/AIDS Management Clinician Consultation Center](#) is an excellent resource for telephone consultation. The Center can be contacted at 1-800-933-3413, 9 a.m. to 8 p.m. ET, Monday through Friday.

Table 1. Outline of the Guidelines Development Process

| Topic | Comment |
|-------------------------|---|
| Goal of the Guidelines | The guidelines provide guidance to HIV care practitioners in the United States on the optimal use of antiretroviral (ARV) agents when treating infants, children, and adolescents in early to mid-puberty (sexual maturity rating [SMR] 1–3) with HIV. |
| Panel Members | The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) is composed of approximately 30 voting members who have expertise in the management of HIV infection in infants, children, and adolescents. Members include representatives from the Committee on Pediatric AIDS of the American Academy of Pediatrics and community representatives with knowledge of pediatric HIV infection (e.g., parents and caregivers of children and youth with HIV). The Panel also includes at least one representative from each of the following U.S. Department of Health and Human Services (HHS) agencies: the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), the Health Resources and Services Administration (HRSA), and the National Institutes of Health (NIH). A representative from the Canadian Paediatric and Perinatal HIV/AIDS Research Group and a representative from the Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine participate as nonvoting, <i>ex officio</i> members of the Panel. The U.S. government representatives are appointed by their respective agencies; nongovernmental members are selected after an open announcement to call for nominations. Each member serves on the Panel for a 3-year term with an option for reappointment. A list of current members can be found in the Guidelines Panel Members . |
| Financial Disclosure | All members of the Panel submit an annual financial disclosure statement in writing, reporting any association with manufacturers of ARV drugs or diagnostics used to manage HIV infections. A list of the latest disclosures is available on the Clinicalinfo website. |
| Users of the Guidelines | Providers of care to infants, children, and adolescents with HIV in the United States |
| Developer | Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—a working group of the Office of AIDS Research Advisory Council (OARAC) |
| Funding Source | NIH Office of AIDS Research and HRSA |
| Evidence Collection | A standardized review of recent, relevant literature related to each section of the guidelines is performed by a technical assistance consultant (through funding from HRSA) and provided to individual Panel working groups. The recommendations generally are based on studies published in peer-reviewed journals. The Panel may occasionally use unpublished data to revise the guidelines, particularly when the new information relates to dosing or patient safety. These data come from presentations at major conferences or from the FDA and/or drug manufacturers. |
| Recommendation Grading | Described in Table 2 |

Table 1. Outline of the Guidelines Development Process

| Topic | Comment |
|-----------------------------|---|
| Method of Synthesizing Data | Each section of the guidelines is assigned to a small group of Panel members with expertise in the area of interest. The members synthesize the available data and propose recommendations to the Panel. The Panel discusses all proposals during monthly teleconferences. Proposals are modified based on Panel discussion and then distributed with ballots to all Panel members for concurrence and additional comments. If there are substantive comments or votes against approval, the recommended changes and areas of disagreement are brought back to the full Panel (by email or teleconference) for additional review, discussion, and further modification to reach a final version that is acceptable to all Panel members. The recommendations in these final versions represent endorsement from a consensus of members and are included in the guidelines as official Panel recommendations. |
| Other Guidelines | These guidelines focus on infants, children, and adolescents in early to mid-puberty (SMR 1–3) with HIV. Guidelines for the treatment of adolescents in late puberty (SMR 4–5) are provided by the Panel on Antiretroviral Guidelines for Adults and Adolescents. Separate guidelines outline the use of antiretroviral therapy (ART) during pregnancy and interventions to reduce perinatal HIV transmission , including interventions to prevent perinatal transmission (the Perinatal Guidelines); ART for adults and postpubertal adolescents with HIV ; and ARV prophylaxis for those who experience occupational or nonoccupational exposure to HIV. These and other HIV guidelines are also available on the ClinicalInfo website. |
| Update Plan | The full Panel meets monthly by teleconference to review data that may warrant modification of the guidelines. Smaller working groups of Panel members hold additional teleconferences to review individual drug sections or other specific topics (e.g., What to Start: Initial Combination Antiretroviral Regimens for People with HIV). Updates may be prompted by new drug approvals (or new indications, formulations, or frequency of dosing), new safety or efficacy data, or other information that may have a significant impact on the clinical care of patients. In the event of significant new data that may affect patient safety, the Panel may issue a warning announcement and post accompanying recommendations on the ClinicalInfo website until the guidelines can be updated with appropriate changes. All sections of the guidelines are reviewed at least once a year, with updates as appropriate. |
| Public Comments | A 2-week public comment period follows the release of the updated guidelines on the ClinicalInfo website. The Panel reviews these comments to determine whether additional revisions to the guidelines are indicated. The public may also submit comments to the Panel at any time via the Contact Us webpage. |

Basis for Recommendations

Recommendations in these guidelines are based on scientific evidence and expert opinion. Each recommendation includes a letter (**A**, **B**, or **C**) that represents the strength of the recommendation and a Roman numeral (**I**, **II**, or **III**) that represents the quality of the evidence that supports the recommendation.

When approving drugs for use in children, the U.S. Food and Drug Administration (FDA) often extrapolates efficacy data from adult trials, in addition to using safety and PK data from studies in children.¹⁶ Because of this, recommendations for use of ARV drugs in children often rely, in part, on data from clinical trials or studies in adults. Because the course of HIV disease and the effects of ARV drugs in pediatric and adult populations are expected to be similar enough to permit extrapolation of adult **efficacy** data to pediatric patients, it is appropriate to base approval of ARV drugs for children on evidence from adequate and well-controlled investigations in adults if—

- Supplemental data exist on the PK of the drug in children, indicating that systemic exposure in adults and children is similar; *and*
- Studies are provided that support the safety of using the drug in pediatric patients.¹⁷⁻¹⁹

If a concern exists that concentration–response relationships might be different in children than in adults, then pediatric drug approval should include evidence from studies that relate drug activity to drug levels (pharmacodynamic data) in children. In many cases, the evidence from studies on the use of ARV drugs in adults (especially from randomized clinical trials) is much more substantial and higher in quality than the available evidence from studies in children. Therefore, for pediatric recommendations, the following rationale has been used when the evidence from studies in children is limited or of lower quality:

Quality of Evidence Rating I—Randomized Clinical Trial Data

- Quality of Evidence Rating I will be used if there are data from large, randomized trials **in children** with clinical and/or validated laboratory endpoints.
- Quality of Evidence Rating I* will be used if there are high-quality randomized clinical trial data **in adults** with clinical and/or validated laboratory endpoints **and** pediatric data from well-designed, nonrandomized trials or observational cohort studies with clinical outcomes that are consistent with the adult studies. A rating of I* may be used for quality of evidence if, for example, a randomized Phase 3 clinical trial in adults demonstrates that a drug is effective in ARV-naïve patients, and data from a nonrandomized pediatric trial demonstrate adequate and consistent safety and PK data in the pediatric population.

Quality of Evidence Rating II—Nonrandomized Clinical Trials or Observational Cohort Data

- Quality of Evidence Rating II will be used if there are data from well-designed, nonrandomized trials or observational cohorts **in children**.
- Quality of Evidence Rating II* will be used if there are well-designed, nonrandomized trials or observational cohort studies **in adults** with supporting and consistent information from smaller, nonrandomized trials or cohort studies with clinical outcome data in children. A rating of II* may be used for quality of evidence if, for example, a large observational study in adults demonstrates a clinical benefit to initiating treatment at a certain CD4 cell count, and data from smaller observational studies in children indicate that treatment initiation at a similar CD4 cell count is associated with clinical benefit.

Quality of Evidence Rating III—Expert Opinion

- The criteria do not differ for adults and children.

In an effort to improve the quality of evidence available to guide the management of HIV infection in children, clinicians are encouraged to discuss participation in trials with children and their caregivers. Information about clinical trials for adults and children with HIV can be obtained from the [Clinicalinfo](#) website or by telephone at 1-800-448-0440.

Table 2. Rating Scheme for Recommendations

| Strength of Recommendation | Quality of Evidence for Recommendation |
|--|--|
| A: Strong recommendation for the statement | I: One or more randomized trials in children^a with clinical outcomes and/or validated laboratory endpoints |
| B: Moderate recommendation for the statement | I*: One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints, plus accompanying data in children^a from one or more well-designed, nonrandomized trials or observational cohort studies with clinical outcomes |
| C: Optional recommendation for the statement | II: One or more well-designed, nonrandomized trials or observational cohort studies in children^a with clinical outcomes II*: One or more well-designed, nonrandomized trials or observational cohort studies in adults with clinical outcomes, plus accompanying data in children^a from one or more smaller nonrandomized trials or cohort studies with clinical outcome data III: Expert opinion |

^a These are studies that include children or children and adolescents, but not studies that are limited to postpubertal adolescents.

References

1. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data united states and 6 dependent areas, 2018. 2020. Available at: <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-26-no-2/index.html>.
2. Nesheim SR, Wiener J, Fitz Harris LF, et al. Brief report: estimated incidence of perinatally acquired HIV infection in the United States, 1978-2013. *J Acquir Immune Defic Syndr.* 2017;76(5):461-464. Available at: <https://pubmed.ncbi.nlm.nih.gov/28991886>.
3. Kapogiannis BG, Soe MM, Nesheim SR, et al. Mortality trends in the U.S. Perinatal AIDS Collaborative Transmission Study (1986-2004). *Clin Infect Dis.* 2011;53(10):1024-1034. Available at: <https://pubmed.ncbi.nlm.nih.gov/22002982>.
4. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among U.S. youth and young adults with HIV infection in the era of combination antiretroviral therapy. *Clin Infect Dis.* 2015;61(12):1850-1861. Available at: <https://pubmed.ncbi.nlm.nih.gov/26270680>.
5. Payne H, Chan MK, Watters SA, et al. Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial. *AIDS Res Ther.* 2021;18(1):63. Available at: <https://pubmed.ncbi.nlm.nih.gov/34587974>.
6. Garcia-Broncano P, Maddali S, Einkauf KB, et al. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. *Sci Transl Med.* 2019;11(520). Available at: <https://pubmed.ncbi.nlm.nih.gov/31776292>.
7. Penazzato M, Gnanashanmugam D, Rojo P, et al. Optimizing research to speed Up availability of pediatric antiretroviral drugs and formulations. *Clin Infect Dis.* 2017;64(11):1597-1603. Available at: <https://pubmed.ncbi.nlm.nih.gov/29190337>.
8. Nesheim SR, Linley L, Gray KM, et al. Country of birth of children with diagnosed HIV infection in the United States, 2008-2014. *J Acquir Immune Defic Syndr.* 2018;77(1):23-30. Available at: <https://pubmed.ncbi.nlm.nih.gov/29040167>.
9. Fair CD, Alger S. Prepared but unprepared: a qualitative study of provider perspectives on the preparation and adjustment of U.S. families who internationally adopt children with HIV. *AIDS Care.* 2021;33(10):1363-1367. Available at: <https://pubmed.ncbi.nlm.nih.gov/32741214>.
10. Shetty AK. Infectious Diseases among Refugee Children. *Children (Basel).* 2019;6(12). Available at: <https://pubmed.ncbi.nlm.nih.gov/31783605>.

11. Committee On Pediatric AIDS. Transitioning HIV-infected youth into adult health care. *Pediatrics*. 2013;132(1):192-197. Available at: <https://pubmed.ncbi.nlm.nih.gov/23796739>.
12. Cervia JS. Addressing the needs of youth with HIV infection in the era of combination antiretroviral therapy. *Clin Infect Dis*. 2016;62(7):947. Available at: <https://pubmed.ncbi.nlm.nih.gov/26743091>.
13. Flynn PM, Abrams EJ. Growing up with perinatal HIV. *AIDS*. 2019;33(4):597-603. Available at: <https://pubmed.ncbi.nlm.nih.gov/30531318>.
14. Little KM, Taylor AW, Borkowf CB, et al. Perinatal antiretroviral exposure and prevented mother-to-child HIV infections in the era of antiretroviral prophylaxis in the United States, 1994-2010. *Pediatr Infect Dis J*. 2017;36(1):66-71. Available at: <https://pubmed.ncbi.nlm.nih.gov/27749662>.
15. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. *N Engl J Med*. 2003;349(12):1157-1167. Available at: <https://pubmed.ncbi.nlm.nih.gov/13679531>.
16. FDA-ICH Harmonized Guidelines. The International Council of Harmonisation of Technical Requirements of Pharmaceuticals for Human Use; Overview.: 2022. Available at: <https://www.fda.gov/media/165161/download>. Accessed.
17. Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. *Pediatrics*. 2011;128(5):e1242-1249. Available at: <https://pubmed.ncbi.nlm.nih.gov/22025597>.
18. E11(R1) addendum: clinical investigation of medicinal products in the pediatric population guidance for industry [package insert]. Food and Drug Administration. 2018. Available at: <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM530012.pdf>.
19. ICH Harmonized Guidelines: Pediatric Extrapolation E11A [package insert]. Food and Drug Administration. 2022. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation>.

Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure

Updated: February 20, 2025

Reviewed: February 20, 2025

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">HIV testing is recommended for all sexually active people and should be a routine component of pre-pregnancy care (AII).For all pregnancies, opt-out HIV testing should be done as early as possible during each pregnancy (see Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations and 2018 Quick Reference Guide: Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens from the Centers for Disease Control and Prevention [CDC]) (AII).For all pregnancies, partners should be referred for HIV testing when their status is unknown (AIII).Repeat HIV testing in the third trimester is recommended during pregnancies in which there are negative initial HIV tests and increased risk of acquiring HIV, including pregnancies in which the care is received in facilities that have an HIV incidence of ≥ 1 case per 1,000 patients experiencing pregnancy per year, those who reside in jurisdictions (states or counties) with elevated HIV incidence among females aged 15 to 45 years (>17 per 100,000 females aged 15–45 years), or those who reside in states or territories that require third-trimester testing (AII). Annual state and county-level HIV diagnosis rates are available at CDC's National Center for HIV, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention AtlasPlus webpage.Repeat HIV testing is recommended when there is a sexually transmitted infection during pregnancy, when there are signs and symptoms of acute HIV infection, or when there is ongoing exposure to HIV (AIII). Initiation of pre-exposure prophylaxis (PrEP) is recommended if HIV testing is negative (AIII). See Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods for more information.Expedited^a HIV testing should be performed during labor or after delivery when HIV status is undocumented as well as when HIV tests were negative early in pregnancy but there is increased risk of HIV infection and there was no retest in the third trimester (AII). HIV antigen/antibody testing should be available 24 hours a day, and results should be available within 1 hour. If results of expedited^a HIV testing are positive, intrapartum intravenous zidovudine prophylaxis should be initiated immediately (AI); see Intrapartum HIV Care.When acute HIV infection is suspected during pregnancy or the intrapartum period or while breastfeeding, a plasma HIV RNA assay should be performed in conjunction with an antigen/antibody immunoassay (AIII).When there is a positive HIV test result during labor and delivery or postpartum, a maternal HIV-1/HIV-2 antibody differentiation assay and an HIV RNA assay should be performed (AI). In these situations, an HIV nucleic acid test (NAT) should be performed on the infant, with immediate initiation of presumptive HIV therapy appropriate for an infant at high risk of perinatal HIV transmission (AI); see Diagnosis of HIV Infection in Infants and Children for additional information.If maternal HIV test results are unavailable at birth, the newborn should be tested using an expedited^a antibody test to identify perinatal HIV exposure (AI). If positive, an HIV NAT should be performed on the infant, and standard maternal HIV diagnostic testing should be offered as soon as possible (AI).<ul style="list-style-type: none">In this situation, presumptive HIV therapy appropriate for infants who are at high risk of perinatal HIV transmission should be initiated immediately (AI). See Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV for guidance.When there is an initial positive HIV test during labor or delivery or immediately postpartum and there are plans to breastfeed, the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recommends against breastfeeding. Breast milk should be expressed and stored appropriately until all supplemental HIV tests are reviewed and are negative (AI). |

- When there is increased risk of HIV acquisition postpartum, HIV testing and PrEP should be offered. If breastfeeding is occurring, consult an HIV specialist regarding frequency of HIV testing for the breastfeeding dyad (**AIII**).
- Maternal HIV test results should be documented in the newborn's medical record and communicated to the newborn's primary care provider (**AIII**).
- To identify perinatal HIV exposure and possible HIV infection, HIV testing is recommended for infants and children in foster care and adoptees for whom maternal HIV status is unknown (**AIII**) (see [Diagnosis of HIV Infection in Infants and Children](#)).

^a The term "expedited" is used to designate HIV testing performed in situations when a very short turnaround time is optimal. Expedited testing is dependent on the available HIV tests in each facility and may include antigen/antibody immunoassays or antibody-only assays; see Approved HIV Tests in the text below.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†]Studies that include children or children and adolescents, but not studies limited to postpubertal adolescents

Incident HIV infection during pregnancy, postpartum, or breastfeeding represents a period of high viremia and significantly increased risk of infant HIV acquisition. Similarly, entering pregnancy without knowledge of HIV infection also presents a high risk of perinatal transmission. This section addresses HIV testing in pregnancy, during labor and delivery, and postpartum. The section also addresses HIV testing to identify HIV perinatal and postnatal exposure in infants. For guidance on diagnosis of HIV in infants and children, see [Diagnosis of HIV in Infants and Children](#).

Approved HIV Tests and Recommended HIV Testing Algorithm

There are multiple U.S. Food and Drug Administration (FDA)-approved tests available for the diagnosis of HIV infection. Clinicians should familiarize themselves with the testing available at their facilities, including the turnaround time for receiving results and test performance characteristics (e.g. sensitivity, specificity). For the purposes of this section, three types of testing are discussed: antigen/antibody immunoassays; antibody-only immunoassays; and HIV nucleic acid tests (NATs).

- Antigen/antibody immunoassays: Most routine laboratory testing for HIV currently uses antigen/antibody tests. Because these tests also detect HIV p24 antigen, they can detect acute HIV infection as early as 1 to 2 weeks after appearance of HIV RNA and before appearance of HIV antibody. These tests also detect HIV-2 infection. Laboratory-based tests require trained laboratory staff, and results can be available within 1 hour, but in some hospitals the test may not be readily available 24 hours a day. One FDA-approved antigen/antibody test can be performed at the point of care (POC), provides results after 20 minutes, and must be read before 30 minutes. Using timed seroconversion panels, this POC antigen/antibody test has been shown to detect HIV infection just 1 day later than laboratory-based antigen/antibody tests. However, it has lower specificity than laboratory-based antigen/antibody tests; therefore, false positive results are more likely than with laboratory-based tests.¹
- Antibody-only immunoassays: Many antibody-only immunoassays in current use can be performed using blood from a finger stick or oral fluid and provide results within 30 minutes.

Because of this very short turnaround time, they are often referred to as rapid tests. Many of these tests are also approved by the FDA for POC usage. Because these tests detect only antibody, acute HIV infection may be missed.

- HIV NAT: HIV-1 NAT detects HIV viral nucleic acid in blood. Depending on the type of HIV NAT, it may detect acute HIV infection, help diagnose HIV infection, and assess response to HIV therapy. Different laboratories may have varying turnaround times for HIV NAT; some require several days before results are available.
- In this section, the term expedited is used to designate testing performed in situations when a very short turnaround time is optimal, such as when HIV status is undocumented during labor. Expedited testing should be available in all delivery units 24 hours a day, and results should be available within 1 hour. Expedited testing is dependent on the available HIV tests in each facility and may include any of the three test types. In a setting with low HIV prevalence and/or frequent testing, false positive initial test results will be common. Expedited and/or concurrent NAT can be helpful in managing an initial positive HIV test result. An HIV-1/HIV-2 antibody differentiation assay may be helpful if an antibody response has been mounted.

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV and the Panel on Treatment of HIV During Pregnancy and Interventions to Reduce Perinatal HIV Transmission (the Panels) **recommend that clinicians initiate HIV testing with an immunoassay that can detect HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen (referred to as an HIV antigen/antibody immunoassay)**. The Panels' recommendations for HIV testing are based on the Centers for Disease Control and Prevention's (CDC's) 2014 [Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations](#).²

Individuals with a reactive antigen/antibody immunoassay should be tested further with an **HIV-1/HIV-2 antibody differentiation assay (referred to as supplemental testing)**. Individuals with a reactive antigen/antibody immunoassay and a nonreactive differentiation test should be tested with an FDA-approved plasma HIV RNA assay to assess for acute HIV infection (see the CDC's 2018 Quick Reference Guide: [Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens](#)).

In some clinical settings, initial testing may be conducted with a **rapid HIV test**, which may detect a combination of antigen and antibodies or only HIV antibodies. Positive results on POC rapid tests should be followed first by a laboratory-based antigen/antibody assay using serum or plasma and when reactive, followed by a differentiation assay.³

Clinicians should assess risk of acute HIV infection during pregnancy, particularly late in pregnancy, because there may be a negative result for HIV immunoassays during the window period (the time between infection and when the infection can be detected by a specific laboratory test). The antigen/antibody immunoassay may detect infection as early as 18 days after infection; antibody-only assays may not detect infection until as long as 45 days post-infection. However, during this period, the person with acute HIV will be viremic,⁴ with a high risk of perinatal transmission. The HIV RNA assay can detect the presence of HIV as early as 10 days post-infection. **When acute HIV infection is suspected** during pregnancy, during the intrapartum period, or while breastfeeding, **a plasma HIV RNA assay should be performed in conjunction with an antigen/antibody immunoassay**. See [Early \(Acute and Recent\) HIV Infection](#) for more information.

Discordant or False Positive HIV Test Results

Discordant HIV testing results can occur, requiring careful evaluation and often repeat tests. Early in HIV infection, before HIV seroconversion, the test combination of a positive antigen/antibody screen, negative HIV-1/HIV-2 antibody differentiation assay, and positive HIV RNA assay may be seen. This combination of results can occur because the immunoglobulin G-based antibody differentiation assay is positive later in infection than the antigen capture or the immunoglobulin M result in the antigen/antibody screen.

False positive results do occur with HIV testing. The frequency of false positive HIV testing is dependent both on the specificity of the assay and the prevalence of HIV in the population, so frequency may vary considerably. In a large urban hospital in Dallas, 21,163 women were screened using a combination antigen/antibody immunoassay. Reactive initial screens were followed by supplemental testing recommended by the CDC algorithm. Of the 190 who tested positive, 28 were determined to have a false positive HIV test, yielding a positive predictive value of 83% (95% confidence interval [CI], 77% to 88%) and a false positive rate of 0.16% (95% CI, 0.11% to 0.22%), using the ARCHITECT HIV Ag/Ab assay.⁵ For women screened a second time in pregnancy, the rate of false positive results relative to true positive results may be higher, as it depends on the community risk of HIV acquisition over a short time period (i.e., the 6 months between first- and third-trimester testing).

For any positive HIV screen late in pregnancy, during labor, or immediately postpartum, an HIV RNA assay should be done at the same time as the supplemental HIV-1/HIV-2 antibody differentiation assay. The HIV RNA assay will be needed to resolve questions raised by discordant results between the antigen/antibody screen and the antibody differentiation assay.

The combination of a positive HIV antigen/antibody screen with a negative supplemental HIV-1/HIV-2 antibody differentiation assay and a negative HIV RNA assay is seen when there is a false positive antigen/antibody screen.

Timing and Benefits of HIV Testing Prior to Conception or During Pregnancy

HIV infection should be identified before pregnancy (see [Prepregnancy Counseling and Care](#)) or as early as possible in pregnancy. In the United States, approximately 20% to 34% of infants with perinatal HIV exposure were born to mothers whose HIV diagnosis was not known before pregnancy.⁶ Early diagnosis provides the best opportunity to improve maternal health and pregnancy outcomes and to prevent infant acquisition of HIV. Universal voluntary HIV testing is recommended as the standard of care during all pregnancies in the United States by the Panels, CDC, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and U.S. Preventive Services Task Force.⁷⁻¹¹ HIV testing should be performed during pregnancy wherever care is provided (including emergency departments and prenatal clinics) to avoid missed opportunities to identify HIV infection. Repeat HIV testing should be performed in the third trimester when there is increased risk of acquiring HIV or when living in areas of high HIV incidence. Repeat testing is also recommended when a sexually transmitted infection (STI) is diagnosed during pregnancy, or when symptoms and signs of acute HIV infection are present. When HIV status is unknown or undocumented during labor, providers should test for HIV before delivery or as soon as possible after delivery.¹²⁻¹⁵ Because women are more susceptible to HIV acquisition during pregnancy and the postpartum period,¹⁶ HIV testing provides an opportunity for clinicians to initiate a discussion about preventive interventions, including educating and counseling about pre-exposure prophylaxis (PrEP) when there is risk for acquiring HIV during pregnancy. See [Pre-exposure Prophylaxis \(PrEP\) to](#)

[Prevent HIV During Periconception, Antepartum, and Postpartum Periods](#) and guidance available on [CDC's Pre-exposure Prophylaxis \(PrEP\) webpage](#) for more information.

Determining HIV status before pregnancy or during the antenatal period enables:

- Provision of appropriate antiretroviral therapy (ART) and prophylaxis against opportunistic infections;
- Initiation of treatment to maintain and improve health and to decrease risk of perinatal HIV transmission and transmission to partners^{7,17,18};
- Referral of partners for testing, providing an opportunity for treatment initiation by partners testing positive, PrEP initiation by serodifferent partners testing negative, and counseling on other preventive measures (see [Pre-exposure Prophylaxis \(PrEP\) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods](#));
- Counseling during pregnancy and HIV care about recommended modes of delivery based on individualized risks of perinatal transmission of HIV¹⁹⁻²¹;
- Provision of an appropriate antiretroviral (ARV) prophylaxis regimen to the newborn to reduce risk of infant HIV acquisition (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#));
- Shared decision-making on infant feeding choice, specifically breastfeeding or use of replacement feeding (see [Preventing HIV Transmission During Infant Feeding](#)); and
- Early diagnostic evaluation of infants exposed to HIV, as well as testing of other children, to permit prompt initiation of ART and any indicated prophylaxis measures (see [Diagnosis of HIV Infection in Infants and Children, Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#), and [Table 6. What to Start: Initial Antiretroviral Regimens During Pregnancy When Antiretroviral Therapy Has Never Been Received](#)).^{8,22,23}

Finally, all HIV testing should be performed in a manner that is consistent with state and local regulations. The CDC recommends the “opt-out” approach, which is allowed in many jurisdictions and involves notification that HIV testing will be performed as part of routine pregnancy care unless the choice is made not to be tested.⁷ The “opt-in” approach involves obtaining specific consent before testing, and this approach has been associated with lower testing rates.^{24,25} Despite the guidelines for universal HIV screening during pregnancy, recent studies indicate that fewer than 80% of women report having been tested for HIV during pregnancy.^{26,27} The mandatory newborn HIV testing approach, which has been adopted by several states, involves testing newborns with or without parental consent. In some areas, this applies to all newborns; in others, it applies only when prenatal or intrapartum maternal testing has been declined.

Repeat HIV Testing in the Third Trimester

Repeat HIV testing during the third trimester, before 36 weeks of gestation, is recommended when there were negative results on the initial HIV tests during pregnancy and:

- There is high risk of acquiring HIV (i.e., injection drug use or sex with people who inject drugs, exchange of sex for money or drugs, sex partner with HIV who has a detectable or unknown HIV viral load, new sex partner or more than one sex partner during the current pregnancy,⁷ suspected or diagnosed STI during pregnancy,¹⁰ recent immigration from a high-burden HIV setting, partner who either recently immigrated from a high-burden HIV setting or recently traveled to such a setting); or

- Health care is being provided by facilities where prenatal screening identifies one or more HIV cases per 1,000 patients experiencing pregnancy screened or the jurisdiction of residence (state or county) has an elevated incidence rate of HIV in females aged 15 to 45 years. An annual HIV diagnosis rate ≥ 17 per 100,000 females aged 15 to 45 years can be used as a proxy for elevated HIV incidence. Annual state- and county-level HIV diagnosis rates by age are available at the CDC's National Center for HIV, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention [AtlasPlus webpage^{7,10}](#); or
- The states or territories of residence have statutes or regulations that require third-trimester HIV testing. In a 2020 article, these included Arizona, Connecticut, Delaware, Florida, Georgia, Illinois, Louisiana, Maryland, Nevada, New Jersey, North Carolina, Tennessee, Texas, Virginia, and West Virginia.²⁸ State-level clinical guidelines may also recommend third-trimester HIV testing (e.g., New York). Clinicians should check current requirements and recommendations in their jurisdictions; or
- There are signs or symptoms of acute HIV (e.g., fever, lymphadenopathy, skin rash, myalgia, headaches, oral ulcers, leukopenia, thrombocytopenia, elevated transaminase levels).^{7,10,29,30}
- There is self-perception as being at increased risk for HIV infection (regardless of whether or not any of the above criteria apply). When testing is declined earlier in pregnancy, providers should offer testing again during the third trimester.

An antigen/antibody immunoassay should be used for third-trimester testing because these tests have a higher sensitivity in the setting of acute HIV infection than older antibody tests.^{2,31} If acute HIV infection is suspected, a plasma HIV RNA assay should be performed in conjunction with an antigen/antibody immunoassay. See [Early \(Acute and Recent\) HIV Infection](#) for more information.

Providers should be proactive in assessing HIV acquisition risk during pregnancy and implementing third-trimester HIV retesting when indicated. A study in Baltimore found that only 28% of women were retested for HIV despite the high incidence of HIV in Maryland and a high frequency of clinical risk factors.¹⁵ A study of data from 2007 to 2014 on children in Florida with perinatal HIV exposure found that perinatal HIV transmission was associated with poor or late prenatal care, diagnosis of HIV during labor and delivery or after birth, and, in some cases, acute maternal infection (as indicated by negative results for initial tests).³²

When determining the timing of repeat HIV testing in the third trimester, some clinicians conduct testing at or around 28 weeks of gestation in conjunction with the recommended timing of syphilis testing. This approach limits the number of blood draws and allows adequate time for syphilis treatment and congenital syphilis prophylaxis. Some clinicians also conduct a third test for HIV at the time of delivery hospitalization admission.

HIV Testing During Labor When HIV Status is Unknown

When HIV status is undocumented during labor or HIV testing was negative early in pregnancy but there is an increased risk of HIV infection and there was no retesting in the third trimester, expedited HIV testing should be performed.^{7-9,22,33,34}

- Perform an expedited HIV test—either an antigen/antibody immunoassay that can provide results within 1 hour or the most sensitive rapid test (includes rapid POC tests) available during labor. An HIV RNA assay should also be performed when there is suspected acute HIV infection. In a setting with low prevalence and/or frequent testing, false positive initial test results will be common. Expedited and/or concurrent NATs can be helpful in managing an initial positive HIV test result.³⁵

- If the initial HIV test result is negative (nonreactive), no further testing is required unless acute HIV infection is suspected (see Acute HIV Infection During Pregnancy or Breastfeeding below).²
- A positive antigen/antibody immunoassay or rapid HIV test result must be immediately followed by a supplemental HIV-1/HIV-2 antibody differentiation assay, as well as a maternal HIV RNA assay and an HIV NAT for the infant.² If possible, contact the laboratory to prioritize results.
- For delivery units, every effort should be made to have the ability to run a confirmatory supplemental test (HIV-1/HIV-2 antibody differentiation assay) 7 days a week. If possible, results of HIV RNA assays should be available in 24 hours or less.
- When there is a positive HIV test result or suspected acute HIV infection during labor, provide counseling about HIV test results and implications for care.
 - Initiate **intravenous** zidovudine during labor (see [Intrapartum HIV Care](#)).
 - Immediately initiate presumptive HIV therapy appropriate for infants who are at high risk of perinatal HIV transmission (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#) or contact the [National Clinician Consultation Center Perinatal HIV/AIDS hotline](#)).
 - When there are plans to breastfeed, the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission strongly advises against initiating breastfeeding given the high risk of perinatal transmission. Breast milk should be expressed and stored appropriately; it should not be used for infant feeding unless all supplemental HIV test results are reviewed and determined to be negative (see [Preventing HIV Transmission During Infant Feeding](#)).

HIV Testing During the Postpartum Period

When there has been no testing for HIV during pregnancy or labor, expedited testing during the immediate postpartum period should be offered. Postpartum HIV testing should be done using the antigen/antibody immunoassay to screen for established and acute HIV; results should be obtained in <1 hour. If acute HIV infection is a possibility, then a plasma HIV RNA test should be sent as well.

When HIV testing is requested postpartum or there is increased risk of HIV acquisition (e.g., injection drug use or sex with people who inject drugs, exchange of sex for money or drugs, sex partner with HIV who has a detectable or unknown HIV viral load, new sex partner or more than one sex partner during the current pregnancy,⁷ suspected or diagnosed STI during pregnancy,¹⁰ recent immigration from a high-burden HIV setting, partner that either recently immigrated from a high-burden HIV setting or recently traveled to such a setting) HIV testing and PrEP should be offered. See [Pre-exposure Prophylaxis \(PrEP\) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods](#) for more information. If breastfeeding is occurring, consult an HIV specialist regarding frequency of HIV testing in the breastfeeding dyad.

When an initial maternal or infant HIV test is positive **or there is high suspicion of acute HIV infection**, it is strongly recommended that clinicians initiate presumptive HIV therapy appropriate for infants who are at high risk of perinatal HIV transmission, ideally ≤6 hours after birth (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Providers should counsel against breastfeeding pending the results of supplemental testing, which should include a plasma HIV RNA assay. Breast milk can be expressed while HIV diagnostic testing is being completed, but it should not be given to the infant until HIV negative maternal testing is confirmed. If supplemental test results are negative and acute HIV is excluded, infant ARV drugs can be discontinued. In the absence of ongoing HIV exposure, breastfeeding can be initiated.

Consultation with a pediatric HIV specialist is strongly recommended if questions remain about the potential for acute infection while lactating or ongoing infant risk of HIV exposure.

Infant HIV Testing When Maternal HIV Test Results Are Unavailable

When maternal HIV test results are unavailable (e.g., testing declined during pregnancy, infant or child is in foster care) or their accuracy cannot be evaluated (e.g., for internationally adopted infants and children), HIV testing of these infants or children is indicated to identify HIV exposure and possible infection.⁸ If maternal HIV test results are unavailable, the infant should be tested using an expedited antibody test to identify perinatal HIV exposure. If positive, an HIV NAT should be performed on the infant, presumptive HIV therapy appropriate for infants at high risk for perinatal HIV transmission should be initiated immediately (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#) for guidance), and standard maternal HIV diagnostic testing should be offered as soon as possible. For older infants and children, the choice of test will vary based on the age of the child (see [Diagnosis of HIV Infection in Infants and Children](#)).

Acute HIV Infection During Pregnancy or Breastfeeding

Pregnancy and the early postpartum period are times of increased risk for HIV infection.³⁶ Risk of HIV exposure should be assessed when considering becoming pregnant, during all pregnancies and postpartum periods when there have been previous negative HIV tests, and when breastfeeding. When there are risk factors for HIV acquisition before, during, and after pregnancy, prevention counseling and appropriate interventions should be provided, including PrEP if indicated^{36,37} (see [Prepregnancy Counseling and Care](#) and [Pre-exposure Prophylaxis \[PrEP\] to Prevent HIV During Periconception, Antepartum, and Postpartum Periods](#) for more information). When there is acute HIV during pregnancy or lactation, there is an increased risk of perinatal transmission; acute HIV also increase risk for sexual transmission of HIV (see [Early \[Acute and Recent\] HIV Infection](#)). The antigen/antibody immunoassay will detect acute HIV infection earlier than other immunoassays—within approximately 18 days of acquisition. When acute HIV infection is suspected, a plasma HIV RNA test should be sent as well as the antigen/antibody test, because virologic tests can detect the presence of HIV approximately 5 days earlier than the antigen/antibody immunoassay. When acute HIV infection is possible and breastfeeding is ongoing, counsel about the Panel's recommendation to cease breastfeeding immediately until HIV infection is confirmed or excluded.³⁸ Breast milk can be expressed and stored appropriately while HIV diagnostic testing is completed. Expressed breast milk should not be used for infant feeding until all supplemental HIV test results are reviewed and determined to be negative. Breastfeeding can resume if HIV infection is excluded and there is no ongoing risk. Care during pregnancy or breastfeeding for the breastfeeding dyad when there is acute or early HIV should follow the recommendations in the Perinatal Guidelines (see [Early \[Acute and Recent\] HIV Infection](#), [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#), and [Preventing HIV Transmission During Infant Feeding](#)).

Other Issues

Clinicians should be aware of public health surveillance systems and regulations that may exist in their jurisdictions for reporting infants who have been exposed to HIV; this is in addition to mandatory reporting of confirmed HIV, including infants with confirmed HIV. Reporting infants who have been exposed to HIV allows the appropriate public health functions to be accomplished.

References

1. Delaney KP, Hanson DL, Masciotra S, et al. Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure. *Clin Infect Dis.* 2017;64(1):53-59. Available at: <https://pubmed.ncbi.nlm.nih.gov/27737954>.
2. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014. Available at: <http://stacks.cdc.gov/view/cdc/23447>.
3. Centers for Disease Control and Prevention. Technical update: use of the determine HIV 1/2 Ag/Ab combo test with serum or plasma in the laboratory algorithm for HIV diagnosis. 10/4/2017. Available at: <https://stacks.cdc.gov/view/cdc/48472>.
4. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. June 27, 2014. Available at: <http://dx.doi.org/10.15620/cdc.23447>.
5. Adhikari EH, Macias D, Gaffney D, et al. Diagnostic accuracy of fourth-generation ARCHITECT HIV Ag/Ab Combo assay and utility of signal-to-cutoff ratio to predict false-positive HIV tests in pregnancy. *Am J Obstet Gynecol.* 2018;219(4):408 e401-408 e409. Available at: <https://pubmed.ncbi.nlm.nih.gov/29913173>.
6. Nesheim SR, FitzHarris LF, Mahle Gray K, Lampe MA. Epidemiology of perinatal HIV transmission in the United States in the era of its elimination. *Pediatr Infect Dis J.* 2019;38(6):611-616. Available at: <https://pubmed.ncbi.nlm.nih.gov/30724833>.
7. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006;55(RR-14):1-17; quiz CE11-14. Available at: <https://pubmed.ncbi.nlm.nih.gov/16988643>.
8. Chadwick EG, Ezeanolue EE, Committee On Pediatric AIDS. Evaluation and management of the infant exposed to HIV in the United States. *Pediatrics.* 2020;146(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/33077537>.
9. Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. *Ann Intern Med.* 2012;157(10):719-728. Available at: <https://pubmed.ncbi.nlm.nih.gov/23165663>.
10. American College of Obstetricians Gynecologists, Committee on Obstetric Practice HIV Expert Work Group. ACOG committee opinion no. 752: prenatal and perinatal human immunodeficiency virus testing. *Obstet Gynecol.* 2018;132(3):e138-e142. Available at: <https://pubmed.ncbi.nlm.nih.gov/30134428>.
11. U.S. Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV infection: US preventive services task force recommendation statement. *JAMA.* 2019;321(23):2326-2336. Available at: <https://pubmed.ncbi.nlm.nih.gov/31184701>.

12. Whitmore SK, Taylor AW, Espinoza L, et al. Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico. *Pediatrics*. 2012;129(1):e74-81. Available at: <https://pubmed.ncbi.nlm.nih.gov/22144694>.
13. Ezeanolue EE, Pharr JR, Hunt A, et al. Why are children still being infected with HIV? Impact of an integrated public health and clinical practice intervention on mother-to-child HIV transmission in Las Vegas, Nevada, 2007–2012. *Ann Med Health Sci Res*. 2015;5(4):253-259. Available at: <https://pubmed.ncbi.nlm.nih.gov/26229713>.
14. Taylor AW, Nesheim SR, Zhang X, et al. Estimated perinatal HIV infection among infants born in the United States, 2002–2013. *JAMA Pediatr*. 2017;171(5):435-442. Available at: <https://pubmed.ncbi.nlm.nih.gov/28319246>.
15. Liao C, Golden WC, Anderson JR, Coleman JS. Missed opportunities for repeat HIV testing in pregnancy: implications for elimination of mother-to-child transmission in the United States. *AIDS Patient Care STDS*. 2017;31(1):20-26. Available at: <https://pubmed.ncbi.nlm.nih.gov/27936863>.
16. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. *J Infect Dis*. 2018;218(1):16-25. Available at: <https://pubmed.ncbi.nlm.nih.gov/29514254>.
17. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505. Available at: <https://pubmed.ncbi.nlm.nih.gov/21767103>.
18. Baggaley RF, White RG, Hollingsworth TD, Boily MC. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. *Epidemiology*. 2013;24(1):110-121. Available at: <https://pubmed.ncbi.nlm.nih.gov/23222513>.
19. Jamieson DJ, Read JS, Kourtis AP, et al. Cesarean delivery for HIV-infected women: recommendations and controversies. *Am J Obstet Gynecol*. 2007;197(3 Suppl):S96-100. Available at: <https://pubmed.ncbi.nlm.nih.gov/17825656>.
20. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French Perinatal Cohort (EPF-ANRS CO1). *Clin Infect Dis*. 2010;50(4):585-596. Available at: <https://pubmed.ncbi.nlm.nih.gov/20070234>.
21. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. *AIDS*. 2008;22(8):973-981. Available at: <https://pubmed.ncbi.nlm.nih.gov/18453857>.
22. Havens PL, Mofenson LM, American Academy of Pediatrics Committee on Pediatric AIDS. Evaluation and management of the infant exposed to HIV-1 in the United States. *Pediatrics*. 2009;123(1):175-187. Available at: <https://pubmed.ncbi.nlm.nih.gov/19117880>.

23. Hegazi A, Forsyth S, Prime K, Bashh Adolescent Special Interest Group. Testing the children of HIV-infected parents: 6 years on from ‘Don’t forget the children.’ *Sex Transm Infect.* 2015;91(2):76-77. Available at: <https://pubmed.ncbi.nlm.nih.gov/25316913>.
24. Boer K, Smit C, van der Flier M, et al. The comparison of the performance of two screening strategies identifying newly-diagnosed HIV during pregnancy. *Eur J Public Health.* 2011;21(5):632-637. Available at: <https://pubmed.ncbi.nlm.nih.gov/21051473>.
25. Yudin MH, Moravac C, Shah RR. Influence of an “opt-out” test strategy and patient factors on human immunodeficiency virus screening in pregnancy. *Obstet Gynecol.* 2007;110(1):81-86. Available at: <https://pubmed.ncbi.nlm.nih.gov/17601900>.
26. Olakunde BO, Pharr JR, Adeyinka DA. HIV testing among pregnant women with prenatal care in the United States: an analysis of the 2011–2017 National Survey of Family Growth. *Int J STD AIDS.* 2020;31(7):680-688. Available at: <https://pubmed.ncbi.nlm.nih.gov/32538331>.
27. Koumans EH, Harrison A, House LD, et al. Characteristics associated with lack of HIV testing during pregnancy and delivery in 36 U.S. states, 2004–2013. *Int J STD AIDS.* 2018;29(12):1225-1233. Available at: <https://pubmed.ncbi.nlm.nih.gov/29969977>.
28. Salvant Valentine S, Caldwell J, Tailor A. Effect of CDC 2006 revised HIV testing recommendations for adults, adolescents, pregnant women, and newborns on state laws, 2018. *Public Health Rep.* 2020;135(1_suppl):189S-196S. Available at: <https://pubmed.ncbi.nlm.nih.gov/32735201>.
29. Sansom SL, Jamieson DJ, Farnham PG, et al. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. *Obstet Gynecol.* 2003;102(4):782-790. Available at: <https://pubmed.ncbi.nlm.nih.gov/14551009>.
30. Richey LE, Halperin J. Acute human immunodeficiency virus infection. *Am J Med Sci.* 2013;345(2):136-142. Available at: <https://pubmed.ncbi.nlm.nih.gov/23095473>.
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2023. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new>.
32. Trepka MJ, Mukherjee S, Beck-Sague C, et al. Missed opportunities for preventing perinatal transmission of human immunodeficiency virus, Florida, 2007–2014. *South Med J.* 2017;110(2):116-128. Available at: <https://pubmed.ncbi.nlm.nih.gov/28158882>.
33. Yee LM, Miller ES, Statton A, et al. Sustainability of statewide rapid HIV testing in labor and delivery. *AIDS Behav.* 2018;22(2):538-544. Available at: <https://pubmed.ncbi.nlm.nih.gov/28986656>.
34. Scott RK, Crochet S, Huang CC. Universal rapid human immunodeficiency virus screening at delivery: a cost-effectiveness analysis. *Infect Dis Obstet Gynecol.* 2018;2018:6024698. Available at: <https://pubmed.ncbi.nlm.nih.gov/29731602>.

35. Wesolowski LG, Delaney KP, Lampe MA, Nesheim SR. False-positive human immunodeficiency virus enzyme immunoassay results in pregnant women. *PLoS One*. 2011;6(1):e16538. Available at: <https://pubmed.ncbi.nlm.nih.gov/21304592>.
36. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. *J Infect Dis*. 2018;218(1):16-25. Available at: <https://pubmed.ncbi.nlm.nih.gov/29514254>.
37. Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis. *AIDS*. 2020;34(5):761-776. Available at: <https://pubmed.ncbi.nlm.nih.gov/32167990>.
38. Abuogi L, Noble L, Smith C, et al. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. *Pediatrics*. 2024. Available at: <https://pubmed.ncbi.nlm.nih.gov/38766700>.

Preventing HIV Transmission During Infant Feeding

Updated: December 19, 2024

Reviewed: December 19, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">• When there is potential for perinatal HIV transmission, evidence-based, patient-centered counseling should be provided to support shared decision-making about infant feeding. Counseling about infant feeding should begin prior to conception or as early as possible in pregnancy; information about and plans for infant feeding should be reviewed throughout pregnancy and again after delivery (AIII). During counseling, inform that—<ul style="list-style-type: none">○ Replacement feeding with properly prepared formula or pasteurized donor human milk from a milk bank eliminates the risk of postnatal HIV transmission to the infant through breastfeeding.○ Achieving and maintaining viral suppression through antiretroviral therapy (ART) during pregnancy and postpartum decreases breastfeeding transmission risk to less than 1%, but not zero.• Replacement feeding with formula or banked pasteurized donor human milk is recommended to eliminate the risk of HIV transmission through breastfeeding when ART is not being taken and/or viral suppression has not been achieved during pregnancy (at a minimum throughout the third trimester), as well as at delivery (AI).• When ART is being taken for HIV and a sustained undetectable viral load is achieved, counseling about the options of formula feeding, use of banked donor milk, or breastfeeding should be provided. Those who choose to breastfeed should be supported in this decision (AIII).• If formula feeding is chosen, providers should support in this decision. Providers should ask about potential barriers to formula feeding and explore ways to address them (AII).• In the case of a detectable viral load during breastfeeding, the Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommend breastfeeding be stopped temporarily or discontinued and replacement feeding initiated while the viral load is rechecked, causes for the viremia are assessed, and, when applicable, adherence counseling is reinforced (AI) (see Situations to Consider Stopping or Modifying Breastfeeding in the text below). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥ 200 copies/mL (CIII).<ul style="list-style-type: none">○ Depending on the level and persistence of viremia, next steps may include initiating or modifying infant antiretroviral prophylaxis, permanently stopping breastfeeding, and considering the need for additional infant HIV testing (see Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV, Table 14, Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding, and Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV in Diagnosis of HIV Infection in Infants and Children).○ If the repeat parental viral load is undetectable, a joint decision should be made by the parent and providers about whether breastfeeding may resume (AIII).• Engaging Child Protective Services or similar agencies is not an appropriate response to infant feeding choices impacted by HIV (AIII).• Clinicians are encouraged to consult the National Perinatal HIV/AIDS Hotline (1-888-448-8765) with HIV-related questions about infant feeding (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Counseling about infant feeding is an integral component of HIV care during pregnancy and postpartum. Ideally, this counseling should begin before pregnancy, continue during pregnancy, and be reviewed again after delivery. Patient-centered counseling should assess opinions and plans about infant feeding, engage in shared decision-making, and assist in implementing plans for infant feeding. Previously, replacement feeding with properly prepared formula or banked, pasteurized donor human milk was recommended as the only option for infant feeding in the United States because it is generally available and eliminates any risk of HIV transmission through breastfeeding. However, breastfeeding provides certain benefits to the breastfeeding dyad that are not possible with formula feeding. In addition, the risk of transmission through breastfeeding is very low, but not zero, for women on antiretroviral therapy (ART) with a sustained undetectable HIV viral load.¹⁻⁴

The Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (the Panels) recommend that clinicians engage parents in patient-centered counseling and shared decision-making regarding infant feeding. In 2024, the American Academy of Pediatrics published an updated opinion on breastfeeding in the context of HIV, stating “pediatricians should be prepared to offer a family-centered, nonjudgmental, harm reduction approach to support people with HIV on ART with sustained viral suppression below 50 copies per mL who desire to breastfeed.”⁴ As part of this process, providers and parents should discuss both replacement feeding and breastfeeding and address the possible use of infant antiretroviral (ARV) prophylaxis during breastfeeding in addition to the ARV prophylaxis recommended for all infants with perinatal HIV exposure. These conversations need to take place during pregnancy as well as throughout the duration of breastfeeding, particularly if viral load becomes detectable (see [Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding](#) and [Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Counseling should also address issues related to breast health (e.g., mastitis), mixed feeding, and weaning.

Panel recommendations are in line with the opinions of multiple experts and community organizations that have called for a patient-centered approach to infant feeding decision-making and providing access to the information, support, and tools parents need to make informed infant feeding decisions.⁴⁻¹³ A 2016 survey of 93 clinicians in the United States who provide specialty care to women with HIV found that one-third of the providers were aware that women in their care breastfed their infants after being advised not to do so.¹⁴ These findings underscore the importance of open communication and shared decision-making that provide an opportunity to understand patients’ values and infant feeding preferences, thus allowing appropriate care and support for breastfeeding dyads.

Most of the data on HIV transmission via breast milk come from studies conducted in low- and middle-income countries. However, there is growing interest in breastfeeding by people with HIV and health care providers in the United States and other higher-income countries. Data about breastfeeding with HIV in these settings are limited but have been explored in a number of studies. A 2020 case series¹⁵ described breastfeeding of three infants with perinatal HIV exposure in Canada. Eight observational studies published after that time have reported on groups of 7 to 72 breastfeeding infants estimated to reflect a total of 184 to 214 unique infants in Germany,^{16,17} Italy,¹⁸ Switzerland,¹⁹ and the United States and Canada.²⁰⁻²³ In these publications, participants who breastfed were on ART, generally started before or in the first trimester of pregnancy, and were documented to be virally suppressed (viral load <50 to <400 copies/mL) at the time of delivery and/or in late pregnancy. A few cases of low-level viremia were reported postpartum, with cessation of

breastfeeding in most instances. Infant ARV prophylaxis varied within and across study locations, including no ARV prophylaxis, zidovudine (ZDV) and/or nevirapine (NVP) for 4 to 6 weeks after birth, or continuing prophylaxis through one month after weaning. Some centers chose therapeutic dosing with three-drug ARV regimens for either the first 4 to 6 weeks after birth or through weaning. Although none of the studies identified cases of HIV transmission related to breastfeeding, the studies were not designed to evaluate transmission (see the subsection on Risk of Transmission below), the number of participating infants was small, and follow-up has not been completed for all participants. Some infants are still breastfeeding, and a small number were lost to follow-up. Challenges during breastfeeding—including mastitis, inadequate milk supply with need for formula supplementation, episodes of detectable viral load, and difficulty weaning—require further study to inform optimal management.

Clinicians who provide HIV care who have questions about infant feeding or are considering breastfeeding are encouraged to consult with an expert and/or the [National Perinatal HIV/AIDS Hotline](#) (1-888-448-8765).

Overview of Counseling and Management

When ART for HIV is being taken with a consistently suppressed viral load during pregnancy (at a minimum during the third trimester) and at the time of delivery, the Panel recommends counseling about the options of formula feeding, banked donor milk, or breastfeeding and supporting in infant feeding decisions.

When ART is not being taken and/or a suppressed viral load is not achieved at delivery, replacement feeding with formula or banked pasteurized donor human milk is recommended to eliminate the risk of HIV transmission. However, it is important to recognize that accessing an adequate supply of formula may be difficult sometimes, and there may be cost and access barriers to obtaining donor milk. For anyone with HIV who chooses replacement feeding, systems of care should ensure supportive access to clean water, safe formula, and banked human milk, if available.

Other countries have updated their guidelines for management of breastfeeding in the context of HIV: Switzerland in 2018,¹⁹ Australia in 2021,²⁴ the United Kingdom in 2020¹⁰ and 2022,²⁵ and Canada in 2023.²⁶ A number of institutions in the United States have developed their own protocols for counseling and providing HIV care when there is an interest in breastfeeding.^{20,27-29} Although these country guidelines and institution-level protocols have some differences, they all entail common elements: standardized counseling regarding infant feeding options during HIV care, a multidisciplinary team-based approach, lactation support, adherence counseling and support, and close monitoring of the breastfeeding dyad.²⁵ Approaches to infant prophylaxis are quite variable (see [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). In a provider survey conducted in 2021, institutional protocols supporting breastfeeding with HIV were rare but were associated with higher degrees of provider comfort when patients chose to breastfeed.³⁰

Special Concerns

Engaging Child Protective Services or similar agencies is not an appropriate response to infant feeding choices impacted by HIV.

There have been numerous reports that after expressing interest in or intention to breastfeed, providers threatened to make a report to Child Protective Services or actually did so. Such engagements can be extremely harmful to families; can exacerbate the stigma and discrimination associated with HIV; and are disproportionately applied to minoritized individuals, including Black, Indigenous, and other people of color.³¹⁻³³

Other Considerations

Patients should be asked nonjudgmental questions about their self-expression, including how they want to be referred to as a parent (e.g., mother, father, another name), and how they want to describe infant feeding (e.g., breastfeeding, another name). Some patients may desire to feed their infants their own milk, although some may find it dysphoric.³⁴ Counseling about infant feeding options, as discussed in this section, should be provided to all pregnancies impacted by HIV. There are no evidence-based guidelines on timing of restarting testosterone after giving birth or while breastfeeding. In one published case report of restarting testosterone 13 months postpartum while still lactating, the calculated milk-to-plasma ratio was under 1.0, the calculated relative infant dose was under 1%, the infant had no observable side effects, and the infant serum testosterone concentrations remained undetectable.³⁵

Approach to Counseling

Health care providers who provide HIV care during pregnancy or prepregnancy should initiate conversations about infant feeding early in pregnancy, or prior to the pregnancy, and the discussion should continue during the pregnancy.

One approach is to say, “Have you thought about how you would like to feed your baby? Formula feeding eliminates the risk of HIV transmission through breast milk. Less than 1 of 100 breastfed infants would be expected to acquire HIV through breast milk when ART is being taken and a sustained undetectable viral load is achieved while lactating; however, the risk is not zero. What information can I provide to help you decide?”

When breastfeeding with HIV is being considered, providers should engage in patient-centered, evidence-based counseling about infant feeding, allowing for shared decision-making. It should be a private, nonjudgmental conversation to understand the motivations for breastfeeding (e.g., bonding, health benefits for the breastfeeding dyad) and potential barriers to formula feeding (e.g., concern about formula feeding inadvertently disclosing HIV status, barriers to accessing formula, cultural concerns). Factors such as resource accessibility, the need for informed lactation support, and history of medication adherence should be considered when making these decisions. The conversation should also include information about the risks of HIV transmission during breastfeeding, the importance of sustained viral suppression, and common challenges to ART adherence during the postpartum period.

People with HIV desire to be counseled about safe infant feeding practices and have their questions answered without judgment.^{27,36} Community-based organizations have developed patient-facing materials to assist decisions around infant feeding options during pregnancy.³⁷ When the choice is made to breastfeed, counseling should include the importance of adherence to ART, sustained viral suppression during pregnancy and breastfeeding, and engagement in postpartum care. Points to address are listed below:

- The infant feeding options that eliminate the risk of HIV transmission are formula and pasteurized donor human milk.
- Fully suppressive ART during pregnancy and breastfeeding decreases breastfeeding transmission risk to less than 1%, but not zero.
- When ART for HIV is being taken with a sustained undetectable viral load, counsel about the options of formula feeding, use of banked donor milk, or breastfeeding. Those who choose to breastfeed should be supported in this decision.
- For those who choose to breastfeed, exclusive breastfeeding (no formula or other foods) through the first 6 months is recommended. It is important to acknowledge that there may be intermittent need to give formula (e.g., infant weight loss, milk supply not yet established, not having enough stored milk, transient increases in viral load).
- The postpartum period, which can be difficult for all parents, can present several challenges to medication adherence and engagement in care. Ensuring that parents have access to both a supportive clinical team and peer support in the postpartum period is beneficial in promoting medication adherence and viral load monitoring (see [Postpartum HIV Management and Follow-Up](#)).
- Access to a provider who is a breastfeeding specialist certified by the Academy of Breastfeeding Medicine (when available) or a lactation consultant with expertise in supporting breastfeeding with HIV is beneficial.
- As most studies of breastfeeding in mothers with HIV were conducted in resource-limited settings, more information is needed about the risk of HIV transmission through breastfeeding in higher-resource settings and when adherent to ART with sustained viral suppression starting early in pregnancy.
- Breastfeeding provides numerous health benefits such as reduction in hypertension, type 2 diabetes, and breast and ovarian cancers and benefits for the breastfed infant such reduction in asthma, gastroenteritis and otitis media.³⁸

Some providers and/or institutions have chosen to require a signed form acknowledging the counseling provided; others have felt this practice is too stigmatizing and prefer to document the infant feeding discussion in the patient's chart without requiring a signed form.

Approach to Management

If the decision is made to breastfeed, several measures should be taken to reduce the possibility of HIV transmission. Care of the breastfeeding dyad should be coordinated prior to delivery among the maternity care provider, HIV provider, infant provider, breastfeeding specialist certified by the Academy of Breastfeeding Medicine (when available), lactation consultant, and social worker, all of whom may need education about new approaches to infant feeding with HIV.^{20,26-30} Recommendations for management include the following:

- Support ART adherence and engagement in care throughout pregnancy and breastfeeding.
 - Provide case management and/or social work support from individual(s) with perinatal support experience.

- Ensure continued access to ARV medications throughout the breastfeeding period, recognizing that patients may have changes to insurance status and may need support applying for assistance programs.
 - Provide early active referral to a supportive lactation consultant, preferably a breastfeeding medicine provider when available, beginning prenatally or at delivery and continuing until breastfeeding is well established. The lactation consultant should be knowledgeable in concerns regarding HIV transmission and the situations in which to consider stopping or temporarily interrupting breastfeeding. (Refer to the next section on Situations in which to Consider Stopping or Modifying Breastfeeding.)
 - Screen and provide support for postpartum depression and other mental health conditions that are highly prevalent after giving birth and may affect ART adherence. Postpartum depression occurs more frequently with HIV compared to without HIV³⁹ (see [Postpartum HIV Management and Follow-Up](#)).
- Document sustained viral suppression before delivery and throughout breastfeeding.
 - No data exist to inform the appropriate frequency of viral load testing while breastfeeding. One approach is to monitor the plasma viral load of the parent every 1 to 2 months during breastfeeding.^{21,40}
 - Decide which clinician (e.g., prenatal care provider or primary care HIV clinician) is responsible for following viral loads of the parent postpartum and continuing counseling/education around breastfeeding.
 - If viral load becomes detectable, switching to replacement feeding is recommended (see [Situations to Consider Stopping or Modifying Breastfeeding below](#)). There are no data that clearly define a specific viral load threshold for permanent discontinuation of breastfeeding. Most experts recommend permanent discontinuation of breastfeeding when viral load is ≥ 200 copies/mL. Guidance about infant ARV management when viremia develops during breastfeeding is provided in [Antiretroviral Prophylaxis for Infants Exposed to Detectable HIV RNA During Breastfeeding in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#); see [Table 14. Antiretroviral Management of Infants With Exposure to HIV or Exposure During Breastfeeding](#) and [Table 14.1 Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#).
- Recommend exclusive breastfeeding in the first 6 months of life, followed by the introduction of complementary foods (e.g., solids) with continued breastfeeding, if desired.³⁸ Some parents may choose to stop breastfeeding and switch to formula prior to 6 months of age.
 - Provide support for exclusive breastfeeding, acknowledging that there may be scenarios where formula supplementation is needed. There is no evidence that formula supplementation increases the risk of HIV acquisition in the breastfed infant in the context of parental ART and viral suppression. In pre-ART studies, exclusive breastfeeding was associated with lower rates of HIV transmission compared to mixed feeding (a term used to describe infants fed breast milk plus other liquid or solid foods, including formula).^{41,42} The highest risk in these studies was from very early introduction of solids (before 2 months of age).^{41,43} Whether this remains a risk factor when viral suppression is sustained during breastfeeding has not been studied.
 - If supplementation is needed during a hospital stay, prioritize the use of pasteurized donor human milk when feasible.

- Administer appropriate ARV prophylaxis starting at birth; see Antiretroviral Prophylaxis for Breastfeeding Infants, [Table 14. Antiretroviral Management of Infants With Exposure to HIV or Exposure During Breastfeeding](#) and [Table 14.1 Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed in Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#).
- If detectable viral load develops during breastfeeding, the Panels recommend that breastfeeding be temporarily stopped or discontinued and replacement feeding initiated. Additional infant ARV prophylaxis and infant testing are also recommended, see Situations to Consider Stopping or Modifying Breastfeeding, below, [Table 14](#), [Table 14.1](#), and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#).
- Provide guidance on good breast care, including strategies to avoid and promptly resolve over-production of breast milk, milk stasis, and breast engorgement, which can lead to sore nipples, mastitis, or breast abscess. Promptly identify and treat mastitis, thrush, and cracked or bleeding nipples. These conditions may increase the risk of HIV transmission through breastfeeding, although the impact of these conditions in the context of ART and viral suppression is unknown.
- Develop a joint plan for weaning with family and providers. Since very rapid weaning was associated with increased risk of HIV shedding into breast milk and risk of transmission in the pre-ART era,⁴⁴⁻⁴⁶ weaning over a 2- to 4-week period might be safer, paying special attention to good breast care and avoidance of breast engorgement and milk stasis.
- There is little evidence to guide the infant HIV testing schedule during breastfeeding, and there have been transmissions detected many weeks or even months after reported cessation of breastfeeding.⁴⁷ Information about HIV testing for infants who are being breastfed is available in [Diagnosis of HIV Infection in Infants and Children](#) (see [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#)).

Situations to Consider Stopping or Modifying Breastfeeding

Situations may arise in which there is a need to temporarily stop or discontinue breastfeeding and initiate replacement feeding, such as a detectable viral load or developing mastitis or bleeding nipples during breastfeeding. If the situation is temporary, some options to consider while expressing breast milk until the condition has resolved or viral load becomes undetectable include: (1) giving previously stored expressed milk from a date when viral suppression was achieved while encouraging pumping and discarding breast milk to ensure that breastfeeding can resume; (2) pumping and flash heating breast milk before feeding it to the infant; (3) providing replacement feeding with formula or pasteurized donor human milk while encouraging pumping and discarding breast milk to ensure that breastfeeding can resume; or (4) permanently stopping breastfeeding. Flash heating, which has been documented to eliminate HIV from breast milk, involves placing a sample of milk in a glass container within a small pot of water, heating the water to a boil, and immediately removing the milk from the heated water when the water has boiled.^{48,49} Once cooled to room temperature, milk can be given to the infant via bottle or cup.

In the case of mastitis or bleeding nipples, pump and either flash heat or discard milk from the affected breast while continuing to feed or pump from the unaffected breast.

In the case of a viral load that becomes detectable while breastfeeding, the Panels recommend temporarily stopping or discontinuing breastfeeding and initiating replacement feeding, using one of the options described above, engaging in shared decision-making, assessing the etiology of the

viremia, and repeating the viral load. Due to the risk of postnatal transmission associated with viremia during breastfeeding, the Panels advise immediate cessation of breastfeeding if viral load becomes detectable; this guidance is more directive than counseling when ART is being taken with sustained viral suppression. Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥ 200 copies/mL. The exact association between degree and duration of viremia and lactational transmission is not known. In situations where viremia is low and an addressable cause has been identified, the added risk of short-term continued breastfeeding until a repeat viral load is available is likely to be low.

Any viremia is an opportunity to review the risks and benefits of continued breastfeeding, adherence strategies, and other considerations, such as ARV prophylaxis for the breastfeeding infant (see [Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding](#) and [Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#) in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)). If the repeat viral load is undetectable, a joint decision should be made by the parent and the clinician about whether breastfeeding may resume. If the repeat viral load remains detectable, support should be provided to continue replacement feeding.

The [Diagnosis of HIV Infection in Infants and Children](#) section provides guidance about HIV diagnostic testing for infants who are being breastfed. If after counseling, the choice is made to continue to breastfeeding with viremia, the parent and provider should remain engaged; the provider should offer guidance on ARV prophylaxis and testing for the infant and assist the parent to rapidly regain and maintain virologic suppression. Consultation with an expert or the [National Perinatal HIV/AIDS Hotline](#) (1-888-448-8764) is recommended.

Infant HIV Infection

If an infant has a positive nucleic acid test (NAT) result, it should be confirmed with a repeat NAT as soon as possible (see [Diagnosis of HIV Infection in Infants and Children](#)). Antigen–antibody combination immunoassays are not recommended for diagnosis in infants because of the transplacental transfer of HIV antibodies during pregnancy.

In the event of HIV transmission via breastfeeding, consult a pediatric HIV specialist and promptly initiate a full ART regimen for the infant (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children With HIV](#) in the [Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection](#)). If an infant acquires HIV, breastfeeding may be continued. Drug-resistance testing should be done on the infant's viral isolate. If resistance is identified, the ARV regimen can be adjusted appropriately.

Factors Affecting Decisions About Infant Feeding

Several factors affect parents' decisions about infant feeding. Patient-centered counseling should be conducted in a manner that supports the family by sharing the risks and benefits of feeding options; listening to beliefs, values, and interests of parents; addressing concerns; and engaging in shared decision-making to identify and support each family's infant feeding decision.

Benefits of Breastfeeding

In general, breastfeeding is widely considered to be the healthiest infant feeding option for both parents and infants in the general population (see the Centers for Disease Control and Prevention [Recommendations and Benefits: Breastfeeding](#)). Breastfeeding is associated with improved neonatal immune status and a lower risk of infants developing asthma, obesity, type 1 diabetes, severe lower respiratory disease, otitis media, sudden infant death syndrome, gastrointestinal infections, and necrotizing enterocolitis. In addition to bonding with infants and avoiding the monetary costs of formula, benefits to breastfeeding include decreased risk of hypertension; type 2 diabetes; and breast, endometrial, and ovarian cancers.³⁸ An exclusive focus on the risk of perinatal HIV transmission via breastfeeding fails to acknowledge the health benefits of lactating and the health benefits that may be lost by prohibiting breastfeeding with HIV.

Access Considerations

Black women are disproportionately affected by HIV. People of color and their infants also experience a greater burden of many health conditions that research has shown may be alleviated by breastfeeding.⁵⁰ These outcomes are largely driven by the effects of structural racism, poverty, and segregation. Research has also shown that systemic racism contributes to lower uptake and continuation of breastfeeding among Black individuals without HIV.⁵¹ These issues should be considered as part of counseling and support for decisions around infant feeding with HIV in the United States. It is also important to recognize that, even in the United States, some people have limited access to safe water and/or difficulty obtaining formula. It is estimated that 17% of the U.S. population relied on privately owned wells for water in 2010; these are not regulated and are not subject to Environmental Protection Act standards.⁵²

Cultural Considerations

Environmental, social, familial, and personal pressures to consider breastfeeding may be faced during pregnancy.^{5,12,50,53-58} Many factors affect a woman's decision to breastfeed her infant; these include bonding; maternal and infant health benefits; social, cultural, and religious factors; and concerns about HIV-related stigma and disclosure.^{19,23,54}

Some women, especially those from a country or cultural background where breastfeeding is the norm, fear that not breastfeeding will lead to disclosure of their HIV status.^{5,57,58} Focus groups held in Canada elucidated the importance of discussing infant feeding options and motivations to breastfeed, especially among women who had immigrated from other countries where they had been encouraged to breastfeed.¹³

Risk of HIV Transmission to Infants Through Breastfeeding

Both the evidence regarding the risk of HIV transmission via breastfeeding and the strategies to reduce this type of transmission come from studies conducted in low- and middle-income countries, where rates of infant mortality are high and many families do not have access to safe water and affordable formula. Without maternal ART or infant ARV prophylaxis, the risk of an infant acquiring HIV through breastfeeding is 15% to 20% over 2 years.^{59,60} The mechanisms of HIV transmission by breastfeeding are not fully understood.^{61,62} This lack of current knowledge, and the fact that rare HIV

transmissions during breastfeeding have occurred when breast milk and/or plasma HIV viral load was undetectable, complicate decision-making.^{63,64}

Studies have shown that maternal ART throughout pregnancy and breastfeeding or infant ARV prophylaxis during breastfeeding can reduce, but not eliminate, the risk of breast milk–associated HIV transmission.⁶⁵⁻⁶⁹ However, in most of these studies, ART was initiated late in pregnancy, and ARV medications for women or infants were only provided for 6 months after birth, with limited data on maternal plasma HIV viral load during breastfeeding. A systematic review and meta-analysis published in 2017 identified six studies with ART started at some point during pregnancy and continued for at least 6 months postpartum that provided estimates of postnatal transmission rates, excluding peripartum infections diagnosed before 6 weeks of age. The pooled postnatal transmission rate at 6 months was 1.1% (95% confidence interval, 0.32% to 1.85%), with substantial heterogeneity. Transmission rates in the included studies ranged from 0.2% to 3.1%.⁷⁰

As ART has become more widely available for women during pregnancy and the postpartum period, studies have evaluated HIV transmission during breastfeeding among women who continued ART longer than women in previous studies. The PROMISE (Promoting Maternal and Infant Survival Everywhere Study) trial, which included more than 2,400 women with CD4 T lymphocyte cell counts ≥ 350 cells/mm³, compared the efficacy of prolonged infant ARV prophylaxis with daily oral NVP to maternal ART in preventing HIV transmission during breastfeeding. Both treatments continued through cessation of breastfeeding or 18 months postpartum, whichever came first. This study reported estimated transmission rates of 0.3% at 6 months and 0.6% at 12 months in both arms.¹ Both maternal HIV RNA load and maternal HIV drug resistance were independently associated with breastfeeding transmission.⁷¹ A secondary analysis of the PROMISE trial demonstrated an association between maternal viral load and HIV transmission among mother–baby pairs in the maternal ART arm but not in the infant ARV prophylaxis arm. Two infants in the maternal ART arm acquired HIV despite maternal viral load measured as not detected or detected but less than 40 copies/mL on the date that the infants’ first samples tested positive for HIV RNA.⁶³

Smaller studies have also looked at HIV transmission in the context of maternal ART and viral load monitoring. Two cases of HIV transmission during breastfeeding were reported among 186 infants born during a study in Tanzania; the first occurred in the infant of a mother who had a high viral load 1 month after delivery, and the second occurred after a mother discontinued ART. No cases of HIV transmission were reported among infants who were born to virally suppressed mothers who remained in care.⁷²

In a prospective follow-up of 475 breastfeeding mother–infant pairs in Zimbabwe, there were two postpartum transmissions, both from women with HIV RNA levels $>1,000$ copies/mL.⁷³ In a secondary analysis of the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study, increased maternal ART adherence was associated with lower breast milk and plasma viral loads. Higher breast milk and plasma viral loads were associated with increased breast milk transmission. When maternal plasma viral load remained <100 copies/mL during breastfeeding, there were no occurrences of infant HIV acquisition.⁶⁴

There have been at least five additional published cases of HIV transmission when maternal viral load was <50 copies/mL close to the time of transmission. Two cases are from an observational study in Malawi. In one, ART was started 8 weeks before delivery, and maternal plasma RNA was <37 copies/mL at 1 month, 3 months, 6 months, and 12 months postpartum. The infant was breastfed until 9 months of age and tested positive for HIV at 12 months of age after testing negative at months

1, 3, and 6. HIV RNA measured in the breast milk was 293 copies/mL at 1 month postpartum and <37 copies/mL at months 3 and 6. In the second case, ART was started 14 weeks before delivery, and maternal plasma RNA was <37 copies/mL at 1 month and 3 months postpartum. The infant tested positive for HIV at 3 months of age, after testing negative at 1 month. HIV RNA measured in the breast milk was <37 copies/mL at 1 month postpartum and 90 copies/mL at 3 months.⁷⁴

The Mma Bana study in Botswana compared triple nucleoside reverse transcriptase inhibitor (NRTI) therapy (abacavir, ZDV, and lamivudine [3TC]) to protease inhibitor (PI)-based therapy (lopinavir/ritonavir plus ZDV and 3TC). There were two lactational transmissions where maternal plasma and breast milk RNA were <50 copies/mL at 1 and 3 months postpartum, both in the NRTI arm. In one case, ART was started 4 weeks before delivery and viral load was elevated at delivery; the infant tested positive for HIV at 94 days of life after testing negative at 28 days. In the other case, ART was started 14 weeks before delivery and HIV RNA was <50 copies/mL at delivery, although issues with adherence were reported; the infant tested positive for HIV at 91 days of life after testing negative at 21 days.⁷⁵ In DOLPHIN-2 (Dolutegravir in Pregnant HIV Mothers and Their Neonates), which compared dolutegravir- versus efavirenz (EFV)-based ART started in the third trimester, out of 268 mother–infant pairs, there was one breastfeeding HIV transmission in the Efv group. HIV was diagnosed in the infant at 72 weeks of age (16 months), and maternal viral load was <50 copies/mL at 12 weeks, 24 weeks, 48 weeks, and 72 weeks postpartum.^{1,2,63,71}

In all these studies, maternal ART was initiated in the second or third trimester or postpartum. No studies have systematically evaluated the risk of HIV transmission through breastfeeding when maternal ART is started before pregnancy or in the first trimester and continued throughout breastfeeding.

In the Tshilo Dikotla Study (Botswana), frequent monitoring of HIV viral load occurred in pregnancy and postpartum while breastfeeding was ongoing, counseling was offered on adherence to ARV medications for both mothers and infants, and infant virologic diagnostic tests were performed routinely. Women were maintained on ART, and infants received 4 weeks of prophylactic ZDV or NVP. If a woman had a detectable viral load, she was encouraged to switch to formula feeding, but shared decision-making was employed. Among 247 participants, 19 had detectable viral loads at some point during breastfeeding. Twelve chose to stop breastfeeding, and seven continued to breastfeed with ongoing counseling and frequent viral load checks. There were no cases of HIV transmission via breastfeeding.⁷⁶

Safety of Antiretroviral Drugs During Breastfeeding

Parents are often concerned about infant exposure to ARV medications through breast milk. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) NVP, EFV, and etravirine have been detected in breast milk; however, the levels of these ARV medications that have been detected in breast milk are lower than those seen in maternal plasma. Among PIs, lopinavir, ritonavir, and atazanavir have been found in very low concentrations in breast milk, with little to no drug detectable in the blood of the breastfed infant.⁷⁷ NRTIs show more variability than PIs and NNRTIs. Tenofovir concentrations from tenofovir disoproxil fumarate (TDF) are very low in breast milk, and the drug is undetectable in the blood of the breastfed infant.⁷⁷⁻⁷⁹ Emtricitabine and 3TC have more accumulation in breast milk and can sometimes be detected in the blood of the breastfed infant (in 19% and 36% of infants, respectively).⁷⁷ A subanalysis of the BAN study confirmed higher levels of the NRTIs ZDV and 3TC in breast milk than in maternal plasma, in contrast to NNRTIs and PIs. The study demonstrated that higher drug concentrations in the maternal plasma and breast milk compartments were associated

with lower levels of the virus in both compartments and a lower incidence of viral transmission during breastfeeding.⁸⁰ Data on the transfer of integrase strand transfer inhibitors to breast milk in humans are limited; data do show that dolutegravir is found in breast milk at levels that are about 3% of those seen in maternal plasma.⁸¹ For more details on the passage of ARV medications into breast milk, see the individual drug sections in [Appendix B: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy](#).

A systematic data review showed a decrease in maternal bone mineral content among breastfeeding mothers who were receiving TDF-based ART compared to mothers who received no ART, but whether this persisted after discontinuation of breastfeeding was not known.⁸² The clinical significance of the reduced bone mineral density is uncertain. Subsequent studies in Africa have shown TDF-based ART to be associated with a decrease in bone mineral density during lactation. In one study, bone mineral density decline through 74 weeks postpartum was greater in breastfeeding women with HIV receiving TDF than in those receiving ZDV-based ART.⁸³ A second study comparing bone mineral density in women with HIV receiving TDF-based ART to women without HIV showed accelerated loss during lactation, with only partial recovery by 3 months after cessation of lactation.⁸⁴

The rates of serious adverse events among infants who receive ARV prophylaxis during breastfeeding are low (see Safety of Antiretroviral Drugs for Infant Prophylaxis in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)). In infants, serious adverse events that are associated with the use of ART by breastfeeding mothers appear to be relatively uncommon. In two studies that compared the efficacy of maternal ART (ZDV-based ART in one study and TDF-based ART in the other) to infant NVP prophylaxis with no maternal ART during breastfeeding for prevention of postnatal HIV transmission, no significant differences in infant adverse events were observed between study arms.^{1,66} In breastfed infants in the PROMISE study, week 26 mean lumbar spine bone mineral content was lower in infants in the maternal ART group than in the infant NVP group. This difference (about 0.23 g) was less than one-half standard deviation, considered unlikely to be clinically relevant. No infant renal safety concerns were observed.⁸⁵ An infant who acquires HIV while breastfeeding is at risk for developing ARV medication resistance due to subtherapeutic drug levels in breast milk.^{71,86-88} A longitudinal retrospective study of Kenyan women with HIV from the pre-ART era showed no statistically significant difference in the composition of the bacterial microbiome of breast milk from women receiving combination antiretroviral (cART) and those receiving no ARV medications during breastfeeding.⁸⁹

Likewise, the rates of serious adverse events among infants who receive extended ARV prophylaxis during breastfeeding are low. In one study, the rate of adverse events in infants receiving 6 months of NVP was not significantly different from the rate in infants receiving placebo.⁶⁶ For additional information, see Safety of Antiretroviral Drugs for Infant Prophylaxis in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#). Studies to date have examined only short-term adverse events, and few data are available on whether there might be long-term consequences of these drug exposures.

References

1. Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. *J Acquir Immune Defic Syndr.* 2018;77(4):383-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239901>.
2. Malaba TR, Nakatudde I, Kintu K, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. *Lancet HIV.* 2022;9(8):e534-e543. Available at: <https://pubmed.ncbi.nlm.nih.gov/35905752>.
3. Behrens GMN, Aebi-Popp K, Babiker A. Close to zero, but not zero: what is an acceptable HIV transmission risk through breastfeeding? *J Acquir Immune Defic Syndr.* 2022;89(4):e42. Available at: <https://pubmed.ncbi.nlm.nih.gov/34897228>.
4. Abuogi L, Noble L, Smith C, et al. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. *Pediatrics.* 2024. Available at: <https://pubmed.ncbi.nlm.nih.gov/38766700>.
5. Yudin MH, Kennedy VL, MacGillivray SJ. HIV and infant feeding in resource-rich settings: considering the clinical significance of a complicated dilemma. *AIDS Care.* 2016;28(8):1023-1026. Available at: <https://pubmed.ncbi.nlm.nih.gov/26881474>.
6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet.* 2021;396(10267):1994-2005. Available at: <https://pubmed.ncbi.nlm.nih.gov/33308425>.
7. Morrison P, Israel-Ballard K, Greiner T. Informed choice in infant feeding decisions can be supported for HIV-infected women even in industrialized countries. *AIDS.* 2011;25(15):1807-1811. Available at: <https://pubmed.ncbi.nlm.nih.gov/21811145>.
8. Johnson G, Levison J, Malek J. Should providers discuss breastfeeding with women living with HIV in high-income countries? an ethical analysis. *Clin Infect Dis.* 2016;63(10):1368-1372. Available at: <https://pubmed.ncbi.nlm.nih.gov/27572099>.
9. Kahlert C, Aebi-Popp K, Bernasconi E, et al. Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting? *Swiss Med Wkly.* 2018;148:w14648. Available at: <https://pubmed.ncbi.nlm.nih.gov/30044473>.
10. British HIV Association. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). 2020. Available at: <https://www.bhiva.org/file/5f1aab1ab9ab/BHIVA-Pregnancy-guidelines-2020-3rd-interim-update.pdf>
11. Gostin LO, Kavanagh MM. The ethics of breastfeeding by women living with HIV/AIDS: a concrete proposal for reforming department of health and human services recommendations. *J Law Med Ethics.* 2019;47(1):161-164. Available at: <https://pubmed.ncbi.nlm.nih.gov/30994078>.

12. Well Project Expert consensus Statement [press release]. 2020.
13. Khan S, Kennedy VL, Loutfy M, et al. "It's not easy": infant feeding in the context of HIV in a resource-rich setting: strengths, challenges and choices, a qualitative study. *J Assoc Nurses AIDS Care*. 2021;32(1):105-114. Available at: <https://pubmed.ncbi.nlm.nih.gov/33177433>.
14. Tuthill EL, Tomori C, Van Natta M, Coleman JS. "In the United States, we say, 'No breastfeeding,' but that is no longer realistic": provider perspectives towards infant feeding among women living with HIV in the United States. *J Int AIDS Soc*. 2019;22(1):e25224. Available at: <https://pubmed.ncbi.nlm.nih.gov/30657639>.
15. Nashid N, Khan S, Loutfy M, et al. Breastfeeding by women living with human immunodeficiency virus in a resource-rich setting: a case series of maternal and infant management and outcomes. *J Pediatric Infect Dis Soc*. 2020;9(2):228-231. Available at: <https://pubmed.ncbi.nlm.nih.gov/30753640>.
16. Haberl L, Audebert F, Feiterna-Sperling C, et al. Not recommended, but done: breastfeeding with HIV in Germany. *AIDS Patient Care STDS*. 2021;35(2):33-38. Available at: <https://pubmed.ncbi.nlm.nih.gov/33571048>.
17. Weiss F, von Both U, Rack-Hoch A, et al. Brief report: HIV-positive and breastfeeding in high-income settings: 5-year experience from a perinatal center in Germany. *J Acquir Immune Defic Syndr*. 2022;91(4):364-367. Available at: <https://pubmed.ncbi.nlm.nih.gov/35944107>.
18. Prestileo T, Adriana S, Lorenza DM, Argo A. From undetectable equals untransmittable (U=U) to breastfeeding: is the jump short? *Infect Dis Rep*. 2022;14(2):220-227. Available at: <https://pubmed.ncbi.nlm.nih.gov/35447879>.
19. Crisinel PA, Kusejko K, Kahlert CR, et al. Successful implementation of new Swiss recommendations on breastfeeding of infants born to women living with HIV. *Eur J Obstet Gynecol Reprod Biol*. 2023;283:86-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/36801775>.
20. Abuogi L, Smith C, Kinzie K, et al. Development and implementation of an interdisciplinary model for the management of breastfeeding in women with HIV in the United States: experience from the children's hospital colorado immunodeficiency program. *J Acquir Immune Defic Syndr*. 2023;93(5):395-402. Available at: <https://pubmed.ncbi.nlm.nih.gov/37104739>.
21. Koay WLA, Rakhmanina NY. Supporting mothers living with HIV in the United States who choose to breastfeed. *J Pediatric Infect Dis Soc*. 2022;11(5):239. Available at: <https://pubmed.ncbi.nlm.nih.gov/35238385>.
22. Levison J, McKinney J, Duque A, et al. Breastfeeding among people with HIV in North America: a multisite study. *Clin Infect Dis*. 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/37078712>.
23. Yusuf HE, Knott-Grasso MA, Anderson J, et al. Erratum to: experience and outcomes of breastfed infants of women living with HIV in the United States: findings from a single center breastfeeding support initiative. *J Pediatric Infect Dis Soc*. 2022;11(5):240. Available at: <https://pubmed.ncbi.nlm.nih.gov/35285911>.

24. Allan B, Machon KE. The optimal scenario and context of care. ASHM guidance for healthcare providers regarding infant feeding options for people living with HIV with highlights from breastfeeding and women living with HIV in Australia. *The Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine*. 2021. Available at: https://ashm.org.au/wp-content/uploads/2022/04/Resource_ASHM-HIV-Infant-feeding-Guidance_FINAL.pdf.
25. British HIV Association. Interim BHIVA position statement on HIV and mixed infant feeding. 2022. Available at: <https://www.bhiva.org/file/639b0a86a19c7/BHIVA-position-statement-on-HIV-and-mixed-infant-feeding.pdf>
26. Khan S, Tsang KK, Brophy J, et al. Canadian Pediatric & Perinatal HIV/AIDS Research Group consensus recommendations for infant feeding in the HIV context. *J Assoc Med Microbiol Infect Dis Can*. 2023;8(1):7-17. Available at: <https://pubmed.ncbi.nlm.nih.gov/37008587>.
27. Lazenby GB, Sundstrom B, Momplaisir FM, et al. Attitudes on breast feeding among persons with HIV who have given birth and their perceptions of coercion during counseling on safe infant feeding practices. *AIDS Care*. 2022;1-11. Available at: <https://pubmed.ncbi.nlm.nih.gov/36435965>.
28. McKinney J, Mirani G, Levison J. Providers have a responsibility to discuss options for infant feeding with pregnant people with human immunodeficiency virus in high-income countries. *Clin Infect Dis*. 2023;76(3):535-539. Available at: <https://pubmed.ncbi.nlm.nih.gov/36097892>.
29. Powell AM, Knott-Grasso MA, Anderson J, et al. Infant feeding for people living with HIV in high resource settings: a multi-disciplinary approach with best practices to maximise risk reduction. *Lancet Reg Health Am*. 2023;22:100509. Available at: <https://pubmed.ncbi.nlm.nih.gov/37287494>.
30. Lai A, Young ES, Kohrman H, et al. Tilting the scale: current provider perspectives and practices on breastfeeding with HIV in the United States. *AIDS Patient Care STDS*. 2023;37(2):84-94. Available at: <https://pubmed.ncbi.nlm.nih.gov/36787411>.
31. Putnam-Hornstein E, Ahn E, Prindle J, et al. Cumulative rates of child protection involvement and terminations of parental rights in a California birth cohort, 1999-2017. *Am J Public Health*. 2021;111(6):1157-1163. Available at: <https://pubmed.ncbi.nlm.nih.gov/33856882>.
32. Roberts D. The color of child welfare. 2002. Available at: https://www.academia.edu/34771496/Shattered_Bonds_The_Color_of_Child_Welfare
33. Wall-Wieler E, Roos LL, Nickel NC, et al. Mortality among mothers whose children were taken into care by child protection services: a discordant sibling analysis. *American Journal of Epidemiology*. 2018;187(6):1182-1188. Available at: <https://pubmed.ncbi.nlm.nih.gov/29617918>.
34. MacDonald T, Noel-Weiss J, West D, et al. Transmasculine individuals' experiences with lactation, chestfeeding, and gender identity: a qualitative study. *BMC Pregnancy Childbirth*. 2016;16:106. Available at: <https://pubmed.ncbi.nlm.nih.gov/27183978>.
35. Oberhelman-Eaton S, Chang A, Gonzalez C, et al. Initiation of gender-affirming testosterone therapy in a lactating transgender man. *J Hum Lact*. 2022;38(2):339-343. Available at: <https://pubmed.ncbi.nlm.nih.gov/34490813>.

36. Pagano-Therrien J, Griswold MK, Amoah RK. "Go with the flow": a qualitative description of infant feeding experiences among women with HIV in the United States. *J Assoc Nurses AIDS Care*. 2023;34(4):376-388. Available at: <https://pubmed.ncbi.nlm.nih.gov/37199426>.
37. The Well Project. Overview of infant feeding options for parents living with HIV. 2022. Available at: <https://www.thewellproject.org/hiv-information/overview-infant-feeding-options-parents-living-hiv>
38. Meek JY, Noble L. Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. *Pediatrics*. 2022;150(1). Available at: <https://pubmed.ncbi.nlm.nih.gov/35921640>.
39. Zhu QY, Huang DS, Lv JD, et al. Prevalence of perinatal depression among HIV-positive women: a systematic review and meta-analysis. *BMC Psychiatry*. 2019;19(1):330. Available at: <https://pubmed.ncbi.nlm.nih.gov/31666033>.
40. Yusuf HE, Knott-Grasso MA, Anderson J, et al. Experience and outcomes of breastfed infants of women living with HIV in the United states: findings from a single-center breastfeeding support initiative. *J Pediatric Infect Dis Soc*. 2022;11(1):24-27. Available at: <https://pubmed.ncbi.nlm.nih.gov/34888664>.
41. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. *Lancet*. 2007;369(9567):1107-1116. Available at: <https://pubmed.ncbi.nlm.nih.gov/17398310>.
42. Coutsoudis A, Pillay K, Spooner E, et al. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African vitamin A study group. *Lancet*. 1999;354(9177):471-476. Available at: <https://pubmed.ncbi.nlm.nih.gov/10465172>.
43. Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. *PLoS One*. 2009;4(10):e7397. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19834601>.
44. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. *N Engl J Med*. 2008;359(2):130-141. Available at: <https://pubmed.ncbi.nlm.nih.gov/18525036>.
45. Thea DM, Aldrovandi G, Kankasa C, et al. Post-weaning breast milk HIV-1 viral load, blood prolactin levels and breast milk volume. *AIDS*. 2006;20(11):1539-1547. Available at: <https://pubmed.ncbi.nlm.nih.gov/16847409>.
46. Kuhn L, Kim HY, Walter J, et al. HIV-1 concentrations in human breast milk before and after weaning. *Sci Transl Med*. 2013;5(181):181ra151. Available at: <https://pubmed.ncbi.nlm.nih.gov/23596203>.
47. King CC, Kourtis AP, Persaud D, et al. Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding. *AIDS*. 2015;29(15):1953-1961. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26153671>.

48. Israel-Ballard K, Chantry C, Dewey K, et al. Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. *J Acquir Immune Defic Syndr.* 2005;40(2):175-181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16186735>.
49. Israel-Ballard K, Donovan R, Chantry C, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. *J Acquir Immune Defic Syndr.* 2007;45(3):318-323. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17514015>.
50. Gross MS, Taylor HA, Tomori C, Coleman JS. Breastfeeding with HIV: an evidence-based case for new policy. *J Law Med Ethics.* 2019;47(1):152-160. Available at: <https://pubmed.ncbi.nlm.nih.gov/30994076>.
51. Hinson TD, Skinner AC, Spatz DL. Subject matter experts identify health equity concerns in breastfeeding for African American women. *J Perinat Neonatal Nurs.* 2021;35(2):160-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/33346570>.
52. Murray A, Hall A, Weaver J, Kremer F. Methods for estimating locations of housing units served by private domestic wells in the United States Applied to 2010. *J Am Water Resour Assoc.* 2021;57(5):1-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/34987281>.
53. Levison J, Weber S, Cohan D. Breastfeeding and HIV-infected women in the United States: harm reduction counseling strategies. *Clin Infect Dis.* 2014;59(2):304-309. Available at: <https://pubmed.ncbi.nlm.nih.gov/24771330>.
54. Greene S, Ion A, Elston D, et al. "Why aren't you breastfeeding?": how mothers living with HIV talk about infant feeding in a "breast is best" world. *Health Care Women Int.* 2015;36(8):883-901. Available at: <https://pubmed.ncbi.nlm.nih.gov/24527767>.
55. Tariq S, Elford J, Tookey P, et al. "It pains me because as a woman you have to breastfeed your baby": decision-making about infant feeding among African women living with HIV in the UK. *Sex Transm Infect.* 2016;92(5):331-336. Available at: <https://pubmed.ncbi.nlm.nih.gov/26757986>.
56. Freeman-Romilly N, Nyatsanza F, Namiba A, Lyall H. Moving closer to what women want? A review of breastfeeding and women living with HIV in the UK and high-income countries. *HIV Med.* 2020;21(1):1-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/31825556>.
57. Etowa J, Babatunde S, Hannan J, et al. Motherhood among Black women living with HIV: A "north-south" comparison of sociocultural and psychological factors. *Health Care Women Int.* 2021;42(3):304-322. Available at: <https://pubmed.ncbi.nlm.nih.gov/33600277>.
58. Etowa J, Nare H, Kakuru DM, Etowa EB. Psychosocial experiences of HIV-positive women of African descent in the cultural context of infant feeding: a three-country comparative analyses. *Int J Environ Res Public Health.* 2020;17(19). Available at: <https://pubmed.ncbi.nlm.nih.gov/33003622>.
59. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. *JAMA.* 2000;283(9):1167-1174. Available at: <https://pubmed.ncbi.nlm.nih.gov/10703779>.

60. World Health Organization. HIV Transmission through breastfeeding: a review of available evidence; 2007 update. 2008. Available at:
http://apps.who.int/iris/bitstream/10665/43879/1/9789241596596_eng.pdf
61. Weinberg GA, Nachman S. Breastfeeding by women living with HIV in the United States: are the risks truly manageable? *J Pediatric Infect Dis Soc.* 2022;11(3):92-93. Available at.
<https://pubmed.ncbi.nlm.nih.gov/34939650>.
62. Waitt C, Low N, Van de Perre P, et al. Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. *Lancet HIV.* 2018;5(9):e531-e536. Available at: <https://pubmed.ncbi.nlm.nih.gov/29960731>.
63. Flynn PM, Taha TE, Cababasay M, et al. Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component. *J Acquir Immune Defic Syndr.* 2021;88(2):206-213. Available at:
<https://pubmed.ncbi.nlm.nih.gov/34108383>.
64. Davis NL, Miller WC, Hudgens MG, et al. Maternal and breastmilk viral load: impacts of adherence on peripartum HIV infections averted-the Breastfeeding, Antiretrovirals, and Nutrition Study. *J Acquir Immune Defic Syndr.* 2016;73(5):572-580. Available at:
<https://pubmed.ncbi.nlm.nih.gov/27846071>.
65. White AB, Mirjahangir JF, Horvath H, et al. Antiretroviral interventions for preventing breast milk transmission of HIV. *Cochrane Database Syst Rev.* 2014(10):CD011323. Available at:
<https://pubmed.ncbi.nlm.nih.gov/25280769>.
66. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med.* 2010;362(24):2271-2281. Available at:
<https://pubmed.ncbi.nlm.nih.gov/20554982>.
67. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2012;379(9812):221-228. Available at: <https://pubmed.ncbi.nlm.nih.gov/22196945>.
68. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet.* 2016;387(10018):566-573. Available at: <https://pubmed.ncbi.nlm.nih.gov/26603917>.
69. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. *Lancet Infect Dis.* 2011;11(3):171-180. Available at: <https://pubmed.ncbi.nlm.nih.gov/21237718>.
70. Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *J Int AIDS Soc.* 2017;20(1):21251. Available at: <https://pubmed.ncbi.nlm.nih.gov/28362072>.

71. Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance Is associated with vertical transmission and Is prevalent in infected infants. *Clin Infect Dis*. 2022;74(11):2001-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/34467974>.
72. Luoga E, Vanobberghen F, Bircher R, et al. Brief report: no HIV transmission from virally suppressed mothers during breastfeeding in rural Tanzania. *J Acquir Immune Defic Syndr*. 2018;79(1):e17-e20. Available at: <https://pubmed.ncbi.nlm.nih.gov/29781882>.
73. Zijenah LS, Bandason T, Bara W, et al. Impact of Option B(+) combination antiretroviral therapy on mother-to-child transmission of HIV-1, maternal and infant virologic responses to combination antiretroviral therapy, and maternal and infant mortality rates: a 24-month prospective follow-up study at a primary health care clinic, in Harare, Zimbabwe. *AIDS Patient Care STDS*. 2022;36(4):145-152. Available at: <https://pubmed.ncbi.nlm.nih.gov/35438521>.
74. Giuliano M, Andreotti M, Liotta G, et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. *PLoS One*. 2013;8(7):e68950. Available at: <https://pubmed.ncbi.nlm.nih.gov/23894379>.
75. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. *N Engl J Med*. 2010;362(24):2282-2294. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554983>.
76. Volpe LJ, Powis KM, Legbedze J, et al. A counseling and monitoring approach for supporting breastfeeding women living with HIV in Botswana. *J Acquir Immune Defic Syndr*. 2022;89(2):e16. Available at: <https://pubmed.ncbi.nlm.nih.gov/34723927>.
77. Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. *J Antimicrob Chemother*. 2018;73(4):1013-1019. Available at: <https://pubmed.ncbi.nlm.nih.gov/29309634>.
78. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. *PLoS Med*. 2016;13(9):e1002132. Available at: <https://pubmed.ncbi.nlm.nih.gov/27676257>.
79. Palombi L, Pirillo MF, Marchei E, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. *J Antimicrob Chemother*. 2016;71(4):1027-1030. Available at: <https://pubmed.ncbi.nlm.nih.gov/26679247>.
80. Davis NL, Corbett A, Kaullen J, et al. Antiretroviral drug concentrations in breastmilk, maternal HIV viral load, and HIV transmission to the infant: results from the BAN Study. *J Acquir Immune Defic Syndr*. 2019;80(4):467-473. Available at: <https://pubmed.ncbi.nlm.nih.gov/30570527>.
81. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DOLPHIN-1 study). *PLoS Med*. 2019;16(9):e1002895. Available at: <https://pubmed.ncbi.nlm.nih.gov/31539371>.

82. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. *AIDS*. 2017;31(2):213-232. Available at: <https://pubmed.ncbi.nlm.nih.gov/27831952>.
83. Stranix-Chibanda L, Tierney C, Sebikari D, et al. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. *PLoS One*. 2021;16(2):e0246272. Available at: <https://pubmed.ncbi.nlm.nih.gov/33544759>.
84. Nabwire F, Prentice A, Hamill MM, et al. Changes in bone mineral density during and after lactation in Ugandan women with HIV on tenofovir-based antiretroviral therapy. *J Bone Miner Res*. 2020;35(11):2091-2102. Available at: <https://pubmed.ncbi.nlm.nih.gov/32573842>.
85. Vhembo T, Baltrusaitis K, Tierney C, et al. Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial. *J Acquir Immune Defic Syndr*. 2023;93(5):431-437. Available at: <https://pubmed.ncbi.nlm.nih.gov/37199427>.
86. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. *Clin Infect Dis*. 2011;52(8):1069-1076. Available at: <https://pubmed.ncbi.nlm.nih.gov/21460326>.
87. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. *PLoS Med*. 2011;8(3):e1000430. Available at: <https://pubmed.ncbi.nlm.nih.gov/21468304>.
88. Aebi-Popp K, Kahlert CR, Crisinel PA, et al. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. *J Antimicrob Chemother*. 2022;77(12):3436-3442. Available at: <https://pubmed.ncbi.nlm.nih.gov/36177836>.
89. Maqsood R, Skidmore PT, Holland LA, et al. Dynamic changes in breast milk microbiome in the early postpartum period of Kenyan women living with HIV are influenced by antibiotics but not antiretrovirals. *Microbiol Spectr*. 2022;10(2):e0208021. Available at: <https://pubmed.ncbi.nlm.nih.gov/35384692>.

Diagnosis of HIV Infection in Infants and Children

Updated: December 19, 2024

Reviewed: December 19, 2024

Panel's Recommendations

- Virologic assays (HIV RNA or HIV DNA nucleic acid tests [NATs]) that directly detect HIV must be used to diagnose HIV in infants and children aged <18 months with perinatal HIV exposure; HIV antibody and HIV antigen/antibody tests should not be used (AII).
- Plasma HIV RNA or cell-associated HIV DNA NATs are generally equally recommended (AII).
- An assay that detects HIV non-B subtype viruses or Group O infections (e.g., an HIV RNA NAT or a total DNA/RNA test) is recommended for use in infants and children perinatally exposed to known or suspected non-B subtype virus or Group O infections (AII).
- Virologic diagnostic testing using an HIV NAT (see [Table 3](#) below) is recommended for all infants with perinatal HIV exposure at the following ages:
 - Birth (AII)
 - The test at birth generally should be performed in all infants with perinatal HIV exposure but is not necessary for infants at low risk of HIV acquisition (HIV RNA levels <50 copies/mL from 20 weeks of gestation through delivery put infants at low risk of HIV acquisition). Birth testing should be performed in infants at low risk of HIV acquisition if there are plans to breastfeed or there are concerns about loss to follow-up (BIII).
 - 14 to 21 days (AII)
 - 1 to 2 months (AII)
 - 4 to 6 months (AII)
- For infants who receive presumptive HIV therapy, additional virologic diagnostic testing is recommended 2 to 6 weeks after antiretroviral (ARV) drugs are discontinued (BII).
- A positive virologic test should be confirmed as soon as possible by a repeat virologic test (AII).
- Definitive exclusion of HIV infection in non-breastfed infants is based on two or more negative virologic tests (and no positive virologic tests), with one negative test obtained at age ≥1 month (and at least 2–6 weeks after discontinuation of infant ARVs) and one at age ≥4 months, or two negative HIV antibody tests from separate specimens that were obtained at age ≥6 months (AII).
- Additional HIV testing (e.g., HIV NAT, HIV antibody, HIV antigen/antibody) is not needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth (AII).
- For infants with perinatal HIV exposure who are being breastfed, virologic diagnostic testing is recommended at birth, 14 to 21 days, 1 to 2 months, and 4 to 6 months of age (AII). An additional virologic test should be performed if the gap between the tests at ages 1 to 2 months and 4 to 6 months is greater than 3 months. See [Preventing HIV Transmission During Infant Feeding](#).
 - Virologic diagnostic testing should be performed at least every 3 months during breastfeeding (BII);
 - After cessation of breastfeeding, irrespective of when breastfeeding ends, virologic diagnostic testing should be performed at 4 to 6 weeks and 4 to 6 months after cessation (BII).

Infants with potential HIV exposure after birth (e.g., diagnosis of HIV during breastfeeding, premasticated feeding, sexual abuse, contaminated blood products, percutaneous exposure) require additional testing using HIV antigen/antibody and/or HIV NAT assays, based on age at time of exposure and the maternal HIV status at delivery (AII).

- Age-appropriate HIV testing is also recommended for infants and children with signs and/or symptoms of HIV, even in the absence of documented or suspected HIV exposure (All).
- For children aged ≥ 18 months, HIV antibody (or HIV antigen/antibody) tests are recommended for diagnostic testing (All).
 - When early (acute or recent) HIV infection is suspected, additional testing with an HIV NAT may be necessary to diagnose HIV infection (All).

Note: The [National Perinatal HIV Hotline](#) provides consultations on issues related to the management of perinatal HIV infection, including diagnostic testing (1-888-448-8765; 24 hours a day, 7 days a week).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children^t with clinical outcomes and/or validated endpoints; I^{*} = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children^t from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children^t with long-term outcomes; II^{*} = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children^t from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

^t Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Diagnosis of HIV in Infants and Children

HIV can be diagnosed definitively by virologic testing in most non-breastfed infants with perinatal HIV exposure by age 1 to 2 months and in all by age 4 to 6 months. Antibody tests, including antigen/antibody combination immunoassays, do not establish the presence of HIV in infants because HIV antibodies that have been transferred transplacentally **may be detected** (i.e., false positive); therefore, a virologic test must be used.^{1, 2} Positive virologic tests (i.e., nucleic acid tests [NATs]—a class of tests that includes HIV RNA and HIV DNA polymerase chain reaction [PCR] assays and related RNA qualitative or quantitative assays) indicate likely HIV infection. Plasma HIV RNA and HIV DNA NATs are generally equally recommended. However, both tests can be affected by antiretroviral therapy (ART) through transplacental transfer of antiretroviral (ARV) drugs to the fetus during pregnancy or by ARV drugs administered to the infant as prophylaxis or presumptive HIV therapy. In general, qualitative HIV proviral DNA PCR assays from whole blood detecting cell-associated virus are less affected by ARVs.

A positive HIV test result should be confirmed as soon as possible by repeat virologic testing, because false-positive results can occur with both RNA and DNA assays.³ A 2019 systematic review provides additional information on the **global and regional molecular epidemiology** of Group M subtype infections and recombinants among subtypes.⁴ Newer HIV RNA PCR assays are usually “dual-target” assays, which target two separate highly conserved regions on the HIV genome. Dual-target HIV assays are better than older RNA assays at detecting non–subtype B HIV infection and Group O strains^{5–10} (See [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

Antigen/antibody combination immunoassays that detect HIV-1/2 antibodies and HIV-1 p24 antigen **are not recommended** for diagnosis of HIV infection in infants **with known perinatal HIV exposure**. In the first months of life, the antigen component of antigen/antibody tests is less sensitive than an HIV NAT, and antibody tests should not be used for HIV diagnosis in infants and children aged <18 months.^{11–13} Children with perinatal HIV exposure who are aged ≥ 18 months occasionally have residual HIV antibodies from the antepartum period; definitive confirmation of HIV infection in children in this age group who remain HIV antibody–positive should be based on a NAT (see Special

Situations below). Diagnosis in children aged ≥ 18 months relies primarily on HIV antibody and antigen/antibody tests (see Diagnostic Testing in Children with Postnatal HIV Exposure below).¹

An infant who has a positive HIV antibody test but the maternal HIV status is unknown (see [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#)) should be assumed to have been exposed to HIV. The infant should undergo HIV diagnostic testing, as described in Timing of Diagnostic Testing in Infants with Perinatal HIV Exposure below,³ and receive presumptive HIV therapy as soon as possible (see [Antiretroviral Management of Infants with In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)).

Timing of Diagnostic Testing in Infants With Perinatal HIV Exposure

Confirmation of HIV infection is based on the results of positive virologic tests from two separate blood samples in infants and children < 18 months. [Table 3](#) below summarizes the timing of recommended virologic diagnostic testing for infants based on HIV transmission risk. Infants at high risk of perinatal HIV transmission may require additional virologic testing, given the increased risk of infection and concern that ARV prophylaxis, particularly combination ARV prophylaxis or presumptive HIV therapy, may reduce the sensitivity of diagnostic testing. The risk of transmission is determined based on whether ART is being taken and viral suppression is achieved and sustained during pregnancy and postpartum.

HIV infection can be **presumptively excluded** in non-breastfed infants with two or more negative virologic tests (one at age ≥ 2 weeks and one at age ≥ 4 weeks), one negative virologic test at age ≥ 8 weeks at least 2 weeks after discontinuing multidrug ARV prophylaxis/presumptive therapy, or one negative HIV antibody test at age ≥ 6 months.^{1,3}

Definitive exclusion of HIV infection in non-breastfed infants is based on two or more negative virologic tests, with one negative test obtained at age ≥ 1 month (and at least 2–6 weeks after discontinuation of [infant ARVs](#)) and one at age ≥ 4 months, or two negative HIV antibody tests from separate specimens that were obtained at age ≥ 6 months. For both presumptive and definitive exclusion of HIV infection, a child must have no other laboratory evidence (i.e., no positive virologic test results or low CD4 T lymphocyte cell count/percentage) or clinical evidence of HIV infection and must not be breastfeeding. No additional HIV testing of any kind (e.g., NAT, antibody, antigen/antibody) is needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth.

Pneumocystis jirovecii pneumonia (PCP) prophylaxis is recommended for infants with **indeterminate** HIV infection status starting at age 4 to 6 weeks until they are determined to be definitively or presumptively without HIV infection.¹⁴ Thus, PCP prophylaxis can be avoided or discontinued if HIV infection is presumptively excluded (see [Initial Postnatal Management of the Neonate Exposed to HIV](#) and [Pneumocystis jirovecii Pneumonia](#) in the [Pediatric Opportunistic Infection Guidelines](#)).

Virologic Testing at Birth

Virologic testing at birth provides insights about the timing of HIV transmission and supports early HIV diagnosis for rapid initiation of ART when indicated (see [When to Initiate Antiretroviral Treatment in Children With HIV Infection](#) in the [Pediatric Antiretroviral Guidelines](#)). Infants who have a positive virologic test result at or before age 48 hours are considered to have early (*in utero*)

infection, whereas non-breastfed infants who have a negative virologic test result during the first week of life and subsequently have positive test results are considered to have late (intrapartum) infection.¹⁵⁻¹⁷

In addition to early HIV diagnosis, results of birth testing are used in clinical decisions about infant ARV management. Negative HIV virologic testing at birth would rule out *in utero* infection and allow de-escalation of a three-drug presumptive HIV therapy regimen for some infants. See [Table 13](#) and associated content in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#).

Virologic testing at birth should generally be performed for all infants with perinatal HIV exposure but is not necessary for infants who are at low risk of infection (HIV RNA levels <50 copies/mL from 20 weeks gestation through delivery put infants at low risk of HIV acquisition) unless there are plans to breastfeed. When breastfeeding is planned for an infant at low risk of HIV acquisition, a birth test provides baseline information, should the infant subsequently have a positive test. Virologic testing at birth should also be considered whenever there are concerns that the newborn may be lost to follow-up without testing.

Specimens for HIV testing at birth should be obtained before or immediately after initiating an ARV drug regimen; however, presumptive HIV therapy or ARV prophylaxis should not be delayed.

Blood samples from the umbilical cord should not be used for diagnostic evaluation because of the potential for contamination with maternal blood.

Virologic Testing at Age 14 to 21 Days

Some children with perinatal HIV exposure can have a positive NAT between 14 and 21 days of age.³ Early identification of infection permits transition from presumptive HIV therapy to treatment doses of ART (see [When to Initiate Antiretroviral Treatment in Children With HIV Infection](#) in the [Pediatric Antiretroviral Guidelines](#)).

Virologic Testing at Age 1 to 3 Months

Testing performed at age 1 to 3 months is intended to maximize the likelihood of detecting HIV infection in infants with perinatal HIV exposure. In the HIV Prevention Trials Network 040 study, 93 of 140 infants with HIV (66.4%) were identified at birth. Infants who received negative test results in the first 7 days of life received an HIV diagnosis when the next diagnostic test was performed at 3 months of age.¹⁸ For infants at high risk of perinatal HIV transmission, the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV and the Panel on Treatment of HIV During Pregnancy and Interventions to Reduce Perinatal Transmission suggest performing an additional virologic test 2 to 6 weeks after ARV drugs are discontinued (i.e., at age 8–12 weeks when the infant receives 6 weeks of prophylaxis), given the increased risk of infection and concern that ARV prophylaxis, particularly combination ARV prophylaxis or presumptive HIV therapy, may reduce the sensitivity of diagnostic testing.^{18, 19} In these situations, many experts recommend one test at age 4 to 6 weeks to allow prompt diagnosis of HIV in infants with an additional test at 8 to 12 weeks of life (i.e., 2–6 weeks after cessation of prophylaxis or presumptive HIV therapy) to capture additional cases (see [Table 3](#) below). For infants at low risk of HIV transmission, a single test obtained at 1 to 2 months of age may be timed to occur 2 to 4 weeks after cessation of ARV prophylaxis.

Virologic Testing at Age 4 to 6 Months

Infants with HIV exposure who have had negative virologic assays at age 14 to 21 days and at age 1 to 2 months, who have had no positive virologic tests, who have no clinical evidence of HIV infection, and who are not breastfed should be retested at age 4 to 6 months for definitive exclusion of HIV infection.

Antibody Testing at Age 6 Months and Older

Two or more negative results of HIV antibody tests that were performed in non-breastfed infants at age ≥ 6 months also can be used to exclude HIV infection definitively in children with no clinical or virologic laboratory-documented evidence of HIV infection.^{20, 21}

Antibody Testing at Age ≥ 18 Months to Document Seroreversion

In general, no additional HIV testing of any kind (e.g., NAT, antibody, antigen/antibody) is needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth.

Virologic Testing for Infants With Perinatal HIV Exposure Who Are Being Breastfed

Some may choose to breastfeed with HIV (see [Preventing HIV Transmission During Infant Feeding](#)). A descriptive study of 72 people with HIV who breastfed their infants in North America reported high variability in policies, infant ARV prophylaxis, and infant and parental testing practices among institutions and noted the need to identify best care practices.²² [Table 3](#) summarizes the recommended diagnostic testing schedule for infants who are being breastfed. Infants with perinatal HIV exposure who are being breastfed should have virologic diagnostic testing at the standard time points: 14 to 21 days, 1 to 2 months, and 4 to 6 months (see [Table 3](#) below). In addition, a virologic test at birth is recommended to provide baseline information should the infant subsequently have a positive test. In some cases, an additional virologic test should be performed between the 1-to-2-month and 4-to-6-month time points if the gap between tests is greater than 3 months. Infants continuing to be breastfed beyond 6 months of age should have virologic diagnostic testing at least every 3 months during breastfeeding. At cessation of breastfeeding, virologic diagnostic testing should be performed at 4 to 6 weeks and 4 to 6 months after breastfeeding has ended, regardless of the age of the child when breastfeeding is discontinued. If the infant is receiving extended ARV prophylaxis during breastfeeding, an additional test should be done at least 2 weeks after cessation of ARV prophylaxis. If an infant's virologic test result is positive, a repeat test should be performed as soon as possible and ART should be initiated.

No data exist to inform the appropriate frequency of maternal viral load testing during breastfeeding. One approach is to monitor plasma viral load every 1 to 2 months during breastfeeding. Additional infant virologic testing using an HIV NAT is indicated if the maternal viral load becomes detectable during breastfeeding (for infant ARV prophylaxis considerations, see [Table 14](#) and [Table 14.1](#) in [Antiretroviral Management for Infants With *In Utero*, *Intrapartum*, or *Breastfeeding* Exposure to HIV](#)). If maternal viral load is detectable and breastfeeding continues, some Panel members would recommend monthly virologic testing of the infant as an approach to early detection of HIV infection during ongoing exposure. After cessation of breastfeeding, irrespective of when breastfeeding ends,

virologic testing should be performed at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding. If the breastfed infant is receiving presumptive HIV therapy or ARV prophylaxis, this virologic testing should be performed at least 2 weeks after discontinuation of infant ARV administration. Consultation with an expert and/or the [National Perinatal HIV Hotline](#) (8884488765) is recommended in these situations and for questions about HIV diagnostic testing for infants with perinatal HIV exposure who are being breastfed. For additional information, see [Preventing HIV Transmission During Infant Feeding](#).

Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV

| Infants With Perinatal HIV Exposure ^a | |
|---|---|
| Risk Category | Age at HIV NAT ^{b,c} Testing |
| Infants at High Risk of HIV Acquisition Infants with perinatal HIV exposure to— <ul style="list-style-type: none">• Viremia (HIV RNA ≥50 copies/mL) in the 4 weeks prior to delivery• Early (acute or recent) HIV during pregnancy or HIV diagnosed in labor or postpartum Note: Viremia can be documented by a laboratory or presumed by other clinical factors (e.g., new diagnosis, ART adherence challenges, stopping ART prior to delivery). | Birth 14–21 days 1–2 months 2–3 months (see note below) 4–6 months All infants at high risk of perinatal HIV transmission should have specimens obtained for HIV testing at birth before or immediately after initiating an ARV drug regimen; however, presumptive HIV therapy should not be delayed. Note: Additional virologic testing is recommended 2 to 6 weeks after infant ARV drugs are discontinued (i.e., at age 2 to 3 months if the infant receives 6 weeks of ARV drugs). If an infant's NAT test result is positive, a repeat test should be performed as soon as possible and ART should be initiated. |
| Infants at Low Risk of HIV Acquisition Who Are Not Being Breastfed Infants with perinatal HIV exposure to— <ul style="list-style-type: none">• Sustained viral suppression (<50 copies/mL) from 20 weeks of gestation through delivery Note: Ideally, sustained viral suppression is documented by HIV RNA testing, including at least two consecutive tests obtained at least 4 weeks apart with HIV RNA <50 copies/mL, but can be based on the clinical judgment of providers. | Birth (see note below) 14–21 days 1–2 months (see note below) 4–6 months Note: A birth test generally should be performed but is not necessary for infants at low risk of HIV acquisition unless there are concerns that the newborn could be lost to follow-up without further testing. Note: For infants at low risk of HIV acquisition, testing may be timed to occur at least 2 weeks after cessation of ZDV prophylaxis. |
| Infants Not Meeting Criteria for High or Low Risk of HIV Acquisition <ul style="list-style-type: none">• In these clinical scenarios, some infants may receive presumptive HIV therapy and others may receive only ZDV prophylaxis. | For all infants in this group, a NAT should be obtained at birth and the NAT testing schedule for infants at high risk of HIV acquisition (shown above) should be followed. |

| | The timing of virologic testing 2 to 6 weeks after ARV drugs are discontinued will vary based on the duration of infant ARV drugs. |
|--|--|
| See Table 13 and Table 13.1 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV for information about presumptive HIV therapy and ZDV prophylaxis, including duration of ARV drugs. | |
| Infants With Perinatal HIV Exposure at Low Risk of HIV Acquisition Who Are Being Breastfed | |
| Guidance for Virologic Testing During Breastfeeding | Age at HIV NAT ^{b,c} Testing |
| From Birth to Age 6 Months A NAT test at birth is recommended for infants with perinatal HIV exposure who are at low risk of HIV acquisition and are being breastfed. | Birth 14–21 days 1–2 months (see note below) 4–6 months Note: NAT testing of the infant should be performed at least every 3 months during breastfeeding. An additional virologic test should be performed if the gap between the tests at ages 1 to 2 months and 4 to 6 months is greater than 3 months. In addition to the standard time points after birth, NAT testing also should be performed at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding, regardless of the age when breastfeeding ends. |
| If Breastfeeding Continues Beyond 6 Months of Age | NAT testing of the infant should be performed at least every 3 months during breastfeeding and at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding, regardless of the age when breastfeeding ends. |
| If Viremia Develops While Breastfeeding (a detectable viral load) | Prompt NAT testing of the infant Additional testing time points are based on the clinical scenario and use of infant ARV prophylaxis or presumptive HIV therapy; see Table 14 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV . If there is a detectable maternal viral load and breastfeeding continues, some Panel members would recommend monthly virologic testing of the infant as an approach to early detection of HIV infection during ongoing exposure. Consultation with an expert is recommended to determine the need for infant ARV prophylaxis or presumptive HIV therapy and additional testing time points. |
| Consultation with an expert and/or the National Perinatal HIV Hotline (888-448-8765) is recommended for questions about HIV diagnostic testing for infants with perinatal HIV exposure who are being breastfed. See Table 14 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV for information about extended ARV prophylaxis and presumptive HIV therapy during breastfeeding. See Preventing HIV Transmission During Infant Feeding for additional guidance about breastfeeding. | |

^aThis table summarizes standard time points for HIV virologic diagnostic testing of infants according to risk of perinatal acquisition.

^b HIV RNA or HIV DNA NATs that directly detect HIV.

^c If maternal HIV-2 infection is suspected or confirmed, infant testing for HIV-2 can follow the same schedule (see Virologic Assays to Diagnose HIV-2 Infections below).

Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test; ZDV = zidovudine

Diagnostic Testing in Children With Postnatal HIV Exposure

Infants and children with potential HIV exposure after birth (e.g., HIV diagnosed during breastfeeding, premasticated feeding, sexual abuse, contaminated blood products, percutaneous exposure) require age-appropriate testing. Infants with perinatal HIV exposure who have these additional exposures after birth require HIV NAT testing for diagnosis. Infants aged <18 months who were not exposed to HIV at delivery and infants aged ≥18 months who have these potential exposures require HIV antigen/antibody testing, unless the time between potential exposure and testing indicates that the patient is in the window for seroconversion, when an HIV NAT is more sensitive. Repeat testing may still be required (see [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#) for additional information).

New HIV Diagnosis While Breastfeeding

Infants may be exposed to HIV through breastfeeding if acute or primary maternal HIV infection occurs or when pre-existing HIV infection was not diagnosed during pregnancy or postpartum.²³ Diagnosis of HIV during breastfeeding should prompt health care professionals to counsel to discontinue breastfeeding immediately to reduce the risk of postnatal transmission to the infant. In these situations, infant virologic diagnostic testing using an HIV NAT is recommended immediately and 14 to 21 days, 4 to 6 weeks, and 4 to 6 months after the infant's last exposure to breast milk (i.e., cessation of breastfeeding). A virologic test also should be performed at least 2 weeks after cessation of presumptive HIV therapy if provided (see [ARV Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Duplicate tests are not needed if some of these time points overlap with standard post-natal testing. For additional information, consult the [National Perinatal HIV Hotline](#) (1-888-448-8765).

Premastication

Receipt of solid food that has been premasticated or prewarmed in the mouth by a caregiver with HIV is associated with risk of HIV transmission.²⁴⁻³⁰ If this occurs in children with perinatal HIV exposure aged <18 months with prior negative virologic tests, it will be necessary for such children to undergo virologic diagnostic testing because they may have residual HIV antibodies from the antepartum period (see Special Situations below).

Additional Routes of HIV Transmission

Additional routes of HIV transmission in children include sexual abuse, receipt of contaminated blood products, and needlestick with contaminated needles. It may be difficult to obtain a history of HIV exposure. Therefore, age-appropriate HIV testing is recommended for infants and children with signs and/or symptoms of HIV infection, even in the absence of documented or suspected perinatal or non-perinatal HIV exposure. Acquisition of HIV in older children is possible through accidental needlestick injuries, sexual transmission, or injection drug use. Medical procedures performed in settings with inadequate infection control practices may pose a potential risk; although tattooing or

body piercing present a potential risk of HIV transmission, no reported cases of HIV transmission from these activities have been documented.³¹

Diagnostic Testing

Diagnosis of HIV-1 infection in infants and children with non-perinatal HIV exposure only or in children with perinatal HIV exposure who are aged ≥ 18 months relies primarily on HIV antibody and antigen/antibody tests.^{1,32} U.S. Food and Drug Administration (FDA)-approved diagnostic tests include the following:

- Antigen/antibody combination immunoassays, which detect HIV-1/2 antibodies and HIV-1 p24 antigen. These tests are recommended for initial testing to screen for established infection with HIV-1 or HIV-2 and for acute HIV-1 infection. However, p24 antigen from HIV-1 non-B strains, HIV-1 non-M strains, and HIV-2 strains may not be detected.³³ Recent data suggest that the use of immunoassays and rapid diagnostic test combination algorithms that have limited HIV antigen breadth may not be adequate for diagnosis of HIV infection in children following early treatment with ART.³⁴
- HIV-1/HIV-2 antibody differentiation immunoassay, which differentiates HIV-1 antibodies from HIV-2 antibodies. This immunoassay is recommended for supplemental testing.
- HIV-1 NAT. A NAT always is indicated as an additional test to diagnose acute HIV infection.

For information on diagnosis of HIV-2 infection, see Virologic Assays to Diagnose HIV-2 Infections below.

Special Situations

Late Seroreversion (Aged ≥ 18 Months)

Non-breastfed children with perinatal HIV exposure, no other HIV transmission risk factor, and no clinical or virologic laboratory evidence of HIV infection may have residual HIV antibodies from the antepartum period up to age 24 months. These children are called late seroreverters.³⁵⁻³⁸ In one study, 14% of children with HIV exposure who did not have HIV infection seroreverted after age 18 months.³⁸ More recent data from Thailand associated late seroreversion with the antenatal use of protease inhibitors in pregnant women with HIV. In this study, late seroreversion also was associated with the use of fourth-generation combination antigen/antibody immunoassays.³⁹ These children may have had positive immunoassay results, but supplemental antibody test results indicated indeterminate HIV status. In such cases, repeat antibody testing at a later date confirmed seroreversion. Due to the possibility of residual maternal HIV antibodies, virologic testing is necessary to definitively exclude or confirm HIV infection in children with perinatal HIV exposure who have a positive HIV antibody (or antigen/antibody) test at age ≥ 18 months. Virologic testing will distinguish late-seroreverting children who do not have HIV but have residual antibodies from children who have antibodies due to underlying HIV infection. Age-appropriate HIV testing also is recommended for infants and children with signs and/or symptoms of HIV, even in the absence of documented or suspected HIV exposure.

Postnatal HIV Infection in Children With Perinatal HIV Exposure and Prior Negative Virologic Test Results for Whom There Are Additional HIV Transmission Risks

In contrast to late seroreverters, in rare situations, postnatal HIV infections have been reported in children with HIV exposure who had prior negative HIV virologic test results. This occurs in children who acquire HIV through an additional risk factor after completion of testing.

Suspicion of HIV-2 or Non-Subtype B HIV-1 Infections With False-Negative Virologic Test Results

Children with non–subtype B HIV-1 and children with HIV-2 may have false-negative virologic tests but persistent positive immunoassay results.^{40–42} The diagnostic approach in these situations is discussed below in Virologic Assays to Diagnose Group M Non–Subtype B and Group O HIV-1 Infections and in Virologic Assays to Diagnose HIV-2 Infections.

Virologic Assays to Diagnose HIV in Infants Younger Than 18 Months With Perinatal HIV-1 Exposure

HIV RNA Assays

HIV quantitative RNA assays detect extracellular viral RNA in plasma. Their specificity has been shown to be 100% at birth and age 1 month, 3 months, and 6 months and is comparable to the specificity of HIV DNA PCR.¹⁹ Testing at birth will detect HIV RNA in infants who acquire HIV *in utero* and not in those who acquire HIV from exposure during delivery or immediately before delivery (i.e., during the intrapartum period). Studies have shown that HIV RNA assays identify 25% to 58% of infants with HIV infection from birth through the first week of life, 89% at age 1 month, and 90% to 100% by age 2 months to 3 months. These results are similar to the results of HIV DNA PCR for early diagnosis of HIV.³

The sensitivity of HIV RNA assays is affected by maternal antenatal ART or ARV drugs administered to the infant as prophylaxis or presumptive therapy.⁴³ In one study, the sensitivity of HIV RNA assays was not associated with the type of maternal ART or infant ARV prophylaxis, but HIV RNA levels at 1 month were significantly lower in infants with HIV who were receiving multidrug prophylaxis. In contrast, the median HIV RNA levels were high by age 3 months in both groups after stopping prophylaxis.¹⁹ Between 2010 and 2016, a significant decline in baseline viremia was noted in South Africa’s Early Infant Diagnosis program, with loss of detectability documented among some infants with HIV. This decline may have reflected the administration of various prophylactic ARV regimens during those years.⁴⁴ Further studies are necessary to evaluate the sensitivity of HIV RNA assays during receipt of multidrug ARV prophylaxis or presumptive HIV therapy in infants when maternal antenatal ART was received.

An HIV quantitative RNA assay can be used as a confirmatory test for infants who have an initial positive HIV DNA PCR test result. In addition to providing virologic confirmation of infection status, an HIV RNA measurement assesses baseline viral load. An HIV genotype can be performed on the same sample to guide initial ARV treatment in an infant with HIV.

An HIV qualitative RNA assay is an alternative diagnostic test that can be used for infant testing.¹⁶
₄₅₋₄₉

HIV DNA PCR and Related Assays

HIV DNA PCR is a sensitive technique that is used to detect intracellular HIV viral DNA in peripheral blood mononuclear cells. The specificity of the HIV DNA PCR is 99.8% at birth and 100% at age 1 month, 3 months, and 6 months. Studies have shown that HIV DNA PCR assays identify 20% to 55% of infants with HIV infection from birth through the first week of life, with the same caveat as for RNA testing—testing at birth detects only *in utero* HIV infection and not infection in those infants who acquire HIV during the intrapartum period. This percentage increases to >90% by age 2 weeks to 4 weeks and to 100% at age 3 months and 6 months.^{3, 16}

Two studies provided data on diagnostic testing at different time points in infants with confirmed HIV infection, including those who had negative test results at birth. One study noted that among 47 infants with HIV infection who had negative DNA PCR test results at birth, 68% were identified during the period of neonatal ARV prophylaxis at 4 to 6 weeks; by 3 months, all 47 infants were identified.¹⁸ Another study from Cape Town evaluated the sensitivity of HIV DNA assays within 8 days of life during and after initiating ART in infants with HIV. The infants had been exposed to ART *in utero* and ARV drugs for prophylaxis and treatment. In seven infants who achieved virologic suppression (defined as a continuous downward trend in plasma HIV RNA, with <100 copies/mL after 6 months), total HIV DNA continued to decay over 12 months. The authors noted that one infant had undetectable HIV DNA after 6 days on treatment, another had undetectable HIV DNA after 3 months, and a third had undetectable HIV DNA after 4 months, suggesting that rapid decline of HIV-1 RNA and DNA may complicate definitive diagnosis.⁵⁰ A data set of 38,043 infants from the Western Cape province of South Africa who were tested at a median age of 45 days showed that infants who received the World Health Organization Option B+ ARV regimen had fewer indeterminate DNA PCR results than infants who were receiving older ARV regimens.⁵¹ Another group of South African investigators reported similar findings in a study of a cohort of 5,743 neonates from Johannesburg who were exposed to HIV.⁵²

The AMPLICOR® HIV-1 DNA test has been used widely for diagnosis of HIV in infants perinatally exposed to HIV-1 infection since it was introduced in 1992. However, it is no longer commercially available in the United States. The sensitivity and specificity of noncommercial HIV-1 DNA tests that use individual laboratory reagents may differ from the sensitivity and specificity of an FDA-approved commercial test. These considerations underscore the importance of testing with HIV NATs at 4 months—well after neonatal ARV prophylaxis or presumptive HIV therapy has stopped.

Other Issues

Virologic Assays to Diagnose Group M Non-Subtype B and Group O HIV-1 Infections

Although HIV-1 Group M subtype B is the predominant viral subtype found in the United States, multiple subtypes and recombinant forms also are found in the United States.⁵³ Data from the CDC National HIV Surveillance System (NHSS) showed that the number of non-U.S. born children with HIV **living in the United States** has exceeded the number of U.S.-born children with HIV since 2011, with 65.5% of non-U.S. born children with HIV born in sub-Saharan Africa and 14.3% in Eastern Europe.⁵⁴ In an evaluation of infants who received a perinatal HIV infection diagnosis in New York

State in 2001 and 2002, 16.7% of infants had acquired a non–subtype B strain of HIV compared with 4.4% of infants born in 1998 and 1999.⁵⁵ Among a group of 40 children who visited a pediatric HIV clinic in Rhode Island between 1991 and 2012, 14 (35%) acquired HIV with non-B HIV-1 subtypes. All 14 children were either born outside the United States or their parents were of foreign origin.⁵⁶ In an analysis of 1,277 unique sequences collected in Rhode Island from 2004 to 2011, 8.3% were non-B subtypes (including recombinant forms). Twenty-two percent of participants with non-B subtypes formed transmission clusters, including individuals with perinatally acquired infection.⁵⁷ In an analysis of 3,895 HIV-1 sequences that were collected between July 2011 and June 2012 in the United States, 5.3% were determined to be non-B subtypes (including recombinant forms).

Evolving immigration patterns may be contributing to local and regional increases in HIV-1 subtype diversity. Non–subtype B viruses predominate in other parts of the world, such as subtype C in regions of Africa and India and subtype CRF01 in much of Southeast Asia. Group O HIV strains are seen in West-Central Africa.⁵⁸ Non–subtype B and Group O strains may be seen in countries with links to these geographical regions.^{59–63} The geographical distribution of HIV groups is available at the [HIV Sequence Database](#).

Current HIV RNA PCR assays and the qualitative diagnostic RNA assays are better at detecting non–subtype B HIV infection and the less-common Group O strains than older RNA assays^{5–10, 49} (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)). The increased sensitivity is due to amplification of more than one highly conserved region of the HIV genome. HIV DNA assays, though generally less sensitive, may be more sensitive in detecting HIV infection when the infant is receiving ART because identification is based on detection of cell-associated DNA in whole blood or dried blood spots and does not rely on active viral replication.^{16, 64}

A qualitative RNA assay, a quantitative RNA assay, or a total DNA/RNA (total nucleic acid) test should be used for infant testing in addition to a DNA PCR assay when evaluating an infant exposed to HIV infection linked to an area that is endemic for non–subtype B HIV or Group O strains, such as Africa or Southeast Asia. **These additional tests are also indicated** when initial testing is negative using an HIV DNA PCR test and non–subtype B or Group O perinatal exposure is suspected. Two negative HIV antibody test results obtained at age ≥ 6 months provide further evidence to rule out HIV infection definitively. Clinicians should consult with an expert in pediatric HIV infection; state or local public health departments or CDC may be able to assist in obtaining referrals for diagnostic HIV testing.

Chimeric Antigen Receptor T-Cell and Lentiviral-Based Gene Therapy May Give Rise to False-Positive HIV NAT Results

Chimeric antigen receptor (CAR) T-cell immunotherapy is a major advancement in cancer therapeutics, including for pediatric B-cell acute lymphoblastic leukemia. Reprogramming of T cells is achieved by using gammaretroviral or lentiviral vectors. Recent reports indicate that these vectors may interfere with long terminal repeat genomes in HIV NAT results and, thus, produce false-positive results. As CAR T-cell therapy becomes more widely available for multiple indications, it will be important for clinicians to recognize that routine HIV-1 NAT results may give rise to false results. In addition, lentiviral vector–based gene therapy as treatment for severe combined immunodeficiency can give rise to false-positive HIV NAT results. Laboratories should, therefore, have appropriate alternate HIV-1 NAT resulting platforms made available for this emerging patient population.^{65–69}

Virologic Assays to Diagnose HIV-2 Infections

HIV-2 infection is endemic in Angola; Mozambique; West African countries, including Benin, Burkina Faso, Cape Verde, the Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome, Senegal, Sierra Leone, and Togo; and parts of India.⁷⁰⁻⁷² HIV-2 infection also is well documented in France and Portugal, which have large numbers of immigrants from these regions.^{73, 74} HIV-1 and HIV-2 coinfection may occur, but this rarely is described outside areas where HIV-2 is endemic. HIV-2 is rare in the United States. Although accurately diagnosing HIV-2 can be difficult, it is clinically important because HIV-2 strains are resistant to several ARV drugs that were developed to suppress HIV-1.⁷⁵⁻⁷⁷ (See [HIV-2 Infection and Pregnancy](#).)

HIV-2 should be suspected if HIV infection is linked to an area that is endemic for HIV-2 infection or if HIV test results are suggestive of HIV-2 infection (i.e., positive initial HIV 1/2 immunoassay test result and HIV-1 RNA viral loads that are at or below the limit of detection in the absence of treatment). The current recommendation is to use an HIV-1/HIV-2 antibody differentiation immunoassay for supplemental testing.¹

Between 2010 and 2017, an increase in the number of HIV-1/HIV-2 differentiation test results was reported to the CDC's NHSS. More than 99.9% of all HIV infections identified in the United States were categorized as HIV-1, and the number of HIV-2 diagnoses (mono-infection or dual-infection) remained extremely low (<0.03% of all HIV infections).⁷⁸

Infant testing with HIV-2-specific DNA PCR tests should be performed at time points similar to those used for HIV-1 testing when evaluating an infant exposed to known or suspected HIV-2 infection. HIV-2 DNA PCR testing can be arranged by the HIV surveillance program of the state or local health department through their public health laboratory, or the CDC, because this assay is not commercially available.^{79, 80} Clinicians should consult with an expert in pediatric HIV infection when caring for infants with suspected or known exposure to HIV-2.^{70, 81}

The diagnosis of HIV-2 in children with only non-perinatal exposure or in children with perinatal exposure aged ≥ 18 months should also follow the Centers for Disease Control and Prevention and Association of Public Health Laboratories 2014 [laboratory testing guidelines](#), which recommend using an HIV-1/HIV-2 antibody differentiation immunoassay that distinguishes between HIV-1 and HIV-2 antibodies for supplemental testing. All HIV-2 cases should be reported to the HIV surveillance program of the state or local health department; additional HIV-2 DNA PCR testing can be arranged by a local public health laboratory or by CDC if an HIV-1/HIV-2 antibody differentiation immunoassay is inconclusive. HIV-2 DNA PCR testing may be necessary for definitive diagnosis, although this assay is not commercially available.^{79, 80}

References

1. Branson BM, Owen, MS, Weslowski, LG. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014. Available at: <https://dx.doi.org/10.15620/cdc.23447>.
2. Donovan M, Palumbo P. Diagnosis of HIV: challenges and strategies for HIV prevention and detection among pregnant women and their infants. *Clin Perinatol.* 2010;37(4):751-63, viii. Available at: <https://pubmed.ncbi.nlm.nih.gov/21078448>.
3. Chadwick EG, Ezeanolue EE, Committee on Pediatric AIDS. Evaluation and management of the infant exposed to HIV in the United States. *Pediatrics.* 2020;146(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/33077537>.
4. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. *Lancet Infect Dis.* 2019;19(2):143-155. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30509777>.
5. Church D, Gregson D, Lloyd T, et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. *J Clin Microbiol.* 2011;49(1):118-24. Available at: <https://pubmed.ncbi.nlm.nih.gov/21084515>.
6. Cobb BR, Vaks JE, Do T, et al. Evolution in the sensitivity of quantitative HIV-1 viral load tests. *J Clin Virol.* 2011;52 Suppl 1S77-82. Available at: <https://pubmed.ncbi.nlm.nih.gov/22036041>.
7. Katsoulidou A, Rokka C, Issaris C, et al. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. *Virol J.* 2011;810. Available at: <https://pubmed.ncbi.nlm.nih.gov/21219667>.
8. Gueudin M, Leoz M, Lemee V, et al. A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection. *J Clin Microbiol.* 2012;50(3):831-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/22170927>.
9. Xu S, Song A, Nie J, et al. Comparison between the automated Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 assay and its version 1 and Nuclisens HIV-1 EasyQ version 2.0 assays when measuring diverse HIV-1 genotypes in China. *J Clin Virol.* 2012;53(1):33-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22051503>.
10. Muenchhoff M, Madurai S, Hempenstall AJ, et al. Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. *PLoS One.* 2014;9(8):e103983. Available at: <https://pubmed.ncbi.nlm.nih.gov/25157919>.
11. Tamhane M, Gautney B, Shiu C, et al. Analysis of the optimal cut-point for HIV-p24 antigen testing to diagnose HIV infection in HIV-exposed children from resource-

- constrained settings. *J Clin Virol.* 2011;50(4):338-41. Available at: <https://pubmed.ncbi.nlm.nih.gov/21330193>.
12. Wessman MJ, Theilgaard Z, Katzenstein TL. Determination of HIV status of infants born to HIV-infected mothers: a review of the diagnostic methods with special focus on the applicability of p24 antigen testing in developing countries. *Scand J Infect Dis.* 2012;44(3):209-15. Available at: <https://pubmed.ncbi.nlm.nih.gov/22074445>.
 13. Bhowan K, Sherman GG. Performance of the first fourth-generation rapid human immunodeficiency virus test in children. *Pediatr Infect Dis J.* 2013;32(5):486-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/23190776>.
 14. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2019. Available at: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf>
 15. Jourdain G, Mary JY, Coeur SL, et al. Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. *J Infect Dis.* 2007;196(11):1629-36. Available at: <https://pubmed.ncbi.nlm.nih.gov/18008246>.
 16. Lilian RR, Kalk E, Bhowan K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. *J Clin Microbiol.* 2012;50(7):2373-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22518871>.
 17. Lilian RR, Kalk E, Technau KG, et al. Birth diagnosis of HIV infection on infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. *Pediatr Infect Dis J.* 2013;32(10):1080-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/23574775>.
 18. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med.* 2012;366(25):2368-79. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
 19. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. *J Pediatr.* 2012;160(1):60-6 e1. Available at: <https://pubmed.ncbi.nlm.nih.gov/21868029>.
 20. Kuhn L, Schramm DB, Shiao S, et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. *AIDS.* 2015;29(9):1053-60. Available at: <https://pubmed.ncbi.nlm.nih.gov/25870988>.
 21. Payne H, Mkhize N, Otwombe K, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the children with HIV early antiretroviral therapy (CHER) trial: a retrospective analysis. *Lancet Infect Dis.* 2015;15(7):803-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/26043884>.

22. Levison J, McKinney J, Duque A, et al. Breastfeeding among people with HIV in North America: a multisite study. *Clin Infect Dis*. 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/37078712/>.
23. Swain CA, Kaufman S, Miranda W, et al. Postpartum mother-to-child transmission of HIV in a breastfeeding infant. *Pediatrics*. 2022;149(2). Available at: <https://pubmed.ncbi.nlm.nih.gov/35043205/>.
24. Centers for Disease Control and Prevention. Premastication of food by caregivers of HIV-exposed children--nine U.S. sites, 2009–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(9):273-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/21389930/>.
25. Gaur AH, Freimanis-Hance L, Dominguez K, et al. Knowledge and practice of prechewing/prewarming food by HIV-infected women. *Pediatrics*. 2011;127(5):e1206-11. Available at: <https://pubmed.ncbi.nlm.nih.gov/21482608/>.
26. Hafeez S, Salami O, Alvarado M, et al. Infant feeding practice of premastication: an anonymous survey among human immunodeficiency virus-infected mothers. *Arch Pediatr Adolesc Med*. 2011;165(1):92-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/21199989/>.
27. Maritz ER, Kidd M and Cotton MF Premasticating food for weaning African infants: a possible vehicle for transmission of HIV. *Pediatrics*. 2011;128(3):e579-90. Available at: <https://pubmed.ncbi.nlm.nih.gov/21873699/>.
28. Ivy W, 3rd, Dominguez KL, Rakhmanina NY, et al. Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations. *J Acquir Immune Defic Syndr*. 2012;59(2):207-12. Available at: <https://pubmed.ncbi.nlm.nih.gov/22027873/>.
29. Gaur AH, Cohen RA, Read JS, et al. Prechewing and prewarming food for HIV-exposed children: a prospective cohort experience from Latin America. *AIDS Patient Care STDS*. 2013;27(3):142-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/23477456/>.
30. Nash SH, Rutledge M, Frenkel LM, et al. HIV transmission through premastication. *Pediatrics*. 2022;150(4). Available at: <https://pubmed.ncbi.nlm.nih.gov/36052601/>.
31. Centers for Disease Control and Prevention. HIV transmission. 2018.
32. Alexander TS. Human immunodeficiency virus diagnostic testing: 30 years of evolution. *Clin Vaccine Immunol*. 2016;23(4):249-53. Available at: <https://pubmed.ncbi.nlm.nih.gov/26936099/>.
33. Ly TD, Plantier JC, Leballais L, et al. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24Ag according to genotype could compromise the diagnosis of early HIV infection. *J Clin Virol*. 2012;55(2):121-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22795598/>.

34. Puthanakit T, Ananworanich J, Akapirat S, et al. Pattern and frequency of seroreactivity to routinely used serologic tests in early-treated infants with HIV. *J Acquir Immune Defic Syndr*. 2020;83(3):260-266. Available at: <https://pubmed.ncbi.nlm.nih.gov/31917751>.
35. Sohn AH, Thanh TC, Thinh le Q, et al. Failure of human immunodeficiency virus enzyme immunoassay to rule out infection among polymerase chain reaction-negative Vietnamese infants at 12 months of age. *Pediatr Infect Dis J*. 2009;28(4):273-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/19289981>.
36. Gulia J, Kumwenda N, Li Q, et al. HIV seroreversion time in HIV-1-uninfected children born to HIV-1-infected mothers in Malawi. *J Acquir Immune Defic Syndr*. 2007;46(3):332-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/17786126>.
37. Alcantara KC, Pereira GA, Albuquerque M, et al. Seroreversion in children born to HIV-positive and AIDS mothers from Central West Brazil. *Trans R Soc Trop Med Hyg*. 2009;103(6):620-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/19339030>.
38. Gutierrez M, Ludwig DA, Khan SS, et al. Has highly active antiretroviral therapy increased the time to seroreversion in HIV exposed but uninfected children? *Clin Infect Dis*. 2012;55(9):1255-61. Available at: <https://pubmed.ncbi.nlm.nih.gov/22851494>.
39. Chatpornvorarux S, Maleesatharn A, Rungmaitree S, et al. Delayed seroreversion in HIV-exposed uninfected infants. *Pediatr Infect Dis J*. 2019;38(1):65-69. Available at: <https://pubmed.ncbi.nlm.nih.gov/30239474>.
40. Kline NE, Schwarzwald H, Kline MW. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. *Pediatr Infect Dis J*. 2002;21(9):885-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/12380591>.
41. Zaman MM, Recco RA, Haag R. Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn infants. *Clin Infect Dis*. 2002;34(3):417-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/11774090>.
42. Obaro SK, Losikoff P, Harwell J, et al. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. *Pediatr Infect Dis J*. 2005;24(2):183-4. Available at: <https://pubmed.ncbi.nlm.nih.gov/15702052>.
43. Saitoh A, Hsia K, Fenton T, et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. *J Infect Dis*. 2002;185(10):1409-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/11992275>.
44. Mazanderani AH, Moyo F, Kufa T, et al. Brief report: declining baseline viremia and escalating discordant HIV-1 confirmatory results within South Africa's Early Infant Diagnosis program, 2010–2016. *J Acquir Immune Defic Syndr*. 2018;77(2):212-216. Available at: <https://pubmed.ncbi.nlm.nih.gov/29084045>.

45. Food and Drug Administration. APTIMA HIV-1 RNA qualitative assay. 2019. Available at:
<https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm149922.htm>.
46. Pierce VM, Neide B, Hodinka RL. Evaluation of the Gen-Probe Aptima HIV-1 RNA qualitative assay as an alternative to Western blot analysis for confirmation of HIV infection. *J Clin Microbiol.* 2011;49(4):1642-5. Available at:
<https://pubmed.ncbi.nlm.nih.gov/21346052>.
47. Fiscus SA, McMillion T, Nelson JA, et al. Validation of the Gen-Probe Aptima qualitative HIV-1 RNA assay for diagnosis of human immunodeficiency virus infection in infants. *J Clin Microbiol.* 2013;51(12):4137-40. Available at:
<https://pubmed.ncbi.nlm.nih.gov/24088864>.
48. Nelson JA, Hawkins JT, Schanz M, et al. Comparison of the Gen-Probe Aptima HIV-1 and Abbott HIV-1 qualitative assays with the Roche Amplicor HIV-1 DNA assay for early infant diagnosis using dried blood spots. *J Clin Virol.* 2014;60(4):418-21. Available at: <https://pubmed.ncbi.nlm.nih.gov/24929752>.
49. Hans L, Allmen NV, Edelmann A, et al. Early diagnosis of HIV-1 and HIV-2 using COBAS HIV-1/HIV-2 qualitative test: a novel qualitative nucleic acid amplification test for plasma, serum, and dried blood spot specimens. *J Acquir Immune Defic Syndr.* 2021;87(5):1187-1195. Available at: <https://pubmed.ncbi.nlm.nih.gov/33883470>.
50. Veldsman KA, Maritz J, Isaacs S, et al. Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge. *AIDS.* 2018;32(5):629-634. Available at: <https://pubmed.ncbi.nlm.nih.gov/29334551>.
51. Maritz J, Maharaj JN, Cotton MF, et al. Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. *J Clin Virol.* 2017;95:86-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/28898704>.
52. Technau KG, Mazanderani AH, Kuhn L, et al. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort. *J Int AIDS Soc.* 2017;20(Suppl 6):21761. Available at: <https://pubmed.ncbi.nlm.nih.gov/28872276>.
53. Pyne MT, Hackett J, Jr., Holzmayr V, et al. Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. *J Clin Microbiol.* 2013;51(8):2662-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/23761148>.
54. Nesheim SR, Linley L, Gray KM, et al. Country of birth of children with diagnosed HIV infection in the United States, 2008–2014. *J Acquir Immune Defic Syndr.* 2018;77(1):23-30. Available at: <https://pubmed.ncbi.nlm.nih.gov/29040167>.

55. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. *J Acquir Immune Defic Syndr*. 2006;42(5):614-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/16868498>.
56. Rogo T, DeLong AK, Chan P, et al. Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island. *Clin Infect Dis*. 2015;60(9):1426-35. Available at: <https://pubmed.ncbi.nlm.nih.gov/25637585>.
57. Chan PA, Reitsma MB, DeLong A, et al. Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island. *Infect Genet Evol*. 2014;28:358-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/24721515>.
58. Bush S, Tebit DM. HIV-1 group O origin, evolution, pathogenesis, and treatment: unraveling the complexity of an outlier 25 years later. *AIDS Rev*. 2015;17(3):147-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/26450803>.
59. Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, et al. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. *AIDS Res Hum Retroviruses*. 2009;25(6):625-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/19500016>.
60. Deshpande A, Jauvin V, Pinson P, et al. Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. *AIDS Res Hum Retroviruses*. 2009;25(6):633-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/19534630>.
61. Chaix ML, Seng R, Frange P, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. *Clin Infect Dis*. 2013;56(6):880-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/23223603>.
62. Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000–2007. *AIDS*. 2011;25(5):679-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/21297424>.
63. Dauwe K, Mortier V, Schauvliege M, et al. Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate. *BMC Infect Dis*. 2015;15:524. Available at: <https://pubmed.ncbi.nlm.nih.gov/26572861>.
64. Mitchell C, Dross S, Beck IA, et al. Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. *Clin Infect Dis*. 2014;58(8):1190-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/24501389>.
65. Hauser JR, Hong H, Babady NE, et al. False-positive results for human immunodeficiency virus type 1 nucleic acid amplification testing in chimeric antigen

- receptor T cell therapy. *J Clin Microbiol*. 2019;58(1):e01420-19. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31694968>.
66. Laetsch TW, Maude SL, Milone MC, et al. False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. *Blood*. 2018;131(23):2596-2598. Available at: <https://pubmed.ncbi.nlm.nih.gov/29669777>.
67. Ariza-Heredia EJ, Granwehr BP, Viola GM, et al. False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. *Diagn Microbiol Infect Dis*. 2017;88(4):305-307. Available at: <https://pubmed.ncbi.nlm.nih.gov/28610774>.
68. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. *Leukemia*. 2018;32(7):1529-1541. Available at: <https://pubmed.ncbi.nlm.nih.gov/29654266>.
69. De Ravin SS, Gray JT, Throm RE, et al. False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. *Mol Ther*. 2014;22(2):244-245. Available at: <https://pubmed.ncbi.nlm.nih.gov/24487563>.
70. Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000–2008. *Clin Infect Dis*. 2010;51(11):1334-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/21039219>.
71. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. *Clin Infect Dis*. 2011;52(6):780-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21367732>.
72. Prince PD, Matser A, van Tienen C, et al. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. *AIDS*. 2014;28(4):549-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/23921613>.
73. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003–2006. *AIDS*. 2007;21(17):2351-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/18090288>.
74. Thiebaut R, Matheron S, Taieb A, et al. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. *AIDS*. 2011;25(6):865-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21358376>.
75. Menendez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. *Antiviral Res*. 2014;10270-86. Available at: <https://pubmed.ncbi.nlm.nih.gov/24345729>.
76. Tchounga BK, Inwoley A, Coffie PA, et al. Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African database to evaluate AIDS collaboration. *J Int AIDS Soc*. 2014;1719064. Available at: <https://pubmed.ncbi.nlm.nih.gov/25128907>.

77. Balestre E, Ekouevi DK, Tchounga B, et al. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort. *J Int AIDS Soc.* 2016;19(1):20044. Available at: <https://pubmed.ncbi.nlm.nih.gov/26861115>.
78. Peruski AH, Wesolowski LG, Delaney KP, et al. Trends in HIV-2 diagnoses and use of the HIV-1/HIV-2 differentiation test - United States, 2010–2017. *MMWR Morb Mortal Wkly Rep.* 2020;69(3):63-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/31971928>.
79. Shanmugam V, Switzer WM, Nkengasong JN, et al. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. *J Acquir Immune Defic Syndr.* 2000;24(3):257-63. Available at: <https://pubmed.ncbi.nlm.nih.gov/10969350>.
80. Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. *J Clin Microbiol.* 2011;49(10):3491-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21813718>.
81. Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. *Clin Infect Dis.* 2010;51(7):833-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/20804413>.

Clinical and Laboratory Monitoring of Pediatric HIV Infection

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">Absolute CD4 T lymphocyte (CD4) cell count and plasma HIV RNA (viral load) should be measured at the time of HIV diagnosis, and, if a child is not started on antiretroviral therapy (ART) after diagnosis, this monitoring should be repeated at least every 3 to 4 months thereafter (AIII).Absolute CD4 count is recommended for monitoring immune status in children with HIV of all ages, with CD4 percentage as an alternative for children aged <5 years (AII).Additional CD4 count and plasma viral load monitoring should be performed to evaluate children with suspected clinical, immunologic, or virologic deterioration or to confirm an abnormal value (AIII). CD4 count can be monitored less frequently (every 6–12 months) in children and adolescents who are adherent to therapy, have sustained virologic suppression and CD4 count values that are well above the threshold for opportunistic infection risk, and have stable clinical status (AII). Viral load measurement every 3 to 4 months is generally recommended to monitor ART adherence (AIII).Antiretroviral (ARV) drug-resistance testing is recommended at the time of HIV diagnosis, before initiation of therapy in all ART-naïve patients, and before switching regimens in patients with treatment failure (AII). Genotypic resistance testing is preferred for this purpose (AIII). See Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines.Review the history of all previously used ARVs and available resistance test results when making decisions about the choice of new ARVs because mutations may not be detected once the prior drugs have been discontinued (AII).Phenotypic resistance testing should be considered (usually in addition to genotypic resistance testing) for patients with known or suspected complex drug resistance mutation patterns, which generally arise after a patient has experienced virologic failure on multiple ARV regimens (CIII).Viral co-receptor tropism assays are recommended whenever a CCR5 antagonist is being considered for treatment (AI*). The use of tropism assays also should be considered for patients who demonstrate virologic failure while receiving therapy that contains a CCR5 antagonist (AI*). See Co-Receptor Tropism Assays in the Adult and Adolescent Antiretroviral Guidelines.After initiation of ART or after a change in ARV regimen, children should be evaluated for clinical adverse effects and should receive support for treatment adherence within 1 week to 2 weeks; laboratory testing for toxicity and viral load response is recommended at 2 to 4 weeks after treatment initiation or change in ARV regimen and every 3 to 4 months thereafter (see Table 6 below) (AIII).Children on ART should be monitored for therapy adherence, effectiveness, and toxicities routinely (every 3–4 months) (see Table 6 below) (AI*). See the sections on Adherence to Antiretroviral Therapy in Children and Adolescents with HIV and Management of Medication Toxicity or Intolerance. |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion*

[†]*Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents*

Laboratory monitoring of children with HIV poses unique and challenging issues. In particular, the normal ranges of CD4 T lymphocyte (CD4) cell counts and plasma HIV RNA concentrations (viral loads) can vary significantly by age. The CD4 counts and viral load values that predict the risk of disease progression also change as a child ages. This section will address immunologic, virologic, general laboratory, and clinical monitoring of children with HIV, with information that is relevant to both those who have recently received an HIV diagnosis and those who are receiving antiretroviral therapy (ART).

Clinical and Laboratory Monitoring of Children with HIV

Initial Evaluation of Children Who Recently Received an HIV Diagnosis, or Are Entering or Transferring to a New Care Setting

Children who have recently received an HIV diagnosis should have their CD4 counts and plasma viral loads measured. Children with HIV should have a complete, age-appropriate medical history and physical examination (see [Table 6](#) below). Their growth and development should be evaluated for signs of HIV-associated abnormalities. Testing also should be performed to assess for HIV-associated conditions, including the following:

- Anemia, leukopenia, thrombocytopenia
- Hypoalbuminemia
- Nephropathy (urinalysis)
- **Renal insufficiency (creatinine)**
- Hyperglycemia
- Hepatic **transaminitis**

Baseline screening tests for coinfections and opportunistic infections (OIs), including tests for the following, should be performed:

- **Tuberculosis**, with tuberculin skin test if aged <2 years, or an interferon gamma release assay if aged ≥2 years
- **Hepatitis B virus (HBV)**, with HBV surface antibody, HBV surface antigen, and HBV core antibody tests
- **Hepatitis C virus (HCV)**, with HCV nucleic acid (HCV RNA) testing if aged <18 months or HCV antibody if aged ≥18 months
- **Cytomegalovirus (CMV)**, with CMV antibody tests if aged >12 months

Monitoring for OIs should follow the guidelines that are appropriate for the child's exposure history and clinical setting (see the [Pediatric Opportunistic Infection Guidelines](#)). Children with HIV who are relocating from outside the United States may benefit from additional evaluations—such as gastrointestinal parasites, lead level, and thyroid function. See [Centers for Disease Control and Prevention International Adoption](#).¹

Laboratory confirmation of HIV infection should be obtained when available documentation is incomplete (see [Diagnosis of HIV Infection in Infants and Children](#)). Genotypic resistance testing should be performed, even if ART is not initiated immediately. In addition, a full antiretroviral (ARV) drug history should be obtained; this history should include any exposure to

ARV drugs for the prevention of perinatal HIV transmission (see [Drug-Resistance Testing](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)). HLA-B*5701 testing should be conducted on initial laboratory screening to allow for possible abacavir (ABC) initiation, and an alternative ARV drug should be used if the HLA-B*5701 test result is positive² (see the [Abacavir](#) section in [Appendix A. Pediatric Antiretroviral Drug Information](#)).

Before initiating therapy or making changes to a patient's ARV regimen, a clinician and multidisciplinary team members (where available) should assess potential barriers to adherence and discuss the importance of adherence with the patient and/or their caregiver (see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)).

If a child does not initiate ART after receiving an HIV diagnosis, the child's CD4 count and plasma viral load should be monitored at least every 3 to 4 months.

Evaluation at Initiation of Antiretroviral Therapy

At the time of ART initiation, a physical examination should be performed, including assessment of weight and height, [sexual maturity rating](#), and baseline labs for CD4 count, and plasma viral load should be obtained to monitor ART response (see [Table 6](#) below). To set the baseline for monitoring ART toxicity (see [Management of Medication Toxicity or Intolerance](#)), a complete blood count, urinalysis, and serum chemistry panel (including levels of electrolytes, creatinine, glucose, and hepatic transaminases) should be performed (see [Table 6](#) below). The levels of serum lipids (cholesterol and triglycerides) also should be measured. For information about the adverse effects (AEs) associated with a specific ARV drug, see [Appendix A. Pediatric Antiretroviral Drug Information](#) for complete information on each drug. Tables 17a–17k in [Management of Medication Toxicity or Intolerance](#) provide information about specific toxicities associated with ARV drugs (e.g., [osteopenia and osteoporosis](#), [lipodystrophies and weight gain](#), [nephrotoxic effects](#)) and include guidance for prevention, monitoring, and management.

Clinical and Laboratory Monitoring After Initiating or Changing an Antiretroviral Regimen

Children who start ART or who change to a new regimen should be monitored to assess the effectiveness, tolerability, and AEs of the regimen and to evaluate medication adherence. Clinicians and multidisciplinary teams should schedule frequent clinical in-person and/or telemedicine visits to monitor patients closely during the first few months after initiating a new ARV regimen. The first few weeks of ART can be particularly difficult for children and their caregivers; they must adjust their schedules to allow consistent and routine administration of medication doses. Children also may experience the AEs of medications, and both children and their caregivers need assistance to determine whether the effects are temporary and tolerable or more serious or long term, requiring a clinical visit. It is critical that providers communicate with caregivers and children in a supportive, nonjudgmental manner and use plain language. This approach promotes interactive reporting and ensures that providers can have a productive dialogue with both children and their caregivers, particularly in situations where medication adherence is reported to be inconsistent.

Telemedicine visits and telehealth communication platforms are particularly relevant to the care of adolescent patients based on their technology access and habits.^{3,4} Additional check-ins via telephone and/or telehealth (emails, text messaging, app-based communications) may support adherence and early identification of medication side effects. The continuity of patient and caregiver interactions is an opportunity for clinicians and the multidisciplinary team to provide support and discuss adherence with patients and their caregivers.

A systematic review of randomized controlled trials from the last 10 years that used a telemedicine approach as a study intervention or assessed telemedicine as a subspecialty of pediatric care found that telemedicine services for the general public and pediatric care are comparable to or better than in-person services.⁵ Use of telemedicine as remote, technology-based access to clinical services in HIV care is growing and has been shown to achieve similar outcomes as those associated with in-person care.⁶ People with HIV on ART achieve similar clinical responses to therapy, adherence to treatment, quality-of-life scores, and psychological and emotional status, whether treated through telemedicine or in person.⁷⁻⁹

When selecting the format for clinical follow-up, it is important to recognize differences and similarities between in-person and telemedicine visits (see [Table 4](#) below). The benefits of telemedicine visits include patient and caregiver convenience, lack of travel, flexibility, and ability to visualize ART handling/swallowing and conduct directly observed therapy in the home setting. Telemedicine visits, however, require technological access and capacity and limit the provider's ability to conduct physical examinations and obtain laboratory testing on site,⁶⁻⁸ as well as to perform periodic measurements of body weight, which are important for dose modification in rapidly growing infants, and to monitor for excessive weight gain as a possible AE of some ARVs. Cooperative children can be weighed and have their height measured at home if a scale and measuring tape are available, with simple instructions for continuity, or directly observed during a synchronous visit or obtained from a recent pediatric or other specialty in-office visit.¹⁰ Additionally, providers need to arrange and coordinate access to the laboratory testing and be familiar with state and local requirements for carrying out, documenting, and billing telemedicine visits. Although both in-person and telemedicine visits involve considerations for stigma, privacy, and confidentiality, these considerations differ between health care and home/community-based settings. For example, the caregiver who has not disclosed the HIV and ART status of the child at home might prefer in-person visits at the clinic or specific hours and/or alternative locations for a telemedicine visit.

Table 4. Characteristics and Requirements for In-Person Clinic Visits vs. Telemedicine Visits

| | In-Person Visits | Telemedicine Visits |
|--|------------------|---------------------|
| Patient/caregiver convenience | | ✓ |
| Flexibility (time and locations) of appointments | | ✓ |
| Confidentiality concerns | ✓ | ✓ |
| Directly observed therapy in home settings | | ✓ |
| Physical assessment (e.g., skin rashes) | ✓ | ✓ |
| Physical exam, including weight and height | ✓ | ✓ ^a |
| Adherence support and counseling | ✓ | ✓ |
| Mental health assessment and counseling | ✓ | ✓ |
| Multidisciplinary support (assessment and coordination of nutritional and social services) | ✓ | ✓ |
| Laboratory testing on site | ✓ | |
| Travel to clinic | ✓ | |

Table 4. Characteristics and Requirements for In-Person Clinic Visits vs. Telemedicine Visits

| | | |
|---|---|---|
| Technology requirements (internet access, equipment, skills) | | ✓ |
| Legal and administrative guidelines for visit documentation and billing | ✓ | ✓ |

^a Cooperative children can be weighed and have their height measured at home if a scale and measuring tape are available, with simple instructions for continuity, or directly observed during a synchronous visit or obtained from a recent pediatric or other specialty in-office visit.

Within 2 Weeks of Initiating Antiretroviral Therapy

Within 2 weeks of initiating ART, children should be evaluated either in person, through telemedicine, or by telephone. During this evaluation, clinicians should identify clinical AEs and provide support for adherence. Many clinicians plan additional contacts (in person, through telemedicine, by telephone, or via email/texts/apps) with children and caregivers to support adherence during the first few weeks of therapy.

Two to 4 Weeks After Initiating Antiretroviral Therapy

Most experts recommend performing laboratory testing at 2 to 4 weeks (but no later than 8 weeks) after initiating ART to assess virologic response and laboratory toxicities, although this recommendation is based on limited data. The laboratory chemistry tests that a patient requires will depend on the ARV regimen that the patient is receiving (see [Table 6](#) below). Plasma viral load monitoring is important as a marker of response to ART because a decline in viral load suggests that the patient is adherent to the regimen, that the appropriate doses are being administered, and that the virus is susceptible to the drugs in the regimen. Some experts favor measuring viral load at 2 weeks to ensure that viral load is declining. A significant decrease in viral load should be observed 4 to 8 weeks after initiation of ART.

Clinical and Laboratory Monitoring for Children Who Are Stable on Long-Term Antiretroviral Therapy

After the initial phase of ART initiation (1–3 months), clinicians should assess a patient’s adherence to the regimen and the regimen’s effectiveness (as measured by CD4 count and plasma viral load) every 3 to 4 months. Additionally, clinicians should review a patient’s history of drug toxicities and evaluate each patient for any new AEs using physical examinations and the relevant laboratory tests. Generally, if laboratory evidence of toxicity is identified, testing should be performed more frequently until the toxicity resolves, but specific management is guided by the degree of toxicity and ARV regimen. Tables 17a–17k in [Management of Medication Toxicity or Intolerance](#) provide information about specific toxicities associated with ARV drugs.

[Table 6](#) below provides one proposed general monitoring schedule, which should be adjusted based on the specific ARV regimen that a child is receiving.

A patient’s baseline CD4 count affects how rapidly CD4 count improves after ART initiation; children with very low CD4 counts may take longer than 1 year to achieve their highest values after viral load suppression.¹¹ Studies that have critically evaluated the frequency of laboratory monitoring in both adults and children, particularly CD4 count and plasma viral load, support less frequent monitoring in stable patients who have been consistently virologically suppressed for ≥1 year.^{12–18}

The [Adult and Adolescent Antiretroviral Guidelines—Laboratory Testing](#) currently supports performing plasma viral load testing every 6 months for individuals who have both—

- Consistent virologic suppression \geq 2 years *and*
- CD4 counts that are consistently >300 cells/mm³.

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV finds value in continuing to perform viral load testing every 3 to 4 months to provide enhanced monitoring of adherence or disease progression among children and adolescents. Some experts monitor CD4 count less frequently (e.g., every 6–12 months) in children and adolescents who are adherent to therapy, who have CD4 count values well above the threshold for OI risk, and who have had sustained virologic suppression and stable clinical status for more than 2 years.¹⁹ Furthermore, some experts monitor viral load more often (with each injection) in adolescents receiving injectable cabotegravir and rilpivirine.²⁰

Testing at the Time of Switching Antiretroviral Regimens

When a patient switches regimens to simplify ART, clinicians should obtain the appropriate laboratory test results at baseline for the toxicity profile of the new regimen. Follow-up should include a measurement of plasma viral load at 4 weeks (and not >8 weeks) after the switch to ensure that the new regimen is effective. If the regimen is switched because the regimen is failing (see [Recognizing and Managing Antiretroviral Treatment Failure](#)), resistance testing should be performed while a patient is still receiving the failing regimen. This optimizes the chance of identifying resistance mutations, because resistant strains may revert to wild type within a few weeks of stopping ARV drugs (see [Drug-Resistance Testing](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)). Clinicians should consider performing phenotypic resistance testing, including co-receptor tropism testing, in addition to genotypic viral resistance testing in children who have experienced prolonged or repeated periods of viral nonsuppression on multiple ARV regimens.²¹

Immunologic Monitoring in Children: General Considerations

When interpreting CD4 counts and percentages in children, clinicians must consider age as a factor. CD4 count and percentage values in healthy infants without HIV are considerably higher than values observed in adults without HIV; these infant values slowly decline to adult values by age 5 years (see [Table 5](#) below).²²

Table 5. CD4 Cell Counts and Percentages in Healthy Children: Distribution by Age

| | Age | | | | | | |
|-------------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|--------------------|--------------------|
| | 0–3 Months | 3–6 Months | 6–12 Months | 1–2 Years | 2–6 Years | 6–12 Years | 12–18 Years |
| CD4 cell count ^{a,b} | 2,600 (1,600–4,000) | 2,850 (1,800–4,000) | 2,670 (1,400–4,300) | 2,160 (1,300–3,400) | 1,380 (700–2,200) | 980 (650–1,500) | 840 (530–1,300) |
| CD4 percentage ^{a,c} | 52 (35–64) | 46 (35–56) | 46 (31–56) | 41 (32–51) | 38 (28–47) | 37 (31–47) | 41 (31–52) |

^a Values presented as median (10th to 90th percentile)

^b n = 699

^c n = 709

Source: Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol*. 2003;112(5):973–980.

The current pediatric HIV disease classification is based on absolute CD4 count, which is the preferred assay for monitoring and estimating the risk for disease progression and OIs²³ (see [Table A. HIV Infection Stage Based on Age-Specific CD4 Count or Percentage in Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization](#)).

However, some clinicians find it useful to monitor CD4 percentages because they remain relatively consistent, whereas absolute CD4 counts vary with age and changes in total leukocyte counts. CD4 counts and percentages are best measured when patients are clinically stable, as several factors, including mild intercurrent illness and exercise, can transiently decrease levels.²⁴ Low CD4 values should be confirmed by a repeat test at least 1 week after the first test to inform clinical decisions.

CD4 count and percentage decline as HIV infection progresses; patients with lower CD4 counts or percentage values have a poorer prognosis than patients with higher values (see [Tables A](#), [Table B](#), and [Table C](#) in [Appendix D: Supplemental Information](#)). Children with higher baseline CD4 percentages, younger ages (<4 years), or early ART initiation²⁵ can potentially recover normal CD4 counts, whereas children with severe baseline immune suppression may not achieve normal CD4 levels with ART.²⁶⁻²⁸ Although CD4 cells decline as a result of HIV infection, CD8 T lymphocyte (CD8) cells expand soon after infection. In adults with HIV, low CD4/CD8 ratios are a prognostic indicator for serious non-AIDS events.²⁹ In children with perinatal HIV, the CD4/CD8 ratio inversely correlates with immune activation, senescence, and exhaustion.²⁹ Some clinicians find CD4/CD8 ratios useful for gauging overall immune dysfunction. Guidelines recommend that all people with HIV receive ART, regardless of their CD4 count and clinical stage. However, CD4 counts are used to determine HIV stage, potential for immunologic recovery, and when to initiate or stop [OI prophylaxis](#) (see [When to Initiate Antiretroviral Treatment in Children with HIV Infection](#)).

HIV RNA Monitoring in Children: General Considerations

Quantitative HIV RNA assays measure the plasma concentration of HIV RNA as copies/mL. Without therapy, plasma viral load initially rises to peak level during the period of primary infection in adults and adolescents and then declines by as much as 2 to 3 log₁₀ copies to reach a stable lower level (the virologic set point) approximately 6 to 12 months after acute infection.^{30,31} In adults with HIV, the virologic set point correlates with the subsequent risk of disease progression or death in the absence of therapy.³²

The pattern of change in plasma viral load in untreated infants with perinatal HIV differs from that in adults and adolescents with HIV. In the absence of treatment, plasma viral load peaks by age 2 months and remains high until 12 months, and then slowly declines until age 4 to 5 years.^{33-34,35} This pattern probably reflects the lower efficiency of a developing immune system in containing viral replication and, possibly, the rapid expansion of HIV-susceptible cells that occurs with somatic growth.³⁶

Despite the established association between high plasma viral load and disease progression, a specific HIV RNA concentration has only moderate predictive value for disease progression and death in an individual child.³⁷ In both children and adults with HIV, CD4 count or percentage and plasma viral load are independent predictors of disease progression and mortality risk, and using the two markers together more accurately defines prognosis.³⁷⁻⁴⁰

Methodological Considerations When Interpreting and Comparing HIV RNA Assays

Based on accumulated experience with currently available assays, the current definition of virologic suppression is a plasma viral load that is below the quantification limit of the assay used (generally

<20 copies/mL to 75 copies/mL) (see [Table 7](#) below). This definition of suppression has been much more thoroughly investigated in adults with HIV than in children with HIV (see the [Adult and Adolescent Antiretroviral Guidelines](#)). Temporary viral load elevations (“blips”) are often detected in adults on ART⁴¹ and generally defined as up to 200 copies/mL, but they may be as high as 500 copies/mL in children on ART⁴²; these temporary elevations do not represent virologic failure as long as the values have returned to below the level of detection when testing is repeated. For definitions and management of virologic treatment failure, see [Recognizing and Managing Antiretroviral Treatment Failure](#). These definitions of virologic suppression and virologic failure are recommended for clinical use. Research protocols or surveillance programs may use different definitions.

Several different methods can be used for quantitating HIV RNA, each of which has a different level of sensitivity (see [Table 7](#) below). Because different assays use different methods to measure HIV RNA, and because the tests have different levels of sensitivity, clinicians should consistently use a single HIV RNA assay method to monitor an individual patient when possible.⁴³⁻⁴⁵ Moreover, because of biologic variability, only differences >0.7 log₁₀ copies/mL (a fivefold difference) in infants aged <2 years and differences >0.5 log₁₀ copies/mL (a threefold difference) in children aged ≥2 years should be considered as clinically significant plasma viral load changes.

The predominant HIV-1 subtype in the United States is subtype B, and early assays were designed to detect this subtype. Current kit configurations for all companies have been designed to detect and quantitate essentially all viral subtypes (see [Diagnosis of HIV Infection in Infants and Children](#)). This ability is important in many regions of the world where non-B subtypes are predominant, as well as in the United States for immigrant and adopted children who are born outside the United States or to non-U.S.-born parents.^{43,46-50}

Genetic Testing for Management of HIV

Modern disease intervention strategies often employ genetic testing to evaluate the genes of humans and pathogens. This approach to treatment is an important component in the rise of precision medicine. Clinicians who manage HIV have routinely probed HIV genetic sequences for mutations that are associated with HIV drug resistance. Some ARV drugs are metabolized differently based on specific human genotypes. For example, studies have shown that certain genotypes can affect efavirenz exposure in young children.⁵¹⁻⁵⁴ In addition, some human genetic polymorphisms are associated with drug toxicity or AEs (e.g., using HLA-B*5701 testing to predict ABC hypersensitivity)⁵⁵; for more information, see the [Abacavir](#) section in [Appendix A. Pediatric Antiretroviral Drug Information](#). Future clinical practice will likely feature broader applications of multiple forms of genetic testing to guide management of health and disease.

Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy^a

| Laboratory Testing | Entry Into Care ^{a,b} | ART Initiation ^c | Weeks 1–2 on Therapy | Weeks 2–4 on Therapy | Every 3–4 Months ^d | Every 6–12 Months ^d | Virologic Failure (Prior to Switching ARV Regimens) |
|--|--------------------------------|-----------------------------|----------------------|----------------------|-------------------------------|--------------------------------|---|
| Medical History and Physical Examination ^{e,f} | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ |
| Adherence Evaluation ^f | | ✓ | ✓ | ✓ | ✓ | | ✓ |
| CD4 Count ^d | ✓ | ✓ | | | ✓ | ✓ | ✓ |
| Plasma Viral Load ^g | ✓ | ✓ | | ✓ | ✓ | | ✓ |
| Resistance Testing | ✓ | | | | | | ✓ |
| CBC with Differential ^d | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Chemistries ^{d,h} | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ |
| Lipid Panel ⁱ | ✓ | ✓ | | | | ✓ | |
| Random Plasma Glucose ^j | | ✓ | | | | ✓ | |
| Urinalysis | ✓ | ✓ | | | | ✓ | |
| HBV Screening ^k | ✓ | | | | | | ✓ |
| Pregnancy Test for Youth and Young Adults of Childbearing Potential ^l | ✓ | ✓ | | | | | ✓ |
| HLA-B*5701 ^m | ✓ | | | | | | |
| HCV Screening ⁿ | ✓ | | | | | | |
| TB Screening ^o | ✓ | | | | | ✓ | |
| CMV Ab ^p | ✓ | | | | | ✓ | |

^a See the texts on immunologic, virologic, general laboratory, and clinical monitoring of children with HIV for details on recommended laboratory tests to perform.

^b If a child does not initiate ART after receiving an HIV diagnosis, the child's CD4 count and plasma viral load should be monitored at least every 3 to 4 months.

^c If ART is initiated within 30 to 90 days of a pre-therapy laboratory result, repeat testing may not be necessary.

Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy

^d CD4 count, CBC, and chemistries can be monitored less frequently (every 6–12 months) in children and youth who are adherent to therapy, who have CD4 count values that are well above the threshold for opportunistic infection risk, and who have had sustained virologic suppression and stable clinical status for more than 2 to 3 years. Viral load testing every 3 to 4 months is generally recommended to monitor ARV adherence.

^e Pay special attention to changes in weight that might occur after altering an ARV regimen. Weight gain or weight loss may occur when using some ARV drugs (see [Table 17h. Lipodystrophies and Weight Gain](#)).

^f Virtual visits may be appropriate at some time points, particularly for adherence assessments and for visits for established patients, see [Table 4](#) above.

^g Some experts monitor viral load more often (with each injection) in adolescents initiating injectable CAB and RPV. Viral load monitoring should be performed 4 to 8 weeks after a switch to long-acting CAB and RPV. HIV RNA also should be checked in patients with unplanned missed visits and delayed dosing of long-acting CAB and RPV. When viremia develops during long-acting therapy, resistance testing, including integrase resistance testing, should be performed. Follow-up dosing in patients with missed doses should not be delayed while waiting for viral load and resistance test results. However, regimen changes should be prompted if resistance to CAB and/or RPV is discovered (see [Optimizing Antiretroviral Therapy in the Setting of Viral Suppression in the Adult and Adolescent Antiretroviral Guidelines](#)).

^h Chemistries refer to a comprehensive metabolic panel. Some experts perform a comprehensive panel at entry and routinely test Cr, ALT, AST, with additional tests tailored to the history of the individual patient.

ⁱ If lipid levels have been abnormal in the past, more frequent monitoring may be needed. For patients treated with TDF, more frequent urinalysis should be considered.

^j Random plasma glucose is collected in a gray-top blood collection tube or other designated tube. Some experts would consider monitoring HgbA1C, rather than routine blood glucose, in children at risk for prediabetes/diabetes.

^k Baseline HBV screening is recommended with HBsAb, HBsAg, and HBcAb. HBV screening is also recommended for individuals who have previously demonstrated no immunity to HBV and who are initiating a regimen that contains ARV drugs with activity against HBV, specifically 3TC, FTC, TAF, or TDF.

^l See the [Prepregnancy Counseling and Care](#) in the [Perinatal Guidelines](#).

^m Conduct HLA-B*5701 on entry or prior to initiating ABC if not done previously. Choose an alternative ARV drug if the patient is HLA-B*5701 positive (see the [Abacavir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

ⁿ Baseline hepatitis C screening is recommended with HCV nucleic acid (HCV RNA) testing if aged <18 months or Hepatitis C antibody if aged ≥18 months. If HCV testing is positive, refer to the [Infectious Diseases Society of America HCV in Children guidelines](#) for management.

^o TB screening is recommended at baseline and annually with tuberculin skin test if aged <2 years or interferon gamma release assay if aged ≥2 years (see [Mycobacterium tuberculosis](#) in the [Pediatric Opportunistic Infection Guidelines](#)).

^p CMV antibody testing is recommended at age 1 year (or at baseline evaluation if aged >1 year at initial visit) and then annually for CMV-seronegative infants and children with HIV who are immunosuppressed (i.e., CD4 count <100 cells/mm³ or CD4 percentage <10%) (see [Cytomegalovirus](#) in the [Pediatric Opportunistic Infection Guidelines](#)).

Key: 3TC = lamivudine; ABC = abacavir; ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; CAB = cabotegravir; CBC = complete blood count; CD4 = CD4 T lymphocyte; CMV = cytomegalovirus; Cr = creatinine; FTC = emtricitabine; HBV = hepatitis B virus; HBsAb = HBV surface antibody; HBsAg = HBV surface antigen; HBcAb = HBV core antibody; HCV = hepatitis C virus; HgbA1C = glycosylated hemoglobin; RPV = rilpivirine; TAF = tenofovir alafenamide; TB = tuberculosis; TDF = tenofovir disoproxil fumarate

Table 7. Primary Food and Drug Administration–Approved Assays for Monitoring Viral Load

| Assay | Abbott Real Time | NucliSens EasyQ v2.0 | COBAS AmpliPrep/TaqMan v2.0 | Versant v1.0 | Aptima HIV-1 Quant Assay |
|------------------------------|------------------------------|------------------------------|------------------------------|---------------------------------|------------------------------|
| Method | Real-time RT-PCR | Real-time NASBA | Real-time RT-PCR | Real-time RT-PCR | Real-time TMA |
| Dynamic Range | 40–10 ⁷ copies/mL | 25–10 ⁷ copies/mL | 20–10 ⁷ copies/mL | 37–11×10 ⁷ copies/mL | 30–10 ⁷ copies/mL |
| Specimen Volume ^a | 0.2–1 mL | 0.1–1 mL | 1 mL | 0.5 mL | ≥0.4 mL |
| Manufacturer | Abbott Laboratories | bioMérieux | Roche | Siemens | Hologic, Inc. |

^a Laboratories often request large blood volumes for standard viral load testing. Consider contacting the local laboratory to determine minimum blood volume required to run the assay. Smaller volumes for children can be accommodated.

Key: NASBA = nucleic acid sequence–based amplification; RT-PCR = reverse transcription-polymerase chain reaction; TMA = transcription-mediated amplification

References

1. Eckerle JK, Bresnahan MM, Kroupina M, et al. International adoption: a review and update. *Pediatr Rev.* 2021;42(5):245-257. Available at: <https://pubmed.ncbi.nlm.nih.gov/33931509>.
2. Jesson J, Dahourou DL, Renaud F, et al. Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis. *Lancet HIV.* 2016;3(2):e64-75. Available at: <https://pubmed.ncbi.nlm.nih.gov/26847228>.
3. Hightow-Weidman LB, Muessig KE, Bauermeister J, et al. Youth, technology, and HIV: recent advances and future directions. *Curr HIV/AIDS Rep.* 2015;12(4):500-515. Available at: <https://pubmed.ncbi.nlm.nih.gov/26385582>.
4. Curfman A, McSwain SD, Chuo J, et al. Pediatric telehealth in the COVID-19 pandemic era and beyond. *Pediatrics.* 2021;148(3). Available at: <https://pubmed.ncbi.nlm.nih.gov/34215677>.
5. Shah AC, Badawy SM. Telemedicine in pediatrics: systematic review of randomized controlled trials. *JMIR Pediatr Parent.* 2021;4(1):e22696. Available at: <https://pubmed.ncbi.nlm.nih.gov/33556030>.
6. Koay WLA, Prabhakar S, Neilan A, et al. Brief report: supporting access to HIV care for children and youth during the COVID-19 pandemic with telemedicine and rideshare. *J Acquir Immune Defic Syndr.* 2021;88(4):384-388. Available at: <https://pubmed.ncbi.nlm.nih.gov/34710072>.
7. Dandachi D, Lee C, Morgan RO, et al. Integration of telehealth services in the healthcare system: with emphasis on the experience of patients living with HIV. *J Investig Med.* 2019;67(5):815-820. Available at: <https://pubmed.ncbi.nlm.nih.gov/30826803>.
8. Ohl ME, Richardson K, Rodriguez-Barradas MC, et al. Impact of availability of telehealth programs on documented HIV viral suppression: a cluster-randomized program evaluation in the veterans health administration. *Open Forum Infect Dis.* 2019;6(6):ofz206. Available at: <https://pubmed.ncbi.nlm.nih.gov/31211155>.
9. Health Resources and Services Administration (HRSA). Telehealth programs. 2019. Available at: <https://www.hrsa.gov/telehealth>.
10. Regelmann MO, Conroy R, Gourgari E, et al. Pediatric endocrinology in the time of COVID-19: considerations for the rapid implementation of telemedicine and management of pediatric endocrine conditions. *Horm Res Paediatr.* 2020;93(6):343-350. Available at: <https://pubmed.ncbi.nlm.nih.gov/33486483>.
11. Krogstad P, Patel K, Karalius B, et al. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents. *AIDS.* 2015;29(6):683-693. Available at: <https://pubmed.ncbi.nlm.nih.gov/25849832>.
12. Arrow Trial team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. *Lancet.* 2013;381(9875):1391-1403. Available at: <https://pubmed.ncbi.nlm.nih.gov/23473847>.

13. Buscher A, Mugavero M, Westfall AO, et al. The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression. *AIDS Patient Care STDS*. 2013;27(8):459-466. Available at: <https://pubmed.ncbi.nlm.nih.gov/23886048>.
14. Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. *JAMA Intern Med*. 2013;173(18):1746-1748. Available at: <https://pubmed.ncbi.nlm.nih.gov/23978894>.
15. Buclin T, Telenti A, Perera R, et al. Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. *PLoS One*. 2011;6(4):e18578. Available at: <https://pubmed.ncbi.nlm.nih.gov/21494630>.
16. Gaur AH, Flynn PM, Bitar W, Liang H. Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy. *AIDS Res Hum Retroviruses*. 2013;29(3):418-422. Available at: <https://pubmed.ncbi.nlm.nih.gov/23016543>.
17. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts ≥ 300 cells/ μ L and HIV-1 suppression? *Clin Infect Dis*. 2013;56(9):1340-1343. Available at: <https://pubmed.ncbi.nlm.nih.gov/23315315>.
18. Davies MA, Ford N, Rabie H, et al. Reducing CD4 monitoring in children on antiretroviral therapy with virologic suppression. *Pediatr Infect Dis J*. 2015;34(12):1361-1364. Available at: <https://pubmed.ncbi.nlm.nih.gov/26379169>.
19. Kosalaraksa P, Boettiger DC, Bunupuradah T, et al. Low risk of CD4 decline after immune recovery in human immunodeficiency virus-infected children with viral suppression. *J Pediatric Infect Dis Soc*. 2017;6(2):173-177. Available at: <https://pubmed.ncbi.nlm.nih.gov/27295973>.
20. Rakhmanina N, Richards K, Adeline Koay WL. Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: considerations for dosing schedule and monitoring. *J Acquir Immune Defic Syndr*. 2023;92(3):e14-e17. Available at: <https://pubmed.ncbi.nlm.nih.gov/36480701>.
21. Agwu AL, Yao TJ, Eshleman SH, et al. Phenotypic co-receptor tropism in perinatally HIV-infected youth failing antiretroviral therapy. *Pediatr Infect Dis J*. 2016;35(7):777-781. Available at: <https://pubmed.ncbi.nlm.nih.gov/27078121>.
22. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol*. 2003;112(5):973-980. Available at: <https://pubmed.ncbi.nlm.nih.gov/14610491>.
23. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States. *MMWR Recomm Rep*. 2014;63(RR-03):1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/24717910>.
24. Raszka WV, Jr., Meyer GA, Waecker NJ, et al. Variability of serial absolute and percent CD4+ lymphocyte counts in healthy children born to human immunodeficiency virus 1-infected parents. Military pediatric HIV consortium. *Pediatr Infect Dis J*. 1994;13(1):70-72. Available at: <https://pubmed.ncbi.nlm.nih.gov/7909598>.

25. Schroter J, Anelone AJN, de Boer RJ, et al. Quantification of CD4 recovery in early-treated infants living with HIV. *J Acquir Immune Defic Syndr*. 2022;89(5):546-557. Available at: <https://pubmed.ncbi.nlm.nih.gov/35485581/>.
26. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2009;28(6):488-492. Available at: <https://pubmed.ncbi.nlm.nih.gov/19504731/>.
27. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. *Clin Infect Dis*. 2008;46(11):1751-1760. Available at: <https://pubmed.ncbi.nlm.nih.gov/18426371/>.
28. Yin DE, Warshaw MG, Miller WC, et al. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. *Pediatrics*. 2014;134(4):e1104-1116. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25266426>.
29. Ron R, Moreno E, Martinez-Sanz J, et al. CD4/CD8 ratio during human immunodeficiency virus treatment: time for routine monitoring? *Clin Infect Dis*. 2023;76(9):1688-1696. Available at: <https://pubmed.ncbi.nlm.nih.gov/36883584/>.
30. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. *JAMA*. 1995;274(7):554-558. Available at: <https://pubmed.ncbi.nlm.nih.gov/7629984/>.
31. Katzenstein TL, Pedersen C, Nielsen C, et al. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. *AIDS*. 1996;10(2):167-173. Available at: <https://pubmed.ncbi.nlm.nih.gov/8838704/>.
32. Mellors JW, Kingsley LA, Rinaldo CR, Jr., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med*. 1995;122(8):573-579. Available at: <https://pubmed.ncbi.nlm.nih.gov/7887550/>.
33. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. *N Engl J Med*. 1997;336(19):1337-1342. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9134873>.
34. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. *J Infect Dis*. 1998;178(1):101-108. Available at: <https://pubmed.ncbi.nlm.nih.gov/9652428/>.
35. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. *J Pediatr*. 1995;126(4):592-595. Available at: <https://pubmed.ncbi.nlm.nih.gov/7699539>.
36. Krogstad P, Uittenbogaart CH, Dickover R, et al. Primary HIV infection of infants: the effects of somatic growth on lymphocyte and virus dynamics. *Clin Immunol*. 1999;92(1):25-33. Available at: <https://pubmed.ncbi.nlm.nih.gov/10413650>.

37. Mofenson LM, Korelitz J, Meyer WA, 3rd, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. *J Infect Dis.* 1997;175(5):1029-1038. Available at: <https://pubmed.ncbi.nlm.nih.gov/9129063>.
38. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. *Ann Intern Med.* 1997;126(12):929-938. Available at: <https://pubmed.ncbi.nlm.nih.gov/9182469>.
39. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med.* 1997;126(12):946-954. Available at: <https://pubmed.ncbi.nlm.nih.gov/9182471>.
40. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. *JAMA.* 1998;279(10):756-761. Available at: <https://pubmed.ncbi.nlm.nih.gov/9508151>.
41. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. *J Infect Dis.* 2012;205(8):1230-1238. Available at: <https://pubmed.ncbi.nlm.nih.gov/22438396>.
42. Coovadia A, Abrams EJ, Strehlau R, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. *JAMA.* 2015;314(17):1808-1817. Available at: <https://pubmed.ncbi.nlm.nih.gov/26529159>.
43. Bourlet T, Signori-Schmuck A, Roche L, et al. HIV-1 load comparison using four commercial real-time assays. *J Clin Microbiol.* 2011;49(1):292-297. Available at: <https://pubmed.ncbi.nlm.nih.gov/21068276>.
44. Yan CS, Hanafi I, Kelleher AD, et al. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. *J Clin Virol.* 2010;49(4):249-253. Available at: <https://pubmed.ncbi.nlm.nih.gov/20884287>.
45. Jennings C, Harty B, Granger S, et al. Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. *J Clin Microbiol.* 2012;50(8):2737-2747. Available at: <https://pubmed.ncbi.nlm.nih.gov/22692747>.
46. Haas J, Geiss M, Bohler T. False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus (HIV) type 1 in children infected with HIV strains of African origin. *J Infect Dis.* 1996;174(1):244-245. Available at: <https://pubmed.ncbi.nlm.nih.gov/8656008>.
47. Kline NE, Schwarzwald H, Kline MW. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. *Pediatr Infect Dis J.* 2002;21(9):885-886. Available at: <https://pubmed.ncbi.nlm.nih.gov/12380591>.
48. Zaman MM, Recco RA, Haag R. Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn

infants. *Clin Infect Dis*. 2002;34(3):417-418. Available at: <https://pubmed.ncbi.nlm.nih.gov/11774090>.

49. Luft LM, Gill MJ, Church DL. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. *Int J Infect Dis*. 2011;15(10):e661-670. Available at: <https://pubmed.ncbi.nlm.nih.gov/21767972>.
50. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott real-time HIV-1 PCR assays. *J Acquir Immune Defic Syndr*. 2011;56(3):239-243. Available at: <https://pubmed.ncbi.nlm.nih.gov/21164353>.
51. Bienczak A, Cook A, Wiesner L, et al. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. *Br J Clin Pharmacol*. 2016;82(1):185-198. Available at: <https://pubmed.ncbi.nlm.nih.gov/26991336>.
52. Bolton Moore C, Capparelli EV, Samson P, et al. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. *AIDS*. 2017;31(8):1129-1136. Available at: <https://pubmed.ncbi.nlm.nih.gov/28323755>.
53. Nikanjam M, Tran L, Chadwick EG, et al. Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. *AIDS*. 2022;36(4):525-532. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34873089>.
54. Chala A, Kitabi EN, Ahmed JH, et al. Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia. *CPT Pharmacometrics Syst Pharmacol*. 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/36840416>.
55. Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. *BMC Infect Dis*. 2017;17(1):256. Available at: <https://pubmed.ncbi.nlm.nih.gov/28399804>.

When to Initiate Antiretroviral Treatment in Children with HIV Infection

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">• Antiretroviral therapy (ART) should be initiated in all infants and children with HIV infection (AI for children aged <3 months, AI* for older children).<ul style="list-style-type: none">○ Rapid ART initiation (defined as initiating ART immediately or within days of HIV diagnosis), accompanied by a discussion of the importance of adherence and provision of subsequent adherence support, is recommended for all children with HIV (AI*).• If a child with HIV has not initiated ART, health care providers should closely monitor the virologic, immunologic, and clinical status at least every 3 to 4 months (AIII).<ul style="list-style-type: none">○ ART initiation should be discussed and strongly encouraged at every visit (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†]Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents

Overview

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends initiating treatment for all children with HIV as soon as is feasible after diagnosis. Multiple studies have shown a benefit to early antiretroviral therapy (ART) initiation¹⁻³ and that ART initiation within the first year of life is associated with reduced size of viral reservoirs.⁴ Treatment initiation in young infants with HIV during the early stages of infection may control viral replication before HIV can evolve into diverse and potentially more pathogenic quasi-species.⁵ Initiation of therapy at higher CD4 T lymphocyte (CD4) cell counts has been associated with the presence of fewer drug-resistant mutations at virologic failure in adults.⁶ Early therapy has also been shown to preserve immune function and prevent clinical disease progression in perinatal infection⁷⁻⁹ and may prevent or reduce persistent inflammation, a precipitant of cardiovascular, kidney, and liver disease and malignancy.^{10,11}

Rapid treatment initiation, defined as therapy initiated immediately or within days of HIV diagnosis, is recommended except in children with cryptococcal meningitis, tuberculous meningitis, and disseminated *Mycobacterium avium* complex disease. Due to concerns regarding the risk of immune reconstitution inflammatory syndrome, ART initiation may be deferred until the optimal timing relative to treatment of these opportunistic infections. Timing of ART initiation in these cases should be discussed with a pediatric HIV specialist (see [Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV](#)). A recent retrospective review of children and adolescents with HIV in six African countries between 2013 and 2020 showed that there

was no mortality difference if ART was initiated <2 weeks ($n = 266$) versus 2 weeks to 2 months ($n = 398$) after starting anti-tuberculous therapy for pulmonary tuberculosis (TB).¹² This finding supporting ART initiation in pediatric patients within the first 2 weeks of treatment for TB is consistent with [World Health Organization Updated Recommendations on HIV Prevention, Infant Diagnosis, Antiretroviral Initiation and Monitoring, March 2021](#),¹³ which advocate for ART initiation within 2 weeks of TB treatment initiation for infants and children, except when signs and symptoms of meningitis are present.

Although rapid initiation of ART is recommended in all children with HIV, individual clinical and/or psychosocial factors may lead patients, caregivers, and providers to make a collaborative decision to defer ART initiation. When making the decision to defer ART, medical factors—such as the opportunity to limit seeding of the viral reservoir in newborns, the child's HIV disease stage,¹⁴ and the presence of HIV-related signs and symptoms¹⁵—need to be balanced against any potential barriers to rapid ART initiation. If ART is deferred, the health care provider should continue to educate and work with the family to overcome barriers to treatment, as well as closely monitor the child's virologic, immunologic, and clinical status at least every 3 to 4 months (**AIII**) (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)). Clinicians should initiate ART in children with HIV for whom treatment has been deferred when at least one of the following conditions occur:

- HIV RNA levels increase
- CD4 count or percentage values decline (e.g., approaching Centers for Disease Control and Prevention Stage 2 or 3) (see [Appendix C. CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Disease Categorization](#))¹⁴
- The child develops new HIV-related clinical symptoms (see [Appendix C. CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Disease Categorization](#))¹⁵
- The ability of a caregiver and child to adhere to the prescribed regimen improves

Survival and Health Benefits Associated with Early Initiation of Antiretroviral Therapy

The Children with HIV Early Antiretroviral Therapy (CHER) trial was a randomized clinical trial in South Africa that initiated ART in infants with HIV who were aged 6 to 12 weeks and were asymptomatic with normal CD4 percentages (>25%). Immediately initiating ART resulted in a 75% reduction in early mortality among these infants compared with delaying treatment until the infants met clinical or immune criteria according to the standard of care at the time of the study.² Consistent with the CHER trial, data from a number of observational studies in the United States, Europe, and South Africa demonstrated that infants who received early treatment were less likely to progress to AIDS or death, and they also had improved growth and lower morbidity compared with those who started treatment later.¹⁶⁻²⁰

In general, studies that evaluate later initiation of ART in children have a selection bias: children with perinatal infection and rapidly progressing disease may have died prior to receiving an HIV diagnosis or ART, and children who present later for ART initiation may be slower progressors with a better prognosis. However, in the multicenter, open-label Pediatric Randomised Early versus Deferred Initiation in Cambodia and Thailand (PREDICT) trial, which randomized 300 children with HIV aged 1 year to 12 years at enrollment (median age 6.4 years) to immediately initiate ART or to defer treatment until their CD4 percentage was <15%, better gain in height among children who started ART immediately was reported.²¹ Similarly, other studies have reported an association between younger age at initiation of ART and more rapid growth reconstitution.^{17,22-24} Studies

conducted in and outside the United States have reported an association between delayed ART initiation and delay of pubertal development and menarche.²⁵ Finally, among 32 youths with perinatally acquired HIV (PHIV) from the Pediatric HIV/AIDS Cohort Study (PHACS), DNA methylation evaluating epigenetic aging was compared to chronologic aging over time. Higher viral load and lower CD4 count were associated with epigenetic aging that exceeded chronologic aging, highlighting the value of achieving early viral suppression and maintaining or reconstituting immune function as close to an HIV diagnosis as possible.²⁶

A proteomics study of children who initiated ART early (within 12 weeks of birth) versus later (12–50 weeks after birth) identified a protein signature among later initiators associated with a proinflammatory state. This proinflammatory state was associated with elevated lipid levels and other metabolites and clinical parameters, suggestive of a higher risk of premature onset of atherosclerotic disease and metabolic disorders in adulthood.¹⁰ Furthermore, a recent cross-sectional study from Mozambique found that earlier age at ART initiation was independently associated with improved large artery stiffness in childhood, as measured by pulse wave velocity, independent of the effect of elevated visceral fat, lipids, and insulin resistance.¹¹

Neurodevelopmental Benefits Associated with Early Initiation of Antiretroviral Therapy

Early infant initiation of ART has been associated with improved neurodevelopmental outcomes compared with later initiation of ART. Examples include a CHER trial substudy in which infants who initiated ART early had significantly better gross motor and neurodevelopmental profiles than those whose therapy was deferred.²⁷ Additionally, in a cohort from Thailand, the prevalence of global developmental impairment was 22% (95% confidence interval [CI], 11% to 27%) among children with HIV who initiated ART within 3 months of birth compared with 44% (95% CI, 23% to 66%) among children who initiated ART from ages 3 to 12 months.²⁸ Among Kenyan children who initiated ART within 1 year of birth (early ART; n = 54) versus 1.5 to 6 years after birth (late ART; n = 27) between 2007 and 2009 and were prospectively assessed for neurocognitive outcomes at a median age of 6.9 years, the children with later ART initiation had significantly higher odds of impairment in global cognition, short-term memory, visuospatial processing, learning, planning, nonverbal test performance, and motor skills (adjusted odds ratios 2.87–16.22; P values ≤ 0.05).²⁹ Lastly, a study of South African infants with PHIV who initiated ART within 21 days of life (median 6 days) found that neurodevelopmental scores at approximately 11.5 months of age were within the normal range for age in the domains of locomotor, personal–social, hearing and language, and visual–motor.³⁰

Immune Benefits Associated with Early Initiation of Antiretroviral Therapy

In the CHER study, infants who were treated early had decreased immune activation, greater recovery of CD4 cells, expanded CD4-naïve T cells, and retention of innate effector frequencies, resulting in greater immune reconstitution than that achieved in infants who received deferred ART.⁹ The IMPAACT 1115 Phase 1/2 proof-of-concept study of very early ART initiation began treatment of 54 infants within 10 days of birth. CD4 counts were ≥1,500 cells/mm³, and CD4 percentages were ≥25% among 84% of infants at 24 weeks after treatment initiation and among 80% of infants at 48 weeks after treatment initiation.³¹ In a small study in Botswana, infants who initiated ART within the first 7 days of life were found to have decreased immune activation, a more polyfunctional HIV-1-specific CD8 cell response, and a markedly reduced HIV latent reservoir compared with infants who initiated ART later in the first year of life.³² Available data suggest that both children and adults who initiate treatment with a higher CD4 percentage or CD4 count have better immune

recovery than patients who initiate treatment with lower CD4 percentages or CD4 counts.^{23,33-35} Among 1,236 children with PHIV in the United States, only 36% of those who started ART with CD4 percentages <15% achieved CD4 percentages >25% after 5 years of therapy compared with 59% of children who started with CD4 percentages of 15% to 24%.³⁶ Finally, earlier age at ART initiation results in higher rates of CD4:CD8 ratio normalization and improved immunogenicity of childhood vaccines.³⁷⁻³⁹

Early initiation of suppressive ART (i.e., in infants aged <6 months) results in a significant proportion of infants with HIV who fail to produce their own HIV-specific antibodies. These infants appear to be HIV seronegative when tested; however, viral reservoirs remain, and viral rebound occurs if ART is stopped.⁴⁰⁻⁴⁵

Viral Suppression and Viral Reservoirs with Early Initiation of Antiretroviral Therapy

Early initiation of ART within the first 7 days of life, compared with initiation between 8 and 28 days of life, resulted in a fourfold faster time to viral suppression among infants in a multinational study.⁴⁶ Studies that compared the size of viral reservoirs in children who initiated ART before age 12 weeks with those in children who initiated ART at ≥12 weeks to ≤2 years of age found that viral reservoir size after 1 year and 4 years of ART significantly correlated with younger age at ART initiation and younger age at viral control.⁴⁷⁻⁴⁹ Among 27 children in the Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies (EPIICAL) Consortium who initiated ART before 2 years of age and maintained a viral load <50 copies/mL for more than 5 years, total HIV-1 DNA levels measured at a median of 12 years after treatment initiation were reduced (interquartile range 7.3–15.4), with younger age and viral load at the time of ART initiation each associated with lower reservoir levels.⁵⁰ In the CHER study, early ART initiation and longer duration of ART was associated with lower proviral DNA levels at age 5 years.⁵¹ Finally, in the Early Infant Treatment Study in Botswana, 40 infants initiated ART at a median 2 days of life, with 2 infants dying within 12 to 24 weeks of treatment initiation. Low reservoirs were noted among the 38 who survived to 96 weeks, even though most infants experienced periods of detectable HIV-1 RNA between 24 to 96 weeks. Low pre-ART reservoir size was predictive of preserved CD4 count and low viral reservoirs.⁵²

These findings suggest that initiating ART soon after an infant acquires HIV can limit the size of the HIV viral reservoir, and smaller reservoirs may provide some level of protection against viral rebound in the setting of treatment nonadherence—a frequent event for infants with HIV who are destined for lifelong treatment. Furthermore, very low levels of markers of HIV persistence have been reported in infants who initiated ART early and who had sustained control of plasma viremia.^{40,53}

The report of a prolonged remission in a child with PHIV in Mississippi generated discussion about early initiation of ART as presumptive treatment in newborns at high risk of HIV acquisition.^{54,55} Two other children have experienced prolonged remission following early ART initiation. A child from the CHER study received ART between 2 and 10 months of age and in 2019, at the age of 9.5 years, had HIV-1 detectable only at very low levels (plasma RNA 6.6 copies/mL) and no detectable replication-competent virus.⁵⁶ A French child was treated with ART from 3 months of age through approximately 6 years of age, and in 2016, at 18.6 years of age and still off ART, HIV RNA had remained below 50 copies/mL with stable CD4 counts.⁵⁷

These experiences have prompted increasing support for initiating treatment as soon as the diagnosis is made and, if possible, during the first weeks of life to limit reservoir formation and possibly

facilitate ART-free remission. Although a limited number of case reports describe lengthy remissions in children with PHIV who have undergone treatment interruption, current ART has not been shown to eradicate HIV infection, because HIV persists in CD4 cells and other long-lived cells.⁵⁶⁻⁵⁹ For these reasons, the Panel **does not recommend empiric treatment interruption** outside of a clinical trial setting.

Managing treatment in neonates with HIV is complex from a medical and social perspective. Because of limited safety and pharmacokinetic data for antiretroviral (ARV) drugs in full-term infants aged <2 weeks and preterm infants aged ≤4 weeks, drug and dose selection in this age group is challenging^{60,61} (see [What to Start](#) and [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Hepatic and renal function are immature in newborns who are undergoing rapid maturational changes during the first few months of life, which can result in substantial differences in ARV dose requirements between young infants and older children.^{62,63} When drug concentrations are subtherapeutic—because of inadequate dosing, poor absorption, or incomplete adherence—ARV drug resistance can develop rapidly, particularly in young infants who experience high levels of viral replication. Frequent follow-up for dose optimization during periods of rapid growth is especially important when treating young infants. Furthermore, clinicians should continually assess a patient’s adherence and address potential barriers to adherence during this time (see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)).

Summary

The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of HIV diagnosis) for all children who receive an HIV diagnosis, regardless of clinical, immunologic, or virologic status. The urgency of rapid ART initiation is especially critical for children aged <1 year who carry the highest risk of rapid disease progression and mortality. However, in ART-naive children and adolescents with cryptococcal meningitis, **tuberculous meningitis**, and disseminated *Mycobacterium avium* complex disease, the Panel recommends initiation of treatment for the opportunistic infection first, ahead of ART initiation (see [Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV](#)). Timing of ART initiation in these cases should be discussed with a pediatric HIV specialist.

In preparation for ART initiation, it is important to assess and discuss issues associated with adherence with caregivers and, when developmentally appropriate, with children. Intensive follow-up during the first few weeks to months after ART initiation is also recommended to support the child and caregiver. Medication adherence is the core requirement for successful virologic control. The Panel recognizes that achieving consistent adherence in children is often challenging.^{64,65} Incomplete adherence leads to loss of viral control and the selection of drug-resistant mutations, but forcibly administrating ARV drugs to younger children may result in treatment aversion, which often persists into adulthood.

References

1. Schomaker M, Leroy V, Wolfs T, et al. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. *Int J Epidemiol.* 2017;46(2):453-465. Available at: <https://pubmed.ncbi.nlm.nih.gov/27342220>.
2. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med.* 2008;359(21):2233-2244. Available at: <https://pubmed.ncbi.nlm.nih.gov/19020325>.
3. Shiau S, Strehlau R, Technau KG, et al. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. *AIDS.* 2017;31(3):355-364. Available at: <https://pubmed.ncbi.nlm.nih.gov/27828785>.
4. Massanella M, Puthanakit T, Leyre L, et al. Continuous prophylactic antiretrovirals/antiretroviral therapy since birth reduces seeding and persistence of the viral reservoir in children vertically infected with human immunodeficiency virus. *Clin Infect Dis.* 2021;73(3):427-438. Available at: <https://pubmed.ncbi.nlm.nih.gov/32504081>.
5. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2007;23(3):381-390. Available at: <https://pubmed.ncbi.nlm.nih.gov/17411371>.
6. Palumbo PJ, Fogel JM, Hudelson SE, et al. HIV drug resistance in adults receiving early vs. delayed antiretroviral therapy: HPTN 052. *J Acquir Immune Defic Syndr.* 2018;77(5):484-491. Available at: <https://pubmed.ncbi.nlm.nih.gov/29293156>.
7. Rinaldi S, Pallikkuth S, Cameron M, et al. Impact of early antiretroviral therapy initiation on HIV-specific CD4 and CD8 T cell function in perinatally infected children. *J Immunol.* 2020;204(3):540-549. Available at: <https://pubmed.ncbi.nlm.nih.gov/31889024>.
8. Planchais C, Hocqueloux L, Ibanez C, et al. Early antiretroviral therapy preserves functional follicular helper T and HIV-specific B cells in the gut mucosa of HIV-1-infected individuals. *J Immunol.* 2018;200(10):3519-3529. Available at: <https://pubmed.ncbi.nlm.nih.gov/29632141>.
9. Azzoni L, Barbour R, Papasavvas E, et al. Early ART results in greater immune reconstitution benefits in HIV-infected infants: working with data missingness in a longitudinal dataset. *PLoS One.* 2015;10(12):e0145320. Available at: <https://pubmed.ncbi.nlm.nih.gov/26671450>.
10. Tarazona-Diez L, Rull A, Herrero P, et al. Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. *J Antimicrob Chemother.* 2021;76(11):2993-3001. Available at: <https://pubmed.ncbi.nlm.nih.gov/34463735>.
11. Dobe IS, Mocumbi AO, Majid N, Ayele B, Browne SH, Innes S. Earlier antiretroviral initiation is independently associated with better arterial stiffness in children living with perinatally acquired HIV with sustained viral suppression in Mozambique. *South Afr J HIV Med.* 2021;22(1):1282. Available at: <https://pubmed.ncbi.nlm.nih.gov/34858652>.

12. Kay A, Mendez-Reyes J, Devezin T, et al. Optimal timing of antiretroviral therapy initiation in children and adolescents with human immunodeficiency virus-associated pulmonary tuberculosis. *Clin Infect Dis.* 2023;76(1):10-17. Available at: <https://pubmed.ncbi.nlm.nih.gov/36097966>.
13. World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva, Switzerland. 2021. Available at: <https://www.who.int/publications/i/item/9789240022232>.
14. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States. *MMWR Recomm Rep.* 2014;63(RR-03):1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/24717910>.
15. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR.* 1994;43(RR-12):1-10. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00032890.htm>.
16. Goetghebuer T, Le Chenadec J, Haelterman E, et al. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. *Clin Infect Dis.* 2012;54(6):878-881. Available at: <https://pubmed.ncbi.nlm.nih.gov/22198788>.
17. Shiao S, Arpadi S, Strehlau R, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. *J Pediatr.* 2013;162(6):1138-1145 e1132. Available at: <https://pubmed.ncbi.nlm.nih.gov/23312691>.
18. Iyun V, Technau KG, Eley B, et al. Earlier antiretroviral therapy initiation and decreasing mortality among HIV-infected infants initiating antiretroviral therapy within 3 months of age in South Africa, 2006–2017. *Pediatr Infect Dis J.* 2020;39(2):127-133. Available at: <https://pubmed.ncbi.nlm.nih.gov/31725119>.
19. Tagarro A, Dominguez Rodriguez S, Violari A, et al. Poor outcome in early treated HIV perinatally infected infants in Africa. Abstract 806. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, Massachusetts. Available at: <https://www.croiconference.org/abstract/poor-outcome-in-early-treated-hiv-perinatally-infected-infants-in-africa>.
20. Anderson K, Iyun V, Eley BS, et al. Hospitalization among infants who initiate antiretroviral therapy before 3 months of age. *AIDS.* 2023;37(3):435-445. Available at: <https://pubmed.ncbi.nlm.nih.gov/36695356>.
21. Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. *Lancet Infect Dis.* 2012;12(12):933-941. Available at: <https://pubmed.ncbi.nlm.nih.gov/23059199>.
22. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC. Younger age at HAART initiation is associated with more rapid growth reconstitution. *AIDS.* 2011;25(3):345-355. Available at: <https://pubmed.ncbi.nlm.nih.gov/21102302>.

23. Simms V, Rylance S, Bandason T, et al. CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence. *AIDS*. 2018;32(14):1977-1982. Available at: <https://pubmed.ncbi.nlm.nih.gov/29927784>.
24. Traisathit P, Urien S, Le Coeur S, et al. Impact of antiretroviral treatment on height evolution of HIV infected children. *BMC Pediatr*. 2019;19(1):287. Available at: <https://pubmed.ncbi.nlm.nih.gov/31421667>.
25. Mwambenu B, Ramoloko V, Laubscher R, Feucht U. Growth and the pubertal growth spurt in South African adolescents living with perinatally-acquired HIV infection. *PLoS One*. 2022;17(1):e0262816. Available at: <https://pubmed.ncbi.nlm.nih.gov/35077489>.
26. Shiau S, Brummel SS, Kennedy EM, et al. Longitudinal changes in epigenetic age in youth with perinatally acquired HIV and youth who are perinatally HIV-exposed uninfected. *AIDS*. 2021;35(5):811-819. Available at: <https://pubmed.ncbi.nlm.nih.gov/33587437>.
27. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. *AIDS*. 2012;26(13):1685-1690. Available at: <https://pubmed.ncbi.nlm.nih.gov/22614886>.
28. Jantarabenjakul W, Chonchaiya W, Puthanakit T, et al. Low risk of neurodevelopmental impairment among perinatally acquired HIV-infected preschool children who received early antiretroviral treatment in Thailand. *J Int AIDS Soc*. 2019;22(4):e25278. Available at: <https://pubmed.ncbi.nlm.nih.gov/30990969>.
29. Benki-Nugent S, Tamasha N, Mueni A, et al. Early antiretroviral therapy reduces severity but does not eliminate neurodevelopmental compromise in children with HIV. *J Acquir Immune Defic Syndr*. 2023;93(1):7-14. Available at: <https://pubmed.ncbi.nlm.nih.gov/36693138>.
30. Laughton B, Naidoo S, Dobbels E, et al. Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. *South Afr J HIV Med*. 2019;20(1):1008. Available at: <https://pubmed.ncbi.nlm.nih.gov/31745434>.
31. Nelson BS, Tierney C, Persaud D, et al. Infants receiving very early antiretroviral therapy have high CD4 counts in the first year of life. *Clin Infect Dis*. 2023;76(3):e744-e747. Available at: <https://pubmed.ncbi.nlm.nih.gov/36031390>.
32. Garcia-Broncano P, Maddali S, Einkauf KB, et al. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. *Sci Transl Med*. 2019;11(520). Available at: <https://pubmed.ncbi.nlm.nih.gov/31776292>.
33. Picat MQ, Lewis J, Musiime V, et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. *PLoS Med*. 2013;10(10):e1001542. Available at: <https://pubmed.ncbi.nlm.nih.gov/24204216>.
34. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med*. 2013;368(3):218-230. Available at: <https://pubmed.ncbi.nlm.nih.gov/23323898>.

35. Desmonde S, Dicko F, Koueta F, et al. Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. *AIDS*. 2014;28(11):1645-1655. Available at: <https://pubmed.ncbi.nlm.nih.gov/24804858>.
36. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. *Clin Infect Dis*. 2008;46(4):507-515. Available at: <https://pubmed.ncbi.nlm.nih.gov/18199042>.
37. Seers T, Vassallo P, Pollock K, Thornhill JP, Fidler S, Foster C. CD4:CD8 ratio in children with perinatally acquired HIV-1 infection. *HIV Med*. 2018;19(9):668-672. Available at: <https://pubmed.ncbi.nlm.nih.gov/30084150>.
38. Moonsamy S, Suchard M, Madhi SA. Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants. *PLoS One*. 2019;14(4):e0215079. Available at: <https://pubmed.ncbi.nlm.nih.gov/31002702>.
39. Pensiero S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. *Proc Natl Acad Sci U S A*. 2009;106(19):7939-7944. Available at: <https://pubmed.ncbi.nlm.nih.gov/19416836>.
40. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. *AIDS*. 2014;28(7):1015-1020. Available at: <https://pubmed.ncbi.nlm.nih.gov/24384692>.
41. Payne H, Mkhize N, Otwombe K, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the children with HIV early antiretroviral therapy (CHER) trial: a retrospective analysis. *Lancet Infect Dis*. 2015;15(7):803-809. Available at: <https://pubmed.ncbi.nlm.nih.gov/26043884>.
42. Kuhn L, Schramm DB, Shiao S, et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. *AIDS*. 2015;29(9):1053-1060. Available at: <https://pubmed.ncbi.nlm.nih.gov/25870988>.
43. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. *Pediatr Infect Dis J*. 2015;34(3):e48-51. Available at: <https://pubmed.ncbi.nlm.nih.gov/25742088>.
44. Wamalwa D, Benki-Nugent S, Langat A, et al. Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy. *AIDS*. 2016;30(15):2303-2313. Available at: <https://pubmed.ncbi.nlm.nih.gov/27177316>.
45. Veldsman KA, Laughton B, Janse van Rensburg A, et al. Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age. *AIDS*. 2021;35(8):1247-1252. Available at: <https://pubmed.ncbi.nlm.nih.gov/34076614>.
46. Dominguez-Rodriguez S, Tagarro A, Palma P, et al. Reduced time to suppression among neonates with HIV initiating antiretroviral therapy within 7 days after birth. *J Acquir Immune Defic Syndr*. 2019;82(5):483-490. Available at: <https://pubmed.ncbi.nlm.nih.gov/31714427>.

47. McManus M, Mick E, Hudson R, et al. Early combination antiretroviral therapy limits exposure to HIV-1 replication and cell-associated HIV-1 DNA levels in infants. *PLoS One*. 2016;11(4):e0154391. Available at: <https://pubmed.ncbi.nlm.nih.gov/27104621>.
48. Martinez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. *Clin Infect Dis*. 2015;61(7):1169-1178. Available at: <https://pubmed.ncbi.nlm.nih.gov/26063721>.
49. van Zyl GU, Bedison MA, van Rensburg AJ, Laughton B, Cotton MF, Mellors JW. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. *J Infect Dis*. 2015;212(1):39-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/25538273>.
50. Foster C, Dominguez-Rodriguez S, Tagarro A, et al. The CARMA study: early infant antiretroviral therapy-timing impacts on total HIV-1 DNA quantitation 12 years later. *J Pediatric Infect Dis Soc*. 2021;10(3):295-301. Available at: <https://pubmed.ncbi.nlm.nih.gov/32678875>.
51. Payne H, Chan MK, Watters SA, et al. Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial. *AIDS Res Ther*. 2021;18(1):63. Available at: <https://pubmed.ncbi.nlm.nih.gov/34587974>.
52. Ajibola G, Maswabi K, Hughes MD, et al. Brief Report: Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial. *J Acquir Immune Defic Syndr*. 2023;92(5):393-398. Available at: <https://pubmed.ncbi.nlm.nih.gov/36729692>.
53. Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. *Clin Infect Dis*. 2014;59(7):1012-1019. Available at: <https://pubmed.ncbi.nlm.nih.gov/24917662>.
54. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at: <https://pubmed.ncbi.nlm.nih.gov/24152233>.
55. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. *N Engl J Med*. 2015;372(8):786-788. Available at: <https://pubmed.ncbi.nlm.nih.gov/25693029>.
56. Violari A, Cotton MF, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Commun*. 2019;10(1):412. Available at: <https://pubmed.ncbi.nlm.nih.gov/30679439>.
57. Frange P, Faye A, Avettand-Fenoel V, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. *Lancet HIV*. 2016;3(1):e49-54. Available at: <https://pubmed.ncbi.nlm.nih.gov/26762993>.

58. Shiau S, Abrams EJ, Arpadi SM, Kuhn L. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? *Lancet HIV*. 2018;5(5):e250-e258. Available at: <https://pubmed.ncbi.nlm.nih.gov/29739699>.
59. Koofhethile CK, Moyo S, Kotokwe KP, et al. Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: a case report with implications for clinical care. *Medicine (Baltimore)*. 2019;98(47):e18014. Available at: <https://pubmed.ncbi.nlm.nih.gov/31764816>.
60. Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M. The last and first frontier—emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. *J Int AIDS Soc*. 2015;18(Suppl 6):20271. Available at: <https://pubmed.ncbi.nlm.nih.gov/26639118>.
61. Clarke DF, Penazzato M, Capparelli E, et al. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. *Expert Rev Clin Pharmacol*. 2018;11(1):83-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/29039686>.
62. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV*. 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.
63. Chadwick EG, Yoge R, Alvero CG, et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. *AIDS*. 2011;25(5):643-649. Available at: <https://pubmed.ncbi.nlm.nih.gov/21297419>.
64. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. *Annu Rev Med*. 2010;61:169-185. Available at: <https://pubmed.ncbi.nlm.nih.gov/19622036>.
65. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. *Pediatrics*. 2007;119(6):e1371-1383. Available at: <https://pubmed.ncbi.nlm.nih.gov/17533177>.

What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV

Updated: June 27, 2024

Reviewed: June 27, 2024

Panel's Recommendations

- The selection of an initial antiretroviral regimen for the treatment of HIV infection in infants and children should be individualized based on factors that include patient characteristics (e.g., age, weight), regimen characteristics (e.g., efficacy, safety, tolerability), clinical and practical considerations, patient and family preferences, and the results of HIV resistance testing (AI^{III}) (see Table A below and [Appendix A. Pediatric Antiretroviral Drug Information](#)).
- For infants and children initiating treatment for HIV for the first time, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends initiating antiretroviral treatment (ART) with three drugs: a dual-nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone plus an integrase strand transfer inhibitor anchor drug, when possible. In some circumstances, an ART regimen of two NRTIs plus a non-nucleoside reverse transcriptase inhibitor or a boosted protease inhibitor as the anchor drug may be indicated for initial treatment (AI^{*}). See [Table 8. Antiretroviral Treatment Regimens Recommended for Initial Therapy for HIV Infection in Infants and Children](#) below.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I^{} = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II^{*} = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion*

[†] *Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents*

Criteria Used for Recommendations

In general, the recommendations of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) are based on reviews of pediatric and adult clinical trial data published in peer-reviewed journals, data prepared by manufacturers for U.S. Food and Drug Administration (FDA) review, and data presented in abstract format at major scientific meetings. Few randomized, Phase 3 clinical trials of antiretroviral treatment (ART) regimens in pediatric patients have directly compared different treatment regimens. Most pediatric drug data come from Phase 1/2 safety and pharmacokinetic (PK) trials and nonrandomized, open-label studies. In general, even in studies of adults, assessment of drug efficacy and potency is primarily based on surrogate marker endpoints, such as viral load ([plasma HIV RNA concentration](#)) and CD4 T lymphocyte (CD4) cell count. The Panel modifies recommendations on optimal initial therapy for children as new data become available, new therapies or drug formulations are developed, and additional toxicities are recognized.

When developing recommendations for specific antiretroviral (ARV) drugs or regimens, the Panel considers the following information:

- Data demonstrating durable viral suppression, immunologic improvement, and clinical improvement (when available) with the drug or regimen, preferably in children. However, if pediatric data are lacking, evidence in adolescents and adults is considered.
- The extent of pediatric experience with a specific drug or regimen.
- The incidence and types of short-term and long-term drug toxicity in people who are taking the drug or regimen, focusing on toxicities that are reported in children.
- The availability and acceptability of formulations that are appropriate for pediatric use, including ease of administration, formulation options (e.g., syrups, powders, or granules vs. chewable tablets vs. pediatric dispersible tablets), palatability, pill size, and number of pills or volume of oral solution needed for an appropriate dose.
- Dosing frequency and food and fluid requirements.
- The potential for drug interactions with other medications.

ART regimens recommended for use in children with HIV should generally consist of a backbone of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus a third active anchor drug from one of the following classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI) with a PK enhancer (also known as a booster; the two drugs used for this purpose are cobicistat [COBI or c] and ritonavir [RTV or r]).

The Panel classifies recommended ARV drugs or ART regimens for initial treatment of HIV infection in infants and children into one of two categories:

Preferred: ARV drugs or drug combinations are designated as *Preferred* for initial ART in ART-naïve infants and children when clinical trial data in children or, more often, in adults have demonstrated optimal and durable efficacy and when pediatric studies using surrogate markers have demonstrated safety and appropriate drug exposure. Age and weight requirements, formulations, dosing frequency, potential drug interactions, and other factors are also considered when designating ARV drugs or ART regimens as *Preferred*.

Alternative: Drugs or drug combinations are designated as *Alternative* for initial therapy when clinical trial data in children or adults show efficacy but the drugs or drug combinations have disadvantages when compared with *Preferred* regimens. Drugs or drug combinations may be classified as *Alternative* for use in initial ART regimens in children if they are less effective or durable than a *Preferred* regimen in children or adults; if specific concerns exist about toxicity, dosing, formulation, administration, or interaction; or if experience with the use of these drugs or drug combinations in children is limited.

ARV drugs or regimens that are not recommended for initial ART in children are discussed in [What Not to Start: Regimens Not Recommended for Initial Antiretroviral Therapy in Children](#). For detailed pediatric information on each drug, see [Appendix A. Pediatric Antiretroviral Drug Information](#).

Factors to Consider When Selecting an Initial ART Regimen

ART regimens for infants and children should contain three fully active drugs for durable and potent virologic suppression. When possible, the initial treatment should reflect an option that only requires once-

daily dosing and minimizes the number of liquid formulations, dispersible tablets, or pills that must be administered. Therefore, Panel recommendations reflect once-daily ARV regimens and single-tablet regimens whenever feasible.

Panel recommendations about ARV drugs and drug combinations for initial ART regimens in infants and children are influenced by the availability of FDA-approved drugs. FDA drug approvals of pediatric formulations and approvals for the use of adult formulations in children are based on weight but include age limitations for some drugs. Although age can be used as an initial guide when selecting ARV drugs for use in infants and children, body weight is the preferred determinant for drug selection and drug dosing in infants and children. Gestational age at birth and postnatal age must also be considered in the selection of some drugs for infants. Many drugs that are recommended for use in young infants do not have dosing recommendations for infants born prior to 37 weeks of gestational age (i.e., born preterm).

When making recommendations, the Panel considers efficacy and factors affecting the efficacy of a regimen, age and weight requirements, potential toxicity, tolerability, and drug or regimen characteristics that affect administration and adherence (e.g., formulations, pill size, dosing frequency). Table A below summarizes factors to consider when selecting an ART regimen for infants and children. Details about ARV formulations, fixed-dose combinations, dosing, and administration to infants and children are provided in [Appendix A. Pediatric Antiretroviral Drug Information](#). Advantages and disadvantages of ARV components recommended for initial therapy in infants and children are summarized in Table B and [Table 9](#) below. Additional information is provided in the [Adult and Adolescent Antiretroviral Guidelines](#) (see [Table B. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy](#)).

The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of diagnosis), accompanied by a discussion about the importance of adherence and provision of adherence support for all children with HIV (see [When to Initiate Antiretroviral Treatment in Children with HIV Infection](#) and [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)).

Table A. Factors to Consider When Selecting an Antiretroviral Treatment Regimen for Children

| Factors to Consider | Key Questions and Comments |
|------------------------------------|--|
| Acquired potential drug resistance | Are there any concerns that the child ^a may have HIV virus resistant to certain ARV drugs? |
| Age and weight | Are dosing, PK, and safety information for an ARV drug available based on the child's weight and age? Are there weight and/or age requirements for ARV drug use per FDA approvals or Panel recommendations, including gestational age and postnatal age requirements? Do efficacy and safety data support the choice of specific ARV drugs as part of an initial ART regimen? Is weight-band dosing information available? Weight-band dosing minimizes the need for frequent dose adjustments. |
| Available formulations | What drug formulations are available for potential treatment regimens (e.g., liquids, dispersible tablets, film-coated tablets that must be swallowed whole, tablets that can be crushed or split)? If pills are available, what is the pill size? |

| | |
|--|---|
| | Are multiclass single-tablet regimens available? See Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class and Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . |
| Frequency of dosing | Is a once-daily regimen possible? |
| Preparation and administration of medication by caregivers | <p>How complicated is preparing the medications needed for the ART regimen?</p> <p>What can be done to ensure that caregivers can safely and accurately administer the medications?</p> <p>Providers should complete the following:</p> <ul style="list-style-type: none"> • Provide medication teaching by trained medical staff. • Provide correctly sized oral syringes. • For liquids, ensure that bottles include stoppers to minimize spilling and medication wastage. • Provide medication calendars after discussing who will be administering the ART and identifying the most convenient time for administration. • Address any food restrictions or requirements for ARVs to be given with food. • Repeat teaching at each clinic visit. |
| Palatability and tolerance | How palatable and well tolerated is the regimen? |
| Ability to swallow pills | <p>Can this child swallow pills or be taught how to swallow pills?</p> <p>The age that a child can learn the skill of swallowing pills varies. Usually, children aged 4 years and older can be taught to swallow pills.</p> |
| Drug-drug interactions | Does the child require chronic treatment for any other conditions (e.g., mental health conditions, seizure disorders, tuberculosis)? If so, are there any potential drug interactions? See the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker . |
| Contraindications | Are there contraindications to prescribing a specific ARV or ART regimen? For example, a positive HLA-B*5701 allele test result is a contraindication for use of abacavir. |
| Comorbidities | Are there conditions or comorbidities that affect ARV choices for the drug regimen? Examples include tuberculosis, hepatitis B virus infection, and, for adolescents, pregnancy. |
| Toxicity | <p>What are the most common side effects and safety profiles for the ARV(s)? See Appendix A. Pediatric Antiretroviral Drug Information.</p> <p>Are there specific toxicity or side effect considerations for individual children (e.g., weight gain in children or adolescents who are overweight or obese, depression)?</p> |
| Availability, ^a cost, and insurance coverage | <p>Are the medications and formulations needed readily available? Some new drugs or pediatric formulations may not be available in certain areas, or concerns may exist about maintaining a continuous supply.</p> <p>Does the child have insurance coverage?</p> <p>Are there co-pays and, if so, can the family afford the costs?</p> <p>Does the regimen require prior authorization?</p> |

^a For the sake of brevity, the term "child" encompasses infants, children, and prepubertal adolescents.

^b Because some ARV medications or pediatric formulations may not be available in certain hospitals or geographic areas, clinicians should check availability and advocate for additions to formularies at local hospitals and/or pharmacies as needed.

Key: ART = antiretroviral therapy; ARV = antiretroviral; FDA = U.S. Food and Drug Administration; PK = pharmacokinetic

Panel Recommendations for Initial ART Regimens in Infants and Children

The following subsections group Panel recommendations for initial ART regimens for children, including prepubertal adolescents, with HIV infection according to a child's age (birth to <30 days, ≥30 days to <2 years, ≥2 to <12 years, and ≥12 years). These guidelines provide recommendations for prepubertal children and adolescents (i.e., those with [sexual maturity ratings](#) [SMR] of 1 to 3).¹ The [Adult and Adolescent Guidelines](#)² address recommendations for postpubertal adolescents (i.e., those with an SMR of 4 and 5); see [What to Start](#). It is important to point out that pediatric approvals for most drugs are now based on specific weight parameters and that weight, rather than SMR, is a key determinant in ARV drug selection.

Preferred regimens for initial ART in infants aged <30 days with HIV-1 infection include a backbone of two NRTIs. INSTI-based regimens (INSTI plus two NRTIs) plus an INSTI or a NNRTI as the anchor drug are *Preferred* for initial ART in infants and children aged ≥30 days with HIV-1 infection whenever possible.

Preferred anchor drugs, by age and weight, are listed below with *Alternative* options discussed in subsections by age group:

- Newborns and infants aged <30 days: nevirapine (NVP), **regardless of weight**, or raltegravir (RAL) if weight ≥2 kg; see [Table 8](#) below regarding gestational age considerations.
- Infants and children aged ≥30 days and weighing ≥3 kg: dolutegravir (DTG)
- Children aged ≥2 years and weighing ≥14 kg: DTG or bictegravir (BIC). BIC is available only as a component of the fixed-dose combination (FDC) tablet BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF).

INSTI-based regimens have become the *Preferred* option for initial ART regimens in infants and children (and adults) whenever possible due to their virologic efficacy, lack of drug interactions, and favorable toxicity profile.³⁻⁶ This pediatric recommendation is consistent with recommendations for initial ART in adults and adolescents (see the [What to Start: Initial Combination Antiretroviral Regimens for People with HIV](#) section of the [Adult and Adolescent Antiretroviral Guidelines](#)). Adult comparative trials have shown that INSTI-containing regimens have superior efficacy compared with PI-containing and NNRTI-containing regimens,^{7,8} and **an increasing number** of studies have evaluated the PK, safety, tolerability, and **efficacy** of these drugs in infants, children, and adolescents (see the [Raltegravir](#), [Dolutegravir](#), and [Bictegravir](#) sections).

RAL is a first-generation INSTI and is the only INSTI option FDA approved for use in infants aged <30 days. INSTI-based regimens using second-generation INSTIs that have greater efficacy and a higher barrier to resistance than RAL (i.e., **DTG** or **BIC** depending on age and weight), are recommended for initial therapy in children.

Planning for Transitions in ART Regimens

When initiating treatment in infants and children, it is recognized that there may be more potent drug options, options with lower administration burden on a caregiver, and options with lower liquid volume requirements or pill burden as an infant or child gains weight or increases in age and develops the ability to swallow pills. This section briefly addresses planning regimen transitions. Information and recommendations about the sequence and selection of ARV drugs after initial therapy are provided in other Guidelines sections. [Modifying Antiretroviral Regimens in Children with Sustained Viral Suppression on Antiretroviral](#)

[Therapy](#) discusses modifications to simplify or optimize treatment or to manage a specific toxicity. [Recognizing and Managing Treatment Failure](#) discusses situations where viral suppression has not been reached on initial ARV therapy. [Management of Medication Toxicity or Intolerance](#) provides an overview of management with links to toxicity tables (e.g., [Lipodystrophies and Weight Gain](#), [Dyslipidemia](#)) that address specific issues.

Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Antiretroviral Therapy Regimens

Dual-NRTI combinations form the backbone of ART regimens for the treatment of HIV in both adults and children and are used in combination with an anchor drug from one of the following ARV classes: INSTIs, PIs, or NNRTIs. Dual-NRTI backbones recommended by the Panel as part of *Preferred* or *Alternative* ART regimens for children or for use in special circumstances are listed below, with links to sections in [Appendix A. Pediatric Antiretroviral Drug Information](#) that provide detailed information about the formulations, dosing, safety, and use of each drug in infants and children.

- [\(Zidovudine \[ZDV\] or abacavir \[ABC\]\) plus \(lamivudine \[3TC\] or FTC\)](#)
- [TAF](#) plus FTC for children weighing ≥ 14 kg. Some FDCs for complete ART regimens that include TAF have varying weight and age requirements.
- [Tenofovir disoproxil fumarate \(TDF\)](#) for children aged ≥ 2 years and weighing ≥ 10 kg plus 3TC or FTC

Dual-NRTI selection is influenced by a child's weight and age, as well as the availability of FDCs for NRTI combinations or FDCs for complete ART regimens. The advantages and disadvantages of the different dual-NRTI backbone options that are recommended for initial therapy in children are shown in [Table 9](#) and discussed briefly below.

ZDV has been shown to be safe and effective as part of ART regimens for infants and children; however, hematologic toxicity (anemia, neutropenia, and/or thrombocytopenia) may affect its use in some children.^{9,10} Twice-daily dosing of ZDV is required for all ages. Other NRTIs that require only once-daily dosing in children are available (e.g., ABC [for some age groups], FTC, TAF). Hematological toxicity and twice-daily dosing requirements limit the long-term use of ZDV in children.

ABC is only approved by the FDA for use in children aged ≥ 3 months, but the Panel recommends use of ABC from birth in full-term infants (see [Abacavir](#)).^{11,12} The Panel supports ABC dosing in neonates that is based on PK simulation models and has been endorsed by the World Health Organization. A negative test for the HLA-B*5701 allele must be obtained prior to use of ABC.

3TC and FTC are considered interchangeable as part of ART regimens; both are well tolerated and are associated with few adverse effects (AEs). FTC can be substituted for 3TC as one component of a *Preferred* dual-NRTI backbone (i.e., FTC plus ABC, TDF, or ZDV). Both 3TC and FTC select for the M184V resistance mutation, which is associated with high-level resistance to both drugs, a modest decrease in susceptibility to ABC, and improved susceptibility to ZDV and TDF as a result of possible decreased viral fitness.^{13,14}

TDF-containing regimens are efficacious and well tolerated. However, reductions in bone mineral density can manifest in children and adults soon after initiating TDF, the clinical significance of which is unknown.¹⁵⁻²⁰ This reduction in bone density is reversible with drug discontinuation. Although TDF is associated with a decline in glomerular filtration rate, the effect is generally small, and severe glomerular

toxicity is rare.^{21,22} Irreversible renal failure is very rare, but cases have been reported.²³ With long-term use of TDF, renal toxicity can occur at the site of the proximal convoluted tubules, with clinical manifestations ranging from asymptomatic proteinuria to progressively declining glomerular filtration rates.^{21,24} Before starting treatment, clinicians should consider whether the benefits of using TDF outweigh the potential risks described above. The combination of TDF with atazanavir (ATV)/r, darunavir (DRV)/r, or lopinavir (LPV)/r increases plasma tenofovir concentrations and the risk of TDF-associated toxicity.²⁵

TAF is only available in FDC tablets that must be swallowed. With TAF, the active drug tenofovir (TFV) achieves higher intracellular concentrations and lower plasma concentrations than TDF. Bone and renal toxicity associated with TDF is linked to higher plasma concentrations of TFV, which may explain why these toxicities do not occur with TAF. Use of COBI- or RTV-boosted PIs in combination with TAF/FTC is not recommended in children weighing <35 kg because these drugs can increase TAF exposure, and no data are available on the use of this combination. In children and adolescents weighing ≥35 kg, boosted PIs can be used with TAF/FTC.

Weight gain and increased risk for clinical obesity have been reported in adults with the use of TAF- and INSTI-containing regimens,^{26,27} but these side effects have not been clearly demonstrated in children.²⁸⁻³⁰ Furthermore, use of TAF-containing regimens has also been associated with increased levels of total and low-density lipoprotein cholesterol and triglycerides. When these concerns arise, regimens containing TDF may be preferable. However, providers must consider the risks of proximal renal tubular injury, rare irreversible renal failure, and decreased bone mineral density that can occur when TDF is used.

NRTI Backbone Selection with Hepatitis B Virus Coinfection

When selecting the NRTI backbone for an initial ART regimen, FTC, 3TC, TDF, and TAF have antiviral activity and efficacy against hepatitis B virus (HBV) and should be considered for use in children with HBV/HIV coinfection. For a comprehensive review, see the [Hepatitis B Virus](#), [Hepatitis C Virus](#), and [Mycobacterium tuberculosis \(TB\)](#) sections of the [Pediatric Opportunistic Infection Guidelines](#).

Recommended Initial ART Regimens for Infants from Birth to <30 Days of Age

Panel recommendations for the anchor drugs for *Preferred* and *Alternative* initial ART regimens in infants aged <30 days (i.e., RAL, NVP, and LPV/r) reflect FDA approval by current weight and the infant's postmenstrual age (calculated as gestational age at birth plus postnatal age) at the time the ARV regimen or specific ARV drug is initiated.

Preferred Regimens

- Term infants (≥37 weeks gestation) or preterm infants with a postmenstrual age ≥37 weeks at the time of treatment initiation:
 - [NVP](#) plus [ZDV](#) plus ([3TC](#) or [FTC](#)) *or*
 - [RAL](#) (for infants weighing ≥2 kg) plus [ZDV](#) plus ([3TC](#) or [FTC](#))
- Preterm infants with a postmenstrual age ≥32 weeks to <37 weeks at the time of treatment initiation:
 - [NVP](#) plus [ZDV](#) plus ([3TC](#) or [FTC](#))
- Preterm infants with a postmenstrual age <32 weeks at the time of treatment initiation:

- Consultation with a pediatric HIV expert or the [National Perinatal HIV/AIDS Hotline](#) (1-888-448-8765) is recommended.

Rationale

The Panel recommends RAL or NVP administered with an NRTI backbone of ZDV plus 3TC as an initial regimen for the treatment of HIV-1 infection in infants. These regimens consist of ARV drugs that are FDA approved, with extensive data on the safety and efficacy of their use in infants and children.³¹⁻³⁷ The selection of anchor drug and regimen will depend on several factors, such as ARV resistance during pregnancy, the infant's gestational age at birth, current postmenstrual age, weight at treatment initiation, the caregiver's perceived ease of preparing and dosing, availability of appropriate formulations, and availability of medications in the outpatient setting. These have been summarized in [Table B. Advantages and Disadvantages of ARVs Recommended for Initial Antiretroviral Therapy in Infants From Birth to <30 Days of Age](#) below. Resistance testing should be performed at the time of HIV diagnosis and before initiation of ART but should not delay treatment initiation. Initial ART regimens can be modified if needed based on results (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

At the time of HIV diagnosis, some infants at high risk for HIV acquisition may have initiated presumptive HIV therapy. The regimens recommended for presumptive HIV therapy are addressed in [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#) and are the same as the ARV regimens recommended for treatment of HIV infection in neonates. Therefore, once the diagnosis of HIV-1 is established in the neonate, the regimen for presumptive HIV therapy can be continued—now as definitive ART—with virologic monitoring to establish successful viral suppression (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

At the time of HIV diagnosis, some infants at low risk for HIV acquisition might be receiving ZDV alone as prophylaxis. If the infant has a positive HIV nucleic acid test, a complete ART regimen should be initiated without waiting for the results of a confirmatory test. In this case, ZDV may be continued with the addition of a second NRTI and either RAL or NVP. If RAL or NVP is not an option, a LPV/r-based regimen appropriate for the infant's age and weight can be used (see *Alternative Regimens* below). If confirmatory testing indicates the infant does not have HIV infection, ART can be discontinued.

Alternative Regimens

Alternative Anchor Drug

- Infants with a postmenstrual age \geq 42 weeks **and** a postnatal age of \geq 14 days
 - [LPV/r](#) plus [ZDV](#) plus ([3TC](#) or [FTC](#))

LPV/r: The Panel recommends LPV/r oral solution in combination with the NRTI backbone recommended in *Preferred Regimens* above as an *Alternative* anchor drug for infants with a postmenstrual age of \geq 42 weeks of gestation and a postnatal age of $>$ 14 days. LPV/r oral solution contains 42.4% (volume/volume) alcohol and 15.3% (weight/volume) propylene glycol. Use of this drug in infants before 42 weeks postmenstrual age and before a postnatal age of 14 days, at a time when hepatic metabolic function and kidney excretory function are maturing, can lead to accumulation of LPV, alcohol, and propylene glycol, resulting in serious cardiac, renal, metabolic, or respiratory problems. For more information about LPV/r use in newborns, refer to the [Lopinavir/Ritonavir](#) section in [Appendix A. Pediatric Antiretroviral Drug Information](#).

Alternative NRTI Backbone

- Term infants (≥ 37 weeks gestation)
 - ABC plus (3TC or FTC) if HLA-B*5701 negative

ABC: A negative test for the HLA-B*5701 allele must be obtained prior to use of ABC. Although ABC is not FDA approved for use in infants aged <3 months, the Panel recommends ABC as part of an *Alternative NRTI backbone* for full-term infants from birth (see Abacavir). An ABC dosing recommendation using PK simulation models has been endorsed by the World Health Organization using weight-band dosing for full-term neonates. A recent study of infants with HIV in a South African cohort, stratified by age (<28 days and ≥ 28 days) and weight (<3 kg and ≥ 3 kg), demonstrated the safety and effectiveness of ABC in infants aged <3 months and in neonates weighing <3 kg.^{11,12,38}

Table B. Advantages and Disadvantages of Anchor Drugs Recommended for Initial Antiretroviral Therapy Regimens in Infants From Birth to <30 Days of Age

| Preferred and Alternative Anchor Drugs ^a | Advantages | Disadvantages |
|---|--|---|
| RAL | <ul style="list-style-type: none"> • FDA-approved INSTI for use in term newborns weighing ≥ 2 kg • Produces rapid reduction in viral load • Safe and well tolerated • Avoids use of NVP and exposure to another class of ARVs (NNRTIs) | <ul style="list-style-type: none"> • First-generation INSTI with lower barrier to resistance than DTG or BIC • Granule formulation requires a multistep preparation before administration. • Caregivers must be taught how to properly prepare granule formulation. Explain that only a small volume of the prepared granule suspension is used; the rest must be discarded and cannot be reused. • Limited to use in term infants (≥ 37 weeks of gestation) or preterm infants with a postmenstrual age ≥ 37 weeks at the time of treatment initiation |
| NVP | <ul style="list-style-type: none"> • Available in convenient oral solution • Can be used in preterm newborns with a gestational age ≥ 32 weeks | <ul style="list-style-type: none"> • Not a Preferred ARV outside the neonatal period due to the potential for toxicity and development of viral resistance, though it can be used if clinically indicated • Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen • A single mutation can confer resistance to this drug and, in some instances, to all NNRTIs. |
| LPV/r | <ul style="list-style-type: none"> • Available in convenient oral solution • More durable than RAL or NVP | <ul style="list-style-type: none"> • Should not be administered to neonates before a postmenstrual age of 42 weeks (calculated as gestational age at birth plus |

| Preferred and Alternative Anchor Drugs^a | Advantages | Disadvantages |
|---|-------------------|--|
| | | <p>postnatal age) and a postnatal age <14 days</p> <ul style="list-style-type: none"> Poor palatability and bitter taste may cause incomplete dosing if infant spits it out. Not a Preferred ARV outside the neonatal period due to issues with palatability and concerns about toxicity, though it can be used if clinically indicated |

^a This table focuses on advantages and disadvantages regarding the selection of anchor drugs for ART regimens used in infants aged <30 days. Additional information is available in [Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Infants and Children](#).

Key: ART = antiretroviral therapy; ARV = antiretroviral; BIC = bictegravir; DTG = dolutegravir; FDA = U.S. Food and Drug Administration; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; RAL = raltegravir

Practical and Clinical Considerations

The clinician should provide the infant's caregiver with information about prescribed medications, including names, doses, dose times, potential side effects, and how to properly administer the medications.

Appropriately sized oral syringes should be dispensed, and liquid medications should include bottle adapter plugs to minimize wastage. Practice preparing and administering the medications should be completed and documented in the medical record. This is especially important when RAL is prescribed because there is a multistep process to prepare the infant dose using the oral granules for suspension (see [Raltegravir](#)). ARV availability and complexity of preparation and administration may affect decisions about the use of NVP versus RAL. It is recommended that a medication calendar be provided and that the caregiver be involved in deciding the most convenient times for the medications to be administered. Clinicians should ensure that insurance covers the prescribed ART regimen and that the infant's local pharmacy stocks all components of the regimen. For neonates who are initiating ART while still in the hospital, clinicians should provide caregivers with the appropriate information and an initial supply of medications before discharge.

At each clinic visit, the clinician and caregiver should review the process of preparing the different liquid formulations of the medications to ensure that correct volumes and doses are being administered. When appropriate, weight-band dosing should be used and doses should be adjusted based on weight gain and age. This is particularly important during the first weeks of life, when changes to drug metabolism and renal function occur that impact appropriate dosing recommendations (see [Appendix A. Pediatric Antiretroviral Drug Information](#)). Refills should be arranged with pharmacies that stock the ARV drugs.

Special Situations

- ARV Drug Resistance:** Infants can acquire HIV infection with drug-resistant virus. Transmitted drug resistance has been demonstrated with NNRTIs, NRTIs, PIs, and INSTIs, although transmitted resistance to INSTIs is very rare.³⁹ Therefore, when viral suppression was not achieved during pregnancy and drug resistance is suspected, the parent's ARV resistance data should be reviewed, if available, and

consultation with a pediatric HIV expert is recommended. In neonates, a *Preferred* ART regimen should be commenced immediately; this may later be changed or modified based on the results of baseline infant HIV genotyping (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

- **HIV-2 Infection:** ART regimens for infants with HIV-2 infection only or infants with HIV-2 and HIV-1 coinfection should include ARVs that are active against HIV-2. Because NNRTIs are not active against HIV-2, NVP should not be used. A RAL-based regimen is recommended for infants with HIV-2 or with HIV-2 and HIV-1 coinfection: RAL (for full-term infants weighing ≥ 2 kg) plus ZDV plus (3TC or FTC). Consultation with a pediatric HIV expert or the [National Perinatal HIV/AIDS](#) Hotline (1-888-448-8765) is recommended for the care of infants weighing <2 kg or with a gestational age <37 weeks.

Planning ARV Transitions

Although the ARV regimen started in the first 29 days of life can be continued, the Panel recommends that consideration be given to changing the regimen to a DTG-containing regimen after the infant reaches the appropriate age and weight; see *Preferred Regimens for Children Aged ≥ 30 Days to <2 Years* below. This change should be considered because DTG has greater efficacy and durability than RAL or NVP,⁴⁰ DTG dispersible tablets are easier to prepare and administer than RAL granules, and DTG is available in a FDC formulation.

Recommended Initial ART Regimens for Infants and Children Aged ≥ 30 Days to <2 Years

Preferred Regimens

- Aged ≥ 30 days to <2 years and weighing ≥ 3 kg^a
 - DTG plus ABC plus (3TC or FTC) if HLA-B*5701 negative *or*
 - DTG plus ZDV plus (3TC or FTC) *or*
- Aged ≥ 3 months to <2 years and weighing ≥ 6 kg to <25 kg
 - DTG plus ABC plus 3TC as a FDC (Triumeq PD) if HLA-B*5701 negative

^aFor infants aged ≥ 30 days who weigh <3 kg, therapy should be initiated using one of the regimens described in Recommended Initial ART Regimens for Infants from Birth to <30 Days of Age above (e.g., NVP or RAL). Transition to a DTG-based regimen should be considered when the infant's weight is ≥ 3 kg.

Rationale

It is assumed that all children in this age group are unable to swallow pills and will require treatment with ARVs in liquid, dispersible tablet, powder packet, or chewable tablet formulations.

For infants and children weighing ≥ 3 kg who are starting ART at ≥ 30 days of age, the Panel recommends initiation of an INSTI-based ART regimen using DTG plus two NRTIs. DTG is a second-generation INSTI that has a higher barrier to resistance than RAL and is FDA approved for use in this age group. While there is low potential for development of resistance with DTG, young infants may initially have very high HIV viral loads and continue to have low-level viremia during the first year of life. The overall risk of developing resistance with DTG-based ART in young infants is unknown.

INSTIs have better efficacy and safety profiles than NNRTIs or PIs, and DTG has been studied extensively in children.^{3,5} Importantly, the FDC of DTG/ABC/3TC has proven efficacy and a good safety profile, with weight-band dosing that achieves PK targets.⁴¹

For infants aged ≥ 30 days to ≤ 6 weeks receiving presumptive HIV therapy with RAL or NVP plus two NRTIs at the time of HIV diagnosis, the Panel recommends changing to one of the DTG-based regimens listed above using DTG dispersible tablets. The liquid formulations of the NRTIs used as part of presumptive HIV therapy (usually ZDV plus 3TC) can be continued; no change in NRTIs is required.

Alternative Regimens

Alternative Anchor Drugs

- LPV/r: LPV is available as an oral solution coformulated with RTV, and twice-daily dosing is recommended. LPV/r should be administered with food to improve tolerability.^{34,42,43} Poor taste and palatability of the oral solution may become an issue for young children and limit acceptance of this regimen. LPV/r has a high genetic barrier to drug resistance. However, poor acceptance of formulation, gastrointestinal side effects, and poor weight gain may limit its use in this age group.⁴⁴
- ATV/r: ATV/r can be considered an *Alternative* to LPV/r in children weighing ≥ 15 kg.⁴⁵ ATV and RTV are available as separate powder packets that are mixed with either soft food or formula and administered once daily. The powder formulation of ATV can be used in children weighing ≥ 15 kg to < 25 kg. The powder formulations have poor palatability and may be difficult to tolerate in this age group.
- NNRTIs: NVP could be considered if there is resistance or intolerance to both PIs and INSTIs. However, NVP is generally not recommended as an initial treatment in this age group as the low genetic barrier to resistance during a time of significant viremia may lead to drug resistance to all members of the NNRTI class of drugs.³⁵ Efavirenz (EFV) is not recommended for children < 3 years of age due to highly variable PK in young children, difficulty in determining an appropriate dose without therapeutic drug monitoring, and side effects (i.e., neurologic toxicity).⁴⁶

NRTI Backbones in Alternative Regimens

- Twice-daily dosing: An NRTI backbone of ZDV plus 3TC twice daily or ABC plus 3TC twice daily allows for all medications to be administered at the same time when given in combination with LPV/r or RAL. There is considerable experience with ZDV and 3TC in this age group. ABC is associated with less bone marrow toxicity than ZDV and may be the *Preferred* NRTI for long-term use.

Practical and Clinical Considerations

DTG plus ZDV plus 3TC can be initiated immediately. However, due to the potential of ABC hypersensitivity, a negative test for the HLA-B*5701 allele must be obtained before initiating a regimen of DTG plus ABC plus 3TC. HLA-B*5701 should be included in the initial work-up for all infants and children with HIV. ABC is not FDA approved for use in infants aged < 3 months, but the Panel does recommend use of twice-daily ABC for infants aged ≥ 30 days. In decisions about selecting ABC as a component of the initial regimen for children aged < 2 years, clinicians should consider concerns regarding delays initiating treatment related to HLA-B*5701 testing versus the advantages of using an FDC.

For infants who are aged ≥ 30 days and ≥ 3 kg in weight, DTG is available as dispersible tablets that are administered separately, along with the liquid formulations of ZDV and 3TC. For infants and children

weighing ≥ 6 kg to <25 kg who are initiating therapy at ≥ 3 months of age, DTG plus ABC plus 3TC is available as dispersible FDC tablets (Triumeq PD) that can be administered once daily and provide a number of advantages:

- Tablets are mixed in water (volume depends on the number of tablets needed for weight-band dosing; see [Dolutegravir](#) for details about dosing and preparation).
- Once-daily dosing improves adherence to ARVs.
- Use of the FDC formulation avoids the need to measure and administer liquid ZDV and 3TC separately and minimizes difficulties in accurately measuring the volumes needed.
- Use of the FDC minimizes the need to adjust doses frequently as the infant or child grows.

When teaching families about preparing the medications, it should be explained that dispersible tablets need to be mixed in water because there is a lack of data about dispersing DTG or DTG/ABC/3TC dispersible tablets in other liquids, such as formula or breast milk. With once-daily dosing, it is particularly important to emphasize the critical importance of not missing any doses.

Special Situations

- **DTG dispersible tablets not available:** If DTG dispersible tablets are not available, RAL can be administered using either the oral granules for suspension dispersed in water or as the chewable tablets dispersed in juice or formula/milk.⁴⁷ RAL oral granules for suspension require a multistep process to prepare each dose, and twice-daily dosing is required. RAL also has a lower genetic barrier to resistance compared to DTG.
- **Identification of viral resistance:** If viral resistance is identified in baseline genotype testing, the initial ART regimen may need to be modified.
 - **INSTI resistance:** If resistance to INSTIs is present, the regimen should consist of the NRTI backbone plus a PI. Use of LPV/r is recommended in this situation, as it is coformulated with ritonavir in a formulation suitable for administration in this age group. If there is multidrug ARV resistance, consultation with a pediatric HIV expert is recommended.
 - **Presence of M184V resistance mutation:** If the M184V/I mutation associated with FTC and 3TC is present, these medications should be continued if the new regimen contains TDF, TAF, or ZDV. The presence of this mutation may increase susceptibility to these NRTIs.
- **HLA-B*5701 positive:** ART regimens with ABC should not be given due to ABC-associated hypersensitivity.
- **Presence of HBV infection:** In HIV/HBV coinfection, an ART regimen should include two NRTIs active against HBV (see Selection of Dual–Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Antiretroviral Therapy Regimens above). However, regimens containing only one active NRTI (3TC or FTC) may be used when children in this age group don't meet the weight criteria for use of a second NRTI active against HBV. They should be changed to a TAF/FTC-containing regimen as soon as possible after they weigh ≥ 14 kg.
- **HIV-2 infection:** ART regimens for infants and children with HIV-2 infection only or those with HIV-2/HIV-1 coinfection should include ARVs that are active against HIV-2. Consultation with a pediatric HIV expert is recommended for the care of infants and children with HIV-2.

Planning ARV Transitions

For infants aged ≥ 3 months and weighing ≥ 6 kg who initiated treatment on DTG plus ZDV plus (3TC or FTC), the Panel recommends changing to a regimen of once-daily DTG plus ABC plus 3TC that is available as dispersible FDC tablets (Triumeq PD) in order to simplify measurement of ARV doses and administration. A negative test for the HLA-B*5701 allele must be obtained prior to initiation of an ABC-containing regimen.

There are additional options for transitioning to other INSTI-containing preparations as children become older and are able to swallow pills, such as the FDC BIC/FTC/TAF (Biktarvy), which can be used in children aged ≥ 2 years and weighing ≥ 14 kg (see discussion in Recommended Initial ART Regimens for Children Aged ≥ 2 Years to <12 Years below). The NRTI backbone FTC/TAF is available in a FDC (Descovy) that can be used in combination with an anchor drug, such as DTG, in children weighing ≥ 14 kg who are able to swallow pills.

Recommended Initial ART Regimens for Children Aged ≥ 2 Years to <12 Years

Preferred Regimens

In considering an initial ART regimen for children aged ≥ 2 years to <12 years, some children, particularly younger children, may not be able to swallow pills, whereas older children may be able to take pills. It is recommended that clinicians counsel families about teaching children how to swallow pills, as this increases the number of ARV options and simplifies regimens.⁴⁸ Children as young as 4 years of age can be taught how to swallow pills. In addition to age and ability to swallow pills, the weight of the child must also be taken into consideration. Therefore, the Panel recommendations for what regimen to start are presented for children unable to swallow pills and those who are able. FDA-approved pill formulations are based on a child's weight, followed by recommendations for those who are able to swallow pills and the minimum weight allowed for dosing. Please refer to [Appendix A. Pediatric Antiretroviral Drug Information](#) for specific dosing of ARV drugs by weight band.

Preferred Regimens for Children Aged ≥ 2 Years to ≤ 12 Years Who Are Not Able to Swallow Pills

- DTG plus ABC plus 3TC in the dispersible FDC formulation (Triumeq PD) for children weighing 6 kg to <25 kg if HLA-B*5701 negative *or*
 - DTG film-coated tablets (Tivicay) plus ABC plus (3TC or FTC) in liquid formulations for children weighing ≥ 25 kg if HLA-B*5701 negative (see [Dolutegravir](#) for special instructions about administering DTG tablets to children who are not able to swallow pills)
- DTG plus FTC plus TAF for children weighing ≥ 14 kg (see [Dolutegravir](#) and [Tenofovir Alafenamide](#) for available formulations of DTG [Tivicay, Tivicay PD], dosage strengths of FTC/TAF [Descovy], and special instructions for administering DTG film-coated tablets and FTC/TAF tablets to children who are not able to swallow pills) *or*
- DTG in dispersible tablets plus ZDV plus (3TC or FTC) in liquid formulations

The dispersible FDC tablet of DTG/ABC/3TC (Triumeq PD) is a once-daily regimen. A child must have a negative HLA-B*5701 allele screening test prior to initiation of treatment to ensure that the child will not be at risk for a hypersensitivity reaction to ABC.

When the DTG/ABC/3TC dispersible FDC tablet cannot be used (i.e., it is not available or results of HLA-B*5701 testing are unknown or positive) and the child weighs <14 kg at treatment initiation, the Panel recommends initiating a regimen of DTG plus ZDV plus 3TC. DTG is available as dispersible tablets (Tivicay PD) dosed once daily that can be used in children weighing 6 kg to <25 kg. ZDV and 3TC are both available in liquid formulations and require twice-daily dosing. If DTG/ABC/3TC cannot be used and the child weighs ≥14 kg, DTG plus FTC/TAF (Descovy) is recommended by the Panel. FTC/TAF (Descovy) is available in two different-strength tablets, with the lower-strength tablet for children weighing ≥14 kg to <25 kg.

Preferred Regimens for Children Aged ≥2 Years to ≤12 Years Who Are Able to Swallow Pills

For children weighing <14 kg, see regimens listed above for children who are not able to swallow pills.

- BIC plus FTC plus TAF (FDC BIC/FTC/TAF, Biktarvy) for children weighing ≥14 kg
- DTG plus FTC plus TAF (DTG, Tivicay, plus the FDC FTC/TAF, Descovy) for children weighing ≥14 kg
- DTG plus ABC plus 3TC (FDC DTG/ABC/3TC, Triumeq) for children weighing ≥25 kg if HLA-B*5701 negative

Rationale

The Panel recommends initiating ART with a once-daily, single-tablet regimen of BIC/FTC/TAF (Biktarvy) for children weighing ≥14 kg. Two different strengths of BIC/FTC/TAF tablets are available, with the lower-strength tablet for children weighing ≥14 kg and <25 kg. The product label states that for children who are unable to swallow a whole tablet, the BIC/FTC/TAF tablet can be split and each part taken separately, as long as all parts are ingested within approximately 10 minutes.⁴⁹

DTG/3TC/ABC (Triumeq) is another *Preferred* single-tablet regimen option for children weighing ≥25 kg; however, the DTG/3TC/ABC pill is much larger than the BIC/FTC/TAF pill and might be more challenging to swallow, particularly for younger children. If DTG/3TC/ABC is selected, documentation of a negative HLA-B*5701 screening should occur prior to treatment initiation. For children weighing ≥14 kg, the film-coated tablet of DTG (Tivicay) used in conjunction with the FDC tablets of FTC/TAF (Descovy) is also recommended by the Panel.

The FDC of BIC/FTC/TAF (Biktarvy) has been studied in adolescents aged 12 years to <18 years and weighing ≥35 kg (Cohort 1), children aged 6 years to <12 years and weighing ≥25 kg (Cohort 2), and children aged ≥2 years and weighing ≥14 kg to <25 kg (Cohort 3). All participants had maintained viral loads <50 copies/mL for ≥6 months. Cohorts 1 and 2 received the adult formulation of BIC/FTC/TAF. Children in Cohort 3 received BIC 30 mg/FTC 120 mg/TAF 15 mg. Overall, the drug was well tolerated in all participants in all cohorts. Drug exposure in all cohorts was similar to the exposure observed in adults. At 24 weeks, all 50 adolescents (Cohort 1) and 50 children (Cohort 2) maintained viral suppression, and at Week 48, 49 of 50 participants in each cohort maintained suppression.⁵⁰ Among children in Cohort 3, after 24 weeks, all 12 participants maintained viral suppression.

DTG, studied in the multinational open-label IMPAACT 1093 study^{3,51,52} and ODYSSEY^{4,10,53} has been demonstrated to be safe, efficacious, and well tolerated in children. The dispersible tablet formulation of the FDC ABC 60 mg/DTG 5 mg/3TC 30 mg (Triumeq PD) has been studied in IMPAACT P2019 to confirm dosing of the three-drug FDC in pediatric patients aged <12 years (NCT03760458). In IMPAACT P2019,

children are being dosed in five weight bands aligned with WHO-preferred weight bands. Results of the initial PK and safety assessments for 35 participants in weight bands ≥ 6 kg demonstrated acceptable PK parameters and tolerability for all cohorts and confirmed dosing according to World Health Organization weight bands.⁴¹

Alternative Regimens

Anchor Drugs

When concern for INSTI resistance exists, the following anchor drugs represent *Alternative* treatment options when paired with two fully active NRTIs.

- **ATV plus RTV or COBI:** ATV is available as a powder packet that should be mixed with solid food and administered once daily. ATV powder should be coadministered with RTV once daily for a child aged ≥ 2 years and weighing ≥ 15 kg to ≤ 25 kg. RTV is also available in powder packets; the powder formulation has poor palatability and may be difficult to tolerate. For a child weighing ≥ 15 kg who is able to swallow pills, the capsule formulation of ATV can be dosed once daily with the RTV tablets (i.e., ATV/r). Boosting ATV with COBI is only an option if the child weighs ≥ 35 kg and is able to swallow pills. The FDC of COBI-boosted ATV (ATV/c) can be administered once daily.
- **DRV plus RTV or COBI:** DRV, dosed twice daily, is an option for children aged ≥ 3 years to <12 years and weighing ≥ 20 kg. However, DRV requires a PK enhancer or boosting agent, such as RTV or COBI. DRV is available as a solution or tablet that can be administered with a RTV powder packet or tablet. Boosting DRV with COBI is only an option if the child weighs ≥ 40 kg. COBI-boosted DRV (DRV/c) is available in a once-daily FDC (Prezcobix).
- **NNRTIs:** An NNRTI-based regimen using NVP, EFV, or doravirine (DOR) could be considered if there is resistance or intolerance to both PIs and INSTIs. EFV is not recommended by the Panel for use in children aged <3 years due to highly variable PK in young children, difficulty in determining an appropriate dose without therapeutic drug monitoring, and side effects (i.e., neurologic toxicity) (see [Efavirenz](#)). DOR is approved for use in children weighing ≥ 35 kg, and recent data found that once-daily dosing of DOR/3TC/TDF was safe and well tolerated for maintaining viral suppression through 96 weeks in adolescents.⁵⁴

Practical and Clinical Considerations

The availability of FDC formulations and method of administration are important considerations in the selection of a *Preferred* initial regimen.

- BIC/FTC/TAF (Biktarvy) is a single-tablet regimen for children weighing ≥ 14 kg. The tablet may not be crushed or dissolved; however, it can be split in half prior to dosing for ease of swallowing. BIC/FTC/TAF is available in two formulations for children able to swallow pills, including BIC 30 mg/FTC 120 mg/TAF 15 mg for children weighing ≥ 14 kg to <25 kg and BIC 50 mg/FTC 200 mg/TAF 25 mg for children weighing ≥ 25 kg.
- ABC/DTG/3TC (Triumeq PD) are dispersible tablets that can be used in children weighing <25 kg and should be dissolved in water. Each tablet contains all three drugs. The number of tablets per dose is based on a child's weight.

- ABC/DTG/3TC (Triumeq) is a nondispersible, single-tablet regimen option for children weighing ≥ 25 kg who are able to swallow whole pills. However, a disadvantage is the larger pill size, which can make swallowing challenging compared with the other recommended options.
- DTG plus FTC/TAF is dosed once daily. DTG is available as dispersible tablets (Tivicay PD) and as a film-coated tablet (Tivicay). FTC/TAF (Descovy) is available in two different strengths as a single tablet to be swallowed. See [Dolutegravir](#) and [Tenofovir Alafenamide](#) for specific weight parameters and for special instructions about administering these ARVs to children who are not able to swallow pills.

Special Situations

- Identification of viral resistance: If viral resistance is identified in baseline genotypic testing, the initial ART regimen may need to be modified.
 - INSTI resistance:** If resistance to INSTIs is present, the regimen should consist of the NRTI backbone plus a boosted PI. PI options include ATV or DRV, both of which should be boosted with either RTV or COBI. See *Alternative Regimens* Anchor Drugs above for age and weight restrictions for each PI in conjunction with its formulation and its boosting agent. If there is multidrug ARV resistance, consultation with a pediatric HIV expert is recommended.
 - Presence of M184V resistance mutation:** Regimens should contain at least two, but preferably three, fully active drugs for durable and potent virologic suppression. If the M184V/I mutation associated with FTC and 3TC is present, these medications should be continued if the regimen contains TDF, TAF, or ZDV. The presence of this mutation may increase susceptibility to these NRTIs.
- HLA-B*5701 positive:** ARV regimens with ABC should be avoided due to ABC-associated hypersensitivity.
- Presence of HBV infection:** The ART regimen should include two NRTIs active against HBV (see Selection of Dual–Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Antiretroviral Therapy Regimens above). The Panel recommends the FDC FTC/TAF (Descovy) as the NRTI backbone for children with HIV/HBV coinfection.
- HIV-2 infection:** ART regimens for children with HIV-2 infection only or those with HIV-2/HIV-1 coinfection should include ARVs that are active against HIV-2. Consultation with a pediatric HIV expert is recommended for the care of infants and children with HIV-2.

Planning ARV Transitions

Among children aged ≥ 2 years to < 12 years who initiated treatment when they were unable to swallow pills or whose weight precluded use of a pill option, once children can swallow pills and are of an appropriate age, the Panel recommends transitioning to the once-daily FDC of BIC/FTC/TAF (Biktarvy), so long as there are no contraindications.

Recommended Regimens for Children and Adolescents Aged ≥ 12 Years

Recommendations for initial ART regimens for adolescents are also addressed in [What to Start](#) in the [Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV](#) (see [Adolescents and Young Adults with HIV](#)), with an overview provided here.

Pubertal changes during adolescence encompass increased growth velocity, changes in body composition, and development of secondary sexual characteristics. It is recognized that these changes can affect the PK and pharmacodynamics of drugs. Adolescents with perinatal HIV infection are more likely to have delayed puberty and growth compared to their uninfected peers.⁵⁵ However, regimens recommended for initial ART in the [Adult and Adolescent Guidelines](#) provide adequate drug exposure and are effective and safe when used for people with HIV infection in this age bracket above a minimum weight, regardless of pubertal stage.

Preferred Regimens

For adolescents aged ≥ 12 years who do not have a history of using long-acting cabotegravir (CAB-LA) for HIV preexposure prophylaxis (PrEP), *Preferred* ART regimens are listed below.

- [BIC](#) plus [FTC](#) plus [TAF](#) (FDC [BIC/FTC/TAF](#), Biktarvy) for adolescents weighing ≥ 25 kg
- [DTG](#) plus [ABC](#) plus [3TC](#) (FDC [DTG/ABC/3TC](#), Triumeq) for adolescents weighing ≥ 25 kg
- [DTG](#) plus [FTC](#) plus [TAF](#) (FDC [FTC/TAF](#), Descovy) for adolescents weighing ≥ 35 kg

DRV-based regimens are recommended for initial therapy in adolescents who previously received CAB-LA for PrEP (see *Alternative Regimens* below).

In the unlikely event that some adolescents aged ≥ 12 years are not able to swallow pills or weigh <25 kg, please refer to the *Preferred* regimens in the 2- to 12-year age group above and [Table 8](#) below.

Rationale

The *Preferred* regimens (BIC/FTC/TAF and DTG/ABC/3TC) are consistent with the Panel's recommendations for the 2- to 12-year age group and are available as FDC single-tablet regimens that contain the appropriate dose of the three drugs for the specified weight. These FDC regimens are also the same as those recommended for use in adults and adolescents without delay in pubertal onset, allowing for the continuation of the same initial *Preferred* regimen as patients transition through puberty in adolescence to adulthood. The third regimen, DTG plus FTC plus TAF, is not a single-tablet regimen and has the disadvantage of requiring use of two tablets for each dose.

The [Adult and Adolescent Guidelines](#) also recommend the two-drug regimen DTG/3TC as an option for initial ART in some individuals (see [What to Start](#)). However, the Panel does not recommend a DTG/3TC regimen for initial therapy in adolescents because data are limited about its use for this age group and there are concerns about the efficacy and durability of two-drug ART regimens related to gaps or lapses in ARV adherence common in adolescents.

Alternative Regimens

- [DRV/c](#) plus [TAF](#) plus [FTC](#) (FDC [DRV/c/TAF/FTC](#), Symtuza) for adolescents weighing ≥ 40 kg
- [DRV/c](#) (FDC, Prezcobix) plus [TDF/FTC](#) (FDC, Truvada) for adolescents weighing ≥ 40 kg

Boosted DRV regimens are approved for use in adolescents and can be used if there are concerns about INSTI resistance (e.g., adolescents diagnosed with HIV who have a history of CAB-LA use for PrEP). These *Alternative* regimens give the provider a choice between using a TAF-containing regimen as a single daily FDC tablet (first option) or a TDF-containing regimen consisting of two daily tablets (second option). These

alternate choices will be driven by concern for renal and bone disease in the patient (i.e., the need to avoid TDF) or adverse weight or lipid issues in the patient (i.e., the need to avoid TAF).

Practical and Clinical Considerations

Clinicians should provide the education and support that caregivers and adolescents need in order to administer or take ARVs correctly and adhere to the ART regimen (see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)). Adolescents may have difficulty adhering to daily oral medications. Among many other factors, the number of pills and the pill size are important considerations. Additionally, in considering the optimal regimen for initiation, the clinician should understand whether the adolescent will be supervised to take treatment or is expected to take their treatment independently. *Preferred* initial therapy with a single tablet dosed once daily helps maintain adherence and viral suppression. Biktarvy is one of the smallest FDC single-tablet regimens currently available (see [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)).

Several other issues unique to adolescents need to be addressed when initiating HIV treatment. Some may be living with caregivers who are not aware of their diagnosis and may still be accessing care under their parent or caregiver's health insurance plan. Communications between health insurance companies and caregivers can compromise confidentiality and result in accidental disclosure. Clinicians and social workers need to work around this issue, and in some instances, assist the patient in establishing their own access to HIV drugs and/or health insurance. Some adolescents may be emancipated and living on their own but need access to affordable health insurance. In other instances, adolescents with HIV have been rejected by their families and are homeless. Rapid initiation of HIV treatment, though desirable, may have to be deferred until social barriers to adherence are addressed. Adolescents can have other comorbidities, such as depression and increased risk for suicide. These issues are heightened in adolescents whose sexual/romantic attractions and/or self-expression are less common. Food insecurity and other social determinants of health that can affect an adolescent's ability to safely initiate and adhere to HIV treatment should be evaluated and available support offered, if possible. Finally, use of patient-centered language can be beneficial in establishing and maintaining rapport with adolescents, facilitating sustained engagement in care. For additional information, see [Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV](#) and [Adolescents and Young Adults with HIV](#) in the [Adult and Adolescent Antiretroviral Guidelines](#).

Special Situations

Where weight gain and increased risk for clinical obesity is a concern, or the adolescent has a high-risk lipid profile, a TAF-containing regimen may not be appropriate as a component of a preferred initial regimen (see [Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Antiretroviral Therapy Regimens](#) above). A FDC single-tablet regimen containing the NNRTI DOR with a backbone of TDF/FTC can be considered when initiating treatment in adolescents with these concerns.⁵⁴ However, providers must take into account the risks of proximal tubular injury, rare irreversible renal failure, and decreased bone mineral density that can occur when TDF is used.

Planning ARV Transitions

Adherence to daily oral medications is particularly challenging for adolescents,^{56,57} with lower rates of virologic suppression compared to adults.⁵⁸ CAB and RPV (Cabenuva) is a two-drug long-acting ART regimen administered as two intramuscular injections on a bimonthly schedule that is approved for adolescents weighing ≥ 35 kg and adults with HIV who are virologically suppressed on an oral regimen.

Although it is not an option for initial therapy, it provides an option for adolescents who wish to maintain viral suppression without the need for daily oral medications. In select circumstances, some adolescents experiencing difficulties with adherence to an oral ART regimen could receive intensive adherence support to achieve viral suppression on their initial regimen as a bridge to switching to long-acting injectable CAB and RPV (see [Management of Children Receiving Antiretroviral Therapy: Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy](#)).⁵⁹

Table 8. Antiretroviral Treatment Regimens Recommended for Initial Therapy for HIV Infection in Infants and Children: Birth to <12 Years of Age

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) designates regimens as *Preferred* based on efficacy, ease of administration, acceptable toxicity, and other considerations. *Alternative* regimens also have demonstrated efficacy, but clinical experience with these regimens is limited, or these regimens are more difficult to administer than *Preferred* regimens. Regimens should be tailored to the individual patient by weighing the advantages and disadvantages of each combination (see [Table A. Factors to Consider When Selecting an Antiretroviral Treatment Regimen for Infants, Children and Adolescents](#) and [Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Infants and Children](#)).

Many agents have multiple formulations and age and weight recommendations. Refer to [Appendix A. Pediatric Antiretroviral Drug Information](#) for additional information and recommended doses and formulations. In addition, many drugs that are recommended for use in newborns do not have dosing recommendations for premature infants. Additional information regarding dosing recommendations in this population can be found in [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#).

Children who are receiving effective and tolerable antiretroviral regimens can continue using those regimens as they age, even if the combinations they are receiving are no longer *Preferred* regimens. Refer to the [Management of Children Receiving Antiretroviral Therapy](#) sections for additional guidance about transitioning children to other regimens as they grow.

Panel recommendations for children and adolescents aged ≥12 years are not included in this table; see Recommended Regimens for Children and Adolescents Aged ≥12 Years in the text.

See the [Adult and Adolescent Antiretroviral Guidelines](#) for recommendations about initial antiretroviral therapy for adolescents.

| Preferred Initial Regimens and ARV Drugs Based on Age and Weight at Time of Treatment Initiation | | | |
|--|--|--|--|
| 8A. Infants from Birth to <30 Days of Age | | | |
| Panel Recommendation ^{a,b} | Regimen or ARV Drug | Age and/or Weight Restriction ^c | Formulations and Comments ^c |
| Preferred ART regimens for infants ≥37 weeks of gestation and aged <30 days and preterm infants with a postmenstrual age | NNRTI (NVP) or INSTI (RAL) plus two NRTIs <ul style="list-style-type: none"> • NVP plus ZDV plus (3TC or FTC) or • RAL plus ZDV plus (3TC or FTC) | None ≥2 kg (RAL) | All oral solutions RAL granules for oral suspension plus oral |

| | | | |
|---|---|---|---|
| of ≥37 weeks at treatment initiation | | | solutions for ZDV plus (3TC or FTC) |
| Preferred ART regimen for preterm infants ≥32 to <37 weeks of gestation | NNRTI (NVP) plus two NRTIs • <u>NVP</u> plus <u>ZDV</u> plus (<u>3TC</u> or <u>FTC</u>) | None | All oral solutions |
| Preferred ART regimens for preterm infant <32 weeks of gestation | Consultation with a pediatric HIV expert or the National Perinatal HIV/AIDS Hotline (1-888-448-8765) is recommended | | |
| Alternative ART regimens for infants | PI (LPV/r) plus two NRTIs • <u>LPV/r</u> plus <u>ZDV</u> plus (<u>3TC</u> or <u>FTC</u>) | Postmenstrual age ≥42 weeks and a postnatal age of >14 days (LPV/r) | All oral solutions |
| Alternative NRTI backbone for infants | • <u>ABC</u> plus (<u>3TC</u> or <u>FTC</u>) if HLA-B*5701 negative | ≥37 weeks of gestation | All oral solutions Use of ABC ^d requires negative HLA-B*5701 testing. |

| Preferred Initial Regimens and ARV Drugs Based on Age and Weight at Time of Treatment Initiation | | | |
|---|---|---|---|
| 8B. Infants and Children Aged ≥30 Days to <2 Years | | | |
| Panel Recommendation^{a,b} | Regimen or ARV Drug | Age and/or Weight Restriction^c | Formulations and Comments^c |
| Preferred ART regimens for infants and children aged ≥30 days to <2 years | INSTI (DTG)^{e,f} plus two NRTIs • <u>DTG</u> plus <u>ZDV</u> plus (<u>3TC</u> or <u>FTC</u>) or • <u>DTG</u> plus <u>ABC</u> plus (<u>3TC</u> or <u>FTC</u>) if HLA-B*5701 negative • <u>DTG/ABC/3TC</u> in FDC if HLA-B*5701 negative | DTG ≥30 days and ≥3 kg to <25 kg DTG ≥30 days and ≥3 kg to <25 kg ≥3 months and ≥6 kg to <25 kg (Triumeq PD) ≥25 kg (Triumeq) | DTG dispersible tablets plus oral solutions (ABC ^d , ZDV, 3TC, or FTC) DTG/ABC/3TC in FDC dispersible tablets (Triumeq PD) DTG/ABC/3TC FDC tablets if ≥25 kg (Triumeq). See Dolutegravir for special instructions if a child is unable to swallow pills. |
| Alternative anchor drugs to replace DTG in an ART regimen with a Preferred NRTI backbone for infants and children aged ≥30 days to <2 years | • <u>LPV/r^f</u> (boosted PI) • <u>ATV</u> plus <u>RTV</u> (boosted PI) | Postmenstrual age ≥42 weeks and postnatal age >14 days ATV ≥15 kg to <25 kg | LPV/r oral solution ATV is available in powder packets; RTV is available in 100 mg tablets and 100 mg powder packets. |

| | | | |
|--|----------------------|----------|--------------|
| | • NVP (NNRTI) | <3 years | NVP solution |
|--|----------------------|----------|--------------|

| Preferred Initial Regimens and ARV Drugs Based on Age and Weight at Time of Treatment Initiation | | | |
|--|---|---|---|
| 8C. Children Aged ≥2 Years to <12 Years | | | |
| Panel Recommendation ^{a,b} | Regimen or ARV Drug | Age and/or Weight Restriction ^c | Formulations and Comments ^c |
| <i>Preferred ART regimens for children aged ≥2 years to <12 years who are unable to swallow pills</i> | <p>INSTI (DTG) plus two NRTIs</p> <ul style="list-style-type: none"> • DTG/ABC/3TC in FDC if HLA-B*5701 negative • DTG plus ZDV plus (3TC or FTC) • DTG plus FTC/TAF; FTC/TAF in FDC (Descovy) | <p>≥3 months and 3 kg to <25 kg (Triumeq PD)</p> <p>≥30 days and ≥3 kg (DTG)</p> <p>≥30 days and ≥3 kg (DTG) ≥14 kg to <25 kg (FTC/TAF)</p> | <p>For children who are unable to swallow pills</p> <p>DTG/ABC/3TC in FDC dispersible tablets (Triumeq PD)</p> <p>DTG dispersible tablets plus oral solutions (ZDV, 3TC, or FTC)</p> <p>TAF available as FTC/TAF in FDC (Descovy) only; not available as an individual drug. See <u>Tenofovir Alafenamide</u> for special instructions about administering FTC/TAF to children who are not able to swallow pills.</p> <p>For children who are ≥25 kg and unable to swallow pills, see <u>Dolutegravir</u> and <u>Tenofovir Alafenamide</u> for special instructions about administering DTG 50 mg and FTC/TAF (200 mg FTC/25 mg TAF).</p> |
| <i>Preferred ART regimens for children</i> | INSTI (BIC or DTG) plus two NRTIs | | For children who are able to swallow pills |

| | | | |
|--|---|--|---|
| aged ≥ 2 years to <12 years who are able to swallow pills | <ul style="list-style-type: none"> • BIC plus FTC plus TAF in FDC^{g,h} • DTG plus ZDV plus (3TC or FTC) • DTG plus ABC plus 3TC in FDC if HLA-B*5701 negative • DTG plus FTC/TAF; FTC/TAF in FDC (Descovy)ⁱ | <p>Aged ≥ 2 years and ≥ 14 kg to <25 kg (BIC 30 mg/FTC 120 mg/TAF 15 mg)</p> <p>≥ 25 kg (BIC 50 mg/FTC 200 mg/TAF 25 mg)</p> <p>≥ 14 kg (DTG tablets, Tivicay)</p> <p>≥ 25 kg</p> <p>Aged ≥ 30 days and ≥ 3 kg (DTG)</p> <p>≥ 14 kg (FTC/TAF)</p> | <p>BIC is only available in the FDC BIC/FTC/TAF.</p> <p>The product label states that for children who are unable to swallow a whole tablet, the BIC/FTC/TAF tablet can be split and each part taken separately, as long as all parts are ingested within approximately 10 minutes; see Bictegravir.</p> <p>DTG/ABC/3TC in FDC tablets (Triumeq)</p> <p>TAF available as FTC/TAF in FDC (Descovy) only; not available as an individual drug. See Tenofovir Alafenamide.</p> |
| <p>Alternative anchor drugs in an ART regimen with a Preferred NRTI backbone for children aged ≥ 2 years to <12 years</p> | <ul style="list-style-type: none"> • ATV powder plus RTV powder (boosted PI) • ATV capsules plus RTV tablets (boosted PI) • ATV plus COBI in FDC tablet (ATV/c, boosted PI) • DRV plus RTV (boosted PI) • DRV plus COBI in FDC tablet (DRV/c, boosted PI) • NVP • NVP XR • EFV • DOR | <p>≥ 15 kg to ≤ 25 kg</p> <p>≥ 15 kg</p> <p>≥ 35 kg</p> <p>≥ 20 kg</p> <p>≥ 40 kg</p> <p>None</p> <p>Aged ≥ 6 years</p> <p>Aged ≥ 3 years and ≥ 10 kg</p> <p>≥ 35 kg</p> | <p>ATV is available in 50 mg powder packets; RTV is available in 100 mg powder packets.</p> <p>ATV and RTV powder can be mixed with soft food or liquid.</p> <p>DRV is available in an oral solution or tablets to be taken with RTV powder or tablets.</p> <p>NVP solution or immediate release tablets</p> <p>EFV capsules can be opened and used as a sprinkle formulation for children who are unable to swallow pills.</p> <p>Available as a single tablet regimen (DOR/3TC/TDF)</p> |

^a Panel recommendations summarized in this table are for children with HIV-1 infection.

^b Recommendations for ARV drugs or ART regimens to be used in special circumstances are addressed in the text (e.g., ARV resistance, HBV coinfection).

^c Additional information about FDCs is available in [Appendix A. Pediatric Antiretroviral Drug Information](#), [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#).

^d ABC is not approved by the U.S. Food and Drug Administration (FDA) for use in full-term neonates and infants aged <3 months. Recent data from the IMPAACT P1106 trial and two observational cohorts provide reassuring data on the safety of ABC in infants when initiated at the age of <3 months (see [Abacavir](#)). Before ABC administration, a negative HLA-B*5701 allele test result should be available. An FDC tablet that contains ABC/3TC (Epzicom and generic) is available for use in children weighing ≥25 kg.

^e If DTG dispersible tablets are not available, RAL can be administered using either the oral granules for suspension dispersed in water or as the chewable tablets dispersed in juice, formula, or milk.

^f An NRTI backbone of ZDV plus 3TC twice daily or ABC plus 3TC twice daily allows for all medications to be administered at the same time when given in combination with LPV/r or RAL. There is considerable experience with ZDV and 3TC in this age group. ABC is associated with less bone marrow toxicity than ZDV and may be the preferred NRTI for long-term use.

^g There are two different strengths of BIC/FTC/TAF tablets, with the lower-strength tablet for children weighing ≥14 kg and <25 kg.

^h The product label for BIC/FTC/TAF (Biktarvy) states that for children who are unable to swallow a whole tablet, the BIC/FTC/TAF tablet can be split and each part taken separately, as long as all parts are ingested within approximately 10 minutes.

ⁱ FTC plus TAF is recommended as a Preferred NRTI combination for children and adolescents weighing ≥14 kg when used with an INSTI or NNRTI; an FDC tablet that contains FTC/TAF (Descovy) is available in two strengths, with dosage determined by a child's weight (see [Tenofovir Alafenamide](#)). FTC/TAF is approved by the FDA for children weighing ≥14 kg when used in the regimen BIC/FTC/TAF, which is also available in two strengths, with dosage determined by a child's weight. FTC/TAF is a Preferred NRTI combination for children and adolescents weighing ≥35 kg when used with a boosted PI; FTC/TAF is not approved or recommended for use with a boosted PI in children weighing <35 kg.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ART = antiretroviral therapy; ATV = atazanavir; BIC = bictegravir; DOR = doravirine; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; HBV = hepatitis B virus; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

Table 9. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Infants and Children

See [Appendix A. Pediatric Antiretroviral Drug Information](#) and [Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) for more information. For detailed information about drug interactions, see [Drug–Drug Interactions](#) and [ARV class-specific tables 24a-24g and 25a-25b](#) in [Adult and Adolescent Antiretroviral Guidelines](#), the [HIV Drug Interaction Checker](#), and updated prescribing information.

Note: Drugs within each ARV class are listed in alphabetical order.

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|------------------------|--|--|
| All INSTIs | INSTI Class Advantages <ul style="list-style-type: none"> Well tolerated | INSTI Class Disadvantages <ul style="list-style-type: none"> Possible weight gain in adults, especially Black/African American women Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4, UGT1A1). Information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker. Oral absorption can be reduced by simultaneous administration with drugs or supplements containing polyvalent cations. |
| BIC | <ul style="list-style-type: none"> Once-daily administration No food requirement Coformulated with TAF/FTC (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) Higher barrier to resistance than RAL | <ul style="list-style-type: none"> The FDC tablet is not recommended for patients with hepatic impairment or an estimated CrCl <30 mL/min. CNS side effects, particularly sleep disturbances. Depression and suicidal ideation (rare; usually in patients with preexisting psychiatric conditions). CYP3A4 and UGT1A1 substrate (but not a CYP3A4 inducer or inhibitor); potential for drug–drug interactions Inhibits tubular secretion of creatinine resulting in an increase in serum creatinine without affecting glomerular function. This is generally benign but can be misinterpreted by clinicians not aware of this side effect. Added follow-up may be required in patients with underlying renal disease. |
| DTG | <ul style="list-style-type: none"> Once-daily administration No food requirement Coformulated with ABC/FTC and with 3TC (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) Single-agent DTG pills are available in several doses and are small in size. | <ul style="list-style-type: none"> UGT1A1 substrate; potential for drug–drug interactions. CNS side effects, particularly sleep disturbances. Depression and suicidal ideation (rare; usually in patients with preexisting psychiatric conditions). Inhibits tubular secretion of creatinine resulting in an increase of serum creatinine without affecting glomerular function. This is generally benign but can be misinterpreted by clinicians not aware of this side effect. |

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|------------------------|---|---|
| | <ul style="list-style-type: none"> DTG and the FDC ABC/DTG/3TC are available as dispersible tablets for suspension. Higher barrier to resistance than RAL | Added follow-up may be required in patients with underlying renal disease. |
| RAL | <ul style="list-style-type: none"> No food requirement Available in tablet, chewable tablet, and oral granules for suspension formulations Chewable tablets can be crushed and mixed with various liquids for infants aged ≥ 4 weeks who weigh ≥ 3 kg. Favorable lipid profile | <ul style="list-style-type: none"> Lower barrier to resistance than boosted PI-, BIC-, or DTG-based regimens Oral absorption of RAL can be reduced by simultaneous administration with drugs or supplements containing polyvalent cations. UGT1A1 substrate; potential for drug interaction Depression and suicidal ideation (rare; usually in patients with preexisting psychiatric conditions) Increases in creatine kinase, myopathy, and rhabdomyolysis have been reported. Potential for rare systemic allergic reaction or hepatitis Granule formulation requires a multistep preparation before administration; caregiver must be taught how to properly prepare this formulation. Higher pill burden than other INSTI-based regimens. No FDC formulation. |
| All NNRTIs | NNRTI Class Advantages <ul style="list-style-type: none"> Longer half-life allows for once daily dosing of DOR, EFV, and RPV. Lower risk of dyslipidemia and fat maldistribution than PIs PI-sparing Lower pill burden than PIs for children taking the solid formulation; easier to use and adhere to than PI-based regimens. | NNRTI Class Disadvantages <ul style="list-style-type: none"> Prevalence of NNRTI-resistant viral strains in ART-naive patients and the drugs' low barrier for the development of resistance. A single mutation can confer resistance, with cross-resistance between EFV and NVP. Rare but serious and potentially life-threatening cases of skin rash (including SJS) and hepatic toxicity. All NNRTIs pose this risk, but the risk is greatest with NVP; these toxic effects have not been reported in neonates. Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4). Information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker. |
| DOR | <ul style="list-style-type: none"> Once-daily administration Available as a single-drug tablet and coformulated with TDF/FTC (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) No food requirement | <ul style="list-style-type: none"> Neuropsychiatric AEs, but fewer than reported for EFV DOR is contraindicated when coadministered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers (see Doravirine). Potential for CYP3A4 drug interactions Treatment-emergent DOR resistance mutations may confer resistance to certain NNRTIs. |

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|------------------------|--|--|
| | <ul style="list-style-type: none"> Has continued antiviral activity in the setting of some NNRTI mutations Favorable lipid profile Not associated with weight gain compared with boosted DRV or EFV | |
| EFV | <ul style="list-style-type: none"> Once-daily administration Available as a single-drug tablet and coformulated with TDF/FTC and TDF/3TC (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) Can give with food (but avoid high-fat meals). Usually recommended to be taken on an empty stomach. Capsules can be opened and added to food. | <ul style="list-style-type: none"> CNS side effects, including dizziness, abnormal dreams, headache, depression, suicidality, insomnia, somnolence. Bedtime dosing is recommended to reduce CNS effects. Rash (generally mild); QTc prolongation, dyslipidemia Potential for CYP3A4 drug interactions No commercially available liquid formulation Limited data on dosing for children aged <3 years No data on dosing for children aged <3 months |
| NVP | <ul style="list-style-type: none"> Liquid formulation is available. Dosing information for young infants is available. No food requirement Extended-release formulation that allows once-daily dosing in older children is available. | <ul style="list-style-type: none"> Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen Higher incidence of rash/HSR than other NNRTIs Higher rates of serious hepatic toxicity than EFV Decreased virologic response compared with EFV Twice-daily dosing necessary in children with BSA <0.58 m² Low barrier to resistance |
| RPV | <ul style="list-style-type: none"> Once-daily dosing Available as single-drug tablet and coformulated with TDF/FTC and TAF/FTC (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) | <ul style="list-style-type: none"> Should not use in patients with viral loads >100,000 copies/mL Food requirement. Must be taken with a ≥500 kcal meal at a consistent time each day; this may affect adherence. Potential for CYP3A4 drug interactions RPV oral absorption is reduced with increased gastric pH. Use of RPV with PPIs is contraindicated; see Adult Drug–Drug Interactions for dosing recommendations when RPV is coadministered with H2 blocker or antacids. Low barrier to resistance Side effects include depression, headache, skin rash, and QTc prolongation. |

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|--------------------------------------|---|--|
| All PIs | <p>PI Class Advantages</p> <ul style="list-style-type: none"> • NNRTI-sparing • Clinical, virologic, and immunologic efficacy are well-documented. • Higher barrier to resistance than NNRTIs and RAL. Resistance to PIs requires multiple mutations. • When combined with a dual-NRTI backbone, a regimen that contains a PI targets HIV at two steps of viral replication by inhibiting the activity of viral reverse transcriptase and protease enzymes. | <p>PI Class Disadvantages</p> <ul style="list-style-type: none"> • Metabolic complications, including dyslipidemia, fat maldistribution, and insulin resistance. • Potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4) Information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker. • Higher pill burden than NRTI-based or NNRTI-based regimens for patients taking solid formulations. • Poor palatability of liquid preparations, which may affect adherence. • Most PIs require RTV or COBI boosting, resulting in drug-drug interactions that are associated with RTV or COBI. |
| ATV/r and ATV/c Unboosted ATV | <ul style="list-style-type: none"> • Once-daily dosing • Powder formulation is available for young children. • ATV has less effect on TG and total cholesterol levels than other PIs (but RTV boosting may be associated with elevations in these parameters). | <ul style="list-style-type: none"> • No liquid formulation • Food requirement • Indirect hyperbilirubinemia is common but asymptomatic. Scleral icterus may be distressing to the patient, which may affect adherence. Other side effects include cholelithiasis, nephrolithiasis, and PR interval prolongation. • Must be used with caution in patients with preexisting conduction system defects (can prolong the PR interval of an ECG) • ATV boosted with RTV or COBI is recommended. Both RTV and COBI are associated with a large number of drug-drug interactions. CYP3A4 substrate and inhibitor. • ATV absorption is reduced when ATV is given with acid-lowering therapies. • COBI inhibits active tubular secretion of creatinine and can increase serum creatinine without affecting renal glomerular function. This is generally benign but can be misinterpreted by clinicians not aware of this side effect. Added follow-up may be required in patients with underlying renal disease. |
| DRV/c or DRV/r | <ul style="list-style-type: none"> • Can be used once daily in children aged ≥12 years. • Liquid formulation is available. • DRV requires a boosting agent. • Available as single-drug tablet and coformulated as DRV/c and DRV/c/TAF/FTC (see Appendix A) | <ul style="list-style-type: none"> • Pediatric pill burden high with current tablet dose formulations • Food requirement • Must be boosted with RTV or COBI to achieve adequate plasma concentrations. |

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|--|--|---|
| | <p>Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class</p> | <ul style="list-style-type: none"> Contains sulfa moiety. The potential for cross-sensitivity between DRV and other drugs in sulfonamide class is unknown. Other side effects include hyperlipidemia and increase in transaminases. RTV and COBI are associated with a large number of potential drug–drug interactions. COBI inhibits active tubular secretion of creatinine and can increase serum creatinine without affecting renal glomerular function. This is generally benign but can be misinterpreted by clinicians not aware of this side effect. Added follow-up may be required in patients with underlying renal disease. Can be used only once daily in the absence of certain PI-associated resistance mutations. |
| LPV/r | <ul style="list-style-type: none"> LPV is only available coformulated with RTV in liquid and tablet formulations. Tablets can be given without food, but they may be better tolerated when taken with a meal or snack. | <ul style="list-style-type: none"> Poor palatability of liquid formulation (bitter taste) Liquid formulation should be administered with food. RTV is associated with a large number of drug–drug interactions. Should not be administered to neonates before a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth) and a postnatal age ≥ 14 days. Must be used with caution in patients with pre-existing conduction system defects (can prolong PR and QT interval of an ECG) |
| ABC plus (3TC or FTC) | <ul style="list-style-type: none"> Palatable liquid formulations No food requirement Available in FDC tablets (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) | <ul style="list-style-type: none"> Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC. ABC use has been associated with CV disease and cardiac events in some, but not all, observational studies conducted in adults. |
| FTC/TAF for children aged ≥ 6 years | <ul style="list-style-type: none"> Once-daily dosing Small tablet size Lower risk of TFV-associated renal and bone toxicity with TAF than with TDF in adults. Available in FDC tablets (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) | <ul style="list-style-type: none"> Limited data on the safety and efficacy of this combination in children Increased lipid levels |

| ARV Class/ Agent(s) | Advantages | Disadvantages |
|------------------------|---|--|
| | <ul style="list-style-type: none"> Active against HBV; a recommended dual-NRTI option for patients with HBV/HIV coinfection | |
| TDF plus (3TC or FTC) | <ul style="list-style-type: none"> Once-daily dosing for TDF Resistance is slow to develop. Lower risk of mitochondrial toxicity than other NRTIs No food requirement TDF is available as reduced-strength tablets and oral powder for use in younger children. Available in FDC tablets (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class) Active against HBV; a recommended dual-NRTI option for patients with HBV/HIV coinfection. | <ul style="list-style-type: none"> Limited pediatric experience Potential bone and renal toxicity |
| ZDV plus (3TC or FTC) | <ul style="list-style-type: none"> Extensive pediatric experience Coformulations of ZDV and 3TC are available for children weighing ≥ 30 kg. Palatable liquid formulations No food requirement FTC is available as a palatable liquid formulation that can be administered once daily. | <ul style="list-style-type: none"> Bone marrow suppression and lipoatrophy with ZDV ZDV requires twice-daily dosing. |

Key: 3TC = lamivudine; ABC = abacavir; AE = adverse event; ATV = atazanavir; BIC = bictegravir; BSA = body surface area; CNS = central nervous system; COBI = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P450; DOR = doravirine; DRV = darunavir; DTG = dolutegravir; ECG = electrocardiogram; EFV = efavirenz; FDC = fixed-dose combination; FTC = emtricitabine; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson Syndrome; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; TG = triglyceride; ZDV = zidovudine

References

1. Guidi JCA, Sapra A. Physiology, sexual maturity rating. In: Secondary Guidi JCA, Sapra A, eds^eds. Subsidiary Guidi JCA, Sapra A, trans. Secondary Physiology, sexual maturity rating. Vol. ed. Treasure Island (FL) ineligible companies. Disclosure: Amit Sapra declares no relevant financial relationships with ineligible companies.: 2024.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents adults and adolescents with HIV. 2024. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new>.
3. Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. *Lancet HIV*. 2022;9(5):e332-e340. Available at: <https://pubmed.ncbi.nlm.nih.gov/35489377>.
4. Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022;9(9):e638-e648. Available at: <https://pubmed.ncbi.nlm.nih.gov/36055295>.
5. Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Med*. 2021;385(27):2531-2543. Available at: <https://pubmed.ncbi.nlm.nih.gov/34965338>.
6. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial. *Lancet*. 2017;390(10107):2063-2072. Available at: <https://pubmed.ncbi.nlm.nih.gov/28867497>.
7. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis*. 2013;13(11):927-935. Available at: <https://pubmed.ncbi.nlm.nih.gov/24074642>.
8. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19490. Available at: <https://pubmed.ncbi.nlm.nih.gov/25393999>.
9. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS*. 2007;21(8):947-955. Available at: <https://pubmed.ncbi.nlm.nih.gov/17457088>.

10. Pediatric European Network for Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet*. 2002;359(9308):733-740. Available at: <https://pubmed.ncbi.nlm.nih.gov/11888583>.
11. Bekker A, Decloedt EH, Slade G, et al. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). *Clin Infect Dis*. 2021;72(11):2032-2034. Available at: <https://pubmed.ncbi.nlm.nih.gov/32697327>.
12. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV*. 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.
13. Borroto-Esoda K, Vela JE, Myrick F, et al. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. *Antivir Ther*. 2006;11(3):377-384. Available at: <https://pubmed.ncbi.nlm.nih.gov/16759055>.
14. Ross L, Parkin N, Chappay C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. *AIDS*. 2004;18(12):1691-1696. Available at: <https://pubmed.ncbi.nlm.nih.gov/15280780>.
15. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics*. 2006;118(3):e711-718. Available at: <https://pubmed.ncbi.nlm.nih.gov/16923923>.
16. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. *J Acquir Immune Defic Syndr*. 2005;40(4):448-450. Available at: <https://pubmed.ncbi.nlm.nih.gov/16280700>.
17. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics*. 2005;116(6):e846-854. Available at: <https://pubmed.ncbi.nlm.nih.gov/16291735>.
18. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother*. 2004;48(1):124-129. Available at: <https://pubmed.ncbi.nlm.nih.gov/14693529>.
19. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004;292(2):191-201. Available at: <https://pubmed.ncbi.nlm.nih.gov/15249568>.
20. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-

- up study. *Clin Drug Investig.* 2011;31(6):407-415. Available at: <https://pubmed.ncbi.nlm.nih.gov/21528939>.
21. Hall AM. Update on tenofovir toxicity in the kidney. *Pediatr Nephrol.* 2013;28(7):1011-1023. Available at: <https://pubmed.ncbi.nlm.nih.gov/22878694>.
 22. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis.* 2010;51(5):496-505. Available at: <https://pubmed.ncbi.nlm.nih.gov/20673002>.
 23. Wood SM, Shah SS, Steenhoff AP, et al. Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. *AIDS Patient Care STDS.* 2009;23(1):1-4. Available at: <https://pubmed.ncbi.nlm.nih.gov/19183077>.
 24. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J.* 2009;28(7):619-625. Available at: <https://pubmed.ncbi.nlm.nih.gov/19561425>.
 25. Tenofovir disoproxil fumarate (Viread) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021356s058,022577s014lbl.pdf.
 26. Bosch B, Akpomiemie G, Chandiwana N, et al. Weight and metabolic changes after switching from tenofovir alafenamide/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz to TDF/lamivudine/DTG. *Clin Infect Dis.* 2023;76(8):1492-1495. Available at: <https://pubmed.ncbi.nlm.nih.gov/36519389>.
 27. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV.* 2020;7(10):e666-e676. Available at: <https://pubmed.ncbi.nlm.nih.gov/33010240>.
 28. Frange P, Avettand-Fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort. *HIV Med.* 2022;23(9):1019-1024. Available at: <https://pubmed.ncbi.nlm.nih.gov/35306718>.
 29. Belfrage E, Soeria-Atmadja S, Naver L. Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir. *BMC Pediatr.* 2023;23(1):339. Available at: <https://pubmed.ncbi.nlm.nih.gov/37403042>.
 30. O'Rourke J, Townsend CL, Milanzi E, et al. Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. *J Int AIDS Soc.* 2023;26(2):e26037. Available at: <https://pubmed.ncbi.nlm.nih.gov/36823283>.

31. Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr*. 2014;65(5):535-541. Available at: <https://pubmed.ncbi.nlm.nih.gov/24326597>.
32. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at: <https://pubmed.ncbi.nlm.nih.gov/30527329>.
33. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA*. 2010;304(10):1082-1090. Available at: <https://pubmed.ncbi.nlm.nih.gov/20823434>.
34. Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. *Clin Infect Dis*. 2016;63(8):1113-1121. Available at: <https://pubmed.ncbi.nlm.nih.gov/27439527>.
35. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *N Engl J Med*. 2012;366(25):2380-2389. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716976>.
36. Kuhn L, Strehlau R, Shiao S, et al. Early antiretroviral treatment of infants to attain HIV remission. *EClinicalMedicine*. 2020;18:100241. Available at: <https://pubmed.ncbi.nlm.nih.gov/31993578>.
37. Persaud D, Bryson Y, Nelson BS, et al. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. *Lancet HIV*. 2024;11(1):e20-e30. Available at: <https://pubmed.ncbi.nlm.nih.gov/38061376>.
38. de Waal R, Rabie H, Technau KG, et al. Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. *Antivir Ther*. 2023;28(2):13596535231168480. Available at: <https://pubmed.ncbi.nlm.nih.gov/37038365>.
39. Francois K, Van Onacker JD, Jordan MR, et al. First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers. *AIDS*. 2023;37(13):2097-2099. Available at: <https://pubmed.ncbi.nlm.nih.gov/37755428>.
40. Townsend CL, O'Rourke J, Milanzi E, et al. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. *J Int AIDS Soc*. 2022;25(11):e25970. Available at: <https://pubmed.ncbi.nlm.nih.gov/36377082>.
41. Brooks KM, Kiser JJ, Ziembka L, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV

- (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. *Lancet HIV*. 2023;10(8):e506-e517. Available at: <https://pubmed.ncbi.nlm.nih.gov/37541705>.
42. Chadwick EG, Capparelli EV, Yoge R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. *Aids*. 2008;22(2):249-255. Available at: <https://pubmed.ncbi.nlm.nih.gov/18097227>.
43. Chadwick EG, Yoge R, Alvero CG, et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. *AIDS*. 2011;25(5):643-649. Available at: <https://pubmed.ncbi.nlm.nih.gov/21297419>.
44. Lindsey JC, Hughes MD, Violari A, et al. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. *Pediatr Infect Dis J*. 2014;33(8):846-854. Available at: <https://pubmed.ncbi.nlm.nih.gov/25222305>.
45. Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS*. 2011;25(12):1489-1496. Available at: <https://pubmed.ncbi.nlm.nih.gov/21610486>.
46. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. *J Acquir Immune Defic Syndr*. 2007;45(2):133-136. Available at: <https://pubmed.ncbi.nlm.nih.gov/17417100>.
47. Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. *J Pediatric Infect Dis Soc*. 2015;4(4):e76-83. Available at: <https://pubmed.ncbi.nlm.nih.gov/26582887>.
48. Patel A, Jacobsen L, Jhaveri R, Bradford KK. Effectiveness of pediatric pill swallowing interventions: a systematic review. *Pediatrics*. 2015;135(5):883-889. Available at: <https://pubmed.ncbi.nlm.nih.gov/25896843>.
49. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210251s015lbl.pdf.
50. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. *Lancet Child Adolesc Health*. 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760>.

51. Viani R, Alvero C, Fenton T, et al. Long-term safety and efficacy of dolutegravir in HIV treatment-experienced adolescents. Presented at: Infectious Disease Week; 2015. San Diego, CA. Available at.
52. Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results. Presented at: Conference on Retroviruses and Opportunistic Infections 2016. Boston, MA. Available at: <https://www.croiconference.org/abstract/impaact-1093-dolutegravir-6-12-year-old-hiv-infected-children-48-week-results-0/>.
53. Moore CL, Turkova A, Mujuru H, et al. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. *BMC Infect Dis*. 2021;21(1):5. Available at: <https://pubmed.ncbi.nlm.nih.gov/33446115/>.
54. Rungmaitree S, Aurpibul L, Best BM, et al. Efficacy, safety, and tolerability of doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets in adolescents living with HIV: results through week 96 from IMPAACT 2014. *J Pediatric Infect Dis Soc*. 2023;12(12):602-609. Available at: <https://pubmed.ncbi.nlm.nih.gov/37815035/>.
55. Williams PL, Abzug MJ, Jacobson DL, et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. *AIDS*. 2013;27(12):1959-1970. Available at: <https://pubmed.ncbi.nlm.nih.gov/24145244/>.
56. Kacanek D, Huo Y, Malee K, et al. Nonadherence and unsuppressed viral load across adolescence among U.S. youth with perinatally acquired HIV. *AIDS*. 2019;33(12):1923-1934. Available at: <https://pubmed.ncbi.nlm.nih.gov/31274538/>.
57. Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *AIDS*. 2014;28(13):1945-1956. Available at: <https://pubmed.ncbi.nlm.nih.gov/24845154/>.
58. Han WM, Law MG, Egger M, et al. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. *Lancet HIV*. 2021;8(12):e766-e775. Available at: <https://pubmed.ncbi.nlm.nih.gov/34856180/>.
59. Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. *Clin Infect Dis*. 2023;76(3):e645-e651. Available at: <https://pubmed.ncbi.nlm.nih.gov/35913500/>.

What Not to Start: Regimens Not Recommended for Initial Antiretroviral Therapy in Infants and Children

Updated: June 27, 2024

Reviewed: June 27, 2024

This section describes antiretroviral (ARV) drugs and drug combinations that either are not recommended for use **in initial antiretroviral treatment (ART) regimens** in infants and children or lack sufficient data to recommend their use in children **who have not received ART**. Although many ARV agents and combinations are available, some are not recommended for use as part of an initial **ART regimen**, but they may be used in ARV-experienced children (see [Recognizing and Managing Antiretroviral Treatment Failure](#)). Several ARV drugs that are no longer available or recommended for use in children for several years have been removed from this chapter, including the nucleoside reverse transcriptase inhibitors (NRTIs) stavudine and didanosine; the protease inhibitors (PIs) indinavir, nelfinavir, saquinavir, tipranavir, and fosamprenavir; and the fusion inhibitor enfuvirtide (see [Archived Drugs in Appendix A. Pediatric Antiretroviral Drug Information](#)). The PI ritonavir is no longer recommended for use as the sole PI in an ARV regimen but is used at a reduced dose as a pharmacokinetic (PK) enhancer (boosting agent) with other ARV drugs (e.g., atazanavir, darunavir).

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) classifies ARV drugs and drug combinations that are not recommended for use in ARV-naive children into one of three categories:

- ***Not Recommended for Initial Therapy:*** These include ARV drugs and drug combinations that are not recommended for initial **ART regimens** in children because they produce an inferior virologic response, they pose potential serious safety concerns (including potentially overlapping toxicities), they are associated with pharmacologic antagonism, or better options are available within a drug class. These drugs and drug combinations are listed in [Table 10](#), and selected drugs or drug combinations are discussed below.
- ***Insufficient Data to Recommend for Initial Therapy:*** ARV drugs and drug combinations that are approved for use in adults but have insufficient, limited, or no PK and/or safety data for children cannot be recommended for initial therapy in children. However, these drugs and drug combinations may be appropriate to consider when managing treatment-experienced children (see [Management of Children Receiving Antiretroviral Therapy](#)). These drugs also are listed in [Table 10](#), and selected drugs or drug combinations are discussed below.
- ***Antiretroviral Drug Regimens That Are Never Recommended:*** Several ARV drugs and drug combinations should never be used in children or adults. They are summarized in [Table 11](#). Clinicians also should be aware of the components of fixed-dose combination (FDC) tablets so that patients do not inadvertently receive a double dose of a drug contained in such a combination.

Antiretroviral Drugs and Drug Combinations Not Recommended for Initial Therapy in Children

Atazanavir without Ritonavir or Cobicistat Boosting

Although unboosted atazanavir (ATV) is approved by the U.S. Food and Drug Administration (FDA) for use in treatment-naïve adolescents—aged ≥ 13 years and weighing ≥ 40 kg—who are unable to

tolerate ritonavir (RTV), data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)/Pediatric AIDS Clinical Trials Group (PACTG) 1020A study indicate that adolescents require higher doses of unboosted ATV (as measured by milligram per meter squared of body surface area) than adults to achieve adequate drug concentrations.¹ Because of these findings, the Panel **does not recommend** using ATV without RTV boosting.

Efavirenz-Based Regimens for Children Aged ≥ 3 Months to 3 Years

Efavirenz (EFV) is approved by the FDA for use in children aged >3 months and weighing ≥ 3.5 kg. An Efv-based regimen was shown to have variable PK in studies of young children; therefore, at this time, the Panel **does not recommend** using Efv in children aged <3 years (see the [Efavirenz](#) section in [Appendix A. Pediatric Antiretroviral Drug Information](#)). When the use of Efv is being considered for children aged <3 years, cytochrome P450 (CYP) 2B6 genotyping should be performed, if available, to predict a patient's metabolic rate for Efv. Therapeutic drug monitoring also can be considered. Additionally, Efv in children <3 years may be considered in the setting of HIV/tuberculosis coinfection because Efv is one of the few ARV drugs with minimal drug–drug interactions seen with other ARV drugs and rifampin.²

Elvitegravir-Based Regimens

Elvitegravir (EVG) is a first-generation integrase strand transfer inhibitor (INSTI) that is available in two FDC tablets: EVG/cobicistat (EVG/c)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) and EVG/c/FTC/tenofovir alafenamide (TAF). Cobicistat is a specific, potent CYP3A inhibitor that has no activity against HIV. It is used as a PK enhancer that allows once-daily dosing of EVG.

The FDC regimens EVG/c/FTC/TDF and EVG/c/FTC/TAF are approved by the FDA for use in ART-naive adults, children, and adolescents with HIV—EVG/c/FTC/TDF for those weighing ≥ 35 kg and EVG/c/FTC/TAF for those weighing ≥ 25 kg. However, the Panel does not recommend EVG-based regimens for initial ART in children or adolescents because EVG has a lower genetic barrier to the development of resistance compared to second-generation INSTIs.³ The Panel recommends initial ART with INSTI-based regimens that include dolutegravir (DTG) or bictegravir, according to age and weight indications (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV](#)).

Etravirine-Based Regimens

Etravirine (ETR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has been studied in treatment-experienced children aged ≥ 1 years and is now approved by the FDA for use in children aged ≥ 2 years and weighing ≥ 10 kg.^{4–6} ETR is associated with multiple interactions with other ARV drugs, including tipranavir/ritonavir, atazanavir/ritonavir, and unboosted PIs, and must be administered twice daily. The use of ETR likely will not be studied in treatment-naive children.

Maraviroc-Based Regimens

Maraviroc (MVC) is an entry inhibitor approved by the FDA for use in children weighing ≥ 2 kg who have CCR5-tropic HIV-1. It has been used infrequently in children. A recent dose-finding study administered both the liquid and tablet formulations of MVC to treatment-experienced children aged 2 to 18 years who were grouped into four age cohorts.⁷ The initial dose was based on body surface area and scaled from the recommended adult dose. Dose adjustments were required in patients who were not receiving a potent CYP3A4 inhibitor or inducer.⁷ A recent study of MVC in newborns at risk of HIV acquisition and weighing at least 2 kg established a dosing protocol that achieved target

exposures and was deemed safe. No apparent differences in PK parameters were observed among infants of mothers with exposure to EFV and those without. None of the infants had HIV infection, nor were they receiving potent CYP3A inhibitors.⁸ As an entry inhibitor, MVC is under study in intensive treatment trials because of its hypothetical potential to limit the establishment of cell-associated viral reservoirs. However, MVC has several features that limit its role for routine uses, including multiple drug interactions, the need to be administered twice daily, and the fact that tropism assays must be performed prior to its use to ensure the presence of only CCR5-tropic virus. For those reasons, MVC **is not recommended** by the Panel for first-line treatment in **any infant or child.**

Cabotegravir with or without Rilpivirine for Oral or Intramuscular Injections

In 2021, the FDA approved long-acting injectable (LAI) formulations of cabotegravir (CAB), a novel INSTI, and the NNRTI rilpivirine (RPV) for the treatment of HIV in adults to replace a current, stable ARV regimen in patients with no prior history of treatment failure and no known or suspected resistance to CAB or RPV who have demonstrated sustained viral suppression (e.g., 3–6 months). These two LAI ARV drugs are co-packaged and marketed as Cabenuva. In March 2022, the FDA approved Cabenuva for use in children and adolescents aged ≥ 12 years and weighing ≥ 35 kg. An oral lead-in with the oral formulations of **RPV and CAB may be considered** to assess tolerability.⁹ The LAI formulations can then be administered on a monthly or an every 2-month schedule. Clinical trials in adolescents are ongoing and planned for younger children (see the [Cabotegravir](#) section). The regimen of LAI CAB and RPV **is not approved or recommended** for initial ARV therapy.

Regimens that Contain Only Nucleoside Reverse Transcriptase Inhibitors

In adult trials, regimens that contain only NRTIs have shown less potent virologic activity than NNRTI-based or PI-based regimens.^{10,11} Data on the efficacy of triple-NRTI regimens for treatment of ARV-naive children are limited to small observational studies.^{12,13} In a study on the use of the triple-NRTI regimen abacavir plus lamivudine (3TC) plus zidovudine in ARV-experienced children, this combination showed evidence of only modest viral suppression; only 10 of the 102 children had viral loads of <400 copies/mL at Week 48 of treatment.¹⁴ Therefore, regimens that contain only NRTIs **are not recommended** for treatment-naive or treatment-experienced children.

Regimens that Contain Three Drug Classes

The Panel **does not recommend** using regimens that contain agents from three drug classes as initial regimens (e.g., an NRTI plus an NNRTI plus a PI or an INSTI plus an NRTI plus a PI or NNRTI). Although studies of regimens that contain three classes of drugs have demonstrated that these regimens are safe and effective in ARV-experienced children and adolescents, these regimens have not been studied as initial regimens in treatment-naive children and adolescents. These regimens also have the potential to induce resistance to three drug classes, which could severely limit future treatment options.^{15–19} Ongoing studies are investigating the use of drugs from three drug classes to treat neonates.

Regimens that Contain Three Nucleoside Reverse Transcriptase Inhibitors and a Non-nucleoside Reverse Transcriptase Inhibitor

Current data are insufficient to recommend using a regimen that contains three NRTIs plus an NNRTI in young infants. A review of nine cohorts from 13 European countries suggested that this four-drug regimen produced responses that were superior to the responses observed in patients receiving boosted-PI regimens or three-drug NRTI regimens.²⁰ There has been speculation that poor

tolerance and poor adherence to a PI-based regimen may account for some of the differences. The AntiRetroviral Research for Watoto (ARROW) trial, conducted in Uganda and Zimbabwe, randomized 1,206 children (with a median age of 6 years) to receive either a standard NNRTI-based three-drug regimen (two NRTIs and one NNRTI) or a four-drug regimen (three NRTIs and one NNRTI). After a 36-week induction period, the children on the four-drug regimen continued treatment on a regimen that contained two NRTIs plus one NNRTI or a three-NRTI regimen. Although improvements in CD4 T lymphocyte (CD4) cell counts were observed at Week 36 (with a percentage change of approximately 14.4% in the four-drug arm compared with 12.6% in the three-drug arm), these benefits were not sustained after patients switched to the three-drug regimens for the duration of the study. Furthermore, no differences in viral suppression rates were observed between the two arms at Week 36.²¹ Because three-drug regimens have been shown to be effective and well tolerated and because efficacy data are lacking for the four-drug regimen, the Panel **currently does not recommend** the four-drug regimen.

Antiretroviral Drugs and Combinations with Insufficient Data to Recommend for Initial Therapy in Children

Several ARV drugs and drug regimens are not recommended for use as initial therapy in ARV-naive children or for specific age groups because of insufficient pediatric data. In some cases, new agents have shown promise in adult clinical trials but do not have sufficient pediatric PK and safety data to recommend their use as components of an initial therapeutic regimen in children. In addition, some dosing schedules may not be recommended in certain age groups because of insufficient data. As new data become available, these agents may become recommended agents or regimens, as summarized below and listed in [Table 10](#).

Darunavir with Low-Dose Ritonavir-Based Regimens Administered Once Daily for Children Aged ≥3 Years to <12 Years

Whereas modeling studies identified a once-daily dosing schedule for darunavir/ritonavir (DRV/r) that is now approved by the FDA, the Panel is concerned about the lack of direct PK studies for this approach in individuals aged ≥3 years to <12 years. Therefore, the data are not sufficient to recommend once-daily dosing for initial therapy in this age group. For children aged ≥3 years to <12 years, twice-daily DRV/r is a *Preferred* drug combination. For older children who have undetectable viral loads while receiving a twice-daily DRV/r-based regimen, practitioners can consider switching to once-daily DRV/r dosing if no darunavir (DRV)-associated resistance mutations are present. Once-daily dosing helps support adherence by making this drug combination easier to use.

Fostemsavir-Containing Regimens

Fostemsavir (FTR) is an HIV-1 glycoprotein (gp120)-directed attachment inhibitor that is not approved for use in pediatric patients. FTR was approved by the FDA in 2020 for use in adults in combination with other ARV drugs, with approval limited to heavily treatment-experienced adults with multidrug-resistant HIV who are failing their current ART regimen due to resistance, intolerance, or safety considerations. A study evaluating the safety, PK, and antiviral activity of FTR in children and adolescents ≥20 kg who are experiencing virologic failure on their current ART regimen and have dual or triple-class antiretroviral resistance ([PENTA Foundation: NCT04648280](#)) is ongoing and will be completed by June 2028. At this time, the Panel **does not recommend** FTR as part of an initial treatment regimen for HIV-1 infection in children.

Ibalizumab-Containing Regimens

Ibalizumab (IBA) is a humanized IgG4 monoclonal antibody that binds to CD4 extracellular domain 2 and prevents conformational changes in the CD4-HIV envelope gp120 essential for viral entry, thereby blocking HIV entry into CD4 cells.²² IBA is administered by intravenous infusion every 2 weeks following a single loading dose. IBA was approved by the FDA for use in adults with HIV-1 infection who are heavily pretreated, have multidrug-resistant virus, and are experiencing treatment failure. IBA has an orphan drug designation exempting the requirement for pediatric studies under federal law. At this time, because there is no experience with IBA in children, the Panel **does not recommend** its use as initial treatment for HIV-1 infection.

Lenacapavir-Containing Regimens

Lenacapavir (LEN) is a novel HIV-1 capsid inhibitor that interferes with three essential steps of HIV-1 replication: viral nuclear transport, virus assembly and release, and capsid core formation. Initiation of LEN requires the use of a combination of a subcutaneous (SQ) injection and an oral tablet, and maintenance consists of SQ injections every 26 (± 2) weeks.²³ LEN was approved by the FDA in 2022 for use in heavily treatment-experienced adults with multidrug-resistant HIV-1 in whom current ARV regimens failed due to resistance, intolerance, or safety issues. LEN must be used in combination with an optimized background regimen. The safety and efficacy of LEN in children have not yet been established. This, together with the approval for use of LEN in ARV-experienced individuals who are experiencing virologic failure on their current regimens, is the reason why the Panel **does not recommend** LEN as initial treatment for HIV-1 in infants or children.

Two-Drug Regimens

In adults, oral two-drug/two-class ARV regimens can be used in patients who have achieved and sustained viral suppression on a three-drug ART regimen and may be used for initial therapy in some individuals. In general, adults who have had viral suppression for at least 3 to 6 months and with known susceptibility to the ARV drugs in the two-drug regimen have success after switching to these regimens. Regimens that demonstrated efficacy in adult clinical trials include DTG plus RPV, DTG plus 3TC or emtricitabine, and boosted DRV plus DTG. At this time, no data support this strategy in children, and it **is not recommended** by the Panel. Although the Panel **does not recommend** oral two-drug regimens for initial treatment in children, some two-drug regimens might be considered for adolescents receiving ART when simplification or avoidance of NRTIs is desired based on data from adults, see [Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy](#).

A two-drug/two-class regimen of LAI CAB and RPV has been approved by the FDA for use in adults and in children and adolescents aged ≥ 12 years and weighing ≥ 35 kg who have achieved and sustained viral suppression on another combination ARV regimen. However, this LAI regimen **is not recommended** for initial therapy.

Table 10. Antiretroviral Regimens or Components That Are Not Recommended for Initial Treatment of HIV Infection in Children and Adolescents

| ARV Regimen | Rationale |
|--|---|
| Regimens containing only NRTIs | Inferior virologic efficacy |
| Regimens containing three drug classes | Potential to induce multiclass resistance Use as an initial regimen in children has not been studied |
| Regimens containing three NRTIs and one NNRTI | Added cost and complexity outweigh any benefit |
| Full-dose, dual-PI regimens | Insufficient data to recommend; potential for added toxicities |
| Oral regimens containing only two ARV drugs | Not FDA approved for pediatric use |
| ARV Component | Rationale |
| Unboosted ATV-containing regimens in children | Inadequate drug exposure |
| CAB | Not FDA approved for use in ARV-naive individuals or in children aged <12 years and weighing <35 kg |
| DRV/r in children <3 years | Potential for seizures |
| Once-daily DRV-based regimens in children aged ≥3 years to <12 years | Insufficient data to recommend |
| EFV-based regimens for children aged <3 years | CYP2B6 genotyping required to determine appropriate dosing |
| ETR-based regimens | Insufficient data to recommend; unlikely to be used as initial therapy |
| EVG-based regimens | First-generation INSTIs with lower barriers to resistance than second-generation INSTIs (BIC and DTG) that are now available for initial ARV regimens in children |
| FTR | Not FDA approved for use in ARV-naive adults or for pediatric use |
| IBA | Not FDA approved for use in ARV-naive adults or for pediatric use |
| LEN | Not FDA approved for use in ARV-naive adults or for pediatric use |
| LPV/r dosed once daily | Inadequate drug exposure |
| MVC-based regimens | Only effective for CCR5-tropic virus |
| TDF-containing regimens in children aged <2 years | Potential bone toxicity Appropriate dose has yet to be determined |

Key: ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; CAB = cabotegravir; CYP = cytochrome P450; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; Efv = efavirenz; ETR = etravirine; EVG = elvitegravir; FDA = U.S. Food and Drug Administration; FTR = fostemsaviv; IBA = ibalizumab; INSTI = integrase strand transfer inhibitor; LEN = lenacapavir; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; TDF = tenofovir disoproxil fumarate

Table 11. Antiretroviral Regimens or Components That Are Never Recommended for Treating HIV in Children and Adolescents

| ARV Regimen or Component ^a | Rationale | Exceptions |
|--|--|--|
| One ARV Drug Alone (Monotherapy) | Rapid development of resistance Inferior antiviral activity compared with regimens that include ≥ 3 ARV drugs Monotherapy "holding" regimens are associated with more rapid CD4 count declines than nonsuppressive ART. | Infants with perinatal HIV exposure and negative virologic tests who are receiving 4–6 weeks of ZDV prophylaxis to prevent perinatal transmission of HIV |
| Two NRTIs Alone | Rapid development of resistance Inferior antiviral activity compared with regimens that include ≥ 3 ARV drugs | Not recommended for initial therapy Some clinicians may opt to continue using two NRTIs alone in patients who achieve virologic goals with this regimen. |
| Any Regimen Containing 3TC Plus FTC | Similar resistance profile and no additive benefit | No exceptions |
| Any Regimen Containing TDF and TAF | No data to support potential additive efficacy or toxicity | No exceptions |
| Dual-NNRTI Combinations | Enhanced toxicity | No exceptions |
| TDF Plus ABC Plus (3TC or FTC) as a Triple-NRTI Regimen | High rate of early viral failure when this triple-NRTI regimen was used as initial therapy in treatment-naïve adults | No exceptions |
| NVP as Component of Initial ARV Therapy Regimen in Adolescent Girls with CD4 Counts >250 cells/mm ³ or Adolescent Boys with CD4 Counts >400 cells/mm ³ | Increased incidence of symptomatic (including serious and potentially fatal) hepatic events in these patient groups | Only if benefit clearly outweighs risk |

^a Several ARV drugs that are no longer available or that have not been recommended for use in children for several years have been removed from this chapter, including the NRTIs stavudine and didanosine; the protease inhibitors fosamprenavir, indinavir, nelfinavir, saquinavir, and tipranavir; and the fusion inhibitor enfuvirtide (see [Archived Drugs](#)).

Key: 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; CD4 = CD4 T lymphocyte; FTC = emtricitabine; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

References

1. Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS*. 2011;25(12):1489-1496. Available at: <https://pubmed.ncbi.nlm.nih.gov/21610486>.
2. Bwakura Dangarembizi M, Samson P, Capparelli EV, et al. Establishing dosing recommendations for efavirenz in HIV/TB-coinfected children younger than 3 years. *J Acquir Immune Defic Syndr*. 2019;81(4):473-480. Available at: <https://pubmed.ncbi.nlm.nih.gov/31241542>.
3. Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. *Retrovirology*. 2018;15(1):56. Available at: <https://pubmed.ncbi.nlm.nih.gov/30119633>.
4. Konigs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. *AIDS*. 2012;26(4):447-455. Available at: <https://pubmed.ncbi.nlm.nih.gov/22156961>.
5. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the Phase II PIANO study. *HIV Med*. 2014;15(9):513-524. Available at: <https://pubmed.ncbi.nlm.nih.gov/24589294>.
6. MacBrayne CE, Rutstein RM, Wiznia AA, et al. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. *AIDS*. 2021;35(9):1413-1421. Available at: <https://pubmed.ncbi.nlm.nih.gov/33831904>.
7. Giaquinto C, Mawela MP, Chokephaibulkit K, et al. Pharmacokinetics, safety and efficacy of maraviroc in treatment-experienced pediatric patients infected with CCR5-tropic HIV-1. *Pediatr Infect Dis J*. 2018;37(5):459-465. Available at: <https://pubmed.ncbi.nlm.nih.gov/29023357>.
8. Rosebush JC, Best BM, Chadwick EG, et al. Pharmacokinetics and safety of maraviroc in neonates. *AIDS*. 2021;35(3):419-427. Available at: <https://pubmed.ncbi.nlm.nih.gov/33252481>.
9. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf.
10. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. *AIDS*. 2003;17(14):2045-2052. Available at: <https://pubmed.ncbi.nlm.nih.gov/14502007>.
11. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. *AIDS*. 2003;17(7):987-999. Available at: <https://pubmed.ncbi.nlm.nih.gov/12700448>.
12. Saavedra J, McCoig C, Mallory M, et al. Clinical experience with triple nucleoside (NRTI) combination ZDV/3TC/abacavir (ABC) as initial therapy in HIV-infected children. Presented

at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001. Chicago, IL.

13. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. *Paediatr Drugs*. 2004;6(3):147-159. Available at: <https://pubmed.ncbi.nlm.nih.gov/15170362>.
14. Saez-Llorens X, Nelson RP, Jr., Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNA3006 Study Team. *Pediatrics*. 2001;107(1):E4. Available at: <https://pubmed.ncbi.nlm.nih.gov/11134468>.
15. Spector SA, Hsia K, Yong FH, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. *J Infect Dis*. 2000;182(6):1769-1773. Available at: <https://pubmed.ncbi.nlm.nih.gov/11069252>.
16. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. *N Engl J Med*. 1999;341(25):1874-1881. Available at: <https://pubmed.ncbi.nlm.nih.gov/10601506>.
17. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2002;21(7):659-663. Available at: <https://pubmed.ncbi.nlm.nih.gov/12237599>.
18. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial—PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. *AIDS Res Hum Retroviruses*. 2000;16(12):1113-1121. Available at: <https://pubmed.ncbi.nlm.nih.gov/10954886>.
19. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. *Clin Infect Dis*. 2002;34(7):991-1001. Available at: <https://pubmed.ncbi.nlm.nih.gov/11880966>.
20. Judd A, and EP, Paediatric HIV Cohort Collaboration study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996–2008: treatment response and duration of first-line regimens. *AIDS*. 2011;25(18):2279-2287. Available at: <https://pubmed.ncbi.nlm.nih.gov/21971357>.
21. Arrow Trial team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. *Lancet*. 2013;381(9875):1391-1403. Available at: <https://pubmed.ncbi.nlm.nih.gov/23473847>.
22. Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. *Front Microbiol*. 2017;8:2323. Available at: <https://pubmed.ncbi.nlm.nih.gov/29230203>.

23. Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. *Expert Rev Anti Infect Ther.* 2023;21(6):565-570. Available at: <https://pubmed.ncbi.nlm.nih.gov/37067160/>.

Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV

Updated: December 19, 2024

Reviewed: December 19, 2024

Panel's Recommendations

Antiretroviral Management for Infants With Exposure to HIV During the *In Utero* and Intrapartum Periods

- All newborns with *in utero* (antepartum) or intrapartum exposure to HIV should receive one or more antiretroviral (ARV) drugs, dosed appropriately for the infant's gestational age and weight and initiated as close to the time of birth as possible, preferably within 6 hours (AII).

ARV regimen selection for infants with *in utero* or intrapartum exposure to HIV should be based on predicted risk for transmission, determined by maternal HIV RNA levels (see [Table 12](#), [Table 13](#), [Table 13.1](#), and [Figure 1](#) below) (AII).

Infants at high risk of HIV infection from *in utero* or intrapartum exposure, defined as being perinatally exposed to viremia (HIV RNA ≥ 50 copies/mL) in the 4 weeks prior to delivery, should be provided a three-drug ARV regimen, administered from birth for 2–6 weeks, that serves as presumptive HIV therapy or enhanced prophylaxis. If the duration of the three-drug regimen is shorter than 6 weeks, zidovudine (ZDV) should be continued alone to complete a total of 6 weeks of prophylaxis (AII).

- Infants at low risk of *in utero* and intrapartum HIV acquisition, defined as being perinatally exposed to HIV RNA levels <50 copies/mL from 20 weeks of gestation through delivery, should receive ZDV alone for a duration of 2 weeks (AII).
- Infants not meeting criteria for high or low risk should have ARV regimens and durations based on case-specific factors related to the level and timing of viremia during the pregnancy (AII) (see [Table 13](#)).
- An HIV nucleic acid test (NAT) should generally be performed at birth for all infants (AII) but is not necessary for infants at low risk who are not being breastfed (BIII). See [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3, Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing.

Antiretroviral Management for Infants With Exposure to HIV During the Breastfeeding Period

- Recommendations about extended ARV prophylaxis are based on the current and anticipated maternal virologic status during breastfeeding (see [Table 14](#) and [Table 14.1](#) below). Ideally, plans should be made during the antepartum period; reassessment should take place both at delivery and regularly during the breastfeeding period (AII).

For infants at low risk of HIV acquisition during breastfeeding, some Panel members do not recommend extended ARV prophylaxis; however, other Panel members do recommend extended ARV prophylaxis with either nevirapine (NVP) or lamivudine (3TC) (CIII). The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (the Panels) did not reach consensus. Infants are considered at low risk of transmission during breastfeeding when (1) maternal antiretroviral therapy is being taken while breastfeeding and sustained maternal virologic suppression (HIV RNA <50 copies/mL) was achieved for at least 3 months prior to delivery and (2) the provider and patient are confident that maternal ART adherence will be maintained during breastfeeding (AII).

- For infants currently at low risk of HIV acquisition during breastfeeding but with concerns for future risk, the Panels recommend extended ARV prophylaxis with either NVP or 3TC (BIII). Adherence support should always be provided during breastfeeding ([Table 14](#)) (AIII).
- Extended ARV prophylaxis during breastfeeding, when used, should ensure continuous prophylaxis through the postnatal period. Most experts recommend transitioning to NVP or 3TC after the completion of initial ZDV prophylaxis. However, either NVP or 3TC can be given from birth, replacing ZDV and providing both initial postnatal prophylaxis and extended prophylaxis during breastfeeding (BIII).

- Extended ARV prophylaxis during breastfeeding, when used, should continue until either 6 weeks after the last exposure to breast milk or 6 weeks after concerns about maternal virologic suppression have resolved—whichever occurs first (BIII).

Recommendations for Infant Antiretroviral Management When the Infant is Exposed to New Viremia

- Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in [Preventing HIV Transmission During Infant Feeding](#) (AII). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥ 200 copies/mL (CIII).
- An infant HIV NAT should be performed (AII) (see [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing).
- New viremia with HIV RNA ≥ 200 copies/mL:** If a maternal HIV RNA level ≥ 200 copies/mL (viremia) develops or there is presumed viremia (e.g., reports nonadherence to ARVs), the Panels recommend the initiation of a three-drug ARV regimen for the infant for 4–6 weeks (AII) (see [Table 14](#) and [Table 14.1](#)).
- New viremia with HIV RNA < 200 copies/mL:** When maternal viremia that is quantifiable but < 200 copies/mL develops, some Panel members recommend the initiation of a three-drug presumptive HIV therapy, other members recommend the initiation of single-drug ARV prophylaxis (NVP or 3TC), and others recommend infant ARV management based on repeat maternal HIV RNA testing (CII). The Panels did not reach consensus on management; consultation with an expert is suggested (see [Table 14](#)).

Infant ARV Management When Perinatal HIV Exposure is Related to a New Diagnosis of HIV During Breastfeeding

- Infants exposed to newly diagnosed maternal HIV infection during breastfeeding should be managed like infants at high risk of *in utero* or intrapartum HIV acquisition and receive a three-drug presumptive HIV therapy regimen for 2–6 weeks (see [Table 14](#)) and replacement feeding. If the duration of the three-drug regimen is shorter than 6 weeks, ZDV should be continued alone to complete a total of 6 weeks of prophylaxis (AII). See [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing.

Providers with questions about ARV management of perinatal HIV exposure or exposure to HIV during breastfeeding should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline](#) (1-888-448-8765), which provides free clinical consultation on all aspects of perinatal HIV, including newborn care (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Risk of *In Utero* or Intrapartum HIV Transmission and Antiretroviral Management of Infants

All infants with *in utero* or intrapartum exposure to HIV should receive antiretroviral (ARV) drugs during the immediate neonatal period to reduce the risk of HIV transmission, with selection of the appropriate ARV regimen guided by the level of transmission risk. HIV transmission can occur *in utero*, intrapartum, or during breastfeeding.

This section addresses ARV management of infants with exposure to HIV-1 recommended by the Panel on the Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission (Perinatal Panel) and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (Pediatric Panel). Information about ARV management for infants perinatally exposed to HIV-2 infection is available in [HIV-2 Infection and Pregnancy](#).

The maternal viral load (**HIV RNA level**) is the most important risk factor for *in utero* and *intrapartum* HIV transmission to the infant. Infants are at an increased risk for HIV acquisition when antiretroviral therapy (ART) is not being taken during pregnancy and when antepartum treatment does not result in antepartum viral suppression, particularly in the 4 weeks prior to delivery, but even in the second half of pregnancy. Higher viral load correlates with higher risk of transmission. A spectrum of transmission risk depends on these and other factors, including mode of delivery and health status during pregnancy and delivery. Although current assays can detect very low levels of HIV RNA, data from studies on transmission and viral load that were conducted prior to the availability of highly sensitive tests indicate that an HIV RNA level <50 copies/mL sufficiently predicts low risk of HIV transmission.^{1,2}

Risk of HIV Transmission In Utero

The risk of *in utero* HIV transmission is believed to increase with gestational age, with the highest rate of *in utero* infection occurring in the third trimester. However, methodological challenges in assessing the timing of fetal infection limit the precision of risk estimates by gestational age. A definitive diagnosis of *in utero* infection during pregnancy would require invasive sampling, carrying risk that is not ethically or medically indicated. There are case reports of HIV being identified in fetal tissue as early as 8-, 15-, and 20-weeks' gestation, but whether they represented established infection remains unclear.³⁻⁵ In a study of fetal thymuses in the second trimester, polymerase chain reaction (PCR) testing revealed that 2 of 100 samples had HIV-1.⁶ For this reason, the Panels have a 20 week-gestational age as a conservative gestational age threshold below which *in utero* transmission is unlikely to occur. A modeling study using profiles of viral culture positivity and seroconversion from a cohort of 95 French infants suggests that the vast majority of *in utero* HIV infection occurs in the third trimester.⁷ Another approach has been to examine how well ARVs initiated at different gestational ages prevent *in utero* transmission. Among 34 women in a U.K./Irish cohort who started ARVs during pregnancy, HIV transmission was more likely when ARVs were started later in pregnancy (median gestational age at initiation of 30.1 weeks, interquartile range [IQR] 27.4–32.6 weeks vs. 25.9 weeks, IQR 22.4–28.7 weeks, $P < 0.001$).⁸ Another model made estimates of relative time of *in utero* or intrapartum transmission based on timing of ARV initiation; they estimated 3% of transmissions occurred before 14 weeks' gestation, 17% from 14 to 36 weeks, 50% from 36 weeks through onset of labor, and 30% from intrapartum exposure.⁹ In summary, *in utero* HIV transmission in the context of maternal viremia is considered rare in the first trimester, uncommon but possible in the second trimester, and most common in the third trimester.

Risk of HIV Transmission Intrapartum (During Labor and Delivery)

The highest risk of vertical HIV transmission is from exposure in the intrapartum period (i.e., during labor and delivery). Risk increases with the level of maternal viremia.² Recommended interventions to reduce the risk of intrapartum transmission include ART for all pregnancies, intravenous zidovudine (ZDV) during labor and delivery, and scheduled cesarean delivery when there is a detectable HIV-1 viral load >1,000 copies/mL (see [Intrapartum HIV Care](#)).

Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period

[Table 12](#) below summarizes *in utero* and intrapartum HIV transmission risk according to HIV RNA levels at three antenatal time periods for the purpose of selecting infant ARV prophylaxis. Because robust data are not available to define thresholds of risk across pregnancy, the Panels have defined time points balancing available evidence with implications for clinical management. Transmission

risk categories inform ARV choice and management of prophylaxis and presumptive HIV therapy for infants with HIV exposure.

The assessment of transmission risk is generally but not exclusively dependent on HIV RNA levels during the antepartum period. The Perinatal Panel recommends assessing maternal **HIV RNA levels at the initial antenatal visit with a review of prior levels, 2 to 4 weeks after initiating (or changing) ART, and monthly until RNA levels are undetectable. Maternal HIV RNA levels should also be assessed at least every 3 months during pregnancy and at approximately 36 weeks of gestation, or within 4 weeks of delivery** (see [Initial Evaluation and Continued Monitoring of HIV During Pregnancy](#)). However, discussion around transmission risk may not align exactly with the recommended time frames, and clinicians must continue to utilize judgment to assess risk. For example, viremia could be presumed based on reports of poor adherence for several weeks, even without a documented test. Conversely, a missed HIV RNA test in a patient with years of virologic control may not merit concern. Incident HIV infection during pregnancy and lack of receipt of ART have been previously cited as risk factors for transmission; the current guidelines incorporate the risks of those scenarios within the framework of documented or presumed viremia.

Table 12. Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period

| Antenatal Time Period | | | Transmission Risk | |
|---------------------------------|---|---------------------------------------|-------------------|-------------|
| HIV RNA at <20 Weeks' Gestation | HIV RNA ≥20 Weeks' Gestation to 4 Weeks Prior to Delivery | HIV RNA at ≤4 Weeks Prior to Delivery | In Utero | Intrapartum |
| N/A ^a | N/A ^a | ≥50 copies/mL ^b | High | High |
| N/A ^a | ≥50 copies/mL ^b | <50 copies/mL | Low to moderate | Low |
| ≥50 copies/mL ^b | <50 copies/mL | <50 copies/mL | Low | Low |
| <50 copies/mL | <50 copies/mL | <50 copies/mL | Low | Low |

^a HIV RNA levels in this time period do not change the transmission risk categorization because transmission risk is determined by viremia later in gestation.

^b HIV RNA values of ≥50 copies/mL can be documented or presumed (e.g., early [acute or recent] HIV, new diagnosis of HIV, or known lapse in adherence).

Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV

Historically, the use of ARV drugs in the newborn period was referred to as ARV prophylaxis because it primarily focused on protection against newborn acquisition of HIV. More recently, clinicians have **additionally sought to consider and optimize the management of** newborns at **elevated risk for HIV acquisition *in utero*** and initiate three-drug ARV regimens as presumptive HIV therapy. In this section, the following terms will be used:

- **ARV Prophylaxis:** The administration of ARV drugs to a newborn without HIV infection to reduce the risk of HIV acquisition.
- **Presumptive HIV Therapy:** The administration of a three-drug ARV regimen to newborns at elevated risk of HIV acquisition. Presumptive HIV therapy is intended to be early treatment for a newborn who has already acquired HIV but doesn't have documentation of infection; it also

serves as enhanced ARV prophylaxis against HIV acquisition among infants at high risk but not yet infected.

- **ART:** The administration of a three-drug ARV regimen to infants and children with documented HIV infection (see [Diagnosis of HIV Infection in Infants and Children](#) and [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#)).


The terms ARV prophylaxis and presumptive HIV therapy describe the potential roles of ARV drugs when the HIV status of an infant is unknown, and they often overlap in neonates at high risk. For example, a presumptive HIV therapy regimen also provides drug exposure that would serve as prophylaxis for a newborn. However, it is important to note that some two-drug and three-drug ARV regimens used historically were designed and studied as prophylaxis, including some that used doses of nevirapine (NVP) that target lower exposures than the doses used for treatment of HIV infection.

The Panels recommend initiating ARV prophylaxis or presumptive HIV therapy as soon as possible after birth, preferably within 6 hours. Although the maximum interval during which newborn ARV prophylaxis can be initiated and still be beneficial is unknown, most studies support providing ARV drugs as early as possible after delivery.¹⁰⁻¹⁵

The guidance summarized in this section applies to infants perinatally exposed to HIV unless otherwise noted. The algorithm in [Figure 1](#) and [Table 13](#) provide an overview of neonatal ARV management recommendations according to the risk of HIV transmission from *in utero* and intrapartum exposure based on HIV RNA levels at time points during pregnancy and other factors, such as receipt of and adherence to ART. [Table 13.1](#) summarizes the recommended ARV dosing for prophylaxis or presumptive HIV therapy in newborns with *in utero* or intrapartum HIV exposure. Additional information about dose selection for newborns, including preterm infants (<37 weeks gestational age), can be found in [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#).

The [National Perinatal HIV Hotline](#) (1-888-448-8765) is a federally funded service that provides free clinical consultation on difficult cases to providers who are providing HIV care during pregnancy and for newborns after pregnancy, and consultants can provide referrals to local or regional pediatric HIV specialists.

Figure 1. Algorithm for Antiretroviral Management of Infants With *In Utero* or Intrapartum HIV Exposure by Risk of HIV Transmission



^a Early (acute or recent) HIV infection in pregnancy may result in a scenario where viremia occurs early in gestation but is suppressed after 20 weeks and through the remainder of pregnancy until delivery. In these situations, decision-making guided by the clinical scenario is recommended (see Table 13).

Key: ARV = antiretroviral; NAT = nucleic acid test; PCR = polymerase chain reaction; ZDV = zidovudine

Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV

| Clinical Setting | Risk of Acquisition | | Neonatal ARV Management ^{a,b} | Rationale |
|---|---------------------|-------------|---|---|
| | <i>In Utero</i> | Intrapartum | | |
| High Risk of Acquisition | | | | |
| HIV RNA ≥50 copies/mL in the 4 weeks prior to delivery Viremia can be documented by lab or presumed by other clinical factors (e.g., new diagnosis, ART adherence problems, reports of having stopped ART prior to delivery). | High | High | Presumptive HIV therapy using a three-drug regimen of ZDV and 3TC plus either NVP (treatment dose) or RAL Duration is from birth for 2–6 weeks; consensus not reached by members of the Panel. ^c If the duration of a three-drug regimen is <6 weeks, and the birth NAT is negative, ZDV should be continued alone to complete a total of 6 weeks of prophylaxis. HIV NAT obtained before or immediately after starting presumptive therapy with three drugs ^{d,e} | Viremia in the 4 weeks immediately prior to delivery confers very high risk for <i>in utero</i> and intrapartum transmission. Plasma HIV RNA levels of 50–200 copies/mL could be expected to confer lower risk than those >200 copies/mL but could also be an indicator of poor adherence and raise concern for higher levels of viremia at other times. |
| Low Risk of Acquisition | | | | |
| HIV RNA <50 copies/mL from 20 weeks' gestation through delivery Ideally documented by at least two consecutive tests at least four weeks apart with HIV RNA <50 copies/mL, but can be based on clinical judgment of providers. | Low | Low | ZDV for 2 weeks | Sustained virologic suppression from 20 weeks' gestation is associated with extremely low risk of transmission <i>in utero</i> or intrapartum. Although <i>in utero</i> transmission events have been documented prior to 20 weeks, the extremely low frequency of these events does not merit the presumptive HIV therapy approach. |
| Other Clinical Scenarios | | | | |
| HIV RNA ≥50 copies/mL at >20 weeks' gestation, but HIV RNA <50 copies/mL in the 4 weeks prior to delivery | Low to Moderate | Low | HIV NAT at Birth ^{d,e} <i>Two Options for ARV Management</i> 1. Presumptive HIV therapy with a three-drug regimen, | Viremia in the late second and third trimester elevates risk of <i>in utero</i> transmission (increasing risk with higher HIV RNA levels and longer duration |

Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV

| Clinical Setting | Risk of Acquisition | | Neonatal ARV Management ^{a,b} | Rationale |
|---|--|--|---|--|
| | <i>In Utero</i> | Intrapartum | | |
| | | | <p>as described above for infants at high risk. If birth the HIV NAT is negative, de-escalate the prophylaxis regimen to ZDV alone to complete 2–6 weeks total.^c</p> <p>2. ZDV prophylaxis for 2–6 weeks</p> | <p>of viremia).</p> <p><i>Option 1.</i> Some Panel members believe that the potential benefit of early treatment for an infant who acquired the infection <i>in utero</i> merits a presumptive HIV therapy approach.</p> <p><i>Option 2.</i> Other Panel members believe that the marginal potential benefit and anticipated low frequency of <i>in utero</i> infection do not merit the additional complexity of and potential toxicity of presumptive HIV therapy and favor ZDV prophylaxis only.</p> <p>All infants should receive a minimum of 2 weeks ZDV prophylaxis, but up to 6 weeks may be used when indicated based on risk assessment.</p> |
| Early (acute or recent) HIV at any point during pregnancy | Moderate to High depending on maternal HIV RNA levels and weeks' gestation | High if HIV RNA ≥50 copies/mL in the last 4 weeks of pregnancy | HIV NAT at birth ^{d,e} Manage infant ARVs according to the level and timing of the maternal viremia as described in the rows above (just as for an infant exposed to established infection). | <p>Early or recent HIV diagnosed at any time during pregnancy is a unique situation because very high HIV RNA levels place infants at high risk of HIV acquisition.</p> <p>For infants perinatally exposed to known HIV infection, risk of transmission increases when viremia occurs later in pregnancy. Some Panel members would manage all cases with presumptive therapy, whereas others would only use it for viremia after 20 weeks' gestation.</p> |

Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV

| Clinical Setting | Risk of Acquisition | | Neonatal ARV Management ^{a,b} | Rationale |
|--|---------------------|--------------------|---|---|
| | <i>In Utero</i> | Intrapartum | | |
| Unconfirmed maternal HIV status with at least one positive HIV test at delivery or postpartum <i>or</i> Newborn has a positive HIV antibody test | High/ Uncertain | High/ Uncertain | HIV NAT at birth ^{d,e} Presumptive HIV therapy with a three-drug regimen as described above for newborns with a high risk of <i>in utero</i> or intrapartum HIV acquisition If supplemental testing confirms a negative maternal HIV status, discontinue infant ARV drugs immediately. | Supplemental maternal HIV testing and/or NAT testing of the infant is required to determine the level of risk and need to continue infant presumptive HIV therapy or initiate ART. ^e |

^a Infant ARVs should be initiated in the first 6 hours after delivery, especially for infants with a high risk of acquisition. See Table 13.1 for ARV dosing.

^b See [HIV-2 Infection and Pregnancy](#) for ARV prophylaxis recommendations for infants perinatally exposed to HIV-2 mono-infection. In the event of maternal HIV-2 infection or HIV-1 and HIV-2 coinfection, the infant ARV regimen should be based on the determination of low or high risk of HIV-1 transmission as described in the above table using ARVs that are active against HIV-2. Because HIV-2 is not susceptible to NVP, RAL should be used in presumptive HIV therapy regimens for infants at high risk of HIV acquisition with exposure to HIV-2 or to both HIV-1 and HIV-2.

^c The optimal duration of three-drug regimen in newborns who are at a high risk for HIV acquisition is unknown. Newborns who are at a high risk for HIV acquisition should receive the ZDV component for 6 weeks. The other two ARVs, (3TC and NVP) or (3TC and RAL), may be administered for 2 to 6 weeks; the recommended duration for treatment with three ARVs varies depending on infant HIV NAT results, maternal viral load at the time of delivery, and the additional risk factors for HIV transmission. Consultation with an expert in pediatric HIV is recommended when selecting a therapy duration because this decision should be based on case-specific risk factors and interim infant HIV NAT results.

^d NAT test at birth should be obtained before or immediately after starting ARVs. See [Diagnosis of HIV Infection in Infants and Children](#) for additional information about HIV testing and NATs.

^e When a newborn HIV NAT is positive, infant ART should be initiated without waiting for the results of confirmatory HIV NAT testing, given the low likelihood of a false-positive HIV NAT (see [When to Initiate Antiretroviral Treatment in Children with HIV Infection](#) and [What to Start in the Pediatric Antiretroviral Guidelines](#)). However, the specimen for confirmatory HIV testing should be obtained prior to ART initiation.

Note: Providers with questions about ARV management of infants should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline](#) (1-888-448-8765).

Key: 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test; NVP = nevirapine; the Panels = the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; RAL = raltegravir; ZDV = zidovudine

Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV^a

This table provides dosing for antiretroviral (ARV) prophylaxis and presumptive HIV therapy in infants with *in utero* or intrapartum exposure to HIV. Dosing for additional ARV prophylaxis during breastfeeding is provided in [Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#).

For infants with HIV infection, recommendations for initial ARV therapy regimens and ARV dosing are available in the [Pediatric Antiretroviral Guidelines](#); see [What to Start](#) and [Appendix A. Pediatric Antiretroviral Drug Information](#).

| ARV Drug | Drug Doses by Gestational Age at Birth | | | | | | | | |
|---------------|--|-------------|---|---------------|------|---------------|--------|---------------|------|
| ZDV | <p>≥35 Weeks of Gestation at Birth</p> <p><i>Birth to Age ≤6 Weeks</i></p> <ul style="list-style-type: none"> • ZDV 4 mg/kg per dose orally twice daily or alternative simplified weight-band dosing (see table below) <p>Simplified Weight-Band Dosing for Newborns Aged ≥35 Weeks of Gestation From Birth to 4 Weeks</p> <table border="1"> <thead> <tr> <th>Weight Band</th><th>Volume of ZDV 10 mg/mL Oral Syrup Twice Daily</th></tr> </thead> <tbody> <tr> <td>2 kg to <3 kg</td><td>1 mL</td></tr> <tr> <td>3 kg to <4 kg</td><td>1.5 mL</td></tr> <tr> <td>4 kg to <5 kg</td><td>2 mL</td></tr> </tbody> </table> <p>≥30 Weeks to <35 Weeks of Gestation at Birth</p> <p><i>Birth to Age 2 Weeks</i></p> <ul style="list-style-type: none"> • ZDV 2 mg/kg per dose orally twice daily <p><i>Age 2 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> • ZDV 3 mg/kg per dose orally twice daily <p><30 Weeks of Gestation at Birth</p> <p><i>Birth to Age 4 Weeks</i></p> <ul style="list-style-type: none"> • ZDV 2 mg/kg per dose orally twice daily <p><i>Age 4 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> • ZDV 3 mg/kg per dose orally twice daily | Weight Band | Volume of ZDV 10 mg/mL Oral Syrup Twice Daily | 2 kg to <3 kg | 1 mL | 3 kg to <4 kg | 1.5 mL | 4 kg to <5 kg | 2 mL |
| Weight Band | Volume of ZDV 10 mg/mL Oral Syrup Twice Daily | | | | | | | | |
| 2 kg to <3 kg | 1 mL | | | | | | | | |
| 3 kg to <4 kg | 1.5 mL | | | | | | | | |
| 4 kg to <5 kg | 2 mL | | | | | | | | |
| 3TC | <p>≥32 Weeks of Gestation at Birth</p> <p><i>Birth to Age <4 Weeks</i></p> <ul style="list-style-type: none"> • 3TC 2 mg/kg per dose orally twice daily | | | | | | | | |

Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV^a

| ARV Drug | Drug Doses by Gestational Age at Birth | | | | | | | | | | | | | | | | |
|---|---|-------------|--|---|----------------------------------|---------------|--------------------------|---------------|--------------------------|---------------|--------------------------|---|--------------------------------|---------------|---------------------------|---------------|--------------------------|
| | <p><i>Age ≥4 Weeks to ≤6 weeks</i></p> <ul style="list-style-type: none"> • 3TC 4 mg/kg per dose orally twice daily | | | | | | | | | | | | | | | | |
| NVP ^b | <p>≥37 Weeks of Gestation at Birth</p> <p><i>Birth to Age ≤6 Weeks</i></p> <ul style="list-style-type: none"> • NVP 6 mg/kg per dose orally twice daily <p>≥34 Weeks to <37 Weeks of Gestation at Birth</p> <p><i>Birth to Age <1 Week</i></p> <ul style="list-style-type: none"> • NVP 4 mg/kg per dose orally twice daily <p><i>Age ≥1 Week to ≤6 Weeks</i></p> <ul style="list-style-type: none"> • NVP 6 mg/kg per dose orally twice daily <p>≥32 Weeks to <34 Weeks of Gestation at Birth</p> <p><i>Birth to Age <2 Weeks</i></p> <ul style="list-style-type: none"> • NVP 2 mg/kg per dose orally twice daily <p><i>Age ≥2 Weeks to <4 Weeks</i></p> <ul style="list-style-type: none"> • NVP 4 mg/kg per dose orally twice daily <p><i>Age ≥4 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> • NVP 6 mg/kg per dose orally twice daily | | | | | | | | | | | | | | | | |
| RAL | <p>≥37 Weeks of Gestation at Birth and Weighing ≥2 kg^c</p> <p><i>Birth to Age 6 Weeks</i></p> <table border="1"> <thead> <tr> <th>Body Weight</th><th>Volume (Dose) of RAL 10 mg/mL Suspension</th></tr> </thead> <tbody> <tr> <td>Birth to 1 Week: Once-Daily Dosing</td><td>Approximately 1.5 mg/kg per dose</td></tr> <tr> <td>2 kg to <3 kg</td><td>0.4 mL (4 mg) once daily</td></tr> <tr> <td>3 kg to <4 kg</td><td>0.5 mL (5 mg) once daily</td></tr> <tr> <td>4 kg to <5 kg</td><td>0.7 mL (7 mg) once daily</td></tr> <tr> <td>1 to 4 Weeks: Twice-Daily Dosing</td><td>Approximately 3 mg/kg per dose</td></tr> <tr> <td>2 kg to <3 kg</td><td>0.8 mL (8 mg) twice daily</td></tr> <tr> <td>3 kg to <4 kg</td><td>1 mL (10 mg) twice daily</td></tr> </tbody> </table> | Body Weight | Volume (Dose) of RAL 10 mg/mL Suspension | Birth to 1 Week: Once-Daily Dosing | Approximately 1.5 mg/kg per dose | 2 kg to <3 kg | 0.4 mL (4 mg) once daily | 3 kg to <4 kg | 0.5 mL (5 mg) once daily | 4 kg to <5 kg | 0.7 mL (7 mg) once daily | 1 to 4 Weeks: Twice-Daily Dosing | Approximately 3 mg/kg per dose | 2 kg to <3 kg | 0.8 mL (8 mg) twice daily | 3 kg to <4 kg | 1 mL (10 mg) twice daily |
| Body Weight | Volume (Dose) of RAL 10 mg/mL Suspension | | | | | | | | | | | | | | | | |
| Birth to 1 Week: Once-Daily Dosing | Approximately 1.5 mg/kg per dose | | | | | | | | | | | | | | | | |
| 2 kg to <3 kg | 0.4 mL (4 mg) once daily | | | | | | | | | | | | | | | | |
| 3 kg to <4 kg | 0.5 mL (5 mg) once daily | | | | | | | | | | | | | | | | |
| 4 kg to <5 kg | 0.7 mL (7 mg) once daily | | | | | | | | | | | | | | | | |
| 1 to 4 Weeks: Twice-Daily Dosing | Approximately 3 mg/kg per dose | | | | | | | | | | | | | | | | |
| 2 kg to <3 kg | 0.8 mL (8 mg) twice daily | | | | | | | | | | | | | | | | |
| 3 kg to <4 kg | 1 mL (10 mg) twice daily | | | | | | | | | | | | | | | | |

Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV^a

| ARV Drug | Drug Doses by Gestational Age at Birth | |
|---|---|---------------------------------------|
| | 4 kg to <5 kg | 1.5 mL (15 mg) twice daily |
| | 4 to 6 Weeks: Twice-Daily Dosing | Approximately 6 mg/kg per dose |
| | 3 kg to <4 kg | 2.5 mL (25 mg) twice daily |
| | 4 kg to <6 kg | 3 mL (30 mg) twice daily |
| | 6 kg to <8 kg | 4 mL (40 mg) twice daily |
| ABC ^d Note: The Panels do not recommend ABC as part of three-drug regimen for newborns with HIV exposure. However, in situations where ZDV is not available or the infant has ZDV-associated toxicity, ABC could be considered an alternative to ZDV. | <p>≥37 Weeks' Gestation at Birth</p> <p><i>Birth to <1 Month</i></p> <ul style="list-style-type: none"> ABC 2 mg/kg per dose orally twice daily <p><i>Age ≥1 Month to ≤6 Weeks</i></p> <ul style="list-style-type: none"> ABC 4 mg/kg per dose orally twice daily | |

^a The optimal duration of three-drug regimens for newborns at high risk of HIV acquisition is unknown; all infants should receive the ZDV component of the three-drug regimen for 6 weeks. The other two ARVs, (3TC and NVP) or (3TC and RAL), may be administered for 2 to 6 weeks; the recommended duration for these ARVs varies depending on infant HIV NAT results, maternal viral load at the time of delivery, and additional risk factors for HIV transmission. Consultation with an expert in pediatric HIV is recommended when selecting a therapy duration because this decision should be based on case-specific risk factors and interim infant HIV NAT results.

^b The NVP doses for infants ≥32 to <37 weeks' gestation at birth and infants ≥37 weeks' gestation at birth are not yet approved by the FDA. The FDA also has not approved a dose of NVP for infants aged <1 month. The doses for infants ≥32 to <34 weeks' gestation at birth are based on modeling and might underestimate potential toxicity in infants of 32 to <34 weeks gestational age because the doses used to develop the model were lower than the doses now recommended. See [Nevirapine](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#) for additional information about dosing.

^c RAL dosing is increased at 1 week and 4 weeks of age because metabolism by UGT1A1 is low at birth and increases rapidly during the next 4 to 6 weeks of life. No dosing information is available for preterm infants or infants weighing <2 kg at birth. The current dosing regimen with two dose changes in the first month of life may be challenging for some families. To minimize dosing changes, some experts increase to the 3-mg/kg twice-daily dose upon discharge on day 4 or 5 of life.

^d ABC is approved by the FDA for use in children aged ≥3 months when administered as part of an ARV regimen. ABC also has been reported to be safe in infants and children ≥1 month of age. More recently, an ABC dosing recommendation using PK simulation models has been endorsed by the WHO using weight-band dosing for full-term infants from birth to 1 month of age. See [Abacavir](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#) for additional information about the use of ABC between birth and 1 month of age. At this time, the Panels do not recommend ABC as part of a presumptive HIV therapy regimen. However, in situations where ZDV is not available or the infant has ZDV-associated toxicity, ABC could be considered an alternative to ZDV. This substitution should be considered in circumstances where increased risk of ZDV toxicity may exist, such as in infants with anemia or neutropenia. Because of ABC-associated hypersensitivity, negative testing for HLA-B*5701 allele should be confirmed prior to the administration of ABC.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; FDA = U.S. Food and Drug Administration; IV = intravenous; NVP = nevirapine; the Panels = the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; PK = pharmacokinetic; RAL = raltegravir; UGT = uridine diphosphate glucotransferase; WHO = World Health Organization; ZDV = zidovudine

Recommendations for Infant Antiretroviral Drugs in Specific Clinical Situations

In this section, [Table 13. Antiretroviral Management for Infants With In Utero or Intrapartum Exposure to HIV](#), and [Figure 1. Antiretroviral Management Algorithm for Infants With In Utero or Intrapartum HIV Exposure by Risk of Transmission](#), the Panels present available data and recommendations for ARV management of newborns born with *in utero* and intrapartum exposure to HIV.

Infants at High Risk of HIV Acquisition From In Utero or Intrapartum Exposure

The Panels recommend that all newborns at high risk for HIV acquisition from *in utero* and intrapartum exposure have an HIV nucleic acid test (NAT) at birth to determine *in utero* HIV infection status and receive presumptive HIV therapy (see [Table 13](#) and [Figure 1](#)).^{14,16-21} HIV infection newly diagnosed during pregnancy is generally associated with high HIV RNA levels that would confer an elevated high risk of transmission to the infant, especially in the case of recent (early or acute) infection (see [Table 13](#) and [Early \(Acute and Recent\) HIV Infection](#)).

Presumptive HIV Therapy

Early, effective treatment of HIV infection in infants restricts the viral reservoir size, reduces HIV genetic variability, and modifies the immune response.²²⁻³¹ Because of these potential benefits of early ART the Panels recommend a three-drug presumptive HIV therapy regimen consisting of two nucleoside reverse transcriptase inhibitors (ZDV plus lamivudine [3TC]) plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI) (NVP at treatment dose, see [Table 13.1](#)) or an integrase strand transfer inhibitor (INSTI) (raltegravir [RAL]) for newborns at high risk of acquisition of HIV:

- ZDV plus 3TC plus NVP (at treatment dose, see [Table 13.1](#)) or
- ZDV plus 3TC plus RAL

In the event of maternal HIV-2 infection or concomitant HIV-1 and HIV-2 infection, the RAL-containing regimen should be used for presumptive therapy because HIV-2 is not susceptible to NVP.

Although no clinical trials have compared the safety and efficacy of presumptive HIV therapy with single-drug or two-drug regimens, existing data suggest that presumptive HIV therapy in neonates has not been associated with serious adverse events (see [Antiretroviral Drug Safety of Infant Prophylaxis below](#)).

The pharmacokinetic (PK) and safety data of the three-drug regimens used for presumptive HIV therapy have provided reassuring evidence for its use in the neonatal period. Although the use of NVP to prevent HIV transmission has been found to be safe in neonates and newborns of low birthweight, these prophylaxis-dose regimens target trough drug levels that are at least tenfold lower than targeted therapeutic levels. However, studies of treatment doses of NVP and RAL have established safe doses that achieve targeted PK parameters.^{21,32-37}

At this time, the Panels do not recommend abacavir (ABC) as part of a presumptive HIV therapy regimen. However, in situations where ZDV is not available or the infant has ZDV-associated toxicity, ABC could be considered an alternative to ZDV. This substitution should be considered in

circumstances where an increased risk of ZDV toxicity may exist, such as in infants with anemia or neutropenia. Negative testing for HLA-B*5701 allele should be confirmed prior to the administration of ABC. New dosing recommendations for ABC in neonates based on the IMPAACT P1106 trial and two observational European and African cohorts are now available from the World Health Organization (WHO).³⁸ ABC is not approved by the U.S. Food and Drug Administration for use in neonates and infants aged <3 months. However, 2 mg/kg per dose twice daily has been modeled using PK simulation and is endorsed by WHO using weight-band dosing for full-term infants from birth through 1 month of age. Limited observational data suggested safety of ABC when initiated in neonates <1 month of age (see [Abacavir](#) in the [Pediatric Antiretroviral Guidelines](#)).³⁹

The optimal duration of a three-drug regimen in newborns at high risk of HIV acquisition is unknown. Consulting an expert in pediatric HIV is recommended when selecting a therapy duration based on case-specific risk factors and interim HIV NAT results. HIV NAT diagnostic testing at birth (prior to or immediately after starting ARVs) is recommended for infants at high risk for HIV acquisition. A positive birth NAT test indicates *in utero* HIV infection. Panel members varied in their recommendations for the duration of presumptive HIV therapy. Some Panel members would opt to discontinue additional medications and complete 6 weeks ZDV prophylaxis alone if infant birth NAT results are negative, whereas other Panel members would continue presumptive HIV therapy for 2 to 6 weeks, depending on the risk of HIV transmission. Panel members agreed that ZDV should be continued for 6 weeks in all scenarios, regardless of the duration of the other two drugs. If the birth NAT is positive, the infant should receive an ART regimen recommended for the treatment of HIV infection (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children With HIV](#) and [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#)).

Newborns at Low Risk of HIV Acquisition from In Utero or Intrapartum Exposure

An infant perinatally exposed to HIV RNA levels <50 copies/mL and no HIV RNA levels ≥50 copies/mL after 20 weeks' gestation is considered to have low risk of HIV acquisition and should receive prophylaxis with ZDV alone for 2 weeks.

When ART is taken during pregnancy and labor and viral load is undetectable near or at the time of delivery, the risk of HIV acquisition in newborns is <1%.² In the Pediatric AIDS Clinical Trials Group (PACTG) 076 study, ZDV alone reduced the incidence of HIV transmission by 66%, and ZDV is recommended as prophylaxis for neonates when maternal ART resulted in consistent viral suppression during pregnancy.⁴⁰ Other studies have also compared NVP to ZDV infant prophylaxis.^{41,42} The ANRS French Perinatal Cohort observed that NVP infant prophylaxis was associated with less anemia than ZDV infant prophylaxis. The optimal minimum duration of neonatal ZDV prophylaxis has not been established in clinical trials. A 6-week ZDV regimen was studied in newborns in PACTG 076.⁴³ However, evidence supporting a reduced duration of ZDV prophylaxis in infants born to mothers who were suppressed virologically during pregnancy and at the time of delivery is mounting.⁴⁴⁻⁴⁶

No studies directly compare the efficacy of a 2-week versus 4-week duration of infant ZDV prophylaxis. However, high-income countries have some experience with a 2-week duration of infant prophylaxis. The United States, as well as the United Kingdom and other European countries, recommends a 2-week neonatal ZDV prophylaxis regimen when the risk of HIV acquisition from exposure is low and/or very low, with varying criteria across countries.^{47,48} Compared with the

6-week ZDV regimen, a 2 to 4 week ZDV regimen has been reported to allow earlier recovery from anemia in otherwise healthy newborns.^{49,50} In a cohort of 87 Swiss infants born to women with HIV RNA levels <50 copies/mL in the last trimester who did not receive ARV prophylaxis, **in accordance with Swiss ARV guidance at that time**, none acquired HIV infection.⁵¹

Other Clinical Scenarios

An infant perinatally exposed to **HIV RNA levels ≥50 copies/mL after 20 weeks of gestation but HIV RNA levels <50 copies/mL for the 4 weeks prior to delivery** is considered to have low-to-moderate risk for *in utero* and low risk for intrapartum acquisition of HIV (see [Table 12](#)). This assessment takes into consideration that low-level viremia could reflect intermittent adherence between laboratory tests. Low-level viremia (e.g., ≥50 copies/mL to 200 copies/mL) is not expected to confer a high risk of *in utero* transmission of HIV but has been associated with elevated risk of subsequent virologic failure.^{52,53} The Panels did not reach consensus on infant ARV management (see [Table 13](#)) for this clinical scenario and consider factors such as the magnitude and duration of elevated HIV RNA levels,² maternal adherence to ART, and parental input in decision-making.

Some Panel members recommend that these infants receive presumptive HIV therapy until the results of birth HIV NAT are available. If the birth HIV NAT is negative, excluding *in utero* HIV acquisition, the Panels recommend de-escalation of presumptive HIV therapy to ZDV prophylaxis to complete ZDV for a total of 6 weeks. This provides a balanced risk/benefit approach to quickly identifying *in utero* HIV acquisition, limiting exposure to presumptive HIV therapy in the event HIV transmission has not occurred *in utero*, and promptly administering very early presumptive therapy in the event of *in utero* infection. Very early ART has been shown to provide durable virologic suppression and reduce early viral reservoirs enabling HIV remission in some children with *in utero* HIV acquisition.^{31,54} See [When to Initiate Antiretroviral Therapy in Children With HIV Infection](#). However, other Panel members argue that the data supporting the potential benefit of early ART has not been demonstrated for this specific scenario, would likely apply to a small number of infants, and carries risk of avoidable toxicity to infants without *in utero* infection; for these reasons, they recommend 2 to 6 weeks of ZDV prophylaxis. Providers must decide which rationale aligns with their own assessment and should consider involving parents in the decision.

When early (acute or recent) HIV is diagnosed during pregnancy, infant ARVs should be managed according to the gestational timing of maternal viremia (see [Table 13](#)). Because HIV RNA levels are generally very high in these situations, some Panel members would manage all infants with a three-drug ARV regimen even with undetectable maternal viral load after 20 weeks. Other Panel members would base decisions about infant ARVs on the timing of viremia.

When there is a positive maternal HIV test at delivery or postpartum or infants have a positive HIV antibody test after birth, infants should receive a three-drug regimen as described above for infants at high risk of HIV acquisition. If supplemental testing confirms a negative maternal HIV status, infant ARV drugs should be discontinued immediately.

Newborns Exposed to Antiretroviral Drug-Resistant Virus

The optimal approach to selecting an ARV regimen for newborns exposed to ARV drug-resistant virus is unknown. Some studies have suggested that ARV drug-resistant virus may have decreased replicative capacity (reduced viral fitness) and transmissibility.⁵⁵ The transmission of drug-resistant virus **to infants** does occur.⁵⁶⁻⁶² Whether resistant virus increases the risk of vertical HIV acquisition

by the infant remains unclear. A secondary analysis of data from the *Eunice Kennedy Shriver National Institute of Child Health and Human Development–HIV Prevention Trials Network* (HPTN) 040/PACTG 1043 did not find that the presence of drug-resistance mutations in mothers who had not received ARV drugs before the start of the study increased the risk of *in utero* or peripartum transmission (adjusted odds ratio 0.8; 95% confidence interval [CI], 0.4–1.5).⁶¹ However, a case-control study found that resistance to NNRTIs in the breastfeeding mother was an independent risk factor for the vertical transmission of HIV during breastfeeding in the PROMISE trial.⁶³

Although no trials have compared the efficacy of neonatal prophylaxis regimens customized to address maternal drug resistance, the Panels recommend considering maternal drug resistance when selecting the three-drug regimen for presumptive HIV therapy. For example, an infant at high risk of infection perinatally exposed to HIV with NNRTI resistance could potentially benefit from a three-drug regimen based on RAL rather than NVP. However, other factors must also be considered, such as gestational age (limits the number of agents with available dosing) and feasibility for the caregiver to administer the regimen (e.g., the preparation of RAL is more difficult than NVP).

Maraviroc (MVC) has been approved recently for infants ≥ 2 kg and may provide an additional ARV option for newborns perinatally exposed to multidrug-resistant HIV-1 that remains CCR5-tropic.⁶⁴ However, the lack of data about MVC as prophylaxis or treatment in infants and the risk of drug interactions will limit its role for routine use in neonates.

For assistance in selecting a three-drug ARV regimen for newborns perinatally exposed to known or suspected drug resistance, consultation with a pediatric HIV specialist or the [National Perinatal HIV hotline](#) (1-888-448-8765) is recommended.

Antiretroviral Prophylaxis for Breastfeeding Infants

HIV care should include counseling about infant feeding options (e.g., formula feeding, banked donor human milk, breastfeeding) throughout pregnancy. The conversation should include decision-making about the risk and potential benefits of ARV prophylaxis. Recommendations and dosing for infant ARV prophylaxis during breastfeeding are summarized in [Table 14](#) and [Table 14.1](#). In general, infant ARV prophylaxis during breastfeeding should begin after initial ZDV prophylaxis is completed. However, some experts recommend initiating ARV prophylaxis with NVP or 3TC in place of ZDV from birth for simplicity. The duration of extended infant ARV prophylaxis can also vary based on provider and parent preference. The most conservative course is to continue prophylaxis until 6 weeks after the last exposure to breast milk. However, long-standing maternal virologic suppression may be exhibited during breastfeeding, and with provider's guidance, the decision may be made to stop prophylaxis while continuing to breastfeed. The Panels recommend patient-centered, evidence-based counseling to support shared decision-making about infant feeding. See [Preventing HIV Transmission During Infant Feeding](#) for more information on counseling, management, and monitoring.

Antiretroviral Prophylaxis for Breastfeeding Infants in the Setting of Sustained Virologic Suppression ($HIV\ RNA <50$ Copies/mL)

The Panels could not reach consensus on recommendations regarding the use of extended infant ARV prophylaxis during breastfeeding. For infants considered to be at low risk, Panel members agreed on the provision of 2 weeks of ZDV to infants for standard prophylaxis for HIV exposure, but some Panel members prefer to extend the duration of ZDV prophylaxis to 4 to 6 weeks when the

infant is being breastfed. For the period after initial postnatal prophylaxis, some Panel members recommend no additional prophylaxis when virologic suppression is maintained throughout breastfeeding, but other Panel members recommend extended ARV prophylaxis with NVP or 3TC during breastfeeding. Both NVP and 3TC have been used effectively for extended prophylaxis during breastfeeding.^{65,66} 3TC has been studied through 12 months of age and requires twice-daily administration.⁶⁶ NVP has been studied through 18 months of age and is given once daily.⁶⁵ Concerns related to the use of NVP include impaired efficacy in the context of maternal NNRTI and the development of NNRTI resistance if an infant acquires HIV while receiving NVP during breastfeeding (see Newborns Exposed to Antiretroviral Drug-Resistant Virus above).

When extended prophylaxis is used, most experts recommend transitioning to NVP or lamivudine 3TC after completion of the initial ZDV prophylaxis. However, NVP can be given from birth, replacing ZDV and providing both initial postnatal prophylaxis and extended prophylaxis during breastfeeding. ZDV should not be used for a period of more than 6 weeks.

Given the lack of consensus by the Panels for a recommendation about extended ARV prophylaxis during breastfeeding, the Panels advise providers to involve the parent(s) in open discussion and shared decision-making, weighing values about risk tolerance (for transmission and toxicity) and other issues related to infant prophylaxis (e.g., prematurity). For additional information, see Safety of Antiretroviral Drugs Used for Infant Prophylaxis below.

Most data to guide decisions about infant ARV prophylaxis during breastfeeding are from studies in sub-Saharan Africa, where breastfeeding is recommended for all pregnancies impacted by HIV infection and standard practice for prophylaxis also differs. The WHO recommends six weeks of NVP for all infants who are breastfed when maternal ART is being received in resource-limited countries.⁶⁷ In the PROMISE study, among 1,219 infants of mothers on ART, there were seven HIV transmissions reported. Among these, five mothers had documented detectable viral loads immediately prior to the first report of the infant's positive HIV NAT; the remaining two mothers had elevated viral loads in subsequent testing.⁶⁸ Note that these two infants had their first detectable HIV NAT at weeks 13 and 38 of life, beyond 6 weeks of age where infant NVP was administered according to WHO guidelines.

In the Breastfeeding, Antiretrovirals, and Nutrition study, a sub-study of 31 infants with HIV and 232 infants who were uninfected and their mothers⁶⁹ demonstrated that there were no HIV transmissions when the mother consistently maintained a viral load less than 100 copies/mL. Bispo et al. have reported a meta-analysis of 11 studies of breastfeeding mothers with HIV who started ART before or during pregnancy and continued until at least 6 months postnatally.⁷⁰ This meta-analysis was limited by the heterogeneity in studies but reported an overall postnatal HIV transmission rate of 1.08% (95% CI, 0.32–1.85) at 6 months in infants who tested HIV negative at 4 to 6 weeks of age. In a *post-hoc* analysis of the HPTN 046 study, which showed <1% risk of postnatal HIV transmission in both the extended NVP and placebo arms, the addition of infant prophylaxis did not further reduce breastfeeding transmission in mothers who were receiving ART.⁷¹

See ARV Prophylaxis for Infants When There Is a Concern About Risk of Future Viremia During Breastfeeding, below, for additional data supporting the efficacy of NVP and 3TC as prophylaxis during breastfeeding.

Taken together, existing data support the efficacy of maternal ART during breastfeeding with documented sustained viral suppression to prevent postnatal transmission of HIV, suggesting

that the recommended management of 2 weeks of ZDV prophylaxis for infants at low risk of *in utero* or intrapartum exposure is appropriate for breastfed infants when sustained maternal HIV RNA levels of <50 copies/mL have been achieved. This approach is currently recommended by the British HIV Association (BHIVA).⁴⁷

Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding

Maternal HIV RNA levels should be monitored periodically during breastfeeding because the status of viral suppression can change over time (see [Preventing HIV Transmission During Infant Feeding](#)). Decisions about infant antiretroviral (ARV) management during breastfeeding should be based on clinical assessment and incorporate shared decision-making when indicated.

Providers with questions about ARV management of infants should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline](#) (1-888-448-8765).

| Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels | Description | Infant ARV Management During Breastfeeding ^a |
|--|--|--|
| Sustained Viral Suppression (HIV RNA <50 copies/mL) | When sustained maternal virologic suppression during pregnancy (at a minimum during the third trimester has been achieved, documented by at least two HIV RNA measurements below the limits of detection at least 1 month apart) and breastfeeding and there are no concerns about adherence | <ul style="list-style-type: none"> After completion of 2-week ZDV prophylaxis in infants at low risk of <i>in utero</i> or intrapartum transmission, some Panel members recommend no additional ARV prophylaxis, but others recommend extended prophylaxis with NVP or 3TC during breastfeeding. The Panels did not reach consensus about the use of extended ARV prophylaxis during breastfeeding (see Table 14.1). Most Panel members recommend that, if used, extended ARV prophylaxis should be continued until 6 weeks after last exposure to breast milk. However, it may be reasonable to discontinue prophylaxis earlier when concern for maternal viremia is low. |
| Current HIV RNA Levels <50 copies/mL But Concerns About Future Risk | When maternal virologic suppression has been achieved during pregnancy but there is concern about future risk (e.g., ART adherence or loss of virologic suppression for other reasons) during breastfeeding | <ul style="list-style-type: none"> Consider extended ARV prophylaxis with NVP or 3TC (see Table 14.1). Recommended duration is until 6 weeks after last exposure to breast milk. Providers and parents may consider cessation earlier if concerns about future risk for viremia have resolved. Provide added adherence support as indicated. |

Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding

| Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels | Description | Infant ARV Management During Breastfeeding ^a |
|--|---|--|
| New Viremia During Breastfeeding (HIV RNA ≥ 200 copies/mL) | When maternal viremia with HIV RNA ≥ 200 copies/mL develops or presumed viremia (e.g., nonadherence, interrupted access to ARVs) | <ul style="list-style-type: none"> • Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in Preventing HIV Transmission During Infant Feeding). Most experts recommend permanent discontinuation of breastfeeding if HIV RNA ≥ 200 copies/mL, but some support resuming breastfeeding once re-suppressed. • Perform infant HIV NAT.^a • Initiate presumptive HIV therapy using three-drug regimen of ZDV, 3TC, and DTG.^b For infants aged <4 weeks, ZDV and 3TC plus NVP (treatment dose) or RAL should be used. See Table 14.1 for dosing information. • Duration of 2–6 weeks; consensus was not reached by Panel members. • If the duration of the three-drug regimen is <6 weeks, and the NAT is negative, continue ZDV alone to complete a total of 6 weeks of prophylaxis. |
| New Viremia During Breastfeeding (HIV RNA <200 copies/mL) | The Panels did not reach consensus about neonatal management when maternal viremia develops that is quantifiable but <200 copies/mL. | <ul style="list-style-type: none"> • Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in Preventing HIV Transmission During Infant Feeding). • Perform infant HIV NAT.^a • Some Panel members recommend initiation of presumptive ARV therapy (as described for new viremia ≥ 200 copies/mL, above); other Panel members recommend initiation of single-drug ARV prophylaxis (see Table 14.1). • Some Panel members recommend management based on repeat HIV RNA testing. • Consultation with an expert is suggested. |

Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding

| Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels | Description | Infant ARV Management During Breastfeeding ^a |
|--|---|--|
| New Diagnosis of HIV When Breastfeeding | Newly diagnosed maternal HIV while breastfeeding infant | <ul style="list-style-type: none"> • Stop breastfeeding and initiate replacement feeding. • Perform infant HIV NAT.^a • Initiate presumptive HIV therapy using three-drug regimen of ZDV, 3TC, and DTG.^b For infants aged <4 weeks, ZDV and 3TC plus NVP (treatment dose) or RAL should be used. See Table 14.1 for dosing information. • Duration of 2 to 6 weeks; consensus was not reached by Panel members. • If the duration of three-drug regimen is <6 weeks and the NAT is negative, continue ZDV alone to complete a total of 6 weeks of prophylaxis. |

^a An HIV NAT at birth is recommended for all breastfeeding infants. A NAT should be obtained before or immediately after starting ARVs. See [Diagnosis of HIV Infection in Infants and Children](#) for additional information about infant NATs during breastfeeding and follow-up testing after maternal viremia.

^b DTG, a second-generation integrase strand transfer inhibitor with a higher barrier to resistance than RAL, can be used in infants aged ≥4 weeks and weighing ≥3 kg.

Note: Given limited data, decisions about infant ARV prophylaxis during breastfeeding should be based on shared decision-making with the infant's parents.

Key: 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; DTG = dolutegravir; NAT = nucleic acid test; NVP = nevirapine; the Panels = Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; RAL = raltegravir; ZDV = zidovudine

Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed

| ARV Prophylaxis for Infants When Maternal Sustained Viral Suppression is Achieved | |
|---|---|
| Recommended Regimen | Recommended Duration and Dosing |
| ZDV | ZDV administered for 2 weeks <i>after birth</i> (see Table 13.1 for dosing) |
| Options for Extended Postnatal Prophylaxis ^a | |
| Recommended Regimen | Recommended Duration and Dosing |
| ZDV | ZDV administration continued for 4–6 weeks <i>after birth</i> (See Table 13.1 for dosing; note that ZDV is not recommended for prophylaxis beyond this initial postnatal period.) |

Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed

| NVP ^{b,c} | <p>NVP administered starting at birth or after completion of initial prophylaxis ZDV, through 6 weeks after cessation of breastfeeding</p> <p>Simplified Age-Based NVP Dosing for Newborns ≥ 32 Weeks' Gestation Receiving Extended NVP Prophylaxis During Breastfeeding^{b,c}</p> <table border="1" data-bbox="714 382 1405 819"> <thead> <tr> <th data-bbox="714 382 959 502">Age</th><th data-bbox="959 382 1405 502">Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily</th></tr> </thead> <tbody> <tr> <td data-bbox="714 502 959 601">Birth to 6 weeks</td><td data-bbox="959 502 1405 601">2.0 to < 3.0 kg: 10 mg (1.0 mL) \geq 3.0 kg: 15 mg (1.5 mL)</td></tr> <tr> <td data-bbox="714 601 959 665">6 weeks to 6 months</td><td data-bbox="959 601 1405 665">20 mg (2.0 mL)</td></tr> <tr> <td data-bbox="714 665 959 728">6 months to 9 months</td><td data-bbox="959 665 1405 728">30 mg (3.0 mL)</td></tr> <tr> <td data-bbox="714 728 959 819">9 months to 18 months</td><td data-bbox="959 728 1405 819">40 mg 4.0 mL</td></tr> </tbody> </table> | Age | Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily | Birth to 6 weeks | 2.0 to < 3.0 kg: 10 mg (1.0 mL) \geq 3.0 kg: 15 mg (1.5 mL) | 6 weeks to 6 months | 20 mg (2.0 mL) | 6 months to 9 months | 30 mg (3.0 mL) | 9 months to 18 months | 40 mg 4.0 mL |
|--|--|----------------------------------|--|------------------------------------|---|---------------------|----------------|----------------------|----------------|-----------------------|--------------|
| Age | Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily | | | | | | | | | | |
| Birth to 6 weeks | 2.0 to < 3.0 kg: 10 mg (1.0 mL) \geq 3.0 kg: 15 mg (1.5 mL) | | | | | | | | | | |
| 6 weeks to 6 months | 20 mg (2.0 mL) | | | | | | | | | | |
| 6 months to 9 months | 30 mg (3.0 mL) | | | | | | | | | | |
| 9 months to 18 months | 40 mg 4.0 mL | | | | | | | | | | |
| 3TC | <p>3TC administered starting after completion of initial prophylaxis ZDV, through 6 weeks after cessation of breastfeeding</p> <p>Age 2 Weeks to <4 Weeks</p> <ul style="list-style-type: none"> • 3TC 2 mg/kg per dose orally twice daily <p>Age ≥ 4 Weeks to 12 months</p> <ul style="list-style-type: none"> • Use simplified weight-band dosing outlined in the table below. <p>Simplified Weight-Band Dosing for 3TC (10 mg/ml Solution) When Used as Prophylaxis During Breastfeeding^d</p> <table border="1" data-bbox="714 1184 1405 1495"> <thead> <tr> <th data-bbox="714 1184 959 1284">Weight Band</th><th data-bbox="959 1184 1405 1284">Dose and Volume of 3TC 10 mg/mL Oral Solution Administered Twice Daily</th></tr> </thead> <tbody> <tr> <td data-bbox="714 1284 959 1347">2 to < 3 kg</td><td data-bbox="959 1284 1405 1347">10 mg (1 mL)</td></tr> <tr> <td data-bbox="714 1347 959 1410">3 kg to <4 kg</td><td data-bbox="959 1347 1405 1410">15 mg (1.5 mL)</td></tr> <tr> <td data-bbox="714 1410 959 1474">4 kg to <8 kg</td><td data-bbox="959 1410 1405 1474">25 mg (2.5 mL)</td></tr> <tr> <td data-bbox="714 1474 959 1495">\geq8 kg</td><td data-bbox="959 1474 1405 1495">50 mg (5 mL)</td></tr> </tbody> </table> | Weight Band | Dose and Volume of 3TC 10 mg/mL Oral Solution Administered Twice Daily | 2 to < 3 kg | 10 mg (1 mL) | 3 kg to <4 kg | 15 mg (1.5 mL) | 4 kg to <8 kg | 25 mg (2.5 mL) | \geq 8 kg | 50 mg (5 mL) |
| Weight Band | Dose and Volume of 3TC 10 mg/mL Oral Solution Administered Twice Daily | | | | | | | | | | |
| 2 to < 3 kg | 10 mg (1 mL) | | | | | | | | | | |
| 3 kg to <4 kg | 15 mg (1.5 mL) | | | | | | | | | | |
| 4 kg to <8 kg | 25 mg (2.5 mL) | | | | | | | | | | |
| \geq 8 kg | 50 mg (5 mL) | | | | | | | | | | |
| Recommended Infant ARV Management When Maternal Viremia Develops or HIV is Diagnosed During Breastfeeding^a | <table border="1" data-bbox="714 1607 1405 1902"> <thead> <tr> <th data-bbox="714 1607 703 1670">Presumptive HIV Therapy Regimens</th><th data-bbox="703 1607 1405 1670">Recommended Duration and Dosing</th></tr> </thead> <tbody> <tr> <td data-bbox="714 1670 703 1902">ZDV plus 3TC plus DTG^e</td><td data-bbox="703 1670 1405 1902"> <p>Three-drug presumptive HIV therapy regimen. ZDV and 3TC plus NVP or RAL should be used in place of DTG for infants aged <4 weeks and/or weighing <3 kg.^{e,f} See Table 13.1 for dosing of ZDV and 3TC in infants aged <6 weeks. Refer to drug sections in Appendix A: Pediatric Antiretroviral Drug Information for appropriate age-based dosing of DTG and for dosing of ZDV, 3TC, NVP, or RAL in infants aged >6 weeks.</p> </td></tr> </tbody> </table> | Presumptive HIV Therapy Regimens | Recommended Duration and Dosing | ZDV plus 3TC plus DTG ^e | <p>Three-drug presumptive HIV therapy regimen. ZDV and 3TC plus NVP or RAL should be used in place of DTG for infants aged <4 weeks and/or weighing <3 kg.^{e,f} See Table 13.1 for dosing of ZDV and 3TC in infants aged <6 weeks. Refer to drug sections in Appendix A: Pediatric Antiretroviral Drug Information for appropriate age-based dosing of DTG and for dosing of ZDV, 3TC, NVP, or RAL in infants aged >6 weeks.</p> | | | | | | |
| Presumptive HIV Therapy Regimens | Recommended Duration and Dosing | | | | | | | | | | |
| ZDV plus 3TC plus DTG ^e | <p>Three-drug presumptive HIV therapy regimen. ZDV and 3TC plus NVP or RAL should be used in place of DTG for infants aged <4 weeks and/or weighing <3 kg.^{e,f} See Table 13.1 for dosing of ZDV and 3TC in infants aged <6 weeks. Refer to drug sections in Appendix A: Pediatric Antiretroviral Drug Information for appropriate age-based dosing of DTG and for dosing of ZDV, 3TC, NVP, or RAL in infants aged >6 weeks.</p> | | | | | | | | | | |

Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed

| | |
|--|---|
| | Presumptive HIV therapy is recommended for a duration of 2–6 weeks (see Table 14). |
|--|---|

^a Consultation and referrals to local or regional Pediatric HIV specialists are available through the [National Perinatal HIV Hotline](#) (1-888-448-8765).

^b NVP dosing is adapted from the [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach](#). For infants at low risk of transmission, these doses can be given from birth. (Simplified Age-Based Dosing for Newborns ≥32 Weeks' Gestation Receiving Extended NVP Prophylaxis During Breastfeeding in the World Health Organization's [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach](#), July 2021)

^c 3TC should be used as extended ARV prophylaxis during breastfeeding when there is evidence or concern for maternal NVP resistant virus (including HIV-2 infection or HIV-1/HIV-2 co-infection) or when an infant cannot tolerate NVP. Dosing recommendations for 3TC are included in the table.

^d Dosing for extended 3TC prophylaxis during breastfeeding, based on established 3TC dosing for treatment and weight-band dosing used in PROMISE-EPI Source: Mennecier A, Kankasa C, et al. Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial. *Lancet*. 2024;403(10434):1362-1371. <https://pubmed.ncbi.nlm.nih.gov/38484756/>.

^e DTG, a second-generation integrase strand transfer inhibitor with a higher barrier to resistance than RAL, is preferred in infants aged ≥4 weeks and weighing ≥3 kg.

^f When maternal HIV infection is diagnosed while breastfeeding, a three-drug presumptive HIV therapy regimen is recommended for the infant, with a duration of 2–6 weeks (see [Table 14.1](#)). The same regimen is recommended for infants at high risk of HIV acquisition after *in utero* or intrapartum exposure (see [Table 13](#) and [Table 13.1](#)). No trials have evaluated the use of multidrug regimens to prevent transmission after cessation of breastfeeding with early (acute or recent) HIV infection. Some Panel members recommend presumptive HIV therapy until the infant's HIV status can be determined. If the infant's initial HIV NAT is negative, the optimal duration of presumptive HIV therapy is unknown. A 28-day course may be reasonable based on current recommendations for nonoccupational HIV exposure.

Key: 3TC = lamivudine; ARV = antiretroviral; NVP = nevirapine; RAL = raltegravir; ZDV = zidovudine

Antiretroviral Prophylaxis for Infants When There Is Concern About the Risk of Future Viremia During Breastfeeding

When there is an interest in breastfeeding and the criteria for the lowest anticipated risk of breast milk transmission is met, with current and recent HIV RNA levels of <50 copies/mL, there may be concern about future adherence in the postpartum period or factors that may impact virologic suppression (e.g., postpartum depression, interrupted access to ARVs).⁷² Lapses in adherence in the postpartum period are common, with increased risk among women of younger age and more recent ART initiation.⁷³ Providers may consider additional adherence history and postpartum adherence challenges following prior pregnancies when making recommendations about infant prophylaxis during breastfeeding. There may be anticipated changes in social structure, such as moving to a new home, in the postpartum period that may generate new challenges to adherence. It is also important for providers to elicit parents' concerns, regardless of the provider's assessment. If there are concerns about ARV adherence during breastfeeding, the Panels recommend extended infant ARV prophylaxis during breastfeeding with either NVP or 3TC and the addition of maternal adherence support (see [Table 14](#) and [Table 14.1](#)).

Data suggest that infant prophylaxis can be very effective in preventing breast milk transmission in the context of maternal viremia. In the PROMISE trial, only 7 of the 1,211 (0.58%) analyzed infants in the infant NVP prophylaxis arm acquired HIV infection.⁶⁸ A randomized controlled trial in Burkina Faso and Zambia found that initiation of same day infant 3TC prophylaxis in women with a

viral load of >1,000 copies/mL during breastfeeding resulted in a reduction in postnatal HIV transmission compared to local standard of care.⁶⁶ Although findings did not reach statistical significance because the study was underpowered, the findings suggest that early infant diagnosis, in conjunction with on-demand HIV RNA testing in the breastfeeding mother and extended infant prophylaxis, could be a valuable approach in eliminating postnatal HIV transmission risk. A pooled analysis of these trials reported that mothers with a viral load of 40 to 1,000 copies/mL in the initial 6 to 8 weeks postpartum were at high risk for having a viral load >1,000 copies/mL at 6 or 12 months postpartum.⁷⁴ Given the efficacy demonstrated in the trials, the Panels believe that extended ARV prophylaxis should be considered for breastfeeding infants when there is concern about future risk of HIV exposure during episodes of maternal viremia.

Antiretroviral Prophylaxis for Infants Exposed to Detectable HIV RNA During Breastfeeding

Parents should receive counseling and be involved in decision-making about infant ARV prophylaxis and management of infant feeding. In situations where there is increased risk of postnatal transmission due to the development/occurrence of viremia during breastfeeding, the Panels advise initiation of additional infant ARV prophylaxis to prevent breastfeeding-associated HIV transmission. When detectable maternal HIV RNA levels develop during breastfeeding, the infant should be tested for HIV infection (using a NAT) prior to or immediately after initiating ARVs, as well as at specified time points after cessation of breastfeeding and completion of presumptive HIV therapy (see [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedule for Infants With Perinatal and Breastfeeding Exposure to HIV](#)). If infant HIV testing returns a positive HIV NAT result, see [Infants with HIV Infection](#) below and [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#).

When new maternal viremia develops, the Panels recommend that breastfeeding be stopped temporarily or discontinued and replacement feeding initiated (see [Situations to Consider Modifying or Stopping Breastfeeding in Preventing HIV Transmission During Infant Feeding](#)). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is ≥200 copies/mL. This guidance is more directive than counseling when suppressive ART is being taken. In situations where viremia is lower and an addressable cause has been identified, the added risk of short term continued breastfeeding would be less.

Management of New Maternal Viremia With HIV RNA ≥200 Copies/mL While Breastfeeding

In cases where new maternal viremia with an HIV RNA level ≥200 copies/mL occurs while breastfeeding, the Panels recommend immediate initiation of infant presumptive HIV therapy using a three-drug regimen of ZDV plus 3TC plus DTG (NVP or RAL in place of DTG, if infant age < 4 weeks) (see [Table 14](#) and [Table 14.1](#) above). The drugs should be administered together for 2 to 6 weeks, with duration based on timing of results of infant NAT. As for management of high risk around the time of birth, if 3TC plus (DTG or NVP or RAL) are discontinued, ZDV should be continued alone to complete a total of 6 weeks prophylaxis.

As noted above, in cases where new maternal viremia with an HIV RNA level ≥200 copies/mL develops while breastfeeding, the Panels recommend permanent cessation of breastfeeding. However, the decision may be made to continue to breastfeed in which case longer durations of

ARVs for infants may be indicated. Discussion with parents and consultation with the [National Perinatal HIV Hotline](#) (1-888-448-8765) or consultation with another expert is suggested.

Management of New Maternal Viremia With HIV RNA <200 Copies/mL While Breastfeeding

In cases where new maternal viremia that is quantifiable but with HIV RNA <200 copies/mL occurs while breastfeeding, some Panel members recommend initiation of presumptive HIV therapy for the infant, other Panel members recommend initiation of single-drug ARV prophylaxis (with NVP or 3TC), and other Panel members recommend infant ARV management based on repeat maternal HIV RNA testing. The rationale for the cutoff of 200 copies/mL is that low-level viremia <200 copies/mL has been shown to predict future virologic failure with HIV RNA >200 copies/mL.⁷⁵ The Panels did not reach consensus about infant ARV prophylaxis or presumptive HIV therapy in this situation (see [Table 14](#)). Discussion with parents and consultation with the [National Perinatal HIV Hotline](#) (1-888-448-8765) or consultation with another expert is suggested.

Special Situations in Breastfeeding Infants

Initiation or Continuation of Breastfeeding With Viremia

The Panels strongly advise against initiating or continuing breastfeeding [infants at high risk of HIV acquisition from *in utero*, intrapartum, and/or postnatal exposure](#). Replacement feeding with formula or banked pasteurized donor human milk is recommended given the high risk of postnatal HIV transmission associated with viremia during breastfeeding (see [Preventing HIV Transmission During Infant Feeding](#)). Discussion with parents and consultation with the [National Perinatal HIV Hotline](#) (1-888-448-8765) or consultation with another expert is recommended.

Infants Exposed to Newly Diagnosed Maternal HIV While Breastfeeding

When maternal HIV is suspected (e.g., a positive initial screening test), breastfeeding should be discontinued immediately, until HIV is ruled out. Pumping and temporarily discarding or freezing breast milk can be recommended when maternal HIV while breastfeeding is suspected but HIV serostatus is not yet confirmed and continuation of breastfeeding is desired. If HIV is ruled out, breastfeeding can resume. Given the high risk of HIV transmission when HIV is acquired or diagnosed during breastfeeding, the Panels advise against breastfeeding and recommend replacement feeding with formula or banked pasteurized donor human milk if maternal HIV infection is confirmed while breastfeeding.⁷⁶ See [New HIV Diagnosis While Breastfeeding](#) in [Diagnosis of HIV Infection in Infants and Children](#) for guidance about infant testing.

Breastfed infants exposed to newly diagnosed maternal HIV diagnosis during breastfeeding are considered to be at high risk of HIV acquisition and treated accordingly with a three-drug presumptive HIV therapy regimen for 2 to 6 weeks (see [Table 14](#) and [Table 14.1](#)). No trials have evaluated the use of multidrug regimens to prevent transmission after cessation of breastfeeding by a parent with early (acute or recent) HIV infection. Given the higher risk of postnatal transmission from early (acute or recent) HIV infection while breastfeeding, an alternative approach favored by some Panel members is to offer presumptive HIV therapy until the infant's HIV status can be determined. If the infant's initial HIV NAT is negative, the optimal duration of presumptive HIV therapy is unknown. A 28-day course may be reasonable based on current recommendations for nonoccupational HIV exposure. The [National Perinatal HIV Hotline](#) (1-888-448-8765) can provide

referrals to local or regional pediatric HIV specialists.

Safety of Antiretroviral Drugs Used for Infant Prophylaxis

This section is intended to provide the information needed for clinical management and counseling parents on decision-making around infant prophylaxis. When used alone for prophylaxis in low-risk scenarios during the neonatal period and breastfeeding, ARVs appear highly safe. The most prominent toxicity in the neonatal period is anemia from ZDV given alone or in combination regimens; anemia occurs after 2–4 weeks but recovers with the cessation of treatment to levels similar to controls (see [Initial Postnatal Management of the Neonate Exposed to HIV](#)). During the breastfeeding period, 3TC has been shown to be safe through at least 41 weeks. NVP has been shown to be safe for infants from birth through 18 months of life; one trial identified cases with concerns of a hypersensitivity reaction, but larger subsequent trials did not report hypersensitivity reactions. Three-drug combinations appear safe within the durations currently recommended (i.e., 2–6 weeks).

Based on existing safety data, longitudinal laboratory monitoring for adverse events is not needed in otherwise healthy infants receiving currently recommended ARVs used for prophylaxis in the first 6 weeks of life. The American Academy of Pediatrics recommends periodic monitoring of hematologic and liver toxicity in breastfeeding infants receiving ARV prophylaxis beyond this period and for extended durations.⁷⁷

Zidovudine

ZDV was the first agent studied for prophylaxis against HIV transmission to infants and remains the standard of care for prophylaxis in low-risk situations. The major side effect from short-term (6 weeks or less) use of ZDV appears to be transient anemia.

- In the landmark PACTG 076 trial, 415 infants were randomized and received ZDV or placebo; hemoglobin levels in the ZDV arm were lower at the end of the 6-week treatment course but recovered and were equivalent between arms by 12 weeks.⁴³ No other toxicities were significantly different between arms, and no new toxicities were identified through 18 months of follow up.⁷⁸
- Subsequent trials of 6-week regimens of ZDV alone did not identify other significant toxicities.²⁰
- A 4-week ZDV regimen, compared with the 6-week ZDV regimen, has been reported to result in earlier recovery from anemia in infants who are HIV-exposed but otherwise healthy.⁴⁹ Severe cases of anemia can be treated with erythropoietin⁷⁹; substitution of ZDV with 3TC and/or NVP⁴¹ can also be considered.

Lamivudine

3TC has been extensively studied in combination with ZDV, but data primarily from two trials support the safety of 3TC used alone as prophylaxis during breastfeeding through at least 41 weeks of life.

- The Mitra Study was an open-label single-arm prospective cohort trial in which 398 infants were treated with ZDV + 3TC from birth to 1 week of age, and then with 3TC alone for the duration of breastfeeding (maximum of 6 months) plus 2 weeks after stopping breastfeeding.⁸⁰ No serious adverse events were attributed to the study drug.

- In ANRS 12174, 1,273 infants were randomized at 7 days to receive either lopinavir/ritonavir (LPV/r) or 3TC through the completion of breastfeeding (median duration 41 weeks)⁸¹; there were no differences in adverse events rates between the arms.
- In ANRS 12397 PROMISE-EPI, in infants breastfed by mothers with HIV who were viremic during pregnancy, 3TC was initiated as prophylaxis at 6 weeks and 6 months, and continued through 12 months of age; the initial report noted no safety concerns, but the full results have not yet been published.^{82,83}

Nevirapine

Several trials support the safety of once-daily NVP in the first 6 weeks of life and through breastfeeding. Although reactions concerning hypersensitivity were reported in the Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial, no cases have been identified in subsequent large trials or from clinical programs. Strong data also support the safety of twice-daily NVP used in a three-drug presumptive HIV therapy regimen.

- In the SWEN trial, infants were randomized to either single dose ($n = 1,047$) or 6-week courses ($n = 977$) of once-daily NVP; adverse events were common overall (~40%) but without significant differences by arm.⁸¹
- In the BAN trial, 2,369 mother-infant dyads were randomized to infant prophylaxis with once-daily NVP, maternal ARV treatment, or enhanced control until the cessation of breastfeeding but no longer than 28 weeks.⁸⁴ A hypersensitivity reaction (rash, with eosinophilia in 10 infants, with or without fever) developed in 16 (1.9%) infants within 4 weeks after the initiation of NVP therapy; reactions resolved after NVP was replaced with 3TC. Hypersensitivity was the only adverse event significantly different between arms.
- In HPTN 046, 1,519 breastfeeding infants were randomized to 6 months of once-daily NVP or placebo (after 6 weeks of NVP from birth); no differences in adverse event rates were noted by arm through 12 months of follow up.⁸¹
- In the PEPI-Malawi trial, 3,016 infants were randomized to receive NVP with 1 week of ZDV (control), once daily NVP extended through 14 weeks, or NVP + ZDV extended through 14 weeks.⁸⁵ Among the three arms, no significant differences were seen in serious adverse event rates overall, nor among adverse events deemed probably associated with study drugs. However, the extended NVP + ZDV arm had significantly more serious adverse events deemed possibly related to NVP or ZDV, the most common of which was neutropenia.
- In IMPAACT 1077BF, the breastfeeding component of the PROMISE trial, 2,431 mother-infant dyads were randomized to either maternal ART or infant NVP prophylaxis (once daily) continued until 18 months after delivery or breastfeeding cessation⁶⁵; the median duration of breastfeeding was 16 months in both arms. No differences were seen between study arms in Grade 3 or 4 adverse event rates or liver or skin toxicity. Of the 1,204 infants in the NVP arm who started on the study-recommended regimen, only 20 (2%) stopped the recommended regimen because of concerns of toxicity, and no cases of hypersensitivity were reported.
- The French Perinatal Cohort observed less frequent Grade 2 or higher anemia in 830 infants receiving once-daily NVP versus ZDV prophylaxis in a high-resource setting.⁴¹
- In IMPAACT P1115, infants at high risk of HIV acquisition were given NVP twice daily as part of a three-drug presumptive HIV therapy approach; NVP was dosed as 6 mg/kg twice daily for

term neonates (\geq 37 weeks gestational age) or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates (34 to $<$ 37 weeks gestational age).²¹ Among 438 neonates enrolled, 389 (89%) were born at term; 36 were subsequently found to have *in utero* HIV infection. Division of AIDS (DAIDS) Grade 3 or 4 adverse events that were classified as at least possibly related to ARVs were reported in 30 infants (7%; 95% CI, 5–10) but did not lead to cessation of NVP in any cases; neutropenia (25 neonates [6%]) and anemia (six neonates [1%]) were the most commonly reported toxicities.

Abacavir

Data on the use of ABC in HIV-exposed neonates are limited, but suggest it is well tolerated. In a metanalysis and population PK model that included data from three separate PK trials with a total of 45 infants aged $<$ 3 months and born to women with HIV, no adverse events of Grade 3 or greater were attributed to ABC.⁸⁶ At this time, the Panels suggest using ABC in neonates as an alternative to ZDV in rare situations and only after negative HLA-B*5701 allele testing.

Raltegravir

The primary toxicity of concern with the use of RAL in the neonatal period has been the potential increase in bilirubin levels, but at recommended dosing, RAL appears safe. RAL is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, the same enzyme responsible for the elimination of bilirubin; UGT enzyme activity is low at birth, and RAL elimination is prolonged in neonates. In addition, RAL binds to albumin, raising concern that the displacement of bilirubin could lead to hyperbilirubinemia. However, *in vitro* studies suggested RAL would be safe at the drug exposures achieved for treatment.⁸⁷ IMPAACT P1110, the single-arm regulatory Phase 1/2 trial that established dosing for RAL, evaluated safety in 52 infants of 34 weeks gestational age and older; no adverse events were attributed to RAL, and no bilirubin levels exceeded 16 mg/dL.⁸⁸

Combination ARV Regimens

Combination ARV regimens are associated with elevated risk of toxicity compared to single agents, but the three-drug regimens currently recommended for presumptive HIV therapy in neonates (e.g., NVP/ZDV/3TC or RAL/ZDV/3TC) appear very safe when used for 6 or fewer weeks. Early studies of two and three-drug regimens used as prophylaxis suggested that hematologic and mitochondrial toxicity is more common than with exposure to a single NRTI.^{89–93} However, more recent studies provide data about the safety of the ARV regimen that is currently recommended for presumptive HIV therapy, suggesting it is generally well tolerated, but does confer an increased risk of anemia.

- In IMPAACT P1115, 438 infants of at least 34 weeks gestational age at high risk of HIV acquisition initiated NVP plus 2 NRTIs (ZDV + 3TC in 96%) within 48 hours of life and continued until *in utero* infection was excluded by HIV DNA testing at birth (a median of 13 days).²¹ Grade 3 or 4 adverse events at least possibly related to ARVs occurred in 30 (7%) of 438 infants, with neutropenia (25 [6%]) and anemia (6 [1%]) being the most common. Toxicity led to the permanent discontinuation of ZDV in nine (2%) of 438 participants (four found to have *in utero* HIV, and five without) with neutropenia and anemia being the primary reasons for discontinuation; no other ARVs were permanently discontinued because of toxicity.

- A prospective cohort study in Thailand reported a greater proportion of infants receiving ZDV/3TC/NVP for 6 weeks experienced Grade 2 anemia (38%) at 1 month compared to infants receiving ZDV alone (21%, $P = 0.007$).⁹⁴ However, the risk of Grade 3 anemia was lower and similar between arms at 9.2% versus 10.2%, respectively ($P = 0.81$). Hemoglobin levels recovered by 2 months, at which time there was no difference between the arms. No differences in neutropenia or hepatotoxicity between the groups were observed.
- A retrospective study described outcomes of 148 Canadian infants at high risk of HIV transmission treated with three drugs for 6 weeks including ARV based on NVP (40%), nelfinavir (50%), and LPV/r (5%); all together, infants receiving combination regimens had lower hemoglobin levels than infants who received ZDV alone over 6 months, but no difference was seen between the subgroup receiving NVP-based treatment compared to ZDV alone.³²

Generalizability of Available Safety Data

A number of considerations affect the generalizability of the safety data reviewed here to current patient populations.

- The majority of trials included were completed at a time when mothers of infants receiving prophylaxis were not receiving ART. It is possible that ARVs passed through breast milk could add to toxicity in infants also receiving prophylaxis during breastfeeding. Current data suggest that only clinically insignificant, small amounts of approved ARVs enter the breast milk, but this hypothetical possibility must be considered for new agents. See Safety of Antiretroviral Drugs During Breastfeeding in [Preventing HIV Transmission During Infant Feeding](#) for more details.
- This section focused on the risk of severe (Grade 3 or 4) adverse events; most trials did not report the frequencies of lower-grade toxicities. Please see the [DAIDS reference tables](#) for more information.⁹⁵
- The overall rate of adverse events was high in many of the trials. For example, in IMPAACT 1077BF, approximately 35% of infants in both arms experienced Grade 3 adverse events or death, a rate much higher than experienced in settings with more health care resources.⁶⁵ The high rate of events unrelated to study drugs overall may reflect the limited health care resources in the settings in sub-Saharan Africa. However, some data suggest that the normal value ranges developed in the United States may not be applicable in other settings or countries.^{96,97} As a result, it is difficult to extrapolate the individual risk of events for an infant in settings that differ from the trials. However, the possibility of an added risk of adverse events from agents can still be evaluated by comparing arms in randomized trials.
- This section focuses on agents and approaches that are currently recommended. Safety data about approaches that are no longer recommended (e.g., NVP plus ZDV) can be found in archived guidelines.
- Additional information about ARV toxicity can be found in the [Pediatric Antiretroviral Guidelines](#) (see [Appendix A: Pediatric Antiretroviral Drug Information](#)); however, data summarized there are generally from clinical trials and other studies of children with HIV, in whom the coadministration of other ARVs and comorbidities may also have contributed to toxicity.

Infants With HIV Infection

When infant HIV testing returns a positive HIV NAT result, the [Pediatric Antiretroviral Guidelines](#) recommend rapid initiation of ART (defined as initiating ART immediately or within days of HIV diagnosis) without waiting for a confirmatory test, given the low likelihood of a false-positive HIV NAT (see [When to Initiate Antiretroviral Treatment in Children with HIV Infection](#) and [Diagnosis of HIV Infection in Infants and Children](#)). ART should be discontinued if subsequent negative NAT testing excludes the presence of HIV infection. [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#) provides recommendations about initial ART for infants and children with HIV, including those who are receiving presumptive HIV therapy or other ARV prophylaxis at the time of diagnosis.

References

1. Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. *Clin Infect Dis.* 2015;61(11):1715-25. Available at: <https://pubmed.ncbi.nlm.nih.gov/26197844>.
2. Sibiude J, Le Chenadec J, Mandelbrot L, et al. Update of perinatal human immunodeficiency virus type 1 transmission in France: zero transmission for 5482 mothers on continuous antiretroviral therapy from conception and with undetectable viral load at delivery. *Clin Infect Dis.* 2023;76(3):e590-e598. Available at: <https://pubmed.ncbi.nlm.nih.gov/36037040>.
3. Jovaisas E, Koch MA, Schafer A, et al. LAV/HTLV-III in 20-week fetus. *Lancet.* 1985;2(8464):1129. Available at: <https://pubmed.ncbi.nlm.nih.gov/2865600>.
4. Lewis SH, Reynolds-Kohler C, Fox HE, et al. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. *Lancet.* 1990;335(8689):565-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/1689792>.
5. Sprecher S, Soumenkoff G, Puissant F, et al. Vertical transmission of HIV in 15-week fetus. *Lancet.* 1986;2(8501):288-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/2874312>.
6. Brossard Y, Aubin JT, Mandelbrot L, et al. Frequency of early in utero HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. *AIDS.* 1995;9(4):359-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/7794540>.
7. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. *Am J Epidemiol.* 1995;142(12):1330-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/7503054>.
8. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. *AIDS.* 2008;22(8):973-81. Available at: <https://pubmed.ncbi.nlm.nih.gov/18453857>.
9. Kourtis AP, Lee FK, Abrams EJ, et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. *Lancet Infect Dis.* 2006;6(11):726-32. Available at: <https://pubmed.ncbi.nlm.nih.gov/17067921>.
10. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *N Engl J Med.* 1998;339(20):1409-14. Available at: <https://pubmed.ncbi.nlm.nih.gov/9811915>.
11. Van Rompay KK, Otsyula MG, Marthas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. *Antimicrob Agents Chemother.* 1995;39(1):125-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/7695293>.

12. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science*. 1995;270(5239):1197-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/7502044>.
13. Bottiger D, Johansson NG, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. *AIDS*. 1997;11(2):157-62. Available at: <https://pubmed.ncbi.nlm.nih.gov/9030361>.
14. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med*. 2012;366(25):2368-79. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
15. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. *AIDS*. 1995;9(9):F7-11. Available at: <https://pubmed.ncbi.nlm.nih.gov/8527070>.
16. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. *N Engl J Med*. 1999;341(6):385-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/10432323>.
17. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. *N Engl J Med*. 1999;341(6):394-402. Available at: <https://pubmed.ncbi.nlm.nih.gov/10432324>.
18. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr*. 2002;29(5):484-94. Available at: <https://pubmed.ncbi.nlm.nih.gov/11981365>.
19. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2002;359(9313):1178-86. Available at: <https://pubmed.ncbi.nlm.nih.gov/11955535>.
20. Lallement M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV prevention trial (Thailand) investigators. *N Engl J Med*. 2000;343(14):982-91. Available at: <https://pubmed.ncbi.nlm.nih.gov/11018164>.
21. Ruel TD, Capparelli EV, Tierney C, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. *Lancet HIV*. 2021;8(3):e149-e157. Available at: <https://pubmed.ncbi.nlm.nih.gov/33242457>.

22. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. *AIDS Res Hum Retroviruses*. 2007;23(3):381-90. Available at: <https://pubmed.ncbi.nlm.nih.gov/17411371>.
23. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. *J Infect Dis*. 2014;210(10):1529-38. Available at: <https://pubmed.ncbi.nlm.nih.gov/24850788>.
24. Persaud D, Patel K, Karalius B, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. *JAMA Pediatr*. 2014;168(12):1138-46. Available at: <https://pubmed.ncbi.nlm.nih.gov/25286283>.
25. Rainwater-Lovett K, Ziemniak C, Watson D, et al. Paucity of intact non-induced provirus with early, long-term antiretroviral therapy of perinatal HIV infection. *PLoS One*. 2017;12(2):e0170548. Available at: <https://pubmed.ncbi.nlm.nih.gov/28178277>.
26. Rocca S, Zangari P, Cotugno N, et al. Human immunodeficiency virus (HIV)-antibody repertoire estimates reservoir size and time of antiretroviral therapy initiation in virally suppressed perinatally HIV-infected children. *J Pediatric Infect Dis Soc*. 2018;8(5):433-438. Available at: <https://pubmed.ncbi.nlm.nih.gov/30169837>.
27. Shiao S, Abrams EJ, Arpadi SM, et al. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? *Lancet HIV*. 2018;5(5):e250-e258. Available at: <https://pubmed.ncbi.nlm.nih.gov/29739699>.
28. Persaud D, Gaye H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at: <https://pubmed.ncbi.nlm.nih.gov/24152233>.
29. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. *Pediatr Infect Dis J*. 2014;34(3):e48-51. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25251719>.
30. Violari A, Cotton MF, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Commun*. 2019;10(1):412. Available at: <https://pubmed.ncbi.nlm.nih.gov/30679439>.
31. Persaud D, Bryson Y, Nelson BS, et al. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. *Lancet HIV*. 2024;11(1):e20-e30. Available at: <https://pubmed.ncbi.nlm.nih.gov/38061376>.
32. Lau E, Brophy J, Samson L, et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. *J Acquir Immune Defic Syndr*. 2017;74(5):493-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/28114187>.

33. Cressey TR, Punyawudho B, Le Coeur S, et al. Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates. *J Acquir Immune Defic Syndr.* 2017;75(5):554-560. Available at: <https://pubmed.ncbi.nlm.nih.gov/28489732>.
34. Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. *J Acquir Immune Defic Syndr.* 2014;67(3):310-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/25162819>.
35. Clarke DF, Wong RJ, Wenning L, et al. Raltegravir in vitro effect on bilirubin binding. *Pediatr Infect Dis J.* 2013;32(9):978-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/23470680>.
36. Clarke DF, Penazzato M, Capparelli E, et al. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. *Expert Rev Clin Pharmacol.* 2018;11(1):83-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/29039686>.
37. Clarke DF, Acosta EP, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110). *J Acquir Immune defic Syndr.* 2020;84(1):70-77. Available at: <https://pubmed.ncbi.nlm.nih.gov/31913995>.
38. World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva, Switzerland. 2021. Available at: <https://www.who.int/publications/i/item/9789240022232>.
39. Bekker A, Decloedt EH, Slade G, et al. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). *Clin Infect Dis.* 2021;72(11):2032-2034. Available at: <https://pubmed.ncbi.nlm.nih.gov/32697327>.
40. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med.* 1994;331(18):1173-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/7935654>.
41. Dollfus C, Le Chenadec J, Mandelbrot L, et al. Improved hematologic outcomes in HIV1-exposed infants receiving nevirapine compared with zidovudine for postnatal prophylaxis in a high resource setting. *Pediatr Infect Dis J.* 2022;41(5):420-423. Available at: <https://pubmed.ncbi.nlm.nih.gov/35135997>.
42. Jao J, Sun S, Bonner LB, et al. Lower insulin sensitivity in newborns with in utero HIV and antiretroviral exposure who are uninfected in Botswana. *J Infect Dis.* 2022;226(11):2002-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/36240387>.
43. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med.* 1994;331(18):1173-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/7935654>.

44. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. *HIV Med.* 2008;9(7):452-502. Available at: <https://pubmed.ncbi.nlm.nih.gov/18840151>.
45. Ferguson W, Goode M, Walsh A, et al. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. *Pediatr Infect Dis J.* 2011;30(5):408-12. Available at: <https://pubmed.ncbi.nlm.nih.gov/21266939>.
46. Neubert J, Pfeffer M, Borkhardt A, et al. Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine. *BMC Pregnancy Childbirth.* 2013;1322. Available at: <https://pubmed.ncbi.nlm.nih.gov/23347580>.
47. British HIV Association. British HIV association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). 2020. Available at: <https://www.bhiva.org/file/5f1aab1ab9aba/BHIVA-Pregnancy-guidelines-2020-3rd-interim-update.pdf>.
48. Naver L, Albert J, Carlander C, et al. Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024. *Infect Dis (Lond).* 2024;56(8):657-668. Available at: <https://pubmed.ncbi.nlm.nih.gov/38805265>.
49. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. *Pediatr Infect Dis J.* 2010;29(4):376-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/19949355>.
50. Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. *Pediatr Infect Dis J.* 2019;38(7):727-730. Available at: <https://pubmed.ncbi.nlm.nih.gov/31033907>.
51. Traytel A SA, Aebi-Popp K, Crisinel PA, et al. Discontinuation of neonatal postexposure prophylaxis in infants born to HIV-infected mothers with suppressed plasma viral load: safety and implementation of the new Swiss recommendations. *17th European AIDS Conference.* 2019. Available at: <https://onlinelibrary.wiley.com/doi/10.1111/hiv.12814>.
52. Elvstam O, Malmborn K, Elen S, et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort. *Clin Infect Dis.* 2023;76(1):25-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/36100984>.
53. Han WM, Broom J, Bopage R, et al. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database. *Trop Med Int Health.* 2024;29(1):42-56. Available at: <https://pubmed.ncbi.nlm.nih.gov/38009461>.
54. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med.* 2013;369(19):1828-35. Available at: <https://pubmed.ncbi.nlm.nih.gov/24152233>.

55. Bauer GR, Colgrove RC, Larussa PS, et al. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. *AIDS*. 2006;20(13):1707-12. Available at: <https://pubmed.ncbi.nlm.nih.gov/16931934>.
56. De Jose MI, Ramos JT, Alvarez S, et al. Vertical transmission of HIV-1 variants resistant to reverse transcriptase and protease inhibitors. *Arch Intern Med*. 2001;161(22):2738-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/11732941>.
57. Desai N and Mathur M. Selective transmission of multidrug resistant HIV to a newborn related to poor maternal adherence. *Sex Transm Infect*. 2003;79(5):419-21. Available at: <https://pubmed.ncbi.nlm.nih.gov/14573842>.
58. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. *AIDS*. 2005;19(9):989-90. Available at: <https://pubmed.ncbi.nlm.nih.gov/15905684>.
59. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. *Clin Infect Dis*. 2011;52(8):1069-76. Available at: <https://pubmed.ncbi.nlm.nih.gov/21460326>.
60. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. *PLoS Med*. 2011;8(3):e1000430. Available at: <https://pubmed.ncbi.nlm.nih.gov/21468304>.
61. Yeganeh N, Kerin T, Ank B, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. *Clin Infect Dis*. 2018;66(11):1770-1777. Available at: <https://pubmed.ncbi.nlm.nih.gov/29272365>.
62. Bishop MD, Korutaro V, Boyce CL, et al. Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. *J Acquir Immune Defic Syndr*. 2024;96(4):385-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/39175843>.
63. Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance is associated with vertical transmission and is prevalent in infected infants. *Clin Infect Dis*. 2022;74(11):2001-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/34467974>.
64. Rosebush JC, Best BM, Chadwick EG, et al. Pharmacokinetics and safety of maraviroc in neonates. *AIDS*. 2021;35(3):419-427. Available at: <https://pubmed.ncbi.nlm.nih.gov/33252481>.
65. Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. *J Acquir Immune Defic Syndr*. 2018;77(4):383-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239901>.
66. Kankasa C, Mennecier A, Sakana BLD, et al. Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label,

randomised controlled trial. *Lancet*. 2024;403(10434):1362-1371. Available at: <https://pubmed.ncbi.nlm.nih.gov/38484756>.

67. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34370423>.
68. Flynn PM, Taha TE, Cababasay M, et al. Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component. *J Acquir Immune Defic Syndr*. 2021;88(2):206-213. Available at: <https://pubmed.ncbi.nlm.nih.gov/34108383>.
69. Davis NL, Miller WC, Hudgens MG, et al. Maternal and breastmilk viral load: impacts of adherence on peripartum HIV infections averted-the Breastfeeding, Antiretrovirals, and Nutrition Study. *J Acquir Immune Defic Syndr*. 2016;73(5):572-580. Available at: <https://pubmed.ncbi.nlm.nih.gov/27846071>.
70. Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *J Int AIDS Soc*. 2017;20(1):21251. Available at: <https://pubmed.ncbi.nlm.nih.gov/28362072>.
71. Coovadia H, Brown E, Maldonado Y, et al. Efficacy of extended daily infant nevirapine (NVP) through age 6 months compared to 6 weeks for prevention of postnatal mother-to-child transmission (MTCT) of HIV through breastfeeding (BF). *18th Conference on Retroviruses and Opportunistic Infections*. 2011.
72. Momplaisir F, Hussein M, Kacanek D, et al. Perinatal depressive symptoms, human immunodeficiency virus (HIV) suppression, and the underlying role of antiretroviral therapy adherence: a longitudinal mediation analysis in the IMPAACT P1025 Cohort. *Clin Infect Dis*. 2021;73(8):1379-1387. Available at: <https://pubmed.ncbi.nlm.nih.gov/33982083>.
73. Hoffman RM, Warshaw MG, Amico KR, et al. Predictors of viremia in postpartum women on antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2020;83(1):72-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/31651545>.
74. Kania D, Moles JP, Rutagwera D, et al. Understanding vertical transmission: from molecules to populations. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Available at: <https://www.croiconference.org/abstract/maternal-hiv-viral-load-threshold-for-guiding-extended-infant-prophylaxis-initiation>.
75. Aldredge A, Mehta CC, Lahiri CD, et al. Consequences of low-level viremia among women with HIV in the United States. *AIDS*. 2024;38(13):1829-1838. Available at: <https://pubmed.ncbi.nlm.nih.gov/39110550>.
76. Van de Perre P, Lepage P, Homsy J, et al. Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty? *Clin Infect Dis*. 1992;15(3):502-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/1445596>.

77. Abuogi L, Noble L, Smith C, et al. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. *Pediatrics*. 2024;153(6). Available at: <https://pubmed.ncbi.nlm.nih.gov/38766700>.
78. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. *AIDS*. 2005;19(12):1289-97. Available at: <https://pubmed.ncbi.nlm.nih.gov/16052084>.
79. Ascensao JL, Bilgrami S, and Zanjani ED. Erythropoietin. Biology and clinical applications. *Am J Pediatr Hematol Oncol*. 1991;13(4):376-87. Available at: <https://pubmed.ncbi.nlm.nih.gov/1785666>.
80. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the mitra study. *J Acquir Immune Defic Syndr*. 2008;48(3):315-23. Available at: <https://pubmed.ncbi.nlm.nih.gov/18344879>.
81. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet*. 2016;387(10018):566-73. Available at: <https://pubmed.ncbi.nlm.nih.gov/26603917>.
82. Mennecier A, Kankasa C, Fao P, et al. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. *Contemp Clin Trials*. 2021;105106402. Available at: <https://pubmed.ncbi.nlm.nih.gov/33872801>.
83. Kankasa C, Mennecier A, Tassembedo S, et al. Improved strategy to prevent HIV postnatal transmission: a randomized trial. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Available at: <https://www.croiconference.org/abstract/improved-strategy-to-prevent-hiv-postnatal-transmission-a-randomized-trial>.
84. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med*. 2010;362(24):2271-81. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554982>.
85. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. *N Engl J Med*. 2008;359(2):119-29. Available at: <https://pubmed.ncbi.nlm.nih.gov/18525035>.
86. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV*. 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.
87. Clarke DF, Wong RJ, Wenning L, et al. Raltegravir in vitro effect on bilirubin binding. *Pediatr Infect Dis J*. 2013;32(9):978-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/23470680>.
88. Clarke DF, Acosta EP, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection

- (IMPAACT P1110). *J Acquir Immune Defic Syndr*. 2020;84(1):70-77. Available at: <https://pubmed.ncbi.nlm.nih.gov/31913995>.
89. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. *JAMA*. 2001;285(16):2083-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/11311097>.
90. Torres SM, Walker DM, Carter MM, et al. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. *Environ Mol Mutagen*. 2007;48(3-4):224-38. Available at: <https://pubmed.ncbi.nlm.nih.gov/17358033>.
91. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. *AIDS*. 2003;17(14):2053-61. Available at: <https://pubmed.ncbi.nlm.nih.gov/14502008>.
92. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. *J Infect Dis*. 2006;194(8):1089-97. Available at: <https://pubmed.ncbi.nlm.nih.gov/16991083>.
93. Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. *J Acquir Immune Defic Syndr*. 2007;45(1):43-51. Available at: <https://pubmed.ncbi.nlm.nih.gov/17356471>.
94. Anugulruengkitt S, Suntarattiwong P, Ounchanum P, et al. Safety of 6-week neonatal triple-combination antiretroviral postexposure prophylaxis in high-risk HIV-exposed infants. *Pediatr Infect Dis J*. 2019;38(10):1045-1050. Available at: <https://pubmed.ncbi.nlm.nih.gov/31365477>.
95. U.S. Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. 2017. Available at: <https://rsc.cnaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>.
96. Lubega IR, Fowler MG, Musoke PM, et al. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. *J Acquir Immune Defic Syndr*. 2010;55(1):58-64. Available at: <https://pubmed.ncbi.nlm.nih.gov/20588184>.
97. Kourtis AP, Bramson B, van der Horst C, et al. Low absolute neutrophil counts in African infants. *J Int Assoc Physicians AIDS Care (Chic)*. 2005;4(3):73-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/16867975>.

Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">• All adolescents with HIV should receive maximally suppressive antiretroviral therapy; this is urgent for those who are sexually active, considering pregnancy, or pregnant (AII).• ARV regimen selection should include consideration of the adolescent's individual needs and preferences (AIII). See What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV and Management of Children Receiving Antiretroviral Therapy for more information.• All adolescents with HIV should be screened for mental health and substance use disorders (AII).• Reproductive and sexual health issues—including pregnancy intentions, contraceptive methods, safer sex techniques to prevent transmission of HIV and other sexually transmitted infections (STIs), regular STI screening, pre-exposure prophylaxis for partners, pregnancy planning, and preconception care—should be discussed regularly (AII).• Adolescents with HIV can use all available hormonal contraceptive methods (e.g., pill, patch, ring, injection, implant); however, providers should consider potential drug–drug interactions between hormonal contraceptives and antiretroviral medications that could affect contraceptive efficacy (AII*). See Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives in the Perinatal Guidelines.• Pediatric and adolescent care providers should prepare adolescents for the transition into adult care settings (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†] Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents.

Background

Most individuals in the United States who acquired HIV through perinatal transmission are now adolescents or young adults. Most have had a long clinical course with an extensive antiretroviral (ARV) treatment history.^{1,2} Older youth and adults may have initially received nonsuppressive monotherapy or dual therapy prior to the availability of combination ARV regimens, including fixed-dose combination (FDC) formulations. Challenges that affect the treatment of adolescents with perinatally acquired HIV (**PHIV**) include extensive drug resistance, complex regimens, the long-term consequences of HIV and antiretroviral therapy (ART) exposure,³ the developmental transition to adulthood, and psychosocial factors.⁴⁻⁷

In the United States, most adolescents aged ≥ 14 years who recently received HIV diagnoses acquired their infection through non-perinatal transmission (**NPHIV**).⁸ They generally follow a clinical course similar to that of adults, and the [Adult and Adolescent Antiretroviral Guidelines](#) should be consulted for treatment recommendations for these patients. Additional information that is specific to the care of postpubertal adolescents can be found in [Adolescents and Young Adults with HIV](#).

Timing and Selection of Antiretroviral Therapy

All adolescents with HIV (like all people with HIV) should initiate ART as soon as possible after HIV diagnosis. Recommendations for ART selection in adolescents with sexual maturity ratings (SMR) between 1 and 3 can be found in [What to Start: Antiretroviral Treatment Regimens Recommended For Initial Therapy in Infants and Children with HIV](#) and [Appendix A. Pediatric Antiretroviral Drug Information](#). ART recommendations for adolescents and young adults with SMRs of 4 or 5 are available in the [What to Start: Initial Combination Antiretroviral Regimens for People with HIV](#) section of the [Adult and Adolescent Antiretroviral Guidelines](#). Optimizing and simplifying treatment may be especially important when treating adolescents because this can help improve adherence (see [Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy](#)). Clinicians who are treating adolescents of childbearing potential should consider additional factors before initiating ART, including potential drug interactions with contraception and the safety of using certain ARV drugs before conception or during pregnancy (see the Contraception, Pregnancy, and Antiretroviral Therapy section below).

Dosing of Antiretroviral Therapy for Adolescents with HIV

Clinical providers need to pay attention to the transition of adolescents from pediatric to adult ART dosing. Many ARV drugs (e.g., abacavir, emtricitabine, lamivudine, tenofovir disoproxil fumarate [TDF], and some protease inhibitors [PIs]) are administered to children at higher body weight–based doses or body surface area–based doses than would be predicted by direct extrapolation of adult doses. These doses are based on reported pharmacokinetic (PK) data that indicate more rapid drug clearance in children than in adults. Therefore, failure to ensure weight-appropriate dosing in adolescents can result in an increased risk of drug toxicity if higher pediatric dosing is not transitioned to lower adult dosing (often between 25 kg and 40 kg, depending on the particular drug).⁹

Adherence Concerns in Adolescents

Low adherence to ART is a common problem among adolescents with HIV. Both psychosocial and cognitive developmental factors may contribute to adherence challenges, and these factors should be assessed regularly. Assessment of ARV adherence in adolescents with HIV can be challenging, and discordance between self-report and other adherence measures—such as viral load and therapeutic or cumulative drug levels—should prompt open discussions with the adolescent and their caregiver. In one study conducted in Botswana, adolescents whose self-reported adherence and electronic adherence monitoring were discordant reported reasons for not disclosing nonadherence that included fear of disappointing caregivers and providers and a desire to avoid negative feedback or punitive adherence counseling.¹⁰ Providers should encourage open discussions that normalize the difficulties of taking life-long medications and provide positive reinforcement of disclosing adherence challenges. The adolescent’s individual needs and preferences also should be considered when making decisions about initiating or changing ART. Comprehensive systems of care are required to serve both the medical and psychosocial needs of adolescents with HIV, because they are frequently inexperienced with managing their health care and may also lack health insurance. Adolescents with PHIV infection are at risk for neurocognitive impairment, which also can interfere with medication adherence.^{11,12} Many also are at risk for mental health comorbidities, including psychiatric, behavioral, and substance use disorders that may interfere with adherence to ART.^{7,13} Compared with adults, youth have lower rates of viral suppression and higher rates of virologic rebound and loss to follow-up.^{14,15} For further discussion of interventions to promote adherence in adolescents, see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#), [Adolescents and Young](#)

[Adults with HIV](#) in the [Adult and Adolescent Antiretroviral Guidelines](#), and a 2013 review by Agwu and Fairlie.³

A specific challenge is presented by youth who, despite interventions, remain unable to adhere to therapy. In these cases, simplifying treatment to a once-daily regimen, an FDC tablet, or a long-acting injectable ARV regimen may improve adherence. The first long-acting injectable ARV regimen ([cabotegravir and rilpivirine](#)) was approved [in 2022](#) for use in adolescents aged ≥ 12 years and weighing ≥ 35 kg who are virally suppressed; however, data on use in adolescents are limited (see [Cabotegravir](#) and [Rilpivirine](#)),¹⁶⁻¹⁸ and [data are not yet available](#) on its potential use in those with adherence concerns. Alternatives to changing the ARV regimen include, but are not limited to, using cellphone alerts and other [mobile health](#), or mHealth, approaches to remind patients to take their medication and attend clinic visits¹⁹; initiating a short-term deferral of treatment until adherence improves or while adherence-related problems (including mental health and substance use disorders) are aggressively addressed; initiating an adherence testing and training period during which a placebo (e.g., vitamin pill) is administered; scheduling appointments more frequently; employing directly observed therapy; and avoiding regimens with a low genetic resistance threshold. Such decisions should be individualized and the patient's clinical and laboratory status monitored carefully, integrating transportation support and telemedicine options for flexible care engagement. Even small and short-term improvements in virologic suppression may have longer-term clinical value for adolescents with HIV.²⁰

Mental Health and Substance Use Concerns in Adolescents

Adolescent mental distress is a growing concern. Between 2009 and 2019, national youth surveys showed increases in the proportion of youth reporting persistent feelings of sadness or hopelessness, increases in the proportion of youth seriously considering suicide, and a concurrent rise in suicide rates in youth ages 10 to 24 years.^{8,21} During the same period, adolescent use of social media increased exponentially, and potential harmful impacts on youth mental health emerged (see [Protecting Youth Mental Health: The U.S. Surgeon General's Advisory 2021](#) and [Social Media and Youth Mental Health: The U.S. Surgeon General's Advisory 2023](#)).

Many factors can increase the risk of adverse mental health outcomes among adolescents with PHIV, including long-term medical treatment for a chronic disease, hospitalizations, stigma, the neurocognitive impacts of HIV, parental psychiatric and substance use disorders, and family and caregiver stress and loss. The prevalence of mental health disorders in youth with PHIV is high, with nearly 70% of these adolescents meeting the criteria for a psychiatric disorder at some point in their lives.^{7,22-24} The most common conditions include anxiety, behavioral disorders, mood disorders (including depression), and attention deficit hyperactivity disorder. [Trauma experience is also high among people with HIV generally and among youth with PHIV.](#)²⁵⁻²⁷ Additionally, although data are sparse, the prevalence of attempted suicide has been notably higher in adolescents with HIV than in those who have been exposed to HIV but are uninfected.²⁸ The risk of psychosis and severe chronic mental health disorders has been [shown to be](#) higher in adolescents with PHIV than expected in the general young adult population.²⁹ Effectively managing psychiatric comorbidities can improve a patient's adherence to medical care, including ART, and can lead to better academic performance and interpersonal relationships (see [Substance Use Disorders and HIV](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)).^{13,30-32}

Interventions that address mental health in youth with PHIV include pharmacologic interventions; behavioral modification; and individual, family, and group counseling. The use of telehealth or counseling via videoconferencing may be feasible and acceptable and may improve access to mental health treatment for adolescents with HIV.³³ Current evidence suggests that a combination of tailored

psychotherapy—such as cognitive behavioral therapy—and pharmacotherapy can reduce depressive symptoms in adolescents with HIV; however, clinicians who prescribe pharmacotherapy for depression must take potential interactions with ARV drugs into account.^{34,35} One recent study randomized adolescents with HIV with depressive symptoms across 13 U.S. sites to either a cognitive behavioral therapy and medication management algorithm (COMB-R) tailored for adolescents with HIV or enhanced standard of care, including standard psychotherapy and medication management. After 6 months, sites using the COMB-R intervention showed decreased depressive symptoms and higher remission from depression than the enhanced standard of care; however, mean HIV viral load and CD4 cell count were not significantly different between arms.³⁶ Interest in the adoption of trauma-informed care (TIC) practices for people with HIV is emerging; however, research evaluating TIC interventions is limited, and efficacy is mixed.³⁷ Providers may consider utilizing TIC principles for youth with PHIV who have experienced trauma.

Evidence exists that adolescents with PHIV are more likely to have substance use disorders than the general population³⁸; however, available studies on substance use among adolescents with PHIV show age of initiation and rates of substance use similar to age-matched peers without HIV.³⁹ In a comparison of 390 youth with perinatal exposure to HIV versus 211 youth with PHIV, investigators from the Pediatric HIV/AIDS Cohort Study (PHACS) found that nearly half of both groups had ever used alcohol or marijuana, with a majority having used either substance in the last 3 months, and one out of five participants who used marijuana reporting at least daily use.⁴⁰ In another study, there was no difference in substance use between adolescents exposed to HIV and adolescents with HIV. While rates of substance use may not be higher in adolescents with PHIV, the impact on health outcomes—including interference with medication adherence, increased risk taking, and decreased safe sex practices—and the potential for comorbid mental health concerns make addressing substance use in adolescents with HIV an important consideration for HIV care providers.^{41,42}

Providers who are caring for adolescents with HIV should incorporate screening for psychiatric disorders (including suicidality), **trauma exposure and experiences**, and substance use disorders into routine care and refer patients to age-appropriate services as needed. The [American Academy of Pediatrics Guidelines for Adolescent Depression in Primary Care](#) policy statement provides some guidance and screening tools, particularly for depression. Screening tools for substance use—such as [Screening, Brief Intervention, and Referral to Treatment \(SBIRT\)](#) or [Car, Relax, Alone, Forget, Friends, and Trouble \(CRAFFT\)](#)—may be used.⁴³ Providers also should consider emerging substance use trends when screening adolescents with HIV. Further guidance on screening tools for substance use and mental health is provided by the National Institute on Drug Abuse's [Screening and Assessment Tools Chart](#).

Sexually Transmitted Infections in Adolescents

At least half of new sexually transmitted infections (STIs) in the United States occur in youth aged 15 to 24. An analysis of three [Adolescent Medicine Trials Network for HIV/AIDS Interventions](#) studies conducted between 2009 and 2015 identified rates of STIs in adolescents with HIV that were higher than national averages for those without HIV.⁴⁴ Although adolescents with either NPHIV or PHIV had elevated rates of STIs, those with NPHIV had higher rates than those with PHIV. In addition, STIs were more frequent during times when viral load was >400 copies/mL. Clinicians should discuss the risk of STIs with their patients. All adolescents with HIV should be screened for STIs and treated appropriately. Clinicians should regularly obtain a detailed sexual history for adolescents to determine which STI screening tests are appropriate. Screening for STIs in sexually active adolescents with HIV often requires sampling from several body sites—including the oropharynx, rectum, and urethra—because multiple sites of infection are common.⁴⁵ Furthermore, a negative assay at a single site does not preclude the possibility of infection at another site.⁴⁶ For a

more detailed discussion of STIs, see the [Centers for Disease Control and Prevention STI Treatment Guidelines](#),⁴⁷ [Human Papillomavirus Disease](#) in the [Adult and Adolescent Opportunistic Infection Guidelines](#), and [Human Papillomavirus](#) in the [Pediatric Opportunistic Infection Guidelines](#). All female adolescents with HIV who are sexually active should receive gynecologic services. All adolescents with HIV should receive three doses of the 9-valent human papillomavirus vaccination.

Contraception, Pregnancy, and Antiretroviral Therapy

Adolescents with HIV may initiate sexual activity before or after puberty, but adolescents with PHIV do not appear to initiate sexual activity earlier than adolescents without HIV.⁴⁸ Sexually active adolescents are at risk for unintended pregnancy. Approximately half of pregnancies in the United States, including those among women with HIV, are unintended or unplanned.^{49,50} Providers should regularly assess adolescents' desires to become pregnant or avoid pregnancy (also known as their pregnancy intentions). Family planning counseling—including a discussion of the risks of sexual HIV transmission, perinatal HIV transmission, and methods for reducing these risks—should be provided to all youth. Reproductive health options—such as pregnancy planning, preconception care, contraceptive methods, pre-exposure prophylaxis for partners, the concept of Undetectable = Untransmittable (U=U),^{51,52} and safer sex techniques (including instruction on the correct and consistent use of condoms) for prevention of sexual HIV transmission—should be discussed regularly (see [U.S. Medical Eligibility Criteria for Contraceptive Use](#)). Access to sexual health care, including contraception and abortion care, varies by state. To offer complete guidance, providers must be familiar with local laws and regulations. For additional information, refer to [Prepregnancy Counseling and Care](#) and [Reproductive Options When One or Both Partners Have HIV](#) in the [Perinatal Guidelines](#). The American Academy of Pediatrics Committee on Adolescence offers guidance about the integration of sexual and reproductive health care in pediatric clinical settings.⁵³

Interactions Between Contraceptives and Antiretroviral Drugs

People with HIV can use all available contraceptive methods, including hormonal contraceptives, implantable devices, intrauterine devices, transdermal patches, and vaginal rings.⁵⁴

Several PIs and non-nucleoside reverse transcriptase inhibitors alter the metabolism of oral contraceptives, which theoretically may reduce the efficacy of oral contraceptive agents or increase the risk of estrogen-related or progestin-related adverse effects.⁵⁵⁻⁵⁷ Integrase strand transfer inhibitors appear to have no interaction with estrogen-based contraceptives.^{58,59} For more information about potential interactions between ARV drugs and hormonal contraceptives, see [Table 3. Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives](#) in the [Perinatal Guidelines](#).

Concerns about loss of bone mineral density with long-term use of depot medroxyprogesterone acetate (DMPA), with or without coadministration of ART (specifically TDF), should not preclude the use of DMPA as an effective contraceptive, unless clinical evidence indicates bone fragility.

HIV and Pregnancy During Adolescence

Childbearing potential and the possibility of planned and unplanned pregnancy should be considered when selecting an ARV regimen for an adolescent. Adolescents who want to become pregnant should receive preconception counseling and care, including a discussion of pregnancy planning and special considerations when using ARV drugs during pregnancy (see [Prepregnancy Counseling and Care](#) in the [Perinatal Guidelines](#)). Pregnancy should not preclude the use of optimal therapeutic ARV regimens. Clinicians need to consider maternal and fetal safety, as well as the need to prevent perinatal transmission of HIV, when selecting regimens. See Table 7 in the Recommendations for

Use of Antiretroviral Drugs During Pregnancy section of the Perinatal Guidelines for more details about choosing an ARV regimen for use during pregnancy , including among adolescents with HIV. Pregnancies occur as people with PHIV enter adolescence and young adulthood.^{60,61} Some studies suggest higher rates of adverse pregnancy outcomes—such as small-for-gestational-age infants—among those with PHIV than among those with NPHIV. Unplanned pregnancy is not uncommon in youth with PHIV.⁶¹⁻⁶³ One site serving pregnant women with HIV in Baltimore reported higher rates of unintended pregnancy (83.6% vs. 68.8%, $P = 0.016$), lower viral suppression, and higher marijuana use during pregnancy in adolescents with HIV than in adults with HIV.⁶⁴ Adolescents with PHIV also may be more likely to have complex ARV histories, virologic failure, and drug resistance at the time of pregnancy.⁶⁴⁻⁶⁶ However, the rate of perinatal transmission among people with PHIV who are receiving ART appears to be similar to the rate among people on ART with NPHIV.⁶⁷⁻⁷¹

Other Considerations for Adolescents with HIV

Adolescence is a period of emerging recognition of sexual orientation and self-expression. Adolescents with HIV who are lesbian, gay, bisexual, or nonbinary require both culturally competent providers and tailored medical care. Health care providers should ask patients nonjudgmental questions about their sexuality to determine whether they require specific medical and support services **and whether those services are available locally.** It is important to consider the possibility of drug–drug interactions in adolescents who are receiving both ART and medications such as testosterone or estrogen. Additional resources for the care of these adolescents can be found in [Adolescents and Young Adults with HIV](#) in the [Adult and Adolescent Antiretroviral Guidelines](#).

Transitioning Adolescents Into Adult HIV Care Settings

Transition to adult care is defined by Reiss et al. as “a multifaceted, active process that attends to the medical, psychosocial, cognitive and educational, or vocational needs of adolescents as they move from the child- to the adult-focused health care system.”⁷² Facilitating a successful transition for adolescents with HIV from their pediatric/adolescent care clinic to adult care is important but challenging.⁷³⁻⁷⁶ Many adolescents disengage from care during the transition to adult care, putting them at risk for HIV progression and transmission to partners.⁷⁷⁻⁷⁹ Pediatric and adolescent care providers and their multidisciplinary teams should have a formal written plan in place to transition adolescents to adult care. Although transition generally occurs when individuals are in their late teens or early 20s, discussion of and planning for the transition process should be initiated early in the teen years, with involvement from both the adolescent and their parents and/or caregivers. Care models for children and adolescents with PHIV tend to be family centered, consisting of a multidisciplinary team that often includes physicians, nurses, social workers, and mental health professionals. These providers generally have long-standing relationships with patients and their families, and care is rendered in discreet, intimate settings. Qualitative research has demonstrated that established patient–provider relationships among adolescents with HIV and their providers are integral to HIV care engagement and that collaborative approaches to build trusted, new patient–provider relationships are necessary to support successful transition.^{80,81} Although expert care also is provided under the adult HIV care medical model, adolescents and their caregivers may be unfamiliar with the busier, more individual-centered clinics that are typical of adult medical care providers. These providers often expect patients to assume a greater level of responsibility for their care, and adolescents may be uncomfortable with providers with whom they do not have a long-standing relationship.

One multisite study in the United States found that adolescents who transitioned to adult care at an older age reported greater satisfaction with their care than those who transitioned at a younger age. Additionally, adolescents who reported being able to perform certain tasks that were related to their

care (e.g., making appointments, requesting prescriptions, arranging transportation to appointments) were more likely to be engaged in adult care.⁸² Assessments of transition readiness using standardized tools are emerging as a potentially helpful part of the transition process and may be predictive of HIV outcomes, including virologic failure post-transition.^{83,84} It may be beneficial to provide adolescents, caregivers, and their new adult medical care providers with support and guidance regarding the expectations for each person involved in the patient–provider relationship. In this situation, it may be helpful for a pediatric care provider and an adult care provider to share joint care of a patient for a period.

Adolescent care providers should have a candid discussion with the transitioning adolescent and their caregivers to understand what qualities the adolescent considers most important when choosing an adult care setting (e.g., confidentiality, small clinic size, low patient-to-provider ratio, availability of after-school or evening appointments). Social determinants—such as the patient’s developmental status, behavioral/mental health comorbidities, housing, family support, employment status, recent discharge from foster care, peer pressure, illicit drug use, and incarceration—should be considered during transition.

No definitive model of transition to adult HIV care currently exists, and only a limited number of studies have reported on outcomes following transition, although research in this area is ongoing. However, emerging qualitative research has revealed the importance of the patient–provider relationship, including trust, the need for developmentally appropriate preparation for transition, and opportunities for growth and independence.^{76,85} Recent studies have shown potential for successful transition and ongoing retention using models that include an individualized transition plan and a multidisciplinary approach that utilizes providers co-trained in both internal medicine and pediatrics, peer navigators, social workers, mental health support, and a youth-focused care model for adolescents who were already attending adult HIV clinics.⁸⁶⁻⁸⁸

Several studies have shown that youth with HIV who transitioned into adult care settings had higher rates of attrition from care than those who remained in pediatric/adolescent care. Some U.S. studies show that less than half of youth who transitioned care to an adult clinic remained in care after 9 to 12 months.^{77,78,89} Other U.S. sites have reported initial success in transitioning adolescents but with declining post-transition retention over time.⁹⁰ In addition to poor retention in care, several studies have identified poor viral suppression rates in transitioned youth and young adults with HIV.² Pre-transition virologic failure and longer linkage times have been associated with worse outcomes post-transition.^{76,79} Furthermore, some reports from the United Kingdom suggest that the mortality rate of adolescents with HIV increases after transition,^{31,79,91} underscoring the need to critically examine transition and determine the best mechanisms to optimize the long-term outcomes for youth with PHIV.⁷⁷

Some general guidelines, based on emerging evidence and consensus expert opinion, are available about transition plans and who might benefit most from them.^{74,88,92-99} To maximize the likelihood of success, providers should prepare adolescents for transition long before it occurs. Attention to the following key areas could improve retention in care and minimize the risk of ART interruptions:

- Educating HIV care teams and staff about transitioning;
- Beginning discussions about transition early, before the actual transition process;
- Developing a written, individualized transition plan to address comprehensive care needs, including medical, psychosocial, and financial aspects of transitioning;
- Optimizing communication between providers at pediatric/adolescent clinics and providers at adult clinics;

- Identifying adult care providers who are experts in providing care to adolescents and young adults;
- Fostering a trusting patient–provider relationship with new adult care providers;
- Addressing barriers caused by a lack of information, stigma, or disclosure concerns;
- Discussing the differences between the practice styles of adult clinics and pediatric/adolescent clinics;
- Helping youth develop the skills needed to manage their care, including counseling them on appointment management, the appropriate use of a primary care provider, the importance of prompt symptom recognition and reporting, and the importance of managing medications, insurance, and state and federal benefits;
- Identifying an optimal clinic model for a given setting (e.g., simultaneous transition of mental health and/or case management services versus a gradual phase-in);
- Clearly defining the desired outcomes for the transition, such as retention in care, ongoing access to other services (e.g., case management, mental health), clinical outcomes (e.g., viral suppression), and patient satisfaction;
- Implementing ongoing evaluations to measure the success of a transition model;
- Engaging in regular multidisciplinary case conferences between adult and adolescent care providers;
- Implementing interventions that may be associated with improved outcomes, such as support groups and mental health consultation; *and*
- Identifying a care navigator who can provide support during the transition.

References

1. Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. *J Acquir Immune Defic Syndr.* 2011;57(2):165-173. Available at: <https://pubmed.ncbi.nlm.nih.gov/21407086>.
2. Xia Q, Shah D, Gill B, et al. Continuum of care among people living with perinatally acquired HIV infection in New York City, 2014. *Public Health Rep.* 2016;131(4):566-573. Available at: <https://pubmed.ncbi.nlm.nih.gov/27453601>.
3. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. *J Int AIDS Soc.* 2013;16:18579. Available at: <https://pubmed.ncbi.nlm.nih.gov/23782477>.
4. Judd A, Lodwick R, Noguera-Julian A, et al. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. *HIV Med.* 2017;18(3):171-180. Available at: <https://pubmed.ncbi.nlm.nih.gov/27625109>.
5. Hermetet-Lindsay KD, Correia KF, Williams PL, et al. Contributions of disease severity, psychosocial factors, and cognition to behavioral functioning in US youth perinatally exposed to HIV. *AIDS Behav.* 2017;21(9):2703-2715. Available at: <https://pubmed.ncbi.nlm.nih.gov/27475941>.
6. Tarantino N, Brown LK, Whiteley L, et al. Correlates of missed clinic visits among youth living with HIV. *AIDS Care.* 2018;30(8):982-989. Available at: <https://pubmed.ncbi.nlm.nih.gov/29455553>.
7. Bucek A, Leu CS, Benson S, et al. Psychiatric disorders, antiretroviral medication adherence and viremia in a cohort of perinatally HIV-infected adolescents and young adults. *Pediatr Infect Dis J.* 2018;37(7):673-677. Available at: <https://pubmed.ncbi.nlm.nih.gov/29227462>.
8. Centers for Disease Control and Prevention. Youth risk behavior surveillance data summary & trends report: 2011–2021. 2023. Available at: https://www.cdc.gov/nchhstp/dear_colleague/2020/dcl-102320-YRBS-2009-2019-report.html.
9. Rakhmanina N, Phelps BR. Pharmacotherapy of pediatric HIV infection. *Pediatr Clin North Am.* 2012;59(5):1093-1115. Available at: <https://pubmed.ncbi.nlm.nih.gov/23036246>.
10. Lowenthal ED, Ohrenshall R, Moshashane N, et al. Reasons for discordance between antiretroviral adherence measures in adolescents. *AIDS Care.* 2021;1-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/34424796>.
11. Harris LL, Chernoff MC, Nichols SL, et al. Prospective memory in youth with perinatally-acquired HIV infection. *Child Neuropsychol.* 2018;24(7):938-958. Available at: <https://pubmed.ncbi.nlm.nih.gov/28782457>.
12. Rowe K, Buivydaite R, Heinsohn T, et al. Executive function in HIV-affected children and adolescents: a systematic review and meta-analyses. *AIDS Care.* 2021;33(7):833-857. Available at: <https://pubmed.ncbi.nlm.nih.gov/33764813>.

13. Mellins CA, Tassiopoulos K, Malee K, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. *AIDS Patient Care STDS*. 2011;25(7):413-422. Available at: <https://pubmed.ncbi.nlm.nih.gov/21992620>.
14. Gray KM, Ocfemia MCB, Wang X, et al. Characteristics and care outcomes among persons living with perinatally acquired HIV infection in the United States, 2015. *J Acquir Immune Defic Syndr*. 2019;82(1):17-23. Available at: <https://pubmed.ncbi.nlm.nih.gov/31169773>.
15. Kacanek D, Huo Y, Malee K, et al. Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV. *AIDS*. 2019;33(12):1923-1934. Available at: <https://pubmed.ncbi.nlm.nih.gov/31274538>.
16. Lowenthal ED, Chapman J, Calabrese K, et al. Adolescent and parent experiences with long-acting injectables in the MOCHA study. Presented at: Conference on Retroviruses and Opportunistic Infections. February 11, 2022. Available at: https://www.natap.org/2022/CROI/croi_154.htm.
17. Bolton Moore EC, Capparelli E, Calabrese K, et al. Safety and PK of long-acting cabotegravir and rilpivirine in adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections. February 11, 2022. Virtual. Available at: <https://www.croiconference.org/wp-content/uploads/sites/2/resources/2022/croi2022-program-guide.pdf>.
18. Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of long-acting products to transform the treatment and prevention of human immunodeficiency virus (HIV) in infants, children, and adolescents. *Clin Infect Dis*. 2022;75(Suppl 4):S562-S570. Available at: <https://pubmed.ncbi.nlm.nih.gov/36410381>.
19. Mehra N, Tunje A, Hallstrom IK, Jerene D. Effectiveness of mobile phone text message reminder interventions to improve adherence to antiretroviral therapy among adolescents living with HIV: a systematic review and meta-analysis. *PLoS One*. 2021;16(7):e0254890. Available at: <https://pubmed.ncbi.nlm.nih.gov/34293033>.
20. Neilan AM, Bangs AC, Hudgens M, et al. Modeling adherence interventions among youth with HIV in the United States: clinical and economic projections. *AIDS Behav*. 2021;25(9):2973-2984. Available at: <https://pubmed.ncbi.nlm.nih.gov/33547993>.
21. Curtin C. S. State suicide rates among adolescents and young adults aged 10–24: United States, 2000–2018. Centers for Diseases Control and Prevention. 2020. Available at: <https://stacks.cdc.gov/view/cdc/93667>.
22. Mellins CA, Malee KM. Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges. *J Int AIDS Soc*. 2013;16:18593. Available at: <https://pubmed.ncbi.nlm.nih.gov/23782478>.
23. Mellins CA, Brackis-Cott E, Leu CS, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. *J Child Psychol Psychiatry*. 2009;50(9):1131-1138. Available at: <https://pubmed.ncbi.nlm.nih.gov/19298479>.

24. Gadow KD, Chernoff M, Williams PL, et al. Co-occurring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. *J Dev Behav Pediatr*. 2010;31(2):116-128. Available at: <https://pubmed.ncbi.nlm.nih.gov/20110828>.
25. Chenneville T, Drake H, Cario A, Rodriguez C. Adverse childhood experiences among a sample of youth living with HIV in the Deep South. *Int J Environ Res Public Health*. 2022;19(15). Available at: <https://pubmed.ncbi.nlm.nih.gov/35955095>.
26. Morrison C, Corbeli T, Kluisza L, et al. Traumatic event exposure and mental disorders in youth perinatally affected by HIV. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Seattle, Washington. Available at: <https://www.croiconference.org/abstract/traumatic-event-exposure-and-mental-disorders-in-youth-perinatally-affected-by-hiv>.
27. Lynn C, Chenneville T, Bradley-Klug K, et al. Depression, anxiety, and posttraumatic stress as predictors of immune functioning: differences between youth with behaviorally and perinatally acquired HIV. *AIDS Care*. 2019;31(10):1261-1270. Available at: <https://pubmed.ncbi.nlm.nih.gov/30829044>.
28. Kreniske P, Morrison C, Spencer BH, et al. HIV and suicide risk across adolescence and young adulthood: an examination of socio-demographic, contextual and psychosocial risk factors for attempted suicide in a longitudinal cohort of ageing adolescents affected by HIV living in the New York City area. *J Int AIDS Soc*. 2022;25 Suppl 4(Suppl 4):e25984. Available at: <https://pubmed.ncbi.nlm.nih.gov/36176026>.
29. Mallik I, Pasvol T, Frize G, et al. Psychotic disorders in young adults with perinatally acquired HIV: a UK case series. *Psychol Med*. 2022;52(12):2263-2269. Available at: <https://pubmed.ncbi.nlm.nih.gov/33183361>.
30. Kapetanovic S, Wiegand RE, Dominguez K, et al. Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy-experienced perinatally HIV-infected youth. *AIDS Patient Care STDS*. 2011;25(8):493-501. Available at: <https://pubmed.ncbi.nlm.nih.gov/21745118>.
31. Fish R, Judd A, Jungmann E, et al. Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit. *HIV Med*. 2013;15(4):239-244. Available at: <https://pubmed.ncbi.nlm.nih.gov/24112550>.
32. Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *AIDS*. 2014;28(13):1945-1956. Available at: <https://pubmed.ncbi.nlm.nih.gov/24845154>.
33. Saberi P, McCuistian C, Agnew E, et al. Video-counseling intervention to address HIV care engagement, mental health, and substance use challenges: a pilot randomized clinical trial for youth and young adults living with HIV. *Telemed Rep*. 2021;2(1):14-25. Available at: <https://pubmed.ncbi.nlm.nih.gov/33575683>.
34. Brown LK, Kennard BD, Emslie GJ, et al. Effective treatment of depressive disorders in medical clinics for adolescents and young adults living with HIV: a controlled trial. *J Acquir Immune Defic Syndr*. 2016;71(1):38-46. Available at: <https://pubmed.ncbi.nlm.nih.gov/26761270>.

35. Benton TD, Kee Ng WY, Leung D, et al. Depression among youth living with HIV/AIDS. *Child Adolesc Psychiatr Clin N Am.* 2019;28(3):447-459. Available at: <https://pubmed.ncbi.nlm.nih.gov/31076119>.
36. Brown LK, Chernoff M, Kennard BD, et al. Site-randomized controlled trial of a combined cognitive behavioral therapy and a medication management algorithm for treatment of depression among youth living with HIV in the United States. *J Acquir Immune Defic Syndr.* 2021;88(5):497-505. Available at: <https://pubmed.ncbi.nlm.nih.gov/34483297>.
37. Brown MJ, Adeagbo O. Trauma-informed HIV care interventions: towards a holistic approach. *Curr HIV/AIDS Rep.* 2022;19(3):177-183. Available at: <https://pubmed.ncbi.nlm.nih.gov/35353271>.
38. Abrams EJ, Mellins CA, Bucek A, et al. Behavioral health and adult milestones in young adults with perinatal HIV infection or exposure. *Pediatrics.* 2018;142(3). Available at: <https://pubmed.ncbi.nlm.nih.gov/30097528>.
39. Alperen J, Brummel S, Tassiopoulos K, et al. Prevalence of and risk factors for substance use among perinatally human immunodeficiency virus-infected and perinatally exposed but uninfected youth. *J Adolesc Health.* 2014;54(3):341-349. Available at: <https://pubmed.ncbi.nlm.nih.gov/24239286>.
40. Nichols SL, Brummel S, Malee KM, et al. The role of behavioral and neurocognitive functioning in substance use among youth with perinatally acquired HIV infection and perinatal HIV exposure without infection. *AIDS Behav.* 2021;25(9):2827-2840. Available at: <https://pubmed.ncbi.nlm.nih.gov/33616833>.
41. Williams PL, Leister E, Chernoff M, et al. Substance use and its association with psychiatric symptoms in perinatally HIV-infected and HIV-affected adolescents. *AIDS Behav.* 2010;14(5):1072-1082. Available at: <https://pubmed.ncbi.nlm.nih.gov/20725774>.
42. Elkington KS, Cruz JE, Warne P, et al. Marijuana use and psychiatric disorders in perinatally HIV-exposed youth: does HIV matter? *J Pediatr Psychol.* 2016;41(3):277-286. Available at: <https://pubmed.ncbi.nlm.nih.gov/26698841>.
43. Knight JR, Shrier LA, Bravender TD, et al. A new brief screen for adolescent substance abuse. *Arch Pediatr Adolesc Med.* 1999;153(6):591-596. Available at: <https://pubmed.ncbi.nlm.nih.gov/10357299>.
44. Neilan AM, DeMonte JB, Foote JHA, et al. Rates of sexually transmitted infection diagnoses among US youth with perinatally and nonperinatally acquired HIV. *Sex Transm Dis.* 2022;49(3):223-230. Available at: <https://pubmed.ncbi.nlm.nih.gov/34711773>.
45. Loerinc L, Scheel A, Jordan-Thompson S, et al. Incidence, reinfection, and discrepancy between sexual practice and anatomic site positivity of sexually transmitted infections in youth with HIV. *Pediatr Infect Dis J.* 2022;41(4):306-311. Available at: <https://pubmed.ncbi.nlm.nih.gov/34773398>.
46. Sultan B, White JA, Fish R, et al. The “3 in 1” study: pooling self-taken pharyngeal, urethral and rectal samples into a single sample for analysis, for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men (MSM). *J Clin Microbiol.* 2015;54(3):650-656. Available at: <https://pubmed.ncbi.nlm.nih.gov/26719439>.

47. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*. 2015;64(RR-03):1-137. Available at: <https://pubmed.ncbi.nlm.nih.gov/26042815>.
48. Ter Haar AM, Fieten A, Van den Hof M, et al. Sexual development in perinatally HIV-infected young people: a systematic review and explorative study. *Sex Med*. 2022;10(6):100578. Available at: <https://pubmed.ncbi.nlm.nih.gov/36274460>.
49. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. *N Engl J Med*. 2016;374(9):843-852. Available at: <https://pubmed.ncbi.nlm.nih.gov/26962904>.
50. Sutton MY, Patel R, Frazier EL. Unplanned pregnancies among HIV-infected women in care—United States. *J Acquir Immune Defic Syndr*. 2014;65(3):350-358. Available at: <https://pubmed.ncbi.nlm.nih.gov/24189153>.
51. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med*. 2016;375(9):830-839. Available at: <https://pubmed.ncbi.nlm.nih.gov/27424812>.
52. Centers for Disease Control and Prevention. HIV surveillance supplemental report, 2021. Diagnoses of HIV infection in the United States and dependent areas, 2021. 2021;34. Available at: <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>
53. Marcell AV, Burstein GR, Committee on Adolescence. Sexual and reproductive health care services in the pediatric setting. *Pediatrics*. 2017;140(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/29061870>.
54. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. 2021. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/perinatal/guidelines-panel-members?view=full>.
55. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. *Antivir Ther*. 2011;16(2):149-156. Available at: <https://pubmed.ncbi.nlm.nih.gov/21447863>.
56. Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. *Antivir Ther*. 2011;16(2):157-164. Available at: <https://pubmed.ncbi.nlm.nih.gov/21447864>.
57. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. *Eur J Contracept Reprod Health Care*. 2008;13(2):123-132. Available at: <https://pubmed.ncbi.nlm.nih.gov/18465473>.
58. Song IH, Borland J, Chen S, et al. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. *Ann Pharmacother*. 2015;49(7):784-789. Available at: <https://pubmed.ncbi.nlm.nih.gov/25862012>.
59. Patel R, Stalter R, Onono M, et al. Dolutegravir-containing art does not reduce etonogestrel implant concentrations. Abstract 129. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, MA. Available at:

<https://www.croiconference.org/abstract/dolutegravir-containing-art-does-not-reduce-etonogestrel-implant-concentrations>.

60. Kenny J, Williams B, Prime K, et al. Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV. *HIV Med.* 2012;13(5):304-308. Available at: <https://pubmed.ncbi.nlm.nih.gov/22136754>.
61. Byrne L, Thorne C, Foster C, Tookey P. Pregnancy outcomes in women growing up with perinatally acquired HIV in the United Kingdom and Ireland. *J Int AIDS Soc.* 2014;17(4 Suppl 3):19693. Available at: <https://pubmed.ncbi.nlm.nih.gov/25397443>.
62. Jao J, Agwu A, Mhango G, et al. Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women. *AIDS.* 2015;29(1):111-116. Available at: <https://pubmed.ncbi.nlm.nih.gov/25562495>.
63. Jao J, Sigel KM, Chen KT, et al. Small for gestational age birth outcomes in pregnant women with perinatally acquired HIV. *AIDS.* 2012;26(7):855-859. Available at: <https://pubmed.ncbi.nlm.nih.gov/22313958>.
64. Murphy E, Keller J, Argani C, et al. Pregnancy in an urban cohort of adolescents living with human immunodeficiency virus: characteristics and outcomes in comparison to adults. *AIDS Patient Care STDS.* 2021;35(4):103-109. Available at: <https://pubmed.ncbi.nlm.nih.gov/33835849>.
65. Lazenby GB, Mmeje O, Fisher BM, et al. Antiretroviral resistance and pregnancy characteristics of women with perinatal and nonperinatal HIV infection. *Infect Dis Obstet Gynecol.* 2016;2016:4897501. Available at: <https://pubmed.ncbi.nlm.nih.gov/27413359>.
66. Cruz ML, Santos E, Benamor Teixeira Mde L, et al. Viral suppression and resistance in a cohort of perinatally-HIV infected (PHIV+) pregnant women. *Int J Environ Res Public Health.* 2016;13(6). Available at: <https://pubmed.ncbi.nlm.nih.gov/27338425>.
67. Meloni A, Tuveri M, Floridia M, et al. Pregnancy care in two adolescents perinatally infected with HIV. *AIDS Care.* 2009;21(6):796-798. Available at: <https://pubmed.ncbi.nlm.nih.gov/19806493>.
68. Williams SF, Keane-Tarchichi MH, Bettica L, et al. Pregnancy outcomes in young women with perinatally acquired human immunodeficiency virus-1. *Am J Obstet Gynecol.* 2009;200(2):149 e141-145. Available at: <https://pubmed.ncbi.nlm.nih.gov/18973871>.
69. Cruz ML, Cardoso CA, Joao EC, et al. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. *AIDS.* 2010;24(17):2727-2731. Available at: <https://pubmed.ncbi.nlm.nih.gov/20827164>.
70. Elgalib A, Hegazi A, Samarawickrama A, et al. Pregnancy in HIV-infected teenagers in London. *HIV Med.* 2011;12(2):118-123. Available at: <https://pubmed.ncbi.nlm.nih.gov/20807252>.
71. Calitri C, Gabiano C, Galli L, et al. The second generation of HIV-1 vertically exposed infants: a case series from the Italian register for paediatric HIV infection. *BMC Infect Dis.* 2014;14:277. Available at: <https://pubmed.ncbi.nlm.nih.gov/24885649>.

72. Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider perspectives. *Pediatrics*. 2005;115(1):112-120. Available at: <https://pubmed.ncbi.nlm.nih.gov/15629990>.
73. Tepper V, Zaner S, Ryscavage P. HIV healthcare transition outcomes among youth in North America and Europe: a review. *J Int AIDS Soc*. 2017;20(Suppl 3):60-70. Available at: <https://pubmed.ncbi.nlm.nih.gov/28530041>.
74. Judd A, Davies MA. Adolescent transition among young people with perinatal HIV in high-income and low-income settings. *Curr Opin HIV AIDS*. 2018;13(3):236-248. Available at: <https://pubmed.ncbi.nlm.nih.gov/29528851>.
75. Foster C, Fidler S. Optimizing HIV transition services for young adults. *Curr Opin Infect Dis*. 2018;31(1):33-38. Available at: <https://pubmed.ncbi.nlm.nih.gov/29210712>.
76. Ritchwood TD, Malo V, Jones C, et al. Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: a systematic review. *BMC Public Health*. 2020;20(1):1195. Available at: <https://pubmed.ncbi.nlm.nih.gov/32746881>.
77. Ryscavage P, Macharia T, Patel D, et al. Linkage to and retention in care following healthcare transition from pediatric to adult HIV care. *AIDS Care*. 2016;28(5):561-565. Available at: <https://pubmed.ncbi.nlm.nih.gov/26766017>.
78. Tanner AE, Philbin MM, Chambers BD, et al. Healthcare transition for youth living with HIV: outcomes from a prospective multi-site study. *J Adolesc Health*. 2018;63(2):157-165. Available at: <https://pubmed.ncbi.nlm.nih.gov/29887488>.
79. Hussen SA, Chakraborty R, Knezevic A, et al. Transitioning young adults from paediatric to adult care and the HIV care continuum in Atlanta, Georgia, USA: a retrospective cohort study. *J Int AIDS Soc*. 2017;20(1):21848. Available at: <https://pubmed.ncbi.nlm.nih.gov/28872281>.
80. Barr EA, Raybin JL, Dunlevy H, et al. Transition from pediatric and adolescent HIV care to adult HIV care and the patient-provider relationship: a qualitative metasynthesis. *J Assoc Nurses AIDS Care*. 2022;33(2):132-154. Available at: <https://pubmed.ncbi.nlm.nih.gov/33654006>.
81. Momplaisir F, McGlenn K, Grabbill M, et al. Strategies to improve outcomes of youth experiencing healthcare transition from pediatric to adult HIV care in a large U.S. city. *Arch Public Health*. 2023;81(1):49. Available at: <https://pubmed.ncbi.nlm.nih.gov/37004125>.
82. Tassiopoulos K, Huo Y, Patel K, et al. Healthcare transition outcomes among young adults with perinatally acquired human immunodeficiency virus infection in the United States. *Clin Infect Dis*. 2020;71(1):133-141. Available at: <https://pubmed.ncbi.nlm.nih.gov/31584617>.
83. Zanoni BC, Archary M, Sibaya T, et al. Development and validation of the HIV Adolescent Readiness for Transition Scale (HARTS) in South Africa. *J Int AIDS Soc*. 2021;24(7):e25767. Available at: <https://pubmed.ncbi.nlm.nih.gov/34235876>.
84. Harris LR, Hoffman HJ, Griffith CJ, et al. Factors associated with transition of HIV care readiness among adolescents and youth from a specialty pediatric HIV clinic in the United

- States. *AIDS Patient Care STDS*. 2021;35(12):495-502. Available at: <https://pubmed.ncbi.nlm.nih.gov/34851725>.
85. Barr EA, Raybin JL, Dunlevy H, et al. Transition from pediatric and adolescent HIV care to adult HIV care and the patient-provider relationship: a qualitative metasynthesis. *J Assoc Nurses AIDS Care*. 2022. Available at: <https://pubmed.ncbi.nlm.nih.gov/33654006>.
86. Griffith D, Jin L, Childs J, et al. Outcomes of a comprehensive retention strategy for youth with HIV after transfer to adult care in the United States. *Pediatr Infect Dis J*. 2019;38(7):722-726. Available at: <https://pubmed.ncbi.nlm.nih.gov/30985513>.
87. Griffith D, Snyder J, Dell S, et al. Impact of a youth-focused care model on retention and virologic suppression among young adults with HIV cared for in an adult HIV clinic. *J Acquir Immune Defic Syndr*. 2019;80(2):e41-e47. Available at: <https://pubmed.ncbi.nlm.nih.gov/30422910>.
88. Jegede OE, van Wyk B. Transition interventions for adolescents on antiretroviral therapy on transfer from pediatric to adult healthcare: a systematic review. *Int J Environ Res Public Health*. 2022;19(22). Available at: <https://pubmed.ncbi.nlm.nih.gov/36429633>.
89. Farmer C, Yehia BR, Fleishman JA, et al. Factors associated with retention among non-perinatally HIV-infected youth in the HIV research network. *J Pediatric Infect Dis Soc*. 2016;5(1):39-46. Available at: <https://pubmed.ncbi.nlm.nih.gov/26908490>.
90. Hussen SA, Doraivelu K, Goldstein MH, et al. Human immunodeficiency virus (HIV) care continuum outcomes after transition to adult care among a prospective cohort of youth with HIV in Atlanta, Georgia. *Clin Infect Dis*. 2023;76(7):1218-1224. Available at: <https://pubmed.ncbi.nlm.nih.gov/36409586>.
91. Foster C, Ayers S, McDonald S, et al. Clinical outcomes post transition to adult services in young adults with perinatally acquired HIV infection: mortality, retention in care and viral suppression. *AIDS*. 2020;34(2):261-266. Available at: <https://pubmed.ncbi.nlm.nih.gov/31651427>.
92. Gilliam PP, Ellen JM, Leonard L, et al. Transition of adolescents with HIV to adult care: characteristics and current practices of the adolescent trials network for HIV/AIDS interventions. *J Assoc Nurses AIDS Care*. 2011;22(4):283-294. Available at: <https://pubmed.ncbi.nlm.nih.gov/20541443>.
93. New York State Department of Health AIDS Institute. Transitioning HIV-infected adolescents into adult care. 2011. Available at: https://www.medscape.com/viewarticle/748356_2.
94. Andiman WA. Transition from pediatric to adult healthcare services for young adults with chronic illnesses: the special case of human immunodeficiency virus infection. *J Pediatr*. 2011;159(5):714-719. Available at: <https://pubmed.ncbi.nlm.nih.gov/21868035>.
95. Dowshen N, D'Angelo L. Health care transition for youth living with HIV/AIDS. *Pediatrics*. 2011;128(4):762-771. Available at: <https://pubmed.ncbi.nlm.nih.gov/21930548>.
96. Committee On Pediatric AIDS. Transitioning HIV-infected youth into adult health care. *Pediatrics*. 2013;132(1):192-197. Available at: <https://pubmed.ncbi.nlm.nih.gov/23796739>.

97. Sharer M, Fullem A. Transitioning of care and other services for adolescents living with HIV in sub-Saharan Africa. USAID's AIDS Support and Technical Assistance Resources, AIDSTAR-One, Task Order 1. 2012. Available at: <https://www.socialserviceworkforce.org/resources/transitioning-care-and-other-services-adolescents-living-hiv-sub-saharan-africa>.
98. Hussen SA, Chahroudi A, Boylan A, et al. Transition of youth living with HIV from pediatric to adult-oriented healthcare: a review of the literature. *Future Virol.* 2015;9(10):921-929. Available at: <https://pubmed.ncbi.nlm.nih.gov/25983853>.
99. Njuguna IN, Beima-Sofie K, Mburu CW, et al. Transition to independent care for youth living with HIV: a cluster randomised clinical trial. *Lancet HIV.* 2022;9(12):e828-e837. Available at: <https://pubmed.ncbi.nlm.nih.gov/36309040>.

Adherence to Antiretroviral Therapy in Children and Adolescents with HIV

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">Strategies to maximize adherence should be discussed before and/or at initiation of antiretroviral therapy (ART) and before changing regimens (AIII).Adherence to ART must be assessed and promoted at each visit, and strategies to maintain and/or improve adherence must be continually explored (AIII).In addition to viral load monitoring, at least one other method of measuring adherence to ART should be used (AIII).To facilitate adherence, simplified oral ART regimens (e.g., once daily, low pill burden) should be prescribed whenever feasible (AII*).The option of long-acting injectable ART to facilitate and support adherence should be discussed with eligible patients and their caregivers (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children^t with clinical outcomes and/or validated endpoints; I = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion*

^t Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents

Background

Adherence to antiretroviral therapy (ART) is a principal determinant of virologic suppression. Suboptimal adherence may include missed or late doses, treatment interruptions and discontinuations, and subtherapeutic or partial dosing. Poor adherence will result in subtherapeutic plasma antiretroviral (ARV) drug concentrations, facilitating the development of resistance to one or more drugs in a given ARV regimen and possible cross-resistance to other drugs in the same class. Multiple factors—including regimen potency, pharmacokinetics, drug interactions, viral fitness, and the genetic barrier to ARV resistance— influence the adherence–resistance relationship.^{1–3} In addition to compromising the efficacy of the current regimen, suboptimal adherence can limit the options for future effective ARV drug regimens in patients who develop multidrug-resistant HIV; it also can increase the risk of secondary transmission of drug-resistant virus. Chronic nonadherence and persistent viremia can lead to immune dysfunction and clinical complications (see [Recognizing and Managing Antiretroviral Treatment Failure](#)).

With modern ART, the level of adherence needed to achieve viral suppression may be as low as 80% to 85%.^{4,5} However, emerging data indicate that less than 100% ARV adherence is associated with negative immunologic and clinical effects, even if the level of adherence is sufficient to achieve and sustain viral suppression.^{6–9} A recent modeling analysis of data from studies in adults found that increasing adherence in persons with viral suppression could reduce the risk of severe non-AIDS

events and death.⁹ These data point out the need to prioritize addressing and maximizing adherence at visits for all children and adolescents, even those with viral suppression.

Poor adherence to ARV drugs is commonly encountered in the treatment of children and adolescents with HIV. Medication formulation and palatability, frequency of dosing, side effects, drug toxicities, and a child's age and developmental stage can affect adherence. In addition, many psychosocial, behavioral, and structural barriers for children and caregivers have also been associated with inadequate adherence. No consistent predictors of either good or poor adherence in children have been identified.¹⁰⁻¹² However, findings from the U.S. Pediatric HIV/AIDS Cohort Study (PHACS) demonstrated that the prevalence of nonadherence increased with age. Among 381 children and adolescents with perinatally acquired HIV (PHIV), the prevalence of nonadherence increased from 31% to 50% ($P < 0.001$), and the prevalence of unsuppressed viral loads increased from 16% to 40% ($P < 0.001$) between preadolescence and late adolescence/young adulthood.¹³ Similarly, in a report from the Early Pediatric Initiation Canada Cure Cohort, only 73% of the children with PHIV initiated on ART maintained viral suppression 3 years after it was first achieved.¹⁴ Furthermore, several studies have demonstrated that adherence is not static and can vary with time on treatment.¹⁵ In particular, adolescents often struggle to sustain adherence over time. In a study of 933 adolescents in South Africa aged 10 to 19 years who were followed for a 3- to 4-year period, adherence was assessed at baseline and two subsequent times via self-report of previous week ART adherence. Only 37% of participants reported consistent adherence at all three assessments. Both older age ($P = 0.007$) participants and those with horizontally acquired HIV ($P = 0.002$) were more likely to report inconsistent adherence across the three assessments.¹⁶ These findings illustrate the difficulty of maintaining high levels of adherence and underscore the need to support patients and their caregivers in developing strategies for long-term adherence to ART.

Specific Adherence Issues in Children

Adherence is a complex health behavior that is influenced by drug regimen, patient and family factors, and the patient–provider relationship.^{17,18} Despite improvements over the last several years, the availability of once-daily, single-tablet ARV regimens and palatable formulations for infants and young children are still limited. Furthermore, infants and children are dependent on others for medication administration; adult caregivers may face barriers that undermine adherence in children, including forgetting doses, changes in routine, being too busy, and child refusal.^{19,20} Caregivers also may be inadequately prepared to support their child's adherence. In a study of communication strategies among caretakers of children with PHIV in rural South Africa, many caregivers used coercion and threats of grave consequences of nonadherence as a communication strategy to enforce adherence.²¹ Furthermore, some caregivers may place too much responsibility for managing medications on older children and adolescents before they are developmentally able to undertake such tasks.²²

Adherence also may be jeopardized by social and health issues within a family (e.g., substance use, poor physical or mental health, death of a family member or friend, unstable housing, poverty, violence, involvement with the criminal justice system, limited social support).²³⁻²⁶ Because stressful life events can disrupt adherence,¹³ additional monitoring and adherence supports should be implemented at these times. Furthermore, children with PHIV and adolescents with non-perinatally acquired HIV typically enter care at different developmental stages with potentially different levels of caregiver support, which can affect adherence to ART in different ways. For adolescents transitioning from pediatric to adult care, the transition can be a vulnerable time for adherence. Such factors as changing providers, navigating the health care system as the primary medical decision-maker, and changes in insurance status and prescription access can precipitate interruptions in ART and barriers to optimal adherence. Immigrant children and families—particularly, those who have

recently immigrated—may face social and cultural issues and language barriers, which can affect adherence.

Adherence Assessment and Monitoring

Providers should begin assessing potential barriers to adherence and discussing the importance of adherence at initiation of ART and when changing an ARV regimen. Evaluations should assess psychosocial and behavioral factors that may influence adherence, and interventions to help decrease these barriers should be supported. Providers should ask children and adolescents about their experiences with taking medications, as well as concerns and expectations about treatment, or address these issues with caregivers if the child is too young to engage in the conversation. Prior to treatment, it is important that the child/adolescent and/or caregiver explicitly agree to the treatment plan, which should include strategies to support adherence. It is also important to alert children/adolescents and caregivers to potential adverse effects (AEs) of ARV drugs (e.g., nausea, headaches, abdominal discomfort, sleep disturbances), explain how they can be managed, and emphasize the importance of informing the clinical team if they occur.

A routine adherence assessment should be incorporated into every clinical visit. Adherence is difficult to assess accurately; different methods of assessment have yielded different results, and each approach has limitations.²⁷⁻²⁹ Viral load monitoring is the most useful indicator of adherence and is a routine component of monitoring individuals who are on ART (see [Plasma HIV-1 RNA \[Viral Load\]](#) and [CD4 Count Monitoring](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)). It also can be used as positive reinforcement to encourage continued adherence.³⁰ With the introduction of long-acting injectable ART, adherence is related to receiving scheduled injections on time. Therefore, barriers to long-acting injectable ART adherence have shifted from home management to retention barriers. Optimizing adherence requires assessment of such factors as transportation, appointment scheduling, and school or work absences. In addition to viral load monitoring, providers should use at least one other method to assess adherence, such as self-report of missed doses.²⁸ [Table 15](#) below includes common approaches to monitoring medication adherence. When assessing adherence, a nonjudgmental approach and positive rather than negative feedback can be more successful in encouraging accurate reporting related to ART adherence.³¹

Strategies to Improve and Support Adherence

When concerns about adherence emerge, the child/adolescent and/or caregiver should be seen and/or contacted frequently to assess adherence. Strategies to improve and support adherence should be individualized to the child/adolescent and/or caregivers based on the barriers identified, developmental stage, and unique circumstances. Strategies should include simplifying the ARV drug regimen, developing treatment plans that integrate medication administration into daily routines (e.g., associating medication administration with daily activities, such as brushing teeth), optimizing the use of social and community support services, and addressing barriers to attending long-acting injectable ART administration appointments, if applicable. Multifaceted approaches that include regimen-related strategies; educational, behavioral, and supportive strategies focused on children and families; and strategies that focus on health care providers may be more effective than one specific intervention. [Table 16](#) below summarizes some of the strategies that can be used to support and improve adherence to ARV medications. The Centers for Disease Control and Prevention (CDC) offer the evidence-based [Partnership for Health—Medication Adherence](#) to HIV care providers.³²

Regimen-Related Strategies

Oral ARV regimens should be simplified with respect to the number of daily doses and number of pills or volume of liquid prescribed. Efforts should be made to prescribe once-daily ARV regimens and single-tablet regimens whenever feasible (see [Table 18 in Management of Children Receiving Antiretroviral Therapy](#)). Several studies in adults have demonstrated better adherence with once-daily ARV regimens than with twice-daily regimens, as well as with single-tablet formulations than with multiple-tablet regimens.³³⁻³⁷ See [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#) for information about using fixed-dose combination tablets in children.

Long-acting injectable cabotegravir (CAB) and rilpivirine (RPV) is an additional formulation option for adolescents ≥ 12 years of age and who weigh at least 35 kg and who have sustained viral suppression but struggle with daily adherence (see the [Cabotegravir](#) and [Rilpivirine](#) sections for eligibility criteria). This formulation is not currently U.S. Food and Drug Administration approved for use in people who have not achieved sustained viral suppression. Using long-acting injectable CAB and RPV in people who are not virally suppressed and are nonadherent is currently being studied in adults in the Long-Acting Therapy to Improve Treatment Success in Daily LiFE ([LATITUDE](#)) trial.³⁸ A program in San Francisco demonstrated promising findings: adults with such barriers to ART adherence as housing instability, mental illness, and substance use who were treated with long-acting injectable CAB and RPV despite not achieving viral suppression prior to initiation of therapy were able to attend injection appointments and achieve viral suppression with appropriate support and outreach.³⁹

Drugs in the regimen should be chosen to minimize drug interactions and AEs (see [Management of Medication Toxicity or Intolerance](#)).⁴⁰ If drug-specific toxicities are thought to be contributing to nonadherence, efforts should be made to alleviate the AEs by changing the particular drug (or, if necessary, the drug regimen) when feasible. When nonadherence is related to the poor palatability of a liquid formulation or crushed pills, the offending taste can sometimes be masked with a small amount of flavoring syrup or food if simultaneous administration of food is not contraindicated (see [Appendix A. Pediatric Antiretroviral Drug Information](#)).⁴¹ Unfortunately, the taste of lopinavir/ritonavir cannot be masked with flavoring syrup. A small study of children and youth aged 4 years to 21 years found that training children to swallow pills was associated with improved adherence at 6 months post-training.⁴² In poorly adherent children who are at risk of disease progression and who have severe and persistent aversion to taking medications, the use of a gastrostomy tube may be considered.⁴³

Family-Related Adherence Strategies

Education is an essential component of establishing good medication adherence. Educating families about adherence should begin before initiating or changing ARV medications and should include a discussion of the goals of therapy, the importance of optimizing adherence, and the specific plans for supporting and maintaining a child's medication adherence. Caregiver adherence education strategies should include written and visual materials; a daily schedule illustrating times and doses of medications; and demonstration of the use of syringes, medication cups, and pill boxes. Additionally, it may be helpful to assess the medication adherence of the caregiver or other household members who currently take ARV drugs or other chronic medications. Several behavioral tools can be used to integrate taking medications into a child's daily routine. The use of behavior modification

techniques, especially the application of positive reinforcements and the use of small incentives (including financial incentives) for taking medications, can be effective tools to promote adherence.⁴⁴

Because psychological issues and mental health disorders (e.g., depression, substance use) can affect ART adherence, recognition and treatment of these conditions is an essential part of preventing and treating nonadherence.^{45,46} The ability to talk with children about their medications is also important. If the child has not been informed of their HIV status, HIV disclosure should be discussed with the caregivers. In a systematic review of adolescents living in sub-Saharan Africa, 12 studies with 4,422 participants found that knowledge of HIV status was associated with adherence to ART (odds ratio [OR] 1.88; 95% confidence interval [CI], 1.21–2.94; $P = <0.001$).⁴⁷ In interviews with caregivers of children with HIV in South Africa, investigators found that caregivers who had disclosed to their child that they (i.e., the child) had HIV were truthful in their communications and named the disease as HIV, but communication about HIV was infrequent and focused on pill taking. By comparison, those who had not disclosed used deception, deflection, and coercion in response to health-related questions and to enforce adherence.²¹ The decision to disclose HIV status should not necessarily be expected to improve adherence but should be based on a comprehensive assessment of psychosocial and developmental factors and the needs of the child and family.

The growing use of telemedicine visits, which allow remote and often face-to-face interaction, provides new opportunities to support families and visualize ART handling/swallowing, as well as to conduct directly observed therapy (DOT) in the home setting. The evidence is mixed as to the efficacy of programs that are designed to improve adherence through DOT, but DOT may still be a useful strategy for some people.^{48–50} Among 50 adolescents on atazanavir-based second-line therapy participating in a study of modified directly administered ART (mDAART), mDAART was significantly associated with reduced risk of nonadherence (relative risk [RR] 0.1; 95% CI, 0.02–0.8; $P = 0.023$) but a nonsignificant increase in virological suppression to <1,000 copies/mL ($P = 0.105$) among those randomized to the intervention arm compared to the standard of care arm.⁵¹ A recent randomized controlled trial (RCT) of a 12-week multicomponent intervention—including remote coaching, electronic dose monitoring, and tailored outreach (Triggered Escalating Real-Time Adherence)—for viremic youth in the United States demonstrated improved adherence but not viral suppression compared with the standard of care.²⁵

Other strategies to support adherence include using mobile applications (apps) that remind people to take medications; setting cell phone alarms to go off at medication times; sending text-message reminders; conducting motivational interviews; providing pill boxes, blister packaging, and other adherence support tools; and delivering medications to the home. An analysis using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)—Adolescent model of HIV disease and treatment modeled the impact of a 12-month hypothetical adherence intervention (based on an interactive smartphone-based reminder system) among youth with HIV in the United States. Compared with the standard of care, the analysis showed that youth-targeted adherence interventions, even with modest efficacy to improve virologic suppression, could improve life expectancy, prevent onward HIV transmissions, and be cost effective.⁵²

However, several systematic reviews evaluating the use of mobile phone technologies to improve ART adherence (mHealth) have been published and results continue to be inconclusive on the effectiveness of digital interventions to improve adherence in adolescents. A recent systematic review of digital interventions to improve adherence in youth with HIV who live in sub-Saharan Africa provided mixed evidence, with two of six trials finding significant improvement in viral suppression and the remaining four trials showing no significant improvement in adherence-related measures.⁵³ In another review, the authors found what they described as “ambiguous results with high variability” about the effectiveness of mHealth interventions to improve adherence in low- and

middle-income countries.⁵⁴ Of 17 studies, 56% reported a statistically significant positive impact of mHealth on adherence; 44% reported insignificant results. Another systematic review reported that the efficacy of mobile short message service (SMS) interventions varied depending on the specific SMS intervention tested.⁵⁵

Lowenthal et al. examined the association between medication-specific reactance—an aversive response to perceived threats against personal agency—and treatment failure in a cohort of adolescents with HIV in Botswana. Reactant individuals may hear health messaging as a threat to their perceived freedom and respond by engaging in the opposed behavior. Adolescents, scoring >4 on a 5-point scale had 2.05-fold (95% CI, 1.23–3.41) greater odds of treatment failure than non-reactant youth ($P = 0.043$). Psychological reactance needs further study and may provide some insight into adherence behaviors among youth; it also may be important to consider in adherence counseling and in designing interventions.⁵⁶

Two studies provided evidence of the efficacy of peer-based interventions to improve ART adherence and viral suppression among adolescents and young people with HIV in Africa. In Project YES! in Ndola, Zambia, 273 youth aged 15 to 24 years receiving HIV care in four health facilities, including a pediatric clinic, were randomly assigned to monthly meetings with youth peer mentors. At 6 months, viral suppression improved in both study arms, but among participants in care at the pediatric clinic, the rate of viral suppression increased from 37.5% to 70.5% in the intervention arm versus 60.3% to 59.4% in the comparison arm (interaction term OR, 4.66; 95% CI, 1.84–11.78).⁵⁷ Another RCT tested the efficacy of a peer-led differentiated service delivery intervention on HIV clinical outcomes among adolescents with HIV aged 13 to 19 years in rural Zimbabwe. Sixteen clinics were randomized to standard of care or the enhanced intervention in which adolescents were assigned a community adolescent treatment supporter; attended monthly support group; and received text messages, calls, home visits, and clinic-based counseling. Overall, 212 adolescents were recruited at intervention sites and 284 at control sites, with a median age of 15 years. At 96 weeks, among 479 adolescents with data, 52 (25%) adolescents in the intervention arm versus 97 (36%) in the control arm had viral load >1,000 copies/mL or had died (adjusted prevalence ratio 0.58; 95% CI, 0.36–0.94; $P = 0.03$). The study reported 28 deaths (17 in the intervention arm, 11 in the control arm) and 57 hospital admissions (20 in the intervention arm, 37 in the control arm). These studies demonstrate that peer-based interventions have the potential to improve adherence and health outcomes among youth with HIV.⁵⁸

In addition to clinic- and community-based programs, camp experiences can offer a source of peer support for children and youth with HIV and other chronic illnesses. Although data are limited,^{59–61} many children and youth with HIV report attendance to camp programs to be empowering and helpful to learn about adherence to daily ART.

Further evidence of the efficacy of peer-support interventions for people with HIV comes from a recent systematic review and meta-analysis, including 20 RCTs comprising 7,605 participants from nine countries. The authors found superior retention in care (RR 1.07; 95% CI, 1.02–1.12 at 12 months follow-up) and better ART adherence (RR 1.06; 95% CI, 1.01–1.10 at 3 months follow-up) but no statistically significant difference in viral suppression (RR 1.02; 95% CI, 0.94–1.11 at 6 months follow-up) among peer-support participants.⁶²

Health Care Provider–Related Strategies

To improve and support ART adherence, providers should maintain a nonjudgmental attitude, establish trust with patients and caregivers, and identify mutually acceptable goals for care. Providers can improve adherence through their relationships with patients and families, starting at the first visit

together when they obtain explicit agreement on the medication and treatment plan, as well as strategies to support adherence. Fostering a trusting relationship and engaging in open communication are particularly important. Focus groups and semi-structured interviews were conducted with adolescents and their caregivers participating in a longitudinal adherence study. Participants who self-reported high adherence but for whom electronically monitored data reflected low adherence were selected. Adolescents described hiding and discarding pills and lying about their adherence. Adolescents and parents considered negative feedback for prior poor adherence as motivation for efforts to hide current poor adherence. The authors suggest that positive feedback for truth-telling may help develop family and staff alliances in support of adherence.³¹

Provider characteristics that have been associated with improved adherence in adults include consistency, willingness to give information and ask questions, technical expertise, and commitment to follow-up. Creating an environment in the health care setting that is child-centered and includes caregivers in adherence support also has been shown to improve treatment outcomes. Providing comprehensive multidisciplinary care (e.g., with nurses, case managers, pharmacists, social workers, psychiatric care providers) also may better serve more complex child/adolescent and family needs, including adherence. Provider-initiated education about viral load and counseling targeted at understanding viral load results, the health benefits of undetectable viral load, and the Undetectable = Untransmittable (U=U) concept are other strategies providers can use.

Table 15. Approaches for Monitoring Medication Adherence

| Routine Assessment of Medication Adherence in Clinical Care ^a | Description |
|---|--|
| Monitor viral load. | Viral load monitoring should be done more frequently after initiating or changing medications. ^a |
| Assess a quantitative self-report of missed doses. | Ask the child/adolescent and/or caregiver about the number of missed doses over a defined period (1, 3, or 7 days). |
| Request a description of the medication regimen. | Ask the child/adolescent and/or caregiver about the name, appearance, and number of medications and how often the medications are taken. |
| Assess barriers to medication administration. | Engage the child/adolescent and/or caregiver in a dialogue about potential barriers to adherence and strategies to overcome them. |
| Monitor pharmacy refills. | Approaches include a pharmacy-based or clinic-based assessment of on-time medication refills. |
| Employ telemedicine to monitor and support medication administration. | Telemedicine visits allow remote and often face-to-face contact and provide new opportunities to support families; to visualize ART preparation, handling, and swallowing; and to conduct DOT in the home setting. |
| Conduct announced and unannounced pill counts. | Approaches include asking people to bring medications to the clinic, conducting home visits, or providing referrals to community health nursing. |
| Monitor attendance for ART injection appointments among adolescents on long-acting injectable regimens. | For individuals on long-acting injectable ART, adherence is related to receiving scheduled injections on time. Therefore, reducing barriers to adherence should focus on scheduling convenient appointments, minimizing school and work absences, and ensuring transportation to appointments. |
| Targeted Approaches to Monitoring Adherence in Special Circumstances | Description |
| Implement DOT in person and via telemedicine. | Include a brief period of hospitalization if indicated. |
| Measure drug concentration in plasma or DBS. | Measuring drug concentrations can be considered for particular drugs. |
| Approaches to Monitoring Medication Adherence in Research Settings | Description |
| Measure drug concentrations in hair. | Measuring hair drug concentrations can be considered for particular drugs; it provides a good measure of adherence over time. ^{27,63,64} |
| Use electronic monitoring devices. | Approaches include MEMS caps and Wisepill. |
| Use mobile phone-based technologies. | Approaches include interactive voice response, text messaging, and mobile apps. |

^a See [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#) regarding the frequency of adherence assessment after initiating or changing therapy.

Key: apps = applications; ART = antiretroviral therapy; DBS = dried blood spots; DOT = directly observed therapy; MEMS = Medication Event Monitoring System

Table 16. Strategies to Improve Adherence to Antiretroviral Medications

| Initial Intervention Strategies |
|--|
| <ul style="list-style-type: none">• Establish trust and identify mutually acceptable goals for care.• Obtain explicit agreement on the need for treatment and adherence.• Determine whether the child is aware of their HIV status. Consider talking to the child's caregivers about disclosing this information to the child in a developmentally appropriate way.• Identify psychosocial, behavioral, or structural barriers that may affect adherence and help the child and/or family access resources to help eliminate these barriers.• Identify family, friends, health team members, and others who can support adherence.• Educate the child/adolescent and family about the critical role of adherence in therapy outcome, including the relationship between partial adherence and resistance and the potential impact on future drug regimen choices.• With the child/adolescent and family together, develop a treatment plan that they believe is achievable.• Work with the child/adolescent and family to make specific plans for taking medications as prescribed and for supporting adherence. Assist them in arranging administration during day care, school, and in other settings, when needed. Consider home delivery of medications.• Identify barriers—such as co-pays and insurance access—related to medication access to help prevent interruptions in ART.• Schedule a home visit or telemedicine visit to review medications and determine how they will be administered in the home setting.• In certain circumstances, consider a brief period of hospitalization at the start of therapy for patient education and to assess the tolerability of the chosen medications. |
| Medication Strategies |
| <ul style="list-style-type: none">• Choose the simplest regimen possible; reduce dosing frequency, pill size, and number of pills (see Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class and Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents). Consider long-acting injectable regimens (e.g., long-acting injectable CAB and RPV) for eligible patients.• When choosing a regimen, consider the child/adolescent's routines and potential variations in individual and family activities.• Choose the most palatable medicine possible (pharmacists may be able to add syrups or flavoring agents to improve palatability).• Choose drugs with the fewest AEs; provide anticipatory guidance for managing AEs.• Simplify food requirements for medication administration.• Prescribe drugs carefully to avoid adverse drug–drug interactions.• Assess pill-swallowing capacity and offer pill-swallowing training and aids (e.g., pill-swallowing cup, pill glide). Adjust pill size as needed or check if the pill can be crushed. Consider dispersible formulations if possible. See drug sections in Appendix A: Pediatric Antiretroviral Drug Information for information about available formulations and administration of individual drugs.• Choose ARV regimens with high genetic barriers to resistance, when available, if there are concerns about adherence. |

Table 16. Strategies to Improve Adherence to Antiretroviral Medications

| Follow-Up Intervention Strategies |
|--|
| <ul style="list-style-type: none">• Members of the multidisciplinary team should monitor adherence at each visit. In between visits, adherence can be monitored and supported by telephone, email, text, and other secure applications; confidentiality of any communication approach must be ensured.• Provide ongoing support, encouragement, and understanding of the difficulties associated with maintaining adherence to daily medication regimens.• Provide education and counseling that explain the meaning and significance of viral load results.• Use education aids, including pictures, calendars, and stickers.• Encourage the use of pill boxes, reminders, mobile apps, and alarms.• Provide follow-up clinic visits, telephone calls, text messages, and telemedicine visits to support and assess adherence.• Provide access to support groups, peer groups, summer camp programs, or one-on-one counseling for caregivers and individuals.• Provide referrals and support access to counseling and treatment services for individuals with identified mental health problems, including depression and substance abuse.• Provide pharmacist-based adherence support, such as medication education and counseling, blister packs, refill reminders, automatic refills, and home delivery of medications.• Consider DOT at home, in the clinic, or, in certain circumstances, during a brief period of inpatient hospitalization.• Consider gastrostomy tube use in certain circumstances.• Information on other interventions to consider can be found at the Complete Listing of Medication Adherence Evidence-Based Behavioral Interventions on the CDC's website. |

Key: app = application; AE = adverse effect; ARV = antiretroviral; CAB = cabotegravir; CDC = Centers for Disease Control and Prevention; DOT = directly observed therapy; RPV = rilpivirine

References

1. Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. *AIDS*. 2009;23(9):1035-1046. Available at: <https://pubmed.ncbi.nlm.nih.gov/19381075>.
2. Judd A, Melvin D, Thompson LC, et al. Factors associated with nonadherence to antiretroviral therapy among young people living with perinatally acquired HIV in England. *J Assoc Nurses AIDS Care*. 2020;31(5):574-586. Available at: <https://pubmed.ncbi.nlm.nih.gov/32467489>.
3. Parienti JJ, Fournier AL, Cotte L, et al. Forgiveness of dolutegravir-based triple therapy compared with older antiretroviral regimens: a prospective multicenter cohort of adherence patterns and HIV-RNA replication. *Open Forum Infect Dis*. 2021;8(7):ofab316. Available at: <https://pubmed.ncbi.nlm.nih.gov/34307726>.
4. Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. *J Acquir Immune Defic Syndr*. 2019;82(3):245-251. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31343455>.
5. Viswanathan S, Detels R, Mehta SH, et al. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). *AIDS Behav*. 2015;19(4):601-611. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25342151>.
6. Castillo-Mancilla JR, Brown TT, Erlandson KM, et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. *Clin Infect Dis*. 2016;63(12):1661-1667. Available at: <https://pubmed.ncbi.nlm.nih.gov/27660234>.
7. Castillo-Mancilla JR, Cavassini M, Schneider MP, et al. Association of incomplete adherence to antiretroviral therapy with cardiovascular events and mortality in virologically suppressed persons with HIV: the Swiss HIV Cohort Study. *Open Forum Infect Dis*. 2021;8(2):ofab032. Available at: <https://pubmed.ncbi.nlm.nih.gov/33604408>.
8. Post WS, Haberlen SA, Witt MD, et al. Suboptimal HIV suppression is associated with progression of coronary artery stenosis: the Multicenter AIDS Cohort Study (MACS) longitudinal coronary CT angiography study. *Atherosclerosis*. 2022;353:33-40. Available at: <https://pubmed.ncbi.nlm.nih.gov/35577614>.
9. Castillo-Mancilla JR, Morrow M, Hunt PW, et al. Beyond undetectable: modeling the clinical benefit of improved antiretroviral adherence in persons with human immunodeficiency virus with virologic suppression. *Open Forum Infect Dis*. 2023;10(5):ofad230. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37213424>.
10. MacDonell KK, Jacques-Tiura AJ, Naar S, et al. Predictors of self-reported adherence to antiretroviral medication in a multisite study of ethnic and racial minority HIV-positive youth. *J Pediatr Psychol*. 2016;41(4):419-428. Available at: <https://pubmed.ncbi.nlm.nih.gov/26498724>.
11. Gray ME, Nieburg P, Dillingham R. Pediatric human immunodeficiency virus continuum of care: a concise review of evidence-based practice. *Pediatr Clin North Am*. 2017;64(4):879-891. Available at: <https://pubmed.ncbi.nlm.nih.gov/28734516>.

12. Schlatter AF, Deathe AR, Vreeman RC. The need for pediatric formulations to treat children with HIV. *AIDS Res Treat*. 2016;2016:1654938. Available at: <https://pubmed.ncbi.nlm.nih.gov/27413548>.
13. Kacanek D, Huo Y, Malee K, et al. Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV. *AIDS*. 2019;33(12):1923-1934. Available at: <https://pubmed.ncbi.nlm.nih.gov/31274538>.
14. Kakkar F, Lee T, Hawkes MT, et al. Challenges to achieving and maintaining viral suppression among children living with HIV. *AIDS*. 2020;34(5):687-697. Available at: <https://pubmed.ncbi.nlm.nih.gov/31794519>.
15. Giannattasio A, Albano F, Giacomet V, Guarino A. The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children. *Expert Opin Pharmacother*. 2009;10(17):2773-2778. Available at: <https://pubmed.ncbi.nlm.nih.gov/19929700>.
16. Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence inconsistencies: an assessment of sustained adherence among adolescents in South Africa. *J Int AIDS Soc*. 2021;24(10):e25832. Available at: <https://pubmed.ncbi.nlm.nih.gov/34708912>.
17. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. *Curr HIV/AIDS Rep*. 2009;6(4):194-200. Available at: <https://pubmed.ncbi.nlm.nih.gov/19849962>.
18. Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. *PLoS Med*. 2016;13(11):e1002183. Available at: <https://pubmed.ncbi.nlm.nih.gov/27898679>.
19. Marhefka SL, Koenig LJ, Allison S, et al. Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. *AIDS Patient Care STDS*. 2008;22(8):637-647. Available at: <https://pubmed.ncbi.nlm.nih.gov/18627275>.
20. Skovdal M, Campbell C, Madanhire C, et al. Challenges faced by elderly guardians in sustaining the adherence to antiretroviral therapy in HIV-infected children in Zimbabwe. *AIDS Care*. 2011;23(8):957-964. Available at: <https://pubmed.ncbi.nlm.nih.gov/21400306>.
21. Molokwane M, Madiba S. Truth, deception, and coercion; communication strategies used by caregivers of children with perinatally acquired HIV during the pre-disclosure and post-disclosure period in rural communities in South Africa. *Glob Pediatr Health*. 2021;8:2333794X211022269. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34104705>.
22. Naar-King S, Montepiedra G, Nichols S, et al. Allocation of family responsibility for illness management in pediatric HIV. *J Pediatr Psychol*. 2009;34(2):187-194. Available at: <https://pubmed.ncbi.nlm.nih.gov/18586756>.
23. Cluver LD, Hodes RJ, Toska E, et al. 'HIV is like a tsotsi. ARVs are your guns': associations between HIV-disclosure and adherence to antiretroviral treatment among adolescents in South Africa. *AIDS*. 2015;29 Suppl 1:S57-65. Available at: <https://pubmed.ncbi.nlm.nih.gov/26049539>.

24. Cluver L, Meinck F, Toska E, et al. Multitype violence exposures and adolescent antiretroviral nonadherence in South Africa. *AIDS*. 2018;32(8):975-983. Available at: <https://pubmed.ncbi.nlm.nih.gov/29547438>.
25. Amico KR, Crawford J, Ubong I, et al. Correlates of high HIV viral load and antiretroviral therapy adherence among viremic youth in the United States enrolled in an adherence improvement intervention. *AIDS Patient Care STDS*. 2021;35(5):145-157. Available at: <https://pubmed.ncbi.nlm.nih.gov/33960843>.
26. Haas AD, Technau KG, Pahad S, et al. Mental health, substance use and viral suppression in adolescents receiving ART at a paediatric HIV clinic in South Africa. *J Int AIDS Soc*. 2020;23(12):e25644. Available at: <https://pubmed.ncbi.nlm.nih.gov/33283916>.
27. Pintye J, Bacchetti P, Teeraananchai S, et al. Brief report: lopinavir hair concentrations are the strongest predictor of viremia in HIV-infected Asian children and adolescents on second-line antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2017;76(4):367-371. Available at: <https://pubmed.ncbi.nlm.nih.gov/28825944>.
28. Al-Hassany L, Kloosterboer SM, Dierckx B, Koch BC. Assessing methods of measuring medication adherence in chronically ill children-a narrative review. *Patient Prefer Adherence*. 2019;13:1175-1189. Available at: <https://pubmed.ncbi.nlm.nih.gov/31413546>.
29. Craker L, Tarantino N, Whiteley L, Brown L. Measuring antiretroviral adherence among young people living with HIV: observations from a real-time monitoring device versus self-report. *AIDS Behav*. 2019;23(8):2138-2145. Available at: <https://pubmed.ncbi.nlm.nih.gov/30888573>.
30. Bonner K, Mezochow A, Roberts T, et al. Viral load monitoring as a tool to reinforce adherence: a systematic review. *J Acquir Immune Defic Syndr*. 2013;64(1):74-78. Available at: <https://pubmed.ncbi.nlm.nih.gov/23774877>.
31. Lowenthal ED, Ohrenshall R, Moshashane N, et al. Reasons for discordance between antiretroviral adherence measures in adolescents. *AIDS Care*. 2021:1-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/34424796>.
32. Centers for Disease Control and Prevention. Medication adherence. 2014. Available at: <https://www.cdc.gov/hiv/effective-interventions/treat/pfh-ma/index.html>.
33. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. *Clin Infect Dis*. 2014;58(9):1297-1307. Available at: <https://pubmed.ncbi.nlm.nih.gov/24457345>.
34. Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. *Medicine (Baltimore)*. 2015;94(42):e1677. Available at: <https://pubmed.ncbi.nlm.nih.gov/26496277>.
35. Pantuzza LL, Ceccato M, Silveira MR, et al. Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. *Eur J Clin Pharmacol*. 2017;73(11):1475-1489. Available at: <https://pubmed.ncbi.nlm.nih.gov/28779460>.
36. Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research

Network. *HIV Med.* 2019;20(2):169-174. Available at:
<https://pubmed.ncbi.nlm.nih.gov/30561888>.

37. Altice F, Evuarherhe O, Shina S, et al. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. *Patient Prefer Adherence.* 2019;13:475-490. Available at: <https://pubmed.ncbi.nlm.nih.gov/31040651>.
38. National Institute of Allergy and Infectious Diseases. The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE. 2019. Available at: <https://www.clinicaltrials.gov/study/NCT03635788?id=NCT03635788&rank=1>.
39. M Gandhi, J Salazar, M Hickey, et al. High virologic suppression rates on long-acting ART in a safety-net clinical population. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Seattle, WA. Available at: <https://www.croiconference.org/abstract/high-virologic-suppression-rates-on-long-acting-art-in-a-safety-net-clinic-population>.
40. Pham PA. Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. *AIDS Patient Care STDS.* 2009;23(10):803-807. Available at: <https://pubmed.ncbi.nlm.nih.gov/19795999>.
41. Czyzewski D, Runyan D, Lopez M, et al. Teaching and maintaining pill swallowing in HIV-infected children. *The AIDS Reader.* 2000;10(2):88-94.
42. Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. *Pediatrics.* 2007;119(4):e893-899. Available at: <https://pubmed.ncbi.nlm.nih.gov/17353298>.
43. Shingadia D, Viani RM, Yoge R, et al. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. *Pediatrics.* 2000;105(6):E80. Available at: <https://pubmed.ncbi.nlm.nih.gov/10835093>.
44. Foster C, McDonald S, Frize G, et al. “Payment by results”—financial incentives and motivational interviewing, adherence interventions in young adults with perinatally acquired HIV-1 infection: a pilot program. *AIDS Patient Care STDS.* 2014;28(1):28-32. Available at: <https://pubmed.ncbi.nlm.nih.gov/24428797>.
45. Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. *Ann Behav Med.* 2014;47(3):259-269. Available at: <https://pubmed.ncbi.nlm.nih.gov/24234601>.
46. Bucek A, Leu CS, Benson S, et al. Psychiatric disorders, antiretroviral medication adherence and viremia in a cohort of perinatally HIV-infected adolescents and young adults. *Pediatr Infect Dis J.* 2018;37(7):673-677. Available at: <https://pubmed.ncbi.nlm.nih.gov/29227462>.
47. Mengesha MM, Teshome A, Ajema D, et al. The association between HIV diagnosis disclosure and adherence to anti-retroviral therapy among adolescents living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis. *PLoS One.* 2023;18(5):e0285571. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37167342>.

48. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. *Cochrane Database Syst Rev*. 2011;12(12):CD009513. Available at: <https://pubmed.ncbi.nlm.nih.gov/22161452>.
49. Gaur AH, Belzer M, Britto P, et al. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. *AIDS Res Hum Retroviruses*. 2010;26(9):947-953. Available at: <https://pubmed.ncbi.nlm.nih.gov/20707731>.
50. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. *J Acquir Immune Defic Syndr*. 2010;54(2):167-179. Available at: <https://pubmed.ncbi.nlm.nih.gov/20375848>.
51. Chawana TD, Katzenstein D, Nathoo K, et al. Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic. *J AIDS HIV Res*. 2017;9(1):17-30. Available at: <https://pubmed.ncbi.nlm.nih.gov/31649827>.
52. Neilan AM, Bangs AC, Hudgens M, et al. Modeling adherence interventions among youth with HIV in the United States: clinical and economic projections. *AIDS Behav*. 2021;25(9):2973-2984. Available at: <https://pubmed.ncbi.nlm.nih.gov/33547993>.
53. Griffee K, Martin R, Chory A, Vreeman R. A systematic review of digital interventions to improve ART adherence among youth living with HIV in sub-Saharan Africa. *AIDS Res Treat*. 2022;2022:9886306. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36199816>.
54. Demena BA, Artavia-Mora L, Ouedraogo D, et al. A systematic review of mobile phone interventions (SMS/IVR/calls) to improve adherence and retention to antiretroviral treatment in low-and middle-income countries. *AIDS Patient Care STDS*. 2020;34(2):59-71. Available at: <https://pubmed.ncbi.nlm.nih.gov/32049555>.
55. Amankwaa I, Boateng D, Quansah DY, et al. Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: a systematic review and meta-analysis. *PLoS One*. 2018;13(9):e0204091. Available at: <https://pubmed.ncbi.nlm.nih.gov/30240417>.
56. Lowenthal E, Matesva M, Marukutira T, et al. Psychological reactance is a novel risk factor for adolescent antiretroviral treatment failure. *AIDS Behav*. 2021;25(5):1474-1479. Available at: <https://pubmed.ncbi.nlm.nih.gov/32754779>.
57. Denison JA, Burke VM, Miti S, et al. Correction: Project YES! youth engaging for success: a randomized controlled trial assessing the impact of a clinic-based peer mentoring program on viral suppression, adherence and internalized stigma among HIV-positive youth (15–24 years) in Ndola, Zambia. *PLoS One*. 2020;15(4):e0232488. Available at: <https://pubmed.ncbi.nlm.nih.gov/32324830>.
58. Mavhu W, Willis N, Mufuka J, et al. Effect of a differentiated service delivery model on virological failure in adolescents with HIV in Zimbabwe (Zvandiri): a cluster-randomised controlled trial. *Lancet Glob Health*. 2020;8(2):e264-e275. Available at: <https://pubmed.ncbi.nlm.nih.gov/31924539>.

59. Ness TE, Agrawal V, Guffey D, et al. Impact of using creative arts programming to support HIV treatment in adolescents and young adults in Eswatini. *AIDS Res Ther.* 2021;18(1):100. Available at: <https://pubmed.ncbi.nlm.nih.gov/34930371>.
60. Gillard A, Witt PA, Watts CE. Outcomes and processes at a camp for youth with HIV/AIDS. *Qual Health Res.* 2011;21(11):1508-1526. Available at: <https://pubmed.ncbi.nlm.nih.gov/21709127>.
61. Evangel M, Lut I, Ely A. A longitudinal evaluation of an intensive residential intervention (camp) for 12–16 year olds living with HIV in the UK: evidence of psychological change maintained at six month follow-up. *AIDS Care.* 2019;31(1):85-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/30045639>.
62. Berg RC, Page S, Ogard-Repal A. The effectiveness of peer-support for people living with HIV: a systematic review and meta-analysis. *PLoS One.* 2021;16(6):e0252623. Available at: <https://pubmed.ncbi.nlm.nih.gov/34138897>.
63. Olds PK, Kiwanuka JP, Nansera D, et al. Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. *AIDS Care.* 2015;27(3):327-332. Available at: <https://pubmed.ncbi.nlm.nih.gov/25483955>.
64. Chawana TD, Gandhi M, Nathoo K, et al. Defining a cutoff for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment. *J Acquir Immune Defic Syndr.* 2017;76(1):55-59. Available at: <https://pubmed.ncbi.nlm.nih.gov/28520618>.

Management of Medication Toxicity or Intolerance

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|--|
| <ul style="list-style-type: none">In children with HIV who have severe or life-threatening toxicity (e.g., a hypersensitivity reaction), all antiretroviral (ARV) drugs should be stopped immediately (AIII). Once symptoms of toxicity have resolved, ARV therapy should be resumed with substitution of a different ARV drug or drugs for the offending agent(s) (AI*).When modifying ARV therapy because of toxicity or intolerance to a specific drug in children with virologic suppression, changing one drug in a multidrug regimen is permissible; if possible, an agent with a different toxicity and adverse effect profile should be chosen (AI*).The toxicity and the medication presumed responsible should be documented in the medical record of the patient, and the caregiver and patient should be advised of the drug-related toxicity (AIII).In general, dose reduction is not a recommended option for management of ARV toxicity (AI*). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†] Studies that include children or children/adolescents but not studies limited to postpubertal adolescents

Medication Toxicity or Intolerance

The overall benefits of viral suppression and improved immune function due to effective antiretroviral therapy (ART) far outweigh the risks associated with the adverse effects (AEs) of some antiretroviral (ARV) drugs. AEs have been reported with the use of all ARV drugs, however. Currently recommended ARV regimens are associated with fewer serious and intolerable AEs than regimens used in the past. In the mid-1990s when combination ART was introduced, AEs were among the most common reasons for switching or discontinuing therapy and for medication nonadherence¹⁻³ (see [Adverse Effects of Antiretroviral Agents in the Adult and Adolescent Antiretroviral Guidelines](#)). In recent clinical trials **and real-world observational studies**, however, few ARV-treated patients had treatment-limiting AEs.⁴⁻¹³

The incidence of some longer term complications of ART (e.g., bone or renal toxicity, dyslipidemia, accelerated cardiovascular disease) might be underestimated, because most clinical trials enroll a select group of patients based on highly specific inclusion criteria, and the duration of participant follow-up is relatively short.¹⁴⁻¹⁶ To achieve sustained viral suppression during a child's lifetime, both short- and long-term ART toxicities must be anticipated. The clinician must consider potential AEs and issues with medication palatability when selecting an ARV regimen, as well as the individual child's comorbidities, concomitant medications, and history of drug intolerance or viral resistance.

The AEs caused by ARV drugs can vary from mild, more common symptoms (e.g., gastrointestinal intolerance, fatigue) to infrequent but severe and life-threatening illness. Drug-related toxicity can be acute (i.e., occurring soon after a drug has been administered), subacute (i.e., occurring within 1 or 2 days after administration), or late (i.e., occurring after prolonged drug administration). For a few ARV medications, pharmacogenetic markers associated with the risk of early toxicity have been identified;

however, the only marker that is routinely screened for is HLA-B*5701, a marker for abacavir (ABC) hypersensitivity.¹⁷ For selected children aged <3 years who require treatment with efavirenz (EFV), an additional pharmacogenetic marker, cytochrome P450 2B6 genotype, should be assessed in an attempt to prevent toxicity¹⁷⁻²¹ (see [Efavirenz](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#)). For such agents as Efv, therapeutic ranges for plasma concentrations, as determined by therapeutic drug monitoring (TDM), may indicate the need for dose reduction or modification of ART in patients who experience central nervous system (CNS) AEs.

The most common acute and chronic AEs that are associated with currently recommended ARV drugs or drug classes are presented in Tables 17a–17k, which are listed below. These tables include information on common causative drugs, estimated frequency of occurrence, timing of symptoms, risk factors, potential preventive measures, and suggested clinical management strategies. The tables also include selected references that provide further information about these toxicities in pediatric patients.

- [Table 17a. Central Nervous System Toxicity](#)
- [Table 17b. Dyslipidemia](#)
- [Table 17c. Gastrointestinal Effects](#)
- [Table 17d. Hematologic Effects](#)
- [Table 17e. Hepatic Events](#)
- [Table 17f. Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus](#)
- [Table 17g. Lactic Acidosis](#)
- [Table 17h. Lipodystrophies and Weight Gain](#)
- [Table 17i. Nephrotoxic Effects](#)
- [Table 17j. Osteopenia and Osteoporosis](#)
- [Table 17k. Rash and Hypersensitivity Reactions](#)

Information on toxicities associated with older ARV drugs that are no longer recommended can be found in the [Archived Drugs](#) section and [archived toxicity tables](#).

Management

ART-associated AEs can range from acute and potentially life threatening to chronic and insidious. Serious life-threatening events (e.g., hypersensitivity reaction [HSR] due to ABC, symptomatic hepatotoxicity, severe cutaneous reactions) require the immediate discontinuation of all ARV drugs and re-initiation of an alternative regimen without overlapping toxicity. Toxicities that are not life threatening (e.g., urolithiasis caused by atazanavir, renal tubulopathy caused by tenofovir disoproxil fumarate) usually can be managed by substituting another ARV agent for the presumed causative agent without interrupting ART. Other chronic, non-life-threatening AEs (e.g., dyslipidemia, weight gain) can be addressed either by switching the potentially causative agent for another agent or by managing the AE with additional pharmacological or nonpharmacological interventions, such as lifestyle modification.

Management strategies must be individualized for each child, taking into account the severity of the toxicity, the child's viral suppression status, and the available ARV options. Clinicians should anticipate the appearance of common, self-limited AEs and reassure patients that many AEs will resolve after the first few weeks of ART. For example, when initiating therapy with boosted protease inhibitors (PIs), many patients experience gastrointestinal AEs, such as nausea, vomiting, diarrhea, and abdominal pain.

Instructing patients to take PIs with food may help minimize these AEs. Some patients may require antiemetic and antidiarrheal agents for symptom management. CNS AEs are encountered commonly when initiating therapy with EFV. Symptoms can include dizziness, drowsiness, vivid dreams, or insomnia. Patients should be instructed to take EFV-containing regimens at bedtime and on an empty stomach to help minimize these AEs. Patients should be advised that these AEs usually diminish within 2 to 4 weeks of initiating therapy in most people; however, they may persist for months in some patients and may require a medication change.²² In addition, mild rash can be ameliorated with drugs, such as antihistamines. Addressing AEs is essential, because continued use of an ARV agent that a patient finds intolerable may lead the patient to stop their treatment,²³ risking viral rebound and the development of drug resistance.

In patients who experience intolerable AEs from ART, every attempt should be made to identify the offending agent and replace the drug with another effective agent as soon as possible.^{5,24} For mild-to-moderate toxicities, changing to a drug with a different toxicity profile might be sufficient, and discontinuation of all therapy might not be required. When interrupting a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, many experts will stop the NNRTI for 7 to 14 days before stopping the dual nucleoside analogue reverse transcriptase backbone, because of the long half-life of NNRTI drugs. However, patients who have a severe or life-threatening toxicity (e.g., HSR—see [Table 17k. Rash and Hypersensitivity Reactions](#)) should stop all components of the drug regimen simultaneously, regardless of drug half-life. Once the offending drug or alternative cause for the AE has been determined, planning can begin for—

- Resuming therapy with a new ARV regimen that does not contain the offending drug, *or*
- Resuming therapy with the original regimen if the event is attributable to another cause.

All drugs in the ARV regimen should then be started simultaneously, rather than one at a time, while observing the patient for AEs.

When therapy is changed because of toxicity or intolerance in a patient with virologic suppression, agents with different toxicity and AE profiles should be chosen, when possible.²⁵⁻²⁸ Clinicians should have comprehensive knowledge of the toxicity profile of each agent before selecting a new regimen. In the event of drug intolerance, changing a single drug in a multidrug regimen is permissible only for patients whose viral loads are undetectable.

In general, dose reduction is not a recommended strategy for toxicity management, because inadequate ARV drug levels may lead to decreased virologic efficacy and, for most agents, there is not a clear relationship between drug levels and the AE. Therefore, TDM is rarely recommended; however, it may be considered to assist in the management for a child with mild or moderate toxicity if the toxicity is thought to be the result of a drug concentration exceeding the normal therapeutic range and other ARV options are limited.²⁹⁻³¹ An expert in the management of pediatric HIV should be consulted when considering dose reduction based on the results of TDM. Dose reduction after TDM has been studied most extensively with EFV, because increased CNS toxicity has clearly been associated with higher levels of EFV (see [Efavirenz](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

To summarize, management strategies for drug intolerance include the following:

- Symptomatic treatment of mild-to-moderate transient AEs

- Switching one drug for another drug that is active against a patient's virus (e.g., changing to ABC for zidovudine-related anemia or to a PI or integrase strand transfer inhibitor for EFV-related CNS symptoms) (see [Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy](#))
- Using dose reduction, guided by TDM, after consulting with an expert in pediatric HIV

References

1. Desta Z, Gammal RS, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. *Clin Pharmacol Ther.* 2019;106(4):726-733. Available at: <https://pubmed.ncbi.nlm.nih.gov/31006110>.
2. Szpak R, Lombardi NF, Dias FA, et al. Safety of antiretroviral therapy in the treatment of HIV/AIDS in children: systematic review and meta-analysis. *AIDS Rev.* 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34082441>.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents adults and adolescents with HIV. 2022. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines>.
4. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS.* 2013;27(9):1403-1412. Available at: <https://pubmed.ncbi.nlm.nih.gov/23343913>.
5. Fortuin-de Smidt M, de Waal R, Cohen K, et al. First-line antiretroviral drug discontinuations in children. *PLoS One.* 2017;12(2):e0169762. Available at: <https://pubmed.ncbi.nlm.nih.gov/28192529>.
6. Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. *J Pediatric Infect Dis Soc.* 2015;4(4):e76-83. Available at: <https://pubmed.ncbi.nlm.nih.gov/26582887>.
7. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *Pediatr Infect Dis J.* 2015;34(11):1207-1213. Available at: <https://pubmed.ncbi.nlm.nih.gov/26244832>.
8. Levy ME, Griffith C, Ellenberger N, et al. Outcomes of integrase inhibitor-based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents and young adults with HIV infection. *Pediatr Infect Dis J.* 2020;39(5):421-428. Available at: <https://pubmed.ncbi.nlm.nih.gov/32176183>.
9. Abo YN, Refsum E, Mackie N, et al. Paediatric integrase inhibitor use in a real-life setting: a single-centre cohort experience 2009–2018. *Clin Drug Investig.* 2019;39(6):585-590. Available at: <https://pubmed.ncbi.nlm.nih.gov/30976998>.
10. Ciccullo A, Baldin G, Puttaggio C, et al. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. *Expert Opin Drug Saf.* 2021;20(11):1317-1332. Available at: <https://pubmed.ncbi.nlm.nih.gov/34018892>.
11. Bacha JM, Dlamini S, Anabwani F, et al. Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in Eastern and Southern Africa. *Pediatr Infect Dis J.* 2023;42(7):576-581. Available at: <https://pubmed.ncbi.nlm.nih.gov/36795586>.

12. Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Med.* 2021;385(27):2531-2543. Available at: <https://pubmed.ncbi.nlm.nih.gov/34965338/>.
13. Rolle CP, Castano J, Nguyen V, et al. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting. *Antivir Ther.* 2023;28(2):13596535231163703. Available at: <https://pubmed.ncbi.nlm.nih.gov/36896821/>.
14. Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? *J Virus Erad.* 2018;4(2):72-79. Available at: <https://pubmed.ncbi.nlm.nih.gov/29682298/>.
15. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV.* 2018;5(6):e291-e300. Available at: <https://pubmed.ncbi.nlm.nih.gov/29731407/>.
16. Aurpibul L, Namwongprom S, Sudjaritruk T, Ounjaijean S. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment. *PLoS One.* 2020;15(3):e0230707. Available at: <https://pubmed.ncbi.nlm.nih.gov/32226033/>.
17. Asensi V, Collazos J, Valle-Garay E. Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. *World J Virol.* 2015;4(3):169-177. Available at: <https://pubmed.ncbi.nlm.nih.gov/26279978/>.
18. Sinxadi PZ, Leger PD, McIlheron HM, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. *Br J Clin Pharmacol.* 2015;80(1):146-156. Available at: <https://pubmed.ncbi.nlm.nih.gov/25611810/>.
19. Bolton Moore C, Capparelli EV, Samson P, et al. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3–36 months with HIV infection. *AIDS.* 2017;31(8):1129-1136. Available at: <https://pubmed.ncbi.nlm.nih.gov/28323755/>.
20. Gallien S, Journot V, Loriot MA, et al. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial. *HIV Med.* 2017;18(8):537-545. Available at: <https://pubmed.ncbi.nlm.nih.gov/28145050/>.
21. Soeria-Atmadja S, Osterberg E, Gustafsson LL, et al. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. *PLoS One.* 2017;12(9):e0181316. Available at: <https://pubmed.ncbi.nlm.nih.gov/28886044/>.
22. Wynberg E, Williams E, Tudor-Williams G, et al. Discontinuation of efavirenz in paediatric patients: why do children switch? *Clin Drug Investig.* 2018;38(3):231-238. Available at: <https://pubmed.ncbi.nlm.nih.gov/29181714/>.
23. Ray S, Seth A, Singh S, et al. Short-term adverse drug reactions to antiretroviral therapy in children with HIV: a cohort study. *Indian J Pediatr.* 2023;90(1):9-15. Available at: <https://pubmed.ncbi.nlm.nih.gov/35113365/>.

24. Strehlau R, Shiau S, Arpadi S, et al. Substituting abacavir for stavudine in children who are virally suppressed without lipodystrophy: randomized clinical trial in Johannesburg, South Africa. *J Pediatric Infect Dis Soc.* 2018;7(3):e70-e77. Available at: <https://pubmed.ncbi.nlm.nih.gov/29373687>.
25. Valantin MA, Bittar R, de Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. *J Antimicrob Chemother.* 2010;65(3):556-561. Available at: <https://pubmed.ncbi.nlm.nih.gov/20053692>.
26. Murnane PM, Strehlau R, Shiau S, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term outcomes of a randomized trial. *Clin Infect Dis.* 2017;65(3):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/28419200>.
27. Raffi F, Esser S, Nunnari G, et al. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. *HIV Med.* 2016;17 Suppl 5:3-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/27714978>.
28. Jao J, Yu W, Patel K, et al. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. *HIV Med.* 2018;19(3):175-183. Available at: <https://pubmed.ncbi.nlm.nih.gov/29159965>.
29. Vo TT, Varghese Gupta S. Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection. *Pharmacotherapy.* 2016;36(12):1245-1254. Available at: <https://pubmed.ncbi.nlm.nih.gov/27779789>.
30. Engelbrecht AE, Wiesner L, Norman J, et al. Pediatric antiretroviral therapeutic drug monitoring: a five and a half year experience from a South African tertiary hospital. *J Trop Pediatr.* 2020;66(4):385-394. Available at: <https://pubmed.ncbi.nlm.nih.gov/31754710>.
31. Senneker T, Tseng A. An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. *Curr Opin HIV AIDS.* 2021;16(6):309-320. Available at: <https://pubmed.ncbi.nlm.nih.gov/34475342>.

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|--|---|---|--|--|---|---|
| Global CNS Depression | LPV/r oral solution that contains both ethanol (42.4% v/v) and propylene glycol (15.3% w/v) as excipients | <p>Onset</p> <ul style="list-style-type: none"> • 1–6 days after starting LPV/r <p>Presentation</p> <p><i>Neonates/Premature Infants</i></p> <ul style="list-style-type: none"> • Global CNS depression (e.g., abnormal EEG, altered state of consciousness, somnolence) | Unknown; rare case reports have been published. | <p>Prematurity</p> <p>Low birth weight</p> <p>Aged <14 days (whether birth was premature or term)</p> | <p>Avoid use of LPV/r until a postmenstrual age of 42 weeks and a postnatal age of ≥14 days unless no other alternatives are available. See Lopinavir/Ritonavir.</p> | <p>Discontinue LPV/r; symptoms should resolve in 1–5 days.</p> <p>If needed, reintroducing LPV/r can be considered when the patient is outside the vulnerable period (i.e., a postmenstrual age of 42 weeks and a postnatal age ≥14 days).</p> |
| Neuropsychiatric Symptoms and Other CNS Manifestations | EFV | <p>Onset</p> <ul style="list-style-type: none"> • For many symptoms, onset is 1–2 days after starting EFV. • Many symptoms subside or diminish by 2–4 weeks, but symptoms may persist in a significant proportion of patients. <p>Presentation (May Include One or More of the Following)</p> <p><i>Neuropsychiatric Symptoms</i></p> <ul style="list-style-type: none"> • Abnormal dreams | <p>Variable, depending on age, symptoms, and assessment method</p> <p>Children</p> <ul style="list-style-type: none"> • 24% of patients experienced any EFV-related CNS manifestation in one case series, with 18% of participants requiring drug discontinuation. | <p>Insomnia is associated with elevated EFV trough concentration (≥ 4 mcg/mL).</p> <p>CYP2B6 polymorphisms that decrease EFV metabolism and cause increased EFV serum concentrations (CYP2B6 516 T/T genotype or co-carriage of CYP2B6 516 G/T and 983 T/C variants)</p> | <p>Avoid use of EFV for initial ART in children and adolescents to prevent EFV-associated CNS side effects. See What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV.</p> | <p>If symptoms are excessive or persistent, obtain EFV trough concentration. If EFV trough concentration is >4 mcg/mL and/or symptoms are severe, strongly consider drug substitution if a suitable alternative exists.</p> <p>Alternatively, consider dose reduction with repeat TDM and dose adjustment (with input from an expert pharmacologist).</p> |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|---|--|---|--|------------|
| | | <ul style="list-style-type: none"> • Psychosis • Suicidal ideation or attempted/completed suicide <p><i>Other CNS Manifestations</i></p> <ul style="list-style-type: none"> • Dizziness • Somnolence • Insomnia or poor sleep quality • Impaired concentration • Seizures (including absence seizures) • Cerebellar dysfunction (e.g., tremor, dysmetria, ataxia) <p>Note: CNS side effects (e.g., impaired concentration, abnormal dreams, sleep disturbances) may be more difficult to assess in children.</p> | <ul style="list-style-type: none"> • Five of 45 participants (11%) experienced new-onset seizures in one study of children aged <36 months; two of these participants had alternative causes for seizures. • Cases of cerebellar dysfunction have been reported in children with very high EFV plasma levels. <p>Adults</p> <ul style="list-style-type: none"> • 30% incidence for any CNS manifestations of any severity • 6% incidence for EFV-related, severe CNS manifestations, including suicidality. However, evidence is conflicting about whether EFV use increases the | History of psychiatric illness or use of psychoactive drugs | <p>In situations where EFV treatment may be indicated, consider the following:</p> <ul style="list-style-type: none"> • Administer EFV on an empty stomach, preferably at bedtime. • Prescreen for psychiatric illness; avoid use in the presence of psychiatric illness, including depression or suicidal thoughts. Avoid concomitant use of psychoactive drugs. • Consider using TDM in children with mild or moderate EFV-associated toxicities. | |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|---|-------------------------------------|--|---|
| | | | <p>incidence of suicidality.</p> <ul style="list-style-type: none"> Two case series reported late-onset ataxia with or without encephalopathy associated with high EFV levels. | | | |
| | RPV | <p>Onset</p> <ul style="list-style-type: none"> Most symptoms occur in the first 4–8 weeks of treatment. <p>Presentation</p> <p><i>Neuropsychiatric Symptoms</i></p> <ul style="list-style-type: none"> Depressive disorders Suicidal ideation Abnormal dreams/nightmares <p><i>Other CNS Manifestations</i></p> <ul style="list-style-type: none"> Headache Dizziness Insomnia Somnolence | <p>Children</p> <ul style="list-style-type: none"> Depressive disorders of all severity grades were reported in 19.4% of pediatric patients aged 12–17 years. Severe depressive disorders were reported in 5.6% of patients, including one suicide attempt. Somnolence was reported in 5 of 36 children (14%). | History of neuropsychiatric illness | Monitor carefully for depressive disorders and other CNS symptoms. | Consider drug substitution in cases of severe symptoms. |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|---|---|--|---|
| | | | Adults <ul style="list-style-type: none"> CNS/neuropsychiatric adverse events of all severity grades were reported in 43% of patients at 96 weeks (most were Grade 1). Depressive disorders of all severity grades were reported in 9% of patients; 1% of patients discontinued RPV because of severe depressive disorders. Higher frequency of depression and dizziness reported when coadministered with DTG. | | | |
| | RAL | Onset <ul style="list-style-type: none"> As early as 3–4 days after starting RAL Presentation <ul style="list-style-type: none"> Increased psychomotor activity Headaches | Children <ul style="list-style-type: none"> Increased psychomotor activity was reported in one child. Adults <ul style="list-style-type: none"> Headache | Elevated RAL concentrations Co-treatment with TDF, a PPI, or inhibitors of UGT1A1 Prior history of insomnia or depression | Prescreen for psychiatric symptoms. Monitor carefully for CNS symptoms. Use with caution in the presence of drugs that increase RAL concentration. | Consider drug substitution (RAL or coadministered drug) in cases of severe insomnia or other neuropsychiatric symptoms. |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|---|--|--|--|---|
| | | <ul style="list-style-type: none"> • Insomnia • Depression • Cerebellar dysfunction (e.g., tremor, dysarthria, ataxia) | <ul style="list-style-type: none"> • Insomnia (<5% in adult trials) • Rare case reports of cerebellar dysfunction in adults | | | |
| | DTG | <p>Onset</p> <ul style="list-style-type: none"> • 7–30 days after starting DTG <p>Presentation</p> <p>Neuropsychiatric Symptoms</p> <ul style="list-style-type: none"> • Depression or exacerbation of preexisting depression • Anxiety • Self-harm thoughts, suicidal ideation, or attempted/completed suicide • Drowsiness • Neurocognitive deficits (lower total competence and school performance) <p>Other CNS Manifestations (Generally Mild)</p> <ul style="list-style-type: none"> • Sleep disturbances • Dizziness • Headache | <p>Children</p> <ul style="list-style-type: none"> • In a retrospective cohort analysis, neuropsychiatric events that resulted in discontinuation occurred in 2 of 29 (6.8%) children who initiated DTG. • Significantly higher frequency of self-harm or suicidal thoughts reported in children in the ODYSSEY trial receiving DTG (23%) compared to SOC ARVs (5%). They were transient, self-resolved, and did not lead to treatment changes. | <p>Preexisting depression or other psychiatric illness</p> <p>History of ARV-related neuropsychiatric symptoms</p> <p>Higher frequency of overall neuropsychiatric symptoms reported when DTG is coadministered with ABC, and of depression and dizziness when DTG is coadministered with RPV. However, evidence is conflicting for ABC association.</p> | <p>Use with caution in the presence of psychiatric illness, especially in patients with depression or a history of ARV-related neuropsychiatric symptoms.</p> <p>Consider morning dosing of DTG.</p> | <p>For persistent or severe neuropsychiatric symptoms, consider discontinuing DTG if a suitable alternative exists.</p> <p>For mild symptoms, continue DTG and counsel patient that symptoms likely will resolve with time.</p> |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|--|--|--|--|
| | | | Adults <ul style="list-style-type: none"> 2.7% of the neuropsychiatric AEs reported in a large prospective cohort resulted in treatment discontinuation. Higher frequency of neuropsychiatric symptoms reported with DTG than with other INSTIs. A class effect has been suggested. | | | |
| | BIC | Onset <ul style="list-style-type: none"> 1–63 days after starting BIC (as late as 233 days for schizoaffective disorders) Presentation <p><i>Neuropsychiatric Symptoms</i></p> <ul style="list-style-type: none"> Depression or exacerbation of preexisting depression Suicidal ideation or attempted suicide Schizoaffective disorders Anxiety | Children <ul style="list-style-type: none"> One child (1%) had Grade 2 insomnia and anxiety that led to drug discontinuation in clinical trials. Adults <ul style="list-style-type: none"> Overall, the frequency of neuropsychiatric events in BIC and DTG comparator arms appeared similar in adult clinical trials. | Preexisting depression or other psychiatric conditions History of ARV-related neuropsychiatric symptoms | Use with caution in the presence of psychiatric conditions or in patients with a history of ARV-related neuropsychiatric symptoms. | For persistent or severe neuropsychiatric symptoms, consider discontinuing BIC if a suitable alternative exists. For mild symptoms, continue BIC and counsel patient that symptoms likely will resolve with time. |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|---|--|---|---|---|
| | | <p><i>Other CNS Manifestations (Generally Mild)</i></p> <ul style="list-style-type: none"> • Sleep disturbances • Dizziness • Insomnia | <ul style="list-style-type: none"> • Abnormal dreams, dizziness, and insomnia occurred in 1% to 5% of adults. • Suicidal ideation, suicide attempts, schizoaffective disorders, and depression occurred in <1% of adults. • A recent study reported a 3.3% short-term BIC-related discontinuation rate due to neuropsychiatric AEs after ART switch in a large cohort of adults with HIV in routine clinical practice setting. | | | |
| | CAB | <p>Presentation</p> <p><i>Neuropsychiatric Symptoms (Generally Mild or Moderate, Occasionally Serious)</i></p> <ul style="list-style-type: none"> • Mood disorders, including depression and suicidal ideation or attempt | <p>Children</p> <ul style="list-style-type: none"> • Insomnia was reported in 1 of 8 adolescents in the ongoing MOCHA trial. | <p>Preexisting depression or other psychiatric conditions could be contributing factors, but causal links have not clearly been identified.</p> | <p>Monitor individuals for depressive symptoms or self-injurious thoughts or behavior, especially if prior history of such.</p> | <p>Promptly evaluate severe depressive symptoms, self-injurious behavior, or other CNS symptoms for a possible relationship with CAB, and assess risks and benefits of continued CAB treatment.</p> |

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

| Adverse Effects | Associated ARVs | Onset/ Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|--|---|---------------------------|---|
| | | <ul style="list-style-type: none"> • Anxiety disorders <p><i>Other CNS Manifestations (Generally Mild or Moderate)</i></p> <ul style="list-style-type: none"> • Sleep disorders • Dizziness • Headache • Somnolence | <p>Adults</p> <ul style="list-style-type: none"> • 2–4% pooled incidence was reported in Phase 3 trials for CNS AEs, including sleep disorders, dizziness, and headache. • Less than 2% incidence was reported for depressive disorders, including suicidal ideation, in Phase 3 trials, with comparable incidence in CAB and control groups. | CAB exposure did not differ between study participants with and those without CNS or neuropsychiatric manifestations. | | <p>If CAB is discontinued—</p> <ul style="list-style-type: none"> • Counsel the individual about prolonged residual CAB levels in the blood for 52 weeks or longer, and monitor frequently for symptom resolution. • Ensure that a new suppressive regimen is started within 30 days of last injection. |

Key: ABC = abacavir; AE = adverse event; ARV = antiretroviral; BIC = bictegravir; CAB = cabotegravir; CNS = central nervous system; CYP2B6 = cytochrome P450 2B6; DTG = dolutegravir; EEG = electroencephalogram; EFV = efavirenz; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; MOCHA = More Options for Children and Adolescents; PPI = proton pump inhibitor; RAL = raltegravir; RPV = rilpivirine; SOC = standard of care; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug monitoring; UGT1A = uridine diphosphate-glucuronosyltransferase family 1 member A complex; % v = volume; w = weight

References

1. Allen Reeves A, Fuentes AV, Caballero J, Thomas JE, Mosley II JF, Harrington C. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis. *Sex Transm Infect.* 2021;97(4):261-267. Available at: <https://pubmed.ncbi.nlm.nih.gov/33782144>.
2. Arenas-Pinto A, Grund B, Sharma S, et al. Risk of suicidal behavior with use of efavirenz: results from the strategic timing of antiretroviral treatment trial. *Clin Infect Dis.* 2018;67(3):420-429. Available at: <https://pubmed.ncbi.nlm.nih.gov/29538636>.
3. Apretude (cabotegravir extended-release injectable suspension), for intramuscular use [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf.
4. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s002lbl.pdf.
5. Capetti AF, Di Giambenedetto S, Latini A, et al. Morning dosing for dolutegravir-related insomnia and sleep disorders. *HIV Med.* 2018;19(5):e62-e63. Available at: <https://pubmed.ncbi.nlm.nih.gov/28762661>.
6. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS.* 2013;27(6):939-950. Available at: <https://pubmed.ncbi.nlm.nih.gov/23211772>.
7. Cuzin L, Pugliese P, Katlama C, et al. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. *J Antimicrob Chemother.* 2019;74(3):754-760. Available at: <https://pubmed.ncbi.nlm.nih.gov/30534993>.
8. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. *AIDS.* 2016;30(18):2831-2834. Available at: <https://pubmed.ncbi.nlm.nih.gov/27824625>.
9. Fernandez C, Michie K, et al. Adverse events and discontinuation of dolutegravir-based therapy in naive and experienced HIV patients: tertiary HIV centre experience. Abstract #P212. Presented at: HIV Drug Therapy. 2016. Glasgow, Scotland. Available at: <https://hivglasgow.org/2016-abstracts>.
10. Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. *J Acquir Immune Defic Syndr.* 2017;74(4):423-431. Available at: <https://pubmed.ncbi.nlm.nih.gov/27984559>.

11. Food and Drug Administration. FDA drug safety communication: serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm246002.htm>.
12. FDA application review files, Vocabria and Cabenuva, integrated review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212887Orig1s000,212888Orig1s000IntegratedR.pdf.
13. FDA application review files, Apretude, integrated review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215499Orig1s000IntegratedR.pdf.
14. Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. *J Acquir Immune Defic Syndr.* 2015;69(4):422-429. Available at: <https://pubmed.ncbi.nlm.nih.gov/25850607>.
15. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, Phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760>.
16. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study. *AIDS.* 2004;18(18):2391-2400. Available at: <https://pubmed.ncbi.nlm.nih.gov/15622315>.
17. Hammond CK, Eley B, Ing N, Wilmshurst JM. Neuropsychiatric and neurocognitive manifestations in HIV-infected children treated with efavirenz in South Africa—a retrospective case series. *Front Neurol.* 2019;10:742. Available at: <https://pubmed.ncbi.nlm.nih.gov/31338063>.
18. Hauptfleisch MP, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. *S Afr Med J.* 2015;105(11):897-898. Available at: <https://pubmed.ncbi.nlm.nih.gov/26632310>.
19. Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. *AIDS Rev.* 2019;21(1):4-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/30899113>.
20. Hoffmann C, Schewe K, Fenske S, et al. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. *Antivir Ther.* 2020;25(2):83-90. Available at: <https://pubmed.ncbi.nlm.nih.gov/32235038>.
21. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. *HIV Med.* 2017;18(1):56-63. Available at: <https://pubmed.ncbi.nlm.nih.gov/27860104>.

22. Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting dolutegravir: report of four cases. *AIDS*. 2015;29(13):1723-1725. Available at: <https://pubmed.ncbi.nlm.nih.gov/26372287>.
23. Leutscher PD, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. *Scand J Infect Dis*. 2013;45(8):645-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/23427878>.
24. Lombaard J, Bunupuradah T, et al. Rilpivirine as a treatment for HIV-infected antiretroviral-naïve adolescents: Week 48 safety, efficacy, virology and pharmacokinetics. *Pediatr Infect Dis J*. 2016;35(11):1215-221. <https://pubmed.ncbi.nlm.nih.gov/27294305/>
25. Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. *AIDS*. 2012;26(18):2412-2415. Available at: <https://pubmed.ncbi.nlm.nih.gov/23032413>.
26. Mills A, Garner W, Pozniak A, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, Phase IIIb non-inferiority trial of adults with HIV switching to co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir DF. *Patient*. 2015;8(4):359-371. Available at: <https://pubmed.ncbi.nlm.nih.gov/26045359>.
27. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann Intern Med*. 2014;161(1):1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/24979445>.
28. Mollan KR, Tierney C, Hellwege JN, et al. Race/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants. *J Infect Dis*. 2017;216(5):554-564. Available at: <https://pubmed.ncbi.nlm.nih.gov/28931220>.
29. Munsami L, Schutte CM, de Villiers M, Hiesgen J. Late-onset efavirenz toxicity: a descriptive study from Pretoria, South Africa. *South Afr J HIV Med*. 2023;24(1):1439. Available at: <https://pubmed.ncbi.nlm.nih.gov/36751478>.
30. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at: <https://pubmed.ncbi.nlm.nih.gov/30527329>.
31. Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. *J Int AIDS Soc*. 2014;17:19214. Available at: <https://pubmed.ncbi.nlm.nih.gov/25192857>.

32. Nkhomma ET, Coumbis J, Farr AM, et al. No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. *Medicine (Baltimore)*. 2016;95(3):e2480. Available at: <https://pubmed.ncbi.nlm.nih.gov/26817882>.
33. Perez Valero I, Cabello A, Ryan P, et al. Randomized trial evaluating the neurotoxicity of dolutegravir/abacavir/lamivudine and its reversibility after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: GESIDA 9016. *Open Forum Infect Dis*. 2020;7(12):ofaa482. Available at: <https://pubmed.ncbi.nlm.nih.gov/33335931>.
34. Pinillos F, Dandara C, Swart M, et al. Case report: severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. *BMC Infect Dis*. 2016;16:56. Available at: <https://pubmed.ncbi.nlm.nih.gov/26831894>.
35. Preta LH, Chroboczek T, Treliuyer JM, Chouchana L. Association of depression and suicidal behaviour reporting with HIV integrase inhibitors: a global pharmacovigilance study. *J Antimicrob Chemother*. 2023;78(8):1944-1947. Available at: <https://pubmed.ncbi.nlm.nih.gov/37311223>.
36. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V. Plasma efavirenz concentrations and the association with CYP2B6-516G > T polymorphism in HIV-infected Thai children. *Antivir Ther*. 2009;14(3):315-320. Available at: <https://pubmed.ncbi.nlm.nih.gov/19474465>.
37. Reiss KA, Bailey JR, Pham PA, Gallant JE. Raltegravir-induced cerebellar ataxia. *AIDS*. 2010;24(17):2757. Available at: <https://pubmed.ncbi.nlm.nih.gov/20980871>.
38. Rizzardini G, Overton ET, Okrin C, et al. Long-acting cabotegravir+rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. *J Acquir Immune Defic Syndr*. 2020;85:498-506. Available at: <https://pubmed.ncbi.nlm.nih.gov/33136751>.
39. Rubin LH, O'Halloran JA, Williams DW, et al. Integrase inhibitors are associated with neuropsychiatric symptoms in women with HIV. *J Neuroimmune Pharmacol*. 2022 Feb 17;10:1007/s11481-021-10042-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/35178611>.
40. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403-1412. Available at: <https://pubmed.ncbi.nlm.nih.gov/23343913>.
41. Smith C, Ryom L, Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19512. Available at: <https://pubmed.ncbi.nlm.nih.gov/25394021>.

42. Strehlau R, Martens L, Coovadia A, et al. Absence seizures associated with efavirenz initiation. *Pediatr Infect Dis J*. 2011;30(11):1001-1003. Available at: <https://pubmed.ncbi.nlm.nih.gov/21633320>.
43. Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. *Curr HIV Res*. 2011;9(1):40-53. Available at: <https://pubmed.ncbi.nlm.nih.gov/21198432>.
44. Turkova A, Kekitiinwa A, White E, et al. Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial. Abstract OAB0404. Presented at: 11th IAS Conference on HIV Science 2021. Virtual Conference. Available at: [https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(23\)00164-5/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00164-5/fulltext)
45. Van de Wijer L, McHaile DN, de Mast Q, et al. Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study. *Lancet HIV*. 2019;6(4):e250-e258. Available at: <https://pubmed.ncbi.nlm.nih.gov/30770324>.
46. van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. *PLoS One*. 2013;8(1):e55111. Available at: <https://pubmed.ncbi.nlm.nih.gov/23372824>.
47. Variava E, Sigauke FR, Norman J, et al. Brief report: late efavirenz-induced ataxia and encephalopathy: a case series. *J Acquir Immune Defic Syndr*. 2017;75(5):577-579. Available at: <https://pubmed.ncbi.nlm.nih.gov/28520619>.
48. Vocabria (cabotegravir) tablets,for oral use [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212887s005s006lbl.pdf.
49. Waalewijn H, Turkova A, Rakhmanina N, et al. Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV. *Ther Drug Monit*. 2019;41(4):431-443. Available at: <https://pubmed.ncbi.nlm.nih.gov/31008997>.
50. Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr*. 2015;70(5):515-519. Available at: <https://pubmed.ncbi.nlm.nih.gov/26262777>.
51. Waters L, Fisher M, Winston A, et al. A Phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. *AIDS*. 2011;25(1):65-71. Available at: <https://pubmed.ncbi.nlm.nih.gov/21099666>.

Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia

Updated: April 11, 2022

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|---|--|---|--|--|--|
| Dyslipidemia | PIs <ul style="list-style-type: none"> All PIs, especially RTV-boosted PIs; lower incidence reported with DRV/r and ATV, with or without RTV NRTIs <ul style="list-style-type: none"> Lower incidence reported with TDF than with TAF NNRTIs <ul style="list-style-type: none"> Lower incidence reported with NVP, RPV, and ETR than with EFV INSTIs <ul style="list-style-type: none"> EVG/c | Onset <ul style="list-style-type: none"> As early as 2 weeks to months after beginning therapy Presentation <i>PIs</i> <ul style="list-style-type: none"> ↑ LDL-C, TC, and TG <i>NRTIs</i> <ul style="list-style-type: none"> ↑ LDL-C, TC, and TG. Significant increase in plasma lipid values was observed in adults switching from TDF to TAF, regardless of third agent or presence of a boosting agent. <i>NNRTIs</i> <ul style="list-style-type: none"> ↑ LDL-C, TC, and HDL-C | Reported frequency varies with specific ARV regimen, duration of ART, and the specific laboratory parameters used to diagnose lipid abnormalities. 10% to 20% of young children receiving LPV/r will have lipid abnormalities. 40% to 75% of older children and adolescents with prolonged ART history will have lipid abnormalities. | Advanced-stage HIV disease High-fat, high-cholesterol diet Sedentary lifestyle Obesity Hypertension Smoking Family history of dyslipidemia or premature ASCVD Metabolic syndrome Fat maldistribution | Prevention <ul style="list-style-type: none"> Low-fat diet Exercise Smoking-prevention counseling Use of ARV drugs, such as INSTIs, and to a lesser extent, newer PIs (e.g., ATV, DRV), is associated with a lower prevalence of dyslipidemia. When considering a TDF-based or TAF-based regimen, the lipid-lowering beneficial effect of TDF should be weighed against its potential for increased renal and bone toxicities. | Assess all patients for additional ASCVD risk factors. Patients with HIV are considered to be at moderate risk for ASCVD. ^b ARV regimen changes should be considered, especially when the patient is receiving older PIs (e.g., LPV/r) and/or RTV boosting. Switching to a PI-sparing regimen, a PI-based regimen with a more favorable lipid profile, or COBI boosting causes a decline in LDL-C or TG values. The lipid-lowering effect of an ARV regimen switch on LDL-C is less pronounced than with statin therapy but may be enough to re-establish a healthy lipid profile. Refer patients to a lipid specialist early if LDL-C is ≥250 mg/dL or TG is ≥500 mg/dL. |

Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia

| | | | | | | |
|--|--|--|---|--|--|--|
| | | | Pooled dyslipidemia prevalence of 39.5% and an incidence of 32% (191 per 1,000 person-years) reported in a recent meta-analysis and a recent review of a large consortium of prospective observational cohorts, respectively. | | Monitoring^a <ul style="list-style-type: none">• Obtain fasting (or non-fasting) lipid profile (TC, HDL-C, non-HDL-C, LDL-C, and TG) twice (>2 weeks but ≤3 months apart) and average these results. Monitor every 6 months (for abnormal results) or every 12 months (for normal results).• If TG or LDL-C is elevated or if a patient has additional risk factors, obtain FLP. <p><i>Children with Lipid Abnormalities and/or Additional Risk Factors</i></p> <ul style="list-style-type: none">• Obtain 12-hour FLP before initiating or changing therapy and every 6 months thereafter (more often if indicated). <p><i>Children Receiving Lipid-Lowering Therapy with Statins or Fibrates</i></p> <ul style="list-style-type: none">• Obtain 12-hour FLP, LFT, and CK at 4 weeks, 8 weeks, and 3 months after starting lipid therapy.• If minimal alterations in AST, ALT, and CK are indicated, monitor every 3–4 months during the first year and every 6 months thereafter (or as clinically indicated). | If LDL-C is ≥130 mg/dL but <250 mg or TG is ≥150 mg/dL but <500 mg/dL, the following staged treatment approach is recommended by the NHLBI guidelines ^b : <ul style="list-style-type: none">• Implement diet, nutrition, and lifestyle management for 6–9 months. Consult with a dietician if one is available.• If a 6- to 9-month trial of lifestyle modification fails and the patient is aged ≥10 years, consider implementing lipid-lowering therapy after consulting a lipid specialist.• Statin therapy should be considered for patients with elevated LDL-C levels. NHLBI guidelines provide recommendations for statin therapy in patients with specific LDL-C levels and risk factors.^b Concurrent substitution—preferably to ARV drugs with no inhibitory or inducing effect on CYP3A4 or OATP1B1 (e.g., INSTI)—also should be considered as appropriate to limit drug–drug interaction potential.• Drug therapy can be considered in cases of severe hypertriglyceridemia (TG ≥500 mg/dL). Fibrates (gemfibrozil and fenofibrate) may be used. |
|--|--|--|---|--|--|--|

Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia

| | | | | | | |
|--|--|--|--|--|---|---|
| | | | | | <ul style="list-style-type: none">• Repeat FLP 4 weeks after increasing doses of antihyperlipidemic agents. | The long-term risks of lipid abnormalities in children who are receiving ART are unclear. However, persistent dyslipidemia in children may lead to premature ASCVD. |
|--|--|--|--|--|---|---|

^a Because of the burden of collecting fasting blood samples, some practitioners routinely measure cholesterol and TG from nonfasting blood samples and follow up abnormal values with a test done in the fasted state.

^b Refer to the NHLBI guidelines: [Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents](#).

Key to Symbol:

↑ = increase

Key: ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; ASCVD = atherosclerotic cardiovascular disease; AST = aspartate aminotransferase; ATV = atazanavir; CK = creatine kinase; COBI = cobicistat; CYP3A4 = cytochrome P450 3A4; DRV = darunavir; DRV/r = darunavir/ritonavir; EFV = efavirenz; ETR = etravirine; EVG/c = elvitegravir/cobicistat; FLP = fasting lipid profile; HDL-C = high-density lipoprotein cholesterol; INSTI = integrase strand transfer inhibitor; LDL-C = low-density lipoprotein cholesterol; LFT = liver function test; LPV/r = lopinavir/ritonavir; NHLBI = National Heart, Lung, and Blood Institute; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; OATP1B1 = organic anion transporter polypeptide 1B1; PI = protease inhibitor; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TC = total cholesterol; TDF = tenofovir disoproxil fumarate; TG = triglycerides

References

1. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. *AIDS*. 2009;23(6):661-672. Available at: <https://pubmed.ncbi.nlm.nih.gov/19279441>.
2. Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on lopinavir or nevirapine-based antiretroviral therapy. *Arch Dis Child*. 2013;98(4):258-264. Available at: <https://pubmed.ncbi.nlm.nih.gov/23220209>.
3. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc*. 2013;16:18600. Available at: <https://pubmed.ncbi.nlm.nih.gov/23782481>.
4. Blazquez D, Ramos-Amador JT, Sainz T, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. *BMC Infect Dis*. 2015;15:119. Available at: <https://pubmed.ncbi.nlm.nih.gov/25880777>.
5. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, et al. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. *Pediatr Infect Dis J*. 2015;34(2):e23-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/25068287>.
6. Casado JL, de Los Santos I, Del Palacio M, et al. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART. *HIV Clin Trials*. 2013;14(1):1-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/23372109>.
7. Cid-Silva P, Fernandez-Bargiela N, Margusino-Framinan L, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. *Basic Clin Pharmacol Toxicol*. 2019;124(4):479-490. Available at: <https://pubmed.ncbi.nlm.nih.gov/30388308>.
8. Courlet P, Livio F, Alves Saldanha S, et al. Real-life management of drug-drug interactions between antiretrovirals and statins. *J Antimicrob Chemother*. 2020;75(7):1972-1980. Available at: <https://pubmed.ncbi.nlm.nih.gov/32240298>.
9. Dejkhamron P, Unachak K, Aupribul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. *J Pediatr Endocrinol Metab*. 2014;27(5-6):403-412. Available at: <https://pubmed.ncbi.nlm.nih.gov/24259240>.
10. Echecopar-Sabogal J, D'Angelo-Piaggio L, Chaname-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: a

- systematic review and meta-analysis. *Int J STD AIDS*. 2018;29(5):443-452. Available at: <https://pubmed.ncbi.nlm.nih.gov/28956700>.
11. Echeverria P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. *HIV Med*. 2017;18(10):782-786. Available at: <https://pubmed.ncbi.nlm.nih.gov/28671337>.
 12. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128 Suppl 5(Suppl 5):S213-256. Available at: <https://pubmed.ncbi.nlm.nih.gov/22084329>.
 13. Food and Drug Administration. FDA drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. 2012. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-interactions-between-certain-hiv-or-hepatitis-c-drugs-and-cholesterol>.
 14. Grand M, Bia D, Diaz A. Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis of real-life data. *Curr HIV Res*. 2020;18(1):5-18. Available at: <https://pubmed.ncbi.nlm.nih.gov/31830884>.
 15. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139(25):e1046-e1081. Available at: <https://pubmed.ncbi.nlm.nih.gov/30565953>.
 16. Hazra R, Cohen RA, Gonin R, et al. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. *AIDS*. 2012;26(2):235-240. Available at: <https://pubmed.ncbi.nlm.nih.gov/22008654>.
 17. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected pre-pubertal African children on antiretroviral therapy. *Pediatr Infect Dis J*. 2015;35(1):e1-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/26421804>.
 18. Irira ME, Philemon RN, Mmbaga JY, et al. Dyslipidemia in HIV-infected children and adolescents on antiretroviral therapy receiving care at Kilimanjaro Christian Medical Centre in Tanzania: a cross-sectional study. *Infect Dis (Auckl)*. 2020;13:1178633720948860. Available at: <https://pubmed.ncbi.nlm.nih.gov/32922028>.

19. Jacobson DL, Williams P, Tassiopoulos K, Melvin A, Hazra R, Farley J. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. *J Acquir Immune Defic Syndr.* 2011;57(5):413-420. Available at: <https://pubmed.ncbi.nlm.nih.gov/21602698>.
20. Jao J, Yu W, Patel K, et al. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. *HIV Med.* 2018;19(3):175-183. Available at: <https://pubmed.ncbi.nlm.nih.gov/29159965>.
21. Kauppinen KJ, Kivela P, Sutinen J. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting. *AIDS Patient Care STDS.* 2019;33(12):500-506. Available at: <https://pubmed.ncbi.nlm.nih.gov/31742421>.
22. Lagoutte-Renosi J, Flammang M, Chirouze C, et al. Real-life impact on lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected patients. *Curr HIV Res.* 2021;19(1):84-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/32838719>.
23. Langat A, Benki-Nugent S, Wamalwa D, et al. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age. *Pediatr Infect Dis J.* 2013;32(7):e298-304. Available at: <https://pubmed.ncbi.nlm.nih.gov/23385950>.
24. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. *J Am Coll Cardiol.* 2012;59(11):979-988. Available at: <https://pubmed.ncbi.nlm.nih.gov/22402068>.
25. Lee FJ, Monteiro P, Baker D, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. *HIV Med.* 2016;17(8):605-614. Available at: <https://pubmed.ncbi.nlm.nih.gov/26987376>.
26. Melvin AJ, Montepiedra G, Aaron L, et al. Safety and efficacy of atorvastatin in human immunodeficiency virus-infected children, adolescents and young adults with hyperlipidemia. *Pediatr Infect Dis J.* 2017;36(1):53-60. Available at: <https://pubmed.ncbi.nlm.nih.gov/27749649>.
27. O’Gorman CS, O’Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. *Vasc Health Risk Manag.* 2011;7:1-14. Available at: <https://pubmed.ncbi.nlm.nih.gov/21339908>.

28. Patel K, Lindsey J, Angelidou K, Aldrovandi G, Palumbo P, IMPAACT P1060 Study Team. Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children. *AIDS*. 2018;32(16):2327-2336. Available at: <https://pubmed.ncbi.nlm.nih.gov/30102656>.
29. Ramteke SM, Shiau S, Foca M, et al. Patterns of growth, body composition, and lipid profiles in a South African cohort of human immunodeficiency virus-infected and uninfected children: a cross-sectional study. *J Pediatric Infect Dis Soc*. 2017;7(2):143-150. Available at: <https://pubmed.ncbi.nlm.nih.gov/28481997>.
30. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. *J Acquir Immune Defic Syndr*. 2011;57(5):404-412. Available at: <https://pubmed.ncbi.nlm.nih.gov/21499114>.
31. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet*. 2015;385(9987):2606-2615. Available at: <https://pubmed.ncbi.nlm.nih.gov/25890673>.
32. Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. *Clin Infect Dis*. 2011;52(3):387-395. Available at: <https://pubmed.ncbi.nlm.nih.gov/21189273>.
33. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2012;60(4):369-376. Available at: <https://pubmed.ncbi.nlm.nih.gov/22134152>.
34. Taramasso L, Tatarelli P, Ricci E, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). *BMC Infect Dis*. 2018;18(1):357. Available at: <https://pubmed.ncbi.nlm.nih.gov/30064371>.
35. Tassiopoulos K, Williams PL, Seage GR, 3rd, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. *J Acquir Immune Defic Syndr*. 2008;47(5):607-614. Available at: <https://pubmed.ncbi.nlm.nih.gov/18209684>.
36. Vieira ADS, Silveira G. Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis. *Cien Saude Colet*. 2017;22(8):2659-2669. Available at: <https://pubmed.ncbi.nlm.nih.gov/28793080>.

**Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—
Gastrointestinal Effects**

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|-----------------|---|---|-------------------------------------|--------------|--|--|
| Nausea/Vomiting | All ARV drugs, but most notably RTV-boosted PIs | <p>Onset</p> <ul style="list-style-type: none"> • Early <p>Presentation</p> <ul style="list-style-type: none"> • Nausea and emesis, both of which may be associated with anorexia and/or abdominal pain | Varies by ARV agent; generally <15% | Unknown | <p>Instruct patient to take PIs with food.</p> <p>Monitor for weight loss and ARV adherence.</p> | <p>Reassure the patient that these adverse effects generally improve over time (usually in 6–8 weeks).</p> <p>Consider switching to ARV drugs with smaller tablet sizes (see Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents).</p> <p>Provide supportive care.</p> <p>In extreme or persistent cases, use antiemetics or switch to another ARV regimen.</p> |
| Diarrhea | All ARV drugs, but most notably RTV-boosted PIs | <p>Onset</p> <ul style="list-style-type: none"> • Early <p>Presentation</p> <ul style="list-style-type: none"> • More frequent bowel movements and stools that are generally soft | Varies by ARV agent; generally <15% | Unknown | Monitor for weight loss and dehydration. | <p>In prolonged or severe cases, exclude infectious or noninfectious (e.g., lactose intolerance) causes of diarrhea.</p> |

Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|-----------------|---|---|---------------------|--|--|---|
| | | | | | | <p>Reassure patient that this adverse effect generally improves over time (usually in 6–8 weeks). Consider switching to another ARV regimen in persistent and severe cases.</p> <p>Treatment data in children are lacking; however, the following strategies may be useful when the ARV regimen cannot be changed:</p> <ul style="list-style-type: none">• Modifying the diet• Using bulk-forming agents (e.g., psyllium)• Using antimotility agents (e.g., loperamide)• Using crofelemer, which is approved by the FDA to treat ART-associated diarrhea in adults aged ≥ 18 years; no pediatric data are available. |
| Pancreatitis | Rare, but may occur with NRTIs or RTV-boosted PIs | Onset <ul style="list-style-type: none">• Any time, usually after months of therapy | <2% | Use of concomitant medications that are associated with pancreatitis (e.g., TMP-SMX, pentamidine, ribavirin) | Measure serum amylase and lipase concentrations if persistent abdominal pain develops. | <p>Discontinue offending agent and avoid reintroduction.</p> <p>Manage symptoms of acute episodes.</p> |

Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|-----------------|-----------------|--|---------------------|--|-----------------------|---|
| | | <p>Presentation</p> <ul style="list-style-type: none">Emesis, abdominal pain, and elevated amylase and lipase levels (asymptomatic hyperamylasemia or elevated lipase do not in and of themselves indicate pancreatitis) | | <p>Hypertriglyceridemia</p> <p>Advanced HIV infection</p> <p>Previous episode of pancreatitis</p> <p>Alcohol use</p> | | If pancreatitis is associated with hypertriglyceridemia, consider using interventions to lower TG levels. |

Key: ART = antiretroviral therapy; ARV = antiretroviral; FDA = U.S. Food and Drug Administration; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RTV = ritonavir; TG = triglyceride; TMP-SMX = trimethoprim sulfamethoxazole

References

1. Basile FW, Fedele MC, Lo Vecchio A. Gastrointestinal diseases in children living with HIV. *Microorganisms*. 2021;9(8). Available at: <https://pubmed.ncbi.nlm.nih.gov/34442651>.
2. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1,434 Malawian children. *J Int AIDS Soc*. 2010;13:31. Available at: <https://pubmed.ncbi.nlm.nih.gov/20691049>.
3. Castro JG, Chin-Beckford N. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. *Expert Rev Clin Pharmacol*. 2015;8(6):683-690. Available at: <https://pubmed.ncbi.nlm.nih.gov/26517110>.
4. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. *Infect Dis Ther*. 2014;3(2):103-122. Available at: <https://pubmed.ncbi.nlm.nih.gov/25388760>.
5. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human immunodeficiency virus-associated diarrhea: still an issue in the era of antiretroviral therapy. *Dig Dis Sci*. 2015;60(8):2236-2245. Available at: <https://pubmed.ncbi.nlm.nih.gov/25772777>.
6. Logan C, Beadsworth MB, Beeching NJ. HIV and diarrhoea: what is new? *Curr Opin Infect Dis*. 2016;29(5):486-494. Available at: <https://pubmed.ncbi.nlm.nih.gov/27472290>.
7. Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study. *AIDS Care*. 2010;22(6):677-686. Available at: <https://pubmed.ncbi.nlm.nih.gov/20467943>.
8. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med*. 2009;163(2):164-171. Available at: <https://pubmed.ncbi.nlm.nih.gov/19188649>.
9. Oumar AA, Diallo K, Dembele JP, et al. Adverse drug reactions to antiretroviral therapy: prospective study in children in Sikasso (Mali). *J Pediatr Pharmacol Ther*. 2012;17(4):382-388. Available at: <https://pubmed.ncbi.nlm.nih.gov/23411444>.
10. Szoke D, Ridolfo A, Valente C, Galli M, Panteghini M. Frequency of pancreatic hyperamylasemia in human immunodeficiency virus-positive patients in the highly active antiretroviral therapy era. *Am J Clin Pathol*. 2016;145(1):128-133. Available at: <https://pubmed.ncbi.nlm.nih.gov/26712880>.

11. Tian X, Yao Y, He G, Jia Y, Wang K, Chen L. Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database. *Sci Rep.* 2021;11(1):12438. Available at: <https://pubmed.ncbi.nlm.nih.gov/34127681>.
12. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. *J Acquir Immune Defic Syndr.* 2012;59(3):274-280. Available at: <https://pubmed.ncbi.nlm.nih.gov/22126740>.
13. Wattanutchariya N, Sirisanthana V, Oberdorfer P. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment. *HIV Med.* 2013;14(4):226-232. Available at: <https://pubmed.ncbi.nlm.nih.gov/23094820>.
14. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1,469 HIV-1-infected participants. *J Int Assoc Physicians AIDS Care (Chic).* 2012;11(4):252-259. Available at: <https://pubmed.ncbi.nlm.nih.gov/22544446>.

Table 17d. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hematologic Effects

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|---------------------|-----------------|---|---|---|---|--|
| Anemia ^a | ZDV | <p>Onset</p> <ul style="list-style-type: none"> Variable; weeks to months after starting therapy <p>Presentation</p> <p><i>More Common</i></p> <ul style="list-style-type: none"> Asymptomatic Mild fatigue Pallor Tachypnea <p><i>Rare</i></p> <ul style="list-style-type: none"> Congestive heart failure | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none"> Severe anemia is uncommon but might be coincident with physiologic Hgb nadir. <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none"> Anemia is two to three times more common with ZDV-containing regimens than with all other regimens. | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none"> Premature birth is the most common risk factor. <i>In utero</i> exposure to ZDV-containing regimens Advanced maternal HIV Neonatal blood loss Combination ARV prophylaxis or presumptive HIV therapy, although no particular regimen has been identified as being worse than others. <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none"> Underlying hemoglobinopathy (e.g., sickle cell disease, G6PD deficiency) | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none"> Obtain CBC at birth. Consider repeating CBC at 4 weeks for neonates who are at higher risk (e.g., those born prematurely or who are known to have low birth Hgb) and for neonates who receive ZDV beyond 4 weeks. <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none"> Avoid using ZDV in children with severe anemia when alternative agents are available. Obtain CBC as part of routine care (see Clinical and Laboratory Monitoring of Pediatric HIV Infection). | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none"> Anemia rarely requires intervention unless it is symptomatic or Hgb <7.0 g/dL. ZDV administration can be limited to 4 weeks in low-risk neonates (see Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV). <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none"> Discontinue non-ARV, marrow-toxic drugs, if feasible. Treat coexisting iron deficiency, OIs, and malignancies. For persistent, severe anemia that is thought to be associated with ARV drugs (typically macrocytic |

Table 17d. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hematologic Effects

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|-----------------|-----------------|--|--------------------------|---|--|---|
| | | | | <ul style="list-style-type: none">• Myelosuppressive drugs (e.g., TMP-SMX, rifabutin)• Iron deficiency• Advanced or poorly controlled HIV disease• OIs of the bone marrow• Malnutrition | | anemia), switch to a regimen that does not contain ZDV. |
| Macrocytosis | ZDV | Onset <ul style="list-style-type: none">• Within days or weeks of starting therapy Presentation <ul style="list-style-type: none">• Asymptomatic, but MCV often is >100 fL• Sometimes associated with or may progress to anemia | >90% to 95% for all ages | None | No monitoring required—macrocytosis can be detected if CBC is obtained as part of routine care (see Clinical and Laboratory Monitoring of Pediatric HIV Infection). | No management required. |

Table 17d. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hematologic Effects

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|--------------------------|-----------------|--|--|---|--|---|
| Neutropenia ^a | ZDV | <p>Onset</p> <ul style="list-style-type: none">• Variable <p>Presentation</p> <ul style="list-style-type: none">• Asymptomatic | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none">• Rare <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none">• 2% to 4% of children on ARV drugs• Highest rates occur in children on ZDV-containing regimens | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none">• <i>In utero</i> exposure to ARV drugs• Combination ARV prophylaxis, particularly ZDV plus 3TC and NVP <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none">• Advanced or poorly controlled HIV infection• Myelosuppressive drugs (e.g., TMP-SMX, ganciclovir, hydroxyurea, rifabutin) | <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none">• Obtain CBC as part of routine care. | <p>Newborns Exposed to HIV</p> <ul style="list-style-type: none">• No established threshold for intervention; some experts would consider using an alternative NRTI for prophylaxis if ANC reaches <500 cells/mm³. ZDV administration can be limited to 4 weeks in low-risk neonates (see Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV). <p>Children with HIV Who Are Taking ARV Drugs</p> <ul style="list-style-type: none">• Discontinue non-ARV, marrow-toxic drugs, if feasible.• Treat coexisting OIs and malignancies.• In cases of persistent, severe neutropenia that is thought to be associated with ARV drugs, switch to a regimen that does not contain ZDV. |

^a HIV infection itself, OIs, and medications that are used to prevent OIs (e.g., TMP-SMX) can all contribute to anemia and neutropenia. Prolonged use of NVP with ZDV in three drug regimens for the prevention of perinatal HIV transmission has been associated with increased rates of anemia and neutropenia in some, but not all, studies. The effects are of uncertain clinical significance and appear to be transient.

Key: 3TC = lamivudine; ANC = absolute neutrophil count; ARV = antiretroviral; CBC = complete blood count; fL = femtoliter; G6PD = glucose-6-phosphate dehydrogenase; g/dL = grams per deciliter; Hgb = hemoglobin; MCV = mean cell volume; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; OI = opportunistic infection; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

References

1. Arrow Trial Team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. *Lancet*. 2013;381(9875):1391-1403. Available at: <https://pubmed.ncbi.nlm.nih.gov/23473847>.
2. Bunupuradah T, Kariminia A, Chan KC, et al. Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy. *Int J Infect Dis*. 2013;17(10):e806-e810. Available at: <https://pubmed.ncbi.nlm.nih.gov/23764352>.
3. Dollfus C, Le Chenadec J, Mandelbrot L, et al. Improved hematologic outcomes in HIV1-exposed infants receiving nevirapine compared with zidovudine for postnatal prophylaxis in a high resource setting. *Pediatr Infect Dis J*. 2022;41(5):420-423. Available at: <https://pubmed.ncbi.nlm.nih.gov/35135997>.
4. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. *J Acquir Immune Defic Syndr*. 2011;56(5):428-436. Available at: <https://pubmed.ncbi.nlm.nih.gov/21266910>.
5. Esan MO, Jonker FA, Hensbroek MB, Calis JC, Phiri KS. Iron deficiency in children with HIV-associated anaemia: a systematic review and meta-analysis. *Trans R Soc Trop Med Hyg*. 2012;106(10):579-587. Available at: <https://pubmed.ncbi.nlm.nih.gov/22846115>.
6. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis. *HIV Med*. 2019;20(5):291-307. Available at: <https://pubmed.ncbi.nlm.nih.gov/30844150>.
7. Greiter BM, Kahlert CR, Eberhard N, Sultan-Beyer L, Berger C, Paioni P. Lymphocyte subsets in HIV-exposed uninfected infants: the impact of neonatal postexposure prophylaxis with zidovudine. *Open Forum Infect Dis*. 2020;7(4):ofaa108. Available at: <https://pubmed.ncbi.nlm.nih.gov/32368562>.
8. Illan Ramos M, Soto Sanchez B, Mazariegos Orellana D, et al. Safety and experience with combined antiretroviral prophylaxis in newborn at high-risk of perinatal infection, in a cohort of mother living with HIV-infant pairs. *Pediatr Infect Dis J*. 2021;40(12):1096-1100. Available at: <https://pubmed.ncbi.nlm.nih.gov/34870390>.
9. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. *AIDS Res Ther*. 2015;12:26. Available at: <https://pubmed.ncbi.nlm.nih.gov/26279668>.

10. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. *Pediatr Infect Dis J.* 2010;29(4):376-379. Available at: <https://pubmed.ncbi.nlm.nih.gov/19949355>.
11. Lau E, Brophy J, Samson L, et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. *J Acquir Immune Defic Syndr.* 2017;74(5):493-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/28114187>.
12. Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, renal, hematologic, and inflammatory markers in HIV-infected children on long-term suppressive antiretroviral therapy. *J Pediatric Infect Dis Soc.* 2017;6(3):e109-e115. Available at: <https://pubmed.ncbi.nlm.nih.gov/28903520>.
13. Mocroft A, Lifson AR, Touloumi G, et al. Haemoglobin and anaemia in the SMART study. *Antivir Ther.* 2011;16(3):329-337. Available at: <https://pubmed.ncbi.nlm.nih.gov/21555815>.
14. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis.* 2016;16(2):169-179. Available at: <https://pubmed.ncbi.nlm.nih.gov/26481928>.
15. Nanthatanti N, Charoenphak S, Sungkanuparph S. Progression of non-anemic macrocytosis to anemia in HIV-positive persons receiving zidovudine-containing regimens in resource-limited setting. *Int J STD AIDS.* 2022;33(14):1193-1198. Available at: <https://pubmed.ncbi.nlm.nih.gov/36254724>.
16. Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. *Pediatr Infect Dis J.* 2019;38(7):727-730. Available at: <https://pubmed.ncbi.nlm.nih.gov/31033907>.
17. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med.* 2012;366(25):2368-2379. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
18. Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. *BMC Pediatr.* 2012;12:170. Available at: <https://pubmed.ncbi.nlm.nih.gov/23114115>.
19. Renner LA, Dicko F, Koueta F, et al. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS. *J Int AIDS Soc.* 2013;16(1):18024. Available at: <https://pubmed.ncbi.nlm.nih.gov/24047928>.

20. Shet A, Bhavani PK, Kumarasamy N, et al. Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. *BMC Pediatr.* 2015;15:164. Available at: <https://pubmed.ncbi.nlm.nih.gov/26482352>.
21. Smith C, Forster JE, Levin MJ, et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. *PLoS One.* 2015;10(5):e0127062. Available at: <https://pubmed.ncbi.nlm.nih.gov/26000984>.
22. Smith C, Weinberg A, Forster JE, et al. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir. *Infect Dis Obstet Gynecol.* 2016;2016:9848041. Available at: <https://pubmed.ncbi.nlm.nih.gov/27127401>.
23. Szpak R, Lombardi NF, Dias FA, Borba HHL, Pontarolo R, Wiens A. Safety of antiretroviral therapy in the treatment of HIV/AIDS in children: systematic review and meta-analysis. *AIDS Rev.* 2021;23(4):196-203. Available at: <https://pubmed.ncbi.nlm.nih.gov/34082441>.
24. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. *Eur J Clin Pharmacol.* 2017;73(4):463-468. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350228>.
25. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis.* 2008;198(11):1599-1608. Available at: <https://pubmed.ncbi.nlm.nih.gov/19000014>.

Table 17e. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hepatic Events

Updated: April 11, 2022

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|--|---|---------------------|---|---|--|
| Hepatitis | Most ARV drugs have been associated with hepatitis, but a strong association exists between hepatitis and the use of NVP and EFV. NVP, EFV, ABC, RAL, DTG, and MVC have been associated with hepatitis in the context of HSRs. NRTIs, especially ZDV, have been associated with lactic acidosis and hepatic steatosis. | <p>Onset</p> <ul style="list-style-type: none"> Acute toxic hepatitis occurs most commonly within the first few months of therapy, but it can occur later. Steatosis presents after months or years of therapy. Patients with HBV coinfection can experience a hepatitis flare with the initiation or withdrawal of 3TC, FTC, TDF, or TAF. A flare also can occur with the emergence of resistance to 3TC or FTC (especially if the patient is receiving only one anti-HBV agent). Note that TDF and TAF have high barriers to resistance when used to treat HBV. | Uncommon | HBV or HCV coinfection Underlying liver disease Use of other hepatotoxic medications and supplements (e.g., St. John's wort [<i>Hypericum perforatum</i>], chaparral [<i>Larrea tridentata</i>], germander [<i>Teucrium chamaedrys</i>]) Alcohol use Pregnancy Obesity Higher drug concentrations of PIs For NVP-Associated Hepatic Events in Adults <ul style="list-style-type: none"> Female sex with pre-NVP CD4 count $>250 \text{ cells/mm}^3$ Male sex with pre-NVP CD4 count $>400 \text{ cells/mm}^3$ | <p>Prevention</p> <ul style="list-style-type: none"> Avoid concomitant use of hepatotoxic medications. In patients with elevated levels of hepatic enzymes (>5 times to 10 times ULN) or chronic liver disease, most clinicians would avoid NVP. <p>Monitoring</p> <p><i>For ARV Drugs Other than NVP</i></p> <ul style="list-style-type: none"> Obtain AST and ALT levels at baseline and at least every 3–4 months thereafter^b; monitor at-risk patients more frequently (e.g., those with HBV or HCV coinfection or elevated baseline AST and ALT levels). | Evaluate the patient for other infectious and noninfectious causes of hepatitis and monitor the patient closely. Asymptomatic Hepatitis <ul style="list-style-type: none"> Potentially offending ARV drugs should be discontinued if ALT or AST level is >5 times ULN. Symptomatic Hepatitis <ul style="list-style-type: none"> Discontinue all ARV drugs and other potentially hepatotoxic drugs. If a patient experiences hepatitis that is attributed to NVP, NVP should be discontinued permanently. |

Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|---|---------------------|---|---|--|
| | | <ul style="list-style-type: none">• Hepatitis can be a manifestation of IRIS if it occurs early in therapy, especially in patients with HBV or HCV coinfection. <p>Presentation</p> <ul style="list-style-type: none">• Asymptomatic elevation of AST and ALT levels• Symptomatic hepatitis with nausea, fatigue, and jaundice• Hepatitis may present in the context of HSR with rash, lactic acidosis, and hepatic steatosis. | | <ul style="list-style-type: none">• Population-specific HLA types^a | <i>For NVP</i> <ul style="list-style-type: none">• Obtain AST and ALT levels at baseline, at 2 weeks, 4 weeks, and then every 3 months. | <ul style="list-style-type: none">• Consider viral causes of hepatitis: HAV, HBV, HCV, EBV, and CMV. |

Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------------------|-----------------|--|---|------------------|--|---|
| Indirect Hyperbilirubinemia | ATV | Onset <ul style="list-style-type: none">• Within the first months of therapy Presentation <ul style="list-style-type: none">• Can be asymptomatic or associated with jaundice• Levels of direct bilirubin can be normal or slightly elevated when levels of indirect bilirubin are very high.• Normal AST and ALT | In long-term follow-up, 9% of children who were receiving ATV had at least one total bilirubin level >5 times ULN, and 1.4% of children experienced jaundice. | None established | Monitoring <ul style="list-style-type: none">• No ongoing monitoring is needed.• After an initial rise over the first few months of therapy, unconjugated bilirubin levels generally stabilize; levels can improve over time. | Isolated indirect hyperbilirubinemia is not an indication to stop ATV. Psychological impact of jaundice should be evaluated, and alternative agents should be considered. Jaundice can result in nonadherence, particularly in adolescents; this side effect should be discussed with patients. |

^a For example, HLA-DRB1*0101 in White people, HLA-DRB1*0102 in South African people, and HLA-B35 in Thai people and White people.

^b Less frequent monitoring can be considered in children whose clinical status has been stable for >2 years to 3 years (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

Key: 3TC = lamivudine; ABC = abacavir; ALT = alanine transaminase; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; CD4 = CD4 T lymphocyte; CMV = cytomegalovirus; DTG = dolutegravir; EBV = Epstein-Barr virus; EFV = efavirenz; FTC = emtricitabine; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human leukocyte antigen; HSR = hypersensitivity reaction; IRIS = immune reconstitution inflammatory syndrome; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ULN = upper limit of normal; ZDV = zidovudine

References

1. Anadol E, Lust K, Boesecke C, et al. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. *PLoS One*. 2018;13(1):e0191118. Available at: <https://pubmed.ncbi.nlm.nih.gov/29346443>.
2. Aurpibul L, Bunupuradah T, Sophan S, et al. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. *Pediatr Infect Dis J*. 2015;34(6):e153-158. Available at: <https://pubmed.ncbi.nlm.nih.gov/25970117>.
3. Bienczak A, Denti P, Cook A, et al. Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. *AIDS*. 2017;31(7):905-915. Available at: <https://pubmed.ncbi.nlm.nih.gov/28060017>.
4. Cai J, Osikowicz M, Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients. *AIDS*. 2019;33(8):1267-1282. Available at: <https://pubmed.ncbi.nlm.nih.gov/31008799>.
5. Cotton MF, Liberty A, Torres-Escobar I, et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to <11 years of age: the PRINCE-2 study. *Pediatr Infect Dis J*. 2018;37(6):e149-e156. Available at: <https://pubmed.ncbi.nlm.nih.gov/29206747>.
6. Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. *HIV AIDS (Auckl)*. 2016;8:47-65. Available at: <https://pubmed.ncbi.nlm.nih.gov/27022304>.
7. European P, Paediatric HIVCCSGiE. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. *Antivir Ther*. 2016;21(4):353-358. Available at: <https://pubmed.ncbi.nlm.nih.gov/26561496>.
8. European Paediatric HC-iSGitEP, Paediatric HIVCCiE. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. *AIDS*. 2017;31(1):127-135. Available at: <https://pubmed.ncbi.nlm.nih.gov/27898593>.
9. Gervasoni C, Cattaneo D, Filice C, Galli M, Gruppo Italiano Studio Nimi. Drug-induced liver steatosis in patients with HIV infection. *Pharmacol Res*. 2019;145:104267. Available at: <https://pubmed.ncbi.nlm.nih.gov/31077811>.
10. Gowda C, Newcomb CW, Liu Q, et al. Risk of acute liver injury with antiretroviral therapy by viral hepatitis status. *Open Forum Infect Dis*. 2017;4(2):ofx012. Available at: <https://pubmed.ncbi.nlm.nih.gov/28470014>.

11. Huntington S, Thorne C, Newell ML, et al. Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. *AIDS*. 2015;29(7):801-809. Available at: <https://pubmed.ncbi.nlm.nih.gov/25710412>.
12. Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. *BMJ Open Gastroenterol*. 2017;4(1):e000166. Available at: <https://pubmed.ncbi.nlm.nih.gov/29119002>.
13. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the Data Collection on Adverse Events of Anti-HIV Drugs Study. *Open Forum Infect Dis*. 2016;3(1):ofw009. Available at: <https://pubmed.ncbi.nlm.nih.gov/26925429>.
14. Leger P, Chirwa S, Nwogu JN, et al. Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation. *Pharmacogenet Genomics*. 2018;28(1):1-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/29117017>.
15. Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, renal, hematologic, and inflammatory markers in HIV-infected children on long-term suppressive antiretroviral therapy. *J Pediatric Infect Dis Soc*. 2017;6(3):e109-e115. Available at: <https://pubmed.ncbi.nlm.nih.gov/28903520>.
16. Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High rates of drug-induced liver injury in people living with HIV coinfecting with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial. *Clin Infect Dis*. 2020;70(12):2675-2682. Available at: <https://pubmed.ncbi.nlm.nih.gov/31622456>.
17. Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. *Hepatology*. 2017;65(1):363-373. Available at: <https://pubmed.ncbi.nlm.nih.gov/27677775>.
18. Neukam K, Mira JA, Collado A, et al. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: the HEPAVIR SEG-HEP Cohort. *PLoS One*. 2016;11(2):e0148104. Available at: <https://pubmed.ncbi.nlm.nih.gov/26848975>.
19. Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. *Cells*. 2021;10(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/34065305>.
20. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. *J Acquir Immune Defic Syndr*. 2013;62(2):e55-57. Available at: <https://pubmed.ncbi.nlm.nih.gov/23328091>.

21. Phung BC, Sogni P, Launay O. Hepatitis B and human immunodeficiency virus co-infection. *World J Gastroenterol.* 2014;20(46):17360-17367. Available at: <https://pubmed.ncbi.nlm.nih.gov/25516647>.
22. Pillaye JN, Marakalala MJ, Khumalo N, Spearman W, Ndlovu H. Mechanistic insights into antiretroviral drug-induced liver injury. *Pharmacol Res Perspect.* 2020;8(4):e00598. Available at: <https://pubmed.ncbi.nlm.nih.gov/32643320>.
23. Pokorska-Spiewak M, Stanska-Perka A, Popielska J, et al. Prevalence and predictors of liver disease in HIV-infected children and adolescents. *Sci Rep.* 2017;7(1):12309. Available at: <https://pubmed.ncbi.nlm.nih.gov/28951598>.
24. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group protocol 1020A. *Pediatr Infect Dis J.* 2015;34:162-167. Available at: <https://pubmed.ncbi.nlm.nih.gov/25232777>.
25. Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. *Ther Adv Infect Dis.* 2017;4(1):18-36. Available at: <https://pubmed.ncbi.nlm.nih.gov/28357062>.
26. Sevinsky H, Zaru L, Wang R, et al. Pharmacokinetics and pharmacodynamics of atazanavir in HIV-1-infected children treated with atazanavir powder and ritonavir: combined analysis of the PRINCE-1 and -2 studies. *Pediatr Infect Dis J.* 2018;37(6):e157-e165. Available at: <https://pubmed.ncbi.nlm.nih.gov/29206748>.
27. Sohrab SS, Suhail M, Ali A, Qadri I, Harakeh S, Azhar EI. Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options. *Virusdisease.* 2018;29(1):19-26. Available at: <https://pubmed.ncbi.nlm.nih.gov/29607354>.
28. Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. *AIDS.* 2016;30(9):1483-1485. Available at: <https://pubmed.ncbi.nlm.nih.gov/26959511>.
29. Sonderup MW, Wainwright HC. Human immunodeficiency virus infection, antiretroviral therapy, and liver pathology. *Gastroenterol Clin North Am.* 2017;46(2):327-343. Available at: <https://pubmed.ncbi.nlm.nih.gov/28506368>.
30. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥ 3 months to < 6 years. *J Int AIDS Soc.* 2015;18:19467. Available at: <https://pubmed.ncbi.nlm.nih.gov/26066346>.
31. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. *PLoS One.* 2019;14(12):e0226375. Available at: <https://pubmed.ncbi.nlm.nih.gov/31856189>.

32. Tadesse BT, Foster BA, Kabeta A, et al. Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study. *HIV Med.* 2019;20(2):147-156. Available at: <https://pubmed.ncbi.nlm.nih.gov/30474906>.
33. The European Pregnancy and Paediatric HIV Cohort Collaboration, (EPPICC) Study Group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. *Eur J Clin Pharmacol.* 2017;73(4):463-468. Available at: <https://pubmed.ncbi.nlm.nih.gov/28028587>.
34. The National Institute of Diabetes and Digestive and Kidney Diseases. Clinical and research information on drug-induced liver Injury. 2019. Available at: <https://pubmed.ncbi.nlm.nih.gov/31643176/>
35. Wu PY, Cheng CY, Liu CE, et al. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. *PLoS One.* 2017;12(2):e0171596. Available at: <https://pubmed.ncbi.nlm.nih.gov/28222098>.

Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus

Updated: April 11, 2022

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|--|---|--|---|---|---|---|
| Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus ^a | ZDV, LPV/r, and possibly other PIs and INSTIs | <p>Onset</p> <ul style="list-style-type: none"> Weeks to months after beginning therapy <p>Presentation</p> <ul style="list-style-type: none"> Asymptomatic fasting hyperglycemia (which sometimes occurs in the setting of lipodystrophy), metabolic syndrome, or growth delay Symptomatic DM (rare) | <p>Children</p> <ul style="list-style-type: none"> IR, 6% to 12% (incidence is higher during puberty, 20% to 30%) IFPG, 0% to 7% IGT, 3% to 4% DM, 0.2 per 100 child-years | Risk Factors for Type 2 DM <ul style="list-style-type: none"> Lipodystrophy Metabolic syndrome Family history of DM High BMI (obesity) | <p>Prevention</p> <ul style="list-style-type: none"> Lifestyle modification (e.g., implementing a diet low in saturated fat, cholesterol, trans fat, and refined sugars; increasing physical activity; ceasing smoking). <p>Monitoring</p> <ul style="list-style-type: none"> Monitor for signs of DM, change in body habitus, and acanthosis nigricans. Obtain RPG levels at initiation of ART, 3–6 months after ART initiation, and yearly thereafter. In patients with an RPG ≥ 140 mg/dL, obtain FPG after an 8-hour fast and consider referring the patient to an endocrinologist. <p>For Patients with Either an RPG ≥ 200 mg/dL plus Symptoms of DM or an FPG ≥ 126 mg/dL</p> <ul style="list-style-type: none"> These patients meet diagnostic criteria for DM; consult an endocrinologist. | <p>Counsel patient on lifestyle modification (e.g., implementing a diet low in saturated fat, cholesterol, trans fat, and refined sugars; increasing physical activity; ceasing smoking).</p> <p>Recommend that the patient consult with a dietician.</p> <p>If the patient is receiving ZDV, switch to TAF, TDF, or ABC.</p> |

Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|-------------------------------|---------------------|--------------|------------------------|---|
| | | | | | | <p>For Patients with an FPG of 100–125 mg/dL</p> <ul style="list-style-type: none"> Impaired FPG suggests insulin resistance; consult an endocrinologist. <p>For Patients with an FPG of <100 mg/dL</p> <ul style="list-style-type: none"> This FPG is normal, but a normal FPG does not exclude IR. Recheck FPG in 6–12 months. |

^aIR, asymptomatic hyperglycemia, IFPG, IGT, and DM form a spectrum of increasing severity.

IR: Often defined as elevated insulin levels for the level of glucose observed.

IFPG: Often defined as an FPG of 100–125 mg/dL.

IGT: Often defined as an elevated 2-hour plasma glucose (PG) of 140–199 mg/dL in a 75-g oral glucose tolerance test (OGTT) (or, if the patient weighs <43 kg, 1.75 g per kg of glucose up to a maximum of 75 g).

DM: Often defined as either an FPG ≥126 mg/dL, an RPG ≥200 mg/dL in a patient with hyperglycemia symptoms, a glycosylated hemoglobin (HgbA1c) of ≥6.5%, or a 2-hour PG ≥200 mg/dL in an OGTT.

However, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV does not recommend performing routine measurements of insulin levels, HgbA1c, or glucose tolerance without consulting an endocrinologist. These guidelines are instead based on the readily available RPG and FPG levels. The HgbA1c test may underestimate glycemia in people with HIV; it is not recommended for diagnosis and may present challenges for monitoring.

Key: ABC = abacavir; ART = antiretroviral therapy; ARV = antiretroviral; BMI = body mass index; DM = diabetes mellitus; FPG = fasting plasma glucose; IFPG = impaired fasting plasma glucose; IGT = impaired glucose tolerance; INSTI = integrase strand transfer inhibitor; IR = insulin resistance; LPV/r = lopinavir/ritonavir; mg/dL = milligrams per deciliter; PI = protease inhibitor; RPG = random plasma glucose; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

References

1. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. *AIDS*. 2009;23(6):661-672. Available at: <https://pubmed.ncbi.nlm.nih.gov/19279441>.
2. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. *Diabetes Care*. 2022;45(Suppl 1):S17-S38. Available at: <https://pubmed.ncbi.nlm.nih.gov/34964875>.
3. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. *Pediatrics*. 2008;122(1):e129-138. Available at: <https://pubmed.ncbi.nlm.nih.gov/18519448>.
4. Dirajlal-Fargo S, Musiime V, Cook A, et al. Insulin resistance and markers of inflammation in HIV-infected Ugandan children in the CHAPAS-3 trial. *Pediatr Infect Dis J*. 2017;36(8):761-767. Available at: <https://pubmed.ncbi.nlm.nih.gov/28067719>.
5. Espiau M, Yeste D, Noguera-Julian A, et al. Metabolic syndrome in children and adolescents living with HIV. *Pediatr Infect Dis J*. 2016;35(6):e171-176. Available at: <https://pubmed.ncbi.nlm.nih.gov/26910591>.
6. Fitch KV. Contemporary lifestyle modification interventions to improve metabolic comorbidities in HIV. *Curr HIV/AIDS Rep*. 2019;16(6):482-491. Available at: <https://pubmed.ncbi.nlm.nih.gov/31776973>.
7. Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. *Pediatr Infect Dis J*. 2015;34(5 Suppl 1):S36-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/25629891>.
8. Geffner ME, Patel K, Jacobson DL, et al. Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents. *AIDS*. 2018;32(5):613-622. Available at: <https://pubmed.ncbi.nlm.nih.gov/29280758>.
9. Geffner ME, Patel K, Miller TL, et al. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the Pediatric HIV/AIDS Cohort Study. *Horm Res Paediatr*. 2011;76(6):386-391. Available at: <https://pubmed.ncbi.nlm.nih.gov/22042056>.
10. Gojanovich GS, Jacobson DL, Jao J, et al. Mitochondrial dysfunction and insulin resistance in pubertal youth living with perinatally acquired HIV. *AIDS Res Hum Retroviruses*. 2020;36(9):703-711. Available at: <https://pubmed.ncbi.nlm.nih.gov/32586116>.

11. Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. *Endocrinol Metab Clin North Am.* 2014;43(3):685-696. Available at: <https://pubmed.ncbi.nlm.nih.gov/25169561>.
12. Hazra R, Hance LF, Monteiro JP, et al. Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children. *Pediatr Infect Dis J.* 2013;32(7):757-759. Available at: <https://pubmed.ncbi.nlm.nih.gov/23360832>.
13. Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected pre-pubertal African children on antiretroviral therapy. *Pediatr Infect Dis J.* 2015;35(1):e1-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/26421804>.
14. Loomba-Albrecht LA, Bregman T, Chantry CJ. Endocrinopathies in children infected with human immunodeficiency virus. *Endocrinol Metab Clin North Am.* 2014;43(3):807-828. Available at: <https://pubmed.ncbi.nlm.nih.gov/25169569>.
15. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among U.S. youth and young adults with HIV infection in the era of combination antiretroviral therapy. *Clin Infect Dis.* 2015;61(12):1850-1861. Available at: <https://pubmed.ncbi.nlm.nih.gov/26270680>.
16. Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. *Transl Res.* 2017;183:41-56. Available at: <https://pubmed.ncbi.nlm.nih.gov/28068521>.
17. Paengsai N, Jourdain G, Salvadori N, et al. Recommended first-line antiretroviral therapy regimens and risk of diabetes mellitus in HIV-infected adults in resource-limited settings. *Open Forum Infect Dis.* 2019;6(10):ofz298. Available at: <https://pubmed.ncbi.nlm.nih.gov/31660327>.
18. Paganella MP, Cohen RA, Harris DR, et al. Association of dyslipidemia and glucose abnormalities with antiretroviral treatment in a cohort of HIV-infected Latin American children. *J Acquir Immune Defic Syndr.* 2017;74(1):e1-e8. Available at: <https://pubmed.ncbi.nlm.nih.gov/27570910>.
19. Patel K, Wang J, Jacobson DL, et al. Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. *Circulation.* 2014;129(11):1204-1212. Available at: <https://pubmed.ncbi.nlm.nih.gov/24366631>.

20. Rebeiro PF, Jenkins CA, Bian A, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. *Clin Infect Dis*. 2021;73(7):e2234-e2242. Available at: <https://pubmed.ncbi.nlm.nih.gov/32936919>.
21. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2009;50(5):499-505. Available at: <https://pubmed.ncbi.nlm.nih.gov/19223782>.
22. Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: republication. *Curr Opin HIV AIDS*. 2021;16(2):106-114. Available at: <https://pubmed.ncbi.nlm.nih.gov/33625041>.
23. Summers NA, Lahiri CD, Angert CD, et al. Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. *J Acquir Immune Defic Syndr*. 2020;85(3):355-362. Available at: <https://pubmed.ncbi.nlm.nih.gov/33060420>.
24. Takemoto JK, Miller TL, Wang J, et al. Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration. *AIDS*. 2017;31(1):15-23. Available at: <https://pubmed.ncbi.nlm.nih.gov/27755108>.

Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|-----------------|---|---|---|---|--|---|
| Lactic Acidosis | <p>NRTIs</p> <ul style="list-style-type: none"> • ZDV • Less likely with 3TC, FTC, ABC, TAF, and TDF <p>Other Drugs</p> <ul style="list-style-type: none"> • See the Risk Factors and Prevention/Monitoring columns for information regarding the toxicity of propylene glycol when LPV/r oral solution is used in neonates. | <p>Onset</p> <ul style="list-style-type: none"> • Generally, after years of exposure • A few cases have been reported shortly after initiation in people with underlying liver disease. <p>Presentation</p> <ul style="list-style-type: none"> • Lactic acidosis may be clinically asymptomatic. <p><i>Lactic Acidosis May Also Present with Insidious Onset of a Combination of Signs and Symptoms</i></p> <ul style="list-style-type: none"> • Generalized fatigue, weakness, and myalgias • Vague abdominal pain, weight loss, unexplained nausea, or vomiting • Dyspnea • Peripheral neuropathy <p>Note: Patients may present with acute multiorgan failure (e.g., fulminant hepatic failure, pancreatic failure, respiratory failure).</p> | <p>3TC, FTC, ABC, TAF, and TDF are less likely to induce clinically significant mitochondrial dysfunction than ZDV.</p> | <p>Adults</p> <ul style="list-style-type: none"> • Female sex • High BMI • Chronic HCV infection • African-American race • Coadministration of TDF with metformin • Overdose of propylene glycol • CD4 count <350 cells/mm³ • Acquired riboflavin or thiamine deficiency • Possible pregnancy • Overdose in setting of renal insufficiency (e.g., 3TC) | <p>Prevention</p> <ul style="list-style-type: none"> • Due to the presence of propylene glycol as a diluent, LPV/r oral solution should not be used in preterm neonates or any neonate who has not attained a postmenstrual age of 42 weeks and a postnatal age of ≥ 14 days. • Monitor for clinical manifestations of lactic acidosis and promptly adjust therapy. <p>Monitoring</p> <p><i>Asymptomatic Patients</i></p> <ul style="list-style-type: none"> • Routine measurement of serum lactate is not recommended. | <p>For Patients with Lactate 2.1–5.0 mmol/L (Confirmed with a Second Test)</p> <ul style="list-style-type: none"> • Consider discontinuing all ARV drugs temporarily while conducting additional diagnostic work-up. <p>For Patients with Lactate >5.0 mmol/L (Confirmed with a Second Test)^b or >10.0 mmol/L (Any One Test)</p> <ul style="list-style-type: none"> • Discontinue all ARV drugs. • Provide supportive therapy (e.g., IV fluids; some patients may require sedation and respiratory support to reduce oxygen demand and ensure adequate oxygenation of tissues). <p>Anecdotal (Unproven) Supportive Therapies</p> <ul style="list-style-type: none"> • Administer bicarbonate infusions, THAM, high doses of thiamine and riboflavin, and oral antioxidants (e.g., L-carnitine, co-enzyme Q10, vitamin C). |

Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|-------------------------------|---------------------|---|--|---|
| | | | | <p>Preterm Infants or Any Neonates Who Have Not Attained a Postmenstrual Age of 42 Weeks and a Postnatal Age of ≥ 14 Days</p> <ul style="list-style-type: none">Exposure to propylene glycol, which is used as a diluent in LPV/r oral solution, because these newborns have a diminished ability to metabolize propylene glycol may lead to accumulation, increasing the risk of adverse events. | <p><i>Patients with Clinical Signs or Symptoms Consistent with Lactic Acidosis</i></p> <ul style="list-style-type: none">Obtain blood lactate level.^aAdditional diagnostic evaluations should include serum bicarbonate, anion gap, and/or arterial blood gas; amylase and lipase; serum albumin; and hepatic transaminases. | <p>Following the resolution of clinical and laboratory abnormalities, resume therapy either with an NRTI-sparing regimen or a revised NRTI-containing regimen. Institute a revised NRTI-containing regimen with caution, using NRTIs that are less likely to induce mitochondrial dysfunction (i.e., ABC, TAF, TDF, FTC, or 3TC). Lactate should be monitored monthly for ≥ 3 months.</p> |

^a Blood for lactate determination should be collected, without prolonged tourniquet application or fist clenching, into a pre-chilled, gray-top, fluoride-oxalate–containing tube and transported on ice to the laboratory to be processed within 4 hours of collection.

^b Management can be initiated before receiving the results of the confirmatory test.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BMI = body mass index; CD4 = CD4 T lymphocyte; FTC = emtricitabine; HCV = hepatitis C virus; IV = intravenous; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; THAM = tris (hydroxymethyl) aminomethane; ZDV = zidovudine

References

1. Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. *Pediatr Infect Dis J.* 2015;34(5 Suppl 1):S36-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/25629891>.
2. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. *J Med Toxicol.* 2014;10(1):26-39. Available at: <https://pubmed.ncbi.nlm.nih.gov/23963694>.
3. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. *J Acquir Immune Defic Syndr.* 2012;59(3):274-280. Available at: <https://pubmed.ncbi.nlm.nih.gov/22126740>.
4. Bartlett AW, Mohamed TJ, Sudjaritruk T, et al. Disease- and treatment-related morbidity in adolescents with perinatal HIV infection in Asia. *Pediatr Infect Dis J.* 2019;38(3):287-292. Available at: <https://pubmed.ncbi.nlm.nih.gov/30281549>.
5. Tshamala HK, Aketi L, Tshibassu PM, et al. The lipodystrophy syndrome in HIV-infected children under antiretroviral therapy: a first report from the Central Africa. *Int J Pediatr.* 2019;2019:7013758. Available at: <https://pubmed.ncbi.nlm.nih.gov/30941184>.
6. Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. *Pharmacotherapy.* 2019;39(9):946-963. Available at: <https://pubmed.ncbi.nlm.nih.gov/31361914>.
7. Aperis G, Palouras C, Zervos A, Arvanitis A, Alivanis P. Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. *J Ren Care.* 2011;37(1):25-29. Available at: <https://pubmed.ncbi.nlm.nih.gov/21288314>.
8. Konala VM, Adapa KP, Dinesh KP, et al. Lamivudine-associated lactic acidosis. *Am J Ther.* 2022;29(4):449-451. Available at: <https://pubmed.ncbi.nlm.nih.gov/35622009>.
9. Kaletra (lopinavir/ritonavir) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021251s059,021906s054lbl.pdf.
10. Firnhaber C, Smeaton LM, Grinsztejn B, et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. *HIV Clin Trials.* 2015;16(3):89-99. Available at: <https://pubmed.ncbi.nlm.nih.gov/25979186>.
11. Fortuin-de Smidt M, de Waal R, Cohen K, et al. First-line antiretroviral drug discontinuations in children. *PLoS One.* 2017;12(2):e0169762. Available at: <https://pubmed.ncbi.nlm.nih.gov/28192529>.
12. Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. *J Pediatr Pharmacol Ther.* 2014;19(4):277-282. Available at: <https://pubmed.ncbi.nlm.nih.gov/25762872>.

13. Kirmse B, Hobbs L, Aaron L, et al. Acylcarnitines and genetic variation in fat oxidation genes in HIV-infected, antiretroviral-treated children with and without myopathy. *Pediatr Infect Dis J.* 2022;41(8):e306-e311. Available at: <https://pubmed.ncbi.nlm.nih.gov/35622436>.
14. Mamiafo CT, Moor VJ, Nansseu JR, Pieme CA, Tayou C, Yonkeu JN. Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon. *AIDS Res Ther.* 2014;11(1):2. Available at: <https://pubmed.ncbi.nlm.nih.gov/24428886>.
15. Matthews LT, Giddy J, Ghebremichael M, et al. A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. *PLoS One.* 2011;6(4):e18736. Available at: <https://pubmed.ncbi.nlm.nih.gov/21494566>.
16. Moren C, Noguera-Julian A, Garrabou G, et al. Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. *J Acquir Immune Defic Syndr.* 2012;60(2):111-116. Available at: <https://pubmed.ncbi.nlm.nih.gov/22362155>.
17. Tetteh RA, Nartey ET, Lartey M, et al. Association between the occurrence of adverse drug events and modification of first-line highly active antiretroviral therapy in Ghanaian HIV patients. *Drug Saf.* 2016;39(11):1139-1149. Available at: <https://pubmed.ncbi.nlm.nih.gov/27638659>.
18. Wester CW, Eden SK, Shepherd BE, et al. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. *AIDS Res Hum Retroviruses.* 2012;28(8):759-765. Available at: <https://pubmed.ncbi.nlm.nih.gov/22540188>.
19. Arnoux S, Whitsett M, Papadopoulos Z, et al. Successful treatment of tenofovir alafenamide-induced lactic acidosis: a case report. *J Pharm Pract.* 2022;8971900221105042. Available at: <https://pubmed.ncbi.nlm.nih.gov/35635046>.
20. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc.* 2013;16(1):18600. Available at: <https://pubmed.ncbi.nlm.nih.gov/23782481>.
21. Claessens YE, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. *Crit Care Med.* 2003;31(4):1042-1047. Available at: <https://pubmed.ncbi.nlm.nih.gov/12682470>.
22. Kraut JA, Madias NE. Lactic acidosis. *N Engl J Med.* 2014;371(24):2309-2319. Available at: <https://pubmed.ncbi.nlm.nih.gov/25494270>.
23. Marfo K, Garala M, Kvetan V, Gasperino J. Use of tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report. *J Clin Pharm Ther.* 2009;34(1):119-123. Available at: <https://pubmed.ncbi.nlm.nih.gov/19125910>.
24. Jung B, Martinez M, Claessens YE, et al. Diagnosis and management of metabolic acidosis: guidelines from a French expert panel. *Ann Intensive Care.* 2019;9(1):92. Available at: <https://pubmed.ncbi.nlm.nih.gov/31418093>.

Table 17h. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|---|--|---|---|--|---|--|
| Lipodystrophy (Fat Maldistribution) General Information | See below for specific associations. | Onset <ul style="list-style-type: none">• Increase in trunk and limb fat is the first sign; peripheral fat wasting may not appear for 12–24 months after ART initiation. | Frequency is low (<5%) with current regimens. | <ul style="list-style-type: none">• Genetic predisposition• Puberty• HIV-associated inflammation• Older age• Longer duration of ART• Body habitus | Prevention <ul style="list-style-type: none">• Initiate a calorically appropriate low-fat diet and an exercise regimen. Monitoring <ul style="list-style-type: none">• BMI measurement• Waist circumference and waist-hip ratio | <ul style="list-style-type: none">• Physicians should perform a regimen review and consider changing the regimen when lipodystrophy occurs.• Improvement in fat maldistribution can vary following a regimen change. Improvement may occur after several months or years, or it may not occur at all. |
| Central Lipohypertrophy or Lipo-accumulation | Can occur in the absence of ART, but these conditions most often are associated with the use of PIs and EFV. | Presentation <ul style="list-style-type: none">• Central fat accumulation with increased abdominal girth, which may include a dorsocervical fat pad (buffalo hump). Gynecomastia may occur in males, or breast hypertrophy may occur in females, particularly with the use of EFV. | Frequency is low (<5%) with current regimens. | <ul style="list-style-type: none">• Obesity before initiation of therapy• Sedentary lifestyle | Prevention <ul style="list-style-type: none">• Initiate a calorically appropriate low-fat diet and an exercise regimen. Monitoring <ul style="list-style-type: none">• BMI measurement• Waist circumference and waist-hip ratio measurements | <ul style="list-style-type: none">• Counsel patient on lifestyle modification and dietary interventions (e.g., maintaining a calorically appropriate diet that is low in saturated fats and simple carbohydrates and starting an exercise regimen, especially strength training).• Recommend smoking cessation (if applicable) to decrease future CVD risk. |

Table 17h. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|-------------------------------|---------------------|--------------|------------------------|--|
| | | | | | | <ul style="list-style-type: none"> • Consider using an INSTI instead of a PI or EFV, although some INSTIs may be associated with generalized weight gain (see below). <p>Data Are Insufficient to Allow the Panel to Safely Recommend Use of Any of the Following Modalities in Children</p> <ul style="list-style-type: none"> • Recombinant human growth hormone • Growth hormone–releasing hormone • Metformin • Thiazolidinediones • Recombinant human leptin • Anabolic steroids • Liposuction |

Table 17h. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-------------------------------|--|---|---|--|--|---|
| Facial/Peripheral Lipoatrophy | Most cases are associated with the use of ZDV, a thymidine analogue NRTI. | Presentation <ul style="list-style-type: none"> Thinning of subcutaneous fat in the face, buttocks, and extremities, measured as a decrease in trunk/limb fat by DXA or triceps skinfold thickness. Preservation of lean body mass distinguishes lipoatrophy from HIV-associated wasting. | Frequency is low (<5%) with current regimens. | Underweight before ART initiation | Prevention <ul style="list-style-type: none"> Limit the use of ZDV. Monitoring <ul style="list-style-type: none"> Patient self-report and physical examination are the most sensitive methods of monitoring lipoatrophy. | <ul style="list-style-type: none"> Replace ZDV with another NRTI when possible. <p>Data Are Insufficient to Allow the Panel to Safely Recommend Use of Any of the Following Modalities in Children</p> <ul style="list-style-type: none"> Injections of poly-L-lactic acid Recombinant human leptin Autologous fat transplantation Thiazolidinediones |
| Weight Gain | Significant weight gain may occur with all ARV regimens, but it appears to be more pronounced with INSTIs (DTG, BIC, EVG , RAL) and TAF. | Onset <ul style="list-style-type: none"> Gradual weight gain after initiating ARV drugs is common with all currently used regimens. The mechanism for weight gain is unclear and under investigation. | Rate of development of obesity is unclear. | In Infants and Children <ul style="list-style-type: none"> Limited evaluation has demonstrated weight gain, but such observations have not been consistently attributable to specific ARVs In Adolescents <ul style="list-style-type: none"> Female sex Pre-treatment obesity | Prevention <ul style="list-style-type: none"> Initiate a calorically appropriate low-fat diet and an exercise regimen. Monitoring <ul style="list-style-type: none"> BMI measurement Waist circumference and waist-hip ratio measurements | Counsel patient on lifestyle modifications and dietary interventions (e.g., maintaining a calorically appropriate healthy diet that is low in saturated fats and simple carbohydrates and starting an exercise regimen, especially strength training). <p>Children with HIV and significant weight gain should be managed according to standard AAP recommendations for weight management.</p> |

Table 17h. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|-------------------------------|---------------------|---|------------------------|------------|
| | | | | <p>In Adults</p> <ul style="list-style-type: none"> • Low pre-treatment BMI • Older age • Female sex • Black race • Possible genetic polymorphisms | | |

Key: AAP = American Academy of Pediatrics; ART = antiretroviral therapy; ARV = antiretroviral; BIC = bictegravir; BMI = body mass index; CVD = cardiovascular disease; DTG = dolutegravir; DXA = dual energy X-ray absorptiometry; EFV = efavirenz; EVG = elvitegravir; INSTI = integrase strand transfer inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; TAF = tenofovir alafenamide; ZDV = zidovudine

See the archived version of [Supplement III, February 23, 2009, Pediatric Guidelines](#) on the [Clinicalinfo website](#) for a more complete discussion and reference list.

References

1. Alves Junior CAS, de Lima LRA, de Souza MC, Silva DAS. Anthropometric measures associated with fat mass estimation in children and adolescents with HIV. *Appl Physiol Nutr Metab*. 2019;44(5):493-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/30286302>.
2. Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022;9(9):e638-e648. Available at: <https://pubmed.ncbi.nlm.nih.gov/36055295>.
3. Arbeitman LE, O'Brien RC, Somarriba G, et al. Body mass index and waist circumference of HIV-infected youth in a Miami cohort: comparison to local and national cohorts. *J Pediatr Gastroenterol Nutr*. 2014;59(4):449-454. Available at: <https://pubmed.ncbi.nlm.nih.gov/24709829>.
4. Arrive E, Viard JP, Salanave B, et al. Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. *PLoS One*. 2018;13(11):e0206745. Available at: <https://pubmed.ncbi.nlm.nih.gov/30408056>.
5. Bares SH. Is modern antiretroviral therapy causing weight gain? *Clin Infect Dis*. 2020;71(6):1390-1392. Available at: <https://pubmed.ncbi.nlm.nih.gov/31608360>.
6. Belfrage E, Soeria-Atmadja S, Naver L. Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir. *BMC Pediatr*. 2023;23(1):339. Available at: <https://pubmed.ncbi.nlm.nih.gov/37403042>.
7. Berenguer J, Jarrin I, Bellon JM, et al. Obesity-related single-nucleotide polymorphisms and weight gain following first-line antiretroviral therapy. *Clin Infect Dis*. 2023;76(6):977-985. Available at: <https://pubmed.ncbi.nlm.nih.gov/36345912>.
8. Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. *Open Forum Infect Dis*. 2018;5(11):ofy201. Available at: <https://pubmed.ncbi.nlm.nih.gov/30465010>.
9. Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. *Clin Infect Dis*. 2019;70(7):1267-1274. Available at: <https://pubmed.ncbi.nlm.nih.gov/31100116>.
10. Cohen S, Innes S, Geelen SP, et al. Long-term changes of subcutaneous fat mass in HIV-infected children on antiretroviral therapy: a retrospective analysis of longitudinal data from two pediatric HIV-cohorts. *PLoS One*. 2015;10(7):e0120927. Available at: <https://pubmed.ncbi.nlm.nih.gov/26148119>.

11. de Castro JAC, de Lima LRA, Silva DAS. Accuracy of octa-polar bioelectrical impedance analysis for the assessment of total and appendicular body composition in children and adolescents with HIV: comparison with dual energy X-ray absorptiometry and air displacement plethysmography. *J Hum Nutr Diet.* 2018;31(2):276-285. Available at: <https://pubmed.ncbi.nlm.nih.gov/28799180>.
12. de Medeiros R, da Silva TAL, de Oliveira ALV, et al. Influence of healthy habits counseling on biochemical and metabolic parameters in children and adolescents with HIV: longitudinal study. *Nutrients.* 2021;13(9). Available at: <https://pubmed.ncbi.nlm.nih.gov/34579114>.
13. Dos Reis LC, de Carvalho Rondo PH, de Sousa Marques HH, Jose Segri N. Anthropometry and body composition of vertically HIV-infected children and adolescents under therapy with and without protease inhibitors. *Public Health Nutr.* 2015;18(7):1255-1261. Available at: <https://pubmed.ncbi.nlm.nih.gov/25115797>.
14. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. *J Clin Endocrinol Metab.* 2010;95(9):4291-4304. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554713>.
15. Frange P, Avettand-Fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort. *HIV Med.* 2022;23(9):1019-1024. Available at: <https://pubmed.ncbi.nlm.nih.gov/35306718>.
16. Giacomet V, Lazzarin S, Manzo A, et al. Body fat distribution and metabolic changes in a cohort of adolescents living with HIV switched to an antiretroviral regimen containing dolutegravir. *Pediatr Infect Dis J.* 2021;40(5):457-459. Available at: <https://pubmed.ncbi.nlm.nih.gov/33847293>.
17. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics.* 2023;151(2). Available at: <https://pubmed.ncbi.nlm.nih.gov/36622115>.
18. Innes S, Harvey J, Collins IJ, et al. Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. *PLoS One.* 2018;13(4):e0194132. Available at: <https://pubmed.ncbi.nlm.nih.gov/29617438>.
19. Kenny J, Doerholt K, Gibb DM, et al. Who gets severe gynecomastia among HIV-infected children in the United Kingdom and Ireland? *Pediatr Infect Dis J.* 2017;36(3):307-310. Available at: <https://pubmed.ncbi.nlm.nih.gov/27879556>.
20. Koay WLA, Dirajlal-Fargo S, Levy ME, et al. Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC Cohort. *Open Forum Infect Dis.* 2021;8(7):ofab308. Available at: <https://pubmed.ncbi.nlm.nih.gov/34295943>.

21. Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. *Front Endocrinol (Lausanne)*. 2018;9:705. Available at: <https://pubmed.ncbi.nlm.nih.gov/30542325>.
22. Li J, Yusuf EH, Agwu AL. Excessive weight gain associated with dolutegravir initiation in a 10-year-old female with perinatally acquired human immunodeficiency virus: a case report and review of the literature. *J Pediatric Infect Dis Soc*. 2021;10(3):373-375. Available at: <https://pubmed.ncbi.nlm.nih.gov/32448908>.
23. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. *J Clin Endocrinol Metab*. 2008;93(10):3860-3869. Available at: <https://pubmed.ncbi.nlm.nih.gov/18628529>.
24. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. *JAMA*. 2008;300(5):509-519. Available at: <https://pubmed.ncbi.nlm.nih.gov/18677023>.
25. McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. *Clin Infect Dis*. 2016;62(7):853-862. Available at: <https://pubmed.ncbi.nlm.nih.gov/26797215>.
26. Moure R, Domingo P, Gallego-Escuredo JM, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. *Antiviral Res*. 2016;132:59-65. Available at: <https://pubmed.ncbi.nlm.nih.gov/27216995>.
27. Negredo E, Miro O, Rodriguez-Santiago B, et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). *Clin Infect Dis*. 2009;49(6):892-900. Available at: <https://pubmed.ncbi.nlm.nih.gov/19663689>.
28. O'Rourke J, Townsend CL, Milanzi E, et al. Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. *J Int AIDS Soc*. 2023;26(2):e26037. Available at: <https://pubmed.ncbi.nlm.nih.gov/36823283>.
29. Prendergast AJ. Complications of long-term antiretroviral therapy in HIV-infected children. *Arch Dis Child*. 2013;98(4):245-246. Available at: <https://pubmed.ncbi.nlm.nih.gov/23413313>.
30. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. *HIV Clin Trials*. 2010;11(1):39-50. Available at: <https://pubmed.ncbi.nlm.nih.gov/20400410>.

31. Ramteke SM, Shiau S, Foca M, et al. Patterns of growth, body composition, and lipid profiles in a South African cohort of human immunodeficiency virus-infected and uninfected children: a cross-sectional study. *J Pediatric Infect Dis Soc*. 2017;7(2):143-150. Available at: <https://pubmed.ncbi.nlm.nih.gov/28481997>.
32. Santiprabhob J, Chokephaibulkit K, Khantee P, et al. Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors. *Cytokine*. 2020;136:155145. Available at: <https://pubmed.ncbi.nlm.nih.gov/32920318>.
33. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis*. 2020;71(6):1379-1389. Available at: <https://pubmed.ncbi.nlm.nih.gov/31606734>.
34. Sharma TS, Somarriba G, Arheart KL, et al. Longitudinal changes in body composition by dual-energy radiograph absorptiometry among perinatally HIV-infected and HIV-uninfected youth: increased risk of adiposity among HIV-infected female youth. *Pediatr Infect Dis J*. 2018;37(10):1002-1007. Available at: <https://pubmed.ncbi.nlm.nih.gov/29474262>.
35. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. *BMC Infect Dis*. 2010;10:183. Available at: <https://pubmed.ncbi.nlm.nih.gov/20573187>.
36. Spoulou V, Kanaka-Gantenbein C, Bathrellou I, et al. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. *Hormones (Athens)*. 2011;10(2):149-155. Available at: <https://pubmed.ncbi.nlm.nih.gov/21724540>.
37. Su J, Shiau S, Arpadi SM, et al. Switch to efavirenz attenuates lipoatrophy in girls with perinatal HIV. *J Pediatr Gastroenterol Nutr*. 2021;72(1):e15-e20. Available at: <https://pubmed.ncbi.nlm.nih.gov/32804904>.
38. Taramasso L, Di Biagio A, Bovis F, et al. Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study. *Microorganisms*. 2020;8(6). Available at: <https://pubmed.ncbi.nlm.nih.gov/32521616>.
39. Thivalapill N, Simelane T, Mthethwa N, et al. Transition to dolutegravir is associated with an increase in the rate of body mass index change in a cohort of virally suppressed adolescents. *Clin Infect Dis*. 2021;73(3):e580-e586. Available at: <https://pubmed.ncbi.nlm.nih.gov/33119739>.
40. Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. *AIDS*. 2010;24(9):1291-1298. Available at: <https://pubmed.ncbi.nlm.nih.gov/20453626>.

41. Violari A, Masenya M, Blanche S, et al. The DIANA study: continued access to darunavir/ritonavir (DRV/r) and long-term safety follow-up in HIV-1-infected pediatric patients aged 3 to < 18 years. *Drug Saf.* 2021;44(4):439-446. Available at: <https://pubmed.ncbi.nlm.nih.gov/33367975>.
42. Young L, Wohl DA, Hyslop WB, et al. Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy. *HIV Clin Trials.* 2015;16(5):163-169. Available at: <https://pubmed.ncbi.nlm.nih.gov/26249671>.

Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/Monitoring | Management |
|----------------------------------|--|--|---|---|--|---|
| Urolithiasis/ Nephrolithiasis | ATV DRV causes crystalluria, but it is not associated with nephrolithiasis. | Onset <ul style="list-style-type: none"> Weeks to months after starting therapy Clinical Findings <ul style="list-style-type: none"> Crystalluria Hematuria Pyuria Flank pain Increased creatinine levels in some cases | ATV-related nephrolithiasis occurs in <10% of patients and has been reported after stopping ATV. | In adults, elevated urine pH (>5.7) The risk factors in children are unknown. | Prevention <ul style="list-style-type: none"> Maintain adequate hydration. Monitoring <ul style="list-style-type: none"> Obtain urinalysis at least every 6–12 months. | Provide adequate hydration and pain control. Consider using another ARV drug in place of ATV. |
| Renal Dysfunction | TDF | Onset <ul style="list-style-type: none"> Variable; in adults, renal dysfunction may occur weeks to months after initiating therapy. Hypophosphatemia appears at a median of 18 months. Glucosuria may occur after 1 year of therapy. Abnormal urine protein/osmolality ratio may be an early indicator. | Adults <ul style="list-style-type: none"> Approximately 2% of adults experience increased serum creatinine levels. Approximately 0.5% of adults experience severe renal complications. | Risk May Increase in Children with the Following Characteristics <ul style="list-style-type: none"> Aged >6 years Black race, Hispanic/Latino ethnicity Advanced HIV infection | Monitor urine protein, urine glucose, and serum creatinine at 3- to 6-month intervals. Some Panel members routinely monitor serum phosphate levels in patients who are taking TDF. If TDF is the likely cause, consider using an alternative ARV drug. TAF has significantly less toxicity than TDF. Changing from TDF to TAF may improve renal function. | |

Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects

| | | | | | | |
|-------------------------------|---------------------|--|---|--|--|---|
| | | <p>Presentation</p> <p><i>More Common</i></p> <ul style="list-style-type: none">Increased serum creatinine levels, proteinuria, and normoglycemic glucosuriaIncreased urinary protein/creatinine ratio and albumin/creatinine ratioHypophosphatemia, usually asymptomatic; may present with bone and muscle pain or muscle weakness <p><i>Less Common</i></p> <ul style="list-style-type: none">Renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, and nephrogenic diabetes insipidus with polyuria | <p>Children</p> <ul style="list-style-type: none">Approximately 4% of children experience hypophosphatemia or proximal tubulopathy; frequency increases with prolonged TDF therapy and advanced HIV infection. | <ul style="list-style-type: none">HypertensionDiabetesConcurrent use of PIs (especially LPV/r) and preexisting renal dysfunctionLonger duration of TDF treatmentThe presence of the apolipoprotein L1 variants G1 and G2 appears to increase the risk of renal abnormality in children with HIV. These alleles are more common in people of Black descent. | <p>Measure serum phosphate if the patient experiences persistent proteinuria or glucosuria or has symptoms of bone pain, muscle pain, or weakness.</p> <p>Because toxicity risk increases with the duration of TDF treatment, do not decrease the frequency of monitoring over time.</p> | |
| Elevation in Serum Creatinine | DTG, COBI, RPV, BIC | <p>Onset</p> <ul style="list-style-type: none">Within 1 month of starting treatment <p>Presentation</p> <ul style="list-style-type: none">Asymptomatic. These drugs decrease renal tubular secretion of creatinine, leading to an increase in serum creatinine levels without a true change in eGFR. | <p>Common laboratory finding</p> | <p>The risk factors in children are unknown.</p> | <p>Monitor serum creatinine. Assess for renal dysfunction if serum creatinine increases by >0.4 mg/dL or if increases continue over time.</p> | <p>No need to change therapy</p> <p>Reassure the patient about the benign nature of the laboratory abnormality.</p> |

Table 17i. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects

| | | | | | | |
|--|--|--|--|--|--|--|
| | | <ul style="list-style-type: none">• Clinicians need to distinguish between a true change in eGFR and other causes. A true change may be associated with other medical conditions, the continuing rise of serum creatinine levels over time, and albuminuria. | | | | |
|--|--|--|--|--|--|--|

Key: ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; COBI = cobicistat; DRV = darunavir; DTG = dolutegravir; eGFR = estimated glomerular filtration rate; LPV/r = lopinavir/ritonavir; mg/dL = milligrams per deciliter; Panel = the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

References

1. Al Hammond R, Kalaskar A, Rodriguez G, et al. Microalbuminuria in perinatally HIV-infected children and adolescents in the United States. *Open Forum Infect Dis.* 2023;10(7):ofad333. Available at: <https://pubmed.ncbi.nlm.nih.gov/37426950/>.
2. Aliyannissa A, Kuswiyanto RB, Setiabudi D, Nataprawira HM, Alam A, Sekarwana N. Correlation between CD4 count and glomerular filtration rate or urine protein:creatinine ratio in human immunodeficiency virus–infected children. *Kidney Res Clin Pract.* 2020;39(1):40-46. Available at: <https://pubmed.ncbi.nlm.nih.gov/32146732/>.
3. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus–infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J.* 2009;28(7):619-625. Available at: <https://pubmed.ncbi.nlm.nih.gov/19561425/>.
4. Beng H, Rakhmanina N, Moudgil A, et al. HIV-associated CKDs in children and adolescents. *Kidney Int Rep.* 2020;5(12):2292-2300. Available at: <https://pubmed.ncbi.nlm.nih.gov/33305123/>.
5. Bk K, Tiwari S, Chhapola V, Debnath E, Seth A, Jain A. Brief report: subclinical kidney dysfunction in HIV-infected children: a cross-sectional study. *J Acquir Immune Defic Syndr.* 2020;85(4):470-474. Available at: <https://pubmed.ncbi.nlm.nih.gov/33136747/>.
6. Brunel V, Massy N, Malval B. Atazanavir urolithiasis without recent intake of atazanavir. *Ann Biol Clin (Paris).* 2019;77(4):459-460. Available at: <https://pubmed.ncbi.nlm.nih.gov/31418708/>.
7. Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. *Pediatr Infect Dis J.* 2018;37(1):66-70. Available at: <https://pubmed.ncbi.nlm.nih.gov/28719505/>.
8. Campbell L, Barbini B, Burling B, et al. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate. *J Acquir Immune Defic Syndr.* 2021;88(2):214-219. Available at: <https://pubmed.ncbi.nlm.nih.gov/34506361/>.
9. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. *J Antimicrob Chemother.* 2013;68(8):1850-1856. Available at: <https://pubmed.ncbi.nlm.nih.gov/23599359/>.
10. Ekulu PM, Nkoy AB, Betukumesu DK, et al. *APOL1* risk genotypes are associated with early kidney damage in children in sub-Saharan Africa. *Kidney Int Rep.* 2019;4(7):930-938. Available at: <https://pubmed.ncbi.nlm.nih.gov/31317115/>.

11. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr*. 2012;61(1):32-40. Available at: <https://pubmed.ncbi.nlm.nih.gov/22732469>.
12. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *AIDS*. 2019;33(9):1455-1465. Available at: <https://pubmed.ncbi.nlm.nih.gov/30932951>.
13. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. *AIDS*. 2010;24(4):525-534. Available at: <https://pubmed.ncbi.nlm.nih.gov/20139752>.
14. Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally-acquired HIV infection: a single-centre cohort study. *Clin Drug Investig*. 2015;35(5):327-333. Available at: <https://pubmed.ncbi.nlm.nih.gov/25861908>.
15. Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. *PLoS One*. 2015;10(9):e0137660. Available at: <https://pubmed.ncbi.nlm.nih.gov/26360703>.
16. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? *PLoS One*. 2016;11(2):e0149562. Available at: <https://pubmed.ncbi.nlm.nih.gov/26872144>.
17. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med*. 2009;163(2):164-171. Available at: <https://pubmed.ncbi.nlm.nih.gov/19188649>.
18. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. *PLoS One*. 2013;8(10):e77268. Available at: <https://pubmed.ncbi.nlm.nih.gov/24130871>.
19. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. *Pediatr Infect Dis J*. 2013;32(5):495-500. Available at: <https://pubmed.ncbi.nlm.nih.gov/23249917>.
20. Purswani MU, Patel K, Winkler CA, et al. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. *J Acquir Immune Defic Syndr*. 2016;73(1):63-68. Available at: <https://pubmed.ncbi.nlm.nih.gov/27035887>.

21. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J*. 2009;28(3):204-209. Available at: <https://pubmed.ncbi.nlm.nih.gov/19209091>.
22. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. *HIV Med*. 2012;13(9):526-532. Available at: <https://pubmed.ncbi.nlm.nih.gov/22413854>.
23. Seo JW, Kim K, Jun KI, et al. Recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus-positive patients. *Infect Chemother*. 2020;52(3):381-388. Available at: <https://pubmed.ncbi.nlm.nih.gov/32757496>.
24. de Sousa Soares D, Cavalcante MG, Ribeiro SMV, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. *J Pediatr (Rio J)*. 2016;92(6):631-637. Available at: <https://pubmed.ncbi.nlm.nih.gov/27542916>.
25. Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. *AIDS*. 2011;25(2):171-176. Available at: <https://pubmed.ncbi.nlm.nih.gov/21076275>.

Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis

Updated: April 11, 2023

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------------------|---|--|--|---|--|--|
| Osteopenia and Osteoporosis | <p>Any ARV regimen</p> <p>Specific Agents of Concern</p> <ul style="list-style-type: none"> • TDF, especially when used in a regimen that includes a boosting agent (i.e., RTV, COBI) • PIs (LPV, ATV>DRV) • EFV | <p>Onset</p> <ul style="list-style-type: none"> • Any age; decrease in BMD is usually seen soon after initiating ART. <p>Presentation</p> <ul style="list-style-type: none"> • Usually asymptomatic • Rarely presents as osteoporosis, a clinical diagnosis defined by evidence of bone fragility (e.g., a fracture with minimal trauma). | <p>BMD Z-score Less than -2.0</p> <ul style="list-style-type: none"> • <10% in U.S. cohorts • Approximately 10% to 20% in international cohorts | <p>Longer duration and greater severity of HIV disease</p> <p>Detectable viral load</p> <p>Vitamin D insufficiency/deficiency</p> <p>Delayed growth or pubertal delay</p> <p>Low BMI</p> <p>Lipodystrophy</p> <p>Smoking</p> <p>Prolonged systemic corticosteroid use</p> <p>Medroxyprogesterone use</p> <p>Lack of weight-bearing exercise</p> | <p>Prevention</p> <ul style="list-style-type: none"> • Ensure that the patient has sufficient intake and levels of both calcium and vitamin D. • Encourage weight-bearing exercise. • Minimize modifiable risk factors (e.g., smoking, low BMI, use of steroids or medroxyprogesterone). • Use TAF instead of TDF whenever possible. • Use TDF with RPV or an unboosted INSTI. • When using TDF or EFV in a regimen, consider measuring vitamin D levels and supplementing with vitamin D3 if deficiency is identified. | <p>Same options as for prevention</p> <p>Consider changing the ARV regimen (e.g., switching from TDF to TAF and/or from LPV/r to RPV or an unboosted INSTI whenever possible).</p> <p>Supplement with vitamin D3 to raise serum 25-OH-vitamin D concentrations to >30 ng/mL. There is no clear benefit to administering daily supplemental vitamin D3 doses that are >4,000 IU. If patients are receiving a daily dose of vitamin D3 that is >4,000 IU, consider monitoring levels of 25-OH-vitamin D.</p> <p>An increase in BMD was seen in one trial that evaluated the use of alendronate in youth with HIV and low BMD. However, the role of bisphosphonates in managing osteopenia and osteoporosis in children with HIV has not been established.</p> |

Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis

| | | | | | | |
|--|--|--|--|--|--|--|
| | | | | | <p>Monitoring</p> <ul style="list-style-type: none"> • Assess nutritional intake (i.e., calcium, vitamin D, and total calories). • Consider measuring serum 25-OH-vitamin D levels, particularly in patients who are taking ARV drugs of concern.^a • DXA is rarely indicated.^b | |
|--|--|--|--|--|--|--|

^a Drugs of greatest concern are TDF and EFV. Some experts measure 25-OH-vitamin D in children with HIV with additional risk factors, including living at high latitudes, sun avoidance, low dietary intake, and obesity.

^b DXA scanning is not routinely recommended for children and youth who are being treated with TDF. DXA scanning can be considered for children and youth who are receiving additional medications that also affect bone density or have non-HIV-related conditions for which DXA scans may be indicated (e.g., cerebral palsy).

Key: 25-OH-vitamin D = 25-hydroxy vitamin D; ART = antiretroviral therapy; ARV = antiretroviral; ATV = atazanavir; BMD = bone mineral density; BMI = body mass index; COBI = cobicistat; DRV = darunavir; DXA = dual-energy X-ray absorptiometry; EFV = efavirenz; INSTI = integrase strand transfer inhibitor; IU = international unit; LPV = lopinavir; LPV/r = lopinavir/ritonavir; PI = protease inhibitor; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

References¹⁻⁴⁰

1. Arpadi SM, Shiao S, Strehlau R, et al. Efavirenz is associated with higher bone mass in South African children with HIV. *AIDS*. 2016;30(16):2459-2467. Available at: <https://pubmed.ncbi.nlm.nih.gov/27427876>.
2. Aupribul L, Cressey TR, Sricharoenchai S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. *Pediatr Infect Dis J*. 2015;34(4):392-397. Available at: <https://pubmed.ncbi.nlm.nih.gov/25760566>.
3. Bachrach LK, Gordon CM, Section on Endocrinology. Bone densitometry in children and adolescents. *Pediatrics*. 2016;138(4). Available at: <https://pubmed.ncbi.nlm.nih.gov/27669735>.
4. Baranek B, Wang S, Cheung AM, Mishra S, Tan DH. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. *Antivir Ther*. 2020;25(1):21-32. Available at: <https://pubmed.ncbi.nlm.nih.gov/32077867>.
5. Bi X, Liu F, Zhang X, et al. Vitamin D and calcium supplementation reverses tenofovir-caused bone mineral density loss in people taking ART or PrEP: a systematic review and meta-analysis. *Front Nutr*. 2022;9:749948. Available at: <https://pubmed.ncbi.nlm.nih.gov/35433788>.
6. Braithwaite K, McPherson TD, Shen Y, et al. Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate. *South Afr J HIV Med*. 2021;22(1):1243. Available at: <https://pubmed.ncbi.nlm.nih.gov/34522425>.
7. Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. *JAMA*. 2019;322(8):736-745. Available at: <https://pubmed.ncbi.nlm.nih.gov/31454046>.
8. Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral therapy, especially efavirenz, is associated with low bone mineral density in HIV-infected South Africans. *PLoS One*. 2015;10(12):e0144286. Available at: <https://pubmed.ncbi.nlm.nih.gov/26633015>.
9. Eckard AR, Mora S. Bone health in HIV-infected children and adolescents. *Curr Opin HIV AIDS*. 2016;11(3):294-300. Available at: <https://pubmed.ncbi.nlm.nih.gov/26890208>.

10. Eckard AR, O'Riordan MA, Rosebush JC, et al. Effects of vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth. *J Acquir Immune Defic Syndr.* 2017;76(5):539-546. Available at: <https://pubmed.ncbi.nlm.nih.gov/28902705>.
11. Golden NH, Abrams SA, Committee on Nutrition. Optimizing bone health in children and adolescents. *Pediatrics.* 2014;134(4):e1229-1243. Available at: <https://pubmed.ncbi.nlm.nih.gov/25266429>.
12. Gregson CL, Hartley A, Majonga E, et al. Older age at initiation of antiretroviral therapy predicts low bone mineral density in children with perinatally-infected HIV in Zimbabwe. *Bone.* 2019;125:96-102. Available at: <https://pubmed.ncbi.nlm.nih.gov/31082498>.
13. Havens PL, Long D, Schuster GU, et al. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone. *Antivir Ther.* 2018;23(7):623-628. Available at: <https://pubmed.ncbi.nlm.nih.gov/30260797>.
14. Havens PL, Stephensen CB, Van Loan MD, et al. Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: a randomized, placebo-controlled trial. *Clin Infect Dis.* 2018;66(2):220-228. Available at: <https://pubmed.ncbi.nlm.nih.gov/29020329>.
15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-1930. Available at: <https://pubmed.ncbi.nlm.nih.gov/21646368>.
16. Jacobson DL, Lindsey JC, Gordon C, et al. Alendronate improves bone mineral density in children and adolescents perinatally infected with human immunodeficiency virus with low bone mineral density for age. *Clin Infect Dis.* 2020;71(5):1281-1288. Available at: <https://pubmed.ncbi.nlm.nih.gov/31573608>.
17. Jacobson DL, Yu W, Hazra R, et al. Fractures in children and adolescents living with perinatally acquired HIV. *Bone.* 2020;139:115515. Available at: <https://pubmed.ncbi.nlm.nih.gov/32619695>.
18. LaFleur J, Bress AP, Myers J, et al. Tenofovir-associated bone adverse outcomes among a US national historical cohort of HIV-infected veterans: risk modification by concomitant antiretrovirals. *Infect Dis Ther.* 2018;7(2):293-308. Available at: <https://pubmed.ncbi.nlm.nih.gov/29492905>.

19. Lima LR, Silva RC, Giuliano Ide C, Sakuno T, Brincas SM, Carvalho AP. Bone mass in children and adolescents infected with human immunodeficiency virus. *J Pediatr (Rio J)*. 2013;89(1):91-99. Available at: <https://pubmed.ncbi.nlm.nih.gov/23544816>.
20. Lindsey JC, Jacobson DL, Spiegel HM, Gordon CM, Hazra R, Siberry GK. Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal human immunodeficiency virus infection and low bone mineral density for age. *Clin Infect Dis*. 2021;72(6):1059-1063. Available at: <https://pubmed.ncbi.nlm.nih.gov/32584996>.
21. Mahtab S, Scott C, Asafu-Agyei NAA, et al. Prevalence and predictors of bone health among perinatally HIV-infected adolescents. *AIDS*. 2020;34(14):2061-2070. Available at: <https://pubmed.ncbi.nlm.nih.gov/32910060>.
22. McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. *AIDS*. 2018;32(4):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239893>.
23. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis*. 2016;16(1):43-52. Available at: <https://pubmed.ncbi.nlm.nih.gov/26538525>.
24. Negredo E, Langohr K, Bonjoch A, et al. High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. *J Antimicrob Chemother*. 2018;73(9):2452-2459. Available at: <https://pubmed.ncbi.nlm.nih.gov/29860519>.
25. Okonkwo RI, Weidmann AE, Effa EE. Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-infected children: a systematic review. *Drug Saf*. 2016;39(3):209-218. Available at: <https://pubmed.ncbi.nlm.nih.gov/26692394>.
26. Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. *Ann Intern Med*. 2015;162(12):815-824. Available at: <https://pubmed.ncbi.nlm.nih.gov/26075752>.
27. Palchetti CZ, Szejnfeld VL, de Menezes Succi RC, et al. Impaired bone mineral accrual in prepubertal HIV-infected children: a cohort study. *Braz J Infect Dis*. 2015;19(6):623-630. Available at: <https://pubmed.ncbi.nlm.nih.gov/26477385>.

28. Penner J, Ferrand RA, Richards C, Ward KA, Burns JE, Gregson CL. The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: a systematic review. *PLoS One*. 2018;13(11):e0207022. Available at: <https://pubmed.ncbi.nlm.nih.gov/30439968>.
29. Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, et al. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis. *J Int AIDS Soc*. 2020;23(10):e25624. Available at: <https://pubmed.ncbi.nlm.nih.gov/33040465>.
30. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2011;96(1):53-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/21118827>.
31. Rukuni R, Rehman AM, Mukwasi-Kahari C, et al. Effect of HIV infection on growth and bone density in peripubertal children in the era of antiretroviral therapy: a cross-sectional study in Zimbabwe. *Lancet Child Adolesc Health*. 2021;5(8):569-581. Available at: <https://pubmed.ncbi.nlm.nih.gov/34139202>.
32. Shen Y, Shiao S, Strehlau R, et al. Persistently lower bone mass and bone turnover among South African children living with well-controlled HIV. *AIDS*. 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34127577>.
33. Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of osteoporosis in patients living with HIV-a systematic review and meta-analysis. *J Acquir Immune Defic Syndr*. 2020;83(1):1-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/31809356>.
34. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Impact of vitamin D and calcium supplementation on bone mineral density and bone metabolism among Thai adolescents with perinatally acquired human immunodeficiency virus (HIV) infection: a randomized clinical trial. *Clin Infect Dis*. 2021;73(9):1555-1564. Available at: <https://pubmed.ncbi.nlm.nih.gov/34125899>.
35. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Adverse bone health and abnormal bone turnover among perinatally HIV-infected Asian adolescents with virological suppression. *HIV Med*. 2017;18(4):235-244. Available at: <https://pubmed.ncbi.nlm.nih.gov/27477214>.
36. Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. *AIDS*. 2015;29(18):2459-2464. Available at: <https://pubmed.ncbi.nlm.nih.gov/26355674>.

37. Torrejon C, Galaz MI, Vizueta E, et al. Evaluation of bone mineral density in children with vertical infection by HIV. *Rev Chilena Infectol.* 2018;35(6):634-641. Available at: <https://pubmed.ncbi.nlm.nih.gov/31095183>.
38. Van Welzen BJ, Thielen MAJ, Mudrikova T, Arends JE, Hoepelman AIM. Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? *AIDS.* 2019. Available at: <https://pubmed.ncbi.nlm.nih.gov/31021851>.
39. Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). *Antivir Ther.* 2014;19(2):191-200. Available at: <https://pubmed.ncbi.nlm.nih.gov/24430534>.
40. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. *J Clin Endocrinol Metab.* 2011;96(10):3160-3169. Available at: <https://pubmed.ncbi.nlm.nih.gov/21917867>.

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

Updated: June 27, 2024

Reviewed: June 27, 2024

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|------------------------------|--|---|--|--|--|
| Rash | Any ARV drug can cause rash. | <p>Onset</p> <ul style="list-style-type: none"> First few days to weeks after starting new ARV drug(s) <p>Presentation</p> <ul style="list-style-type: none"> Most rashes are mild-to-moderate diffuse maculopapular eruptions <p>Note: A rash can be the initial manifestation of systemic hypersensitivity (see the SJS/TEN/EM major and HSR sections below).</p> | <p>Common (>10%)</p> <ul style="list-style-type: none"> EFV ETR FTC NVP <p>Less Common (5% to 10%)</p> <ul style="list-style-type: none"> ABC ATV DRV TDF <p>Unusual (2% to 4%)</p> <ul style="list-style-type: none"> BIC LPV/r MVC RAL RPV | <ul style="list-style-type: none"> Sulfonamide allergy is a risk factor for rash in patients who are taking PIs that contain a sulfonamide moiety (i.e., DRV). Polymorphisms in CYP2B6 and multiple HLA loci are associated with an increased risk of rash in patients who are taking NVP. | <p>When Starting NVP or Restarting NVP After Interruptions of >14 Days</p> <ul style="list-style-type: none"> Utilize once-daily lead-in dosing.^a This may not be necessary in children ages <2 years.^b Avoid the use of systemic corticosteroids during NVP dose escalation. Assess the patient for rash severity, mucosal involvement, and other signs of systemic reaction. | <p>Mild-to-Moderate Maculopapular Rash without Systemic or Mucosal Involvement</p> <ul style="list-style-type: none"> Most rashes will resolve without intervention; ARV drugs can be continued while monitoring.^a Antihistamines may provide some relief. <p>Severe Rash and/or Rash Accompanied by Systemic Symptoms</p> <ul style="list-style-type: none"> Manage as SJS/TEN/EM major, DRESS, or HSR, as applicable (see below). <p>Rash in Patients Receiving NVP</p> <ul style="list-style-type: none"> Given the elevated risk of HSR, measure hepatic transaminases. If hepatic transaminases are elevated, NVP should be discontinued and not restarted (see the HSR section below). |

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|------------------|--|---|---|---|---|---|
| SJS/TEN/EM Major | Many ARV drugs, especially NNRTIs (see the Estimated Frequency column) | Onset <ul style="list-style-type: none"> First few days to weeks after starting new ARV drug(s) Presentation <ul style="list-style-type: none"> Initial rash may be mild, but it often becomes painful, evolving to blister/bulla formation with necrosis in severe cases. Usually involves mucous membrane ulceration and/or conjunctivitis. Systemic symptoms may also include fever, tachycardia, malaise, myalgia, and arthralgia. | Infrequent <ul style="list-style-type: none"> NVP (0.3%) EFV (0.1%) ETR (<0.1%) Case Reports <ul style="list-style-type: none"> ABC ATV DRV LPV/r RAL ZDV | Adults <ul style="list-style-type: none"> Female sex Patients who are Black, Asian, or Hispanic are at higher risk. | When Starting NVP or Restarting NVP After Interruptions of >14 Days <ul style="list-style-type: none"> Utilize once-daily lead-in dosing.^a This may not be necessary in children aged <2 years.^b Counsel families to report symptoms as soon as they appear. | <ul style="list-style-type: none"> Discontinue all ARV drugs and other possible causative agents (e.g., TMP-SMX). Provide intensive supportive care, including IV hydration, aggressive wound care, eye care, labial adhesion preventive care, pain management, and antipyretics. Parenteral nutrition and antibiotics may also be necessary. Corticosteroids and/or IVIG are sometimes used, but the use of these interventions is controversial. Do not reintroduce the offending medication. In cases where a patient experiences SJS/TEN/EM major while taking an NNRTI, many experts would avoid using other NNRTIs when restarting ART. |
| DRESS | DRV, DTG, EFV, ETR, NVP, RAL, RPV, BIC | Onset <ul style="list-style-type: none"> 1–8 weeks after starting new ARV drug(s) Presentation <ul style="list-style-type: none"> Fever Lymphadenopathy | Rare | <ul style="list-style-type: none"> Unknown Potential association with HLA-B*53:01 and RAL-induced DRESS | Obtain a CBC and AST, ALT, and creatinine levels from patients who present with suggestive symptoms. | <ul style="list-style-type: none"> Discontinue all ARV drugs and other possible causative agents (e.g., TMP-SMX). The role of systemic steroids or IVIG in treatment is unclear; consultation with a specialist is recommended. |

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|---|-----------------|--|---------------------------------|--|--|--|
| | | <ul style="list-style-type: none"> • Facial swelling • Morbilliform to polymorphous rash • Peripheral eosinophilia • Atypical circulating lymphocytes • Internal organ involvement (particularly the liver and/or kidneys) | | | | <ul style="list-style-type: none"> • Provide supportive care for end-organ disease. • Do not reintroduce the offending medication. |
| HSR With or without skin involvement and excluding SJS/TEN | ABC | <p>Onset</p> <p><i>With First Use</i></p> <ul style="list-style-type: none"> • Within first 6 weeks of initiating ABC <p><i>With Reintroduction</i></p> <ul style="list-style-type: none"> • Within hours of initiating ABC <p>Presentation</p> <ul style="list-style-type: none"> • Symptoms include high fever, diffuse skin rash, malaise, nausea, headache, myalgia, arthralgia, diarrhea, vomiting, abdominal pain, pharyngitis, and respiratory symptoms (e.g., dyspnea). | <1% to 9% (varies by ethnicity) | <ul style="list-style-type: none"> • HLA-B*5701 (HSR is very uncommon in people who are HLA-B*5701 negative.) • The prevalence of HLA-B*5701 is generally lower in people from Africa and East Asia. | <ul style="list-style-type: none"> • Screen for HLA-B*5701. ABC should not be prescribed if HLA-B*5701 is present. The medical record should clearly indicate that ABC is contraindicated in these patients. • When starting ABC, counsel patients and families about the signs and symptoms of HSR to ensure prompt reporting of reactions. | <ul style="list-style-type: none"> • Discontinue all ARV drugs and investigate other causes of the symptoms (e.g., a concurrent viral illness). • Provide symptomatic treatment. • Most symptoms resolve within 48 hours after discontinuing ABC. • Do not rechallenge with ABC even if the patient is HLA-B*5701 negative. |

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|--|--|---|--|
| | | <ul style="list-style-type: none"> With continuation of ABC, symptoms may progress to hypotension and vascular collapse. With rechallenge, symptoms can mimic anaphylaxis. | | | | |
| | NVP | <p>Onset</p> <ul style="list-style-type: none"> Occurs most frequently in the first few weeks of therapy but can occur through 18 weeks. <p>Presentation</p> <ul style="list-style-type: none"> Flu-like symptoms (including nausea, vomiting, myalgia, fatigue, fever, abdominal pain, and jaundice) with or without skin rash that may progress to hepatic failure with encephalopathy | <p>Occurs in 4% of patients on average, with a range of 2.5% to 11%.</p> | <p>Adults</p> <ul style="list-style-type: none"> ARV-naïve with a higher CD4 count (>250 cells/mm3 in women; >400 cells/mm3 in men) Female sex (risk is threefold higher in females than in males). <p>Children</p> <ul style="list-style-type: none"> NVP hepatotoxicity and HSR are less common in prepubertal children than in adults, and both are uncommon in infants. | <p>When Starting NVP or Restarting NVP After Interruptions of >14 Days</p> <ul style="list-style-type: none"> A 2-week lead-in period with once-daily dosing, followed by dose escalation to twice daily as recommended, may reduce the risk of reaction.^a This may not be necessary in children aged <2 years.^b Counsel families about signs and symptoms of HSR to ensure prompt reporting of reactions. | <ul style="list-style-type: none"> Discontinue all ARV drugs. Consider other causes of hepatitis and discontinue all hepatotoxic medications. Provide supportive care as indicated and monitor the patient closely. Do not reintroduce NVP. It is unclear whether it is safe to use other NNRTIs after a patient experiences symptomatic hepatitis due to NVP, and many experts would avoid the NNRTI drug class when restarting treatment. |

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|--|---------------------|--|--|--|
| | | | | <ul style="list-style-type: none"> High CD4 percentage is associated with an increased risk of NVP toxicity. In the PREDICT Study, the risk of NVP toxicity (rash, hepatotoxicity, and hypersensitivity) was 2.65 times greater in children who had CD4 percentages $\geq 15\%$ than in children who had CD4 percentages $< 15\%$. | <ul style="list-style-type: none"> Obtain AST and ALT levels in patients with rash. Obtain AST and ALT levels at baseline, before dose escalation, 2 weeks after dose escalation, and thereafter at 3-month intervals. Avoid NVP use in women with CD4 counts $> 250 \text{ cells/mm}^3$ and in men with CD4 counts $> 400 \text{ cells/mm}^3$, unless benefits outweigh risks. Do not use NVP as post-exposure prophylaxis outside of the neonatal period. | |
| | ETR | Onset <ul style="list-style-type: none"> Any time during therapy Presentation <ul style="list-style-type: none"> Symptoms may include rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. | Rare | Unknown | Evaluate for hypersensitivity if the patient is symptomatic. | <ul style="list-style-type: none"> Discontinue all ARV drugs. Rechallenge with ETR is not recommended. |

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

| Adverse Effects | Associated ARVs | Onset/Clinical Manifestations | Estimated Frequency | Risk Factors | Prevention/ Monitoring | Management |
|-----------------|-----------------|-------------------------------|---------------------|--------------|--|--|
| | MVC | Rash preceding hepatotoxicity | Rare | Unknown | Obtain AST and ALT levels from patients with rash or other symptoms of hypersensitivity. | <ul style="list-style-type: none"> Discontinue all ARV drugs. Rechallenge with MVC is not recommended. |
| | DTG | Rash with hepatic dysfunction | Rare | Unknown | Obtain AST and ALT levels from patients with rash or other symptoms of hypersensitivity. | <ul style="list-style-type: none"> Discontinue all ARV drugs. Rechallenge with DTG is contraindicated. |

^a The prescribing information for NVP states that patients who experience rash during the 14-day lead-in period should not have the NVP dose increased until the rash has resolved. However, prolonging the lead-in phase beyond 14 days may increase the risk of NVP resistance because of subtherapeutic drug levels. Children who have persistent mild or moderate rash after the lead-in period should receive individualized care. Consult an expert in HIV care when managing these patients. NVP should be stopped and not restarted if the rash is severe or progressing. See the [Nevirapine](#) section of the Drug Appendix.

^b Lead-in dosing is not recommended when using NVP for either presumptive or definitive HIV therapy in newborns with perinatal HIV exposure or perinatal HIV infection. See the [Nevirapine](#) section of the Drug Appendix and [Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With In Utero or Intrapartum Exposure to HIV](#) in Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV.

Key: ABC = abacavir; ALT = alanine transaminase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; BIC = bictgravir; CBC = complete blood count; CD4 = CD4 T lymphocyte; CYP2B6 = cytochrome P450 family 2 subfamily B member 6; DRESS = drug reaction (or rash) with eosinophilia and systemic symptoms; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EM = erythema multiforme; ETR = etravirine; FTC = emtricitabine; HLA = human leukocyte antigen; **HLA-B*53:01 = human leukocyte antigen gene variant**; HLA-B*5701 = human leucocyte antigen gene variant; HSR = hypersensitivity reaction; IV = intravenous; IVIG = intravenous immune globulin; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PREDICT Study = Personalised Responses to Dietary Composition Trial Study; RAL = raltegravir; RPV = rilpivirine; SJS = Stevens-Johnson syndrome; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

References

1. Pelchen-Matthews A, Larsen JF, Shepherd L, et al. Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study. *HIV Res Clin Pract.* 2021;22(6):160-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/34779362>.
2. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. *AIDS.* 2011;25(10):1271-1280. Available at: <https://pubmed.ncbi.nlm.nih.gov/21505298>.
3. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. *AIDS.* 2008;22(4):540-541. Available at: <https://pubmed.ncbi.nlm.nih.gov/18301070>.
4. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the Phase II PIANO study. *HIV Med.* 2014;15(9):513-524. Available at: <https://pubmed.ncbi.nlm.nih.gov/24589294>.
5. Thomas SJ, Kilgore JT, Becken BA, Cunningham CK, Thompson AB. Raltegravir-associated drug-reaction with eosinophilia and systemic symptoms syndrome in a pediatric patient without characteristic human leukocyte antigen B*57:01 or B*53:01 alleles. *J Pediatric Infect Dis Soc.* 2021;10(3):363-366. Available at: <https://pubmed.ncbi.nlm.nih.gov/32766769>.
6. Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. *Clin Infect Dis.* 2017;64(9):1198-1203. Available at: <https://pubmed.ncbi.nlm.nih.gov/28369189>.
7. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS.* 2013;27(9):1403-1412. Available at: <https://pubmed.ncbi.nlm.nih.gov/23343913>.
8. Shah R, Nabiswa H, Okinda N, Revathi G, Hawken M, Nelson M. Prevalence of HLA-B*5701 in a Kenyan population with HIV infection. *J Infect.* 2018;76(2):212-214. Available at: <https://pubmed.ncbi.nlm.nih.gov/28919349>.
9. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group protocol 1020A. *Pediatr Infect Dis J.* 2015;34(2):162-167. Available at: <https://pubmed.ncbi.nlm.nih.gov/25232777>.

10. Ripamonti D, Benatti SV, Di Filippo E, Ravasio V, Rizzi M. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. *AIDS*. 2014;28(7):1077-1079. Available at: <https://pubmed.ncbi.nlm.nih.gov/24685746>.
11. Puthanakit T, Bunupuradah T, Kosalaraksa P, et al. Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. *Pediatr Infect Dis J*. 2013;32(3):252-253. Available at: <https://pubmed.ncbi.nlm.nih.gov/22986704>.
12. Prasertvit P, Chareonyingwattana A, Wattanakrai P. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity. *Contact Dermatitis*. 2017;77(6):379-384. Available at: <https://pubmed.ncbi.nlm.nih.gov/28782122>.
13. Peter J, Choshi P, Lehloena RJ. Drug hypersensitivity in HIV infection. *Curr Opin Allergy Clin Immunol*. 2019;19(4):272-282. Available at: <https://pubmed.ncbi.nlm.nih.gov/31145192>.
14. Nishijima T, Gatanaga H, Teruya K, et al. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. *J Infect Chemother*. 2014;20(4):285-287. Available at: <https://pubmed.ncbi.nlm.nih.gov/24507978>.
15. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at: <https://pubmed.ncbi.nlm.nih.gov/30527329>.
16. Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? *Int J STD AIDS*. 2018;29(10):1036-1038. Available at: <https://pubmed.ncbi.nlm.nih.gov/29621952>.
17. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med*. 2008;358(6):568-579. Available at: <https://pubmed.ncbi.nlm.nih.gov/18256392>.
18. Lefebvre M, Walencik A, Allavena C, et al. Rate of DRESS syndrome with raltegravir and role of the HLA-B*53: 01 allele. *J Acquir Immune Defic Syndr*. 2020;85(4):e77-e80. Available at: <https://pubmed.ncbi.nlm.nih.gov/33136758>.
19. Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature. *J Am Acad Dermatol*. 2020;83(5):1323-1330. Available at: <https://pubmed.ncbi.nlm.nih.gov/32247873>.

20. Hayes E, Derrick C, Smalls D, Smith H, Kremer N, Weissman S. Short-term adverse events with BIC/FTC/TAF: postmarketing study. *Open Forum Infect Dis.* 2020;7(9):ofaa285. Available at: <https://pubmed.ncbi.nlm.nih.gov/32908943>.
21. Hasan M, Yunihastuti E, Abdullah M. Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients. *Asian Pac J Allergy Immunol.* 2020;12932/AP-080719-0596. Available at: <https://pubmed.ncbi.nlm.nih.gov/32061245>.
22. Fillekes Q, Mulenga V, Kabamba D, et al. Is nevirapine dose escalation appropriate in young, African, HIV-infected children? *AIDS.* 2013;27(13):2111-2115. Available at: <https://pubmed.ncbi.nlm.nih.gov/23595153>.
23. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. *Pediatr Infect Dis J.* 2013;32(12):1354-1358. Available at: <https://pubmed.ncbi.nlm.nih.gov/23743542>.
24. du Toit JD, Kotze K, van der Westhuizen HM, Gaunt TL. Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa. *South Afr J HIV Med.* 2021;22(1):1182. Available at: <https://pubmed.ncbi.nlm.nih.gov/33824730>.
25. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *J Antimicrob Chemother.* 2008;62(5):879-888. Available at: <https://pubmed.ncbi.nlm.nih.gov/18653488>.
26. DiLorenzo MA, Medrano N, Chen JN, et al. Bictegravir-induced drug reaction with eosinophilia and systemic symptoms in a patient with acute human immunodeficiency virus. *Open Forum Infect Dis.* 2023;10(3):ofad066. Available at: <https://pubmed.ncbi.nlm.nih.gov/36879628>.
27. Orkin C, Sadiq ST, Rice L, et al. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. *HIV Med.* 2010;11(3):187-192. Available at: <https://pubmed.ncbi.nlm.nih.gov/19780860>.

Management of Children Receiving Antiretroviral Therapy

Updated: June 27, 2024

Reviewed: June 27, 2024

In the United States, most children with HIV are receiving antiretroviral therapy (ART), making treatment-experienced children the norm. Providers may consider antiretroviral (ARV) regimen changes for the following reasons:

- *Treatment simplification:* Modifying ARV regimens in children who are currently receiving effective ART to simplify the regimen
- *Treatment optimization:* Increasing the treatment potency or barrier to resistance of an effective but older or potentially fragile regimen or improving the adverse-event profile
- *Toxicity management:* Recognizing and managing ARV drug toxicity or intolerance (see [Management of Medication Toxicity or Intolerance](#))
- *Treatment failure:* Recognizing and managing treatment failure (see [Recognizing and Managing Antiretroviral Treatment Failure](#))

Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">• Children who have sustained virologic suppression on their current antiretroviral (ARV) regimen should be evaluated regularly for opportunities to change to a new regimen that facilitates adherence, simplifies administration, increases ARV potency or barrier to drug resistance, and decreases the risk of drug-associated toxicity (AII).• Before changing a patient's ARV regimen, clinicians must carefully consider the patient's previous regimens, past episodes of ARV therapy failure, prior drug-resistance test results, drug cost, and insurance coverage, as well as the patient's ability to tolerate the new drug regimen (AIII). Archived drug resistance can limit the antiviral activity of a new drug regimen.• Children should be monitored carefully after a change in treatment. Viral load measurement is recommended 2 to 4 weeks after a change in a child's ARV regimen (BIII). <p>Rating of Recommendations: A = Strong; B = Moderate; C = Optional</p> <p>Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion</p> <p>[†] Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents</p> |

Clinicians choose initial ARV regimens for children with HIV by evaluating the pharmacokinetic (PK), safety, and efficacy data for the drugs that are available in formulations suitable for the child's age and weight at the start of treatment. New ARV drug options may become available as children grow and

learn to swallow pills and as new drugs, drug formulations, and data become available. Even in cases wherein patients have achieved sustained virologic suppression (i.e., suppression for 6–12 months) on their current regimen, clinicians should consider switching patients to new ARV regimens to permit the use of pills instead of liquids; reduce pill burden; allow the use of once-daily medications; reduce the risk of adverse events; minimize drug interactions; and align a child’s regimen with widely used, efficacious adult regimens.¹ These changes often enhance adherence and improve quality of life.²

Treatment Simplification

Many infants and children with HIV initiated treatment with twice-daily dosing (especially prior to the approval of integrase strand transfer inhibitor [INSTI] medications for pediatric use), and regimens included a variety of drug formulations, depending on which formulations were available for a child’s age and weight. Clinicians should regularly review treatment options as children grow, and offer simplified dosing using coformulated drugs and/or once-daily regimens when appropriate (see [Table 18](#) below). Clinicians also should consider a child’s ART history, drug-resistance test results, and ability to swallow tablets. Efforts to increase the availability of coformulated complete ARV regimens have yielded several once-daily options for children that should be considered. The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2019 study demonstrated safety, efficacy, and appropriate dosing of a fixed-dose combination (FDC) tablet containing abacavir, dolutegravir, and lamivudine (ABC/DTG/3TC) in children aged <12 years, with use of dispersible tablets (Triumeq PD) or an immediate-release tablet (Triumeq) to be swallowed depending on the child’s weight.³ For children weighing ≥14 kg who can swallow pills, additional options include coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF; Biktarvy) or FTC/TAF (Descovy) plus DTG, which is a two-pill, once-daily regimen. Additional coformulated options are available when children reach 25 kg to 35 kg in weight. See [Table 18](#) below for more information on once-daily options and other coformulated complete ARV regimens. Among treatment-naïve youth in the United States aged 13 to 24 years, some evidence exists that single-tablet regimens (STRs) improve the odds of viral suppression⁴; emerging evidence also supports the safety, efficacy, and tolerability of STRs in younger children.^{5–7} Although these data have not been replicated in treatment-experienced adolescents, clinicians should consider using STRs in children and youth with sustained viral suppression because these regimens reduce pill burden and dosing frequency.

If using an FDC once-daily regimen is not possible, clinicians should determine whether the child’s ARV regimen could be simplified in other ways. For example, small studies have shown that children who achieve virologic suppression using twice-daily dosing for certain ARV drugs (e.g., ABC) maintain virologic suppression when they are switched from twice-daily dosing to once-daily dosing of the same drugs (see the [Abacavir](#) and [Nevirapine](#) sections and FDCs in [Appendix A](#), [Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Consideration for Use in Children and Adolescents](#)). However, these studies reported mixed results when switching the dosing for lopinavir/ritonavir (LPV/r) from twice daily to once daily. Therefore, once-daily dosing of LPV/r is not recommended.^{8–11}

Long-acting injectable (LAI) ARV medications may be considered a treatment simplification approach for some virologically suppressed adolescents. The co-packaged, two-drug injectable ARV regimen of cabotegravir and rilpivirine (CAB and RPV; Cabenuva) is approved by the U.S. Food and Drug Administration (FDA) for use in children weighing ≥35 kg and aged ≥12 years, with viral suppression (defined as <50 copies/mL), on a stable ARV regimen, without a history of treatment

failure, and without known or suspected drug resistance to either drug. Studies in adults—such as the First Long-Acting Injectable Regimen (FLAIR) and Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trials—have demonstrated non-inferiority in those receiving monthly CAB and RPV injections compared with adults who stayed on a daily three-drug oral regimen.^{12,13} Similarly, in the ATLAS-2M and SOLAR trials, injections of CAB and RPV every 2 months were found to be non-inferior to monthly injections and once-daily ART, respectively.^{14,15} The IMPAACT 2017 study is currently evaluating CAB and RPV in children aged 12 to 18 years. At 24 weeks of follow-up, injections of CAB and RPV every 2 months maintained viral suppression, showed acceptable PK, and demonstrated an acceptable safety profile in 144 adolescents.¹⁶ Additionally, participating youth and their caregivers reported high acceptability of the treatment and a strong preference for LAI ART over daily oral ART.¹⁷ The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) notes that questions remain, including whether there are additional adverse effects specific to the pediatric population, whether a two-drug nucleoside-sparing regimen for children with significant ARV treatment history¹⁸ will be effective, and what potential implementation challenges will emerge. A single site in the United States has reported on three adolescents and young adults who experienced viremia while on bimonthly injections which resolved with monthly injections. Two of the individuals also experienced postinjection adverse events that self-resolved.¹⁹ However, given the FDA approval for those as young as 12 years of age, some providers may consider injectable CAB and RPV in adolescents who meet the approved indications and may benefit from a long-acting injectable regimen. See the Cabotegravir and Rilpivirine sections for additional information about these drugs and the dosing and administration of CAB and RPV, and see [Management of the Treatment-Experienced Patient: Optimizing Antiretroviral Therapy in the Setting of Viral Suppression](#) in the Adult and Adolescent ARV Guidelines for practical considerations.

Oral two-drug regimens have some data supporting efficacy in pediatric and adult populations. A two-drug FDC tablet containing DTG/RPV—a nucleoside-sparing, dual-therapy regimen that is marketed as Juluca—is approved by the FDA as a complete regimen to replace the current ARV regimen in adult patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months and who have no history of treatment failure. This approval was based on two Phase 3 clinical trials, SWORD-1 and SWORD-2, in which treatment-experienced adults who were virologically suppressed on three- or four-drug regimens were randomized either to switch to DTG/RPV (early-switch group) or stay on their original regimens through 48 weeks and then switch to DTG/RPV (late-switch group). Results from these trials showed similar rates of virologic suppression in both groups (non-inferiority) through 3 years of follow-up.²⁰⁻²² No equivalent data exist for this drug combination in pediatric patients, although a clinical trial is underway in children aged 6 to 12 years. The Panel usually endorses the use of adult formulations in adolescents, and this product may be appropriate for certain adolescents. DTG/RPV regimens could be useful in patients in whom there is concern for toxicity from nucleoside reverse transcriptase inhibitors (NRTIs). Additionally, findings from the PENTA-17 SMILE study evaluating darunavir/ritonavir (DRV/r) combined with an INSTI, including 318 children aged 6 to 18 years in 11 countries, found that DRV/r plus an INSTI was non-inferior to the standard of care in maintaining virologic suppression at 48 weeks in participants without INSTI or protease inhibitor (PI) resistance.²³ Although the Panel does not recommend this combination for initial treatment, it might be considered in situations in which simplification or avoidance of NRTIs is desired. DTG/3TC (Dovato) also has demonstrated non-inferiority to continuation of three- or four-drug regimens in treatment-experienced adults and those without a history of treatment failure in the TANGO and SALSA studies, respectively.^{24,25} In the ongoing DANCE study, DTG/3TC is being evaluated as an initial regimen in ART-naïve adolescents aged 12 to <18 years and weighing ≥25 kg.

and with HIV RNA of 1,000 copies/mL to ≤500,000 copies/mL. Safety and efficacy of DTG/3TC were comparable to adults, and 22 of 32 participants achieved viral suppression at 96 weeks.²⁶ Based on these findings, the FDA has approved DTG/3TC in adolescents aged ≥12 years and weighing ≥25 kg as an initial regimen or for those on a stable ART regimen with no history of treatment failure and no known drug resistance to the individual drugs. The Panel notes that adolescents may have difficulties adhering to therapy and recommends close monitoring with viral load testing in anyone on oral two-drug regimens. The Panel does not recommend two-drug regimens for initial ART in children (see [What to Start](#)).

Treatment Optimization

The aims of treatment optimization may include improving the potency of the regimen, improving a child's growth or other health outcomes through reduced drug side effects and/or better treated HIV, or maximizing palatability. More studies are directly evaluating treatment optimization in children, and early results support the safety and efficacy of regimen switches for those with viral suppression. Older studies have demonstrated sustained viral suppression and improved growth outcomes in young children who have demonstrated good adherence and no baseline resistance and who were switched from LPV/r-based regimens to an efavirenz (EFV)-based regimen (NEVEREST 3).²⁷⁻²⁹ Replacing LPV/r with Efv may provide some benefits (e.g., once-daily dosing and a different side-effect profile), but most pediatric HIV experts would prefer replacing LPV/r with an equally potent PI (e.g., darunavir [DRV] or atazanavir [ATV]) or an INSTI (e.g., elvitegravir [EVG], raltegravir, DTG, or BIC), based on studies in adults and emerging evidence of non-inferiority or superiority in children.^{30,31} Although not a switch trial, findings from the randomized controlled Once-daily DTG-based ART in Young people vS. Standard thErApY (ODYSSEY) study of more than 700 children aged <18 years in eight countries initiating DTG as first- or second-line therapy showed superior virologic and clinical outcomes in children randomized to optimization with DTG-based ART compared with those in the standard of care (PI- or non-nucleoside reverse transcriptase inhibitor [NNRTI]-based regimens), contributing to evidence supporting optimization with DTG-based regimens.³² Results from the younger ODYSSEY cohort of children weighing between 3 kg and 14 kg also showed superiority of DTG-based ART compared with other regimens, more than 70% of which were PI-based regimens.³³ Additionally, several observational studies in sub-Saharan Africa that are evaluating efforts to optimize pediatric ARV regimens have shown improved viral suppression rates in children that were switched to DTG-based regimens.³⁴⁻³⁶ Similarly, a retrospective study from six African countries reporting on 7,898 children and adolescents aged 0 to ≤19 years demonstrated that 93% remained virologically suppressed after switching from NNRTI- and PI-based regimens to DTG-based regimens, and nearly 80% of those previously unsuppressed achieved viral suppression while on DTG.³⁷ The INSTI-based FDC regimen BIC/FTC/TAF also has shown efficacy and high rates of long-term viral suppression in adolescents and children ≥2 years and weighing 14 kg to <25 kg.^{38,39} Similarly, EVG/cobicistat/FTC/TAF has shown efficacy in adolescents. Early results from small, randomized studies also show potential for switches to newer-generation NNRTI medications—such as RPV⁴⁰ and doravirine⁴¹—in children and adolescents weighing ≥35 kg who have been virologically suppressed on a stable ARV regimen.

Toxicity Management

Several studies of small cohorts of children have demonstrated sustained virologic suppression and reassuring safety outcomes when drugs that have greater long-term toxicity risks are replaced with drugs that are thought to have lower toxicity risks (e.g., replacing stavudine with tenofovir disoproxil fumarate (TDF), TAF, zidovudine, or ABC; replacing PIs with NNRTIs), including improved lipid

profiles.⁴²⁻⁴⁶ Similarly, adolescents who were switched from EFV to RPV, a newer generation of NNRTIs, showed similar rates of viral suppression with improved metabolic profiles and cognitive outcomes.⁴⁰ Additionally, studies in adults have shown improved tolerability, lipid profiles, and insulin sensitivity in patients who were switched from PIs to INSTIs,⁴⁷⁻⁵¹ and adults who were switched from EFV to an INSTI have shown improvement in neuropsychiatric symptoms. One study in South Africa showed that prevalence of hepatic steatosis decreased from 17% to 3% among 30 adolescents who switched to a DTG-containing regimen but increased from 8% to 16% among 38 adolescents who continued a non-DTG-containing regimen. Additionally, cholesterol and triglycerides were lower in those who switched to DTG and in whom no excess weight gain was observed.⁵² In other studies, however, the use of INSTIs, as well as TAF, has been associated with weight gain in adults and adolescents, with emerging data showing an association in children.⁵³⁻⁵⁷ Finally, NRTI-sparing regimens, including the dual-drug oral regimens (DRV and an INSTI or DTG/RPV) and the approved long-acting injectable regimen (CAB with RPV) described above, may be considered in patients with NRTI toxicity who otherwise are eligible for these complete ARV regimens. In a small subgroup analysis of the SWORD study, participants switched to DTG/RPV experienced small but statistically significant improvement in bone mineral density and bone turnover markers compared with those who continued on TDF.⁵⁸ Of note, however, is that, although small in number, more participant adverse events that led to discontinuation were reported in the DTG/RPV arm (3%) than in the arm in which participants stayed on their current regimen (<1%).²⁰

Treatment Failure

Treatment failure is another common reason providers change ARV regimens in children with HIV. This topic is covered in [Recognizing and Managing Antiretroviral Treatment Failure](#).

Regimens That Are Not Recommended for Use in Children

Monotherapy PI regimens (DRV/r, LPV/r, atazanavir/ritonavir)^{59,60} and monotherapy regimens of DTG^{61,62} have been used to simplify or reduce the toxicity of regimens in adult patients who have sustained virologic suppression, but with varying success. These strategies are still being explored, but they are not currently recommended as management strategies in children because of the lack of data.^{60,63-66}

Potential Antiretroviral Drug Switches in Children with Virologic Suppression

Table 18 below contains examples of potential ARV drug changes in children with sustained virologic suppression on their current regimen for the purpose of treatment simplification, optimization, or reduced toxicity. When considering such a change, a clinician should first ensure that a recent viral load test indicates that the child is not experiencing virologic failure and that the child has a reliable history of good adherence (assessed by self and parental report, pharmacy refill, prior viral loads, etc.). Clinicians also must consider ART history, tolerability, ability to swallow tablets, and all prior drug-resistance test results to avoid choosing new ARV drugs for which archived drug resistance would reemerge and limit the activity of the regimen.⁶⁷⁻⁷¹ The evidence that supports many of these ARV changes is indirect (i.e., extrapolated from data about drug performance during initial therapy or follow-up therapy after treatment failure). When such changes are made, careful monitoring (e.g., taking a viral load measurement 2–4 weeks after making the switch to the new regimen) is important to ensure that virologic suppression is maintained.

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

This list is not exhaustive and does not necessarily contain all potential treatment options. Instead, it provides examples of changes that could be made. The table includes information only about switching between ARV drugs; **it does not include all the information that clinicians should consider before prescribing these drugs, such as drug cost and the patient's insurance coverage.** Refer to the individual drug sections; [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-Packaged Formulation, by Drug Class](#); and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#) in [Appendix A. Pediatric Antiretroviral Drug Information](#) for further information about the use and administration of specific ARV drugs and FDC formulations.

For images of most of the ARV drugs listed in this table, see the [Antiretroviral Medications](#) section of the National HIV Curriculum. In addition, a resource from the United Kingdom illustrates the relative sizes of individual ARV drug FDC tablets (see the [ARV Chart in HIV i-Base](#)). Although most of the drugs listed in that chart are the same as those in the United States, not all formulations available in the United States are included, and there are differences in a few of the brand names.

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|--|--|--|
| NRTIs | | | |
| ABC Twice Daily | Aged ≥3 months ^b | ABC once daily | See the Abacavir^b section for more information. |
| 3TC Twice Daily | Aged ≥3 years | 3TC once daily | See the Lamivudine section for more information. |
| | Any age (starting at full-term birth) Any weight | FTC once daily | See the Emtricitabine section for more information. |
| ZDV | Aged ≥1 months ^b | ABC | Less long-term mitochondrial toxicity Children aged ≥3 months can take ABC once daily. |
| | Weighing 17 kg to <25 kg | TDF | TDF is a reasonable, once-daily option for HLA-B*5701-positive children for whom ABC is not recommended and in whom ZDV is not tolerated. TDF is available as an oral powder and as low-strength tablets alone or in combination with FTC. |
| | Weighing ≥14 kg | TAF ^c | Less long-term mitochondrial toxicity. Once-daily dosing. Only available in coformulation with other ARV drugs; can further reduce pill burden. TAF is preferred over TDF because of the lower risk of bone and renal toxicity, but it may be associated with weight gain and lipid abnormalities. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|---|---|--|
| | Weighing ≥ 14 kg | FTC/TAF ^c (Descovy) | Once-daily dosing. This combination NRTI medication may be more desirable because of smaller pill size and reduced pill burden. Benefits as described for TAF. |
| Any NRTI | Aged ≥ 12 years Weighing ≥ 35 kg | CAB and RPV co-packaged regimen as Cabenuva | NRTI-sparing regimen. Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | DTG/RPV (Juluca) | NRTI-sparing FDC that is a complete regimen. In addition to age and weight criteria (based on RPV component because DTG was approved for younger ages/lower weights), must be virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months and without history of treatment failure. Should be taken with food. No pediatric data. |
| NNRTIs | | | |
| NVP or EFV | Any age (starting at full-term birth) Weighing ≥ 2 kg | RAL ^d | RAL is preferred over NVP in infants from birth to age 4 weeks who weigh ≥ 2 kg. Both are dosed twice daily in children. Note that DTG and BIC have a higher barrier to resistance than RAL. In a child >1 month of age, DTG is preferred. See DTG below. |
| | Age ≥ 4 weeks Weighing ≥ 3 kg | DTG | DTG is available as a single drug in dispersible and film-coated tablet formulations, or as part of an FDC tablet, all of which can be dosed once daily if no documented resistance or history of failure with INSTI agents exists. DTG plus FTC/TAF (Descovy) in patients weighing at least 14 kg or the weight-appropriate dose of FTC/TDF (Truvada) can be used in children weighing 20 kg to <25 kg. DTG is available as a component of the FDC ABC/DTG/3TC, which is a complete ARV regimen that can be given to infants and children aged ≥ 3 months and weighing ≥ 6 kg to <25 kg in dispersible tablets (Triumeq PD) and to children and adolescents weighing ≥ 25 kg in a single tablet to be swallowed (Triumeq). Higher barrier to resistance, which makes it a good choice for patients who have poor adherence. May improve lipid levels. See the Dolutegravir section for more information. |
| | Aged ≥ 3 months Weighing ≥ 6 kg to <25 kg | ABC/DTG/3TC (Triumeq PD) | Once-daily dosing. Dispersible tablets with dosage for use in children based on weight. Aligns a child's regimen with an efficacious regimen that is used in adults. See the Dolutegravir section for more information. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|---|---|--|
| | Aged ≥3 months Weighing ≥5 kg | ATV/r | ATV/r has a potentially greater barrier to resistance; however, taking ATV/r may be difficult for some patients, as ATV oral powder must be mixed with food or a beverage before administration, and the palatability of the RTV oral solution is poor. |
| | Aged ≥3 years Weighing ≥10 kg | DRV/r | DRV/r has a potentially greater barrier to resistance. DRV/r is administered twice daily to patients aged <12 years but may be administered once daily in children aged ≥12 years who do not have any DRV resistance mutations. Note that the palatability of the RTV oral solution is poor when considering administering to children not able to swallow tablets. |
| | Weighing ≥14 kg | BIC as Biktarvy | Once-daily dosing. BIC is available as a component of the FDC tablet BIC/FTC/TAF (Biktarvy) in two weight-based dose formulations—one formulation for those ≥14 kg to <25 kg and another for those ≥25 kg. This is a complete ARV regimen that can be taken with or without food. |
| | Weighing ≥25 kg | EVG as Genvoya | EVG is available as a component of the FDC tablet EVG/c/FTC/TAF (Genvoya), which is a complete ARV regimen that must be taken with food. |
| | Weighing ≥35 kg | DOR | DOR is available in a once-daily FDC tablet DOR/3TC/TDF (Delstrigo). Fewer side effects than reported with EFV. It has continued activity in the setting of some NNRTI mutations. |
| | Aged ≥12 years Weighing ≥35 kg | CAB and RPV co-packaged regimen as Cabenuva | Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |
| | Aged ≥12 years Weighing ≥35 kg | RPV | Lower incidence of adverse lipid effects. May have fewer sleep disturbances and neuropsychiatric symptoms compared to EFV. RPV has continued activity in the setting of some NNRTI mutations. |
| PIs | | | |
| LPV/r Twice Daily | Any age (starting at full-term birth) Weighing ≥2 kg | RAL ^d | Better palatability. RAL HD can only be given once daily in those weighing ≥40 kg. Unlike LPV/r, the use of RAL is not restricted to infants with a corrected gestational age of ≥42 weeks and a postnatal age of ≥14 days. RAL granules may be difficult to dose for some caregivers. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|--|--|---|
| | Age \geq 4 weeks Weighing \geq 3 kg | DTG | Once-daily dosing if no documented resistance or history of failure with INSTI agents exists. May be better tolerated, and it can be given as a dispersible tablet in young children. DTG is available as a component of the FDC ABC/DTG/3TC, which is a complete ARV regimen that can be given to infants and children aged \geq 3 months and weighing \geq 6 kg to <25 kg in dispersible tablets (Triumeq PD) and to children and adolescents weighing \geq 25 kg in a single tablet to be swallowed (Triumeq). DTG plus FTC/TAF (Descovy) in those weighing at least 14 kg, or the weight-appropriate dose of FTC/TDF (Truvada) can be used in children weighing 20 kg to <25 kg. May improve lipid levels. See the Dolutegravir section for more information. |
| | Aged \geq 3 months Weighing \geq 6 kg to <25 kg | ABC/DTG/3TC (Triumeq PD) | Once-daily dosing. Dispersible tablets with dosage for use in children based on weight. Aligns a child's regimen with an efficacious regimen that is used in adults. See the Dolutegravir section for more information. |
| | Aged \geq 3 years Weighing \geq 10 kg | EFV | Once-daily dosing. Better palatability. Lower incidence of adverse lipid effects. Review NNRTI mutations before use. See the Efavirenz section for concerns about Efavirenz dosing for children aged <3 years. |
| | Aged \geq 3 months Weighing \geq 5 kg | ATV/r | Once-daily dosing. ATV/r may have a lower incidence of adverse lipid effects; however, taking ATV/r may be difficult for some patients, as ATV oral powder must be mixed with food or a beverage before administration, and the palatability of the RTV oral solution is poor. |
| | Aged \geq 3 years Weighing \geq 10 kg | DRV/r | DRV/r may have a lower incidence of adverse lipid effects. DRV/r is administered twice daily to patients aged <12 years, but it may be administered once daily in children aged \geq 12 years who do not have DRV resistance mutations. Note that palatability of the RTV oral solution is poor when considering administering to children not able to swallow tablets. |
| | Weighing \geq 14 kg | BIC as Biktarvy | Once-daily dosing. BIC is available as a component of the FDC tablet BIC/FTC/TAF (Biktarvy) in two weight-based dose formulations—one for those \geq 14 kg to <25 kg and another for those \geq 25 kg. This is a complete ARV regimen that can be taken with or without food. |
| | Weighing \geq 25 kg | EVG as Genvoya | EVG is available as a component of the FDC tablet EVG/c/FTC/TAF (Genvoya), which is a complete ARV regimen that must be taken with food. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|---|---|---|
| | Weighing ≥ 35 kg | DOR | DOR is available in a once-daily FDC tablet DOR/3TC/TDF (Delstrigo). Fewer side effects than reported with EFV. It has continued activity in the setting of some NNRTI mutations. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | CAB and RPV co-packaged regimen as Cabenuva | Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | RPV | May be better tolerated. Lower incidence of adverse lipid effects. It has continued activity in the setting of some NNRTI mutations. |
| INSTIs | | | |
| RAL | Age >1 month and weighing <14 kg Weighing ≥ 14 kg | DTG DTG or BIC | Once-daily dosing. Higher barrier to resistance. DTG is available as a single drug in a dispersible tablet for infants and children weighing ≥ 3 kg; in a dispersible FDC for children weighing ≥ 6 kg to 25 kg; in a single-drug film-coated tablet for children weighing ≥ 14 kg; or as an FDC tablet. All of these can be dosed once daily if no documented resistance or history of failure with INSTI agents exists. DTG plus FTC/TAF (Descovy) in those weighing at least 14 kg or the weight-appropriate dose of FTC/TDF (Truvada) can be used in children weighing 20 kg to <25 kg. DTG is available as a component of the FDC ABC/DTG/3TC, which is a complete ARV regimen that can be given to infants and children aged ≥ 3 months and weighing ≥ 6 kg to <25 kg in dispersible tablets (Triumeq PD) and to children and adolescents weighing ≥ 25 kg in a single tablet to be swallowed (Triumeq). See the Dolutegravir section for more information. BIC has once-daily dosing and a higher barrier to resistance. BIC is available as a component of the FDC tablet BIC/FTC/TAF (Biktarvy) in two weight-based dose formulations—one for those ≥ 14 kg to <25 kg and another for those ≥ 25 kg. This is a complete ARV regimen that can be taken with or without food. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | CAB and RPV co-packaged regimen as Cabenuva | Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---|---|---|---|
| EVG/c | Weighing ≥ 14 kg | DTG or BIC | <p>Once-daily dosing. Higher barrier to resistance. DTG is available as a single drug in a dispersible tablet for infants and children weighing ≥ 3 kg; in a dispersible FDC for children weighing ≥ 6 kg to < 25 kg; in a single-drug film-coated tablet for children weighing ≥ 14 kg; or as an FDC tablet. All of these can be dosed once daily if no documented resistance or history of failure with INSTI agents exists. DTG plus FTC/TAF (Descovy) in those weighing at least 14 kg or the weight-appropriate dose of FTC/TDF (Truvada) can be used in children weighing 20 kg to < 25 kg. DTG is available as a component of the FDC ABC/DTG/3TC, which is a complete ARV regimen that can be given to infants and children aged ≥ 3 months and weighing ≥ 6 kg to < 25 kg in dispersible tablets (Triumeq PD) and to children and adolescents weighing ≥ 25 kg in a single tablet to be swallowed (Triumeq). See the Dolutegravir section for more information.</p> <p>BIC has once-daily dosing and a higher barrier to resistance. BIC is available as a component of the FDC tablet BIC/FTC/TAF (Biktarvy) in two weight-based dose formulations—one for those ≥ 14 kg to < 25 kg and another for those ≥ 25 kg. This is a complete ARV regimen that can be taken with or without food.</p> |
| | Aged ≥ 12 years Weighing ≥ 35 kg | CAB and RPV co-packaged regimen as Cabenuva | Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |
| Other | | | |
| Any Multi-Pill and/or Twice-Daily Regimen | Aged ≥ 3 months Weighing ≥ 6 kg to < 25 kg | ABC/DTG/3TC (Triumeq PD) | Once-daily dosing. Dispersible tablets with dosage for use in children based on weight. Aligns a child's regimen with an efficacious regimen that is used in adults. See the Dolutegravir section for more information. |
| | Weighing ≥ 14 kg | FTC/TAF ^c (Descovy) plus DTG | Once-daily dosing. This regimen may be more desirable because of smaller pill sizes, but it has a higher pill burden (two pills instead of one). Aligns a child's regimen with an efficacious regimen that is used in adults. See the Dolutegravir section for more information. |
| | Weighing ≥ 14 kg | BIC/FTC/TAF (Biktarvy) | Once-daily dosing. Single pill that can be taken with or without food. Available in two weight-based dose formulations—one for those ≥ 14 kg to < 25 kg and another for those ≥ 25 kg. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|---|---|--|
| | Weighing ≥ 25 kg | ABC/DTG/3TC (Triumeq) | Once-daily dosing. Single pill to be swallowed. Aligns a child's regimen with an efficacious regimen that is used in adults. Large pill size may be a deterrent. See the Dolutegravir section for more information. |
| | Weighing ≥ 25 kg | EVG/c/FTC/TAF (Genvoya) | Once-daily dosing. Single pill. Alignment with adult ARV regimens. Must be taken with food. |
| | Weighing ≥ 35 kg | DOR/3TC/TDF (Delstrigo) | Once-daily dosing. Single pill. Aligns a child's regimen with an efficacious regimen that is used in adults. Must be taken with food at a consistent time daily. Renal and bone toxicity of TDF limit its use. Review NNRTI mutations and check for drug-drug interactions before use. |
| | Weighing ≥ 35 kg SMR 4 or 5 | EVG/c/FTC/TDF (Stribild) | Once-daily dosing. Single pill. Aligns a child's regimen with an efficacious regimen that is used in adults. Must be taken with food. Renal and bone toxicity of TDF limit its use. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | CAB and RPV co-packaged regimen as Cabenuva | Long-acting injectable, complete ARV regimen requiring two IM injections every 1 to 2 months that together are an alternative to daily oral ARV regimens. Must consider prior history of treatment failure and known or suspected drug resistance to individual drugs. Injection site reactions are common but do not often result in discontinuation of the regimen. See the Cabotegravir section for more information. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | FTC/RPV/TAF (Odefsey) | Once-daily dosing. Single pill. Aligns a child's regimen with an efficacious regimen that is used in adults. Review NNRTI mutations and check for drug-drug interactions before use. Must be taken with food at a consistent time daily. |
| | Aged ≥ 12 years Weighing ≥ 35 kg SMR 4 or 5 | FTC/RPV/TDF (Complera) | Once-daily dosing. Single pill. Aligns a child's regimen with an efficacious regimen that is used in adults. Review NNRTI mutations and check for drug-drug interactions before use. Must be taken with food at a consistent time daily. Renal and bone toxicity of TDF limit its use. |
| | Aged ≥ 12 years Weighing ≥ 35 kg | DTG/RPV (Juluca) | NRTI-sparing FDC that is a complete regimen. In addition to age and weight criteria (based on RPV component because DTG is approved for younger ages/lower weights), must be virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months and without history of treatment failure. Should be taken with food. No pediatric data. |

Table 18. Examples of Changes in Antiretroviral Regimen Components for Children with Sustained Virologic Suppression

| Current ARV Drug(s) | Age, Weight, and Sexual Maturity Rating Requirements | Potential ARV Drug Switch ^a | Comment |
|---------------------|--|--|---|
| | Aged ≥12 years Weighing ≥25 kg | DTG/3TC (Dovato) | Once-daily, two-drug complete regimen approved in adolescents and adults with no known mutations associated with resistance to the individual components who are either ART-naïve or who are virologically suppressed on a stable ART regimen with no history of treatment failure. Because adolescents may have difficulties adhering to therapy, close monitoring with viral load testing is recommended. |

^a The possibility of planned and unplanned pregnancy should be considered when selecting an ART regimen for an adolescent. When discussing ART options with adolescents and their caregivers, it is important to consider childbearing potential and the benefits and risks of all ARV drugs and to provide the information and counseling needed to support informed decision-making; refer to the Perinatal Guidelines (see [Recommendations for Use of Antiretroviral Drugs During Pregnancy](#), [Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive](#), and [Appendix C. Antiretroviral Counseling Guide for Health Care Providers](#)).

^b For infants and young children who are being treated with liquid formulations of ABC, initiation with once-daily ABC is not generally recommended. In clinically stable patients with undetectable viral loads who have had stable CD4 T lymphocyte cell counts on twice-daily ABC, the dose can be changed from twice daily to once daily **in those aged ≥3 months**. ABC is not approved by the U.S. Food and Drug Administration for use in neonates and infants aged <3 months. Data from the [IMPAACT P1106 trial](#) and two observational cohorts provide reassuring evidence of the safety of ABC in infants aged <3 months. Based on these data, clinicians may consider the use of **twice daily** ABC in infants aged ≥1 month to <3 months, in consultation with a pediatric HIV specialist (see the [Abacavir](#) section for more information).

^c For children and adolescents weighing ≥14 kg to <35 kg, TAF can be used in combination with an INSTI or an NNRTI, but **not** a boosted PI. For children and adolescents weighing ≥35 kg, TAF can be used in combination with an INSTI, NNRTI, or boosted PI.

^d RAL is recommended for twice-daily use in children. Chewable tablets can be used as dispersible tablets starting at 4 weeks of age. RAL HD once daily is **only recommended** for virologically suppressed children weighing ≥40 kg.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; ATV/r = atazanavir/ritonavir; BIC = bictegravir; CAB = cabotegravir; DOR = doravirine; DRV = darunavir; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FTC = emtricitabine; HD = high dose; HLA = human leukocyte antigen; IM = intramuscular; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

References

1. Hsu AJ, Neptune A, Adams C, et al. Antiretroviral stewardship in a pediatric HIV clinic: development, implementation and improved clinical outcomes. *Pediatr Infect Dis J.* 2016;35(6):642-648. Available at: <https://pubmed.ncbi.nlm.nih.gov/26906161>.
2. Maiese EM, Johnson PT, Bancroft T, et al. Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons. *Curr Med Res Opin.* 2016;32(12):2039-2046. Available at: <https://pubmed.ncbi.nlm.nih.gov/27552553>.
3. Brooks KM, Kiser JJ, Ziembka L, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. *Lancet HIV.* 2023;10(8):e506-e517. Available at: <https://pubmed.ncbi.nlm.nih.gov/37541705>.
4. Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network. *HIV Med.* 2019;20(2):169-174. Available at: <https://pubmed.ncbi.nlm.nih.gov/30561888>.
5. Natukunda E, Gaur A, Kosalaraksa P, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. *Lancet Child Adolescent Health.* 2017;1(1):27-34. Available at: <http://www.sciencedirect.com/science/article/pii/S2352464217300093?via%3Dhub>.
6. Liberty A, Strehlau R, Rakhmanina N, et al. Acceptability & palatability of low dose B/F/TAF & E/C/F/TAF in children (≥ 2 y) with HIV. Presented at: International Workshop on HIV & Pediatrics 2020; 2020. Virtual. Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2020/abstract/acceptability-palatability-low-dose>.
7. Rotsaert A, Nostlinger C, Collin O, et al. Acceptability of a new 4-in-1 abacavir/lamivudine/lopinavir/ritonavir paediatric fixed-dose combination: the caregiver-child dyad's perspective. Presented at: International Workshop on HIV & Pediatrics 2020; 2020. Virtual Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2020/abstract/acceptability-new-4-1>.
8. Foissac F, Blanche S, Dollfus C, et al. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. *Br J Clin Pharmacol.* 2011;72(6):940-947. Available at: <https://pubmed.ncbi.nlm.nih.gov/21649692>.
9. Chokephaibulkit K, Prasitsuebsai W, Wittawatmongkol O, et al. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥ 7 years. *Antivir Ther.* 2012;17(7):1263-1269. Available at: <https://pubmed.ncbi.nlm.nih.gov/22954687>.
10. Paediatric European Network for Treatment of AIDS. Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. *AIDS.* 2015;29(18):2447-2457. Available at: <https://pubmed.ncbi.nlm.nih.gov/26558544>.

11. Gondrie IPE, Bastiaans DET, Fraaij PLA, et al. Sustained viral suppression in HIV-infected children on once-daily lopinavir/ritonavir in clinical practice. *Pediatr Infect Dis J*. 2017;36(10):976-980. Available at: <https://pubmed.ncbi.nlm.nih.gov/28475554>.
12. Orkin C, Bernal Morell E, Tan DHS, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label Phase 3 FLAIR study. *Lancet HIV*. 2021;8(11):e668-e678. Available at: <https://pubmed.ncbi.nlm.nih.gov/34656207>.
13. Lowenthal E, Chapman J, Calabrese K, et al. Adolescent and parent experiences with long-acting injectables in the MOCHA study. Presented at: Conference on Retroviruses and Opportunistic Infections; 2022. Virtual. Available at: <https://www.croiconference.org/abstract/adolescent-and-parent-experiences-with-long-acting-injectables-in-the-mocha-study>.
14. Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, Phase 3b, non-inferiority study. *Lancet HIV*. 2021;8(11):e679-e689. Available at: <https://pubmed.ncbi.nlm.nih.gov/34648734>.
15. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. *Lancet HIV*. 2023;10(9):e566-e577. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37567205>.
16. Gaur A, Capparelli E, Baltrusaitis K, et al. Long-acting cabotegravir plus rilpivirine in adolescents with HIV: week 24 IMPAACT 2017(MOCHA) study. Presented at: Conferences on Retroviruses and Opportunistic Infections 2024. Denver, CO. Available at: <https://www.croiconference.org/abstract/long-acting-cabotegravir-plus-rilpivirine-in-adolescents-with-hiv-week-24-impaact-2017mocha-study>.
17. Lowenthal ED, Chapman J, Vaca MZ, et al. IMPACCT 2017 Adolescent/Parent experiences with LA Cabotegravir plus Rilpivirine for HIV treatment. Presented at: Conference on Retroviruses and Opportunistic Infections; 2024. Denver, Colorado. . Available at: https://www.natap.org/2024/CROI/croi_49.htm.
18. Waters L, Sparrowhawk A. Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages. *Curr Opin HIV AIDS*. 2022;17(3):121-126. Available at: <https://pubmed.ncbi.nlm.nih.gov/35439786>.
19. Rakhmanina N, Richards K, Adeline Koay WL. Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: considerations for dosing schedule and monitoring. *J Acquir Immune Defic Syndr*. 2023;92(3):e14-e17. Available at: <https://pubmed.ncbi.nlm.nih.gov/36480701>.
20. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet*. 2018;391(10123):839-849. Available at: <https://pubmed.ncbi.nlm.nih.gov/29310899>.

21. Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. *Lancet HIV*. 2019;6(9):e576-e587. Available at: <https://pubmed.ncbi.nlm.nih.gov/31307948>.
22. van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and -2 randomized clinical trials. *J Acquir Immune Defic Syndr*. 2020;85(3):325-330. Available at: <https://pubmed.ncbi.nlm.nih.gov/32675772>.
23. Compagnucci A, Chan MK, Saidi Y, et al. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV –week 48 results of the DA SMILE Penta-17-ANRS 152 clinical trial. *EClinicalMedicine*. 2023;60:102025. Available at: <https://pubmed.ncbi.nlm.nih.gov/37304494>.
24. Libre JM, Brites C, Cheng CY, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized Trial. *Clin Infect Dis*. 2023;76(4):720-729. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35235656>.
25. Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. *Clin Infect Dis*. 2022;75(6):975-986. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35079789>.
26. Puthanakit T, Aurpibul L, Lopez M, et al. Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)- naive adolescents living with HIV-1: DANCE study week 96 results. Presented at International AIDS Society; July 23-26, 2023, Year; Brisbane, Australia. Available at: https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/450b1aad-cf09-4084-b484-0c909235ec90/450b1aad-cf09-4084-b484-0c909235ec90_viewable_rendition_v.pdf?medcommid=REF--ALL_00509&product=Dolutegravir%2BLamivudine.
27. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. *Lancet Infect Dis*. 2012;12(7):521-530. Available at: <https://pubmed.ncbi.nlm.nih.gov/22424722>.
28. Coovadia A, Abrams EJ, Strehlau R, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. *JAMA*. 2015;314(17):1808-1817. Available at: <https://pubmed.ncbi.nlm.nih.gov/26529159>.
29. Murnane PM, Strehlau R, Shiau S, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term

- outcomes of a randomized trial. *Clin Infect Dis*. 2017;65(3):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/28419200>.
30. Natukunda E, Rodriguez C, McGrath E, et al. B/F/TAF in virologically suppressed adolescents and children: two-year outcomes in 6 to <18 year olds and six-month outcomes in toddlers. Presented at: 13th International Workshop on HIV Pediatrics 2021. Virtual. Available at: https://www.natap.org/2021/IAS/IAS_80.htm.
31. Anugulruengkitt S, A. Gaur, P. Kosalaraksa, A. Liberty, Y. Shao, et al. . Long-term safety & efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (E/C/F/TAF) single-tablet regimen in children and adolescents living with HIV. Abstract 4 Presented at: International Workshop on HIV Pediatrics 2021 2021. Virtual. Available at: https://www.natap.org/2021/IAS/IAS_79.htm.
32. Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Med*. 2021;385(27):2531-2543. Available at: <https://pubmed.ncbi.nlm.nih.gov/34965338>.
33. Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022;9(9):e638-e648. Available at: <https://pubmed.ncbi.nlm.nih.gov/36055295>.
34. Gill MM, Herrera N, Guilaze R, et al. Virologic outcomes and ARV switch profiles 2 years after national rollout of dolutegravir to children less than 15 years in southern Mozambique. *Pediatr Infect Dis J*. 2023;42(10):893-898. Available at: <https://pubmed.ncbi.nlm.nih.gov/37409808>.
35. Kouamou V, Manasa J, Maposphere C, et al. Tenofovir, lamivudine and dolutegravir (TLD) among rural adolescents in Zimbabwe, A cautionary tale. Presented at: International Workshop on HIV Pediatrics 2021. Virtual Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2021/abstract/tenofovir-lamivudine-and-dolutegravir>.
36. Van de Ven R, Antelman G, Masenge T, Kimambo S. Impact of ARV optimization on HIV viral load suppression among children in Tanzania. Presented at: International AIDS Society 2021. Virtual Available at: <https://theprogramme.ias2021.org/Abstract/Abstract/1498>.
37. Bacha JM, Dlamini S, Anabwani F, et al. Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in eastern and southern Africa. *Pediatr Infect Dis J*. 2023;42(7):576-581. Available at: <https://pubmed.ncbi.nlm.nih.gov/36795586>.
38. Rodriguez C. SR, Chokephaibulkit K., , et al. One year outcome of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed children ≥ 2 years weighing 14 to < 25kg. Presented at: Internataional Workshop on HIV & Pediatrics 2022. Montreal, Canada. Available at: https://www.natap.org/2022/IAC/IAC_90.htm.

39. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760>.
40. Phongsamart W, Jantarabenjakul W, Chantaratin S, et al. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. *J Int AIDS Soc.* 2022;25(1):e25862. Available at: <https://pubmed.ncbi.nlm.nih.gov/35001501>.
41. Melvin AJ, Yee KL, Gray KP, et al. Pharmacokinetics, tolerability, and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets in adolescents living with HIV: Week 24 results from IMPAACT 2014. *J Acquir Immune Defic Syndr.* 2023;92(2):153-161. Available at: <https://pubmed.ncbi.nlm.nih.gov/36215957>.
42. Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. *Antivir Ther.* 2005;10(8):917-924. Available at: <https://pubmed.ncbi.nlm.nih.gov/16430197>.
43. Fabiano V, Giacomet V, Vigano A, et al. Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz. *Eur J Pediatr.* 2013;172(8):1089-1096. Available at: <https://pubmed.ncbi.nlm.nih.gov/23636286>.
44. Rosso R, Nasi M, Di Biagio A, et al. Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. *Pediatr Infect Dis J.* 2008;27(1):17-21. Available at: <https://pubmed.ncbi.nlm.nih.gov/18162932>.
45. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. *HIV Med.* 2008;9(5):317-321. Available at: <https://pubmed.ncbi.nlm.nih.gov/18331562>.
46. Gonzalez-Tome MI, Amador JT, Pena MJ, et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. *BMC Infect Dis.* 2008;8:144. Available at: <https://pubmed.ncbi.nlm.nih.gov/18945352>.
47. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. *Lancet Infect Dis.* 2014;14(7):581-589. Available at: <https://pubmed.ncbi.nlm.nih.gov/24908551>.
48. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. *AIDS.* 2010;24(11):1697-1707. Available at: <https://pubmed.ncbi.nlm.nih.gov/20467288>.

49. Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. *AIDS*. 2012;26(4):475-481. Available at: <https://pubmed.ncbi.nlm.nih.gov/22112606>.
50. Bagella P, Squillace N, Ricci E, et al. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. *Infect Drug Resist*. 2019;12:1385-1391. Available at: <https://pubmed.ncbi.nlm.nih.gov/31213857>.
51. Calza L, Colangeli V, Borderi M, et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients. *J Antimicrob Chemother*. 2019;74(3):731-738. Available at: <https://pubmed.ncbi.nlm.nih.gov/30541118>.
52. Rose PC, De la Rey Nel E, Cotton MF, et al. Decreased hepatic steatosis in South African adolescents with perinatal HIV switching to dolutegravir-containing regimens. *Pediatr Infect Dis J*. 2023;42(7):564-572. Available at: <https://pubmed.ncbi.nlm.nih.gov/36917035>.
53. Eckard AR, McComsey GA. Weight gain and integrase inhibitors. *Curr Opin Infect Dis*. 2020;33(1):10-19. Available at: <https://pubmed.ncbi.nlm.nih.gov/31789693>.
54. Sokhela S, Venter WDF, Bosch B, et al. Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens. *Open Forum Infect Dis*. 2024;11(3):ofae007. Available at: <https://pubmed.ncbi.nlm.nih.gov/38529213>.
55. Dirajlal-Fargo S, Koay WLA, Levy ME, et al. Effect of integrase inhibitors on weight gain in children and adolescents with HIV. Abstract 826. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020. Boston, MA. Available at: <https://www.croiconference.org/abstract/effect-of-integrase-inhibitors-on-weight-gain-in-children-and-adolescents-with-hiv>.
56. Yeoh DK, Campbell AJ, Bowen AC. Increase in body mass index in children with HIV, switched to tenofovir alafenamide fumarate or dolutegravir containing antiretroviral regimens. *Pediatr Infect Dis J*. 2021;40(5):e215-e216. Available at: <https://pubmed.ncbi.nlm.nih.gov/33847305>.
57. Mallon PW, Brunet L, Hsu RK, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. *J Int AIDS Soc*. 2021;24(4):e25702. Available at: <https://pubmed.ncbi.nlm.nih.gov/33838004>.
58. McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. *AIDS*. 2018;32(4):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239893>.
59. Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. *Expert Opin Drug Saf*. 2017;16(8):923-932. Available at: <https://pubmed.ncbi.nlm.nih.gov/28621159>.

60. Arribas JR, Girard PM, Paton N, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. *HIV Med.* 2016;17(5):358-367. Available at: <https://pubmed.ncbi.nlm.nih.gov/26709605>.
61. Brenner BG, Thomas R, Blanco JL, et al. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. *J Antimicrob Chemother.* 2016;71(7):1948-1953. Available at: <https://pubmed.ncbi.nlm.nih.gov/27029845>.
62. Wijting IEA, Wit F, Rokx C, et al. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. *EClinicalMedicine.* 2019;17:100210. Available at: <https://pubmed.ncbi.nlm.nih.gov/31891143>.
63. Rokx C, Schurink CA, Boucher CA, Rijnders BJ. Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients. *J Antimicrob Chemother.* 2016;71(6):1632-1636. Available at: <https://pubmed.ncbi.nlm.nih.gov/26888910>.
64. Pinnetti C, Lorenzini P, Cozzi-Lepri A, et al. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication. *J Int AIDS Soc.* 2014;17(4 Suppl 3):19809. Available at: <https://pubmed.ncbi.nlm.nih.gov/25397553>.
65. Santos JR, Llibre JM, Bravo I, et al. Short communication: efficacy and safety of treatment simplification to lopinavir/ritonavir or darunavir/ritonavir monotherapy: a randomized clinical trial. *AIDS Res Hum Retroviruses.* 2016;32(5):452-455. Available at: <https://pubmed.ncbi.nlm.nih.gov/26781004>.
66. Kosalaraksa P, Ananworanich J, Puthanakit T, et al. Long-term lopinavir/ritonavir monotherapy in HIV-infected children. *Pediatr Infect Dis J.* 2013;32(4):350-353. Available at: <https://pubmed.ncbi.nlm.nih.gov/23190774>.
67. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. *J Int AIDS Soc.* 2013;16:18579. Available at: <https://pubmed.ncbi.nlm.nih.gov/23782477>.
68. Wensing AM, Calvez V, Gunthard HF, et al. 2015 Update of the drug resistance mutations in HIV-1. *Top Antivir Med.* 2015;23(4):132-141. Available at: <https://pubmed.ncbi.nlm.nih.gov/26713503>.
69. Dehority W, Deville JG, Lujan-Zilberman J, et al. Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescents. *Int J STD AIDS.* 2013;24(7):549-553. Available at: <https://pubmed.ncbi.nlm.nih.gov/23970770>.
70. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. *J Virol.* 2005;79(15):9625-9634. Available at: <https://pubmed.ncbi.nlm.nih.gov/16014925>.

71. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. *AIDS Patient Care STDS*. 2004;18(5):259-273. Available at: <https://pubmed.ncbi.nlm.nih.gov/15186710>.

Recognizing and Managing Antiretroviral Treatment Failure

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|---|
| <ul style="list-style-type: none">The causes of antiretroviral (ARV) treatment failure—which include poor adherence, drug resistance, poor absorption of medications, inadequate dosing, and drug–drug interactions—should be assessed and addressed (AII).Perform ARV drug-resistance testing when virologic failure occurs, while the patient is still taking the failing regimen (AI*) (see Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines for more information).ARV regimens should be chosen based on treatment history and drug-resistance testing, including both past and current resistance test results (AI*).The new regimen should include at least two, but preferably three, fully active ARV medications; the assessment of anticipated ARV activity should be based on treatment history and past resistance test results (AII*).The goal of therapy following treatment failure is to achieve and maintain virologic suppression, which is defined as a plasma viral load that is below the limits of detection as measured by highly sensitive assays with lower limits of quantification of 20 copies/mL to 75 copies/mL (AI*).When complete virologic suppression cannot be achieved, the goals of therapy are to preserve or restore immunologic function (as measured by CD4 T lymphocyte values), prevent clinical disease progression, and prevent the development of additional drug resistance that could further limit future ARV drug options (AII).Children who require evaluation and management of treatment failure should be managed by or in collaboration with a pediatric HIV specialist (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion*

[†] *Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents*

Categories of Treatment Failure

Treatment failure can be categorized as virologic failure, immunologic failure, clinical failure, or some combination of the three. Immunologic failure refers to a suboptimal immunologic response to therapy or an immunologic decline while on therapy, but no standardized definition exists. Clinical failure is defined as the occurrence of new opportunistic infections (OIs) (excluding immune reconstitution inflammatory syndrome [IRIS]) and/or other clinical evidence of HIV disease progression during therapy. Almost all antiretroviral (ARV) management decisions for treatment failure are based on addressing virologic failure.

Virologic Failure

Virologic failure refers to either an incomplete initial response to therapy or a viral rebound after virologic suppression is achieved. *Virologic suppression* is defined as having a plasma viral load below the lower level of detection, as measured by highly sensitive assays with lower limits of quantitation of <20 copies/mL to <75 copies/mL. *Virologic failure* is defined as the inability to achieve or maintain plasma viral load <200 copies/mL after 6 months of therapy. Laboratory results must be confirmed with repeat testing before a final assessment of virologic failure is made.

Infants with high plasma viral loads at the initiation of antiretroviral therapy (ART) occasionally take longer than 6 months to achieve virologic suppression. Because of this, some experts continue the treatment regimen for infants if their viral load is declining but is still ≥ 200 copies/mL at 6 months. These infants should be monitored closely until they achieve virologic suppression.¹ However, ongoing nonsuppression—especially with non-nucleoside reverse transcriptase inhibitor (NNRTI)—or raltegravir (RAL)-based regimens—increases the risk of drug resistance.^{2,3} RAL, a first-generation integrase strand transfer inhibitor (INSTI), has a low barrier to resistance and requires twice-daily dosing in children and adolescents; it is the only INSTI approved for use in infants <30 days of age. For very young infants started on an antiretroviral therapy (ART) regimen with RAL or the NNRTI nevirapine (NVP), a change to dolutegravir (DTG), a second-generation INSTI, is recommended after 30 days of age for effective and durable viral suppression (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children with HIV](#)).

The clinical implications of HIV RNA levels that are between the lower level of detection and <200 copies/mL in patients on ART remain unclear. Adults with HIV who have detectable viral loads and a quantified result <200 copies/mL after 6 months of ART generally achieve virologic suppression without changing regimens.^{4,5} However, some studies in adults have found that multiple viral load measurements of 50 copies/mL to <200 copies/mL (sometimes characterized as low-level viremia) may be associated with an increased risk of later virologic failure.⁶⁻⁹ In contrast, a recent study that followed a cohort of 57 adult patients with low-level viremia (21–200 copies/mL) reported that none of the patients had resistance to their regimens, and all had adequate plasma ARV concentrations. At 96 weeks of follow-up, 67% remained with low-level viremia, 26% had viral loads <20 copies/mL, and only 7% had virologic failure; none was attributed to viral resistance.¹⁰

“Blips”—defined as isolated episodes of a detectable but low level of plasma viral load (i.e., <500 copies/mL) that are followed by a return to viral suppression—are common and not generally reflective of short-term virologic failure, although they may indicate an increased risk of virologic failure after 12 to 24 months.¹¹⁻¹³ However, repeated or persistent plasma viral loads that are ≥ 200 copies/mL (especially viral loads that are >500 copies/mL) in patients who have previously achieved virologic suppression usually indicate virologic failure.^{5,13-15}

Poor Immunologic Response Despite Virologic Suppression

Poor immunologic response despite virologic suppression is uncommon in children.¹⁶ Patients with baseline severe immunosuppression often take longer than 1 year to achieve immune recovery, even if virologic suppression occurs more promptly (see [Appendix C. Centers for Disease Control and Prevention Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization](#)). Patients who have very low baseline CD4 T lymphocyte (CD4) cell counts before initiating ART are at higher risk of an impaired CD4 response to ART and, based on data from adult studies, may be at higher risk of death and AIDS-defining illnesses despite virologic suppression.¹⁷⁻¹⁹ During the early

treatment period, before immune recovery or in cases of persistent immunosuppression, clinical disease progression can occur. In an international study, 68% of children and adolescents had advanced/severe immunosuppression for age at initiation of ART, and 12% of pediatric and adolescent patients had a poor immunologic response (defined as advanced/severe immunosuppression for age) 1 year after viral suppression (defined as <400 copies/mL).²⁰ Among those with a poor immunologic response at 1 year after viral suppression, a fourfold increased risk of an AIDS diagnosis or death was observed compared with immune responders (rate ratio 4.04; 95% confidence interval [CI], 1.83–8.92). Poor immunologic response dropped to 7% at 2 years and 3% at 3 years in those with continued viral suppression.²⁰ Studies in adults with HIV note that CD4 count recovery at 1 year and 2 years after initiation of initial therapy is independent of the drug class used (i.e., boosted protease inhibitor [PI], INSTI, or NNRTI).²¹

In cases of poor immunologic response despite virologic suppression, clinicians should first exclude laboratory error in CD4 values or viral load measurements and ensure that CD4 values have been interpreted correctly in relation to the natural decline in CD4 count that occurs during the first 5 to 6 years of life. Another laboratory consideration is that some viral load assays may not amplify all HIV groups and subtypes (e.g., HIV-1 non-M groups, HIV-2), resulting in falsely low or negative viral load results (see [Diagnosis of HIV Infection in Infants and Children](#) and [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)). Once laboratory results are confirmed, clinicians should evaluate patients for adverse events, medical conditions, and other factors that can cause CD4 values to decrease (see [Table 19](#) below). Several drugs (e.g., corticosteroids, chemotherapeutic agents) and conditions (e.g., hepatitis C virus, tuberculosis [TB], malnutrition, Sjogren's syndrome, sarcoidosis, syphilis, cirrhosis, acute viral infections) are independently associated with low CD4 values.²²

In summary, poor immunologic response to treatment can occur. Management consists of confirming that CD4 values and viral load measurements are accurate, avoiding the use of drugs that are associated with low CD4 values, and treating other conditions that could impair CD4 recovery. The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) **does not recommend** modifying an ARV regimen based on lack of immunologic response if virologic suppression is confirmed.

Poor Clinical Response Despite Adequate Virologic and Immunologic Responses

Clinicians must carefully evaluate patients who experience clinical disease progression despite favorable immunologic and virologic responses to ART; not all cases represent ART failure. At times, after initiation of ART, patients will suffer a clinical deterioration due to paradoxical worsening of a known OI or unmasking of a previously undiagnosed OI due to a profound immune response (i.e., IRIS) related to successful viral suppression. [These circumstances, including IRIS, do not represent ART treatment failure and do not generally require discontinuation or change in ART.](#)^{23,24} Children who have suffered irreversible damage to their lungs, brain, or other organs—especially during prolonged and profound pre-treatment immunosuppression—may continue to have recurrent infections or symptoms in the damaged organs, because the immunologic improvement may not reverse damage to the organs.²⁵ Such cases do not represent ART failure, and these children would not benefit from a change in ARV regimen. Before a definitive conclusion of ART clinical failure is reached, a child should be evaluated to rule out (and, when indicated, treat) other causes or conditions that can occur with or without HIV-related immunosuppression, such as pulmonary TB, malnutrition, and malignancy.

Occasionally, however, children will develop new HIV-related OIs (e.g., *Pneumocystis jirovecii* pneumonia or esophageal candidiasis that occurs more than 6 months after achieving markedly improved CD4 values and virologic suppression) that are not related to IRIS, pre-existing organ damage, or another cause.¹⁶ Although such cases are rare, they may represent ART clinical failure, and improvement in CD4 values may not necessarily normalize immunologic function. In children who have signs of new or progressive abnormal neurodevelopment, some experts change the ARV regimen, aiming to include agents that are known to achieve higher concentrations in the central nervous system. However, the data regarding the effectiveness of this strategy are inconclusive.^{26,27}

Table 19. Discordance Among Virologic, Immunologic, and Clinical Responses

| Differential Diagnosis of Poor Immunologic Response Despite Virologic Suppression |
|---|
| Poor Immunologic Response Despite Virologic Suppression and Good Clinical Response |
| <ul style="list-style-type: none"> • Laboratory error (in CD4 value or viral load measurement) • Misinterpretation of normal, age-related CD4 count decline (i.e., the immunologic response is not actually poor) • Low pre-treatment CD4 count or percentage • AEs that are associated with the use of certain drugs (e.g., ZDV, TMP-SMX, systemic corticosteroids) • Use of systemic corticosteroids or chemotherapeutic agents • Conditions that can cause low CD4 values (e.g., HCV, acute viral infections, TB, malnutrition, Sjogren's syndrome, sarcoidosis, syphilis) |
| Poor Immunologic and Clinical Responses Despite Virologic Suppression |
| <ul style="list-style-type: none"> • Laboratory error (in CD4 value or viral load measurement) • Falsely low viral load result for an HIV strain/type that is not detected by viral load assay (i.e., HIV-1 non-M groups, HIV-1 non-B subtypes, HIV-2 [although this is unusual with newer viral load assays]) • Persistent immunodeficiency that occurs soon after initiating ART, but before ART-related reconstitution • Primary protein-calorie malnutrition • Untreated TB • Malignancy |
| Differential Diagnosis of Poor Clinical Response Despite Adequate Virologic and Immunologic Responses |
| <ul style="list-style-type: none"> • IRIS • A previously unrecognized, pre-existing infection or condition (e.g., TB, malignancy) • Malnutrition • Clinical manifestations of previous organ damage: brain (e.g., strokes, vasculopathy, worsening neurodevelopmental delay), lungs (e.g., bronchiectasis), cardiac (e.g., cardiomyopathy), renal (e.g., HIV-related kidney disease) • A new clinical event due to a non-HIV illness or condition • A new, or otherwise unexplained, HIV-related clinical event (e.g., treatment failure) |

Key: AE = adverse effect; ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; HCV = hepatitis C virus; IRIS = immune reconstitution inflammatory syndrome; TB = tuberculosis; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

Management of Virologic Failure

The approach to managing and subsequently treating virologic failure will differ depending on the etiology of the problem. When assessing a child with suspected virologic failure, clinicians should evaluate therapy adherence and medication intolerance, confirm that the prescribed dosing is correct (and understood by the child and/or caregiver) for all medications in the regimen, consider possible pharmacokinetic interactions that might lead to low drug levels, and test for possible drug resistance (see [Management of Medication Toxicity or Intolerance](#), [Appendix A. Pediatric Antiretroviral Drug Information](#), and [Drug-Resistance Testing](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)).

Although many factors can contribute to virologic failure, the main barrier to sustained virologic suppression in adults and children is incomplete adherence to medication regimens, with the subsequent emergence of viral mutations that confer partial or complete resistance to one or more components of the ARV regimen. See [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#) for guidance on assessing adherence and strategies for improving adherence.

Virologic Failure with No Antiretroviral Drug Resistance Identified

Persistent viremia in the absence of detectable viral resistance to current medications is usually a result of nonadherence, but it is important to consider other factors, such as poor drug absorption, incorrect dosing, and drug interactions. If adequate drug exposure can be ensured, then adherence to the current regimen should result in virologic suppression. Resistance testing should take place while a child is on therapy. After discontinuing therapy, plasma viral strains may quickly revert to wild type and reemerge as the predominant viral population, in which case, resistance testing can fail to identify the drug-resistant virus (see [Drug-Resistance Testing](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)). In this situation, resistance can be identified by restarting the prior medications while emphasizing adherence and repeating resistance testing in 4 weeks if plasma virus remains detectable. If the HIV plasma viral load becomes undetectable, then nonadherence was likely the original cause of virologic failure.

If a new, more convenient regimen could address the main barrier to adherence, it is reasonable for a clinician to switch a patient to this new regimen (e.g., a single fixed-dose combination [FDC] tablet taken once daily) while closely monitoring adherence and viral load (see [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#) in [Appendix A. Pediatric Antiretroviral Drug Information](#)). Similarly, if an ART side effect or tolerability is found to be impacting adherence, switching to a new regimen with close monitoring should be considered. INSTI-based, once-daily regimens in FDCs address both convenience and tolerability in most cases. However, in cases where clinicians determine that patients have poor adherence to the current regimen and that adherence is unlikely to improve with a new regimen, clinicians should [address barriers](#) to adherence before initiating a new regimen (see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)).

Virologic Treatment Failure with Antiretroviral Drug Resistance Identified

After deciding that a change in therapy is necessary, a clinician should attempt to identify at least two, but preferably three, fully active ARV agents from at least two different drug classes to use in a patient's new regimen. The clinician should consider all of the child's past and recent drug-resistance test results, the child's prior exposure to ARV drugs, whether the child and caregiver is likely to

adhere to the regimen, and whether the child and caregiver find a particular regimen acceptable.²⁸⁻³² This process often requires using agents from one or more drug classes that are new to the child. However, clinicians should be aware that drug-resistance mutations can confer cross-resistance within a drug class, so a drug that is new to the child may still have diminished antiviral potency. Substituting or adding a single drug to a failing regimen is not recommended, because this is unlikely to lead to durable virologic suppression and will likely result in additional drug resistance. When reviewing results of drug-resistance assays, clinicians should review the [Stanford University HIV Drug Resistance Database](#) to determine if a change in the ARV regimen is required and, if a change is required, which ARV agents can be retained. A pediatric HIV specialist should be consulted when determining which new regimen will have the best chance of achieving complete virologic suppression in children who have experienced treatment failure.

The process of switching a patient to a new regimen must include a discussion of treatment adherence and potential toxicity with the child and the child's caregivers. This discussion should be appropriate for the child's age and stage of development. Clinicians should be aware that some medications have conflicting food requirements and concomitant medication restrictions that may complicate the administration of a regimen. Timing of medication administration is particularly important because it helps ensure adequate ARV drug exposures throughout the day. Palatability, pill size, number of pills, and dosing frequency all need to be considered when choosing a new regimen.³³

Therapeutic Options to Achieve Complete Virologic Suppression After Virologic Failure

ARV regimens should be chosen based on a child's treatment history and drug-resistance test results to optimize ARV drug potency in the new regimen (see [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#)). A general strategy for regimen changes is shown in [Table 20](#) below; however, as additional agents are licensed and studied for use in children, newer regimens that are better tailored to the needs of each child may be constructed.

It is important to review individual drug profiles for information about drug interactions and dose adjustments when devising a regimen for children with multiclass drug resistance. [Appendix A, Pediatric Antiretroviral Drug Information](#) provides detailed information on drug formulations, pediatric and adult doses, and toxicity, as well as discussions of the available data on the use of ARV drugs in children. Previously prescribed drugs that were discontinued because of poor tolerance or poor adherence may sometimes be reintroduced if drug resistance did not develop and if prior difficulties with tolerance and adherence can be overcome (e.g., by switching to a new formulation, such as an FDC tablet).

The availability of newer drugs within existing drug classes and the introduction of new classes of drugs increase the likelihood of finding three active drugs, even for children with extensive drug resistance (see [Table 20](#) below). INSTI-based regimens are increasingly used for children who have experienced treatment failure on NNRTI-based regimens or PI-based regimens.^{34,35} Second-generation INSTIs DTG and bictegravir have the advantage of once-daily dosing, small pill size or dispersible formulations, and higher barrier to the development of drug resistance; they also often retain ARV activity in patients who have experienced treatment failure on RAL-based therapy (see the [Dolutegravir](#) and [Bictegravir](#) sections for the latest age and weight indications).³⁶ Caution should be exercised when considering regimens that include first-generation INSTIs with a lower barrier to

resistance (e.g., RAL, elvitegravir) in children who are highly treatment experienced as they are less likely to achieve viral suppression.³⁷

Data from pediatric and adult studies support the efficacy of a regimen that contains a second-generation INSTI (DTG) plus two nucleoside reverse transcriptase inhibitors (NRTIs) for those who experience treatment failure on an initial NNRTI-based regimen. Both the Once-daily DTG-based ART in Young People vs. Standard Therapy (ODYSSEY)³⁸ and Nucleosides And Darunavir/Dolutegravir in Africa (NADIA)³⁹ trials indicate that DTG is non-inferior to a boosted-PI regimen when transitioning from a failing NNRTI-based regimen.

In ODYSSEY, 707 children weighing at least 14 kg, with a median age of 12.2 years, were randomized to DTG-based ART versus standard care for either first-line or second-line treatment. Fifty-six percent (n = 396) of participants were in the second-line therapy group (ODYSSEY B cohort), with an enrollment HIV-1 RNA viral load of at least 500 copies/mL. Participants were randomized 1:1 to either DTG and two NRTIs or second-line standard care (a third new agent and two NRTIs with at least one NRTI with preserved activity); 98% of those in the standard-care group received a boosted PI-based regimen. Boosted-PI regimens were 72% boosted lopinavir, 24% boosted atazanavir, and 1% boosted darunavir. NRTI backbone therapies included abacavir and lamivudine (3TC) in 65% of participants, tenofovir disoproxil fumarate (TDF) and 3TC or TDF and emtricitabine (FTC) in 23% of participants, and zidovudine (ZDV) and 3TC in 11% of participants, and 1% of participants received a different combination. The NRTIs were balanced across the groups. Across both cohorts, the risk of treatment failure was approximately 40% lower (hazard ratio 0.60; 95% CI, 0.42–0.86) in the DTG-based treatment group than in the standard-care group. Within the ODYSSEY B cohort at 96 weeks, 32 of 196 participants (16%) in the DTG group had treatment failures, and 41 of 200 participants (20%) in the standard-care group had treatment failures. Twenty-nine of the 32 participants in the DTG group with treatment failure had a post-treatment resistance test available, with 23 of 29 having at least one major mutation after treatment. In the standard-care cohort, 36 of 40 participants with virologic failure had a major mutation after treatment. In the DTG group, four participants had an INSTI-related mutation, and three of the four were receiving ZDV and 3TC. In the standard-care group, two participants had a new PI-related mutation.

In the NADIA trial, adults experiencing virologic failure on a NNRTI plus 3TC or FTC and TDF regimen were randomized to DTG or darunavir/ritonavir (DRV/r) plus 3TC and secondarily randomized to either TDF or ZDV. At both 48 and 96 weeks, >85% of participants met the primary endpoint of viral suppression, defined as <400 copies/mL in all arms of the study, and the DTG regimen was non-inferior to the DRV/r regimen. At 96 weeks, 9 of 235 (4%) participants on the DTG regimen developed DTG resistance, with the majority (6 of 9) also assigned to ZDV. No PI resistance was developed in the DRV/r group.

If a child experiences virologic failure on an initial PI-based regimen, there are often limited resistance mutations detected, indicating that poor adherence/tolerance of the regimen may be the cause of poor viral control.^{40,41} In these cases, a more tolerable ARV regimen should be sought to improve adherence and achieve virologic suppression. Switching to an INSTI-based regimen can be effective in some PI-experienced children, and these are typically better tolerated than PI-based regimens.^{34,35,42-44}

Some studies in adults have suggested that 3TC can still contribute to suppression of HIV replication in patients with 3TC resistance mutations. Continuation of 3TC also can maintain a 3TC mutation

(184V) that can partially reverse the effects of other mutations that confer resistance to ZDV and TDF.⁴⁵⁻⁴⁷

Studies have compared the use of NRTI-sparing and NRTI-containing regimens in adults with multidrug resistance who experienced virologic failure on a previous regimen. These studies have demonstrated no clear benefit of including NRTIs in the new regimen.^{48,49} One of these studies reported no difference in rate of virologic suppression but a trend toward a higher mortality in adults who were randomized to receive a regimen that included NRTIs than in adults who were randomized to receive an NRTI-sparing regimen.⁴⁹ There are no studies of NRTI-sparing regimens in children with virologic failure and multidrug resistance, but an NRTI-sparing regimen may be a reasonable option for children with extensive NRTI resistance.

Additional Therapeutic Options to Achieve Virologic Suppression When Multidrug-Resistant Virus Is Present

The NNRTIs etravirine (ETR) and rilpivirine can retain activity against NVP-resistant virus or EFV-resistant virus in the absence of certain key NNRTI mutations, but ETR has generally been tested only in regimens that also contain a boosted PI.^{28,50} For this reason, the Panel recommends using ETR as part of a regimen that includes a boosted PI (see the [Etravirine](#) section). Doravirine is a once-daily NNRTI that retains activity against EFV/NVP-resistant virus and is approved by the U.S. Food and Drug Administration (FDA) for use in children and adolescents weighing ≥ 35 kg. Studies have been completed in adolescents aged 12 to <18 years demonstrating safety and tolerability^{51,52} (see the [Doravirine](#) section).

Maraviroc, a CCR5 antagonist, provides a new drug class; however, many ART-experienced children and some ART-naive children already harbor a CXCR4-tropic virus, which precludes its use.^{53,54} Regimens that include an INSTI and a potent boosted PI with or without ETR have been effective during small studies of extensively ART-experienced patients with multiclass drug resistance.⁵⁵⁻⁵⁸

When searching for at least two fully active agents in cases of extensive drug resistance, clinicians should consider the potential availability of new therapeutic agents that are not currently being studied in children or that may be approved for use in children in the future. Information about clinical trials can be found using the [National Institute of Allergy and Infectious Diseases Clinical Trials database](#) and by consulting a pediatric HIV specialist. Children should be enrolled in clinical trials of new drugs whenever possible. See [ClinicalTrials.gov](#) for more information.

Pediatric dosing for off-label use of ARV drugs is problematic, because absorption, hepatic metabolism, and excretion change with age.⁵⁹ In clinical trials of several ARV agents, direct extrapolation of a pediatric dose from an adult dose, based on a child's body weight or body surface area, was shown to result in an underestimation of the appropriate pediatric dose.⁶⁰

Off-label use of ARV agents, however, may be necessary for children with HIV who have limited ARV drug options. In this circumstance, consulting a pediatric HIV specialist for advice about potential regimens, assistance with access to unpublished data from clinical trials or other limited off-label pediatric uses, and referral to suitable clinical trials are recommended.

Two agents that inhibit the attachment of the glycoprotein 120 (gp120) region of the virus to the CD4 molecule are approved for adolescents >18 years with multidrug resistance. Oral fostemsavir (FTR) is a gp120 attachment inhibitor, and ibalizumab (given by infusion twice monthly) is a humanized

monoclonal antibody that targets the gp120 attachment area on the CD4 molecule.^{61,62} Because these represent drugs with new novel targets, they would be expected to be beneficial in patients with multiclass drug resistance. In a Phase 3 study of adults with multidrug-resistant HIV-1 who are heavily treatment experienced, adding FTR to optimized background therapy resulted in improved and sustained viral suppression at 96 weeks in 163 of 272 (60%) of participants.⁶³ It should be noted that resistance can develop with incomplete adherence to these new agents, especially when added to a failing regimen. Although FTR is only approved for adults, research is ongoing to assess safety in the pediatric population.⁶⁴

Lenacapavir (LEN) is a capsid inhibitor that is newly FDA approved for heavily treatment-experienced adults who have limited ARV options due to resistance, safety, or intolerance (see the [Lenacapavir](#) section). A randomized, placebo-controlled, double-blind, multicenter trial ([CAPELLA](#)) evaluated LEN in combination with an optimized background ART regimen in 72 patients with virologic failure who had multidrug-resistant HIV-1 (resistance to at least two antiretroviral medications from at least three main drug classes).⁶⁵ Although open to patients age ≥ 12 years, the youngest patient enrolled was 23 years. The results showed that in cohort one, 21 of 24 (88%) patients in the LEN group had a decrease of at least $0.5 \log_{10}$ copies/mL in viral load by Day 15, as compared to 2 of 12 patients (17%) in the placebo group ($P < 0.001$); 81% of patients in the LEN group achieved durable viral suppression through 26 weeks of LEN plus an optimized background ART regimen. None of the patients developed serious adverse events related to LEN. Those receiving LEN had a greater reduction from baseline in viral load than those who received placebo. Eight participants of 72 enrolled developed LEN resistance.⁶⁶

Management Options When Two Fully Active Agents Cannot Be Identified or Administered

It may be impossible to provide an effective and sustainable therapeutic regimen when there is no combination of currently available agents that are active against an extensively drug-resistant virus in a patient or when a patient is unable to adhere to or tolerate ART.

The decision to continue a nonsuppressive regimen must be made on an individual basis after weighing potential benefits and risks. Specifically, providers must balance the inherent tension between the benefits of virologic suppression and the risks of continued viral replication with potential evolution of viral drug resistance in the setting of inadequate ARV drug exposure (e.g., nonadherence or a nonsuppressive, suboptimal regimen). Nonsuppressive regimens could decrease viral fitness and, thus, slow clinical and immunologic deterioration while a patient is either working on adherence or awaiting access to new agents that are expected to achieve sustained virologic suppression.⁶⁷ However, persistent viremia in the context of ARV drug pressure has the potential to generate additional resistance mutations that could further compromise agents in the same class that might otherwise have been active in subsequent regimens (e.g., continuing first-generation INSTIs or NNRTIs). Patients who continue to use nonsuppressive regimens should be followed more closely than those with stable virologic status, and the potential to successfully initiate a fully suppressive ARV regimen should be reassessed at every opportunity.

The use of NRTI-only holding regimens or a complete interruption of therapy is **not recommended**. One trial, the International Maternal Pediatric Adolescents AIDS Clinical Trials ([IMPAACT P1094](#)), randomized children with the M184V resistance mutation and documented nonadherence to continue their nonsuppressive, non NNRTI-based regimen or to switch to a 3TC (or FTC) monotherapy-

holding regimen. Children who switched to monotherapy were significantly more likely to experience a 30% decline in absolute CD4 count (the primary outcome) over a 28-week period.⁶⁸

Complete treatment interruption also has been associated with immunologic declines and poor clinical outcomes^{69,70}; therefore, it is **not recommended** (see [Antiretroviral Treatment Interruption in Children with HIV](#)).

Table 20. Options for Regimens with at Least Two Fully Active Agents to Achieve Virologic Suppression in Patients with Virologic Failure and Evidence of Viral Resistance

To optimize antiretroviral (ARV) drug effectiveness, clinicians should evaluate a child's treatment history and drug-resistance test results when choosing a new ARV regimen. Doing so is particularly important when selecting the nucleoside reverse transcriptase inhibitor (NRTI) components of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, where drug resistance to the NNRTIs can occur rapidly if the virus is not sufficiently sensitive to the NRTIs. Regimens should contain at least two, but preferably three, fully active drugs for durable and potent virologic suppression. If the M184V/I mutation associated with emtricitabine and lamivudine is present, these medications should be continued if the new regimen contains tenofovir disoproxil fumarate, tenofovir alafenamide, or zidovudine. The presence of this mutation may increase susceptibility to these NRTIs.

Please see individual drug profiles for information about weight and age limitations (e.g., do not use darunavir in children aged <3 years), drug interactions, and dose adjustments when devising a regimen for children with multiclass drug resistance (see [Appendix A. Pediatric Antiretroviral Drug Information](#)). When modifying ARV regimens in children with chronic hepatitis B/HIV coinfection, the new regimen must contain agents active against hepatitis B. Collaboration with a pediatric HIV specialist is especially important when choosing regimens for children with multiclass drug resistance. Regimens in this table are provided as examples, but the list is not exhaustive.

| Prior Failed Regimen | New Regimen Options ^{a,b} |
|-------------------------|--|
| Two NRTIs Plus an NNRTI | Preferred Regimen <ul style="list-style-type: none">• Two NRTIs plus a second-generation INSTI (BIC or DTG)^c Alternative Regimen(s) <ul style="list-style-type: none">• Two NRTIs plus a boosted PI |
| Two NRTIs Plus a PI | Preferred Regimen <ul style="list-style-type: none">• Two NRTIs plus a second-generation INSTI (BIC or DTG)^c Alternative Regimen(s) <ul style="list-style-type: none">• DTG plus a different boosted PI and with or without NRTI(s) |
| Two NRTIs Plus an INSTI | <ul style="list-style-type: none">• Two NRTIs plus a boosted PI• Second-generation INSTI (DTG^c or BIC^c if not used in the prior regimen) with a boosted PI with or without NRTI(s). DTG may need to be given twice daily if a patient has certain documented INSTI mutations, or if there is concern about certain mutations (see the Dolutegravir section for dosing instructions).• Two NRTIs plus an NNRTI^d |

Table 20. Options for Regimens with at Least Two Fully Active Agents to Achieve Virologic Suppression in Patients with Virologic Failure and Evidence of Viral Resistance

| | |
|--|--|
| Failed Regimen(s) That Included NRTI(s), NNRTI(s), and PI(s) | If NRTIs Are Fully Active <ul style="list-style-type: none"> • Second-generation INSTI (DTG or BIC)^c plus two NRTIs If NRTIs Are Not Fully Active^b <ul style="list-style-type: none"> • Second-generation INSTI plus TAF/FTC or TDF/XTC if able to take TAF or TDF • Second-generation INSTI plus two NRTIs with a boosted PI • Second-generation INSTI with a boosted PI (based on resistance results). Consider ETR or RPV based on resistance results, age, and weight. • Consider MVC if additional active drug(s) are needed. • Consider off-label use of approved agents or enrollment in clinical trials for novel antiretroviral treatments. |
|--|--|

^a The possibility of planned and unplanned pregnancy should be considered when selecting an ART regimen for an adolescent. When discussing ART options with adolescents and their caregivers, it is important to consider childbearing potential and the benefits and risks of all ARV drugs and to provide the information and counseling needed to support informed decision-making; refer to the Perinatal Guidelines (see [Recommendations for Use of Antiretroviral Drugs During Pregnancy](#), [Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive](#), and [Appendix C. Antiretroviral Counseling Guide for Health Care Providers](#)).

^b When modifying ARV regimens in children with chronic hepatitis B/HIV coinfection, the new regimen must contain agents active against hepatitis B.

^c RAL, a first-generation INSTI, has a low barrier to resistance and requires twice-daily dosing in children and adolescents; the second-generation INSTIs BIC and DTG have a higher barrier to resistance and only require once-daily dosing. Many Panel members would use BIC/FTC/TAF (Biktarvy) in patients with prior treatment failure who have virus with the M184 mutation (see the [Bictegravir](#) section).

^d NNRTIs could be an option in younger patients with no exposure to NNRTIs and with taste aversion to boosted PIs, if NRTIs have preserved activity.

Key: ART = antiretroviral therapy; ARV = antiretroviral; BIC = bictegravir; DTG = dolutegravir; FTC = emtricitabine; ETR = etravirine; INSTI = integrase strand transfer inhibitor; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; XTC = 3TC (lamivudine) or FTC

References

1. Chadwick EG, Capparelli EV, Yoge R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. *AIDS*. 2008;22(2):249-255. Available at: <https://pubmed.ncbi.nlm.nih.gov/18097227>.
2. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. *Lancet Infect Dis*. 2011;11(4):273-283. Available at: <https://pubmed.ncbi.nlm.nih.gov/21288774>.
3. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). *J Infect Dis*. 2001;183(12):1732-1738. Available at: <https://pubmed.ncbi.nlm.nih.gov/11372025>.
4. Antiretroviral Therapy Cohort Collaboration, Vandenhende MA, Ingle S, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. *AIDS*. 2015;29(3):373-383. Available at: <https://pubmed.ncbi.nlm.nih.gov/25686685>.
5. Boillat-Blanco N, Darling KE, Schoni-Affolter F, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. *Antivir Ther*. 2014;20(2):165-175. Available at: <https://pubmed.ncbi.nlm.nih.gov/24964403>.
6. Laprise C, de Pokomandy A, Baril JG, et al. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. *Clin Infect Dis*. 2013;57(10):1489-1496. Available at: <https://pubmed.ncbi.nlm.nih.gov/23946221>.
7. Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). *Antivir Ther*. 2015;20(6):655-660. Available at: <https://pubmed.ncbi.nlm.nih.gov/25735799>.
8. Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? *J Antimicrob Chemother*. 2016;71(4):1051-1055. Available at: <https://pubmed.ncbi.nlm.nih.gov/26702924>.
9. Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. *AIDS*. 2019;33(13):2005-2012. Available at: <https://pubmed.ncbi.nlm.nih.gov/31306175>.
10. Palich R, Wirden M, Peytavin G, et al. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. *J Antimicrob Chemother*. 2020;75(10):2981-2985. Available at: <https://pubmed.ncbi.nlm.nih.gov/32642769>.

11. Lee KJ, Shingadia D, Pillay D, et al. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean? *Antivir Ther*. 2007;12(6):949-956. Available at: <https://pubmed.ncbi.nlm.nih.gov/17926649>.
12. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA*. 2010;304(10):1082-1090. Available at: <https://pubmed.ncbi.nlm.nih.gov/20823434>.
13. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. *J Infect Dis*. 2012;205(8):1230-1238. Available at: <https://pubmed.ncbi.nlm.nih.gov/22438396>.
14. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. *AIDS*. 2004;18(7):981-989. Available at: <https://pubmed.ncbi.nlm.nih.gov/15096800>.
15. Aleman S, Soderbarg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. *AIDS*. 2002;16(7):1039-1044. Available at: <https://pubmed.ncbi.nlm.nih.gov/11953470>.
16. Krogstad P, Patel K, Karalius B, et al. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents. *AIDS*. 2015;29(6):683-693. Available at: <https://pubmed.ncbi.nlm.nih.gov/25849832>.
17. Resino S, Alvaro-Meca A, de Jose MI, et al. Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency. *Pediatr Infect Dis J*. 2006;25(4):365-368. Available at: <https://pubmed.ncbi.nlm.nih.gov/16567992>.
18. Lewis J, Walker AS, Castro H, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. *J Infect Dis*. 2012;205(4):548-556. Available at: <https://pubmed.ncbi.nlm.nih.gov/22205102>.
19. van Lelyveld SF, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. *AIDS*. 2012;26(4):465-474. Available at: <https://pubmed.ncbi.nlm.nih.gov/22112603>.
20. European Pregnancy and Paediatric HIV Cohort Collaboration Study Group in EuroCoord. Prevalence and clinical outcomes of poor immune response despite virologically suppressive antiretroviral therapy among children and adolescents with human immunodeficiency virus in Europe and Thailand: cohort study. *Clin Infect Dis*. 2020;70(3):404-415. Available at: <https://pubmed.ncbi.nlm.nih.gov/30919882>.
21. Milanes-Guisado Y, Gutierrez-Valencia A, Munoz-Pichardo JM, et al. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients? *J Antimicrob Chemother*. 2020;75(1):200-207. Available at: <https://pubmed.ncbi.nlm.nih.gov/31617904>.

22. Claassen CW, Diener-West M, Mehta SH, et al. Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. *Clin Infect Dis*. 2012;54(12):1806-1813. Available at: <https://pubmed.ncbi.nlm.nih.gov/22460963>.
23. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. *AIDS*. 2009;23(9):1097-1107. Available at: <https://pubmed.ncbi.nlm.nih.gov/19417581>.
24. Meintjes G, Lynen L. Prevention and treatment of the immune reconstitution inflammatory syndrome. *Curr Opin HIV AIDS*. 2008;3(4):468-476. Available at: <https://pubmed.ncbi.nlm.nih.gov/19373007>.
25. Graham SM. Non-tuberculosis opportunistic infections and other lung diseases in HIV-infected infants and children. *Int J Tuberc Lung Dis*. 2005;9(6):592-602. Available at: <https://pubmed.ncbi.nlm.nih.gov/15971385>.
26. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol*. 2008;65(1):65-70. Available at: <https://pubmed.ncbi.nlm.nih.gov/18195140>.
27. Patel K, Ming X, Williams PL, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. *AIDS*. 2009;23(14):1893-1901. Available at: <https://pubmed.ncbi.nlm.nih.gov/19644348>.
28. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. *AIDS*. 2009;23(17):2289-2300. Available at: <https://pubmed.ncbi.nlm.nih.gov/19710593>.
29. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. *Clin Infect Dis*. 2010;50(4):605-612. Available at: <https://pubmed.ncbi.nlm.nih.gov/20085491>.
30. De Luca A, Di Giambenedetto S, Cingolani A, et al. Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. *Antivir Ther*. 2006;11(3):321-327. Available at: <https://pubmed.ncbi.nlm.nih.gov/16759048>.
31. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. *AIDS*. 2000;14(9):F83-93. Available at: <https://pubmed.ncbi.nlm.nih.gov/10894268>.
32. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. *AIDS*. 2002;16(2):209-218. Available at: <https://pubmed.ncbi.nlm.nih.gov/11807305>.
33. Lin D, Seabrook JA, Matsui DM, et al. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada.

Pharmacoepidemiol Drug Saf. 2011;20(12):1246-1252. Available at:
<https://pubmed.ncbi.nlm.nih.gov/21936016>.

34. Briand C, Dollfus C, Faye A, et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. *J Antimicrob Chemother.* 2017;72(3):837-843. Available at:
<https://pubmed.ncbi.nlm.nih.gov/27999017>.
35. Viani RM, Ruel T, Alvero C, et al. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study. *J Pediatric Infect Dis Soc.* 2020;9(2):159-165. Available at:
<https://pubmed.ncbi.nlm.nih.gov/30951600>.
36. Santoro MM, Fornabaio C, Malena M, et al. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. *Int J Antimicrob Agents.* 2020;56(1):106027. Available at:
<https://pubmed.ncbi.nlm.nih.gov/32450199>.
37. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV.* 2018;5(12):e715-e722. Available at:
<https://pubmed.ncbi.nlm.nih.gov/30527329>.
38. Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Med.* 2021;385(27):2531-2543. Available at:
<https://pubmed.ncbi.nlm.nih.gov/34965338>.
39. Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV.* 2022;9(6):e381-e393. Available at:
<https://pubmed.ncbi.nlm.nih.gov/35460601>.
40. Harrison L, Melvin A, Fiscus S, et al. HIV-1 drug resistance and second-line treatment in children randomized to switch at low versus higher RNA thresholds. *J Acquir Immune Defic Syndr.* 2015;70(1):42-53. Available at: <https://pubmed.ncbi.nlm.nih.gov/26322666>.
41. Meyers T, Sawry S, Wong JY, et al. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. *Pediatr Infect Dis J.* 2015;34(2):175-179. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25741970>.
42. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *Pediatr Infect Dis J.* 2015;34(11):1207-1213. Available at:
<https://pubmed.ncbi.nlm.nih.gov/26244832>.
43. Patten G, Puthanakit T, McGowan CC, et al. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. *J Int AIDS Soc.* 2020;23(7):e25580. Available at: <https://pubmed.ncbi.nlm.nih.gov/32722897>.

44. Levy ME, Griffith C, Ellenberger N, et al. Outcomes of integrase inhibitor-based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents and young adults with HIV infection. *Pediatr Infect Dis J.* 2020;39(5):421-428. Available at: <https://pubmed.ncbi.nlm.nih.gov/32176183>.
45. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. *Clin Infect Dis.* 2005;41(2):236-242. Available at: <https://pubmed.ncbi.nlm.nih.gov/15983922>.
46. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. *J Infect Dis.* 1997;176(2):398-405. Available at: <https://pubmed.ncbi.nlm.nih.gov/9237704>.
47. Ross L, Parkin N, Chappay C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. *AIDS.* 2004;18(12):1691-1696. Available at: <https://pubmed.ncbi.nlm.nih.gov/15280780>.
48. Imaz A, Llibre JM, Mora M, et al. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. *J Antimicrob Chemother.* 2011;66(2):358-362. Available at: <https://pubmed.ncbi.nlm.nih.gov/21172789>.
49. Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial. *Ann Intern Med.* 2015;163(12):908-917. Available at: <https://pubmed.ncbi.nlm.nih.gov/26595748>.
50. MacBrayne CE, Rutstein RM, Wiznia AA, et al. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. *AIDS.* 2021;35(9):1413-1421. Available at: <https://pubmed.ncbi.nlm.nih.gov/33831904>.
51. Melvin AJ, Yee KL, Gray KP, et al. Pharmacokinetics, tolerability, and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets in adolescents living with HIV: week 24 results from IMPAACT 2014. *J Acquir Immune Defic Syndr.* 2023;92(2):153-161. Available at: <https://pubmed.ncbi.nlm.nih.gov/36215957>.
52. Rungmaitree S, Aurpibul L, Best BM, et al. Efficacy, safety, and tolerability of doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets in adolescents living with HIV: results through week 96 from IMPAACT 2014. *J Pediatric Infect Dis Soc.* 2023;12(12):602-609. Available at: <https://pubmed.ncbi.nlm.nih.gov/37815035>.
53. Agwu AL, Yao TJ, Eshleman SH, et al. Phenotypic co-receptor tropism in perinatally HIV-infected youth failing antiretroviral therapy. *Pediatr Infect Dis J.* 2016;35(7):777-781. Available at: <https://pubmed.ncbi.nlm.nih.gov/27078121>.
54. Arayapong N, Pasomsub E, Kanlayanadonkit R, et al. Viral tropism in human immunodeficiency virus type 1-infected children and adolescents in Thailand. *J Pediatric Infect Dis Soc.* 2021;10(1):1-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/31981458>.

55. Huerta-Garcia G, Vazquez-Rosales JG, Mata-Marin JA, et al. Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection. *Pediatr Res.* 2016;80(1):54-59. Available at: <https://pubmed.ncbi.nlm.nih.gov/26999770>.
56. Kirk BL, Gomila A, Matshaba M, et al. Early outcomes of darunavir- and/or raltegravir-based antiretroviral therapy in children with multidrug-resistant HIV at a pediatric center in Botswana. *J Int Assoc Provid AIDS Care.* 2013;12(2):90-94. Available at: <https://pubmed.ncbi.nlm.nih.gov/23315674>.
57. Thuret I, Chaix ML, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. *AIDS.* 2009;23(17):2364-2366. Available at: <https://pubmed.ncbi.nlm.nih.gov/19823069>.
58. Capetti AF, Sterrantino G, Cossu MV, et al. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. *Antivir Ther.* 2017;22(3):257-262. Available at: <https://pubmed.ncbi.nlm.nih.gov/27661787>.
59. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. *N Engl J Med.* 2003;349(12):1157-1167. Available at: <https://pubmed.ncbi.nlm.nih.gov/13679531>.
60. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. *Clin Pharmacol Ther.* 2008;83(2):300-306. Available at: <https://pubmed.ncbi.nlm.nih.gov/17609682>.
61. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. *N Engl J Med.* 2018;379(7):645-654. Available at: <https://pubmed.ncbi.nlm.nih.gov/30110589>.
62. Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. *N Engl J Med.* 2020;382(13):1232-1243. Available at: <https://pubmed.ncbi.nlm.nih.gov/32212519>.
63. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. *Lancet HIV.* 2020;7(11):e740-e751. Available at: <https://pubmed.ncbi.nlm.nih.gov/33128903>.
64. Clinicaltrials.gov. Safety and pharmacokinetics evaluation of fostemsavir + (OBT) in HIV-1 Infected children and adolescents who are failing their cART and have dual- or triple-class antiretroviral resistance. 2024. Available at: <https://clinicaltrials.gov/study/NCT04648280?intr=Fostemsavir&term=pediatric&rank=1>
65. Margot NA, Naik V, VanderVeen L, et al. Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir. *J Infect Dis.* 2022;226(11):1985-1991. Available at: <https://pubmed.ncbi.nlm.nih.gov/36082606>.

66. Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. *N Engl J Med.* 2022;386(19):1793-1803. Available at: <https://pubmed.ncbi.nlm.nih.gov/35544387>.
67. Wong FL, Hsu AJ, Pham PA, et al. Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth. *Pediatr Infect Dis J.* 2012;31(12):1279-1283. Available at: <https://pubmed.ncbi.nlm.nih.gov/22926213>.
68. Agwu AL, Warshaw MG, McFarland EJ, et al. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: results of the IMPAACT P1094 randomized trial. *PLoS One.* 2017;12(6):e0178075. Available at: <https://pubmed.ncbi.nlm.nih.gov/28604824>.
69. Saitoh A, Foca M, Viani RM, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. *Pediatrics.* 2008;121(3):e513-521. Available at: <https://pubmed.ncbi.nlm.nih.gov/18310171>.
70. Fairlie L, Karalius B, Patel K, et al. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. *AIDS.* 2015;29(16):2109-2119. Available at: <https://pubmed.ncbi.nlm.nih.gov/26182197>.

Antiretroviral Treatment Interruption in Children with HIV

Updated: June 27, 2024

Reviewed: June 27, 2024

| Panel's Recommendations |
|--|
| <ul style="list-style-type: none">Outside the context of clinical trials, treatment interruptions of antiretroviral therapy (ART) are not recommended for children.Treatment interruption is not recommended as a strategy in clinical settings to confirm diagnosis or to assess remission or cure (AII).Families should receive education and counseling about common causes of temporary unplanned treatment interruptions and ways to prevent them (e.g., automatic refills, mailed prescriptions, planning for the adequate supply of medications when traveling). See Adherence to Antiretroviral Therapy in Children and Adolescents with HIV (BIII).At times, ART may need to be interrupted or changed due to drug-related side effects or toxicity. See Management of Medication Toxicity or Intolerance for guidance (AIII). |

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion*

[†] Studies that include children or children/adolescents, but not studies limited to postpubertal adolescents

Unplanned Treatment Interruptions

Temporary discontinuation of antiretroviral therapy (ART) may be unavoidable in some situations that preclude oral intake, such as serious treatment-related toxicity, acute gastrointestinal illnesses, or planned surgeries. Children might experience interruptions due to antiretroviral (ARV) drugs being out of stock locally or if they run out of ARV drugs during travel or immigration to the United States. Prolonged interruptions of ART also can result from disengagement from care or other social or psychological issues that affect adherence. Some patients, particularly adolescents and young adults, might attempt to conceal long periods of treatment interruption by restarting treatment in the few weeks ahead of clinic visits and viral load testing.

Observational studies of children and youth with unplanned or nonprescribed treatment interruptions suggest that interruptions are common and that prolonged interruptions can lead to immunologic decline.¹⁻⁴ In a retrospective study of 483 children in a French pediatric cohort from the National Agency for Research on AIDS and Viral Hepatitis, 42% of participants had treatment interruptions of ≥3 months (with a median of 12.1 months). Interruption was associated with lower CD4 T lymphocyte (CD4) cell percentages after 4 years, even in those who restarted therapy.⁵ A similar retrospective study of 136 youth (median age 12.9 years) in the United States found that 38 participants (28%) with histories of treatment interruption had lower CD4 counts and higher HIV

RNA levels than participants who had continuous treatment.⁶ A study from the International epidemiology Databases to Evaluate AIDS Southern Africa, which includes 53,674 children aged <16 years, found that lapses in clinical care of greater than 180 days within the first 6 months of treatment were associated with increased mortality (adjusted hazard ratio [AHR] = 1.52; 95% confidence interval [CI], 1.12–2.04); while lapses in care after the first 6 months were not (AHR = 1.05; 95% CI, 0.77–1.44).⁷

The risk of unplanned ART interruptions can be mitigated by clinicians working closely with families. Providers should provide anticipatory guidance about potential short-term interruptions (e.g., sleepovers). If a child will be away from home for an extended period of time (e.g., tourism, education, summer camp), clinicians should help families plan to ensure continuous access to medications. Some pharmacies are able to dispense up to 90 days of treatment, depending on the insurance plan. Pharmacies also are often able to dispense additional doses specifically justified because of travel. Clinicians should review the duration of current prescriptions and anticipate any dose changes that might be needed due to growth of the child and to determine when the prescribed refills will terminate. For prolonged travel within the United States, providers either can proactively order refills at pharmacies close to their travel destinations to ensure they will be in stock or have medications mailed directly to families at other convenient locations. Alternatively, changing the ART regimen to incorporate ARV drugs available in the locations where families will be traveling would make it easier to address cases of lost medications or unanticipated prolonged travel. For additional information, refer to the Centers for Disease Control and Prevention (CDC) webpage on [Traveling Abroad with Medicine | CDC](#), as well as the guideline section on [Adherence to Antiretroviral Therapy in Children and Adolescents with HIV](#).

Unforeseeable events, such as natural disasters or political instability, may occur and displace children from their primary HIV care programs. See [Guidance for Non-HIV-Specialized Providers Caring for People With HIV Who Have Been Displaced by Disasters \(Such as a Hurricane\)](#) for information about how to care for children with HIV who are in these situations.

Structured Treatment Interruptions

Structured treatment interruptions are scheduled periods of time during which ART is not prescribed or administered. This strategy was once considered a method for providing patients with time off ART to reduce the risk of toxicity and costs. Randomized clinical trials of adults with HIV have demonstrated that structured treatment interruptions are associated with significantly higher morbidity and mortality than continuous ART.⁸ Current U.S. Department of Health and Human Services HIV treatment guidelines recommend against planned, long-term structured treatment interruptions in adults (see [Discontinuation or Interruption of Antiretroviral Therapy](#) in the [Adult and Adolescent Antiretroviral Guidelines](#)).

Few studies have evaluated structured treatment interruption in children. In one trial from Europe and Thailand (PENTA 11), 109 children (median age 9 years) on ART and with virologic suppression were randomized to receive continuous therapy (CT) or to undergo treatment interruption. Although no significant differences in rates of adverse events (AEs) were observed between the two groups at 2 years, 19 of 56 children (34%) in the structured treatment interruption arm met CD4 criteria to restart therapy between 6 and 42 weeks after interruption, suggesting that the time off ART provided by this strategy was ultimately limited.^{9,10} The Children with HIV Early Antiretroviral Therapy (CHER) trial in South Africa was designed to determine whether infants who initiated ART early could safely discontinue therapy at either 40 weeks or 96 weeks; infants would reinitiate

treatment based on CD4 decline. The median time to the start of continuous ART after interruption was 3 weeks (interquartile range [IQR] 26–45 weeks) among the infants who discontinued ART after 40 weeks, and 70 weeks (IQR 35–109 weeks) among the infants who discontinued ART after 96 weeks.^{11,12} A secondary analysis of neurodevelopmental outcomes at age 5 years did not show any significant differences among the children in the different study arms.¹³ However, brain magnetic resonance imaging studies in a subset of participants found that children with HIV on interrupted ART (n = 21) had a thicker cortex than uninfected controls in the left frontal and right insular regions, but children with HIV on CT (n = 25) showed no difference from controls; the clinical significance of these differences is not known.¹⁴ In another randomized trial, 12 of 21 infants in the treatment interruption arm met ART restart criteria within 3 months.¹⁵ In summary, although trials of structured treatment interruptions in children have not shown significant short-term morbidity, the gains in time off ART are limited, and the long-term outcomes remain unknown.

The case of an infant from Mississippi who initiated ART soon after birth and had a prolonged period of time without viremia after an unplanned treatment interruption raised the hope that it may be possible to stop or reduce the intensity of ART (e.g., use fewer agents) in some infants (see [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)).^{16,17} However, the “Mississippi infant” had documented viral rebound after 28 months off ART,¹⁸ and additional reports have emerged of infants who experienced rebound viremia after stopping ART, despite having undetectable HIV DNA and RNA while on ART.^{19–21} A South African child aged 9.5 years was reported to have low levels of virus that was not replication competent after receiving ART from approximately 2 to 24 months of age; the factors that led to this outcome remain unknown.²² Future research might identify treatment strategies and diagnostic tests that enable ART to be safely interrupted in some children.

“Analytical” treatment interruptions are currently being incorporated into studies of remission in adults and children, but the potential risks and benefits of strategies need to be critically evaluated.^{23–25}

Currently, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) **does not recommend** treatment interruption as a strategy in clinical settings to confirm diagnosis or to assess remission or cure in infants who reverted to negative serology, tested negative for HIV DNA, or received an initial diagnosis that was based on a single positive nucleic acid test. The Panel encourages providers to consult an expert on pediatric HIV when they are concerned about the validity of the test results that led to treatment initiation in children with HIV.

Short-Cycle Therapy Strategies

One approach, called short-cycle therapy (SCT), schedules 4-day treatment interruptions rather than waiting to restart ART after CD4 count declines or other AEs occur. In one proof-of-concept study (ATN015), 32 participants (aged 12–24 years) underwent short cycles of 4 days on and 3 days off ART.²⁶ Participants received protease inhibitor–based ART and had at least 6 months of documented viral suppression (defined as a viral load <400 copies/mL) and CD4 counts above 350 cells/mm³. Most participants demonstrated good adherence to the schedule, but 12 participants (37.5%) developed confirmed viral load rebounds >400 copies/mL, and 18 participants (56%) left the study. SCT had no impact on CD4 counts.

The BREATHER (PENTA 16) study sought to examine the safety and benefits of SCT with 5 days on and 2 days off ART; PENTA 16 was a noninferiority trial that randomized 199 children and

young adults (aged 8–24 years) for SCT or CT.^{27,28} To enroll, participants had to be receiving efavirenz (EFV) plus two nucleoside reverse transcriptase inhibitors, and they had to have been virologically suppressed (defined as a viral load <50 copies/mL) for >12 months. By 48 weeks, six participants (6%) in the SCT arm and seven participants (7%) in the CT arm experienced confirmed virologic failure, which was defined as a viral load >50 copies/mL (difference –1.2%; 90% CI, –7.3% to 4.9%). Of the six participants in the SCT arm who experienced virologic failure, five were able to regain virologic suppression. Two participants in the SCT arm and five participants in the CT arm had major mutations related to resistance to non-nucleoside reverse transcriptase inhibitors at the time of virologic failure. At 48 weeks, the SCT arm had higher D-dimer levels but no other evidence of increased inflammation across a number of other biomarkers. Participants generally reported appreciating the option of SCT.²⁹

A long-term follow-up study of children from the BREATHER study (which included 194 of the original 199 children) suggests comparable virologic failure rates between the SCT and CT arms after a median of 3.6 years; both arms had a failure rate of approximately 16%.³⁰ The participants in the SCT arm experienced a greater number of serious AEs than participants in the CT arm (20 serious AEs in the SCT arm vs. 8 in the CT arm, with the primary difference being rate of hospitalizations); however, the arms experienced comparable rates of the CDC Grade 3 or 4 AEs. The BREATHER trial suggests that SCT with Efv-based ART may be safe in some adolescents and may yield increased patient satisfaction that could lead to better long-term adherence. However, the Panel currently believes that additional data are needed to decide whether the BREATHER strategy would be safe in different patient populations, with different antiretroviral regimens, outside of the context of a trial, and over longer periods.

Conclusion

Cumulative data have demonstrated that treatment interruptions long enough for viremia to recur are generally harmful to children with HIV. Analytic treatment interruptions to assess for remission are employed in research but not recommended in the clinical context. SCT treatment may be safe and increase satisfaction in some patients, but the Panel concludes that more data are needed before SCT can be recommended for routine use in pediatric populations. Currently, the Panel **does not recommend** structured treatment interruption in the clinical care of children with HIV; additional studies of treatment interruption strategies in specific situations are warranted.

References

1. Gibb DM, Duong T, Leclezio VA, et al. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. *Pediatr Infect Dis J.* 2004;23(5):446-450. Available at: <https://pubmed.ncbi.nlm.nih.gov/15131469>.
2. Saitoh A, Foca M, Viani RM, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. *Pediatrics.* 2008;121(3):e513-521. Available at: <https://pubmed.ncbi.nlm.nih.gov/18310171>.
3. Siberry GK, Patel K, Van Dyke RB, et al. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. *J Acquir Immune Defic Syndr.* 2011;57(3):223-229. Available at: <https://pubmed.ncbi.nlm.nih.gov/21423022>.
4. Bartlett AW, Lumbiganon P, Kurniati N, et al. Use and outcomes of antiretroviral monotherapy and treatment interruption in adolescents with perinatal HIV infection in Asia. *J Adolesc Health.* 2019;65(5):651-659. Available at: <https://pubmed.ncbi.nlm.nih.gov/31395514>.
5. Aupiais C, Faye A, Le Chenadec J, et al. Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children. *Pediatr Infect Dis J.* 2014;33(12):1237-1245. Available at: <https://pubmed.ncbi.nlm.nih.gov/24945880>.
6. Rakhmanina N, Lam KS, Hern J, et al. Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA. *J Int AIDS Soc.* 2016;19(1):20936. Available at: <https://pubmed.ncbi.nlm.nih.gov/27797320>.
7. Davies C, Johnson L, Sawry S, et al. Effect of antiretroviral therapy care interruptions on mortality in children living with HIV. *AIDS.* 2022;36(5):729-737. Available at: <https://pubmed.ncbi.nlm.nih.gov/35152225>.
8. Strategies for Management of Antiretroviral Therapy Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med.* 2006;355(22):2283-2296. Available at: <https://pubmed.ncbi.nlm.nih.gov/17135583>.
9. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. *AIDS.* 2010;24(2):231-241. Available at: <https://pubmed.ncbi.nlm.nih.gov/20010073>.
10. Bunupuradah T, Duong T, Compagnucci A, et al. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. *AIDS.* 2013;27(4):579-589. Available at: <https://pubmed.ncbi.nlm.nih.gov/23135172>.
11. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med.* 2008;359(21):2233-2244. Available at: <https://pubmed.ncbi.nlm.nih.gov/19020325>.

12. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. *Lancet*. 2013;382(9904):1555-1563. Available at: <https://pubmed.ncbi.nlm.nih.gov/24209829>.
13. Laughton B, Cornell M, Kidd M, et al. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy. *J Int AIDS Soc*. 2018;21(5):e25106. Available at: <https://pubmed.ncbi.nlm.nih.gov/29722482>.
14. Nwosu EC, Holmes MJ, Cotton MF, et al. Cortical structural changes related to early antiretroviral therapy (ART) interruption in perinatally HIV-infected children at 5 years of age. *IBRO Neurosci Rep*. 2021;10:161-170. Available at: <https://pubmed.ncbi.nlm.nih.gov/34179869>.
15. Wamalwa D, Benki-Nugent S, Langat A, et al. Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy. *AIDS*. 2016;30(15):2303-2313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27177316>.
16. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at: <https://pubmed.ncbi.nlm.nih.gov/24152233>.
17. Persaud D, Luzuriaga K. Absence of HIV-1 after treatment cessation in an infant. *N Engl J Med*. 2014;370(7):678. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24521123>.
18. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. *N Engl J Med*. 2015;372(8):786-788. Available at: <https://pubmed.ncbi.nlm.nih.gov/25693029>.
19. Mekonen T, Mulang R, Nghimbwasha H, et al. Structured antiretroviral treatment interruptions in vertically HIV-1 infected children with complete pro-viral DNA PCR reversions in Namibia, following durable viral suppression, led to rapid rebound viremias and significant immunologic destruction. Presented at: AIDS Conference. 2016. Durban, South Africa.
20. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. *Pediatr Infect Dis J*. 2014;34(3):e48-51. Available at: Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25742088>
21. Koofhethile CK, Moyo S, Kotokwe KP, et al. Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: a case report with implications for clinical care. *Medicine (Baltimore)*. 2019;98(47):e18014. Available at: <https://pubmed.ncbi.nlm.nih.gov/31764816>.
22. Violari A, Cotton MF, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Commun*. 2019;10(1):412. Available at: <https://pubmed.ncbi.nlm.nih.gov/30679439>.

23. Clinicaltrials.gov. Very early intensive treatment of HIV-infected infants to achieve HIV remission. 2019. Available at: <https://clinicaltrials.gov/ct2/show/NCT02140255>.
24. Julg B, Dee L, Ananworanich J, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV*. 2019;6(4):e259-e268. Available at: <https://pubmed.ncbi.nlm.nih.gov/30885693>.
25. Stecher M, Classen A, Klein F, et al. Systematic review and meta-analysis of treatment interruptions in human immunodeficiency virus (HIV) type 1-infected patients receiving antiretroviral therapy: implications for future HIV cure trials. *Clin Infect Dis*. 2020;70(7):1406-1417. Available at: <https://pubmed.ncbi.nlm.nih.gov/31102444>.
26. Rudy BJ, Sleasman J, Kapogiannis B, et al. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. *AIDS Res Hum Retroviruses*. 2009;25(6):555-561. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19534628>.
27. Butler K, Inshaw J, Ford D, et al. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial. *Health Technol Assess*. 2016;20(49):1-108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27377073>.
28. Breather Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. *Lancet HIV*. 2016;3(9):e421-e430. Available at: <https://pubmed.ncbi.nlm.nih.gov/27562743>.
29. Bernays S, Paparini S, Seeley J, et al. Qualitative study of the BREATHER trial (short cycle antiretroviral therapy): is it acceptable to young people living with HIV? *BMJ Open*. 2017;7(2):e012934. Available at: <https://pubmed.ncbi.nlm.nih.gov/28213595>.
30. Turkova A, Moore CL, Butler K, et al. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): extended follow-up results of a randomised, open-label, non-inferiority trial. *PLoS One*. 2018;13(4):e0196239. Available at: <https://pubmed.ncbi.nlm.nih.gov/29684092>.

Appendix A: Pediatric Antiretroviral Drug Information

Overview

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs)

[Abacavir](#)

[Emtricitabine](#)

[Lamivudine](#)

[Tenofovir Alafenamide](#)

[Tenofovir Disoproxil Fumarate](#)

[Zidovudine](#)

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

[Doravirine](#)

[Efavirenz](#)

[Etravirine](#)

[Nevirapine](#)

[Rilpivirine](#)

Protease Inhibitors (PIs)

[Atazanavir](#)

[Darunavir](#)

[Lopinavir/Ritonavir](#)

Entry and Fusion Inhibitors

[Fostemsavir](#)

[Ibalizumab](#)

[Maraviroc](#)

Capsid Inhibitors

[Lenacapavir](#)

Integrase Inhibitors (INSTIs)

[Bictegravir](#)

[Cabotegravir](#)

[Dolutegravir](#)

[Elvitegravir](#)

[Raltegravir](#)

Pharmacokinetic Enhancers

[Cobicistat](#)

[Ritonavir](#)

Fixed-Dose Combinations

[Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#)

[Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)

Archived Drugs

[Didanosine](#)

[Enfuvirtide](#)

[Fosamprenavir](#)

[Indinavir](#)

[Nelfinavir](#)

[Saquinavir](#)

[Stavudine](#)

[Tipranavir](#)

Appendix A: Pediatric Antiretroviral Drug Information

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

Abacavir (ABC, Ziagen)

Emtricitabine (FTC, Emtriva)

Lamivudine (3TC, Epivir)

Tenofovir Alafenamide (TAF, Vemlidy)

Tenofovir Disoproxil Fumarate (TDF, Viread)

Zidovudine (ZDV, Retrovir)

Abacavir (ABC, Ziagen)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|--|---|
| <p>Pediatric Oral Solution: 20 mg/mL</p> | |
| <p>Tablet: 300 mg (scored)</p> | |
| <p>Generic Formulations</p> <ul style="list-style-type: none">• 300-mg tablet• 20-mg/mL pediatric oral solution | |
| <p>Fixed-Dose Combination Tablets</p> <ul style="list-style-type: none">• [Epzicom and generic] Abacavir 600 mg/lamivudine 300 mg• [Triumeq] Abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg• [Triumeq PD] Abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg | |
| <p>When using fixed-dose combination (FDC) tablets, refer to other sections of Appendix A: Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-Packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents.</p> | |
| <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Neonate (Aged Birth Through <1 Month) Dose</p> <p><i>Oral Solution</i></p> <ul style="list-style-type: none">• Abacavir (ABC) is not approved by the U.S. Food and Drug Administration (FDA) for use in infants aged <3 months.• However, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends ABC 2 mg/kg twice daily for full-term infants from birth through <1 month of age. This recommendation is based on data from pharmacokinetic (PK) modeling of neonatal ABC dosing to target adult plasma ABC exposures, and observational data supporting safety of ABC in neonates. The World Health Organization Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring Annex 1: Dosages for ARV Drugs provides weight-band dosing recommendations for full-term neonates based on the same data. See the Approval, Pharmacokinetics in Neonates and Infants, and Safety in Neonates and Infants sections below. | <ul style="list-style-type: none">• Hypersensitivity reactions (HSRs) can be fatal. HSRs usually occur during the first few weeks of starting therapy. Symptoms may include fever, rash, nausea, vomiting, malaise or fatigue, loss of appetite, and respiratory symptoms (e.g., cough, shortness of breath). |
| Special Instructions | |
| | <ul style="list-style-type: none">• To predict the risk of HSRs, test patients for the HLA-B*5701 allele before starting therapy. Patients who test positive for the HLA-B*5701 allele should not be given ABC. Patients with no prior HLA-B*5701 testing who are tolerating ABC do not need to be tested.• Warn patients and caregivers about the risk of serious, potentially fatal HSRs. Occurrence of an HSR requires immediate and permanent discontinuation of ABC. Do not rechallenge.• ABC and coformulated tablets can be given with or without food. The oral solution does not require refrigeration. |

| <ul style="list-style-type: none"> ABC is not approved by the FDA for use in infants aged <3 months. The Panel recommends ABC 4 mg/kg twice daily in full-term infants aged ≥1 month to <3 months. This recommendation is based on modeling data of the ABC 4 mg/kg twice-daily dose using PK simulation for full-term infants aged ≥1 month to <3 months. The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1106 study and two observational cohorts provide reassuring data on the safety of ABC in infants with HIV aged <3 months. See the Approval, Pharmacokinetics in Neonates and Infants, and Safety in Neonates and Infants sections below. | <ul style="list-style-type: none"> For ABC/DTG/3TC dispersible tablets, fully disperse them in 20 mL of drinking water in the supplied cup and swirl the suspension so that no lumps remain. After full dispersion and within 30 minutes of mixing, administer the oral suspension. Rinse the dosing cup with a small amount of water and give this additional water to the child to ensure that the child takes the full dose and that no medication remains in the dosing cup. ABC/DTG/3TC dispersible tablets should not be swallowed whole, chewed, cut, or crushed. Screen patients for hepatitis B virus (HBV) infection before using ABC FDC tablets that contain 3TC. Severe acute exacerbation of HBV infection can occur when 3TC is discontinued (see Lamivudine). | | | | | | | | | | | | | | | |
|---|---|--------------------------|---------------------|--|----------------------|----------------------|-----------------|-----------------|-------------------|-------------------|-------------------|------------------|-------------------|-------------------|---------------------|--|
| Infant and Child (Aged ≥3 Months) Dose | | | | | | | | | | | | | | | | |
| <i>Oral Solution</i> | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> ABC 8 mg/kg twice daily (maximum 300 mg per dose) or ABC 16 mg/kg once daily (maximum 600 mg per dose) In infants and young children who are being treated with liquid formulations of ABC, initiation with once-daily ABC is not generally recommended. The ABC dose can be changed from twice daily to once daily with the liquid formulation to harmonize with other antiretroviral drugs administered once daily. | | | | | | | | | | | | | | | | |
| Weight-Band Dosing of ABC Tablets for Children and Adolescents Weighing ≥14 kg and <25 kg | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th rowspan="2">Weight</th> <th colspan="3">Scored 300-mg ABC Tablet</th> </tr> <tr> <th>Twice-Daily Dose, AM</th> <th>Twice-Daily Dose, PM</th> <th>Once-Daily Dose</th> </tr> </thead> <tbody> <tr> <td>14 kg to <20 kg</td> <td>½ tablet (150 mg)</td> <td>½ tablet (150 mg)</td> <td>1 tablet (300 mg)</td> </tr> <tr> <td>≥20 kg to <25 kg</td> <td>½ tablet (150 mg)</td> <td>1 tablet (300 mg)</td> <td>1½ tablets (450 mg)</td> </tr> </tbody> </table> | Weight | Scored 300-mg ABC Tablet | | | Twice-Daily Dose, AM | Twice-Daily Dose, PM | Once-Daily Dose | 14 kg to <20 kg | ½ tablet (150 mg) | ½ tablet (150 mg) | 1 tablet (300 mg) | ≥20 kg to <25 kg | ½ tablet (150 mg) | 1 tablet (300 mg) | 1½ tablets (450 mg) | |
| Weight | | Scored 300-mg ABC Tablet | | | | | | | | | | | | | | |
| | Twice-Daily Dose, AM | Twice-Daily Dose, PM | Once-Daily Dose | | | | | | | | | | | | | |
| 14 kg to <20 kg | ½ tablet (150 mg) | ½ tablet (150 mg) | 1 tablet (300 mg) | | | | | | | | | | | | | |
| ≥20 kg to <25 kg | ½ tablet (150 mg) | 1 tablet (300 mg) | 1½ tablets (450 mg) | | | | | | | | | | | | | |
| Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> ABC 300 mg twice daily or ABC 600 mg once daily | | | | | | | | | | | | | | | | |
| [Epzicom] Abacavir/Lamivudine | | | | | | | | | | | | | | | | |
| <i>Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose</i> | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> One tablet once daily | | | | | | | | | | | | | | | | |
| [Triumeq PD] Abacavir/Dolutegravir (DTG)/Lamivudine (3TC) | | | | | | | | | | | | | | | | |
| <i>Child Weighing ≥6 kg to <25 kg and Aged ≥3 Months</i> | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> Dispersible Triumeq PD tablets are FDA approved for children aged ≥3 months and weighing ≥6 to <25 kg. Triumeq PD is not recommended for children weighing ≥25 kg who are eligible for adult Triumeq dosing. | | | | | | | | | | | | | | | | |
| Metabolism/Elimination | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> ABC is systemically metabolized by alcohol dehydrogenase and glucuronyl transferase. The majority of ABC is excreted as metabolites in urine. | | | | | | | | | | | | | | | | |
| Abacavir Dosing in Patients with Hepatic Impairment | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> ABC requires a dose adjustment in patients with mild hepatic insufficiency and is contraindicated with moderate or severe hepatic insufficiency. Do not use Epzicom, Triumeq PD, or Triumeq (or the generic equivalents of these FDC tablets) in patients with impaired hepatic function because the dose of ABC cannot be adjusted. | | | | | | | | | | | | | | | | |
| Abacavir Dosing in Patients with Renal Impairment | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> ABC does not require dose adjustment in patients with renal impairment. Do not use FDC tablets containing 3TC (Epzicom, Triumeq PD, Triumeq, or the generic equivalents of these FDC tablets) in patients with creatinine clearance (CrCl) <30 mL/min or patients on dialysis, because the doses of 3TC cannot be adjusted. Data from FDC DTG/3TC (Dovato) suggest that patients with a sustained CrCl of 30–49 mL/min may experience a higher 3TC exposure and should be monitored for hematologic toxicities and potential FDC discontinuation and subsequent adjustment of the treatment regimen. See package inserts for additional information. | | | | | | | | | | | | | | | | |

- Administer the appropriate number of tablets once daily dispersed in 15-20 mL of water. See Special Instructions below. Triumeq PD tablets should not be swallowed whole, chewed, cut, or crushed.

Weight-Band Dosing of Triumeq PD Tablets for Children Weighing ≥ 6 kg and <25 kg

| Weight | Recommended Daily Dose | Number of Triumeq PD Tablets |
|-------------------------------|---------------------------------------|------------------------------|
| 6 kg to <10 kg ^a | ABC 180 mg DTG 15 mg 3TC 90 mg | 3 ^a |
| 10 kg to <14 kg | ABC 240 mg DTG 20 mg 3TC 120 mg | 4 |
| 14 kg to <20 kg | ABC 300 mg DTG 25 mg 3TC 150 mg | 5 |
| 20 kg to <25 kg | ABC 360 mg DTG 30 mg 3TC 180 mg | 6 |

^aIn infants weighing 6 to <10 kg dosing only requires 15 mL water.

- For use in children who are antiretroviral (ARV) naive or ARV experienced (but integrase strand transfer inhibitor-naive) and who are not being treated with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) or cytochrome P450 (CYP) 3A inducers.

[Triumeq] Abacavir/Dolutegravir/Lamivudine

Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose

- One tablet once daily
- This FDC tablet can be used in patients who are ARV-naive or ARV experienced (but integrase strand transfer inhibitor-naive) and who are not being treated with other drugs that act as UGT1A1 or CYP3A inducers.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Abacavir (ABC) neither inhibits nor is metabolized by hepatic cytochrome P450 enzymes. Therefore, it does not cause significant changes in the clearance of agents, such as protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), that are metabolized through these pathways.

- ABC plasma concentrations can decrease when ABC is used concurrently with the ritonavir-boosted PIs atazanavir/ritonavir, lopinavir/ritonavir (LPV/r), and darunavir/ritonavir.¹⁻³ The mechanism and the clinical significance of the drug interactions with these PIs are unknown. Currently, no recommendations exist for dose adjustments when ABC is coadministered with one of these boosted PIs.
- In the pooled analysis of 230 African children with HIV with a median age of 2.1 years (range 0.1–12.8) and a median weight of 9.8 kg (range 2.5–30.0), the population pharmacokinetics (PK) of ABC showed that children on boosted PI LPV/r or NNRTI efavirenz (EFV) had similar ABC exposures, while concomitant tuberculosis treatment and use of super-boosting with LPV significantly reduced ABC concentrations.⁴
- Alcohol exposure (0.7 g per kg ethanol, which is equivalent to five alcoholic drinks) interferes with ABC metabolism; it affects the activity of alcohol dehydrogenase and glucuronyl transferase. This interference increased ABC area under the curve (AUC) plasma exposure by 41% in adult men with HIV who received ABC 600 mg daily.⁵
- ABC oral solution contains sorbitol, which decreased the exposure of lamivudine (3TC) oral solution in adults when the drugs were administered concurrently.⁶ The clinical significance of this interaction is unknown.

Major Toxicities

- *More common:* Nausea, vomiting, fever, headache, diarrhea, rash, anorexia
- *Less common (more severe):* Serious and sometimes fatal hypersensitivity reactions (HSRs) have been observed in approximately 5% of adults and children (rate varies by race/ethnicity) receiving ABC. HSRs generally occur during the first 6 weeks of therapy, but they have also been reported after a single dose of ABC. The risk of an ABC HSR is associated with the presence of the HLA-B*5701 allele; the risk is greatly reduced by not using ABC in those who test positive for the HLA-B*5701 allele. The HSR to ABC is a multiorgan clinical syndrome usually characterized by rash, or signs or symptoms in two or more of the following groups:
 - Fever
 - Constitutional symptoms, including malaise, fatigue, or achiness
 - Gastrointestinal signs and symptoms, including nausea, vomiting, diarrhea, or abdominal pain
 - Respiratory signs and symptoms, including dyspnea, cough, or pharyngitis
 - Laboratory and radiologic abnormalities, including elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, lymphopenia, and pulmonary infiltrates. Lactic acidosis and severe hepatomegaly with steatosis—including fatal cases—also have been reported. Pancreatitis with laboratory abnormalities can occur.

If an HSR is suspected, ABC **should be stopped immediately and not restarted because hypotension and death may occur upon rechallenge.**

- *Rare:* Increased levels of liver enzymes, elevated blood glucose levels, elevated triglycerides (see information on cardiovascular risk below). Pancreatitis, lactic acidosis, and severe hepatomegaly with steatosis—including fatal cases—have been reported.

- *Rare:* Drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS) syndrome.

Resistance

The International Antiviral Society–USA maintains a [list of updated HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

ABC is approved by the U.S. Food and Drug Administration (FDA) for use in children with HIV aged ≥ 3 months as part of the nucleoside reverse transcriptase inhibitor (NRTI) component of antiretroviral therapy (ART). The World Health Organization (WHO), however, provides dosing guidance for ABC as a component of the NRTI backbone for full-term neonates starting at birth and weighing ≥ 2 kg (see Annex 1: Dosages for ARV Drugs in the WHO [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring](#)). The WHO guidance for ABC dosing in neonates increases the choices of antiretroviral (ARV) agents for the management of newborns in special situations where stock outs of nevirapine or zidovudine (ZDV) may affect the ability to effectively provide postnatal prophylaxis or treatment of neonatal HIV. The WHO recommendation of ABC dosing for infants starting at 1 month of age is based on the inclusion of ABC as a preferred NRTI component of the first- and second-line ARV regimens for children in the WHO [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring](#). This recommendation also takes into account the availability of the President's Emergency Plan for AIDS Relief (PEPFAR) tentatively approved pediatric generic ABC formulations—including coformulations that include 3TC—and the cost of ARV drugs in resource-limited settings.

Efficacy

Both the once-daily and twice-daily doses of ABC have demonstrated durable antiviral efficacy in pediatric clinical trials that is comparable to the efficacy observed for other NRTIs in children.^{7–11} In an observational study of nine cohorts from the International Epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa collaboration, 6- and 12-month viral suppression (<400 copies/mL) rates were evaluated among infants who initiated ART at age <3 months, and were compared with infants aged <28 and ≥ 28 days and weighing <3 and ≥ 3 kg at the time of ART initiation. Viral suppression at 12 months did not differ by age or weight at the time of ART initiation and it was slightly lower in infants on ABC (174/329 [53%]) versus in those on ZDV (77/138 [56%]) (adjusted odds ratio 1.8; 95% confidence interval (CI) 1.0–3.2).¹²

Pharmacokinetics

Pharmacokinetics in Neonates and Infants

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1106 trial reported PK data in 25 infants aged <3 months with HIV who were initiated on a median ABC dose of 10 mg/kg (range, 6–13 mg/kg) twice daily in combination with 3TC and LPV/r after 1 month of

life. Median age was 6 weeks (range, 1.5–11 weeks); median weight was 2,250 g (range 1,360–3,320 g); median gestational age was 36 weeks (range, 27–39 weeks). Sparse and pre-dose PK ABC samples were repeatedly obtained throughout 24 weeks of study follow-up. ABC plasma exposures were high compared to the published data in infants aged >3 months and decreased rapidly between 2 and 8 months of age as the infants matured and ABC clearance increased.¹³ In the Tygerberg cohort study from South Africa, 10 healthy term neonates at the median postnatal age of 10 days (range 6–15) who were administered a single ABC dose of 8 mg/kg before 15 days of life had substantially higher exposures than in infants and children and no reported adverse events.¹⁴ Higher ABC exposures in neonates than in infants and children are likely due to slower drug clearance through immature enzyme pathways.

PK modeling of ABC starting at birth has been conducted using pooled data from 308 ABC concentration measurements obtained from three studies administering ABC liquid to 45 young infants (including 21 full-term neonates <15 days of age with intensive PK).¹⁴ Two of these studies, the Pediatric AIDS Clinical Trials Group (PACTG) 321 study and the Tygerberg cohort, performed intensive PK sampling in full-term neonates receiving ABC for HIV prophylaxis. The third study, IMPAACT P1106, described above, performed sparse PK sampling on full-term and low birth weight (LBW; <2,500 g) infants with HIV. LBW infants were older at the first PK assessment, with a median postnatal age of 73 days (range 41–190) and weight of 3.8 kg (range 2.4–5.8). ABC PK parameters in neonates were estimated using PK simulations to achieve plasma ABC exposures (**area under the curve from time zero to 12 hours after drug administration; AUC₀₋₁₂**) within the expected adult range (3.2–25.2 mcg·hr/mL). The PK model predicted a slow ABC clearance of 2.51 mL/min per kg at birth, which doubled by 4 weeks of age. Simulations predicted that an ABC dose of 2 mg/kg twice daily in full-term neonates from birth to <4 weeks and an ABC dose of 4 mg/kg twice daily in infants aged 4 to 12 weeks would achieve target AUC₀₋₁₂; however, data in LBW infants are lacking.¹⁴ Based on these data, the weight-band dosing of ABC for neonates has been developed for neonates from birth to age <1 month and is included in the WHO [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring](#).¹⁵ This weight-band dosing for neonates approximates the ABC dosing per kg based on the postnatal age (see [Table 1](#) below).

Table 1. Simplified Weight-Band Dosing for Full-Term Neonates from Birth to <1 Month of Age (WHO [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring](#) Annex 1: Table A1.4)

| Birth to <1 Month of Age | | |
|--------------------------|--|---|
| Weight | Volume of ABC Oral Solution 20 mg/mL Twice Daily ^{a,b} | ABC Dose in mg Twice Daily (ranges mg/kg, from lowest to highest weight within the weight band) ^{a,b} |
| 2 kg to <3 kg | 0.4 mL | 8 mg (4.0–2.8 mg/kg) |
| 3 kg to <4 kg | 0.5 mL | 10 mg (3.3–2.6 mg/kg) |
| 4 kg to <5 kg | 0.6 mL | 12 mg (3.0–2.4 mg/kg) |

^a Simplified weight-band dosing exceeds recommended mg/kg ABC dosing in neonates and infants.

^b Neonatal ABC dose is based on birth weight and does not require weight-based adjustment during the first month of life.

Key: ABC = abacavir

For infants aged ≥ 1 month with weight 3 to <6 kg, the WHO [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery, and Monitoring](#) currently recommend a twice-daily dose of 3 mL (60 mg) of ABC 20 mg/mL solution (range 10–20 mg/kg/dose). The weight-band dosing for neonates and infants within the WHO HIV guidelines is higher than the modeled weight-based dosing for practical considerations in resource-limited settings. As new generic pediatric formulations of ABC become available in resource-limited settings, there is potential for the revision of the WHO guidelines for weight-band dosing of ABC for young infants.

Based on the PK modeling from three infant studies¹⁴ and the neonatal and infant safety data from the IMPAACT 1106 study and two observational cohort studies (see Safety in Neonates and Infants below), the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends an ABC dose of 2 mg/kg twice daily for neonates from birth to <1 month of age and an ABC dose of 4 mg/kg twice daily for full-term infants aged ≥ 1 month and <3 months.

Pharmacokinetics in Children

PK studies of ABC in children aged <12 years have demonstrated that metabolic clearance of ABC in adolescents and young adults (aged 13–25 years) is slower than that observed in younger children and approximates clearance seen in older adults.¹⁶

The PKs of ABC administered once daily in children with HIV aged 3 months through 12 years were evaluated in three crossover open-label PK trials of twice-daily versus once-daily dosing of ABC and 3TC (PENTA 13 [n = 14], PENTA 15 [n = 18], and ARROW [n = 36]).^{5,17–20} The data from these three pediatric trials were used to develop a model for ABC PKs; this model predicted that systemic plasma ABC exposure after once-daily dosing would be equivalent to the exposure seen after twice-daily dosing in infants and children aged ≤ 12 years.^{17–21} Both the trials and PK modeling have demonstrated that once-daily dosing with either the tablet or the liquid formulation of ABC produces plasma exposures comparable to those seen with a twice-daily dosing schedule that uses the same total daily dose of ABC.⁵

Dosing

Dosing and Formulations

A total daily dose of ABC 600 mg can be used safely in a person weighing 25 kg.⁵ Doses of the liquid ABC formulation are similar to those used for weight-band dosing with tablet formulations and should be considered for use in younger children who are unable to swallow a pill.²²

In the three ABC dosing pediatric trials described above,^{17–20} only children who had low viral loads and who were clinically stable on the twice-daily dose of ABC were eligible to change to once-daily ABC dosing. Efficacy data from a 48-week follow-up in the ARROW trial demonstrated clinical non-inferiority of once-daily ABC (n = 336) versus twice-daily ABC (n = 333) in tablet form combined with a once-daily or twice-daily 3TC-based ARV regimen.¹¹ To date, no clinical trials have been conducted involving children who initiated therapy with once-daily dosing of the ABC liquid formulation. In children who can be treated with pill formulations, initiating therapy with once-daily dosing of ABC at a dose of 16 mg/kg (with a maximum dose of ABC 600 mg) is recommended. However, twice-daily dosing is recommended for infants and young children who initiate therapy with the liquid formulation of ABC. Switching to once-daily dosing with the liquid formulation could be considered when harmonizing with other antiretroviral drugs administered once daily, such as 3TC and dolutegravir (DTG).

Recent data from the IMPAACT 2019 clinical trial of dispersible and immediate-release ABC/DTG/3TC tablets in children with HIV has validated the FDA-approved dosing in infants and children weighing 10 to <25 kg and established newly proposed dosing of this fixed-dose combination (FDC) (3 tablets once daily of ABC 60 mg, DTG 5 mg, and 3TC 30 mg dispersed in 15–20 mL of water) in infants aged ≥3 months weighing 6 to <10 kg.(Food and Drug Administration 2023) ABC/DTG/3TC dispersible FDC dosing was developed based on PK and safety data in each weight band at the originally selected dosing, which aligned with WHO weight band dosing for the individual ARV agents. Follow-up through 24 weeks confirmed the safety, tolerability, and virological efficacy of both formulations.²³

Toxicity

Safety in Neonates and Infants

Data from the PACTG 321, the IMPAACT P1106 trial, and two observational European and African cohorts provided reassuring data on the safety of ABC in infants when initiated at <3 months of age, including infants with weight <3 kg.^{12,13,24} The IMPAACT P1106 trial reported 24 weeks of safety data in 27 infants in whom repeated dosing of ABC was initiated at the median age of 60 days. Fifteen infants (55.6%; 90% CI, 38.3–72.0) met the safety endpoint of death or a Grade 3 or higher adverse event (AE). None of the AEs were related to ABC, and none led to interruptions or adjustments of ABC dosing. No hypersensitivity reactions were reported with the multi-dose treatment.¹³ In two cohorts of neonates (<1 month of age) who received a single ABC dose, ABC was well tolerated; all reported AEs in the PACTG 321 study were unrelated to ABC, and no AEs were reported in the Tygerberg cohort.^{14,25} The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) reported safety outcomes among 139 children from 13 cohorts in 11 countries in Europe who initiated ABC at age <3 months. By 12 months on ABC, 3.6% (n = 4) had discontinued ABC because of an ART safety concern and 11.8% (n = 15) discontinued ABC for any reason.²⁴ Another observational study of nine cohorts from the IeDEA Southern Africa

collaboration compared safety outcomes (measured as ABC discontinuations and their reasons) between infants who started ABC aged <28 days ($n = 232$) and those aged ≥ 28 days ($n = 605$), and between infants who started ABC with weight <3 kg ($n = 53$) and those with weight ≥ 3 kg ($n = 784$) at the time of ABC initiation.¹² ABC discontinuations at 6 and 12 months were not significantly different in infants who started ART aged <28 days versus ≥ 28 days or in infants who weighed <3 kg versus ≥ 3 kg. ABC discontinuations were less frequent than ZDV discontinuations (adjusted hazard ratio 0.14, 95% CI 0.10–0.20).¹²

Safety in Children and Adolescents

ABC has less of an effect on mitochondrial function than the NRTI ZDV^{7,8} and less bone and renal toxicity than tenofovir disoproxil fumarate.^{26,27}

Systematic review and meta-analysis of the 54 full-text articles on the observational and experimental studies conducted in infants, children, and adolescents with HIV who are aged 10 to 19 years and that included data on safety, efficacy, or both, and were published in English or French between 2009 and 2022 reported that toxic effects due to ABC use in infants, children, and adolescents remain rare and manageable.²⁸

Several observational cohort studies, including contemporary cohort analyses, suggest that an increased risk of cardiovascular disease (CVD) events—such as myocardial infarction, stroke, and invasive cardiovascular procedure—exists in adults who are currently using ABC or who have recently used ABC (see [Cardiovascular Risk in Nucleoside Reverse Transcriptase Inhibitor Options as Part of Initial Therapy in the Adult and Adolescent Guidelines](#)); however, other studies have not substantiated this finding. Limited data are available on the CVD risks associated with ABC use in children. One cohort study of South African adolescents (385 participants with HIV and 63 participants as HIV-negative controls) with a median age of 12 years reported an association between ABC exposure and insulin resistance, which was evaluated using homeostatic model assessment. These findings suggested that the use of ABC may be a CVD risk factor for young people with perinatally acquired HIV.²⁹ In a recent prospective study of 101 virally suppressed (≤ 400 copies/mL) youth aged 10 to 18 years with HIV and 97 uninfected controls from Uganda, the baseline common carotid artery intima-media thickness (IMT) was slightly higher in participants with HIV than in controls ($P < 0.01$), and pulse wave velocity (PWV) did not differ between groups. In longitudinal analyses, the longer ART duration was associated with lower PWV in youth with HIV ($\beta = .008$ [95% CI, -.008 to .003]), while ABC use was associated with greater IMT in youth with HIV ($\beta = .043$ [95% CI, .012–.074]). These findings suggest that in adolescents with HIV, early prolonged ART may prevent progression of subclinical vascular disease, while prolonged ABC use may increase it.³⁰

References

1. Waters LJ, Moyle G, Bonora S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. *Antivir Ther.* 2007;12(5):825-830. Available at: <https://pubmed.ncbi.nlm.nih.gov/17713166>.
2. Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. *Antimicrob Agents Chemother.* 2009;53(5):1937-1943. Available at: <https://pubmed.ncbi.nlm.nih.gov/19273671>.
3. Jackson A, Moyle G, Dickinson L, et al. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. *Antivir Ther.* 2012;17(1):19-24. Available at: <https://pubmed.ncbi.nlm.nih.gov/22267465>.
4. Tikiso T, McIlheron H, Burger D, et al. Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. *Br J Clin Pharmacol.* 2022;88(2):403-415. Available at: <https://pubmed.ncbi.nlm.nih.gov/34260082>.
5. Food and Drug Administration. Triumeq and Triumeq PD package insert. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205551s31,215413s02lbl.pdf.
6. Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. *Clin Pharmacol Ther.* 2018;103(3):402-408. Available at: <https://pubmed.ncbi.nlm.nih.gov/29150845>.
7. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet.* 2002;359(9308):733-740. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11888583>.
8. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS.* 2007;21(8):947-955. Available at: <https://pubmed.ncbi.nlm.nih.gov/17457088>.
9. Adetokunboh OO, Schoonees A, Balogun TA, Wiysonge CS. Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV

infected children and adolescents: a systematic review and meta-analysis. *BMC Infect Dis.* 2015;15:469. Available at: <https://pubmed.ncbi.nlm.nih.gov/26502899>.

10. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis.* 2016;16(2):169-179. Available at: <https://pubmed.ncbi.nlm.nih.gov/26481928>.
11. Musiime V, Kasirye P, Naidoo-James B, et al. Once vs. twice-daily abacavir and lamivudine in African children. *AIDS.* 2016;30(11):1761-1770. Available at: <https://pubmed.ncbi.nlm.nih.gov/27064996>.
12. de Waal R, Rabie H, Technau KG, et al. Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. *Antivir Ther.* 2023;28(2):13596535231168480. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37038365>.
13. Cressey TR, Bekker A, Cababasay M, et al. Abacavir safety and pharmacokinetics in normal and low birth weight infants with HIV. Abstract#843. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020. Boston, MA Available at: <https://www.croiconference.org/abstract/abacavir-safety-and-pharmacokinetics-in-normal-and-low-birth-weight-infants-with-hiv/>.
14. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV.* 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.
15. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. Available at: <https://www.who.int/publications/i/item/9789240031593>
16. Sleasman JW, Robbins BL, Cross SJ, et al. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. *Clin Pharmacol Ther.* 2009;85(4):394-401. Available at: <https://pubmed.ncbi.nlm.nih.gov/19118380>.
17. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. *Pediatr Infect Dis J.* 2006;25(6):533-537. Available at: <https://pubmed.ncbi.nlm.nih.gov/16732152>.
18. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). *Antivir Ther.* 2005;10(2):239-246. Available at: <https://pubmed.ncbi.nlm.nih.gov/15865218>.

19. Paediatric European Network for Treatment of AIDS. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. *Antivir Ther.* 2010;15(3):297-305. Available at: <https://pubmed.ncbi.nlm.nih.gov/20516550>.
20. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. *Antivir Ther.* 2010;15(8):1115-1124. Available at: <https://pubmed.ncbi.nlm.nih.gov/21149918>.
21. Zhao W, Piana C, Danhof M, et al. Population pharmacokinetics of abacavir in infants, toddlers and children. *Br J Clin Pharmacol.* 2013;75(6):1525-1535. Available at: <https://pubmed.ncbi.nlm.nih.gov/23126277>.
22. Kasirye P, Kendall L, Adkison KK, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. *Clin Pharmacol Ther.* 2012;91(2):272-280. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22190066>.
23. Brooks KM, Kiser JJ, Ziembka L, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. *Lancet HIV.* 2023;10(8):e506-e517. Available at: <https://pubmed.ncbi.nlm.nih.gov/37541705>.
24. Crichton S, Collins IJ, Turkova A, et al. Abacavir dosing, effectiveness, and safety in young infants living with HIV in Europe. Abstract #844. Presented at: Conference on Retroviruses and Opportunistic Infections 2020. Boston, MA Available at: <https://www.croiconference.org/abstract/abacavir-dosing-effectiveness-and-safety-in-young-infants-living-with-hiv-in-europe/>.
25. Bekker A, Decloedt EH, Slade G, et al. Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). *Clin Infect Dis.* 2021;72(11):2032-2034. Available at: <https://pubmed.ncbi.nlm.nih.gov/32697327>.
26. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. *J Acquir Immune Defic Syndr.* 2010;55(1):49-57. Available at: <https://pubmed.ncbi.nlm.nih.gov/20431394>.
27. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. *J Infect Dis.* 2011;203(12):1791-1801. Available at: <https://pubmed.ncbi.nlm.nih.gov/21606537>.

28. Jesson J, Saint-Lary L, Revegue M, et al. Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis. *Lancet Child Adolesc Health.* 2022;6(10):692-704. Available at: <https://pubmed.ncbi.nlm.nih.gov/36058225>.
29. Frigati LJ, Jao J, Mahtab S, et al. Insulin resistance in South African youth living with perinatally acquired HIV receiving antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2019;35(1):56-62. Available at: <https://pubmed.ncbi.nlm.nih.gov/30156434>.
30. Dirajlal-Fargo S, Zhao C, Labbato D, et al. Longitudinal changes in subclinical vascular disease in Ugandan Youth with human immunodeficiency virus. *Clin Infect Dis.* 2023;76(3):e599-e606. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36004575>.

Emtricitabine (FTC, Emtriva)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|--|--|
| Pediatric Oral Solution: 10 mg/mL | Capsule: 200 mg |
| Fixed-Dose Combination (FDC) Tablets <ul style="list-style-type: none">• [Atripla and generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Biktarvy]<ul style="list-style-type: none">◦ Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg◦ Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg• [Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg• [Descovy]<ul style="list-style-type: none">◦ Emtricitabine 200 mg/tenofovir alafenamide 25 mg◦ Emtricitabine 120 mg/tenofovir alafenamide 15 mg• [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg• [Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg• [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg• [Truvada]<ul style="list-style-type: none">◦ Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg◦ Emtricitabine 167 mg/tenofovir disoproxil fumarate 250 mg◦ Emtricitabine 133 mg/tenofovir disoproxil fumarate 200 mg◦ Emtricitabine 100 mg/tenofovir disoproxil fumarate 150 mg | |
| When using FDC tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| Neonatal and Infant (Aged 0 to <3 Months) Dose <i>Oral Solution</i> <ul style="list-style-type: none">• Emtricitabine (FTC) 3 mg/kg once daily | <ul style="list-style-type: none">• Hyperpigmentation/skin discoloration on palms and/or soles |

| Child (Aged \geq 3 Months) and Adolescent Dose | Special Instructions |
|--|---|
| Oral Solution | Metabolism/Elimination |
| <p>• FTC 6 mg/kg once daily (maximum 240 mg per dose). The maximum dose of oral solution is higher than the capsule dose because a pediatric pharmacokinetic analysis reported that the plasma exposure for FTC was 20% lower in patients who received the oral solution than in patients who received the capsule formulation.</p> <p><i>Capsules (for Patients Weighing >33 kg)</i></p> <ul style="list-style-type: none"> • FTC 200 mg once daily <p>Adult Dose</p> <p><i>Oral Solution for Patients Who Are Unable to Swallow Capsules</i></p> <ul style="list-style-type: none"> • FTC 240 mg (24 mL) once daily <p><i>Capsules</i></p> <ul style="list-style-type: none"> • FTC 200 mg once daily <p>[Atripla and Generic] Efavirenz/FTC/Tenofovir Disoproxil Fumarate (TDF)</p> <p><i>Child and Adolescent (Weighing \geq40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily • Take on an empty stomach. <p>[Biktarvy] Bictegravir/FTC/Tenofovir Alafenamide (TAF)</p> <p><i>Neonate or Child (Aged <2 Years and Weighing <14 kg) Dose</i></p> <ul style="list-style-type: none"> • No data are available on the appropriate dose of Biktarvy in children aged <2 years and weighing <14 kg. Studies are currently being conducted to identify the appropriate dose for this age and weight group. <p><i>Child, Adolescent, and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily, with or without food. | <ul style="list-style-type: none"> • Although FTC can be administered without regard to food, some FDC tablet formulations that contain FTC have food requirements. • FTC oral solution can be kept at room temperature, up to 77°F (25°C), if used within 3 months; refrigerate oral solution for long-term storage. • Screen patients for hepatitis B virus (HBV) infection before using FTC or FDC tablets that contain FTC. Severe acute exacerbation of HBV infection can occur when FTC is discontinued; therefore, hepatic function and hepatitis B viral load should be monitored for several months after patients with HBV infection stop taking FTC. <p>FTC Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • Atripla should be used with caution in patients with hepatic impairment. • Biktarvy, Genvoya, Stribild, and Symtuza are not recommended for use in patients with severe hepatic impairment. • Complera, Descovy, and Odefsey do not require dose adjustment in mild or moderate hepatic impairment but should not be used in patients with severe hepatic impairment because they have not been studied in this group. <p>FTC Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • Decrease the dose of FTC in patients with impaired renal function. Consult the manufacturer's prescribing information for recommended dose adjustments. • Do not use the FDC tablets Atripla or Complera in patients with creatinine clearance (CrCl) <50 mL/min or in patients who require dialysis. • Do not use the FDC tablets Truvada or Biktarvy in patients with CrCl <30 mL/min. Do not use Truvada in patients who require dialysis. |

- | | |
|--|--|
| <ul style="list-style-type: none"> The U.S. Food and Drug Administration approved Biktarvy for use only in antiretroviral therapy (ART)-naive patients or to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to the individual components of Biktarvy. Some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommend the use of Biktarvy in patients with prior treatment failure and who have virus containing the M184V mutation. See the Bictegravir section for additional information. | <ul style="list-style-type: none"> Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min. TAF-containing formulations are not recommended for use in patients with estimated CrCl <30 mL/min. |
|--|--|

[Complera] FTC/Rilpivirine (RPV)/TDF

Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose

- One tablet once daily in ART-naive patients who have baseline plasma HIV RNA ≤100,000 copies/mL. This dose of Complera also can be used to replace a stable ARV regimen in patients who are currently on their first or second regimen and who have been virologically suppressed (HIV RNA <50 copies/mL) with no history of treatment failure and no known mutations associated with resistance to the individual components of Complera.
- Administer with a meal of at least 500 calories.

[Descovy] FTC/TAF

Child and Adolescent and Adult Dose

| Body Weight | Dose |
|------------------|---|
| ≥14 kg to <25 kg | FTC 120 mg/TAF 15 mg, in combination with an integrase strand transfer inhibitor (INSTI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). In this weight band, Descovy should not be used with protease inhibitors (PIs) that require a cytochrome P450 (CYP) 3A inhibitor (e.g., ritonavir [RTV] or COBI). |
| ≥25 kg to <35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI or an NNRTI. In this weight band, Descovy should not be used with PIs that require a CYP3A inhibitor (i.e., RTV or COBI). |
| ≥35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI, NNRTI, or boosted PI. |

[Genvoya] Elvitegravir/Cobicistat (COBI)/FTC/TAF

Child and Adolescent (Weighing ≥25 kg) and Adult Dose

- One tablet once daily with food in ART-naive patients. This dose of Genvoya also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to the individual components of Genvoya.

[Odefsey] FTC/RPV/TAF

Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose

- One tablet once daily in ART-naive patients with HIV RNA ≤100,000 copies/mL. This dose of Odefsey also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) with no history of treatment failure and no known mutations associated with resistance to the individual components of Odefsey.

- Administer with a meal of at least 500 calories.

[Stribild] Elvitegravir/COBI/FTC/TDF

Child and Adolescent (Weighing ≥35 kg with a Sexual Maturity Rating of 4 or 5) and Adult Dose

- One tablet once daily with food in ART-naive patients. This dose of Stribild also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) with no history of treatment failure and no known mutations associated with resistance to the individual components of Stribild.

[Symtuza] Darunavir (DRV)/COBI/FTC/TAF

Child and Adolescent (Weighing ≥40 kg) and Adult Dose

- One tablet once daily with food in ART-naive patients or in patients who have been virologically suppressed (HIV RNA <50 copies/mL) with no known mutations associated with resistance to DRV or tenofovir.

[Truvada] FTC/TDF

Truvada Dosing Table

Child, Adolescent, and Adult Dose

| Body Weight | FTC/TDF Tablet Once Daily |
|-------------------|----------------------------------|
| 17 kg to <22 kg | One FTC 100-mg/TDF 150-mg tablet |
| 22 kg to <28 kg | One FTC 133-mg/TDF 200-mg tablet |
| 28 kg to <35 kg | One FTC 167-mg/TDF 250-mg tablet |
| ≥35 kg and adults | One FTC 200-mg/TDF 300-mg tablet |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Other nucleoside reverse transcriptase inhibitors (NRTIs):* **Do not use** emtricitabine (FTC) in combination with lamivudine (3TC), because these agents share similar resistance profiles and lack additive benefit. **Do not use** FTC with fixed-dose combination (FDC) medications that contain 3TC or FTC. See [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#), and refer to other sections of the [Drug Appendix](#) for drug interaction information for each individual component of an FDC tablet.
- *Renal elimination:* FTC may compete with other compounds that undergo renal tubular secretion. Drugs that decrease renal function could decrease clearance of FTC.

Major Toxicities

- *More common:* Headache, insomnia, diarrhea, nausea, rash. Hyperpigmentation/skin discoloration, which may be more common in children than in adults.
- *Less common (more severe):* Neutropenia. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Exacerbations of hepatitis have occurred in patients with hepatitis B virus (HBV)/HIV coinfection who switched from regimens that included FTC to regimens that did not include FTC.

Resistance

The International Antiviral Society—USA maintains a list of [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

FTC is approved by the U.S. Food and Drug Administration for once-daily administration in children, starting at birth. FTC often is used as part of a dual-NRTI backbone in antiretroviral (ARV) regimens for children and adolescents because of its once-daily dosing, minimal toxicity, and favorable pediatric pharmacokinetic (PK) data.

Efficacy and Pharmacokinetics

Comparative Clinical Trials

Studies that assess the efficacy and/or potency of nucleoside/nucleotide analogues have been more concerned with the dynamic components of the regimen—such as tenofovir disoproxil fumarate (TDF), tenofovir alafenamide, or abacavir—than the more static components, such as FTC or 3TC. FTC and 3TC have been considered interchangeable, but data to support this conclusion are lacking. Investigators studying the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

compared the efficacy of TDF plus FTC with TDF plus 3TC when these drugs were administered with a ritonavir-boosted protease inhibitor (darunavir, atazanavir, or lopinavir) in antiretroviral therapy (ART)-naive patients.¹ The adjusted hazard ratio for the virologic failure of 3TC-containing regimens compared with FTC-containing regimens within 240 weeks of starting therapy was 1.15 (95% confidence interval, 0.58–2.27). No difference between these regimens was observed in the time to virologic suppression during the first 48 weeks of therapy or time to virologic failure after attaining suppression. A Swiss cohort study found a potential difference in efficacy between FTC and 3TC; however, the difference disappeared after adjusting for pill burden.² Current evidence suggests that FTC and 3TC have equivalent efficacy and toxicity in ARV-naive patients.

Efficacy

Following a dose-finding study (described in the Pharmacokinetics: Liquid Versus Capsule section below),³ a once-daily dose of FTC 6 mg/kg administered in combination with other ARV drugs was studied in 116 patients aged 3 months to 16 years.⁴ The study used a maximum dose of 240 mg of the FTC liquid formulation. PK results showed that the plasma exposures seen in these children and adolescents were similar to those seen in adults who received FTC 200 mg once daily. Follow-up data extending to Week 96 indicated that 89% of ART-naive children and 76% of ARV-experienced children maintained plasma HIV RNA <400 copies/mL (75% of ARV-naive children and 67% of ARV-experienced children had HIV RNA <50 copies/mL). Minimal toxicity was observed during this trial. Pediatric AIDS Clinical Trials Group (PACTG) P1021⁵ evaluated the use of FTC 6 mg/kg (with a maximum dose of FTC 200 mg per day of the liquid formulation) as part of a three-drug regimen dosed once daily to ARV-naive children aged 3 months to 21 years. In this trial, 85% of children achieved HIV RNA <400 copies/mL, and 72% of children maintained virologic suppression (HIV RNA <50 copies/mL) through 96 weeks of therapy. The median CD4 T lymphocyte count rose by 329 cells/mm³ at Week 96.

Pharmacokinetics: Liquid Versus Capsule

A single-dose PK study of the FTC oral solution and FTC capsules enrolled 25 children with HIV aged 2 years to 17 years.³ FTC was found to be well absorbed following oral administration, with a mean elimination half-life of 11 hours (range 9.7–11.6 hours). Plasma concentrations in children who received the once-daily dose of FTC 6 mg/kg were approximately equivalent to those seen in adults who received the standard dose of FTC 200 mg. However, plasma concentrations of FTC after administration of the capsule formulation were approximately 20% higher than those observed after administration of the oral solution in this small cohort of children.

Pharmacokinetics in Infants

A study in South Africa evaluated the PK of FTC in 20 infants aged <3 months with perinatal HIV exposure. The participants received a dose of FTC 3 mg/kg once daily for two 4-day courses, separated by an interval of ≥2 weeks.⁶ FTC exposure (area under the curve [AUC]) in neonates receiving FTC 3 mg/kg once daily was within the range of exposures seen in pediatric patients aged >3 months who received the recommended dose of FTC 6 mg/kg once daily and adults who received the recommended dose of FTC 200 mg once daily. During the first 3 months of life, FTC AUC decreased with increasing age, correlating with an increase in total body clearance of the drug. In a small group of neonates (n = 6) who received a single dose of FTC 3 mg/kg and whose mothers received a single dose of FTC 600 mg during delivery, the FTC AUC exceeded the AUC seen in adults and older children. However, FTC had a half-life of 9.2 hours in these neonates, which is

similar to that observed in adults and older children.⁷ Extensive safety data are lacking for this age range.

Considerations for Use

The FTC oral solution has an advantage over the liquid formulation of 3TC because it can be given once daily at ARV initiation, whereas the liquid formulation of 3TC needs to be given twice daily at ARV initiation. When pill formulations of 3TC or FTC are used, they can be administered once daily.

Both FTC and 3TC have antiviral activity and efficacy against HBV. For a comprehensive review of this topic, see the [Hepatitis B Virus](#) section in the [Pediatric Opportunistic Infection Guidelines](#).

References

1. Rokx C, Gras L, van de Vijver D, et al. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. *HIV Med.* 2016;17(8):571-580. Available at: <https://pubmed.ncbi.nlm.nih.gov/26842457>.
2. Yang WL, Kouyos RD, Scherrer AU, et al. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV cohort study. *J Antimicrob Chemother.* 2015;70(12):3323-3331. Available at: <https://pubmed.ncbi.nlm.nih.gov/26362944>.
3. Wang LH, Wiznia AA, Rathore MH, et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother.* 2004;48(1):183-191. Available at: <https://pubmed.ncbi.nlm.nih.gov/14693538>.
4. Saez-Llorens X, Violari A, Ndiweni D, et al. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. *Pediatrics.* 2008;121(4):e827-835. Available at: <https://pubmed.ncbi.nlm.nih.gov/18332076>.
5. McKinney RE, Jr., Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naïve children and adolescents: Pediatric AIDS Clinical Trials Group protocol P1021. *Pediatrics.* 2007;120(2):e416-423. Available at: <https://pubmed.ncbi.nlm.nih.gov/17646352>.
6. Blum M, Ndiweni D, Chittick Gea. Steady state pharmacokinetic evaluation of emtricitabine in neonates exposed to HIV *in utero*. Presented at: Conference on Retroviruses and Opportunistic Infections. 2006. Denver, CO.
7. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. *Antimicrob Agents Chemother.* 2011;55(12):5914-5922. Available at: <https://pubmed.ncbi.nlm.nih.gov/21896911>.

Lamivudine (3TC, Epivir)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations |
|--|
| Pediatric Oral Solution |
| <ul style="list-style-type: none">• [Epivir] 10 mg/mL• [Epivir HBV]^a 5 mg/mL |
| Tablets |
| <ul style="list-style-type: none">• [Epivir] 150 mg (scored) and 300 mg• [Epivir HBV]^a 100 mg |
| Generic Formulations |
| <ul style="list-style-type: none">• 100-mg, 150-mg, and 300-mg tablets |
| Fixed-Dose Combination (FDC) Tablets |
| <ul style="list-style-type: none">• [Cimduo] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Combivir and generic] Lamivudine 150 mg/zidovudine 300 mg• [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Dovato] Dolutegravir 50 mg/lamivudine 300 mg• [Epzicom] Abacavir 600 mg/lamivudine 300 mg• [Symfi] Efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Symfi Lo] Efavirenz 400 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Temixys] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Triumeq] Abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg• [Triumeq PD] Abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg• [Trizivir] Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg |
| When using FDC tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents . |
| For additional information, see Drugs@FDA or DailyMed . |

| Dosing Recommendations | Selected Adverse Events | | | | | | | | | | | | |
|---|-------------------------|----------------------|----------------------|---------------------------------------|------|------|--|------|------|---|------|------|---|
| <p>Note: See Antiretroviral Management of Infants With <i>In Utero</i>, <i>Intrapartum</i>, or <i>Breastfeeding</i> Exposure to HIV and Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With <i>In Utero</i> or <i>Intrapartum</i> Exposure to HIV for information about using lamivudine (3TC) to prevent perinatal HIV transmission.</p> <p>Neonate (≥ 32 Weeks Gestation at Birth) and Infant (Birth to < 4 Weeks) Dose</p> <p><i>Oral Solution</i></p> <ul style="list-style-type: none"> • 3TC 2 mg/kg twice daily <p>Infant and Child Dose</p> <ul style="list-style-type: none"> • Once-daily dosing of the 3TC oral solution is not recommended when initiating 3TC oral solution in infants and young children. Patients can be transitioned to once-daily treatment with the oral solution when they have been stable on twice-daily treatment for 36 weeks and are aged ≥ 3 years. Please see the note below and refer to the text for more detail. <p><i>Aged ≥ 4 Weeks to < 3 Months</i></p> <ul style="list-style-type: none"> • 3TC 4 mg/kg twice daily of the oral solution <p><i>Aged ≥ 3 Months to < 3 Years</i></p> <ul style="list-style-type: none"> • 3TC 5 mg/kg twice daily of the oral solution (maximum 150 mg per dose) <p><i>Aged ≥ 3 Years</i></p> <ul style="list-style-type: none"> • 3TC 5 mg/kg twice daily of the oral solution (maximum 150 mg per dose); <i>or</i> • 3TC 10 mg/kg once daily of the oral solution (maximum 300 mg per dose) <p>Weight-Band Dosing for the 10-mg/mL 3TC Oral Solution in Children Weighing ≥ 3 kg</p> <table border="1"> <thead> <tr> <th>Weight</th><th>Twice-Daily Dose, AM</th><th>Twice-Daily Dose, PM</th></tr> </thead> <tbody> <tr> <td>3 kg to < 6 kg</td><td>3 mL</td><td>3 mL</td></tr> <tr> <td>6 kg to < 10 kg</td><td>4 mL</td><td>4 mL</td></tr> <tr> <td>10 kg to < 14 kg</td><td>6 mL</td><td>6 mL</td></tr> </tbody> </table> <p><i>Weighing ≥ 14 kg and Able to Swallow Tablets</i></p> <ul style="list-style-type: none"> • Weight-band dosing (see table below; dose is approximately 3TC 5 mg/kg per day twice daily or 3TC 10 mg/kg once daily) | Weight | Twice-Daily Dose, AM | Twice-Daily Dose, PM | 3 kg to < 6 kg | 3 mL | 3 mL | 6 kg to < 10 kg | 4 mL | 4 mL | 10 kg to < 14 kg | 6 mL | 6 mL | <ul style="list-style-type: none"> • Headache <p>Special Instructions</p> <ul style="list-style-type: none"> • 3TC and coformulated tablets can be given with and without food. • Store 3TC oral solution at room temperature. • For abacavir (ABC)/dolutegravir (DTG)/3TC dispersible tablets, fully disperse them in 20 mL of drinking water in the supplied cup and swirl the suspension so that no lumps remain. After full dispersion and within 30 minutes of mixing, administer the oral suspension. Rinse the dosing cup with a small amount of water and give this additional water to the child to ensure that the child takes the full dose and no medication remains in the dosing cup. ABC/DTG/3TC dispersible tablets should not be swallowed whole, chewed, cut, or crushed. • Screen patients for hepatitis B virus (HBV) infection before using 3TC or FDC tablets that contain 3TC. Severe acute exacerbations of HBV can occur after discontinuation of 3TC. Hepatic function and HBV viral load should be monitored for several months after patients with HBV infection stop taking 3TC. Patients with HBV/HIV coinfection who receive Dovato will require additional treatment for chronic HBV infection. • For any FDC tablet containing ABC, test patients for the HLA-B*5701 allele before starting therapy to predict the risk of hypersensitivity reactions. Patients who test positive for the HLA-B*5701 allele should not be given an ABC-containing FDC. Patients with no prior HLA-B*5701 testing who are tolerating an ABC-containing regimen do not need to be tested. See Abacavir. <p>Metabolism/Elimination</p> <p>3TC Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • No change in 3TC dosing is required for patients with hepatic impairment. • FDC tablets containing ABC or ZDV should not be used in patients who have impaired hepatic function. |
| Weight | Twice-Daily Dose, AM | Twice-Daily Dose, PM | | | | | | | | | | | |
| 3 kg to < 6 kg | 3 mL | 3 mL | | | | | | | | | | | |
| 6 kg to < 10 kg | 4 mL | 4 mL | | | | | | | | | | | |
| 10 kg to < 14 kg | 6 mL | 6 mL | | | | | | | | | | | |

- The scored tablet is the preferred formulation for pediatric patients weighing ≥ 14 kg who can swallow a tablet.

Weight-Band Dosing for the Scored, 150-mg 3TC Tablet in Children Weighing ≥ 14 kg

| Weight | Twice-Daily Dose, AM | Twice-Daily Dose, PM | Once-Daily Dose |
|---|------------------------------|------------------------------|----------------------------------|
| 14 kg to <20 kg | $\frac{1}{2}$ tablet (75 mg) | $\frac{1}{2}$ tablet (75 mg) | 1 tablet (150 mg) |
| ≥ 20 kg to <25 kg | $\frac{1}{2}$ tablet (75 mg) | 1 tablet (150 mg) | 1 $\frac{1}{2}$ tablets (225 mg) |
| ≥ 25 kg | 1 tablet (150 mg) | 1 tablet (150 mg) | 2 tablets (300 mg) |

Note: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) supports switching from twice-daily dosing to once-daily dosing of 3TC (using the oral solution or tablets) in children aged ≥ 3 years who have been clinically stable for 36 weeks with undetectable viral loads and stable CD4 T lymphocyte cell counts. Clinicians should choose a once-daily regimen using the once-daily dose of 3TC indicated above (approximately 3TC 10 mg/kg, with a maximum of 3TC 300 mg once daily).

Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose

- 3TC 150 mg twice daily; or
- 3TC 300 mg once daily

[Cimduo] 3TC/Tenofovir Disoproxil Fumarate (TDF)

Child and Adolescent (Weighing >35 kg) and Adult Dose

- One tablet once daily

[Combivir and Generic] 3TC/Zidovudine (ZDV)

Child and Adolescent (Weighing ≥ 30 kg) and Adult Dose

- One tablet twice daily

[Delstrigo] Doravirine/3TC/TDF

Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose

- One tablet once daily in antiretroviral (ARV)-naive patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to the individual components of Delstrigo

[Dovato] DTG/3TC

Adult Dose

- One tablet once daily with or without food as a complete ARV regimen in antiretroviral therapy (ART)-naive adults with no known

- Symfi and Symfi Lo should be used with caution in patients with hepatic impairment; Symfi and Symfi Lo are not recommended for use in moderate or severe hepatic impairment.
- Delstrigo and Dovato do not require dose adjustment in mild or moderate hepatic impairment but have not been studied in patients and so are not recommended with severe hepatic impairment.

3TC Dosing in Patients with Renal Impairment

- Dose adjustment of 3TC is required for patients with renal insufficiency.
- Do not use FDC tablets containing 3TC in patients with creatinine clearance <30 mL/min or patients on dialysis, because the doses of 3TC cannot be adjusted. Data from the FDC DTG/3TC (Dovato) suggest that patients with a sustained creatinine clearance 30–49 mL/min may experience a higher 3TC exposure and should be monitored for hematologic toxicities and potential FDC discontinuation and subsequent adjustment of the treatment regimen. See package inserts for additional information.

| | |
|--|--|
| <p>mutations associated with resistance to the individual components of Dovato</p> <ul style="list-style-type: none"> • Dovato is not approved by the U.S. Food and Drug Administration (FDA) or recommended by the Panel for use in children or adolescents as a complete ARV regimen. However, it could be used as part of a three-drug regimen in patients who meet the minimum body weight requirements for each component drug. <p>[Epzicom] ABC/3TC</p> <p><i>Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily <p>[Symfi] Efavirenz (EFV) 600 mg/3TC/TDF</p> <p><i>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily on an empty stomach <p>[Symfi Lo] EFV 400 mg/3TC/TDF</p> <p><i>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily on an empty stomach • Symfi Lo has not been studied in children (sexual maturity ratings [SMRs] 1–3), and major interindividual variability in EFV plasma concentrations has been found in pediatric patients in a multiethnic setting. The 400-mg dose of EFV may be too low in children or adolescents with SMRs 1 to 3 who weigh ≥ 40 kg. The use of therapeutic drug monitoring is suggested by some Panel members when Symfi Lo is used in pediatric patients who weigh ≥ 40 kg (see the Efavirenz section for more information). <p>[Temixys] 3TC/TDF</p> <p><i>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet once daily <p>[Triumeq PD] ABC/DTG/3TC</p> <p><i>Child Weighing ≥ 10 kg to < 25 kg</i></p> <ul style="list-style-type: none"> • Dispersible Triumeq PD tablets are FDA approved for children weighing ≥ 10 to < 25 kg. Triumeq PD is not recommended for children weighing ≥ 25 kg who are eligible for adult Triumeq dosing. • Administer the appropriate number of tablets for a child's weight once daily, dispersed in 20 mL of water. See Special Instructions. Triumeq PD tablets should not be swallowed whole, chewed, cut, or crushed. | |
|--|--|

Weight-Band Dosing of Triumeq PD Tablets for Children Weighing ≥ 6 kg

| Weight | Recommended Daily Dose | Number of Triumeq PD Tablets |
|--------------------------------|---------------------------------------|------------------------------|
| 6 kg to <10 kg* | ABC 180 mg DTG 15 mg 3TC 90 mg | 3 |
| 10 kg to <14 kg | ABC 240 mg DTG 20 mg 3TC 120 mg | 4 |
| 14 kg to <20 kg | ABC 300 mg DTG 25 mg 3TC 150 mg | 5 |
| 20 kg to <25 kg | ABC 360 mg DTG 30 mg 3TC 180 mg | 6 |
| ≥ 25 kg | Use Triumeq (see below) | |

* Investigational dose (see above).

- For use in children who are ARV-naive or ARV-experienced (but integrase strand transfer inhibitor [INSTI]-naive) and who are not being treated with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) or cytochrome P450 (CYP) 3A inducers

[Triumeq] ABC/DTG/3TC

Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose

- One tablet once daily
- This FDC tablet can be used in patients who are ART-naive or ART-experienced (but INSTI-naive) and who are not being treated with UGT1A1 or CYP3A inducers.

[Trizivir and Generic] ABC/3TC/ZDV

Child and Adolescent (Weighing ≥ 30 kg) and Adult Dose

- One tablet twice daily

^a Epivir HBV oral solution and tablets contain a lower amount of 3TC than Epivir oral solution and tablets. The amount of 3TC in the Epivir HBV solution and tablet was based on dosing for treatment of HBV infection in people without HIV coinfection.

Patients with HIV who are taking Epivir HBV as part of their ARV regimen should receive the appropriate amount of oral solution or the appropriate number of tablets to achieve the higher doses of 3TC that are used to treat HIV.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Drugs that decrease renal function could decrease clearance of lamivudine (3TC).

- **Do not use** 3TC in combination with emtricitabine (FTC), because these drugs have similar resistance profiles and using them together offers no additional benefit.¹ **Do not use** 3TC with fixed-dose combination (FDC) medications that contain 3TC or FTC. Please see [Appendix A](#), [Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#) and refer to other sections of the [Drug Appendix](#) for drug interaction information about each individual component of FDC tablets.

Major Toxicities

- *More common:* Headache, nausea
- *Less common (more severe):* Peripheral neuropathy, lipodystrophy/lipoatrophy
- *Rare:* Increased levels of liver enzymes. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported.

Resistance

The International Antiviral Society—USA maintains a list of [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Although 3TC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of children aged ≥ 3 months, both the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) and the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recommend the use of 3TC from birth.

Considerations for Use

The efficacy and toxicity of 3TC are equivalent to the efficacy and toxicity of FTC. The oral formulation of FTC has an advantage over the liquid formulation of 3TC because it can be given once daily at antiretroviral (ARV) initiation, whereas the liquid formulation of 3TC needs to be given twice daily at ARV initiation. When pill formulations of 3TC or FTC are used, they can be administered once daily.

Comparative Clinical Trials

Investigators studying the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort compared the efficacy of tenofovir disoproxil fumarate (TDF) plus FTC to TDF plus 3TC when these drugs were administered with a ritonavir-boosted protease inhibitor (darunavir, atazanavir, or lopinavir) in ART-naïve patients.² The adjusted hazard ratio for the virologic failure of 3TC-containing regimens compared to FTC-containing regimens within 240 weeks of starting therapy was 1.15 (95% confidence interval, 0.58–2.27). These regimens had no difference in time to virologic suppression during the first 48 weeks of therapy or time to virologic failure after attaining suppression. In a Swiss cohort, Yang et al. found a potential difference in efficacy between FTC and

3TC; however, the difference disappeared after adjusting for pill burden. Current evidence suggests that FTC and 3TC have equivalent efficacy and toxicity in ARV-naive patients.³

Efficacy

3TC has been studied in children with HIV both alone and in combination with other ARV drugs. Extensive data have demonstrated the safety of 3TC and have shown that this drug is associated with clinical improvement and virologic response. It is commonly used in children with HIV as a component of a dual nucleoside reverse transcriptase inhibitor (NRTI) backbone.⁴⁻¹² In one study that evaluated the efficacy of NRTI background components, the combination of 3TC plus abacavir (ABC) was superior to zidovudine (ZDV) plus 3TC or ZDV plus ABC in achieving long-term virologic efficacy.¹³

Pharmacokinetics in Infants

Because of its safety profile and availability in a liquid formulation, 3TC has been given to infants during the first 6 weeks of life starting at a dose of 2 mg/kg every 12 hours before age 4 weeks.⁹ A population pharmacokinetic (PK) analysis of infants who received 3TC affirms that adjusting the dose from 3TC 2 mg/kg to 3TC 4 mg/kg every 12 hours at age 4 weeks provides optimal 3TC exposure for infants with normal maturation of renal function.¹⁴ For infants, the World Health Organization weight-band dosing (which is up to five times higher than the FDA-approved dose) results in greater plasma concentrations than the 3TC 2 mg/kg dose.¹⁵ In HIV Prevention Trials Network (HPTN) 040, 3TC was administered as a component of a three-drug regimen to prevent perinatal transmission during the first 2 weeks of life. For 2 weeks, all infants weighing >2,000 g received 3TC 6 mg twice daily, and infants weighing ≤2,000 g received 3TC 4 mg twice daily. These doses resulted in 3TC exposure that was similar to the exposure seen in infants who received the standard twice-daily dosing schedule of 3TC 2 mg/kg per dose for neonates.¹⁶

Pharmacokinetics of Liquid Versus Tablet Preparations

The PK of 3TC have been studied after either single or repeat doses in 210 pediatric subjects. Pediatric subjects who received 3TC oral solution according to the recommended dose regimen achieved plasma concentrations of 3TC that were approximately 25% lower compared with those of adults with HIV who received the oral solution. Pediatric subjects who received 3TC tablets achieved plasma concentrations that were comparable to or slightly higher than those observed in adults who received tablets. In pediatric subjects, the relative bioavailability of 3TC oral solution is approximately 40% lower than the relative bioavailability of tablets that contain 3TC, despite no difference in the bioavailability of these two formulations among adults. The mechanisms for the diminished relative bioavailability of 3TC oral solution are unknown,¹⁷ but results from a study in adults that compared the PK of 3TC oral solution administered either alone or with increasing concentrations of sorbitol indicate that sorbitol decreases the total exposure of 3TC oral solution.¹⁸ Sorbitol is a component of several ARV solutions, including ABC, as well as common over-the-counter medications that may be used in infants and young children; this may explain the PK discrepancy between the oral solution and tablet formulations. Modeling of PK data in pediatric patients suggests that increasing the oral solution dose to 3TC 5 mg/kg per dose twice daily or 3TC 10 mg/kg per dose once daily (with a maximum of 3TC 300 mg administered daily) in children aged ≥3 months would provide exposures similar to those seen in adult patients who received tablet formulations. However, modeling was done with PK data derived from studies that did not use 3TC liquid formulation, and so modeling may not predict exposures for 3TC oral solution, especially

when used with liquid ABC. The Panel **does not recommend** using a once-daily dose of 3TC until a child is aged ≥ 3 years. After 3 years of age, switching to once-daily dosing with the liquid formulation could be considered when harmonizing with other ARV drugs administered once daily, such as ABC and dolutegravir (DTG).

Dosing Considerations—Once-Daily Versus Twice-Daily Administration

The standard adult dose for 3TC is 300 mg once daily, but data are lacking on once-daily administration of 3TC in children. Population PK data indicate that once-daily dosing of 3TC 8 mg/kg leads to area under the curve over 24 hours (AUC_{0-24h}) values that are similar to those seen in patients taking 3TC 4 mg/kg twice daily, but minimum blood plasma concentration (C_{min}) values are significantly lower and maximum blood plasma concentration (C_{max}) values are significantly higher in children aged 1 year to 18 years.¹⁹ Intensive PK of once-daily versus twice-daily dosing of 3TC were evaluated in children with HIV aged 2 to 13 years in the PENTA (Paediatric European Network for Treatment of AIDS) 13 trial⁴ and in children aged 3 months to 36 months in the PENTA 15 trial.²⁰ Both the PENTA 13 and PENTA 15 trials used a crossover design with doses of 3TC 8 mg/kg once daily or 3TC 4 mg/kg twice daily. AUC_{0-24h} and clearance values were similar between these two dosing schedules, and most children maintained an undetectable HIV RNA value after the switch. An ARROW (AntiRetroviral Research fOr Watoto) trial PK study of 41 children aged 3 to 12 years (median age 7.6 years) in Uganda who were stable on twice-daily 3TC also showed equivalent AUC_{0-24h} and good clinical outcomes (defined by a low disease stage and a high CD4 T lymphocyte [CD4] cell count) after switching to once-daily 3TC. Median follow-up time during this study was 1.15 years.²¹ The larger ARROW trial was a randomized, noninferiority trial that investigated once-daily versus twice-daily doses of 3TC in >600 pediatric patients who had initiated therapy with twice-daily 3TC and who had been receiving therapy for ≥ 36 weeks. Median follow-up time during the study was 114 weeks. Rates of plasma HIV RNA suppression and adverse event profiles for once-daily 3TC were similar to (and statistically non-inferior to) those of twice-daily 3TC.²²

All four of the studies discussed above enrolled patients who had low plasma HIV RNA or who were clinically stable on twice-daily 3TC before switching to once-daily dosing. Therefore, the Panel supports switching from twice-daily to once-daily dosing of 3TC in children aged ≥ 3 years who have been clinically stable for 36 weeks with an undetectable viral load and stable CD4 count. Clinicians should use a 10 mg/kg per dose of 3TC oral solution or a weight-based dose of 3TC tablets (neither exceeding 3TC 300 mg) as part of a once-daily regimen.²³ More long-term clinical trials with viral efficacy endpoints are needed to confirm that once-daily dosing of 3TC can be used effectively as part of an initial ARV regimen in children.

3TC undergoes intracellular metabolism to reach its active form, 3TC triphosphate. In adolescents, the mean half-life of intracellular 3TC triphosphate (17.7 hours) is considerably longer than that of unphosphorylated 3TC in plasma (1.5–2 hours). Intracellular concentrations of 3TC triphosphate are equivalent whether 3TC is given once daily or twice daily in adults and adolescents. This supports a recommendation for once-daily 3TC dosing based on FDA recommendations.^{24,25}

Considerations for Use

Weight-band dosing recommendations for 3TC have been developed for children weighing ≥ 3 kg and receiving either the 10-mg/mL oral solution or the 150-mg scored tablets.^{26–28}

Recent data from the IMPAACT 2019 clinical trial of dispersible and immediate-release ABC/DTG/3TC tablets in children with HIV has confirmed the FDA-approved dosing in infants and children weighing 10 to <25 kg and confirmed newly proposed dosing of this FDC (three tablets once daily of ABC 60 mg, DTG 5 mg, and 3TC 30 mg dispersed in 15–20 mL of water) in infants weighing 6 to <10 kg. ABC/DTG/3TC dispersible FDC dosing was confirmed based on PK and safety data in each weight band at the originally selected dosing, which aligned with WHO weight-band dosing for the individual ARV agents. Follow-up through 24 weeks confirmed the safety, tolerability, and virological efficacy of both formulations. The dosing guidance for infants weighing 6 to <10 kg is awaiting regulatory approval.²⁹

Both FTC and 3TC have antiviral activity and efficacy against hepatitis B virus. For a comprehensive review of this topic, see the [Hepatitis B Virus](#) section in the [Pediatric Opportunistic Infection Guidelines](#).

References

1. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. *J Acquir Immune Defic Syndr.* 2006;42(4):441-449. Available at: <https://pubmed.ncbi.nlm.nih.gov/16791115>.
2. Rokx C, Gras L, van de Vijver D, et al. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naive HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. *HIV Med.* 2016;17(8):571-580 Available at: <https://pubmed.ncbi.nlm.nih.gov/26842457>.
3. Yang WL, Kouyos RD, Scherrer AU, et al. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. *J Antimicrob Chemother.* 2015;70(12):3323-3331. Available at: <https://pubmed.ncbi.nlm.nih.gov/26362944>.
4. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). *Antivir Ther.* 2005;10(2):239-246. Available at: <https://pubmed.ncbi.nlm.nih.gov/15865218>.
5. Chadwick EG, Rodman JH, Britto P, et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. *Pediatr Infect Dis J.* 2005;24(9):793-800. Available at: <https://pubmed.ncbi.nlm.nih.gov/16148846>.
6. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. *Pediatr Infect Dis J.* 2005;24(12):1072-1076. Available at: <https://pubmed.ncbi.nlm.nih.gov/16371868>.
7. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. *Clin Infect Dis.* 2002;34(7):991-1001. Available at: <https://pubmed.ncbi.nlm.nih.gov/11880966>.
8. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. *Pediatr Infect Dis J.* 2006;25(6):533-537. Available at: <https://pubmed.ncbi.nlm.nih.gov/16732152>.
9. Mirochnick M, Stek A, Acevedo M, et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. *J Acquir Immune Defic Syndr.* 2005;39(2):189-194. Available at: <https://pubmed.ncbi.nlm.nih.gov/15905735>.
10. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother.* 1998;42(12):3187-3192. Available at: <https://pubmed.ncbi.nlm.nih.gov/9835513>.

11. Nachman SA, Stanley K, Yoge R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS clinical trials group 338 study team. *JAMA*. 2000;283(4):492-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/10659875>.
12. Scherpbier HJ, Bekker V, van Leth F, et al. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. *Pediatrics*. 2006;117(3):e528-536. Available at: <https://pubmed.ncbi.nlm.nih.gov/16481448>.
13. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS*. 2007;21(8):947-955. Available at: <https://pubmed.ncbi.nlm.nih.gov/17457088>.
14. Tremoulet AH, Capparelli EV, Patel P, et al. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. *Antimicrob Agents Chemother*. 2007;51(12):4297-4302. Available at: <https://pubmed.ncbi.nlm.nih.gov/17893155>.
15. Tremoulet AH, Nikanjam M, Cressey TR, et al. Developmental pharmacokinetic changes of lamivudine in infants and children. *J Clin Pharmacol*. 2012;52(12):1824-1832. Available at: <https://pubmed.ncbi.nlm.nih.gov/22180560>.
16. Mirochnick M, Nielsen-Saines K, Pilotto JH, et al. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. *Pediatr Infect Dis J*. 2011;30(9):769-772. Available at: <https://pubmed.ncbi.nlm.nih.gov/21666540>.
17. Choi SY, Li F, Florian J, Seo SK. Lamivudine and abacavir clinical summary review. 2014. Available at: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM446104.pdf>
18. Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. *Clin Pharmacol Ther*. 2018;103(3):402-408. Available at: <https://pubmed.ncbi.nlm.nih.gov/29150845>.
19. Bouazza N, Hirt D, Blanche S, et al. Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. *Antimicrob Agents Chemother*. 2011;55(7):3498-3504. Available at: <https://pubmed.ncbi.nlm.nih.gov/21576443>.
20. Paediatric European Network for Treatment of AIDS. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. *Antivir Ther*. 2010;15(3):297-305. Available at: <https://pubmed.ncbi.nlm.nih.gov/20516550>.
21. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once-versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. *Antivir Ther*. 2010;15(8):1115-1124. Available at: <https://pubmed.ncbi.nlm.nih.gov/21149918>.

22. Musiime V, Kasirye P, Naidoo-James B, et al. Once vs. twice-daily abacavir and lamivudine in African children. *AIDS*. 2016;30(11):1761-1770. Available at: <https://pubmed.ncbi.nlm.nih.gov/27064996>.
23. Janssen EJH, Bastiaans DET, Valitalo PAJ, et al. Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. *Br J Clin Pharmacol*. 2017;83(6):1287-1297. Available at: <https://pubmed.ncbi.nlm.nih.gov/28079918>.
24. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. *Antimicrob Agents Chemother*. 2004;48(1):176-182. Available at: <https://pubmed.ncbi.nlm.nih.gov/14693537>.
25. Flynn PM, Rodman J, Lindsey JC, et al. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. *Antimicrob Agents Chemother*. 2007;51(10):3516-3522. Available at: <https://pubmed.ncbi.nlm.nih.gov/17664328>.
26. World Health Organization. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: Report of the WHO paediatric antiretroviral working group. 2008. Available at: http://apps.who.int/iris/bitstream/handle/10665/43882/9789241596619_eng.pdf;jsessionid=31285037F69DEBBDEE7C08D16ADD48F7?sequence=1
27. L'Homme R F, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. *AIDS*. 2008;22(5):557-565. Available at: <https://pubmed.ncbi.nlm.nih.gov/18316996>.
28. World Health Organization. Annex 3. Dosages of ARV drugs for adults and adolescents. 2018. Available at: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/arv_guidelines-2018-annex3a.pdf?sfvrsn=1318b82d_3
29. Brooks KM, Kiser JJ, Ziembka L, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. *Lancet HIV*. 2023;10(8):e506-e517. Available at: <https://pubmed.ncbi.nlm.nih.gov/37541705>.

Tenofovir Alafenamide (TAF, Vemlidy)

Updated: June 27, 2024

Reviewed: June 27, 2024

Formulations

Tablet: 25 mg^a

Fixed-Dose (FDC) Combination Tablets

- [Biktarvy]
 - Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg
 - Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg
- [Descovy]
 - Emtricitabine 200 mg/tenofovir alafenamide 25 mg
 - Emtricitabine 120 mg/tenofovir alafenamide 15 mg
- [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg
- [Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg
- [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg

When using FDC tablets, refer to other sections of [Appendix A. Pediatric Antiretroviral Drug Information](#) for information about the individual components of the FDC. See also [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#).

For additional information, see [Drugs@FDA](#) or [DailyMed](#).

| Dosing Recommendations | Selected Adverse Events | | | | | | |
|---|---|------|------------------|--------------------------------|--------|--------------------------------|--|
| <p>[Biktarvy] Bictegravir (BIC)/Emtricitabine (FTC)/Tenofovir Alafenamide (TAF)</p> <p><i>Neonate or Child (Aged <2 Years and Weighing <14 kg) Dose</i></p> <ul style="list-style-type: none">• No data are currently available on the appropriate dose of Biktarvy in children aged <2 years and weighing <14 kg. Studies are currently being conducted to identify the appropriate dose for this age and weight group. <p><i>Child (Aged ≥2 years), Adolescent, and Adult Dose</i></p> <ul style="list-style-type: none">• One tablet once daily, with or without food. | <ul style="list-style-type: none">• Asthenia, headache, diarrhea, nausea• Increased serum lipids | | | | | | |
| <table border="1"><thead><tr><th>Body Weight</th><th>Dose</th></tr></thead><tbody><tr><td>≥14 kg to <25 kg</td><td>BIC 30 mg/FTC 120 mg/TAF 15 mg</td></tr><tr><td>≥25 kg</td><td>BIC 50 mg/FTC 200 mg/TAF 25 mg</td></tr></tbody></table> | Body Weight | Dose | ≥14 kg to <25 kg | BIC 30 mg/FTC 120 mg/TAF 15 mg | ≥25 kg | BIC 50 mg/FTC 200 mg/TAF 25 mg | <p>Special Instructions</p> <ul style="list-style-type: none">• Measure serum creatinine before starting a TAF-containing regimen.• Screen patients for hepatitis B virus (HBV) infection before initiating TAF. Severe acute exacerbation of HBV infection can occur when TAF is discontinued; therefore, hepatic function should be monitored for several months after patients with HBV infection stop taking TAF.• The FDA does not recommend using Genvoya with other ARV drugs, but this FDC tablet has been safely used with DRV.¹ Descovy can be safely used² with DRV or atazanavir in patients weighing ≥35 kg. |
| Body Weight | Dose | | | | | | |
| ≥14 kg to <25 kg | BIC 30 mg/FTC 120 mg/TAF 15 mg | | | | | | |
| ≥25 kg | BIC 50 mg/FTC 200 mg/TAF 25 mg | | | | | | |

| <ul style="list-style-type: none"> The U.S. Food and Drug Administration (FDA) approved Biktarvy for use only in antiretroviral therapy (ART)-naïve patients or to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and no known mutations associated with resistance to the individual components of Biktarvy. Some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommend the use of Biktarvy in patients with prior treatment failure who have the virus with the M184V mutation. See the Bictegravir section for additional information. | <ul style="list-style-type: none"> Do not use Genvoya with EVG, COBI, tenofovir disoproxil fumarate, FTC, lamivudine, or PIs that are coformulated with COBI. When using Odefsey, patients must be able to take it with a meal of at least 500 calories on a regular schedule (a protein drink alone does not constitute a meal), because it contains RPV. | | | | | | | | |
|--|--|------|------------------------|--|------------------------|--|--------------|---|--|
| Metabolism/Elimination | | | | | | | | | |
| | TAF Dosing in Patients with Hepatic Impairment | | | | | | | | |
| | <ul style="list-style-type: none"> TAF-containing formulations do not require dose adjustment in patients with mild or moderate hepatic impairment, but they should not be used in patients with severe hepatic impairment because they have not been studied in that group. | | | | | | | | |
| | TAF Dosing in Patients with Renal Impairment | | | | | | | | |
| | <ul style="list-style-type: none"> The TAF metabolite tenofovir is renally excreted. No dose adjustment of the TAF 25-mg tablet (Vemlidy)^a is required in patients with estimated creatinine clearance (CrCl) ≥ 15 mL/min or in patients with estimated CrCl < 15 mL/min (i.e., end-stage renal disease) who are receiving chronic hemodialysis. See the Vemlidy product label^b for information on the use of the TAF 25-mg tablet in patients with estimated CrCl ≤ 15 mL/min. TAF-containing coformulations are not recommended for use in patients with estimated CrCl < 30 mL/min. | | | | | | | | |
| [Descovy] FTC/TAF <p><i>Child, Adolescent, and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily, with or without food. <table border="1" data-bbox="202 749 840 1467"> <thead> <tr> <th data-bbox="202 749 416 813">Body Weight</th> <th data-bbox="416 749 840 813">Dose</th> </tr> </thead> <tbody> <tr> <td data-bbox="202 813 416 1129">≥ 14 kg to <25 kg</td><td data-bbox="416 813 840 1129">FTC 120 mg/TAF 15 mg, in combination with an integrase strand transfer inhibitor (INSTI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). In this weight band, Descovy should not be used with protease inhibitors (PIs) that require a cytochrome P450 (CYP) 3A inhibitor (i.e., ritonavir [RTV] or cobicistat [COBI]).</td></tr> <tr> <td data-bbox="202 1129 416 1341">≥ 25 kg to <35 kg</td><td data-bbox="416 1129 840 1341">FTC 200 mg/TAF 25 mg, in combination with an INSTI or an NNRTI. In this weight band, Descovy should not be used with PIs that require a CYP3A inhibitor (i.e., RTV or COBI).</td></tr> <tr> <td data-bbox="202 1341 416 1467">≥ 35 kg</td><td data-bbox="416 1341 840 1467">FTC 200 mg/TAF 25 mg, in combination with an INSTI, NNRTI, or boosted PI.</td></tr> </tbody> </table> <p>[Genvoya] Elvitegravir (EVG)/COBI/FTC/TAF</p> <p><i>Child (Aged ≥ 2 Years and Weighing 14 kg to <25 kg) Dose</i></p> <ul style="list-style-type: none"> Data are currently limited on the appropriate dose of Genvoya in children aged ≥ 2 years to <6 years and weighing 14 kg to <25 kg. Studies are being conducted to identify the safety and efficacy of a low-dose Genvoya tablet. See the Elvitegravir section for details. | Body Weight | Dose | ≥ 14 kg to <25 kg | FTC 120 mg/TAF 15 mg, in combination with an integrase strand transfer inhibitor (INSTI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). In this weight band, Descovy should not be used with protease inhibitors (PIs) that require a cytochrome P450 (CYP) 3A inhibitor (i.e., ritonavir [RTV] or cobicistat [COBI]). | ≥ 25 kg to <35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI or an NNRTI. In this weight band, Descovy should not be used with PIs that require a CYP3A inhibitor (i.e., RTV or COBI). | ≥ 35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI, NNRTI, or boosted PI. | |
| Body Weight | Dose | | | | | | | | |
| ≥ 14 kg to <25 kg | FTC 120 mg/TAF 15 mg, in combination with an integrase strand transfer inhibitor (INSTI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). In this weight band, Descovy should not be used with protease inhibitors (PIs) that require a cytochrome P450 (CYP) 3A inhibitor (i.e., ritonavir [RTV] or cobicistat [COBI]). | | | | | | | | |
| ≥ 25 kg to <35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI or an NNRTI. In this weight band, Descovy should not be used with PIs that require a CYP3A inhibitor (i.e., RTV or COBI). | | | | | | | | |
| ≥ 35 kg | FTC 200 mg/TAF 25 mg, in combination with an INSTI, NNRTI, or boosted PI. | | | | | | | | |

| | |
|---|--|
| <p><i>Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food in ART-naive patients. This dose of Genvoya also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and no known mutations associated with resistance to the individual components of Genvoya. <p>[Odefsey] FTC/Rilpivirine (RPV)/TAF</p> <p><i>Child and Adolescent (Aged ≥ 12 Years and Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with a meal in ART-naive patients with HIV RNA $\leq 100,000$ copies/mL. This dose of Odefsey also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and no known mutations associated with resistance to the individual components of Odefsey. <p>[Symtuza] Darunavir (DRV)/COBI/FTC/TAF</p> <p><i>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food in ART-naive patients. This dose of Symtuza also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and no known mutations associated with resistance to the individual components of Symtuza. | |
|---|--|

^a TAF 25-mg tablets (Vemlidy) are approved by the FDA for treatment of HBV. In certain circumstances, TAF 25-mg tablets (Vemlidy) might be used as one component of a combination ARV regimen, with dosing recommendations similar to those for Descovy.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Metabolism:** Tenofovir alafenamide (TAF) is a substrate of the adenosine triphosphate-dependent transporters P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP). Drugs that strongly affect P-gp and BCRP activity may lead to changes in TAF absorption. P-gp inducers are expected to decrease TAF exposure, and P-gp inhibitors are expected to increase absorption and plasma concentrations of TAF.² A study of 98 healthy participants without HIV measured plasma TAF and tenofovir (TFV) exposures when TAF was administered with other antiretroviral (ARV) drugs. Coadministration of TAF with rilpivirine (RPV) and dolutegravir (DTG) did not change either TAF or TFV exposure. Coadministration of TAF with the P-gp and BCRP inhibitor cobicistat (COBI), or coadministration with atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir, increased both TAF and TFV exposures. Coadministration of TAF with darunavir/ritonavir (DRV/r) resulted in unchanged TAF area under the curve (AUC) and doubled

TFV AUC. Coadministration of TAF with the P-gp and BCRP inducer efavirenz decreased TAF and TFV exposures.⁴

- Coadministration of TAF with rifamycins (rifabutin, rifampin, or rifapentine) **is not recommended.**^{3,5}
- Genvoya contains elvitegravir (EVG) and COBI in addition to TAF (see the [Elvitegravir](#) and [Cobicistat](#) sections for details). EVG is metabolized predominantly by cytochrome P450 (CYP) 3A4, secondarily by uridine diphosphate glucuronosyltransferase 1A1/3, and by oxidative metabolism pathways. EVG is a modest inducer of CYP2C9. COBI is an inhibitor of CYP3A4 and a weak inhibitor of CYP2D6; in addition, COBI inhibits the adenosine triphosphate–dependent transporters BCRP and P-gp and the organic anion–transporting polypeptides OATP1B1 and OATP1B3. Potential exists for multiple drug interactions when using both EVG and COBI.
- *Absorption:* Administering EVG and bictegravir (BIC) concurrently with antacids or supplements that contain iron, calcium, aluminum and/or magnesium lowers plasma concentrations of these ARV drugs (see the [Elvitegravir](#) and [Bictegravir](#) sections for details).
- Odefsey contains RPV, which is a CYP3A substrate, and requires dose adjustments when administered with CYP3A-modulating medications.
- Before Genvoya, Odefsey, Descovy, Biktarvy, or Symtuza is administered, a patient’s medication profile should be carefully reviewed for potential drug interactions.
- *Renal elimination:* Drugs that decrease renal function or compete for active tubular secretion (e.g., acyclovir, ganciclovir, high-dose nonsteroidal anti-inflammatory drugs) could reduce clearance of the TAF metabolite TFV or emtricitabine (FTC). Concomitant use of nephrotoxic drugs should be avoided when using Genvoya.
- *Protease inhibitors:* Genvoya should not be administered concurrently with products or regimens that contain ritonavir (RTV) because COBI and RTV have similar effects on CYP3A metabolism.

Major Toxicities

- *More common:* Nausea, diarrhea, headache. Greater weight gain has been reported with the use of TAF than with tenofovir disoproxil fumarate (TDF) in adults and children⁶ (see [Table 17h. Lipodystrophies and Weight Gain](#) for details).
- *Less common (more severe):* Cases of lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside reverse transcriptase inhibitors (NRTIs).

Resistance

The International Antiviral Society–USA maintains a list of [updated HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

TAF is available as a component of several fixed-dose combination (FDC) tablets. These FDC tablets are listed in [Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class](#), and [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#).

Descovy, an FDC tablet that contains FTC and TAF (FTC/TAF), is approved by the U.S. Food and Drug Administration (FDA) for use in children who weigh ≥ 14 kg to < 25 kg at a dose of FTC 120 mg/TAF 15 mg and for children who weigh ≥ 25 kg to < 35 kg at a dose of FTC 200 mg/TAF 25 mg when used as part of an ARV regimen that does not include a boosted protease inhibitor (PI). Descovy is approved by the FDA for use in children who weigh ≥ 35 kg at a dose of FTC 200 mg/TAF 25 mg when used in combination with any ARV drugs, including RTV-boosted or COBI-boosted PIs. Odefsey, an FDC tablet that contains FTC 200 mg, RPV 25 mg, and TAF 25 mg (FTC/RPV/TAF), is approved by the FDA⁷ for use in children who weigh ≥ 35 kg. Genvoya, an FDC tablet that contains EVG 150 mg, COBI 150 mg, FTC 200 mg, and TAF 10 mg (EVG/c/FTC/TAF), is approved by the FDA for use in children who weigh ≥ 25 kg when used without other ARV drugs⁸ (see [Table A](#) below). BIC is available only as part of the FDC tablet Biktarvy, which contains BIC, FTC, and TAF (BIC/FTC/TAF). Biktarvy is approved by the FDA^{9,10} for use in children or adolescents with body weight ≥ 14 kg to < 25 kg at a dose of BIC 30 mg/FTC 120 mg/TAF 15 mg and for children, adolescents, and adults with body weight ≥ 25 kg at a dose of BIC 50 mg/FTC 200 mg/TAF 25 mg.^{10,11-13} Syntuzza, an FDC tablet that contains DRV 800 mg, COBI 150 mg, FTC 200 mg, and TAF 10 mg (DRV/c/FTC/TAF) is approved by the FDA¹⁰ for use in children and adolescents who weigh ≥ 40 kg.

TAF has antiviral activity and efficacy against hepatitis B virus (HBV). Testing for HBV should be performed prior to starting treatment with TAF. If HBV is found, rebound of clinical hepatitis could occur when TAF is stopped. For more information about hepatitis rebound in patients with HBV/HIV coinfection, see the [Hepatitis B Virus](#) section of the [Pediatric Opportunistic Infection Guidelines](#). TAF alone (as Vemlidy) is approved by the FDA for use in people aged ≥ 8 years, but it is approved only for treating HBV, not HIV.

Formulations

TAF-containing pills are smaller than their TDF-containing counterparts, a significant advantage for some pediatric patients who may have trouble swallowing larger pills (see [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)). FTC/TAF available formulations contain either TAF 15 mg (for children weighing 14 to < 25 kg) or TAF 25 mg (for weight ≥ 25 kg), but neither formulation should be used in children weighing < 35 kg in combination with PIs that require boosting with RTV or COBI. Both EVG/c/FTC/TAF and DRV/c/FTC/TAF contain TAF 10 mg, whereas FTC/RPV/TAF contains TAF 25 mg. BIC/FTC/TAF is available in two strengths: one containing TAF 15 mg for children aged ≥ 2 years and weighing < 25 kg and the other containing TAF 25 mg for people weighing ≥ 25 kg. COBI boosts TAF blood concentrations and tenofovir diphosphate (TFV-DP) intracellular exposure after TAF administration. Therefore, in people weighing ≥ 25 kg, administration of EVG/c/FTC/TAF, which contains TAF 10 mg and COBI,

achieves TFV-DP systemic exposure that is similar to the exposure achieved by FTC/RPV/TAF or BIC/FTC/TAF containing TAF 25 mg but no COBI.

Table A. U.S. Food and Drug Administration–Approved Tenofovir Alafenamide-Containing Formulations

| Drug | Contains | Dose of TAF | Minimum Age | Minimum Body Weight or Weight Range | Comment |
|----------|---------------|-------------|-------------|-------------------------------------|---|
| Vemlidy | TAF | 25 mg | 18 years | N/A | Approved for HBV treatment only. |
| Descovy | FTC/TAF | 15 mg | N/A | ≥14 kg to <25 kg | Use with an INSTI or NNRTI, but not with a boosted PI. |
| | FTC/TAF | 25 mg | N/A | ≥25 kg | |
| | FTC/TAF | 25 mg | N/A | 35 kg | Use with any ARV drugs, including a boosted PI. |
| Odefsey | FTC/RPV/TAF | 25 mg | 12 years | 35 kg | Generally not to be used with other ARV drugs. ^a |
| Genvoya | EVG/c/FTC/TAF | 10 mg | N/A | 25 kg | TAF dose is lower due to the COBI boosting. Generally not to be used with other ARV drugs. ^a |
| Syntuzza | DRV/c/FTC/TAF | 10 mg | N/A | 40 kg | TAF dose is lower due to the COBI boosting. Generally not to be used with other ARV drugs. ^a |
| Biktarvy | BIC/FTC/TAF | 15 mg | N/A | ≥14 kg to <25 kg | Generally not to be used with other ARV drugs. ^a |
| | BIC/FTC/TAF | 25 mg | N/A | ≥25 kg | |

^a Consult a specialist in HIV care before using these fixed-dose combination tablets with other ARV agents.

Key: ARV = antiretroviral; BIC = bictegravir; COBI = cobicistat; DRV/c = darunavir/cobicistat; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; HBV = hepatitis B virus; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RPV = rilpivirine; TAF = tenofovir alafenamide

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

Both TDF and TAF are prodrugs of the NRTI TFV. After oral administration, TDF is well absorbed^{12,13} and is so rapidly metabolized to TFV that TDF itself cannot be measured in blood (even when plasma is sampled within 5 minutes of administration).¹⁴ TFV is the main compound that is measurable in plasma after TDF administration. From the bloodstream, TFV enters cells and is phosphorylated to the active agent TFV-DP.

TAF also has good oral bioavailability.^{15,16} Within the enterocyte and liver, TAF is not metabolized to TFV as quickly as TDF, so the plasma TFV concentration is much lower with administration of TAF than with TDF, and the main component in plasma is the prodrug itself, TAF.¹⁷ Once inside the cell, TAF is hydrolyzed to TFV,^{18,19} and then TFV-DP is produced by the same mechanism as for TDF. Relative to TDF, TAF more effectively delivers TFV to cells throughout the body.¹⁵ Therefore, a much lower dose of TAF results in intracellular concentrations of TFV-DP that are higher than the concentrations seen after TDF administration (see [Table B](#) below). In a combined analysis of two randomized crossover directly observed therapy studies of FTC/TAF (200 mg/25 mg) versus FTC/TDF (200 mg/300 mg) in adults without HIV, FTC/TAF produced 6.7- to 7.3-fold higher

TFV-DP in peripheral blood mononuclear cells (PBMCs) compared to FTC/TDF across adherence levels (33%, 67%, or 100%). Additionally, the half-life of TFV-DP in PBMCs appeared numerically but not significantly longer for TAF (2.9 days; 95% confidence interval [CI], 1.5–5.5) than for TDF (2.1 days; 95% CI, 1.5–2.9). These data support a conclusion of increased potency and pharmacological forgiveness with FTC/TAF over FTC/TDF in the PBMC compartment.²⁰

The key pharmacokinetic (PK) difference between TDF and TAF is that TDF results in higher plasma TFV concentrations than TAF, but when administered at FDA-approved doses, both drugs produce high, therapeutically effective intracellular TFV-DP concentrations.^{17,21} Because it is intracellular TFV-DP that suppresses viral replication, TAF should have antiviral efficacy that is equivalent to the antiviral efficacy of TDF. However, the toxicities that are specifically related to high plasma TFV concentrations should not occur when using TAF. High plasma TFV concentration has been linked to TDF-related endocrine disruption that is associated with low bone mineral density (BMD).²² High plasma TFV concentration also has been closely associated with both glomerular^{22–24} and proximal tubular²⁵ renal toxicity.

Table B. Multiple-Dose Pharmacokinetics at Day 10 of Once-Daily Oral Administration in Adults with HIV: Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate

| Parameter | TAF 25 mg (n = 8) | TDF 300 mg (n = 6) |
|---|-------------------|--------------------|
| Plasma TFV AUC _{τau} (ng·h/mL) | 267.7 (26.7) | 1,918.0 (39.4) |
| Plasma TFV C _{max} (ng/mL) | 15.7 (22.1) | 252.1 (36.6) |
| Plasma TFV C _{τau} (ng/mL) | 9.2 (26.1) | 38.7 (44.7) |
| PBMC TFV-DP AUC _{τau} (μM·h) | 21.4 (76.9) | 3.0 (119.6) |

Note: The mean age of participants was 38 years, with a range of 20 to 57 years. Data presented are mean (% coefficient of variation).

Source: Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. *J Acquir Immune Defic Syndr*. 2013;63(4):449-455. Available at: <https://pubmed.ncbi.nlm.nih.gov/23807155>.

Key: AUC_{τau} = area under the curve for the dosing interval (i.e., 24 hours); C_{max} = peak concentration; C_{τau} = concentration at the end of a dosing interval (i.e., at 24 hours, the trough concentration); PBMC = peripheral blood mononuclear cell; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; TFV-DP = tenofovir diphosphate

Tenofovir Alafenamide Efficacy in Clinical Trials in Adults

In adults, TAF is non-inferior to TDF in its ability to control viral load over 48 to 96 weeks when used in combination with EVG, COBI, and FTC^{26–29}; with FTC and RPV³⁰; with DRV, COBI, and FTC^{31–33}; and when TAF and FTC are administered in combination with other ARV drugs.³⁴ In a switch study of adults who were virologically suppressed on a three-drug regimen that included abacavir (ABC), FTC/TAF was non-inferior to a regimen of lamivudine plus ABC plus a third ARV drug over 48 weeks. No differences occurred in BMD or the frequency of renal glomerular toxicities or renal tubular toxicities between these groups, but the TAF group showed a decline in high-density lipoprotein (HDL) cholesterol levels, whereas the ABC group had an increase in HDL cholesterol levels³⁵ (-2 mg/dL vs. +2 mg/dL, respectively; P = 0.0003). Viral load suppression was attained in about 90% of study participants when TAF was given as part of the coformulated BIC/FTC/TAF.^{36–38}

Tenofovir Alafenamide Efficacy in Clinical Trials in Adolescents and Children

The combination of EVG, COBI, FTC, and TAF has been shown to have similar efficacy when used in adults and two groups of children: those weighing ≥ 35 kg and aged ≥ 12 years³⁹ and those weighing ≥ 25 kg and aged ≥ 6 years⁴⁰ (see the [Elvitegravir](#) section for details). In a switch study, treatment with BIC/FTC/TAF resulted in viral load suppression at 48 weeks in 49 of 50 (98%) children aged 6 years to <12 years and in 50 of 50 (100%) children aged 12 years to <18 years⁹ (see the [Bictegravir](#) section for details). Initial evidence in a systematic review suggests good viral suppression and no obvious safety concerns in children and adolescents on TAF-containing regimens for more than 24 to 48 weeks.⁴¹

Pharmacokinetics

Drug Exposure and Virologic Response

Virologic suppression in people who are taking TAF or TDF is most closely related to intracellular TFV-DP concentrations. In adults, TAF generates peripheral blood mononuclear cell TFV-DP concentrations that are twofold²¹ to sevenfold higher than those generated with TDF at clinically meaningful doses.^{17,20,26} Higher TFV-DP concentrations result in a stronger antiviral potency¹⁷ and a higher barrier to resistance.^{42,43} Therefore, because TAF administration leads to higher intracellular TFV-DP concentrations than TDF, TAF may be more effective against NRTI-resistant virus than TDF. The mean TFV-DP concentration is higher in youth aged 12 to 18 years than in adults: 221.8 fmol/million cells (with a coefficient of variation [CV] of 94.4%) versus 120.8 fmol/million cells (CV 91.4%), respectively.³⁹

Drug Exposure and Safety: All Age Groups

FTC/TAF can be safely combined with DTG or raltegravir without concern for drug interactions (see [Table C](#) below). FTC and TAF also have been safely combined with BIC in the FDC tablet Biktarvy.

Table C. Changes in Tenofovir Alafenamide Pharmacokinetic Parameters in the Presence of Co-administered Antiretroviral Drugs in Adult Healthy Volunteers

| Co-administered ARV | Dosage (Once Daily) (mg) | TAF Dosage (Once Daily) (mg) | N | Mean Ratio of TAF C _{max} (90% CI) ^a | Mean Ratio of TAF AUC (90% CI) ^a |
|---------------------|--------------------------|------------------------------|----|--|---|
| Atazanavir | 300 (+100 ritonavir) | 10 | 10 | 1.77 (1.28, 2.44) | 1.91 (1.55, 2.35) |
| Cobicistat | 150 | 8 | 12 | 2.83 (2.20, 3.65) | 2.65 (2.29, 3.07) |
| Darunavir | 800 (+150 cobicistat) | 25 ^b | 11 | 0.93 (0.72, 1.21) | 0.98 (0.80, 1.19) |
| | 800 (+100 ritonavir) | 10 | 10 | 1.42 (0.96, 2.09) | 1.06 (0.84, 1.35) |
| Dolutegravir | 50 | 10 | 10 | 1.24 (0.88, 1.74) | 1.19 (0.96, 1.48) |

| Co-administered ARV | Dosage (Once Daily) (mg) | TAF Dosage (Once Daily) (mg) | N | Mean Ratio of TAF C _{max} (90% CI) ^a | Mean Ratio of TAF AUC (90% CI) ^a |
|---------------------|--------------------------------|------------------------------------|----|--|---|
| Efavirenz | 600 | 40 ^b | 11 | 0.78 (0.58, 1.05) | 0.86 (0.72, 1.02) |
| Lopinavir | 800 (+200 ritonavir) | 10 | 10 | 2.19 (1.72, 2.79) | 1.47 (1.17, 1.85) |
| Rilpivirine | 25 | 25 | 17 | 1.01 (0.84, 1.22) | 1.01 (0.94, 1.09) |

^aRatio represents concentrations of TAF plus the concomitant drug(s) divided by concentrations of TAF alone.

^b Study was conducted with Descovy (emtricitabine [FTC]/TAF).

Source: Table was modified from the U.S. Food and Drug Administration Descovy product label.

Key: ARV = antiretroviral drug; AUC = area under the curve; CI = confidence interval; C_{max} = maximum concentration; TAF = tenofovir alafenamide.

When FTC/TAF, which contains TAF 25 mg, is combined with boosted atazanavir (ATV), DRV, or lopinavir (LPV), the P-gp inhibitors COBI or RTV increase the TAF exposure to higher concentrations than those seen with the use of EVG/c/FTC/TAF, which contains TAF 10 mg. However, the plasma TFV concentrations seen with the use of EVG/c/FTC/TAF or TAF plus DRV or DRV/c are still much lower than those seen with the use of Stribild, an FDC tablet that contains EVG, COBI, FTC, and TDF (see [Table D](#) below).

Table D. Plasma Tenofovir Alafenamide and Plasma Tenofovir Exposures When Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate Are Used with Boosted Antiretroviral Drugs

| Regimen | TAF AUC ^a | TAF AUC Ratio TAF AUC of TAF-Containing Regimen/TAF AUC of Genvoya (Adult Exposure) | TFV AUC ^a | TFV AUC Ratio TFV AUC of TAF-Containing Regimen/TFV AUC of Stribild (Adult Exposure) |
|--|----------------------|--|----------------------|---|
| Adult | | | | |
| Stribild (EVG/c/FTC/TDF 300 mg) | N/A | N/A | 4,400 | 1.00 |
| Genvoya (EVG/c/FTC/TAF 10 mg) | 210 | 1.0 | 290 | 0.07 |
| DRV/r plus TAF 25 mg ^b | 196 | 0.93 | 259 | 0.06 |
| DRV/c plus TAF 25 mg | 239 | 1.1 | 935 | 0.21 |
| Pediatric | | | | |
| Stribild (EVG/c/FTC/TDF 300 mg) for Ages 12–18 years | N/A | N/A | 6,028 | 1.37 |
| Genvoya (EVG/c/FTC/TAF 10 mg) for Ages 12–18 years | 200 | 0.95 | 290 | 0.07 |
| Genvoya (EVG/c/FTC/TAF 10 mg) for Ages 6–12 years | 330 | 1.6 | 440 | 0.10 |

^aAUC: ng·h/mL

^b Values for this row do not come from observed data. These values were predicted based on data from studies that used TAF 10 mg. The AUC values predicted for TAF 25 mg were obtained by multiplying the TAF 10 mg AUC by 2.5 for both TAF and TFV AUC.

Source: Table modified from [U.S. Food and Drug Administration Summary Review of TAF](#) and from the [TAF clinical pharmacology review](#) using data from the [Stribild product label](#) and [Genvoya product label](#).

Key: AUC = area under the curve; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; EVG/c = elvitegravir/cobicistat; FTC = emtricitabine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir

TAF is available in FDA-approved adult FDC tablets at dosages of either 10 mg or 25 mg. The initial clinical trials in adults showing the safety of FTC/TAF with ATV/r or DRV/r used FTC 200 mg/TAF 10 mg.⁴⁴ However, in [Trial GS-US-299-0102](#) (NCT01565850), a Phase 2b trial in adults that compared a regimen of DRV/c plus FTC/TAF 10 mg to a regimen of DRV/c plus FTC/TDF, virologic outcomes at Week 48 were worse for participants in the TAF 10-mg arm than in the TDF arm.⁴⁵ Hence, FTC/TAF 25 mg was initially recommended for approval instead of FTC/TAF 10 mg.⁴⁵ The FDA label states that when FTC 200 mg/TAF 25 mg is combined with boosted ATV, DRV, or LPV in adults, “no clinically significant drug interactions have been either observed or are expected.”² The combination of FTC 200 mg/TAF 25 mg was approved by the FDA for use in adults, independent of the accompanying ARV drugs (which may include a boosted PI or an integrase strand transfer inhibitor [INSTI]),² but some FDC tablets for adults (i.e., EVG/c/FTC/TAF and DRV/c/FTC/TAF) have subsequently been FDA approved with a 10-mg TAF component.^{8,46}

Drug Exposure and Safety: Aged 12 to 18 Years and Weighing ≥ 35 kg

A study of FTC/TAF in 18 children and adolescents (aged 12–18 years and weighing ≥ 35 kg) was performed using FTC 200 mg/TAF 10 mg plus a boosted third ARV drug or FTC 200 mg/TAF 25 mg with an unboosted third ARV drug. The results of this study showed TAF exposures in children and adolescents that were like those seen in adults. TAF was well tolerated and efficacious during the 24 weeks of study. Asymptomatic Grade 3 or 4 elevations in amylase levels were noted in 5 of 28 participants (18%), and Grade 3 or 4 elevations in fasting low-density-lipoprotein (LDL) levels were noted in 2 of 28 participants (7%).⁴⁷

Studies of EVG/c/FTC/TAF in children aged 12 years to 18 years and weighing ≥ 35 kg showed that TAF and TFV exposures were like those found in adults (see [Table D](#) above), and that the drug combination was well tolerated and efficacious over 48 weeks of study.³⁹ Because these TAF and TFV exposures were similar to those seen in adults, FTC 200 mg/TAF 25 mg was also approved by the FDA for use in this age and weight group, independent of the accompanying ARV drugs in the regimen (which may include a boosted PI or an INSTI).²

The formulation of Biktarvy, which contains BIC 50 mg/FTC 200 mg/TAF 25 mg, was administered to 50 children aged 6 years to <12 years and weighing ≥ 25 kg and 50 children and adolescents aged 12 years to <18 years and weighing ≥ 35 kg who had had viral loads <50 copies/mL for at least 6 months. The drug was well tolerated. All 50 participants in the study⁹ had viral loads <50 copies/mL at Week 24, and 49 participants had viral loads <50 copies/mL at Week 48 (see the [Bictegravir](#) section for details).

Drug Exposure and Safety: Aged 6 Years to <12 Years and Weighing 25 kg to <35 kg

Studies of EVG/c/FTC/TAF in children aged 6 years to <12 years who weighed ≥ 25 kg showed that TAF and TFV exposures were somewhat higher than those found in adults (see [Table D](#) above), but the drug combination was well tolerated and efficacious over 24 weeks of study.^{40,48} This led to FDA approval of EVG/c/FTC/TAF for use in children aged ≥ 6 years and weighing ≥ 25 kg.⁸ Follow-up to 96 weeks in a small number of participants showed no change from baseline in the median spine BMD z-score, but there was a decline in the median total body BMD z-score and a possible decline in the median estimated glomerular filtration rate.⁴⁹

Because INSTIs do not increase TAF concentrations, regimens that include FTC/TAF 25 mg plus an INSTI are expected to result in safe drug exposures that are like those seen with coformulated EVG/c/FTC/TAF 10 mg. This led the FDA to approve FTC/TAF 25 mg for use in children aged ≥ 6 years and weighing ≥ 25 kg when used in combination with other ARV drugs that do not include a boosted PI.²

Because boosted ATV, DRV, or LPV increase TAF exposure to concentrations that are higher than those seen with use of EVG/c/FTC/TAF, and because safety and PK studies are ongoing on the use of these combinations in children weighing <35 kg, the safety of FTC/TAF combined with COBI-boosted or RTV-boosted PIs in children weighing between 25 kg and <35 kg cannot be assured.⁵⁰ Therefore, FDA approval for FTC/TAF used in combination with boosted PIs is limited to children weighing ≥ 35 kg (see [Table A](#) above).²

Drug Exposure and Safety: Aged ≥2 Years and Weighing ≥14 kg to <25 kg

Biktarvy tablets consisting of BIC 30 mg/FTC 120 mg/TAF 15 mg were administered to children aged ≥2 years weighing 14 kg to <25 kg and who had viral loads <50 copies/mL on stable ART. At 24 weeks, the median change in CD4 T lymphocyte (CD4) cell count was −100 cells/mm³, and the change in CD4 percentage was +0.5%. HIV RNA at <50 copies/mL was maintained in 20 of the 22 participants at 24 weeks⁵¹ (see the [Bictegravir](#) section for details). Safety and PK studies in children using TAF and FTC with atazanavir/cobicistat or DRV/c are ongoing.⁵⁰

Dosing: Crushing Emtricitabine/Tenofovir Alafenamide Tablets

Viral load suppression was reported in one adult patient with HIV who received crushed FTC/TAF tablets plus crushed DTG tablets. The crushed tablets were mixed with water and administered via a gastrostomy tube. Each dose was followed by a can of a nutritional supplement. No PK parameters were measured.⁵² In adults without HIV, the PKs of crushed DRV/c/FTC/TAF tablets showed decreased TAF bioavailability compared to whole tablets. The clinical implications of these findings are unclear.⁵³ Case reports in adults with HIV who are receiving crushed BIC/FTC/TAF, a film-coated FDC tablet, lacked PK measurements and described inconsistent virological outcomes.⁵⁴ Based on an adult bioequivalence study, crushed BIC/FTC/TAF may lead to suboptimal FTC and TAF exposures.⁵⁵ Thus, crushed BIC/FTC/TAF is not recommended (see the [Bictegravir](#) section for details).

Toxicity

Bone

TAF causes bone toxicity less frequently than TDF.^{26-28,31-34,56,57} For example, in one study of 1,733 randomized adult participants with HIV, those treated with EVG/c/FTC/TAF had a smaller decrease in BMD at the spine (mean change −1.30% vs. −2.86%; $P < 0.0001$) and hip (−0.66% vs. −2.95%; $P < 0.0001$) at 48 weeks than those given EVG/c/FTC/TDF.²⁶ These differences were maintained until 96 weeks.²⁹ The clinical importance of these changes in BMD is unclear.

Renal

Studies in adolescents aged 12 to 17 years³⁹ and adults^{26-28,31,32,34} show that TAF is less frequently associated with glomerular and renal tubular damage than TDF.⁵⁸ For example, in one study of 1,733 randomized adult participants with HIV, those treated with EVG/c/FTC/TAF had a smaller mean increase in serum creatinine (0.08 mg/dL vs. 0.12 mg/dL; $P < 0.0001$) than those given EVC/c/FTC/TDF, and a smaller percent change from baseline in urine protein to creatinine ratio (median % change −3% vs. +20%; $P < 0.0001$) at 48 weeks.²⁶ These differences persisted until 96 weeks of follow-up.²⁹ Safety of EVG/c/FTC/TAF has been demonstrated in adults with estimated creatinine clearances between 30 mL/min and 69 mL/min.⁵⁹ Postmarketing cases of renal impairment—including acute renal failure, proximal renal tubulopathy, and Fanconi syndrome—have been reported with TAF-containing products.^{2,3} TAF may require less intense renal safety monitoring than TDF, but more experience with the drug in broad clinical practice will be needed before a specific recommendation can be made.

Lipids

In treatment-naïve adults who were evaluated after 48 weeks of therapy, initiation of EVG/c/FTC/TAF was associated with increases in serum lipids that were greater than those observed with the initiation of EVG/c/FTC/TDF, with a mean increase in total cholesterol levels of 31 mg/dL versus 23 mg/dL, and a mean increase in LDL cholesterol levels of 16 mg/dL versus 4 mg/dL, respectively. In 48 adolescents who were treated with EVG/c/FTC/TAF, the following median changes from baseline occurred at Weeks 24 and 36: Fasting total cholesterol levels increased 26 mg/dL and 36 mg/dL, respectively; fasting direct LDL levels increased 10 mg/dL and 17 mg/dL, respectively; and fasting triglycerides increased 14 mg/dL and 19 mg/dL, respectively.⁶⁰ Similar TAF-related increases in total cholesterol levels and LDL cholesterol levels have been found when TAF is administered with other combinations of ARV drugs.³² Monitoring serum lipids while the patient is taking TAF-containing FDC tablets is warranted, given these data (see [Table 17b. Dyslipidemia](#) for details).

Weight Gain

Observational data are limited, and no randomized controlled trials have examined TAF-associated weight gain in children. In adults, greater weight gain has been reported with the use of TAF than with the use of TDF⁶¹⁻⁶⁸ (see [Table 17h. Lipodystrophies and Weight Gain](#) for details). Although weight gain at ART initiation might represent a “return to health,”⁶³ patients initiating treatment with TAF had larger increases in weight than those initiating treatment with TDF^{62,63}; increases in weight and body mass index (BMI) have been observed in ARV switch studies, as well.^{64,67,69} In adults, the effect may be greatest in Black females,^{63,67} especially if administered in combination with INSTIs.^{63,65} A study in adult women showed increased BMI with the switch to either an INSTI or TAF, but these BMI increases were only seen in people with BMI <30 kg/m² at baseline.⁶¹

References

1. Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. *J Acquir Immune Defic Syndr.* 2017;74(2):193-200. Available at: <https://pubmed.ncbi.nlm.nih.gov/27753684>.
2. Descovy (emtricitabine and tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208215s020lbl.pdf.
3. Vemlidy (tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208464s014lbl.pdf
4. Begley R, Das M, Zhong L, et al. Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. *J Acquir Immune Defic Syndr.* 2018;78(4):465-472. Available at: <https://pubmed.ncbi.nlm.nih.gov/29649076>.
5. Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. *J Antimicrob Chemother.* 2019;74(6):1670-1678. Available at: <https://pubmed.ncbi.nlm.nih.gov/30815689>.
6. Yeoh DK, Campbell AJ, Bowen AC. Increase in body mass index in children with HIV, switched to tenofovir alafenamide fumarate or dolutegravir containing antiretroviral regimens. *Pediatr Infect Dis J.* 2021;40(5):e215-e216. Available at: <https://pubmed.ncbi.nlm.nih.gov/33847305>.
7. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208351s013lbl.pdf.
8. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207561s029lbl.pdf.
9. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760>.
10. Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide fumarate) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210251s010lbl.pdf.

11. Gaur A, Rodriguez C, McGrath, E.J., Hellstrom, E., Liberty A, Natukunda, E., Kosalaraksa, E., Chokephaibulkit, K., Coluci, A., , et al. Bictegravir/FTC/TAF single-tablet-regimen in adolescents: week 24 results. Presented at: Conference on Retroviruses and Opportunistic Infections. March 4-7; 2018. Boston, Massachusetts. Available at: <https://www.croiconference.org/abstract/bictegravirftctaf-single-tablet-regimen-adolescents-week-24-results>.
12. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. *Antimicrob Agents Chemother.* 2001;45(10):2733-2739. Available at: <https://pubmed.ncbi.nlm.nih.gov/11557462>.
13. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. *Antimicrob Agents Chemother.* 2007;51(10):3498-3504. Available at: <https://pubmed.ncbi.nlm.nih.gov/17664327>.
14. Lee WA, Martin JC. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. *Antiviral Res.* 2006;71(2-3):254-259. Available at: <https://pubmed.ncbi.nlm.nih.gov/16837073>.
15. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. *Antimicrob Agents Chemother.* 2005;49(5):1898-1906. Available at: <https://pubmed.ncbi.nlm.nih.gov/15855512>.
16. Babusis D, Phan TK, Lee WA, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. *Mol Pharm.* 2013;10(2):459-466. Available at: <https://pubmed.ncbi.nlm.nih.gov/22738467>.
17. Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. *J Acquir Immune Defic Syndr.* 2013;63(4):449-455. Available at: <https://pubmed.ncbi.nlm.nih.gov/23807155>.
18. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[[S]-[[[S]-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. *Mol Pharmacol.* 2008;74(1):92-100. Available at: <https://pubmed.ncbi.nlm.nih.gov/18430788>.
19. Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. *Antimicrob Agents Chemother.* 2007;51(2):543-550. Available at: <https://pubmed.ncbi.nlm.nih.gov/17145787>.

20. Yager JL, Brooks KM, Castillo-Mancilla JR, et al. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. *AIDS*. 2021;35(15):2481-2487. Available at: <https://pubmed.ncbi.nlm.nih.gov/34482350>.
21. Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. *AIDS*. 2018;32(6):761-765. Available at: <https://pubmed.ncbi.nlm.nih.gov/29334548>.
22. Havens PL, Kiser JJ, Stephensen CB, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? *Antimicrob Agents Chemother*. 2013;57(11):5619-5628. Available at: <https://pubmed.ncbi.nlm.nih.gov/24002093>.
23. Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. *J Acquir Immune Defic Syndr*. 2013;62(4):375-380. Available at: <https://pubmed.ncbi.nlm.nih.gov/23196828>.
24. Baxi SM, Scherzer R, Greenblatt RM, et al. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. *AIDS*. 2016;30(4):609-618. Available at: <https://pubmed.ncbi.nlm.nih.gov/26558723>.
25. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. *AIDS*. 2010;24(7):1064-1066. Available at: <https://pubmed.ncbi.nlm.nih.gov/20299966>.
26. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. *Lancet*. 2015;385(9987):2606-2615. Available at: <https://pubmed.ncbi.nlm.nih.gov/25890673>.
27. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. *J Acquir Immune Defic Syndr*. 2014;67(1):52-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/24872136>.
28. Mills A, Garner W, Pozniak A, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase IIIb non-inferiority trial of adults with HIV switching to co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir DF. *Patient*. 2015;8(4):359-371. Available at: <https://pubmed.ncbi.nlm.nih.gov/26045359>.

29. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. *J Acquir Immune Defic Syndr.* 2016;72(1):58-64. Available at: <https://pubmed.ncbi.nlm.nih.gov/26829661>.
30. Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. *Lancet HIV.* 2017;4(5):e195-e204. Available at: <https://pubmed.ncbi.nlm.nih.gov/28259777>.
31. Mills A, Crofoot G, Jr., McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. *J Acquir Immune Defic Syndr.* 2015;69(4):439-445. Available at: <https://pubmed.ncbi.nlm.nih.gov/25867913>.
32. Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. *AIDS.* 2018;32(11):1431-1442. Available at: <https://pubmed.ncbi.nlm.nih.gov/29683855>.
33. Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. *Lancet HIV.* 2018;5(1):e23-e34. Available at: <https://pubmed.ncbi.nlm.nih.gov/28993180>.
34. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. *Lancet HIV.* 2016;3(4):e158-165. Available at: <https://pubmed.ncbi.nlm.nih.gov/27036991>.
35. Winston A, Post FA, DeJesus E, et al. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. *Lancet HIV.* 2018;5(4):e162-e171. Available at: <https://pubmed.ncbi.nlm.nih.gov/29475804>.
36. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet.* 2017;390(10107):2073-2082. Available at: <https://pubmed.ncbi.nlm.nih.gov/28867499>.

37. Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. *Lancet HIV*. 2017;4(4):e154-e160. Available at: <https://pubmed.ncbi.nlm.nih.gov/28219610>.
38. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial. *Lancet*. 2017;390(10107):2063-2072. Available at: <https://pubmed.ncbi.nlm.nih.gov/28867497>.
39. Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. *Lancet HIV*. 2016;3(12):e561-e568. Available at: <https://pubmed.ncbi.nlm.nih.gov/27765666>.
40. Natukunda E, Gaur AH, Kosalaraksa P, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. *Lancet Child Adolesc Health*. 2017;1(1):27-34. Available at: <https://pubmed.ncbi.nlm.nih.gov/30169223>.
41. O'Rourke J, Townsend CL, Milanzi E, et al. Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. *J Int AIDS Soc*. 2023;26(2):e26037. Available at: <https://pubmed.ncbi.nlm.nih.gov/36823283>.
42. Margot NA, Liu Y, Miller MD, Callebaut C. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. *Antiviral Res*. 2016;132:50-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/27208653>.
43. Margot NA, Wong P, Kulkarni R, et al. Commonly transmitted HIV-1 drug resistance mutations in reverse-transcriptase and protease in antiretroviral treatment-naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide. *J Infect Dis*. 2017;215(6):920-927. Available at: <https://pubmed.ncbi.nlm.nih.gov/28453836>.
44. Post FA, Yazdanpanah Y, Schembri G, et al. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial. *HIV Clin Trials*. 2017;18(3):135-140. Available at: <https://pubmed.ncbi.nlm.nih.gov/28303753>.

45. Food and Drug Administration. Descovy medical review. 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208215Orig1s000MedR.pdf
46. Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210455s022lbl.pdf.
47. Chen J, Saez-Llorens X, Castano E, et al. Safety, pharmacokinetics, and efficacy of FTC/TAF in HIV-infected adolescents (12–18 years) abstract #843. . Presented at: Conference on Retroviruses and Opportunistic Infections 2018. Boston, MA. Available at: <http://www.croiconference.org/sessions/safety-pk-efficacy-ftctaf-hiv-infected-adolescents-12-18-yrs>.
48. Foca M. Fixed-dose combination therapy for paediatric HIV infection. *The Lancet*. 2017;1(1):3-4. Available at: [http://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(17\)30015-9/fulltext](http://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(17)30015-9/fulltext).
49. Rakhmanina N, Natukunda E, Kosalaraksa P, et al. Safety and efficacy of E/C/F/TAF in virologically suppressed, HIV-infected children through 96 weeks. Abstract 22. Presented at: 11th International Workshop on HIV Pediatrics; 2019. Mexico City, Mexico. Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2019/abstract/safety-and-efficacy-ecftaf>.
50. Mujuru A, Strehalu R, Rakhmanina N, et al. Six-month outcome of F/TAF Cobicistat-boosted Darunavir in children 14 to <25kg. Presented at: Conference on Retroviruses and Opportunistic Infections; 2023. Seattle, Washington. Available at: <https://www.croiconference.org/abstract/six-month-outcome-of-f-taf-cobicistat-boosted-darunavir-in-children-14-to-25kg>.
51. Natukunda E, Rodriguez C, McGrath E, et al. B/F/TAF in virologically suppressed adolescents and children: two-year Outcomes in 6 to <18 year olds and six-month outcomes in toddlers. Presented at: 13th International Workshop on HIV Pediatrics 2021. virtual. Available at: https://www.natap.org/2021/IAS/IAS_80.htm.
52. Fulco PP, Higginson RT. Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine. *Am J Health Syst Pharm*. 2018;75(10):594-595. Available at: <https://pubmed.ncbi.nlm.nih.gov/29748295>.
53. Brown K, Thomas D, McKenney K, et al. Impact of splitting or crushing on the relative bioavailability of the darunavir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. *Clin Pharmacol Drug Dev*. 2019;8(4):541-548. Available at: <https://pubmed.ncbi.nlm.nih.gov/30508308>.
54. Rowe SM, Clary JC, Drummond M, et al. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: a case report and

review of the literature. *Am J Health Syst Pharm.* 2022;79(16):1330-1336. Available at: <https://pubmed.ncbi.nlm.nih.gov/35511892>.

55. Hocqueloux L, Lefevre S, Bois J, et al. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. *J Antimicrob Chemother.* 2022;78(1):161-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/36322475>.
56. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis.* 2016;16(1):43-52. Available at: <https://pubmed.ncbi.nlm.nih.gov/26538525>.
57. DeJesus E, Haas B, Segal-Maurer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. *AIDS Res Hum Retroviruses.* 2018;34(4):337-342. Available at: <https://pubmed.ncbi.nlm.nih.gov/29368537>.
58. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials. *AIDS.* 2019;33(9):1455-1465. Available at: <https://pubmed.ncbi.nlm.nih.gov/30932951>.
59. Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. *J Acquir Immune Defic Syndr.* 2016;71(5):530-537. Available at: <https://pubmed.ncbi.nlm.nih.gov/26627107>.
60. Tauber WB, Lewis LL. Clinical review of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (genvoya). 2015. Available at: <http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm478088.pdf>
61. Lahiri CD, Xu Y, Wang K, et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. *AIDS Res Hum Retroviruses.* 2021;37(6):461-467. Available at: <https://pubmed.ncbi.nlm.nih.gov/33231474>.
62. Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. *Infection.* 2019;47(1):95-102. Available at: <https://pubmed.ncbi.nlm.nih.gov/30269210>.

63. Venter WDF, Moorhouse M, Sakhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med.* 2019;381(9):803-815. Available at: <https://pubmed.ncbi.nlm.nih.gov/31339677>.
64. Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. *AIDS.* 2020;34(6):877-881. Available at: <https://pubmed.ncbi.nlm.nih.gov/32271252>.
65. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? *J Virus Erad.* 2019;5(1):41-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/30800425>.
66. Bares SH. Is modern antiretroviral therapy causing weight gain? *Clin Infect Dis.* 2019;71(6):1390-1392. Available at: <https://pubmed.ncbi.nlm.nih.gov/31608360>.
67. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis.* 2019. Available at: <https://pubmed.ncbi.nlm.nih.gov/31606734>.
68. Kanters S, Renaud F, Rangaraj A, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. *EClinicalMedicine.* 2022;48:101412. Available at: <https://pubmed.ncbi.nlm.nih.gov/35706487>.
69. Surial B, Mugglin C, Calmy A, et al. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. *Ann Intern Med.* 2021;174(6):758-767. Available at: <https://pubmed.ncbi.nlm.nih.gov/33721521>.

Tenofovir Disoproxil Fumarate (TDF, Viread)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | | |
|---|--|--|
| Oral Powder: 40 mg per 1 g of oral powder (one level scoop, measured with supplied dosing scoop, equals 1 g oral powder) | | |
| Tablets: 150 mg, 200 mg, 250 mg, and 300 mg | | |
| Fixed-Dose Combination (FDC) Tablets | | |
| <ul style="list-style-type: none">• [Atripla and generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Cimduo] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg• [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Symfi] Efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Symfi Lo] Efavirenz 400 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Temixys] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Truvada tablet]<ul style="list-style-type: none">◦ Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg◦ Emtricitabine 167 mg/tenofovir disoproxil fumarate 250 mg◦ Emtricitabine 133 mg/tenofovir disoproxil fumarate 200 mg◦ Emtricitabine 100 mg/tenofovir disoproxil fumarate 150 mg | | |
| | | |
| When using FDC tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | | |
| For additional information, see Drugs@FDA or DailyMed . | | |
| Dosing Recommendations | Selected Adverse Events | |
| Neonate and Infant Dose <ul style="list-style-type: none">• Tenofovir disoproxil fumarate (TDF) has not been approved by the U.S. Food and Drug Administration or recommended for use in neonates or infants aged <2 years. | <ul style="list-style-type: none">• Asthenia, headache, diarrhea, nausea, vomiting, flatulence• Glomerular and proximal renal tubular dysfunction• Decreased bone mineral density^a | |
| Child (Aged ≥2 Years to <12 Years) and Weighing ≥10 kg Dose ^a | | |
| <ul style="list-style-type: none">• TDF 8 mg/kg per dose once daily | Special Instructions <ul style="list-style-type: none">• TDF oral powder formulation is available for patients who are unable to swallow tablets.• TDF oral powder should be measured only with the supplied dosing scoop: one level scoop = 1 g powder = TDF 40 mg. | |

TDF Oral Powder Dosing Table

| Body Weight | TDF Oral Powder Once-Daily Scoops of Powder |
|-----------------|--|
| 10 kg to <12 kg | 2 scoops (80 mg) |
| 12 kg to <14 kg | 2.5 scoops (100 mg) |
| 14 kg to <17 kg | 3 scoops (120 mg) |
| 17 kg to <19 kg | 3.5 scoops (140 mg) |
| 19 kg to <22 kg | 4 scoops (160 mg) |
| 22 kg to <24 kg | 4.5 scoops (180 mg) |
| 24 kg to <27 kg | 5 scoops (200 mg) |
| 27 kg to <29 kg | 5.5 scoops (220 mg) |
| 29 kg to <32 kg | 6 scoops (240 mg) |
| 32 kg to <34 kg | 6.5 scoops (260 mg) |
| 34 kg to <35 kg | 7 scoops (280 mg) |
| ≥35 kg | 7.5 scoops (300 mg) |

TDF Tablet Dosing Table

| Body Weight | TDF Tablet Once Daily |
|-----------------|--------------------------|
| 17 kg to <22 kg | 150 mg |
| 22 kg to <28 kg | 200 mg |
| 28 kg to <35 kg | 250 mg |
| ≥35 kg | 300 mg |

Child and Adolescent (Weighing ≥35 kg)^a and Adult Dose

- TDF 300 mg once daily

[Atripla and Generic] Efavirenz/Emtricitabine/TDF

Child and Adolescent (Weighing ≥40 kg) and Adult Dose

- One tablet once daily
- Take on an empty stomach.

[Cimduo] Lamivudine/TDF

Child and Adolescent (Weighing ≥35 kg) and Adult Dose

- One tablet once daily

- Mix TDF oral powder with 2–4 oz of soft food that does not require chewing (e.g., applesauce, yogurt). Administer immediately after mixing to avoid the bitter taste.

- Do not try to mix the TDF oral powder with liquid. The powder may float on the top even after vigorous stirring.

- Although TDF can be administered without food, food requirements vary depending on the other ARV drugs contained in an FDC tablet. Food requirements are listed with dosing recommendations in [Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#).

- Measure serum creatinine and perform a urine dipstick test for protein and glucose before starting a TDF-containing regimen. Serum creatinine should be monitored, and urine should be tested for protein and glucose at intervals during continued therapy (see [Table 17i. Nephrotoxic Effects](#)). Measure serum phosphate if there is clinical suspicion of hypophosphatemia.

- Screen patients for hepatitis B virus (HBV) infection before using TDF. Severe acute exacerbation of HBV infection can occur when TDF is discontinued; therefore, hepatic function should be monitored for several months after patients with HBV infection stop taking TDF.

- Tenovofir alafenamide (TAF) is associated with less bone and renal toxicity than TDF, but it has equal antiviral efficacy. **Do not use TAF and TDF together.** Consider switching from TDF to TAF in appropriate clinical settings.

Metabolism/Elimination

TDF Dosing in Patients with Hepatic Impairment

- No change in TDF dosing is required for patients with hepatic impairment.
- Stribild **should not be used** in patients with severe hepatic impairment.
- Atripla, Symfi, and Symfi Lo should be used with caution in patients with hepatic impairment; Symfi and Symfi Lo are **not recommended** for use in moderate or severe hepatic impairment.

TDF Dosing in Patients with Renal Insufficiency

- The tenovofir metabolite of TDF is renally excreted.
- The dose of TDF should be decreased in patients with impaired renal function (creatinine clearance [CrCl] <50 mL/min). Consult the manufacturer's prescribing information for directions on how to adjust the dose in accordance with CrCl.

| | |
|--|---|
| <p>[Complera] Emtricitabine/Rilpivirine/TDF</p> <p><i>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily in antiretroviral therapy (ART)-naive adults with baseline HIV RNA ≤100,000 copies/mL. This dose of Complera also can be used in virologically suppressed (HIV RNA <50 copies/mL) adults who are currently on their first or second regimen and have no history of virologic failure or resistance to rilpivirine and other antiretroviral (ARV) drugs. Administer with a meal of ≥500 calories. <p>[Delstrigo] Doravirine/Lamivudine/TDF</p> <p><i>Child and Adolescent (Weighing ≥35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily in ART-naive patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and with no known mutations associated with resistance to the individual components of Delstrigo <p>[Stribild] Elvitegravir/Cobicistat/Emtricitabine/TDF</p> <p><i>Adolescent (Weighing >35 kg with a Sexual Maturity Rating [SMR] of 4 or 5) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily in ART-naive adults. This dose of Stribild also can be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen, with no history of treatment failure, and with no known mutations associated with resistance to the individual components of Stribild. Administer with food. <p>[Symfi] Efavirenz 600 mg/Lamivudine/TDF</p> <p><i>Child and Adolescent (Weighing ≥40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily Take on an empty stomach. <p>[Symfi Lo] Efavirenz 400 mg/Lamivudine/TDF</p> <p><i>Child and Adolescent (Weighing ≥35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily Take on an empty stomach. | <ul style="list-style-type: none"> The FDCs Atripla, Cimduo, Complera, Delstrigo, Symfi, Symfi Lo, or Temixys should not be used in patients with CrCl <50 mL/min or in patients who require dialysis. The FDC Truvada should not be used in patients with CrCl <30 mL/min or in patients who require dialysis. The FDC Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min. FTC and TDF require dosage adjustments in patients with these levels of renal impairment, and such adjustments cannot be achieved with an FDC tablet. |
|--|---|

- Symfi Lo has not been studied in children (SMR 1–3), and major inter-individual variability in efavirenz (EFV) plasma concentrations has been found in pediatric patients in a multi-ethnic setting. The 400-mg dose of Efv may be too low in children or adolescents with SMRs of 1–3 who weigh \geq 40 kg. Some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV suggest therapeutic drug monitoring when Symfi Lo is used in pediatric patients weighing \geq 40 kg. See the [Efavirenz](#) section for more information.

[Temixys] Lamivudine/TDF

Child and Adolescent (Weighing \geq 35 kg) and Adult Dose

- One tablet once daily

[Truvada] Emtricitabine/TDF (FTC/TDF)

Child, Adolescent, and Adult Dose

Truvada Dosing Table

| Body Weight | FTC/TDF Tablet Once Daily |
|-------------------------|--------------------------------------|
| 17 kg to <22 kg | One FTC 100 mg/ TDF 150 mg tablet |
| 22 kg to <28 kg | One FTC 133 mg/ TDF 200 mg tablet |
| 28 kg to <35 kg | One FTC 167 mg/ TDF 250 mg tablet |
| \geq 35 kg and adults | One FTC 200 mg/ TDF 300 mg tablet |

^a See the text for a discussion of the concerns about decreased bone mineral density in patients who are receiving TDF, especially in prepubertal patients and those in early puberty (SMR 1 or 2).

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Tenofovir disoproxil fumarate (TDF) is a substrate of the adenosine triphosphate-dependent transporters P-glycoprotein and breast cancer resistance protein. When TDF is coadministered with inhibitors of these transporters, an increase in TDF absorption may be observed, with the potential for enhanced TDF toxicity.¹
- **Renal elimination:** Drugs that decrease renal function or compete for active tubular secretion could reduce clearance of plasma tenofovir (TFV). Avoid frequent or long-term use of nonsteroidal anti-inflammatory drugs in patients who are taking TDF.

- *Other nucleoside reverse transcriptase inhibitors (NRTIs)*: Didanosine (ddI) serum concentrations increase when this drug is coadministered with TDF, and this combination **should not be used** because of the increased risk of ddI toxicity.
- *Protease inhibitors (PIs)*: Atazanavir (ATV) without ritonavir **should not be coadministered** with TDF, because TDF decreases ATV plasma concentrations. The combination of atazanavir/ritonavir, darunavir/ritonavir (DRV/r), and lopinavir/ritonavir increases plasma TFV concentrations and increases the risk of TDF-associated toxicity.^{1,2}
- *Absorption*: Administering elvitegravir (EVG) concurrently with antacids and supplements that contain iron, calcium, aluminum, and/or magnesium lowers plasma concentrations of EVG. Similarly, dolutegravir (DTG) should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral iron supplements, oral calcium supplements, or buffered medications.³ If using Stribild, see the [Elvitegravir](#) section of [Appendix A. Pediatric Antiretroviral Drug Information](#) for additional information.

Major Toxicities

- *More common*: Nausea, diarrhea, vomiting, flatulence
- *Less common (more severe)*: TDF caused bone toxicity (osteomalacia and reduced bone mineral density [BMD]) in animals when given in high doses. Decreases in BMD have been reported in both adults and children taking TDF. Renal toxicity—including increased serum creatinine, glycosuria, proteinuria, phosphaturia, and/or calcinuria and decreased serum phosphate—has been observed. Patients at increased risk of renal glomerular or tubular dysfunction should be closely monitored. Cases of lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported.

Resistance

The International Antiviral Society–USA maintains a [list of updated HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

TDF has been approved by the U.S. Food and Drug Administration (FDA) for use in children aged ≥ 2 years and weighing ≥ 10 kg when used as a component of antiretroviral therapy (ART). TDF is available as a component of fixed-dose combination tablets (see [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)).

TDF has antiviral activity and efficacy against hepatitis B virus (HBV) and is approved by the FDA for HBV treatment in children aged ≥ 2 years and weighing ≥ 10 kg. For a comprehensive review of this topic, see the [Hepatitis B Virus](#) section in the [Pediatric Opportunistic Infection Guidelines](#).

Efficacy in Clinical Trials in Adults Compared with Children and Adolescents

The standard adult dose that was approved by the FDA for adults and children aged ≥ 12 years and weighing ≥ 35 kg is TDF 300 mg once daily. For children aged 2 to 12 years, the FDA-approved dose is TDF 8 mg/kg per dose administered once daily, which closely approximates the dose of TDF 208 mg/m² per dose used in early studies in children.⁴

In adults, the recommended once-daily dose of TDF 300 mg is highly effective when used in combination with other antiretroviral (ARV) drugs.⁵⁻¹² The FDA approved Cimduo and Temixys (both of which contain lamivudine [3TC] 300 mg/TDF 300 mg) and Symfi (efavirenz [EFV] 600 mg/3TC 300 mg/TDF 300 mg) based on results of prior clinical trials.^{6,13} FDA approval of Symfi Lo (EFV 400 mg/3TC 300 mg/TDF 300 mg) was based on a study that compared the use of Efv 400 mg with the use of Efv 600 mg, each administered with emtricitabine 200 mg and TDF 300 mg, in 630 ART-naive adults.¹⁴ See the [Efavirenz](#) section for a detailed discussion of this study. In a large randomized controlled trial comparing second-line ART regimens, continuing TDF was superior to switching to zidovudine, when given in combination with 3TC and either DTG or DRV/r.¹⁵⁻¹⁷

In children, the published efficacy data for TDF-containing ARV combinations are mixed, but potency equal to that in adults has been seen in pediatric patients aged 3 to 18 years with susceptible virus. In children aged 2 years to <12 years, TDF 8 mg/kg per dose once daily was non-inferior to twice-daily zidovudine-containing ART or stavudine-containing ART over 48 weeks of randomized treatment.^{18,19} Virologic success is lower in treatment-experienced patients with extensive multiclass drug resistance.²⁰⁻²² In an analysis of genotypic resistance testing performed on 650 unique patients at a single laboratory in the Republic of South Africa, predicted intermediate or high-level resistance to TDF was lower for children experiencing virologic failure while on abacavir (ABC)-containing (8.5%) and zidovudine-containing (9.4%) regimens than those experiencing virologic failure while on a TDF-containing regimen (24.6%). Clinical data are lacking in children on the efficacy of switching from a failing regimen containing these NRTIs to a regimen containing TDF.²³

Pharmacokinetics

Relationship of Drug Exposure to Virologic Response

Virologic suppression is most closely related to intracellular tenofovir diphosphate (TFV-DP) concentrations and, for TDF, intracellular TFV-DP is linked to plasma TFV concentration.²⁴ A modeling study suggests that children and adolescents who are treated with TDF may have higher intracellular TFV-DP concentrations than adults,²⁵ even though plasma TFV concentrations are lower in children and adolescents, because weight-adjusted renal clearance of TFV is higher in children than in adults.^{4,26,27}

Formulations

Special Considerations

The taste-masked granules that make up the TDF oral powder give the vehicle (e.g., applesauce, yogurt) a gritty consistency. Once mixed with a vehicle, TDF should be administered promptly because its taste becomes bitter when it is allowed to sit for too long.

Toxicity

Bone Toxicity

TDF administration is associated with decreased BMD in both adults^{28,29} and children.^{19,30-32} When treated with TDF, younger children with sexual maturity ratings (SMRs) of 1 and 2 may be at a higher risk of decreased BMD than children with more advanced pubertal development (i.e., SMRs ≥ 3).²⁶ Discontinuation of TDF results in partial or complete recovery of BMD.^{30,33}

In the study that led to FDA approval of TDF in adolescents aged ≥ 12 years and weighing ≥ 35 kg, 6 of 33 participants (18%) in the TDF arm experienced a $>4\%$ decline in absolute lumbar spine BMD in 48 weeks, whereas only 1 of 33 participants (3%) in the placebo arm experienced this decline.²⁰

TDF administration disrupts vitamin D metabolism,^{34,35} and the decrease in BMD associated with TDF initiation was attenuated in adults with coadministration of high doses of vitamin D3 (4,000 IU daily) and calcium carbonate (1,000 mg daily) for the first 48 weeks of TDF treatment.³⁶ During chronic TDF administration, youth with HIV who received vitamin D3 supplements (50,000 IU once monthly) had decreased serum parathyroid hormone levels and increased lumbar spine BMD compared with study participants who were not treated with high doses of vitamin D3.^{34,37} The serum 25-hydroxy vitamin D concentration was 37 ng/mL in the group with improved BMD. Similar improvements in BMD were seen in youth with HIV who were treated with an ARV regimen that included TDF and who received vitamin D3 2,000 IU or 4,000 IU daily.³⁸ Measurement of plasma vitamin D concentration is recommended for patients who are being treated with an ARV regimen that includes TDF, and vitamin D supplementation is recommended for those with vitamin D deficiency (see [Table 17j. Osteopenia and Osteoporosis](#)).

High concentrations of the TDF metabolite plasma TFV have been associated with TDF-related endocrine disruption and low BMD.³⁹ Plasma TFV concentrations are higher when TDF is coadministered with boosted PIs.¹ Tenofovir alafenamide (TAF), which is associated with lower plasma TFV concentrations than TDF, has less effect on parathyroid hormone levels⁴⁰ and causes less decline in BMD than TDF. See the [Tenofovir Alafenamide](#) section for more information. Consider switching from TDF to TAF or avoiding coadministration of TDF with boosted PIs in patients for whom loss of BMD is a concern.

Monitoring Potential Bone Toxicity

The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) does **not recommend** routine dual-energy X-ray absorptiometry monitoring for children or adolescents who are being treated with TDF (see [Table 17j. Osteopenia and Osteoporosis](#)).

TDF has been shown to be effective, and it can be administered once daily; however, the use of TDF has been associated with a risk of BMD loss. Because childhood and early adolescence are important periods of rapid bone accrual, and because children with perinatally acquired HIV are at risk for low peak bone mass,^{41,42} the Panel favors the use of ABC or TAF over TDF in children with SMRs 1 to 3.

Renal Toxicity

New-onset renal impairment and worsening renal impairment have been reported in adults⁴³ and children^{44,45} receiving TDF. In one study, renal toxicity led to the discontinuation of TDF in 6 of 159 (3.7%) children with HIV who were treated with TDF.²² Although TDF is clearly associated with a decline in glomerular filtration rate, the effect is generally small, and severe glomerular toxicity is rare.^{43,44} Irreversible renal failure is quite rare, but cases have been reported.⁴⁶

The main target of TDF nephrotoxicity is the renal proximal tubule.⁴⁴ Case reports highlight the infrequent but most severe manifestations of renal Fanconi syndrome, hypophosphatemia, hypocalcemia, diabetes insipidus, myalgias, bone pain, and fractures.^{47,48}

Subclinical renal tubular damage is more common than clinically apparent renal tubular injury. Increased urinary beta-2 microglobulin was identified in 12 of 44 children (27%) who were treated with TDF and in 2 of 48 children (4%) who were not treated with TDF.⁴⁹ The risks of TDF-associated proteinuria and chronic kidney disease increase with the duration of treatment.^{50,51} Of 89 participants aged 2 to 12 years who received TDF in Gilead Study 352 (where participants had a median drug exposure of 104 weeks), four participants were discontinued from the study for renal tubular dysfunction, with the discontinuations occurring between 84 and 156 weeks on TDF therapy.¹⁸ In adults, renal dysfunction is more common when TDF is used in patients with older age or a pre-existing renal disease⁵²; in children, renal dysfunction may be more common when TDF is used with boosted PIs than with non-nucleoside reverse transcriptase inhibitors.⁵³

Plasma TFV is the TDF metabolite most closely associated with both glomerular^{39,54} and proximal tubular⁵⁵ toxicity. As previously noted, plasma TFV concentrations are higher when TDF is coadministered with boosted PIs.¹ TAF, which generates lower plasma TFV concentrations than TDF, is associated with a lower risk of renal toxicity than TDF⁵⁶ (see [Tenofovir Alafenamide](#)).

Monitoring Potential Renal Toxicity

Because TDF has the potential to decrease creatinine clearance and cause renal tubular dysfunction, the Panel recommends measuring serum creatinine and using a urine dipstick to check protein and glucose concentration before initiating TDF. It is unclear how often creatinine and renal tubular function (urine protein and glucose) should be monitored in asymptomatic patients. Many Panel members monitor creatinine with other blood tests every 3 to 4 months and perform urinalysis every 6 to 12 months. Serum phosphate should be measured if clinically indicated; renal phosphate loss can occur in the presence of normal creatinine and in the absence of proteinuria. Because nephrotoxicity increases with the duration of TDF treatment, monitoring should be continued during long-term therapy with the drug.

Because renal glomerular damage primarily increases the concentration of albumin in urine, and proximal renal tubular damage increases the concentration of low-molecular-weight proteins like beta-2 microglobulin in urine, dipstick urinalysis (which primarily measures urine albumin) may be a relatively insensitive marker for TDF-associated tubular damage. Measuring urine albumin and urine protein and calculating the ratio of urine albumin to urine protein can be helpful in identifying the non-albumin proteinuria that is seen in TDF-associated nephrotoxicity.^{57,58} Although these more complex and expensive tests may be used in research settings, in clinical practice, using a renal dipstick to identify normoglycemic glycosuria and proteinuria is the easiest way to detect renal damage.

References

1. Viread (tenofovir disoproxil fumarate) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021356s058,022577s014lbl.pdf.
2. Bedimo R, Rosenblatt L, Myers J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. *HIV Clin Trials.* 2016;17(6):246-266. Available at: <https://pubmed.ncbi.nlm.nih.gov/27809711/>.
3. Dolutegravir/lamivudine/tenofovir disoproxil fumarate [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/210787PI.pdf.
4. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. *Antimicrob Agents Chemother.* 2004;48(1):124-129. Available at: <https://pubmed.ncbi.nlm.nih.gov/14693529/>.
5. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. *J Acquir Immune Defic Syndr.* 2008;47(1):74-78. Available at: <https://pubmed.ncbi.nlm.nih.gov/17971715/>.
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. *JAMA.* 2004;292(2):191-201. Available at: <https://pubmed.ncbi.nlm.nih.gov/15249568/>.
7. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *N Engl J Med.* 2006;354(3):251-260. Available at: <https://pubmed.ncbi.nlm.nih.gov/16421366/>.
8. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med.* 2009;361(23):2230-2240. Available at: <https://pubmed.ncbi.nlm.nih.gov/19952143/>.
9. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir TDF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis.* 2011;204(8):1191-1201. Available at: <https://pubmed.ncbi.nlm.nih.gov/21917892/>.
10. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. *AIDS.* 2009;23(12):1547-1556. Available at: <https://pubmed.ncbi.nlm.nih.gov/19542866/>.
11. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the

- ASSERT study. *J Acquir Immune Defic Syndr*. 2010;55(1):49-57. Available at: <https://pubmed.ncbi.nlm.nih.gov/20431394>.
12. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals. *Cochrane Database Syst Rev*. 2010(10):CD008740. Available at: <https://pubmed.ncbi.nlm.nih.gov/20927777>.
 13. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. *HIV Med*. 2006;7(7):442-450. Available at: <https://pubmed.ncbi.nlm.nih.gov/16925730>.
 14. ENCORE1 Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis*. 2015;15(7):793-802. Available at: <https://pubmed.ncbi.nlm.nih.gov/25877963>.
 15. Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. *Lancet HIV*. 2022;9(6):e381-e393. Available at: <https://pubmed.ncbi.nlm.nih.gov/35460601>.
 16. Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. *N Engl J Med*. 2021;385(4):330-341. Available at: <https://pubmed.ncbi.nlm.nih.gov/34289276>.
 17. Keene CM, Griesel R, Zhao Y, et al. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. *AIDS*. 2021;35(9):1423-1432. Available at: <https://pubmed.ncbi.nlm.nih.gov/33973876>.
 18. Saez-Llorens X, Castano E, Rathore M, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. *Pediatr Infect Dis J*. 2015;34(4):376-382. Available at: <https://pubmed.ncbi.nlm.nih.gov/25760565>.
 19. Aurpibul L, Cressey TR, Sricharoenchai S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. *Pediatr Infect Dis J*. 2015;34(4):392-397. Available at: <https://pubmed.ncbi.nlm.nih.gov/25760566>.
 20. Della Negra M, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. *Pediatr Infect Dis J*. 2012;31(5):469-473. Available at: <https://pubmed.ncbi.nlm.nih.gov/22301477>.
 21. Della Negra M, De Carvalho AP, De Aquino MZ, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the

- final results of study GS-US-104-0321. *Pediatr Infect Dis J.* 2015;34(4):398-405. Available at: <https://pubmed.ncbi.nlm.nih.gov/25599284>.
22. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J.* 2009;28(3):204-209. Available at: <https://pubmed.ncbi.nlm.nih.gov/19209091>.
 23. Steegen K, Levin L, Evans D, et al. Minimal cross-resistance to tenofovir in children and adolescents failing ART makes them eligible for tenofovir-lamivudine-dolutegravir treatment. *Pediatr Infect Dis J.* 2022;41(10):827-834. Available at: <https://pubmed.ncbi.nlm.nih.gov/35895893>.
 24. Baheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. *Antimicrob Agents Chemother.* 2011;55(11):5294-5299. Available at: <https://pubmed.ncbi.nlm.nih.gov/21896913>.
 25. Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. *AIDS.* 2013;27(2):221-225. Available at: <https://pubmed.ncbi.nlm.nih.gov/23032419>.
 26. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics.* 2005;116(6):e846-854. Available at: <https://pubmed.ncbi.nlm.nih.gov/16291735>.
 27. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother.* 2008;52(2):631-637. Available at: <https://pubmed.ncbi.nlm.nih.gov/18025112>.
 28. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. *Clin Infect Dis.* 2010;51(8):963-972. Available at: <https://pubmed.ncbi.nlm.nih.gov/20828304>.
 29. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. *J Infect Dis.* 2011;203(12):1791-1801. Available at: <https://pubmed.ncbi.nlm.nih.gov/21606537>.
 30. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics.* 2006;118(3):e711-718. Available at: <https://pubmed.ncbi.nlm.nih.gov/16923923>.
 31. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. *J Pediatr.* 2008;152(4):582-584. Available at: <https://pubmed.ncbi.nlm.nih.gov/18346519>.

32. Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-infected children. *Pediatr Infect Dis J.* 2015;34(4):383-391. Available at: <https://pubmed.ncbi.nlm.nih.gov/25247583>.
33. Havens PL, Perumean-Chaney SE, Patki A, et al. Changes in bone mass after discontinuation of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine in young men who have sex with men: extension phase results of Adolescent Trials Network protocols 110 and 113. *Clin Infect Dis.* 2019;70(4):687-691. Available at: <https://pubmed.ncbi.nlm.nih.gov/31179503>.
34. Havens PL, Stephensen CB, Van Loan MD, et al. Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: a randomized, placebo-controlled trial. *Clin Infect Dis.* 2018;66(2):220-228. Available at: <https://pubmed.ncbi.nlm.nih.gov/29020329>.
35. Havens PL, Long D, Schuster GU, et al. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone. *Antivir Ther.* 2018;23(7):623-628. Available at: <https://pubmed.ncbi.nlm.nih.gov/30260797>.
36. Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. *Ann Intern Med.* 2015;162(12):815-824. Available at: <https://pubmed.ncbi.nlm.nih.gov/26075752>.
37. Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. *Clin Infect Dis.* 2012;54(7):1013-1025. Available at: <https://pubmed.ncbi.nlm.nih.gov/22267714>.
38. Eckard AR, O'Riordan MA, Rosebush JC, et al. Effects of vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth. *J Acquir Immune Defic Syndr.* 2017;76(5):539-546. Available at: <https://pubmed.ncbi.nlm.nih.gov/28902705>.
39. Havens PL, Kiser JJ, Stephensen CB, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? *Antimicrob Agents Chemother.* 2013;57(11):5619-5628. Available at: <https://pubmed.ncbi.nlm.nih.gov/24002093>.
40. Van Welzen BJ, Thielen MAJ, Mudrikova T, et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? *AIDS.* 2019;33(9):1531-1534. Available at: <https://pubmed.ncbi.nlm.nih.gov/31021851>.
41. DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. *AIDS.* 2013;27(2):211-220. Available at: <https://pubmed.ncbi.nlm.nih.gov/23032412>.
42. Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. *AIDS.* 2014;28(3):345-353. Available at: <https://pubmed.ncbi.nlm.nih.gov/24072196>.

43. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis*. 2010;51(5):496-505. Available at: <https://pubmed.ncbi.nlm.nih.gov/20673002>.
44. Hall AM. Update on tenofovir toxicity in the kidney. *Pediatr Nephrol*. 2013;28(7):1011-1023. Available at: <https://pubmed.ncbi.nlm.nih.gov/22878694>.
45. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J*. 2009;28(7):619-625. Available at: <https://pubmed.ncbi.nlm.nih.gov/19561425>.
46. Wood SM, Shah SS, Steenhoff AP, et al. Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. *AIDS Patient Care STDS*. 2009;23(1):1-4. Available at: <https://pubmed.ncbi.nlm.nih.gov/19183077>.
47. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. *Pediatr Nephrol*. 2006;21(7):1034-1036. Available at: <https://pubmed.ncbi.nlm.nih.gov/16773419>.
48. Lucey JM, Hsu P, Ziegler JB. Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV. *BMJ Case Rep*. 2013;2013. Available at: <https://pubmed.ncbi.nlm.nih.gov/23843401>.
49. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. *Pediatr Infect Dis J*. 2007;26(10):949-951. Available at: <https://pubmed.ncbi.nlm.nih.gov/17901802>.
50. Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. *AIDS*. 2011;25(2):171-176. Available at: <https://pubmed.ncbi.nlm.nih.gov/21076275>.
51. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. *Pediatr Infect Dis J*. 2013;32(5):495-500. Available at: <https://pubmed.ncbi.nlm.nih.gov/23249917>.
52. Mocroft A, Lundgren JD, Ross M, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med*. 2015;12(3):e1001809. Available at: <https://pubmed.ncbi.nlm.nih.gov/25826420>.
53. Mashingaidze-Mano R, Bwakura-Dangarembizi MF, Maponga CC, et al. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe. *PLoS One*. 2020;15(7):e0235759. Available at: <https://pubmed.ncbi.nlm.nih.gov/32634168>.
54. Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. *J Acquir Immune Defic Syndr*. 2013;62(4):375-380. Available at: <https://pubmed.ncbi.nlm.nih.gov/23196828>.

55. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. *AIDS*. 2010;24(7):1064-1066. Available at: <https://pubmed.ncbi.nlm.nih.gov/20299966>.
56. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *AIDS*. 2019;33(9):1455-1465. Available at: <https://pubmed.ncbi.nlm.nih.gov/30932951>.
57. Sise ME, Hirsch JS, Canetta PA, et al. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. *AIDS*. 2015;29(8):941-946. Available at: <https://pubmed.ncbi.nlm.nih.gov/25784440>.
58. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. *HIV Med*. 2012;13(9):526-532. Available at: <https://pubmed.ncbi.nlm.nih.gov/22413854>.

Zidovudine (ZDV, Retrovir)

Updated: June 27, 2024
Reviewed: June 27, 2024

| Formulations | | | | | |
|---|---|---------------|-----------|---|---|
| Syrup: 10 mg/mL | | | | | |
| Capsule: 100 mg | | | | | |
| Concentrate for Injection or Intravenous Infusion: 10 mg/mL (Retrovir) | | | | | |
| Generic Formulations | | | | | |
| <ul style="list-style-type: none">• 100-mg capsule• 10-mg/mL syrup• 300-mg tablet | | | | | |
| Fixed-Dose Combination (FDC) Tablets | | | | | |
| <ul style="list-style-type: none">• [Generic] Lamivudine 150 mg/zidovudine 300 mg (scored)• [Generic] Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg | | | | | |
| When using FDC tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | | | | | |
| For additional information, see Drugs@FDA or DailyMed . | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | |
| <p>Note: Zidovudine (ZDV) is frequently used in neonates to prevent perinatal transmission of HIV. See Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV and Table 13 for information about using ZDV to prevent perinatal transmission.</p> <p>Recommended Neonatal Dose for Treatment of HIV by Gestational Age at Birth^a</p> <table border="1"><thead><tr><th>Gestational Age at Birth</th><th>Oral ZDV Dose</th></tr></thead><tbody><tr><td>≥35 Weeks</td><td><p>Birth to Age 4 Weeks</p><ul style="list-style-type: none">• ZDV 4 mg/kg twice daily; or• Alternative simplified weight-band dosing</td></tr></tbody></table> | Gestational Age at Birth | Oral ZDV Dose | ≥35 Weeks | <p>Birth to Age 4 Weeks</p> <ul style="list-style-type: none">• ZDV 4 mg/kg twice daily; or• Alternative simplified weight-band dosing | <ul style="list-style-type: none">• Bone marrow suppression leading to anemia and neutropenia, macrocytosis with or without anemia• Nausea, vomiting, headache, insomnia, asthenia• Lactic acidosis/severe hepatomegaly with hepatic steatosis• Lipodystrophy and lipoatrophy• Myopathy (associated with prolonged use of ZDV) and myositis |
| Gestational Age at Birth | Oral ZDV Dose | | | | |
| ≥35 Weeks | <p>Birth to Age 4 Weeks</p> <ul style="list-style-type: none">• ZDV 4 mg/kg twice daily; or• Alternative simplified weight-band dosing | | | | |
| Special Instructions | | | | | |
| <ul style="list-style-type: none">• Give ZDV without regard to food.• If substantial granulocytopenia or anemia develops in patients who are receiving ZDV, it may be necessary to discontinue therapy until bone marrow recovery is observed. In this setting, some patients may require erythropoietin or filgrastim injections or transfusions of red blood cells. | | | | | |

| | <p>Simplified Weight-Band Dosing for Infants with a Gestational Age ≥ 35 Weeks at Birth</p> <p>Note: The doses in this table provide approximately ZDV 4 mg/kg twice daily from birth to age 4 weeks.</p> <table border="1"> <thead> <tr> <th>Weight Band</th><th>Twice-Daily Volume of ZDV 10 mg/mL Syrup</th></tr> </thead> <tbody> <tr> <td>2 kg to <3 kg</td><td>1 mL</td></tr> <tr> <td>3 kg to <4 kg</td><td>1.5 mL</td></tr> <tr> <td>4 kg to <5 kg</td><td>2 mL</td></tr> </tbody> </table> <p>Aged >4 Weeks</p> <ul style="list-style-type: none"> • ZDV 12 mg/kg twice daily | Weight Band | Twice-Daily Volume of ZDV 10 mg/mL Syrup | 2 kg to <3 kg | 1 mL | 3 kg to <4 kg | 1.5 mL | 4 kg to <5 kg | 2 mL | <ul style="list-style-type: none"> • Screen patients for hepatitis B virus (HBV) infection before using FDC products that contain lamivudine (3TC). Severe acute exacerbation of HBV infection can occur when 3TC is discontinued; therefore, hepatic function should be monitored for several months after patients with HBV infection stop taking 3TC. <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> • ZDV is eliminated primarily by hepatic metabolism. The major metabolite is ZDV glucuronide, which is renally excreted. • ZDV is phosphorylated intracellularly to active ZDV triphosphate. <p>ZDV Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • The dose of ZDV may need to be reduced in patients with hepatic impairment. • Do not use FDC products in patients who have impaired hepatic function. <p>ZDV Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • A dose adjustment is required for ZDV in patients with renal insufficiency. • Do not use FDC products in patients with creatinine clearance <50 mL/min and patients who are on hemodialysis. |
|---|---|-------------|--|-------------------------|------|-------------------------|--------|-------------------------|------|--|
| Weight Band | Twice-Daily Volume of ZDV 10 mg/mL Syrup | | | | | | | | | |
| 2 kg to <3 kg | 1 mL | | | | | | | | | |
| 3 kg to <4 kg | 1.5 mL | | | | | | | | | |
| 4 kg to <5 kg | 2 mL | | | | | | | | | |
| ≥ 30 Weeks to <35 Weeks | <p>Birth to Age 2 Weeks</p> <ul style="list-style-type: none"> • ZDV 2 mg/kg twice daily <p>Aged 2 Weeks to 6 Weeks</p> <ul style="list-style-type: none"> • ZDV 3 mg/kg twice daily <p>Aged >6 Weeks</p> <ul style="list-style-type: none"> • ZDV 12 mg/kg twice daily | | | | | | | | | |
| <30 Weeks | <p>Birth to Age 4 Weeks</p> <ul style="list-style-type: none"> • ZDV 2 mg/kg twice daily <p>Aged 4 Weeks to 8 Weeks</p> <ul style="list-style-type: none"> • ZDV 3 mg/kg twice daily <p>Aged >8 Weeks</p> <ul style="list-style-type: none"> • ZDV 12 mg/kg twice daily | | | | | | | | | |

Note: For infants who are unable to tolerate oral agents, the intravenous dose should be 75% of the oral dose, but the dosing interval should remain the same.

Infant (Aged ≥ 35 Weeks Post-conception and ≥ 4 Weeks Post-delivery, Weighing ≥ 4 kg) and Child Dose Weight-Based Dosing for ZDV

| Weight | Twice-Daily Dosing |
|----------------|--------------------|
| 4 kg to <9 kg | 12 mg/kg |
| 9 kg to <30 kg | 9 mg/kg |
| ≥ 30 kg | 300 mg |

| | |
|---|--|
| <p>Alternative Body Surface Area Dosing</p> <p><i>Oral</i></p> <ul style="list-style-type: none"> • ZDV 180–240 mg per m² of body surface area every 12 hours <p>Child and Adolescent (Weighing ≥30 kg) and Adult Dose</p> <ul style="list-style-type: none"> • ZDV 300 mg twice daily <p>Lamivudine (3TC)/ZDV</p> <p><i>Child and Adolescent (Weighing ≥30 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet twice daily <p>Abacavir/3TC/ZDV</p> <p><i>Child and Adolescent (Weighing ≥30 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> • One tablet twice daily | |
|---|--|

^a For premature infants who receive an HIV diagnosis, the time to change to the continuation dose varies with postgestational age and clinical status of the infant.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Bone marrow suppressive/cytotoxic agents, including ganciclovir, valganciclovir, interferon alfa, and ribavirin:* These agents may increase the hematologic toxicity of zidovudine (ZDV).
- *Nucleoside analogues that affect DNA replication:* Nucleoside analogues—such as ribavirin—antagonize *in vitro* antiviral activity of ZDV.
- *Doxorubicin:* Simultaneous use of doxorubicin and ZDV **should be avoided**. Doxorubicin may inhibit the phosphorylation of ZDV to its active form.

Major Toxicities

- *More common:* Hematologic toxicity, including neutropenia and anemia, particularly in patients with advanced HIV disease. Headache, malaise, nausea, vomiting, and anorexia. Neutropenia may occur more frequently in infants who are receiving both lamivudine (3TC) and ZDV than in infants who are receiving only ZDV.¹
- *Less common (more severe):* Myopathy (associated with prolonged use), myositis, and liver toxicity. Cases of lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Fat maldistribution has been observed in patients receiving antiretroviral (ARV) medications.
- *Rare:* Possible increased risk of cardiomyopathy.²⁻⁴

Resistance

The International Antiviral Society–USA maintains a list of [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

ZDV is frequently included as a component of the nucleoside reverse transcriptase inhibitor (NRTI) backbone for antiretroviral therapy (ART), and it has been studied in children in combination with other NRTIs, including abacavir (ABC) and 3TC.⁵⁻⁸ Pediatric experience with ZDV both for treating HIV and for preventing perinatal transmission is extensive. However, the mitochondrial toxicity of ZDV leads many experts to favor the use of ABC or tenofovir alafenamide in cases where the patient's age and the results of viral resistance testing do not restrict the use of these drugs.

Efficacy in Clinical Trials

The combination of ZDV and 3TC has been extensively studied in children and has been a part of ARV regimens in many trials. The safety and efficacy of ZDV plus 3TC were compared to the safety and efficacy of ABC plus 3TC and stavudine (d4T) plus 3TC in children aged <5 years in the CHAPAS-3 (Children with HIV in Africa Pharmacokinetics and Adherence of Simple antiretroviral regimens) study. All regimens also included either nevirapine (NVP) or efavirenz. All the NRTIs had low toxicity and produced good clinical, immunologic, and virologic responses.⁹ A number of studies have evaluated the efficacy and toxicity of different dual-NRTI backbones used as part of combination ART.¹⁰⁻¹²

Infants with Perinatal HIV Exposure

The Pediatric AIDS Clinical Trials Group (PACTG) 076 clinical trial¹³ demonstrated that administering ZDV to pregnant women and their infants could reduce the risk of perinatal HIV transmission by nearly 70%. See [Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#) for further discussion on using ZDV to prevent perinatal transmission of HIV. A dose of approximately ZDV 4 mg/kg of body weight every 12 hours is recommended for prevention of perinatal HIV transmission in neonates and infants with gestational ages \geq 35 weeks. Infants who have been exposed to HIV but are uninfected should continue on the prophylactic dose for 2 to 6 weeks, depending on their gestational age at time of delivery and the risk assessment for perinatal transmission.

Simplified, alternative weight-band dosing has also been developed, and the rationale for these doses is based on the intracellular metabolism of ZDV (see Pharmacokinetics below). The rate-limiting step in the phosphorylation of ZDV to active ZDV triphosphate is the limited amount of thymidylate kinase. Increasing the dose of ZDV will lead to increased ZDV plasma concentrations and increased intracellular concentrations of ZDV monophosphate, but not ZDV diphosphate or ZDV triphosphate.

In 31 infants who received ZDV to prevent perinatal transmission, levels of intracellular ZDV metabolites were measured after delivery. Plasma ZDV and intracellular ZDV monophosphate decreased by roughly 50% between postdelivery Day 1 and Day 28, whereas ZDV diphosphate and ZDV triphosphate remained low throughout the sampling period.¹⁴ ZDV dose is poorly correlated

with the active form of ZDV that is found intracellularly. Because of this, a simplified weight-band dosing approach can be used for the first 4 weeks of life in infants with gestational ages ≥ 35 weeks (see the dosing table above). This approach should simplify the minor dose adjustments that are commonly made based on changes in infant weight during ZDV use in the first 4 weeks of life and will make it easier for caregivers to administer ZDV oral syrup to their infants. The changes in weight and the small differences in ZDV dose will have minor effects on the intracellular concentrations of ZDV triphosphate.

Infants with HIV Infection

The Early Infant Treatment Study in Botswana evaluated the safety and efficacy of initiation of ART in the first week of life. Forty infants who tested positive for HIV within 96 hours of birth were started on ZDV, 3TC, and NVP with successful transition to lopinavir/ritonavir (LPV/r) at 2 to 5 weeks after delivery. Early treatment was found to be safe and effective, with most infants achieving and maintaining viral suppression by 24 weeks of age.¹⁵

For full-term neonates who receive an HIV diagnosis during the first days to weeks of life, the ZDV dose should be increased to the continuation dose at age 4 weeks (see the dosing table above). The activity of the enzymes responsible for glucuronidation is low at birth and increases dramatically during the first 4 to 6 weeks of life in full-term neonates. This increase in metabolizing enzyme activity leads to an increased clearance of plasma ZDV, and the dose of ZDV should be adjusted when ZDV is used to treat HIV after the first 4 weeks in full-term infants.

For premature infants who receive an HIV diagnosis, the time to increase the ZDV dose from the initial dose varies with postgestational age and the clinical status of the neonate. On the basis of population pharmacokinetic (PK) modeling and simulations and data from studies that have evaluated ZDV PKs in premature infants, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends the following:

- For infants with HIV born at ≥ 30 weeks to < 35 weeks, switch to a dose of ZDV 12 mg/kg twice daily at a postgestational age of 6 to 8 weeks.
- For infants born at < 30 weeks, switch to ZDV 12 mg/kg twice daily at a postgestational age of 8 to 10 weeks.¹⁶

Clinicians should perform a careful clinical assessment of the infant, evaluate hepatic and renal function, and review concomitant medications before increasing the ZDV dose to the dose recommended for full-term infants.

Pharmacokinetics

ZDV undergoes intracellular metabolism to achieve its active form, ZDV triphosphate. Phosphorylation requires multiple steps: ZDV is phosphorylated by thymidine kinase to ZDV monophosphate, ZDV monophosphate is phosphorylated by thymidylate kinase to ZDV diphosphate, and ZDV diphosphate is phosphorylated by nucleoside diphosphate kinase to ZDV triphosphate. Overall, ZDV PK in pediatric patients aged > 3 months are like those seen in adults. Although the mean half-life of intracellular ZDV triphosphate (9.1 hours) is considerably longer than that of unmetabolized ZDV in plasma (1.5 hours), once-daily ZDV dosing is not recommended because of the low intracellular ZDV triphosphate concentrations seen with 600-mg, once-daily dosing in adolescents.¹⁷ PK studies, such as PACTG 331, demonstrate that dose adjustments are necessary for

premature infants because they have reduced clearance of ZDV compared with the clearance observed in term newborns of similar postnatal ages.⁶ ZDV has good central nervous system (CNS) penetration (cerebrospinal fluid–to-plasma concentration ratio is 0.68), and ZDV has been used in children with HIV-related CNS disease.⁸

PK and safety of ZDV, 3TC, and LPV/r in children with HIV and severe acute malnutrition (SAM) was studied in International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) P1092.¹⁸ Steady-state PK, safety, and tolerability was compared in children with HIV with and without SAM. Overall safety and tolerability did not differ between the two cohorts, and similar area-under-the-curve values for ZDV, 3TC, and LPV/r were observed in these children who were dosed according to World Health Organization weight-band dosing recommendations.¹⁸

The PK of intravenous ZDV in a premature neonate with gestational age of 32 weeks on extra corporal membrane oxygenation (ECMO) has been reported in a single case report. Based on measurements of ZDV plasma concentrations during and after ECMO, the authors concluded that ECMO did not have an impact on ZDV PK and that standard intravenous dosing of ZDV can be used in preterm neonates.¹⁹

Toxicity

Several studies suggest that the adverse hematologic effects of ZDV may be concentration-dependent, with a higher risk of anemia and neutropenia in patients with higher mean plasma area-under-the-curve values for ZDV.^{5,6,20} A significant reduction in the incidence of hematologic toxicity was observed during a retrospective analysis of infants who received a short course of ZDV (2 weeks) to prevent perinatal HIV transmission.²¹ In this study, 137 infants received ZDV for 2 weeks and 184 infants received ZDV for >2 weeks; of these infants, 168 (91.3%) received 4 weeks of ZDV prophylaxis. The risk of anemia (defined as a Division of AIDS severity grade of mild or higher) was significantly lower in the short-course group at both age 1 month ($P < 0.001$) and age 3 months ($P < 0.001$).²¹ For infants who develop significant anemia while receiving ZDV for prevention of perinatal HIV transmission, early discontinuation may be considered for infants who are determined to be at a low risk of transmission after expert consultation. A recent study conducted in Thailand evaluated the safety of triple ARV neonatal presumptive therapy with ZDV/3TC/NVP for 6 weeks in infants at high risk of acquisition of HIV compared with 4 weeks of monotherapy with ZDV in infants considered at low risk. No significant differences were observed in the incidence of neutropenia, hepatotoxicity, or severe anemia between the triple ARV and the ZDV monotherapy groups.²²

Incidence of hematological toxicity was investigated in the ARROW study, which randomized ART-naive Ugandan and Zimbabwean children to receive either ZDV-containing regimens or ABC-containing regimens. The incidence of severe anemia was similar regardless of ZDV use, and this finding suggests that advanced HIV disease contributed to low hemoglobin values. ZDV use was associated with severe neutropenia in a small number of children.²³ In a retrospective study conducted in Ethiopia, an evaluation of predictors of anemia among children on ART²⁴ was conducted from 2007 to 2017. Study participants receiving ZDV-containing regimens were four times more likely to develop anemia than those children receiving ABC-containing regimens. Other predictors of anemia in addition to ZDV in this patient population included tuberculosis, severe immunosuppression, and undernutrition.

ZDV is associated with greater mitochondrial toxicity than ABC and tenofovir disoproxil fumarate, but it is associated with less mitochondrial toxicity than d4T.^{25,26}

Although the incidence of cardiomyopathy associated with perinatal HIV infection has decreased dramatically since the use of ART became routine, the use of a regimen that contains ZDV may increase the risk.^{2,4} Analysis of data from a U.S.-based multicenter prospective cohort study (PACTG 219/219C) found that ongoing ZDV exposure was independently associated with a higher rate of cardiomyopathy.² As part of the Pediatric HIV/AIDS Cohort Study (PHACS)/Adolescent Master Protocol (AMP) study, echocardiogram measurements were collected between 2008 and 2010 in 325 youth aged 7 to 16 years with perinatally acquired HIV infection. An association between ZDV use and increased end-systolic wall stress was observed in this study. The investigators speculate that alterations in cardiac structure in these children could progress to symptomatic cardiomyopathy later in life.³ A large cohort study to evaluate the prevalence of cardiac dysfunction in children and young adults <26 years of age was conducted in Kenya.⁴ Approximately 28% of participants were found to have evidence of early cardiac dysfunction. Left ventricular ejection fraction negatively correlated with prior ZDV exposure, detectable HIV RNA, and elevated interleukin-6 concentrations.⁴

References

1. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med.* 2012;366(25):2368-2379. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
2. Patel K, Van Dyke RB, Mittleman MA, et al. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. *AIDS.* 2012;26(16):2027-2037. Available at: <https://pubmed.ncbi.nlm.nih.gov/22781228>.
3. Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. *AIDS.* 2018;32(16):2337-2346. Available at: <https://pubmed.ncbi.nlm.nih.gov/30102660>.
4. McCrary AW, Nyandiko WM, Ellis AM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. *AIDS.* 2020;34(4):539-548. Available at: <https://pubmed.ncbi.nlm.nih.gov/31794518>.
5. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. *Ann Intern Med.* 1989;110(4):279-285. Available at: <https://pubmed.ncbi.nlm.nih.gov/2643914>.
6. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. *J Pediatr.* 2003;142(1):47-52. Available at: <https://pubmed.ncbi.nlm.nih.gov/12520254>.
7. McKinney RE, Jr., Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The protocol 043 study group. *N Engl J Med.* 1991;324(15):1018-1025. Available at: <https://pubmed.ncbi.nlm.nih.gov/1672443>.
8. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. *N Engl J Med.* 1988;319(14):889-896. Available at: <https://pubmed.ncbi.nlm.nih.gov/3166511>.
9. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis.* 2016;16(2):169-179. Available at: <https://pubmed.ncbi.nlm.nih.gov/26481928>.
10. Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet.* 2002;359(9308):733-740. Available at: <https://pubmed.ncbi.nlm.nih.gov/11888583>.

11. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS*. 2007;21(8):947-955. Available at: <https://pubmed.ncbi.nlm.nih.gov/17457088>.
12. Mega TA, Usamo FB, Negera GZ. Immunologic response of HIV-infected children to different regimens of antiretroviral therapy: a retrospective observational study. *AIDS Res Treat*. 2020;2020:6415432. Available at: <https://pubmed.ncbi.nlm.nih.gov/32855823>.
13. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med*. 1994;331(18):1173-1180. Available at: <https://pubmed.ncbi.nlm.nih.gov/7935654>.
14. Kinai E, Kato S, Hosokawa S, et al. High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. *J Acquir Immune Defic Syndr*. 2016;72(3):246-253. Available at: <https://pubmed.ncbi.nlm.nih.gov/26859826>.
15. Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. *Clin Infect Dis*. 2021;72(3):388-393. Available at: <https://pubmed.ncbi.nlm.nih.gov/31927562>.
16. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. *J Clin Pharmacol*. 2003;43(2):133-140. Available at: <https://pubmed.ncbi.nlm.nih.gov/12616665>.
17. Flynn PM, Rodman J, Lindsey JC, et al. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. *Antimicrob Agents Chemother*. 2007;51(10):3516-3522. Available at: <https://pubmed.ncbi.nlm.nih.gov/17664328>.
18. Owor M, Tierney C, Ziembka L, et al. Pharmacokinetics and safety of zidovudine, lamivudine, and lopinavir/ritonavir in HIV-infected children with severe acute malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. *Pediatr Infect Dis J*. 2021;40(5):446-452. Available at: <https://pubmed.ncbi.nlm.nih.gov/33464021>.
19. Emonts M, Waalewijn H, Colbers A, et al. First reported use of zidovudine for prevention of perinatal HIV transmission in a premature neonate on extra corporal membrane oxygenation. *AIDS*. 2018;32(14):2084-2085. Available at: <https://pubmed.ncbi.nlm.nih.gov/30157085>.
20. Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to world health organization weight bands in Ugandan HIV-infected children. *Pediatr Infect Dis J*. 2014;33(5):495-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/24736440>.

21. Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. *Pediatr Infect Dis J*. 2019;38(7):727-730. Available at: <https://pubmed.ncbi.nlm.nih.gov/31033907>.
22. Anugulruengkitt S, Suntarattiwong P, Ounchanum P, et al. Safety of 6-week neonatal triple-combination antiretroviral postexposure prophylaxis in high-risk HIV-exposed infants. *Pediatr Infect Dis J*. 2019;38(10):1045-1050. Available at: <https://pubmed.ncbi.nlm.nih.gov/31365477>.
23. Musiime V, Cook A, Nahirya Ntege P, et al. The effect of long-term zidovudine on hematological parameters in the ARROW randomized trial. Presented at: The 22nd Conference on Retroviruses and Opportunistic Infections 2014. Boston, MA. Available at: <https://www.croiconference.org/wp-content/uploads/sites/2/posters/2014/919.pdf>.
24. Techane MA, Anlay DZ, Tesfaye E, Agegnehu CD. Incidence and predictors of anemia among children on antiretroviral therapy at the University of Gondar comprehensive specialized hospital, Northwest Ethiopia, 2007-2017: a retrospective follow-up study. *HIV AIDS (Auckl)*. 2020;12:951-962. Available at: <https://pubmed.ncbi.nlm.nih.gov/33364852>.
25. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. *AIDS*. 2006;20(16):2043-2050. Available at: <https://pubmed.ncbi.nlm.nih.gov/17053350>.
26. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. *JAMA*. 2002;288(2):207-215. Available at: <https://pubmed.ncbi.nlm.nih.gov/12095385>.

Appendix A: Pediatric Antiretroviral Drug Information

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors

Doravirine (DOR, Pifeltro)

Efavirenz (EFV, Sustiva)

Etravirine (ETR, Intelence)

Nevirapine (NVP, Viramune)

Rilpivirine (RPV, Edurant)

Doravirine (DOR, Pifeltro)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|---|
| Tablet: 100 mg | |
| Fixed-Dose Combination (FDC) Tablet <ul style="list-style-type: none">• [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg <p>When using FDC tablets, refer to other sections of the Appendix A: Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents.</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose <ul style="list-style-type: none">• DOR 100 mg once daily in antiretroviral (ARV)-naïve patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to DOR <p>[Delstrigo] DOR/Lamivudine (3TC)/Tenofovir Disoproxil Fumarate (TDF)</p> <p><i>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none">• One tablet once daily in ARV-naïve patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to the individual components of Delstrigo | <ul style="list-style-type: none">• Nausea• Abdominal pain• Diarrhea• Abnormal dreams• Insomnia, somnolence |
| Special Instructions | |
| | <ul style="list-style-type: none">• DOR can be taken with or without food.• Screen patients for hepatitis B virus (HBV) infection before using Delstrigo, which contains 3TC and TDF. Severe acute exacerbation of HBV can occur when 3TC or TDF are discontinued; therefore, hepatic function and HBV viral load should be monitored for several months after halting therapy with 3TC or TDF. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">• DOR is metabolized by the enzyme cytochrome P450 3A.• DOR has multiple interactions with several drugs (see Drug Interactions section below).• When DOR is coadministered with rifabutin, the dose should be increased from DOR 100 mg once daily to DOR 100 mg twice daily. When DOR/3TC/TDF (Delstrigo) is coadministered with rifabutin, an additional 100-mg dose of freestanding DOR needs to be administered approximately 12 hours later. (See Drug Interactions below.) |

| | |
|--|---|
| | <p>DOR Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> Dose adjustment is not required in patients with mild or moderate hepatic impairment. DOR has not been studied in patients with severe hepatic impairment. <p>DOR Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> Dose adjustment is not required when using DOR in patients with mild, moderate, or severe renal impairment. DOR use has not been studied in patients with end-stage renal disease or in patients on dialysis. DOR administered with 3TC and TDF as components of Delstrigo is not recommended in patients with estimated creatinine clearance <50 mL/min. |
|--|---|

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Doravirine (DOR) is a cytochrome P450 (CYP) 3A substrate that is associated with several important drug interactions with drugs that are strong CYP3A enzyme inducers. Coadministration with these drugs may cause significant decreases in DOR plasma concentrations and potential decreases in efficacy, which can lead to the development of resistance. Before DOR is administered, a patient's medication profile should be reviewed carefully for potential drug interactions with DOR.^{1,2}
- In a Phase 1 trial (described below under Efficacy in Clinical Trials), DOR plasma exposure transiently decreased by 62% when DOR was started immediately after stopping EFV. A *post hoc* analysis of the Phase 3 DRIVE-SHIFT study (described below under Efficacy in Clinical Trials), however, showed that at Week 4, DOR plasma levels in patients who had switched from an EFV-based regimen to a DOR-based regimen were similar to DOR plasma levels in patients who switched from a protease inhibitor (PI)-based regimen to a DOR-based regimen (all of the regimens in the study used a backbone of lamivudine [3TC] plus tenofovir disoproxil fumarate [TDF]).³ A similar effect of prior EFV-based ART on the pharmacokinetics (PK) of DOR was demonstrated in IMPAACT 2014 (described below under Efficacy in Clinical Trials) among adolescents weighing ≥ 45 kg who switched from EFV-based ART to DOR-based ART with 3TC/TDF.⁴
- DOR should not be coadministered** with the following drugs: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; or St. John's wort.^{5,6}
- Drug interactions between DOR and rifabutin induce the metabolism of DOR and require an additional dose of DOR 100 mg to be administered 12 hours after a fixed-dose combination of DOR/3TC/TDF or an increase of the DOR dose to 100 mg twice daily.^{2,5,6}

Major Toxicities

- More common:* Nausea, headache, fatigue, diarrhea, abdominal pain, abnormal dreams.

- *Less common (more severe):* Neuropsychiatric adverse events (AEs), including insomnia, somnolence, dizziness, and altered sensorium. Immune reconstitution inflammatory syndrome may occur.

Resistance

The International Antiviral Society–USA maintains a list of updated [drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

DOT is expected to have activity against HIV with isolated non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance that is associated with mutations at positions 103, 181, or 190. Some single mutations and combinations of viral mutations, however, have been shown to significantly decrease susceptibility to DOT. Specifically, clinical HIV isolates containing the Y188L mutation alone or in combinations with K103N or V106I, combinations of V106A with G190A and F227L, or combinations of E138K with Y181C and M230L have shown ≥100-fold reduction in susceptibility to DOT.^{5,6} In patients with multiple NNRTI mutations, consult an HIV expert and a resistance database to evaluate the potential efficacy of DOT.

Pediatric Use

Approval

DOT is approved by the U.S. Food and Drug Administration (FDA) for use in children and adolescents weighing ≥35 kg.^{5,6} [IMPAACT 2014](#), a Phase 1/2 study (described below under Efficacy in Clinical Trials) evaluated the PK, safety, and tolerability of DOT and DOT/3TC/TDF in children and adolescents with HIV.⁴

Efficacy in Clinical Trials

The efficacy of DOT was evaluated using data from four randomized adult clinical trials. The first study was a Phase 2b dose-selection, double-blind trial that enrolled treatment-naïve adults with HIV.⁷ The efficacy trials included two randomized, multicenter, double-blind, active-controlled Phase 3 trials ([DRIVE-FORWARD](#) and [DRIVE-AHEAD](#)) in treatment-naïve adults⁸⁻¹¹ and one open-label, active-controlled, randomized noninferiority trial that enrolled virologically suppressed adults on antiretroviral therapy ([DRIVE-SHIFT](#)).¹²

The dose-selection trial enrolled treatment-naïve adults stratified by HIV RNA level at screening (≤100,000 copies/mL or >100,000 copies/mL) and randomized participants to receive one of four different doses (25 mg, 50 mg, 100 mg, or 200 mg) of once-daily DOT or EFV 600 mg with open-label emtricitabine (FTC) 200 mg/TDF 300 mg. After dose selection at Week 24, all participants were switched to DOT 100 mg and, with additional enrollment, 216 participants were randomized to receive once-daily DOT 100 mg (n = 108) or EFV 600 mg (n = 108) for 96 weeks with FTC/TDF. At Week 24, 72.9% of participants on DOT 100 mg and 73.1% of participants on EFV 600 mg had HIV RNA <40 copies/mL.⁷

In the DRIVE-FORWARD trial, adult subjects received either DOT 100 mg (n = 383) or darunavir 800 mg/ritonavir 100 mg (DRV/r) (n = 383) once daily, each in combination with FTC/TDF or abacavir/3TC.⁸ In the DRIVE-AHEAD trial, adult subjects received either coformulated DOT/3TC/TDF (n = 364) or EFV/FTC/TDF (n = 364) once daily.⁹ An integrated efficacy analysis

from both trials (DRIVE-FORWARD and DRIVE-AHEAD) at Week 48 demonstrated that 84.1% of patients who were treated with the DOR-based regimen achieved HIV RNA <50 copies/mL, compared with 79.9% of patients who were treated with the DRV/r-based regimen and 80.8% of patients who were treated with EFV/FTC/TDF. Results were similar across different baseline viral loads, genders, races, and HIV-1 subtypes.⁹ In a longer-term analysis, at Week 96 in the DRIVE-AHEAD trial, among 728 randomized participants, 77.5% of those treated with DOR/3TC/TDF achieved HIV RNA <50 copies/mL, compared with 73.6% in participants treated with EFV/FTC/TDF. No additional resistance to DOR was observed between Weeks 48 and 96.¹¹ At Week 96 in the DRIVE-FORWARD trial, 277 (95%) of 292 participants who remained on DOR maintained viral suppression (i.e., 73% of the overall 383 participants), whereas 248 (91%) of 273 participants who remained on DRV/r maintained viral suppression (i.e., 66% of the overall 383 participants).¹⁰

In the DRIVE-SHIFT study, adult subjects with HIV who were virologically suppressed for ≥6 months on two nucleoside reverse transcriptase inhibitors plus a boosted PI, boosted elvitegravir, or an NNRTI were randomized to switch to a once-daily, single-tablet regimen of DOR 100 mg/3TC 300 mg/TDF 300 mg or continue their current therapy (baseline regimen). At Week 24, 93.7% on DOR/3TC/TDF versus 94.6% on baseline regimen had HIV-1 RNA <50 copies/mL (difference -0.9 [-4.7 to 3.0]). At Week 48, 90.8% on DOR/3TC/TDF had HIV-1 RNA <50 copies/mL, demonstrating noninferiority versus baseline regimen at Week 24 (difference -3.8 [-7.9 to 0.3]).¹² Participants were switched on Day 1 (immediate-switch group [ISG]; n = 447) or at Week 24 (delayed-switch group [DSG]; n = 209). Long-term efficacy in the extension arm at Week 144 showed virologic suppression (HIV RNA<50 copies/mL) in 80.1% of ISG (351 of 438) and 83.7% of DSG (175 of 209) in FDA snapshot (intent-to-treat) analysis.¹³

IMPAACT 2014 study data in antiretroviral (ARV)-naive or ARV-experienced virologically suppressed adolescents suggest favorable antiviral effect comparable to adult data.⁴ A total of 45 participants, 43 virologically suppressed (50% on EFV-based ART) and 2 ARV-naive adolescents with mean age 15 years (12–17 years), were treated with DOR/3TC/TDF. At Week 24, 42 of 45 (93.3%; 95% confidence interval [CI], 81.7–98.6) achieved or maintained HIV-1 RNA <40 copies/mL in FDA snapshot (intent-to-treat) analysis, while 42 of 43 (97.7%; 95% CI, 87.7–99.9) achieved or maintained HIV-1 RNA <40 copies/mL in observed failure (on-treatment) analysis.⁴

Pharmacokinetics

The PK of DOR have been evaluated in treatment-naive adults aged ≥18 years and both treatment-naive and treatment-experienced adolescents. A Phase 2 trial evaluated DOR across a dose range of 0.25 times to 2 times the recommended dose in treatment-naive participants with HIV who also received FTC/TDF. No exposure-response relationship for efficacy was reported for DOR.⁹

Toxicity

In trials that compared DOR-based regimens and EFV-based regimens, central nervous system (CNS) AEs (dizziness, sleep disorder and disturbances, and altered sensorium) occurred less frequently among the patients who received DOR than among those who received EFV. In the dose-finding trial, CNS AEs were reported in 26.9% of patients on DOR-based regimens, compared with 47.2% of patients on EFV-based regimens at Week 24.⁷ In the integrated safety analysis from the DRIVE-FORWARD and DRIVE-AHEAD trials, 25.5% of patients on DOR-based regimens

experienced CNS AEs at Week 48, compared with 55.9% of patients on EFV-based regimens.^{9,14} Neither DRIVE-FORWARD nor DRIVE-AHEAD included an integrase strand transfer inhibitor-based regimen as an active control. Fewer participants who received DOR-based regimens experienced diarrhea than those treated with DRV/r-based regimens (12.4% vs. 22.5%, respectively). In the DRIVE-SHIFT study, among adults who were receiving a ritonavir-boosted PI at study entry, mean reductions in fasting low-density lipoprotein cholesterol (**LDL-C**) and non-high density lipoprotein cholesterol (**HDL-C**) at Week 24 were significantly greater in people who received DOR/3TC/TDF compared with the baseline PI-based regimen with 3TC/TDF ($P < 0.0001$).¹² The reduction in fasting lipids was maintained through Week 144 in the extension arm of the DRIVE-SHIFT study.¹³ Similarly, the 96 weeks of data from the DRIVE-FORWARD trial supported greater mean reductions in LDL-C (-14.6 mg/dL [95% CI, -18.2 to -11.0]) and non-**HDL-C** (18.4 mg/dL [95% CI, -22.5 to -14.3]) among participants in the DOR arm than among those in the DRV/r arm.¹⁰ At Week 96 in the DRIVE-AHEAD trial, fasting HDL-C levels increased among participants in the EFV/FTC/TDF arm (mean increases of 10.8 and 15.0 mg/dL) but not among participants treated with DOR/3TC/TDF (-0.6 and -2.1 mg/dL), respectively, while the mean changes from baseline in total cholesterol/HDL-C ratio were similar between both arms¹¹ (-0.12 for DOR/3TC/TDF and -0.10 for EFV/FTC/TDF; treatment difference, -0.04 ; 95% CI, -0.23 – 0.15).

In the IMPAACT 2014 study of 43 treatment-experienced and 2 ARV-naive adolescents aged 12 to <18 years on DOR/3TC/TDF at Week 24, there were no Grade **3 or 4** AEs, serious AEs, or premature study **drug discontinuation** due to AEs.⁴

References

1. Boyle A, Moss CE, Marzolini C, Khoo S. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. *Clin Pharmacokinet*. 2019;58(12):1553-1565. Available at: <https://pubmed.ncbi.nlm.nih.gov/31388941>.
2. Khalilieh SG, Yee KL, Sanchez RI, et al. Doravirine and the potential for CYP3A-mediated drug-drug interactions. *Antimicrob Agents Chemother*. 2019;63(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/30783000>.
3. Greaves W, Wan H, Yee KL, et al. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. *Antimicrob Agents Chemother*. 2019;63(12):e01298-01219. Available at: <https://pubmed.ncbi.nlm.nih.gov/31548188>.
4. Melvin AJ, Yee KL, Gray KP, et al. Pharmacokinetics, tolerability, and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets in adolescents living with HIV: week 24 results from IMPAACT 2014. *J Acquir Immune Defic Syndr*. 2023;92(2):153-161. Available at: <https://pubmed.ncbi.nlm.nih.gov/36215957>.
5. Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210807s008lbl.pdf.
6. Doravirine [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210806s007lbl.pdf.
7. Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. *Antivir Ther*. 2019;24(6):425-435. Available at: <https://pubmed.ncbi.nlm.nih.gov/31355775>.
8. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. *Lancet HIV*. 2018;5(5):e211-e220. Available at: <https://pubmed.ncbi.nlm.nih.gov/29592840>.
9. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. *Clin Infect Dis*. 2019;68(4):535-544. Available at: <https://pubmed.ncbi.nlm.nih.gov/30184165>.
10. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, Phase 3 trial. *Lancet HIV*. 2020;7(1):e16-e26. Available at: <https://pubmed.ncbi.nlm.nih.gov/31740348>.
11. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/TDF in treatment-naive adults with human

- immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, Phase 3 DRIVE-AHEAD noninferiority trial. *Clin Infect Dis.* 2021;73(1):33-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/33336698>.
12. Johnson M, Kumar P, Molina JM, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. *J Acquir Immune Defic Syndr.* 2019;81(4):463-472. Available at: <https://pubmed.ncbi.nlm.nih.gov/30985556>.
 13. Kumar P, Johnson M, Molina JM, et al. Brief report: switching to DOR/3TC/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. *J Acquir Immune Defic Syndr.* 2021;87(2):801-805. Available at: <https://pubmed.ncbi.nlm.nih.gov/33633036>.
 14. Thompson M, Orkin C, Molina JM, et al. Once-daily doravirine for initial treatment of adults living with HIV-1: an integrated safety analysis. *Clin Infect Dis.* 2019;70(7):1336-1343 Available at: <https://pubmed.ncbi.nlm.nih.gov/31121013>.

Efavirenz (EFV, Sustiva)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|---|
| Capsules: 50 mg, 200 mg | Tablet: 600 mg |
| Generic Formulations <ul style="list-style-type: none">• 50-mg and 200-mg capsules• 600-mg tablet | |
| Fixed-Dose Combination (FDC) Tablets <ul style="list-style-type: none">• [Atripla and generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Symfi and generic] Efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg• [Symfi Lo] Efavirenz 400 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg | |
| When using FDC tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| Neonatal Dose <ul style="list-style-type: none">• Efavirenz (EFV) is not approved for use in neonates. Pediatric Dose <ul style="list-style-type: none">• Efv capsules can be opened and the contents used as a sprinkle preparation for infants and children who are unable to swallow capsules. <i>Infants and Children Aged 3 Months to <3 Years and Weighing ≥3.5 kg</i> <ul style="list-style-type: none">• The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) does not recommend the use of Efv in children aged 3 months to <3 years due to highly variable pharmacokinetics in this age group. | <ul style="list-style-type: none">• Rash, which is generally mild and transient• Central nervous system (CNS) symptoms, such as fatigue, poor sleeping patterns, insomnia, vivid dreams, impaired concentration, agitation, seizures, depression, suicidal ideation, late-onset ataxia, and encephalopathy• Gynecomastia• Hepatotoxicity• Corrected QT prolongation• Use of Efv may produce false-positive results with some cannabinoid and benzodiazepine tests. |
| Special Instructions | |
| <ul style="list-style-type: none">• Efv capsules and tablets can be swallowed whole, or Efv capsules can be administered by sprinkling the contents of an opened capsule on food, as described below. | |

| <p>Children Aged ≥3 Years and Weighing ≥10 kg</p> <p>Once-Daily Doses of EFV by Weight</p> <table border="1" data-bbox="204 291 768 665"> <thead> <tr> <th data-bbox="204 291 486 354">Weight</th><th data-bbox="486 291 768 354">EFV Dose^{a,b}</th></tr> </thead> <tbody> <tr> <td data-bbox="204 354 486 418">10 kg to <15 kg</td><td data-bbox="486 354 768 418">200 mg</td></tr> <tr> <td data-bbox="204 418 486 481">15 kg to <20 kg</td><td data-bbox="486 418 768 481">250 mg</td></tr> <tr> <td data-bbox="204 481 486 544">20 kg to <25 kg</td><td data-bbox="486 481 768 544">300 mg</td></tr> <tr> <td data-bbox="204 544 486 608">25 kg to <32.5 kg</td><td data-bbox="486 544 768 608">350 mg</td></tr> <tr> <td data-bbox="204 608 486 665">32.5 kg to <40 kg</td><td data-bbox="486 608 768 665">400 mg</td></tr> <tr> <td data-bbox="204 665 486 665">≥40 kg</td><td data-bbox="486 665 768 665">600 mg</td></tr> </tbody> </table> <p>^a The dose in mg can be dispensed in any combination of capsule strengths. Capsules may be administered by sprinkling the contents onto an age-appropriate food (see Special Instructions below).</p> <p>^b Some experts recommend a dose of EFV 367 mg per m² of body surface area (maximum dose 600 mg) due to concerns about underdosing at the upper end of each weight band (see the Pediatric Use section below for details). Weight bands approximate a dose of EFV 367 mg per m² of body surface area, with a maximum dose of 600 mg.</p> <p>Child and Adolescent (Weighing ≥40 kg) and Adult Dose</p> <ul style="list-style-type: none"> • EFV 600 mg once daily <p>[Atripla] EFV 600 mg/Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)</p> <p>Child and Adolescent (Weighing ≥40 kg) and Adult Dose</p> <ul style="list-style-type: none"> • One tablet once daily • Take on an empty stomach. <p>[Symfi] EFV 600 mg/Lamivudine (3TC)/TDF</p> <p>Child and Adolescent (Weighing ≥40 kg) and Adult Dose</p> <ul style="list-style-type: none"> • One tablet once daily • Take on an empty stomach. <p>[Symfi Lo] EFV 400 mg/3TC/TDF</p> <p>Child and Adolescent (Weighing ≥35 kg) and Adult Dose</p> <ul style="list-style-type: none"> • One tablet once daily • Take on an empty stomach. | Weight | EFV Dose ^{a,b} | 10 kg to <15 kg | 200 mg | 15 kg to <20 kg | 250 mg | 20 kg to <25 kg | 300 mg | 25 kg to <32.5 kg | 350 mg | 32.5 kg to <40 kg | 400 mg | ≥40 kg | 600 mg | <ul style="list-style-type: none"> • Bedtime dosing is recommended, particularly during the first 2 to 4 weeks of therapy, to improve tolerability of CNS side effects. • Administer EFV, Atripla, Symfi, or Symfi Lo on an empty stomach. Avoid administration with a high-fat meal because this has the potential to increase absorption. <p>Instructions for Using the EFV Capsule as a Sprinkle Preparation with Food or Formula</p> <ul style="list-style-type: none"> • Hold capsule horizontally over a small container and carefully twist open to avoid spillage. • Gently mix capsule contents with 1 to 2 teaspoons of an age-appropriate soft food (e.g., applesauce, grape jelly, yogurt) or reconstituted infant formula at room temperature. • Administer within 30 minutes of mixing, and do not consume additional food or formula for 2 hours after administration. <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> • Cytochrome P450 (CYP) 2B6 is the primary enzyme for EFV metabolism. CYP2A6, CYP3A4, CYP3A5, and uridine diphosphate glucuronosyltransferases also contribute to metabolism. • CYP3A and CYP2B6 inducer <i>in vivo</i> • Interpatient variability in EFV exposure can be explained in part by polymorphisms in CYP, particularly in CYP2B6. Slower metabolizers are at higher risk of toxicity. See the Therapeutic Drug Monitoring section below for information about the management of mild or moderate toxicity. <p>EFV Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • EFV is not recommended for patients with moderate or severe hepatic impairment. <p>Atripla, Symfi, and Symfi Lo Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • Because Atripla, Symfi, and Symfi Lo are FDC products containing TDF, lamivudine, and/or emtricitabine that require dose adjustments based on renal function, they should not be used in patients with creatinine clearance <50 mL/min or in patients on dialysis. |
|---|-------------------------|-------------------------|-----------------|--------|-----------------|--------|-----------------|--------|-------------------|--------|-------------------|--------|---------------|---------------|---|
| Weight | EFV Dose ^{a,b} | | | | | | | | | | | | | | |
| 10 kg to <15 kg | 200 mg | | | | | | | | | | | | | | |
| 15 kg to <20 kg | 250 mg | | | | | | | | | | | | | | |
| 20 kg to <25 kg | 300 mg | | | | | | | | | | | | | | |
| 25 kg to <32.5 kg | 350 mg | | | | | | | | | | | | | | |
| 32.5 kg to <40 kg | 400 mg | | | | | | | | | | | | | | |
| ≥40 kg | 600 mg | | | | | | | | | | | | | | |

Note: Symfi Lo has not been studied in children (sexual maturity ratings [SMRs] 1–3), and major interindividual variability in EFV plasma concentrations has been found in pediatric patients in a multiethnic setting. The 400-mg dose of EFV may be too low in children or adolescents with SMRs 1 to 3 who weigh ≥ 40 kg. Therapeutic drug monitoring is suggested by some Panel members when Symfi Lo is used in pediatric patients weighing ≥ 40 kg (see the Therapeutic Drug Monitoring section below).

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Coadministration of efavirenz (EFV) with drugs that are primarily metabolized by cytochrome P450 (CYP) 2C9, CYP2C19, CYP2B6, or CYP3A isozymes may result in altered plasma concentrations of the coadministered drugs. Drugs that induce CYP3A and CYP2B6 activity would be expected to increase the clearance of EFV, resulting in lower plasma concentrations. There is potential for multiple drug interactions with EFV. Importantly, dose adjustment or the addition of ritonavir may be necessary when EFV is used in combination with atazanavir (ATV), lopinavir/ritonavir (LPV/r), or maraviroc (MVC).
- Before EFV is administered, a patient's medication profile should be reviewed carefully for potential drug interactions with EFV.
- Corrected QT (QTc) prolongation has been observed with the use of EFV.^{1,2} An alternative to EFV should be considered in patients who are receiving a drug that has a known risk of Torsades de Pointes or in patients who are at higher risk of Torsades de Pointes.

Major Toxicities

- **More common:** Skin rash and increased transaminase levels. Central nervous system (CNS) abnormalities—such as dizziness, somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, euphoria, and seizures—have been reported, primarily in adults. See [Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity](#) for information on managing these toxicities.
- **Rare:** QTc prolongation has been observed with the use of EFV, and Torsades de Pointes has been reported with EFV use.³ An association between EFV and suicidal ideation, suicide, and attempted suicide (especially among those with a history of mental illness or substance use) was found in one retrospective analysis of four comparative trials in adults. This association, however, was not found in analyses of two large observational cohorts.

Resistance

The International Antiviral Society–USA maintains a [list of updated resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

EFV has been approved by the U.S. Food and Drug Administration (FDA) for use as part of antiretroviral (ARV) therapy in children aged ≥ 3 months and weighing ≥ 3.5 kg. The FDA also has approved the use of Symfi Lo, the fixed-dose combination of Efavirenz 400 mg/lamivudine (3TC) 300 mg/tenofovir disoproxil fumarate (TDF) 300 mg, in children weighing ≥ 35 kg.

Efficacy in Clinical Trials

EFV-based regimens have proven virologically superior or non-inferior to a variety of regimens in adults, including those containing LPV/r, nevirapine, rilpivirine, ATV, elvitegravir, raltegravir, and MVC.⁴⁻¹⁰ Efavirenz was shown to be inferior to dolutegravir (DTG) in the SINGLE trial in adults, which compared the virologic response of DTG plus abacavir/3TC with that of Efavirenz/TDF/emtricitabine (FTC) at Weeks 48 and 144. The differences were most likely due to more drug discontinuations in the Efavirenz group.¹¹

In clinical trials in adults and children with HIV, Efavirenz used in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) has been associated with excellent virologic response. FDA approval of Symfi (Efavirenz 600 mg/3TC/TDF) was based on the results from a clinical trial that compared the use of TDF with the use of stavudine when each drug was administered with 3TC and Efavirenz.¹² This trial showed that these regimens were similarly effective. The 96-week results of the Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy (ENCORE) 1 trial, a randomized trial in adults, showed that Efavirenz 400 mg used in combination with TDF and FTC was non-inferior to Efavirenz 600 mg used in combination with TDF and FTC.¹³ Efavirenz used in combination either with two NRTIs or with an NRTI and a protease inhibitor has been studied in children and has shown virologic potency and safety comparable to what has been seen in adults.¹⁴⁻¹⁶

FDA approval of Symfi Lo was based on a comparison between Efavirenz 400 mg and Efavirenz 600 mg, both taken with FTC 200 mg plus TDF 300 mg in 630 ARV-naive adult participants with a mean age of 36 years (range 18–69 years). Sixty-eight percent of participants were male, 37% were of African heritage, 33% were of Asian ethnicity, 17% were Hispanic, and 13% were White. This study showed similar rates of viral load suppression and toxicities among participants in each group.¹³ Because Efavirenz clearance is related to age and CYP2B6 polymorphisms, and because allele frequency varies by ethnicity, some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) suggest using therapeutic drug monitoring (TDM) when using Symfi Lo in pediatric patients weighing ≥ 40 kg.

Pharmacokinetics: Pharmacogenomics

Genetic polymorphisms in the genes that code for enzymes involved in the metabolism of Efavirenz may alter enzyme activity, which causes a high degree of interpatient variability in drug exposure. CYP2B6 is the primary enzyme for Efavirenz metabolism, and pediatric patients with the CYP2B6-516-T/T genotype have reduced metabolism, resulting in higher Efavirenz levels in these patients than in those with the G/G or G/T genotypes.¹⁷⁻²¹ CYP2B6-516-T/T allele frequency varies by ethnicity. In a study of adults from the United States and Italy, this allele had a frequency of 24.4% among White participants, 31.3% among Black participants, and 34.9% among Hispanic participants.²² A retrospective study of pediatric patients in a multiethnic, high-income setting

confirmed that EFV plasma concentrations can vary among patients. The interindividual variability could be explained in large part by polymorphisms in drug metabolizing genes, as well as by age at treatment initiation and time since treatment initiation.²³ International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1070 has shown that aggressive dosing with approximately 40 mg/kg of EFV using opened capsules resulted in therapeutic EFV concentrations in 58% of children aged <3 years with the G/G or G/T genotypes, but excessive exposure occurred in those with the T/T genotype.^{21,24} Optimal dosing may require pre-treatment CYP2B6 genotyping in children aged <3 years (see Pharmacokinetics and Dosing: Infants and Children Aged <3 Years below).^{20,21,24}

Other variants—CYP2B6 alleles and variant CYP2A6 alleles—have been found to influence EFV concentrations in adults and children.^{20,25-28}

Pharmacokinetics and Dosing: Infants and Children Aged <3 Years

The Panel **does not recommend** the use of EFV in children aged 3 months to <3 years.

Pharmacokinetic (PK) data in children aged <3 years or weighing <14 kg have shown that it is difficult to achieve target trough concentrations (C_{trough}) in this age group.^{18,29} IMPAACT P1070 studied children aged <3 years with HIV and tuberculosis (TB) coinfection using doses of EFV that were determined by weight band based on CYP2B6-516-G/G and -G/T genotypes: children with G/G and G/T genotypes were considered extensive metabolizers (EMs), and children with T/T genotypes were considered slow metabolizers (SMs) (see [Table A](#) below). When doses were used without regard to genotype, a dose of approximately 40 mg/kg per day resulted in therapeutic EFV concentrations in an increased proportion of study participants with G/G or G/T genotypes but excessive exposure in a high proportion of participants with T/T genotypes. This dose is higher than the FDA-approved dose of EFV.²⁴ Therefore, doses were modified so that infants and young children with the T/T genotype received a reduced dose. The doses listed for P1070 in [Table A](#) are investigational.

A study evaluated the PK of EFV in children aged <3 years who had TB/HIV coinfection and were receiving anti-TB treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol. The findings from this study reinforced the use of CYP2B6-516 genotype-directed EFV dosing and showed that, in general, the EFV weight-band dose did not need to be modified further for children aged <40 months.^{21,30}

Investigational Dosing for Children Aged 3 Months to <3 Years by CYP2B6 Genotype

Table A. Comparison of Efavirenz Doses Used in P1070 and the FDA-Recommended Doses

| Weight | Protocol P1070 Dosing for Patients with CYP2B6-516-G/G and -G/T Genotypes (EMs) ^a | Protocol P1070 Dosing for Patients with CYP2B6-516-T/T Genotype (SMs) ^a | FDA-Approved Dosing for Children Aged 3 Months to <3 Years (without Regard to CYP2B6 Genotype) |
|------------------|--|--|--|
| 5 kg to <7 kg | 300 mg | 50 mg | 150 mg |
| 7 kg to <7.5 kg | 400 mg | 100 mg | 150 mg |
| 7.5 kg to <10 kg | 400 mg | 100 mg | 200 mg |
| 10 kg to <14 kg | 400 mg | 100 mg | 200 mg |
| 14 kg to <15 kg | 500 mg | 150 mg | 200 mg |
| 15 kg to ≤17 kg | 500 mg | 150 mg | 250 mg |

^a Investigational doses are based on the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) study P1070. Evaluation of the CYP2B6 genotype is required before initiating efavirenz (EFV). Therapeutic drug level monitoring is recommended, with a trough concentration measured 2 weeks after initiating EFV and again at age 3 years for a possible dose adjustment.

Source: Bwakura Dangarembizi M, Samson P, Capparelli EV, et al. Establishing dosing recommendations for efavirenz in HIV/TB-coinfected children younger than 3 years. J Acquir Immune Defic Syndr. 2019;81(4):473-480.

Key: CYP = cytochrome P450; EM = extensive metabolizer; SM = slow metabolizer

The FDA-approved doses of EFV for use in infants and children aged 3 months to <3 years were derived from a population PK model that was based on data from older participants in the Pediatric AIDS Clinical Trials Group (PACTG) 1021 and PACTG 382, as well as from data collected during AI266-922, a study that assessed the PK, safety, and efficacy of using capsule sprinkles in children aged 3 months to 6 years (see [Table A](#) above). The FDA-approved doses are lower than the CYP2B6 EM doses and higher than the CYP2B6 SM doses from the P1070 study. PK modeling, based on P1070 PK data, was used to generate estimates of the percentage of participants who were likely to reach therapeutic EFV target concentrations on FDA-indicated doses, according to the participants' genotypes.²⁴ The study reported that an estimated one-third of EM children who received the FDA-approved dose would experience subtherapeutic EFV exposures, and more than half of SM children who received the FDA-approved dose would have area under the curve (AUC) values that were above the target range.

In another study, PK data modeling was used to determine the impact of the CYP2B6 genotype in infants and children, as well as mothers and breastfeeding infants.³¹ These data were derived from studies of African populations and included data from IMPAACT P1070. In these models, the FDA-approved doses of EFV were approximated by the models for dosing in children aged 3 months to <3 years who were EMs. The investigational doses from IMPAACT P1070 were approximated by the models for dosing in children aged 3 months to <3 years who were SMs.

The Panel **does not recommend** use of EFV in children aged 3 months to <3 years due to highly variable PK in this age group.

Pharmacokinetics: Children Aged \geq 3 Years and Adolescents

Even with the use of FDA-approved pediatric dosing in children aged \geq 3 years, EFV concentrations can be suboptimal.^{17,32-36} Therefore, some experts recommend using TDM in patients who are receiving EFV and possibly using higher doses in young children, especially in certain clinical situations, such as virologic rebound or lack of response in an adherent patient. In one study in which the EFV dose was adjusted in response to measurement of the AUC, the median administered dose was EFV 13 mg/kg (367 mg per m² of body surface area), and the range was from 3 mg/kg to 23 mg/kg (69–559 mg per m² of body surface area).³⁷

Toxicity: Children Versus Adults

The toxicity profile for EFV differs for adults and children. One adverse effect (AE) commonly seen in children is rash, which was reported in up to 40% of children and 27% of adults.³⁸ The rash is usually maculopapular, pruritic, and mild to moderate in severity and rarely requires drug discontinuation. Onset is typically during the first 2 weeks of treatment. Although severe rash and Stevens-Johnson syndrome have been reported, they are rare.

Multiple studies in adults have shown that EFV use is associated with low vitamin D levels, and several studies have found an association between EFV use and low bone mineral density.³⁹⁻⁴² EFV induces CYP3A4 and CYP24 enzymes that may affect vitamin D homeostasis. Because of these findings, the Panel recommends measurement of vitamin D in patients receiving EFV and vitamin D supplementation for those with vitamin D deficiency (see [Table 17j. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis](#)).

In adults, CNS symptoms are commonly reported and affected 29.6% of patients in one meta-analysis of randomized trials.⁴³ These symptoms usually occur early in treatment and rarely require drug discontinuation, but they sometimes can persist for months. Administering EFV at bedtime appears to decrease the occurrence and severity of these neuropsychiatric AEs. For patients who can swallow capsules or tablets, ensuring that EFV is taken on an empty stomach also reduces the occurrence of neuropsychiatric AEs. In several studies, the incidence of neuropsychiatric AEs was correlated with EFV plasma concentrations, and the symptoms occurred more frequently in patients with higher concentrations.⁴⁴⁻⁴⁷ The ENCORE1 study in adults demonstrated that a dose of EFV 400 mg is associated with fewer AEs and a non-inferior virologic response when compared with the recommended 600-mg dose of EFV.^{13,48} A Tanzanian study of children aged 6 to 12 years showed that those who were receiving EFV, especially doses of EFV that were higher than or equal to those recommended by the World Health Organization, had more anxiety and more difficulty concentrating at school than children who were receiving alternative ARV medications.⁴⁹ Adverse CNS events occurred in 14% of children who received EFV in clinical studies⁵⁰ and in 30% of children⁵¹ with plasma EFV concentrations >4 mg/L. Late-onset neurotoxicity, including ataxia and encephalopathy, may occur months to years after initiating EFV. Some events of late-onset neurotoxicity have occurred in patients with certain CYP2B6 genetic polymorphisms who received standard doses of EFV. These polymorphisms have been associated with slow metabolism of EFV and increased EFV levels (see the [package insert for EFV](#)).

An association between EFV and suicidal ideation, suicide, and attempted suicide (especially among those with a history of mental illness or substance abuse) was found in a retrospective analysis of four comparative trials in adults and in the Strategic Timing of AntiRetroviral Treatment (START) Trial, a prospective analysis of adults.^{52,53} This association, however, was not found in the analyses

of two large observational cohorts,^{54,55} and no cases of suicide were reported in a systematic review of randomized trials.⁴³ In patients with preexisting psychiatric conditions, EFV should be used cautiously.

Toxicity: QTc Prolongation

The effect of EFV on the QTc interval was evaluated in a study of 58 healthy adult participants; a variety of CYP2B6 polymorphisms was represented within this group. A positive relationship between EFV concentration and QTc prolongation was observed.¹ Clinicians should consider using an alternative to EFV in patients who are receiving a drug that has a known risk of Torsades de Pointes (e.g., quinidine, clarithromycin) or in patients who are at higher risk for Torsades de Pointes.²

Therapeutic Drug Monitoring

It is reasonable for a clinician to use TDM to determine whether a patient is experiencing toxicity, because the concentration of EFV is higher than the normal therapeutic range for some toxicities.^{56,57} Dose reduction or drug discontinuation would be considered appropriate management of drug toxicity. Dose reduction is best performed in consultation with an expert in pediatric HIV. Also, TDM should be considered when administering EFV to children aged 3 months to <3 years due to increased oral clearance and variable PK properties in this young age group. TDM should also be considered when using a lower dose of EFV—such as the dose found in Symfi Lo—in children weighing ≥40 kg. Two weeks after initiating EFV in patients aged <3 years, clinicians should measure the plasma concentration of EFV. In cases where a dose adjustment may be necessary, clinicians should consult an expert in pediatric HIV infection prior to adjusting the dose. If a child initiated EFV at an investigational dose at <3 years of age, some experts would also measure plasma concentration at age 3 years, after the child transitions to the recommended dose for children aged ≥3 years.

The currently accepted minimum effective concentration of EFV is a mid-dose concentration at 12 hours postdose (C_{12h}) of >1 mg/L in adults, and concentrations of >4.0 mg/L are associated with CNS side effects.⁴⁵ However, the validity of using a single target has been called into question.⁵⁸ In addition, a lower limit of $C_{12h} > 0.7\text{mg/L}$ was most predictive of virologic outcome in a study of 180 adults.⁵⁹ Findings from a study of 128 African children (aged 1.7–13.5 years) suggest that the concentration at 24 hours (C_{24h}) threshold for increased risk of unsuppressed viral load is $C_{24h} 0.65\text{ mg/L}$.⁶⁰

References

1. Abdelhady AM, Shugg T, Thong N, et al. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. *J Cardiovasc Electrophysiol.* 2016;27(10):1206-1213. Available at: <https://pubmed.ncbi.nlm.nih.gov/27333947>.
2. Efavirenz (Sustiva) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf.
3. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. *Ann Pharmacother.* 2002;36(6):1006-1008. Available at: <https://pubmed.ncbi.nlm.nih.gov/12022902>.
4. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. *J Acquir Immune Defic Syndr.* 2004;36(5):1011-1019. Available at: <https://pubmed.ncbi.nlm.nih.gov/15247553>.
5. Torti C, Maggiolo F, Patroni A, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER cohort. *J Antimicrob Chemother.* 2005;56(1):190-195. Available at: <https://pubmed.ncbi.nlm.nih.gov/15917286>.
6. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med.* 2008;358(20):2095-2106. Available at: <https://pubmed.ncbi.nlm.nih.gov/18480202>.
7. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet.* 2009;374(9692):796-806. Available at: <https://pubmed.ncbi.nlm.nih.gov/19647866>.
8. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. *J Infect Dis.* 2010;201(6):803-813. Available at: <https://pubmed.ncbi.nlm.nih.gov/20151839>.
9. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the Phase 3 double-blind randomized ECHO and THRIVE trials. *J Acquir Immune Defic Syndr.* 2012;60(1):33-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/22343174>.
10. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naive

- individuals. *HIV Clin Trials*. 2002;3(3):186-194. Available at: <https://pubmed.ncbi.nlm.nih.gov/12032877>.
11. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr*. 2015;70(5):515-519. Available at: <https://pubmed.ncbi.nlm.nih.gov/26262777>.
 12. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. *HIV Med*. 2006;7(7):442-450. Available at: <https://pubmed.ncbi.nlm.nih.gov/16925730>.
 13. ENCORE1 Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis*. 2015;15(7):793-802. Available at: <https://pubmed.ncbi.nlm.nih.gov/25877963>.
 14. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. *Eur J Med Res*. 2005;10(12):503-508. Available at: <https://pubmed.ncbi.nlm.nih.gov/16356864>.
 15. McKinney RE, Jr., Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group protocol P1021. *Pediatrics*. 2007;120(2):e416-423. Available at: <https://pubmed.ncbi.nlm.nih.gov/17646352>.
 16. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. *N Engl J Med*. 1999;341(25):1874-1881. Available at: <https://pubmed.ncbi.nlm.nih.gov/10601506>.
 17. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. *J Acquir Immune Defic Syndr*. 2007;45(3):280-285. Available at: <https://pubmed.ncbi.nlm.nih.gov/17356468>.
 18. Bolton C, Samson P, Capparelli E, et al. Strong influence of CYP2B6 genotypic polymorphisms on EFV pharmacokinetics in HIV+ children <3 years of age and implications for dosing. Presented at: Conference on Retroviruses and Opportunistic Infections; 2013. Atlanta, GA.
 19. Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.

Antimicrob Agents Chemother. 2014;58(1):136-143. Available at: <https://pubmed.ncbi.nlm.nih.gov/24145522>.

20. Bienczak A, Cook A, Wiesner L, et al. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. *Br J Clin Pharmacol.* 2016;82(1):185-198. Available at: <https://pubmed.ncbi.nlm.nih.gov/26991336>.
21. Nikanjam M, Tran L, Chadwick EG, et al. Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. *AIDS.* 2022;36(4):525-532. Available at: <https://pubmed.ncbi.nlm.nih.gov/34873089>.
22. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. *J Infect Dis.* 2005;192(11):1931-1942. Available at: <https://pubmed.ncbi.nlm.nih.gov/16267764>.
23. Soeria-Atmadja S, Osterberg E, Gustafsson LL, et al. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. *PLoS One.* 2017;12(9):e0181316. Available at: <https://pubmed.ncbi.nlm.nih.gov/28886044>.
24. Bolton Moore C, Capparelli EV, Samson P, et al. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3–36 months with HIV infection. *AIDS.* 2017;31(8):1129-1136. Available at: <https://pubmed.ncbi.nlm.nih.gov/28323755>.
25. di Julio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenet Genomics.* 2009;19(4):300-309. Available at: <https://pubmed.ncbi.nlm.nih.gov/19238117>.
26. Arab-Alameddine M, Di Julio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. *Clin Pharmacol Ther.* 2009;85(5):485-494. Available at: <https://pubmed.ncbi.nlm.nih.gov/19225447>.
27. Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. *J Infect Dis.* 2012;206(9):1453-1461. Available at: <https://pubmed.ncbi.nlm.nih.gov/22927450>.
28. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. *Pharmacogenet Genomics.* 2012;22(12):858-867. Available at: <https://pubmed.ncbi.nlm.nih.gov/23080225>.

29. Capparelli E, Rochon-Duck M, Robbins B, et al. Age-related pharmacokinetics of efavirenz solution. Presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI); 2009. Montreal, Canada.
30. Bwakura Dangarembizi M, Samson P, Capparelli EV, et al. Establishing dosing recommendations for efavirenz in HIV/TB-coinfected children younger than 3 years. *J Acquir Immune Defic Syndr*. 2019;81(4):473-480. Available at: <https://pubmed.ncbi.nlm.nih.gov/31241542>.
31. Pan X, Rowland Yeo K. Physiologically based pharmacokinetic modeling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding Infants. *Clin Pharmacol Ther*. 2023;114(1):182-191. Available at: <https://pubmed.ncbi.nlm.nih.gov/37078251>.
32. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. *J Acquir Immune Defic Syndr*. 2007;45(2):133-136. Available at: <https://pubmed.ncbi.nlm.nih.gov/17417100>.
33. Hirt D, Urien S, Olivier M, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? *Antimicrob Agents Chemother*. 2009;53(10):4407-4413. Available at: <https://pubmed.ncbi.nlm.nih.gov/19635964>.
34. Viljoen M, Gous H, Kruger HS, et al. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. *AIDS Res Hum Retroviruses*. 2010;26(6):613-619. Available at: <https://pubmed.ncbi.nlm.nih.gov/20507205>.
35. Fillekes Q, Natukunda E, Balungi J, et al. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. *J Acquir Immune Defic Syndr*. 2011;58(4):392-398. Available at: <https://pubmed.ncbi.nlm.nih.gov/21926634>.
36. Cressey TR, Aupribul L, Narkbunnam T, et al. Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected Thai children. *J Acquir Immune Defic Syndr*. 2013;62(1):e27-29. Available at: <https://pubmed.ncbi.nlm.nih.gov/23262981>.
37. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. *Clin Pharmacol Ther*. 2008;83(2):300-306. Available at: <https://pubmed.ncbi.nlm.nih.gov/17609682>.
38. Larru B, Eby J, Lowenthal ED. Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. *Pediatric Health Med Ther*. 2014;5:29-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/25937791>.

39. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. *AIDS*. 2010;24(12):1923-1928. Available at: <https://pubmed.ncbi.nlm.nih.gov/20588161>.
40. Hamzah L, Tiraboschi JM, Iveson H, et al. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). *Antivir Ther*. 2016;21(4):287-296. Available at: <https://pubmed.ncbi.nlm.nih.gov/26460504>.
41. Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). *Antivir Ther*. 2014;19(2):191-200. Available at: <https://pubmed.ncbi.nlm.nih.gov/24430534>.
42. Dave JA, Cohen K, Micklesfield LK, et al. Antiretroviral therapy, especially efavirenz, is associated with low bone mineral density in HIV-infected South Africans. *PLoS One*. 2015;10(12):e0144286. Available at: <https://pubmed.ncbi.nlm.nih.gov/26633015>.
43. Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. *J Acquir Immune Defic Syndr*. 2015;69(4):422-429. Available at: <https://pubmed.ncbi.nlm.nih.gov/25850607>.
44. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. *Clin Infect Dis*. 2005;41(11):1648-1653. Available at: <https://pubmed.ncbi.nlm.nih.gov/16267739>.
45. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS*. 2001;15(1):71-75. Available at: <https://pubmed.ncbi.nlm.nih.gov/11192870>.
46. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. *AIDS*. 2002;16(9):1201-1215. Available at: <https://pubmed.ncbi.nlm.nih.gov/12045485>.
47. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. *J Antimicrob Chemother*. 2008;61(6):1336-1339. Available at: <https://pubmed.ncbi.nlm.nih.gov/18343800>.
48. Encore Study Group, Puls R, Amin J, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. *Lancet*. 2014;383(9927):1474-1482. Available at: <https://pubmed.ncbi.nlm.nih.gov/24522178>.

49. Van de Wijer L, McHaile DN, de Mast Q, et al. Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study. *Lancet HIV*. 2019;6(4):e250-e258. Available at: <https://pubmed.ncbi.nlm.nih.gov/30770324>.
50. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403-1412. Available at: <https://pubmed.ncbi.nlm.nih.gov/23343913>.
51. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. *Antivir Ther*. 2009;14(3):315-320. Available at: <https://pubmed.ncbi.nlm.nih.gov/19474465>.
52. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. *Ann Intern Med*. 2014;161(1):1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/24979445>.
53. Arenas-Pinto A, Grund B, Sharma S, et al. Risk of suicidal behavior with use of efavirenz: results from the strategic timing of antiretroviral treatment trial. *Clin Infect Dis*. 2018;67(3):420-429. Available at: <https://pubmed.ncbi.nlm.nih.gov/29538636>.
54. Smith C, Ryom L, Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19512. Available at: <https://pubmed.ncbi.nlm.nih.gov/25394021>.
55. Napoli AA, Wood JJ, Coumbis JJ, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. *J Int AIDS Soc*. 2014;17:19214. Available at: <https://pubmed.ncbi.nlm.nih.gov/25192857>.
56. van Luijn M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. *J Acquir Immune Defic Syndr*. 2009;52(2):240-245. Available at: <https://pubmed.ncbi.nlm.nih.gov/19593159>.
57. Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. *AIDS Res Hum Retroviruses*. 2002;18(12):825-834. Available at: <https://pubmed.ncbi.nlm.nih.gov/12201904>.
58. Dickinson L, Amin J, Else L, et al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-naive HIV-infected patients at 96 weeks: results of the ENCORE1 study. *Clin Pharmacokinet*. 2015. Available at: <https://pubmed.ncbi.nlm.nih.gov/26715213>.

59. Orrell C, Bienczak A, Cohen K, et al. Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. *Int J Antimicrob Agents*. 2016;47(6):466-472. Available at: <https://pubmed.ncbi.nlm.nih.gov/27211824/>.
60. Bienczak A, Denti P, Cook A, et al. Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children. *J Acquir Immune Defic Syndr*. 2016;73(2):161-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/27116047/>.

Etravirine (ETR, Intelence)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | | | | | | | | | | | |
|--|-------------------------|------------------|-----------------|--------|-----------------|--------|-----------------|--------|--------------|--------|--|
| Tablets: 25 mg, 100 mg, 200 mg | | | | | | | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | | | | | | | |
| <p>Neonate and Infant Dose</p> <ul style="list-style-type: none">• Etravirine (ETR) is not approved for use in neonates or infants. <p>Child Dose</p> <ul style="list-style-type: none">• ETR is not approved for use in children aged <2 years. <p>ETR Dosing Table for Antiretroviral Therapy-Experienced Children and Adolescents Aged 2 to 18 Years and Weighing ≥ 10 kg</p> <table border="1"><thead><tr><th>Body Weight</th><th>Twice-Daily Dose</th></tr></thead><tbody><tr><td>10 kg to <20 kg</td><td>100 mg</td></tr><tr><td>20 kg to <25 kg</td><td>125 mg</td></tr><tr><td>25 kg to <30 kg</td><td>150 mg</td></tr><tr><td>≥ 30 kg</td><td>200 mg</td></tr></tbody></table> <ul style="list-style-type: none">• ETR is approved for use in children and adolescents who are treatment experienced. The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends that ETR is used as part of a regimen that includes a ritonavir (RTV)-boosted protease inhibitor (PI) (see Efficacy in Clinical Trials and Drug Interactions below).• Cobicistat-boosted PIs, non-nucleoside reverse transcriptase inhibitors, bictegravir, and elvitegravir/cobicistat should not be used with ETR. Raltegravir and dolutegravir should only be used with ETR with RTV-boosted atazanavir, darunavir, or lopinavir. <p>Adult Dose for Antiretroviral Therapy-Experienced Patients</p> <ul style="list-style-type: none">• ETR 200 mg twice daily with food. | Body Weight | Twice-Daily Dose | 10 kg to <20 kg | 100 mg | 20 kg to <25 kg | 125 mg | 25 kg to <30 kg | 150 mg | ≥ 30 kg | 200 mg | <ul style="list-style-type: none">• Nausea• Diarrhea• Rash, including Stevens-Johnson syndrome• Hypersensitivity with rash; constitutional symptoms; and, sometimes, organ dysfunction, including hepatic failure |
| Body Weight | Twice-Daily Dose | | | | | | | | | | |
| 10 kg to <20 kg | 100 mg | | | | | | | | | | |
| 20 kg to <25 kg | 125 mg | | | | | | | | | | |
| 25 kg to <30 kg | 150 mg | | | | | | | | | | |
| ≥ 30 kg | 200 mg | | | | | | | | | | |
| Special Instructions | | | | | | | | | | | |
| <ul style="list-style-type: none">• ETR tablets are sensitive to moisture; store the tablets at room temperature in the original container with desiccant.• Always administer ETR with food. Area under the curve of ETR is decreased by about 50% when the drug is taken on an empty stomach. The type of food does not affect the exposure to ETR.• Swallowing ETR tablets whole is the preferred means of administration. Although the package insert contains instructions for dispersing ETR tablets in water or other liquids, using this administration method generally results in lower ETR exposures compared with swallowing tablets whole. Children who receive dispersed ETR tablets should switch to swallowing tablets whole as soon as developmentally able. | | | | | | | | | | | |
| Metabolism/Elimination | | | | | | | | | | | |
| <ul style="list-style-type: none">• ETR is an inducer of cytochrome P450 (CYP) 3A4 and an inhibitor of CYP2C9, CYP2C19, and P-glycoprotein. It is a substrate for CYP3A4, CYP2C9, and CYP2C19.• ETR is involved in multiple interactions with antiretroviral agents and other drugs (see Drug Interactions below). | | | | | | | | | | | |

| | |
|--|---|
| | <p>ETR Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • No dose adjustment is required when using ETR in patients with mild or moderate hepatic insufficiency. No dosing information is available for patients with severe hepatic impairment. <p>ETR Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • No dose adjustment is required when using ETR in patients with renal impairment. |
|--|---|

Drug Interactions

Additional information about drug interactions is available in [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Etravirine (ETR) is associated with multiple drug interactions. A patient's medication profile should be carefully reviewed for potential drug interactions before ETR is administered.
- **ETR should not be administered** with tipranavir/ritonavir, fosamprenavir/ritonavir, unboosted protease inhibitors (PIs), or cobicistat-boosted PIs.¹
- **ETR should not be administered** with other non-nucleoside reverse transcriptase inhibitors (NNRTIs) (i.e., nevirapine [NVP], efavirenz [EFV], rilpivirine, doravirine).
- **ETR should not be administered** with bictegravir or elvitegravir/cobicistat. ETR reduces the trough concentration of raltegravir² (RAL) and dolutegravir (DTG). RAL and DTG should be used with ETR only when these drugs are coadministered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir.

Major Toxicities

- *More common:* Nausea, diarrhea, and mild rash. Rash occurs most commonly during the first 6 weeks of therapy. Rash generally resolves after 1 to 2 weeks on continued therapy. A history of NNRTI-related rash does not appear to increase the risk of developing rash with ETR. However, patients who have a history of severe rash with prior NNRTI use **should not receive ETR**.
- *Less common (more severe):* Peripheral neuropathy, severe rash, hypersensitivity reactions (HSRs), and erythema multiforme all have been reported. Instances of severe rash have included Stevens-Johnson syndrome, and HSRs have included constitutional symptoms and organ dysfunction, including hepatic failure. Discontinue ETR immediately if signs or symptoms of severe skin reactions or HSRs develop (including severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, and eosinophilia). Clinicians should monitor a patient's clinical status, including levels of liver transaminases, and initiate appropriate therapy when necessary. Continuing to use ETR after the onset of severe rash may result in a life-threatening reaction. People who have a history of severe rash while using NVP or EFV **should not receive ETR**.

Resistance

The International AIDS Society–USA maintains [a list of updated resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

ETR is approved by the U.S. Food and Drug Administration (FDA) for use in antiretroviral therapy (ART)-experienced children and adolescents aged 2 to 18 years.

Efficacy in Clinical Trials

In the Paediatric study of Intelence As an NNRTI Option (PIANO) study,³ ART-experienced children aged 6 years to <18 years received ETR with a ritonavir (RTV)-boosted PI as part of an optimized background regimen. At Week 24, 67% of these participants had plasma HIV RNA concentrations <400 copies/mL and 52% had HIV RNA <50 copies/mL. At Week 48, 56% of the participants had HIV RNA <50 copies/mL and a mean increase in their CD4 T lymphocyte (CD4) cell counts of 156 cells/mm³ from baseline. At Week 48, 68% of children aged 6 years to <12 years had plasma HIV RNA <50 copies/mL, whereas only 48% of adolescents aged 12 years to <18 years achieved a plasma viral load of <50 copies/mL.

In a retrospective study of 23 children and adolescents with multi-drug resistant HIV receiving ETR-based therapy in Spain, 78% of participants achieved HIV RNA <50 copies/mL at a median of 48.4 weeks of follow-up.⁴ A separate pooled analysis of treatment-experienced children and adolescents <18 years of age on ETR-based therapy showed 69% (85 of 124 patients) with follow-up data through 12 months achieved HIV RNA <50 copies/mL, and 80% (99 of 124 patients) achieved HIV RNA <400 copies/mL.⁵

In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1090 trial,⁶ ART-experienced children aged ≥2 years to <6 years received ETR with an RTV-boosted PI as part of an optimized background regimen. Participants received ETR at a dose of 100 mg twice daily (10 kg to <20 kg) or 125 mg twice daily (20 kg to <25 kg). At Week 48, 75% had an HIV-1 RNA <400 copies/mL or a >2-log reduction in HIV-1 RNA from baseline. The mean increase in CD4 count and CD4 percentage over 48 weeks was 298.5 cells/mm³ and 5.2%, respectively. Due to the PIANO and IMPAACT P1090 study findings, if ETR is utilized to treat an ART-experienced child or adolescent, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends that ETR is part of a regimen that includes an RTV-boosted PI plus an optimized background regimen.

Pharmacokinetics

In a Phase 1 dose-finding study that involved children aged 6 to 17 years, 17 children were given ETR 4 mg/kg twice daily. The study reported that two pharmacokinetic (PK) parameters—area under the curve through 12 hours postdose (AUC_{0-12h}) and minimum plasma concentration—were lower than the corresponding parameters observed in adults during previous studies.⁷ However, a higher dose (ETR 5.2 mg/kg twice daily; maximum 200 mg per dose) yielded acceptable parameters and was chosen for evaluation in the Phase 2 PIANO study. Exposures (mean AUC_{0-12h}) remained lower

in older adolescents than in adults and younger children, and exposures were lower in Asian participants than in either White or Black participants. In the PIANO study, children and adolescents with ETR concentrations in the lowest quartile (<2,704 ng·h/mL or pre-dose concentration [C_{0h}] <145 ng/mL) were less likely to achieve sustained virologic responses (defined as plasma viral loads <50 copies/mL) after 48 weeks of treatment than those with ETR concentrations in the upper three quartiles.³

Table A. Pharmacokinetic Parameters in Children, Adolescents, and Adults Receiving Etravirine Twice Daily with an Optimized Background Regimen, Including a Ritonavir-Boosted Protease Inhibitor

| Population | Mean ETR AUC _{0-12h} (ng·h/mL) | Mean ETR C _{0h} (ng/mL) |
|---------------------------------------|--|-------------------------------------|
| Children Aged 6–11 Years (n = 41) | 5,684 | 377 |
| Adolescents Aged 12–17 Years (n = 60) | 4,895 | 325 |
| Adults (n = 575) | 5,506 | 393 |

Key: AUC_{0-12h} = area under the curve from time zero to 12 hours postdose; C_{0h} = pre-dose concentration; ETR = etravirine

Source: Kakuda TN, Brochot A, Green B, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of etravirine in HIV-1-infected, treatment-experienced children and adolescents in PIANO. *J Clin Pharmacol.* 2016;56(11):1395–1405. Available at: <https://pubmed.ncbi.nlm.nih.gov/27060341/>.

IMPAACT P1090 examined the PK and safety of ETR in treatment-experienced children with HIV aged \geq 2 years to <6 years.⁶ All participants received ETR as part of an optimized background regimen, which included an RTV-boosted PI. The tablets were swallowed whole or dispersed in liquid. ETR was initially given at a dose of 5.2 mg/kg twice daily to a cohort of six children; however, at this dose, the geometric mean ETR AUC_{0-12h} values fell below the target range of 60% of the values seen in adults. Subsequent participants were given twice-daily doses of ETR that were determined by weight band: children weighing 10 kg to <20 kg were given 100 mg twice daily, and children weighing 20 kg to <25 kg were given 125 mg twice daily.

The protocol-specified PK targets for ETR were achieved at these doses; the geometric mean AUC_{0-12h} was 3,823 ng·hr/mL, which was within the target range of 2,713 ng·hr/mL to 6,783 ng·hr/mL (60% to 150% of the AUC_{0-12h} value seen in adults). However, considerable intersubject variability was observed, with 5 (33.3%) of 15 participants having AUC_{0-12h} values that were below the 10th percentile for the adult AUC_{0-12h} range (<2,350 ng·hr/mL). The ETR AUC_{0-12h} values were significantly lower in children who received dispersed tablets than in children who swallowed intact tablets: 2,919 ng·hr/mL (n = 11) versus 10,982 ng·hr/mL (n = 3), respectively ($P = 0.0008$). The Panel recommends that children swallow tablets whole (rather than dispersed in liquid) as soon as developmentally able.

Six children with HIV who were aged 1 year to <2 years also were enrolled in IMPAACT P1090. Although the ETR exposures satisfied protocol-defined PK targets (AUC_{0-12h} between 2,713 ng·hr/mL and 6,783 ng·hr/mL), they were lower in these children compared with historical data in adults and adolescents (geometric mean ETR AUC_{0-12h} of 3,328 ng·hr/mL). Virologic failure, which was defined as a confirmed viral load of \geq 400 copies/mL or less than a 2-log reduction in

HIV-1 RNA from baseline, occurred in four of six children by Week 48. Thus, the Panel does not recommend the use of ETR in those younger than 2 years of age.

Given that both the PIANO and IMPAACT P1090 trials were conducted in children receiving RTV-boosted PIs as part of their optimized background regimens, the Panel recommends using ETR as part of a regimen that includes an RTV-boosted PI.

Toxicity

In the PIANO study, rash and diarrhea were the most common adverse drug reactions that were deemed to be possibly related to the use of ETR. Rash (Grade 2 or higher) deemed possibly related to ETR occurred in 13% of pediatric participants and emerged at a median of 10 days, lasting a median of 7 days. The occurrence of any rash was observed more frequently in female patients (17 of 64 patients; 26.6%) than in male patients (6 of 37 patients; 16.2%).³ In IMPAACT P1090, adverse drug reactions that were reported for children aged ≥ 2 years to <6 years were comparable in frequency, type, and severity to those reported for adults. Twelve participants (46.2%) developed Grade 1 or 2 rashes within the first 48 weeks of ETR, but no participant discontinued the study prematurely due to rash. Diarrhea occurred in 8 (30.8%) of 26 patients.⁶

References

1. Molto J, Curran A, Miranda C, et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. *J Antimicrob Chemother.* 2018;73(3):732-737. Available at: <https://pubmed.ncbi.nlm.nih.gov/29237008>.
2. Do VT, Higginson RT, Fulco PP. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine. *Am J Health Syst Pharm.* 2011;68(21):2049-2054. Available at: <https://pubmed.ncbi.nlm.nih.gov/22011983>.
3. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. *HIV Med.* 2014;15(9):513-524. Available at: <https://pubmed.ncbi.nlm.nih.gov/24589294>.
4. Briz V, Palladino C, Navarro M, et al. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. *HIV Med.* 2011;12(7):442-446. Available at: <https://pubmed.ncbi.nlm.nih.gov/21395964>.
5. European Pregnancy and Paediatric Infections Cohort Collaboration E, Lyons A, Thompson L, et al. Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand. *Antivir Ther.* 2022;27(3):13596535221092182. Available at: <https://pubmed.ncbi.nlm.nih.gov/36029009>.
6. MacBrayne CE, Rutstein RM, Wiznia AA, et al. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. *AIDS.* 2021;35(9):1413-1421. Available at: <https://pubmed.ncbi.nlm.nih.gov/33831904>.
7. Konigs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. *AIDS.* 2012;26(4):447-455. Available at: <https://pubmed.ncbi.nlm.nih.gov/22156961>.

Nevirapine (NVP, Viramune)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|--|---|
| <p>Oral Suspension: 10 mg/mL</p> <p>Tablets: Immediate-release 200-mg tablets; extended-release (XR) 100-mg and 400-mg tablets</p> <p>Generic Formulations</p> <ul style="list-style-type: none">• 10-mg/mL suspension• Immediate-release 200-mg tablets• XR 400-mg tablets <p>The oral suspension formulation of nevirapine (brand name Viramune) is not typically stocked in local pharmacies or hospitals. Clinicians should direct pharmacies to ask their drug wholesaler to order it from the Boehringer-Ingelheim distribution center. The distribution center should be able to ship the formulation directly to the pharmacy.</p> | |
| | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Note: Nevirapine (NVP) is often used as part of newborn antiretroviral regimens to prevent perinatal transmission of HIV. See Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection.</p> <p>Child and Adolescent Dose</p> <ul style="list-style-type: none">• In most situations, NVP is given once daily for 2 weeks to allow autoinduction of the enzymes involved in its metabolism. This may not be necessary in children aged <2 years.^a• See Special Considerations for Dosing: Neonates and Premature Infants below. <p>Immediate-Release Tablets and Oral Suspension</p> <p><i>Gestational Age of 32 to <34 Weeks</i></p> <ul style="list-style-type: none">• Birth to age 2 weeks: NVP 2 mg/kg per dose twice daily (no lead-in dosing)^a• Age 2 to 4 weeks: NVP 4 mg/kg per dose twice daily• Age 4 to 6 weeks: NVP 6 mg/kg per dose twice daily• Age >6 weeks: NVP 200 mg/m² of body surface area (BSA) per dose twice daily; only make this dose increase for infants with confirmed HIV infection.• This dosing strategy is recommended by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) based on the review of pharmacokinetic (PK) modeling and simulation data. This dosing strategy has not been evaluated in clinical trials and is not approved by the U.S. Food and Drug Administration (FDA). | <ul style="list-style-type: none">• Rash, including Stevens-Johnson syndrome• Symptomatic hepatitis, including fatal hepatic necrosis^b• Severe systemic hypersensitivity syndrome with potential for multisystem organ involvement and shock |
| Special Instructions | |
| | <ul style="list-style-type: none">• The oral suspension must be shaken well before administering, and it should be stored at room temperature.• NVP can be given with or without food.• NVP-associated skin rash usually occurs within the first 6 weeks of therapy. If rash occurs during the initial 14-day lead-in period, do not increase the dose until the rash resolves (see Major Toxicities below).• Extended-release tablets must be swallowed whole. They cannot be crushed, chewed, or divided.• If NVP dosing is interrupted for >14 days, NVP should be restarted with once-daily dosing for 14 days, followed by escalation to the full twice-daily regimen (see Dosing Considerations: Lead-In Dosing below). |

| <p><i>Gestational Age of 34 to <37 Weeks</i></p> <ul style="list-style-type: none"> • Birth to age 1 week: NVP 4 mg/kg per dose twice daily (no lead-in dosing)^a • Age 1 week to 4 weeks: NVP 6 mg/kg per dose twice daily • Age >4 weeks: NVP 200 mg/m² of BSA per dose twice daily; only make this dose increase for infants with confirmed HIV infection. • This dosing strategy is recommended by the Panel based on the review of PK and safety data on this regimen from clinical trials. This dosing strategy is not approved by the FDA. | <ul style="list-style-type: none"> • Most cases of NVP-associated hepatic toxicity occur during the first 12 weeks of therapy; frequent clinical and laboratory monitoring, including liver function tests, is important during this period (see Major Toxicities below). | | | | | | | | |
|--|--|-----------------|--|---------------------------------|--|-----------------------------------|----------------------|--------------------------------|--|
| <p><i>Gestational Age of ≥37 Weeks to Age of <1 Month</i></p> | <h3>Metabolism/Elimination</h3> | | | | | | | | |
| <ul style="list-style-type: none"> • Birth to age 4 weeks: NVP 6 mg/kg per dose twice daily (no lead-in dosing)^a • Age >4 weeks: NVP 200 mg/m² of BSA per dose twice daily; only make this dose increase for infants with confirmed HIV infection. • This dosing strategy is recommended by the Panel based on the review of PK and safety data on this regimen from clinical trials. This dosing strategy is not approved by the FDA. | <ul style="list-style-type: none"> • NVP is a substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. More than 80% of a NVP dose is eliminated in urine as uridine diphosphate glucuronosyltransferase (UGT)-derived glucuronidated metabolites. | | | | | | | | |
| <p><i>Aged ≥1 Month to <8 Years</i></p> | <p>NVP Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • NVP should not be administered to patients with moderate or severe hepatic impairment. | | | | | | | | |
| <p><i>Aged ≥8 Years</i></p> | <p>NVP Dosing in Patients with Renal Failure Who Are Receiving Hemodialysis</p> <ul style="list-style-type: none"> • An additional dose of NVP should be given following each dialysis session. | | | | | | | | |
| <p>Extended-Release Tablets</p> <p><i>Aged ≥6 Years</i></p> <ul style="list-style-type: none"> • Patients aged ≥6 years who are already taking immediate-release NVP tablets twice daily can be switched to extended-release NVP tablets without lead-in dosing.^a | | | | | | | | | |
| <p>Body Surface Area Dosing for Extended-Release NVP Tablets</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #d3d3d3;">Body Surface Area</th> <th style="background-color: #d3d3d3;">Once-Daily Dose</th> </tr> </thead> <tbody> <tr> <td>0.58 m² to 0.83 m²</td> <td>NVP 200 mg (two 100-mg tablets)</td> </tr> <tr> <td>0.84 m² to 1.16 m²</td> <td>NVP 300 mg (three 100-mg tablets)</td> </tr> <tr> <td>≥1.17 m²</td> <td>NVP 400 mg (one 400-mg tablet)</td> </tr> </tbody> </table> | Body Surface Area | Once-Daily Dose | 0.58 m ² to 0.83 m ² | NVP 200 mg (two 100-mg tablets) | 0.84 m ² to 1.16 m ² | NVP 300 mg (three 100-mg tablets) | ≥1.17 m ² | NVP 400 mg (one 400-mg tablet) | |
| Body Surface Area | Once-Daily Dose | | | | | | | | |
| 0.58 m ² to 0.83 m ² | NVP 200 mg (two 100-mg tablets) | | | | | | | | |
| 0.84 m ² to 1.16 m ² | NVP 300 mg (three 100-mg tablets) | | | | | | | | |
| ≥1.17 m ² | NVP 400 mg (one 400-mg tablet) | | | | | | | | |

| | |
|---|--|
| <p><i>Adolescent and Adult Dose</i></p> <ul style="list-style-type: none"> • NVP 200 mg twice daily or NVP 400 mg with the extended-release tablets once daily after lead-in dosing.^{a,b} <p>NVP Used in Combination with Lopinavir/Ritonavir (LPV/r)</p> <ul style="list-style-type: none"> • A higher dose of LPV/r may be needed in patients who also are receiving NVP (see the Lopinavir/Ritonavir section). | |
|---|--|

^a NVP is usually initiated at a lower dose that is increased in a stepwise fashion. NVP induces cytochrome P450 metabolizing enzymes, which results in increased drug clearance. The stepwise increase in dose decreases the occurrence of rash. Clinicians generally should initiate therapy with the immediate-release tablet formulation once daily instead of twice daily for the first 14 days of therapy. If no rashes or other adverse effects emerge after 14 days of therapy, increase the dose of NVP to the age-appropriate full dose of the immediate-release tablet formulation administered twice daily. For example, the recommended oral dose for pediatric patients aged \geq 1 month to <8 years is NVP 200 mg/m² of BSA once daily for the first 14 days, followed by NVP 200 mg/m² of BSA twice daily thereafter. However, in children aged \leq 2 years, some experts initiate NVP without lead-in dosing (see the Dosing Considerations: Lead-In Dosing and Special Considerations for Dosing: Neonates and Premature Infants sections below). In patients who are already receiving the full twice-daily dose of the immediate-release tablets, extended-release tablets can be used without the lead-in period. Patients must swallow extended-release tablets whole. They must not be chewed, crushed, or divided. **Patients must never take more than one form of NVP at the same time.** The dose should not exceed NVP 400 mg daily.

^b Severe life-threatening and, in rare cases, fatal hepatotoxicity—including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure—has occurred in patients who were taking NVP. These toxicities are less common in children than adults. Most cases occur during the first 12 weeks of therapy and may be associated with rash or other signs or symptoms of hypersensitivity reaction (HSR). NVP **should be discontinued and not restarted** in children or adults who develop symptomatic hepatitis, severe transaminase elevations, or HSRs.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Nevirapine (NVP) is metabolized by and induces hepatic CYP3A and CYP2B6; autoinduction of metabolism occurs in 2 to 4 weeks of NVP dosing, leading to a 1.5-fold to twofold increase in NVP clearance. Multiple drug interactions with NVP are possible. Some genetic polymorphisms of CYP2B6 are associated with increased NVP plasma concentrations. The prevalence of CYP2B6 polymorphisms varies among populations and may contribute to differences in NVP exposure. See the [Efavirenz](#) section for more information on how polymorphisms can alter metabolic enzyme activity.
- NVP should not be coadministered to patients who are receiving atazanavir (ATV) (with or without ritonavir) because NVP substantially decreases ATV exposure.
- NVP increases the metabolism of lopinavir (LPV). A dose adjustment of LPV is recommended when the two drugs are coadministered (see the [Lopinavir/Ritonavir](#) section).
- Before NVP is initiated, a patient's medication profile should be carefully reviewed for potential drug interactions.

Major Toxicities

The following toxicities are seen with chronic dosing, not during single-dose NVP prophylaxis.

- **More common:** Skin rash (some severe cases have required hospitalization, and some cases have been life-threatening, including instances of Stevens-Johnson syndrome and toxic epidermal necrolysis), fever, nausea, headache, and elevated hepatic transaminases. In the two largest case series of NVP-induced Stevens-Johnson syndrome in children, the incidence rate was estimated between 1.4% and 7.1%.^{1,2} NVP should be **discontinued and not restarted** in children or adults who develop severe rash, rash with constitutional symptoms (i.e., fever, oral lesions, conjunctivitis, or blistering), or rash with elevated levels of hepatic transaminases. NVP-associated skin rash usually occurs within the first 6 weeks of therapy. If rash occurs during the initial 14-day lead-in period, do not increase the dose until rash resolves. However, the risk of developing NVP resistance with extended lead-in dosing is unknown, and this concern must be weighed against the current antiviral response and a patient's overall ability to tolerate the regimen.
- **Less common (more severe):** These toxicities are less common in children than adults. Most cases occur during the first 12 weeks of therapy and may be associated with rash or other signs or symptoms of hypersensitivity reaction (HSR). Risk factors for NVP-related hepatic toxicity in adults include baseline elevation in serum transaminase levels, hepatitis B or hepatitis C virus infection, female sex, and higher CD4 T lymphocyte (CD4) cell count at time of therapy initiation (CD4 count >250 cells/mm³ in adult females and >400 cells/mm³ in adult males). Children with CD4 percentages >15% have a threefold increase in the risk of rash and hepatotoxicity after initiating NVP.³ HSRs have been reported, including, but not limited to, severe rash or rash accompanied by fever, blisters, oral lesions, conjunctivitis, facial edema, muscle or joint aches, general malaise, and significant hepatic abnormalities. NVP **should be discontinued and not restarted** in children or adults who develop symptomatic hepatitis, severe transaminase elevations, or HSRs.
- **Less common (more severe):** In a cross-sectional study of 201 children with HIV aged 6 to 16 years, 43% of whom had hypertension, the use of NVP was associated with left ventricular hypertrophy (LVH) (adjusted odds ratio 3.14; confidence interval 1.13–8.72; $P = 0.03$) but not left ventricular diastolic dysfunction.⁴ The median duration on antiretroviral therapy (ART) in this cohort was 4.7 years (interquartile range 2.6–6.4 years). Most participants (76.6%) were receiving a regimen that included two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor (NNRTI). However, the use of NVP was not associated with LVH in a more recent study by the same authors. LVH has been associated with NVP use in adults.^{5,6}

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

NVP is approved by the U.S. Food and Drug Administration (FDA) for treatment of HIV in children from infancy (aged ≥ 15 days) onward and remains a mainstay of ART, especially in resource-limited settings.⁷⁻¹⁵ The extended-release tablet formulation has been approved by the FDA for use in children aged ≥ 6 years.

Efficacy in Clinical Trials

Randomized clinical trials in children have demonstrated that lopinavir/ritonavir (LPV/r) is superior to NVP in young children but not in older children. IMPAACT P1060 demonstrated the superiority of LPV/r over NVP in children aged <3 years, as have observational studies. PENPACT-1 and PROMOTE-pediatrics showed no differences in virologic outcomes between an NNRTI-based regimen (with either NVP or efavirenz [EFV]) and a protease inhibitor (PI)-based regimen in older children with HIV.¹⁶⁻²²

In infants and children who were previously exposed to a single dose of NVP to prevent perinatal HIV transmission, NVP-based ART is less likely to control viral load than LPV/r-based ART. In IMPAACT P1060, 153 children with HIV and previous exposure to NVP for perinatal prophylaxis (mean age 0.7 years) were randomly assigned to treatment with zidovudine (ZDV) and lamivudine (3TC) plus either NVP or LPV/r. At 24 weeks post-randomization, 24% of children in the NVP arm had experienced virologic failure compared with 7% of children in the LPV/r arm ($P = 0.0009$); virologic failure was defined as $<1 \log_{10}$ decrease in HIV RNA during Weeks 12 to 24 or HIV RNA >400 copies/mL at Week 24. When all primary endpoints were considered, including virologic failure, death, and treatment discontinuation, the PI arm remained superior; 40% of children in the NVP arm met a primary endpoint, compared with 22% of children in the LPV/r arm ($P = 0.027$).¹⁹ Similar results were reported in a randomized trial that compared NVP and LPV/r in children aged 6 to 36 months who had not been previously exposed to NVP. This finding suggests that LPV/r-based therapy is superior to NVP-based therapy for infants, regardless of past NVP exposure.¹⁶

Extended-release NVP tablets (400 mg) were approved by the FDA for use in children aged ≥ 6 years in November 2012. Trial 1100.1518 was an open-label, multiple-dose, nonrandomized crossover trial performed in 85 pediatric participants with HIV. The participants had received at least 18 weeks of immediate-release NVP tablets and had plasma HIV RNA <50 copies/mL prior to enrollment. Participants were stratified according to age (3 years to <6 years, 6 years to <12 years, and 12 years to <18 years). Participants received immediate-release NVP tablets for 11 weeks. Participants were then treated with NVP extended-release tablets once daily in combination with other antiretroviral (ARV) drugs for 10 days, after which steady-state pharmacokinetics (PK) were determined.²³ Forty participants who completed the initial part of the study were enrolled in an optional extension phase of the trial, which evaluated the safety and antiviral activity of extended-release NVP tablets through a minimum of 24 weeks of treatment. Of the 40 participants who entered the treatment extension phase, 39 completed at least 24 weeks of treatment. After 24 weeks or more of treatment with extended-release tablets,²⁴ all 39 participants continued to have plasma HIV RNA <50 copies/mL.

General Dosing Considerations

Body surface area (BSA) has traditionally been used to guide NVP dosing in infants and young children. It is important to avoid underdosing NVP, because a single point mutation (K103N) in the HIV genome may confer NNRTI resistance to both NVP and EFV. Younger children (aged \leq 8 years) have higher apparent oral clearance than older children. To achieve drug exposures that are comparable to those seen in children aged $>$ 8 years, younger children require higher doses of NVP than older children.^{12,13} Because of this, it is recommended that children aged $<$ 8 years receive NVP 200 mg/m² of BSA per dose twice daily (the maximum dose of the immediate-release tablet formulation is NVP 200 mg twice daily) or NVP 400 mg/m² of BSA administered once daily as the extended-release tablet formulation (the maximum dose of the extended-release tablet formulation is NVP 400 mg once daily). For children aged \geq 8 years, the recommended dose of the immediate-release tablet formulation is NVP 120 mg/m² of BSA per dose (with a maximum dose of NVP 200 mg) administered twice daily. The maximum dose of the extended-release tablet formulation is NVP 400 mg once daily for children aged \geq 6 years.

When adjusting the dose for a growing child, the milligram dose need not be decreased (from NVP 200 mg to NVP 120 mg/m² of BSA) as the child reaches 8 years of age; rather, the milligram dose can be left static if no adverse effects emerge and the dose achieves the appropriate mg/m² of BSA dose as the child grows. Some practitioners dose NVP at 150 mg/m² of BSA every 12 hours or NVP 300 mg/m² of BSA once daily if using the extended-release tablets, regardless of age, as recommended in the FDA-approved product label. Regardless of age, the maximum dose should never exceed NVP 200 mg twice daily for immediate-release formulations of NVP or NVP 400 mg once daily for extended-release formulations of NVP.

Dosing Considerations: Lead-in Dosing

Underdosing during the lead-in period may have potentially contributed to the poorer performance of NVP in the IMPAACT P1060 trial. This potential for underdosing, which can increase the risk of resistance, has led to a re-evaluation of lead-in dosing in children who have never received NVP. Traditionally, NVP is initiated with an age-appropriate dose that is given only once daily instead of twice daily (NVP 200 mg/m² of BSA in infants aged \geq 15 days and children aged $<$ 8 years, using the immediate-release formulations) during the first 2 weeks of treatment to allow the autoinduction of the liver enzymes CYP3A and CYP2B6, which are involved in NVP metabolism.

Studies have previously indicated potential for greater drug toxicity without lead-in dosing; however, most of these studies have been performed in adult cohorts.²⁵ The CHAPAS-1 trial²⁶ randomized 211 children to initiate ART with immediate-release NVP without a lead-in dose (participants received an age-appropriate dose twice daily) or with a lead-in dose (participants received an age-appropriate dose once daily) for 2 weeks, followed by the standard twice-daily dosing of the immediate-release formulation of NVP. Children were followed for a median of 92 weeks (with a range of 68–116 weeks), and no difference emerged in the frequency of Grade 3 or 4 adverse events between the two groups. The group that initiated NVP without a lead-in dose had a statistically significant increase in the incidence of Grade 2 rash, but most participants were able to continue NVP therapy after a brief interruption. Through 96 weeks, a similar percentage of participants in both groups reached the CD4 count and virologic failure endpoints.

After children had been on NVP for 2 weeks, investigators conducted a substudy that examined NVP plasma concentrations 3 to 4 hours after a morning dose of NVP. Among children aged $<$ 2 years, 3 of

23 children (13%) who initiated at full dose had subtherapeutic NVP levels (<3 mg/L) at 2 weeks compared with 7 of 22 children (32%) who initiated at half dose ($P = 0.16$). No rash events occurred in the substudy group of participants aged <2 years; in the parent CHAPAS study, a strong age effect on rash occurrence was seen, with the risk of rash increasing with age. These findings suggest that a lead-in dose may not be necessary in young patients.²⁷

The standard practice has been to reinitiate half-dose NVP for another 2 weeks in children who have interrupted therapy for 7 days or longer; however, given the current understanding of NVP resistance, the half-life of CYP enzymes,²⁸ and the results of CHAPAS-1, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends restarting full-dose NVP in children who interrupt therapy for 14 days or less.

Special Considerations for Dosing: Neonates and Premature Infants

The PK and safety of NVP during the first weeks of life were evaluated as part of IMPAACT P1115. This study demonstrated that NVP dosed at 6 mg/kg twice daily for infants ≥ 37 weeks gestational age (GA) and 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for infants 34 to <37 weeks GA achieved concentrations appropriate for treatment.²⁹ Among 438 infants (389 infants ≥ 37 weeks GA), measured NVP concentrations were above the minimum HIV treatment target (3 mcg/mL) in 90% of infants at Week 1 and 87% of infants at Week 2. Grade 3 and 4 adverse events possibly related to treatment occurred in 7% of infants (with neutropenia and anemia being the most common) but did not lead to NVP cessation.

PK modeling and simulation were performed with partial data from IMPAACT P1106 and P1115 to determine appropriate NVP dosing in premature infants 32 to <34 weeks GA. GA and postnatal age were significantly correlated with NVP oral clearance; thus, the authors recommended a GA-based starting dose for premature infants treated with NVP and a stepwise increase in dosing at 2-week intervals.³⁰ These data might underestimate potential drug toxicity in infants of 32 to <34 weeks GA because the doses used to develop the model were lower than the doses now recommended. NVP is shown to be safe in infants >34 weeks GA, so the risk of toxicity in infants 32 to <34 weeks GA seems low. The Panel considers that this risk–benefit ratio may justify the use of this dose in premature infants 32 to <34 weeks GA.

The Early Infant Treatment Study in Botswana started 40 infants with HIV ≥ 35 weeks GA on NVP 6 mg/kg twice daily (without lead-in dosing) along with ZDV and 3TC at a median age 2 days (range 1–5 days). NVP was switched to LPV/r at Week 2, 3, 4, or 5 according to delivery GA. Although NVP trough concentrations were below the therapeutic target (3,000 ng/mL) for 50% of 2-week measurements, 37 of 40 infants (92.5%) had an HIV RNA decline.³¹ Among this cohort, 38 of 40 participants survived to 96 weeks with a preserved CD4 count and low reservoir, which was predicted by a low pre-ART reservoir size.³² Providers who consider initiating treatment in premature infants or in infants aged <2 weeks should weigh the risks and benefits of using unapproved ART dosing and should incorporate case-specific factors, such as exposure to ARV prophylaxis.

References

1. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. *Pediatr Infect Dis J.* 2013;32(12):1354-1358. Available at: <https://pubmed.ncbi.nlm.nih.gov/23743542>.
2. du Toit JD, Kotze K, van der Westhuizen HM, Gaunt TL. Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa. *South Afr J HIV Med.* 2021;22(1):1182. Available at: <https://pubmed.ncbi.nlm.nih.gov/33824730>.
3. Kea C, Puthanakit T, et al. Incidence and risk factors for nevirapine-related toxicities among HIV-infected Asian children randomized to starting ART at different CD4%. Abstract MOPE240. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; 2011. Rome, Italy,. Available at: <https://f1000research.com/posters/1089267>.
4. Majonga ED, Rehman AM, Simms V, et al. High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. *AIDS.* 2018;32(18):2739-2748. Available at: <https://pubmed.ncbi.nlm.nih.gov/30289814>.
5. Pombo M, Olalla J, Del Arco A, et al. Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. *Eur J Intern Med.* 2013;24(6):558-561. Available at: <https://pubmed.ncbi.nlm.nih.gov/23664642>.
6. Majonga ED, Rehman AM, McHugh G, et al. Incidence and progression of echocardiographic abnormalities in older children with human immunodeficiency virus and adolescents taking antiretroviral therapy: a prospective cohort study. *Clin Infect Dis.* 2020;70(7):1372-1378. Available at: <https://pubmed.ncbi.nlm.nih.gov/31054255>.
7. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. *Pediatrics.* 2007;120(5):e1134-1140. Available at: <https://pubmed.ncbi.nlm.nih.gov/17954553>.
8. King JR, Nachman S, Yoge R, et al. Efficacy, tolerability, and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. *Pediatr Infect Dis J.* 2005;24(10):880-885. Available at: <https://pubmed.ncbi.nlm.nih.gov/16220085>.
9. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. *Clin Infect Dis.* 2002;34(7):991-1001. Available at: <https://pubmed.ncbi.nlm.nih.gov/11880966>.

10. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. *N Engl J Med.* 2004;350(24):2471-2480. Available at: <https://pubmed.ncbi.nlm.nih.gov/15190139>.
11. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. *J Infect Dis.* 1996;174(4):713-721. Available at: <https://pubmed.ncbi.nlm.nih.gov/8843207>.
12. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1-infection. *N Engl J Med.* 1997;336(19):1343-1349. Available at: <https://pubmed.ncbi.nlm.nih.gov/9134874>.
13. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. *Clin Pharmacokinet.* 2000;39(4):281-293. Available at: <https://pubmed.ncbi.nlm.nih.gov/11069214>.
14. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. *AIDS.* 2003;17(11):1639-1647. Available at: <https://pubmed.ncbi.nlm.nih.gov/12853746>.
15. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. *AIDS Res Hum Retroviruses.* 2000;16(12):1113-1121. Available at: <https://pubmed.ncbi.nlm.nih.gov/10954886>.
16. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *N Engl J Med.* 2012;366(25):2380-2389. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716976>.
17. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. *Lancet Infect Dis.* 2011;11(4):273-283. Available at: <https://pubmed.ncbi.nlm.nih.gov/21288774>.
18. Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr.* 2014;65(5):535-541. Available at: <https://pubmed.ncbi.nlm.nih.gov/24326597>.
19. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *N Engl J Med.* 2010;363(16):1510-1520. Available at: <https://pubmed.ncbi.nlm.nih.gov/20942667>.

20. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2007;46(2):187-193. Available at: <https://pubmed.ncbi.nlm.nih.gov/17693883>.
21. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. *JAMA.* 2013;309(17):1803-1809. Available at: <https://pubmed.ncbi.nlm.nih.gov/23632724>.
22. Kekitiinwa A, Spyer M, et al. Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children. *Pediatr Infect Dis J.* 2017;36(6):588-594. Available at: <https://pubmed.ncbi.nlm.nih.gov/28505015/>
23. Giaquinto C, Anabwani G, Feiterna-Sperling C, et al. Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. *Pediatr Infect Dis J.* 2014;33(7):e173-179. Available at: <https://pubmed.ncbi.nlm.nih.gov/24378938>.
24. Anabwani G, Konigs C, Giaquinto C, et al. Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up. *Clin Infect Dis.* 2015;61(3):476-479. Available at: <https://pubmed.ncbi.nlm.nih.gov/25917636>.
25. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. *J Infect Dis.* 1995;171(3):537-545. Available at: <https://pubmed.ncbi.nlm.nih.gov/7533197>.
26. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. *Clin Infect Dis.* 2010;51(9):1081-1089. Available at: <https://pubmed.ncbi.nlm.nih.gov/20868279>.
27. Fillekes Q, Mulenga V, Kabamba D, et al. Is nevirapine dose escalation appropriate in young, African, HIV-infected children? *AIDS.* 2013;27(13):2111-2115. Available at: <https://pubmed.ncbi.nlm.nih.gov/23595153>.
28. Magnusson MO, Dahl ML, Cederberg J, et al. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. *Clin Pharmacol Ther.* 2008;84(1):52-62. Available at: <https://pubmed.ncbi.nlm.nih.gov/17971810>.
29. Ruel TD, Capparelli EV, Tierney C, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. *Lancet HIV.* 2020;S2352-3018(20):30274-30275. Available at: <https://pubmed.ncbi.nlm.nih.gov/33242457>.

30. Bekker A, Hanan N, Violari A, et al. Population pharmacokinetics of nevirapine in preterm infants and prediction of doses needed for treatment in combination with other antiretrovirals. . Presented at: 11th International Workshop on HIV Pediatrics; 2019. Mexico City, Mexico. Available at: <https://www.impaactnetwork.org/ias-2019>.
31. Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. *Clin Infect Dis.* 2020;ciaa02. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31927562>.
32. Ajibola G, Maswabi K, Hughes MD, et al. Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. *J Acquir Immune Defic Syndr.* 2023;92(5):393-398. Available at: <https://pubmed.ncbi.nlm.nih.gov/36729692>.

Rilpivirine (RPV, Edurant)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|---|
| <p>Tablet: 25 mg</p> <p>Fixed-Dose Combination Tablets</p> <ul style="list-style-type: none">[Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg[Juluca] Dolutegravir 50 mg/rilpivirine 25 mg[Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg <p>When using fixed-dose combination (FDC) tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents.</p> <p>Co-packaged Formulations</p> <ul style="list-style-type: none">[Cabenuva Kit] Cabotegravir 400 mg/2 mL (200 mg/mL) and rilpivirine 600 mg/2 mL (300 mg/mL) suspension for intramuscular injection[Cabenuva Kit] Cabotegravir 600 mg/3 mL (200 mg/mL) and rilpivirine 900 mg/3 mL (300 mg/mL) suspension for intramuscular injection <p>When using the co-packaged formulation, refer to the Cabotegravir section for additional information.</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Neonate and Infant Dose</p> <ul style="list-style-type: none">RPV is not approved for use in neonates or infants. <p>Children Aged <12 Years</p> <ul style="list-style-type: none">RPV is not approved for use in children aged <12 years (for more information, see the Pharmacokinetics section below). <p>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</p> <ul style="list-style-type: none">RPV 25 mg once daily with a meal in antiretroviral therapy (ART)-naïve patients who have HIV RNA ≤100,000 copies/mL or in patients who are virologically suppressed (HIV RNA <50 copies/mL) with no history of virologic failure or resistance to RPV and other antiretroviral (ARV) drugs in the new regimen. | <ul style="list-style-type: none">DepressionInsomniaHeadacheRash, which can be severe and include DRESS (drug reaction [or rash] with eosinophilia and systemic symptoms)HepatotoxicityAltered adrenocorticotropic hormone stimulation test of uncertain clinical significance |

| <p>[Complera] Emtricitabine (FTC)/Rilpivirine (RPV)/Tenofovir Disoproxil Fumarate (TDF)</p> <p><i>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</i></p> | <p>Special Instructions</p> |
|--|--|
| <ul style="list-style-type: none"> One tablet once daily with a meal in ART-naïve patients with baseline viral loads ≤100,000 copies/mL. One tablet once daily also can be used to replace the current ARV regimen in patients who are currently on their first or second regimen and who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Complera. | <ul style="list-style-type: none"> Do not start RPV in patients with HIV RNA >100,000 copies/mL because of the increased risk of virologic failure. RPV concentrations are significantly increased when either RPV or DTG/RPV is administered with a moderate- or high-fat meal.¹ Patients must be able to take RPV (or DTG/RPV) with a meal of at least 500 calories on a regular schedule (a protein drink alone does not constitute a meal). Do not use RPV with other non-nucleoside reverse transcriptase inhibitors. Do not use RPV with proton pump inhibitors (e.g., omeprazole, pantoprazole). Antacids should only be taken at least 2 hours before or at least 4 hours after RPV. H2 receptor antagonists (e.g., cimetidine, famotidine) should only be administered at least 12 hours before or at least 4 hours after RPV. Use RPV with caution when coadministering it with a drug that has a known risk of prolonging the QTc interval or causing Torsades de Pointes (for more information, see CredibleMeds). Screen patients for hepatitis B virus (HBV) infection before using FDC tablets that contain TDF or TAF. Severe acute exacerbation of HBV infection can occur when TDF or TAF are discontinued (see the Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide sections). Therefore, hepatic function and hepatitis B viral load should be monitored for several months after therapy with TDF or TAF is discontinued in patients with HBV. Refer to the Cabotegravir section for special instructions when using CAB and RPV for IM injection. |
| <p>[Juluca] Dolutegravir (DTG)/RPV</p> <p><i>Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with a meal as a complete regimen to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Juluca. Not approved for use in children or adolescents (see the Simplification of Treatment section below). | <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> Cytochrome P450 3A substrate Refer to the Cabotegravir section for information about the IM CAB and RPV regimen. |
| <p>[Odefsey] FTC/RPV/Tenofovir Alafenamide (TAF)</p> <p><i>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with a meal in ART-naïve patients with HIV RNA ≤100,000 copies/mL. One tablet once daily also can be used to replace a stable ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Odefsey. | <p>RPV Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> No dose adjustment is necessary in patients with mild or moderate hepatic impairment. |
| <p>[Cabenuva] Cabotegravir (CAB) and RPV Kit</p> <p><i>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> Cabenuva is a two-drug co-packaged product for intramuscular (IM) injection that is approved by the U.S. Food and Drug Administration as a complete regimen for the treatment of HIV-1 in patients with HIV RNA levels <50 copies/mL on a stable ARV regimen with no history of treatment failure and no known or suspected resistance to CAB or RPV. | |

| | |
|--|---|
| <ul style="list-style-type: none"> Oral lead-in dosing for at least 28 days can be used to assess tolerability prior to initiating IM CAB and RPV injections or patients can proceed directly to IM CAB and RPV on the last day of their current ARV regimen. Refer to the Cabotegravir section for dosing information. Long-acting CAB and RPV for IM injection are not approved for children aged <12 years. | <p>RPV Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> RPV decreases tubular secretion of creatinine and slightly increases measured serum creatinine, but it does not affect glomerular filtration. No dose adjustment is necessary in patients with mild or moderate renal impairment. However, RPV should be used with caution in patients with severe renal impairment or end-stage renal disease. These patients should be monitored more frequently for adverse events; renal dysfunction may alter drug absorption, distribution, and metabolism, leading to increased RPV concentrations. The FDC tablet Complera should not be used in patients with creatinine clearance (CrCl) <50 mL/min, and the FDC tablet Odefsey should not be used in patients with CrCl <30 mL/min. Patients with CrCl <30 mL/min who are taking Juluca should be monitored closely. When using Complera, see the Tenofovir Disoproxil Fumarate section of the guidelines; when using Odefsey, see the Tenofovir Alafenamide section. |
|--|---|

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Metabolism:** Rilpivirine (RPV) is a cytochrome P450 (CYP) 3A substrate, and concentrations may be affected when administered with CYP3A-modulating medications.
- A patient's medication profile should be carefully reviewed for potential drug interactions before RPV is administered.
- Coadministering RPV with drugs that increase gastric pH may decrease plasma concentrations of RPV.
 - Antacids should only be taken at least 2 hours before or at least 4 hours after RPV.
 - H2 receptor antagonists should only be administered at least 12 hours before or at least 4 hours after RPV.
 - Do not use** RPV with proton pump inhibitors.
- All the rifamycins significantly reduce RPV plasma concentrations; coadministration of rifampin and oral RPV is **contraindicated**. For patients who are concomitantly receiving rifabutin and oral RPV, the dose of RPV should be doubled to 50 mg once daily and taken with a meal. Intramuscular (IM) RPV given with IM CAB is **contraindicated** with rifampin, rifabutin, and rifapentine.
- In a cohort of adolescent patients, RPV exposure was two to three times greater when RPV was administered in combination with darunavir/ritonavir (DRV/r) than when RPV was administered alone.²

Major Toxicities

- *More common:* Insomnia, headache, rash
- *Less common (more severe):* Depression or mood changes, suicidal ideation

In studies of adults, 7.3% of patients who were treated with RPV showed a change in adrenal function characterized by an abnormal 250-microgram (mcg) adrenocorticotropic hormone (ACTH) stimulation test (peak cortisol level <18.1 mcg/dL). In a study of adolescents, 6 out of 30 patients (20%) developed this abnormality.³ The clinical significance of these results is unknown.

- *Rare:* RPV drug-induced liver injury has been reported.⁴

Resistance

The International Antiviral Society—USA maintains a list of updated [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Transmitted drug resistance to second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be present in infants and children who have recently received a diagnosis of HIV.

Pediatric Use

Approval

With the viral load and antiretroviral (ARV) resistance restrictions noted above, RPV (Edurant) used in combination with other ARV agents, the fixed-dose combination (FDC) tablet emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF; Complera), the FDC tablet emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF; Odefsey), and the long-acting regimen of cabotegravir (CAB) and RPV for IM injection (IM CAB and RPV; Cabenuva) are all approved by the U.S. Food and Drug Administration (FDA) for use in people aged ≥12 years and weighing ≥35 kg. The FDC tablet dolutegravir/rilpivirine (DTG/RPV; Juluca) **is not approved** for use in pediatric or adolescent patients at the time of this review.

Efficacy in Clinical Trials

An RPV-containing regimen has been compared to an efavirenz (EFV)-containing regimen in two large clinical trials in adults—ECHO and THRIVE. In both studies, RPV was shown to be non-inferior to EFK. Patients with pretreatment HIV viral loads ≥100,000 copies/mL who received RPV had higher rates of virologic failure than those who received EFK. These findings resulted in FDA approval for initial therapy with RPV only in patients with HIV viral loads ≤100,000 copies/mL.⁵⁻⁸

A study of antiretroviral therapy (ART)—naïve adolescents aged 12 to 17 years demonstrated that RPV 25 mg, given once daily in combination with two nucleoside reverse transcriptase inhibitors (NRTIs), was well tolerated over 48 weeks. In adolescents with baseline viral loads ≤100,000 copies/mL, 86% had a virologic response at 24 weeks and 79% had a virologic response at 48 weeks. In adolescents with baseline viral loads >100,000 copies/mL, 38% had a virologic response at 24 weeks and 50% had a virologic response at 48 weeks.⁹

Patients must be able to take RPV on a regular schedule and with a full meal, which may limit its usefulness for some adolescents with irregular schedules. The FDC formulation Odefsey is a small pill and can be useful for certain patients who have difficulty swallowing pills or want to switch from a multi-pill regimen and who do not have any drug-resistance mutations associated with components of Odefsey.

A Spanish multicenter observational study enrolled 17 adolescents (aged <18 years) who acquired HIV perinatally to receive FTC/RPV/TDF (Complera) as part of an off-label medication use program. At the time of enrollment, 12 patients were on a protease inhibitor-based regimen, 4 were on an NNRTI-based regimen, and 1 had not received ART. After a median follow-up of 90 weeks (for participants with undetectable viral loads at baseline) or 40 weeks (for participants with detectable viral loads at baseline), 86% and 89% of patients, respectively, maintained and achieved an undetectable viral load. None of the patients discontinued RPV-based therapy because of adverse events (AEs); no skin rashes or central nervous system (CNS)-related events were observed. In addition, serum lipids improved, and two adolescents with a history of insomnia and abnormal dreams while receiving EFV-based therapy did not report similar problems while receiving RPV-based therapy.¹⁰

Another study evaluated 102 virologically suppressed Thai adolescents who were switched from an EFV-based therapy to an RPV-based therapy. Ninety-four of the adolescents remained virologically suppressed through 48 weeks; six experienced virologic failure. Overall, RPV was well tolerated. No improvement in EFV-related symptoms (e.g., sleep, mood, dizziness, headache, concentration) was observed, and no change in quality of life or depression scores could be documented; however, there were significant improvements in some assessments of cognitive and executive function as measured at Week 24.¹¹

Pharmacokinetics

The pharmacokinetics (PK), safety, and efficacy of RPV in children aged <12 years have not been established but are currently being studied in patients aged 6 years to <12 years and weighing ≥17 kg ([ClinicalTrials.gov identifier NCT00799864](#)). The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has agreed that the use of RPV may be appropriate in certain children aged <12 years and weighing ≥35 kg. However, the Panel advises consulting an expert in pediatric HIV infection prior to prescribing RPV for a child in this age and weight group.

An international (India, Thailand, Uganda, and South Africa) Phase 2 trial, Pediatric Study in Adolescents Investigating a New NNRTI TMC278 (PAINT), investigated a 25-mg dose of RPV given in combination with two NRTIs in ARV-naïve adolescents aged 12 years to <18 years who weighed ≥32 kg and who had viral loads ≤100,000 copies/mL.⁹ In the dose-finding phase of the study, 11 adolescents aged >12 years to ≤15 years and 12 adolescents aged >15 years to ≤18 years underwent intensive PK assessment after they took an observed dose of RPV with a meal. PK were comparable to those in adults; results are listed in the table below.¹²

Table A. Rilpivirine Pharmacokinetics in Adults and Adolescents Aged 12 Years to <18 Years

| Parameter | Adults | Adolescents Aged 12 Years to <18 Years |
|------------------------------------|----------------------|---|
| Dose | RPV 25 mg once daily | RPV 25 mg once daily |
| Number of Participants Studied | 679 | 34 |
| AUC_{24h} (ng·h/mL) | | |
| Mean ± SD | 2,235 ± 851 | 2,424 ± 1,024 |
| Median (Range) | 2,096 (198–7,307) | 2,269 (417–5,166) |
| C_{0h} (ng/mL) | | |
| Mean ± SD | 79 ± 35 | 85 ± 40 |
| Median (Range) | 73 (2–288) | 79 (7–202) |

Source: Adapted from Rilpivirine [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202022s014lbl.pdf.

Key: AUC_{24h} = area under the curve after 24 hours; C_{0h} = plasma concentration just prior to next dose; RPV = rilpivirine; SD = standard deviation

In a PK study of adolescents and young adults aged 13 to 23 years who received RPV,² RPV exposure was comparable to the exposure observed during the PAINT study in patients who received 25-mg doses of RPV without DRV/r and substantially higher than the exposure observed in those who received 25-mg doses of RPV with DRV/r (RPV area under the curve in this study was 6,740 ng·h/mL). No dose adjustments are currently recommended for adults when RPV is coadministered with DRV/r, where a similar twofold to threefold increase in RPV exposure has been reported.³

RPV has been reported to have fewer CNS AEs than EFV, and it has been promoted as a replacement ARV drug for some patients who experience CNS effects while receiving EFV. However, concern exists that the prolonged half-life of EFV might result in residual drug levels that could have an impact on RPV levels. A study evaluated 20 Thai adolescents 4 weeks after they switched from EFV to RPV. The PK parameters of RPV in this study population were comparable to those in previous pediatric (PAINT) and adult (ECHO/THRIVE) PK substudies. No virologic failure was detected at 12 or 24 weeks, and no patients discontinued RPV because of AEs.¹³

Simplification of Treatment

Juluca is an FDC tablet that contains DTG 50 mg and RPV 25 mg. The results from two trials in adults (SWORD-1 and SWORD-2) supported FDA approval of DTG/RPV as a complete regimen for treatment simplification or maintenance therapy in certain patients. The two identical SWORD trials enrolled 1,024 patients with suppressed viral replication who had been on stable ART for at least 6 months and had no history of treatment failure or evidence of resistance mutations that are associated with DTG or RPV. The participants were randomized to receive DTG/RPV (“early switch”) or to continue their suppressive ARV regimen. After 48 weeks of treatment, 95% of patients in both arms maintained HIV RNA <50 copies/mL.¹⁴ After 52 weeks, the participants who had been

randomized to continue their suppressive ARV regimen were switched to DTG/RPV (“late switch”). At 148 weeks of treatment, 84% of the early switch patients and 90% of the late switch patients remained virologically suppressed, and only 11 patients receiving dual therapy (DTG/RPV) met virologic failure criteria. No integrase inhibitor resistance was identified.¹⁵ More AEs were reported and more AEs led to treatment discontinuation in the DTG/RPV arm during the comparative randomized phase. In a subgroup of SWORD study patients whose original ARV regimen contained TDF, small but statistically significant increases in hip and spine bone mineral density were observed.¹⁶ Although DTG/RPV as Juluca is not approved for use in adolescents, the doses of both component drugs that make up Juluca are approved for use in adolescents. This product may be appropriate for certain adolescents; however, because the strategy of treatment simplification has not been evaluated in adolescents, who may have difficulties adhering to therapy, the Panel **does not recommend** using Juluca in adolescents and children until more data are available.

Long-Acting Injectable Rilpivirine

A long-acting IM injectable formulation of RPV has recently been approved for coadministration with IM CAB as a complete ARV regimen for children and adolescents aged ≥ 12 years and weighing ≥ 35 kg and adults with HIV RNA levels < 50 copies/mL, on a stable ARV regimen, with no history of treatment failure, and no known or suspected resistance to CAB or RPV.¹⁷ This formulation has been evaluated in adults as monthly or every-other-month IM injections following an initial oral lead-in daily dose for 4 weeks to assess toxicity.¹⁸⁻²⁰ These studies in adult patients demonstrated non-inferior efficacy to standard oral therapy and good participant satisfaction and tolerability through 96 weeks. A follow-on study demonstrated that dosing IM CAB and RPV every 2 months in virally suppressed participants provided similar safety and efficacy to monthly injections through 48 weeks.²¹ Additionally, an extension of one study evaluated the benefit of oral lead-in therapy prior to initiating IM CAB and RPV, demonstrating that initial oral therapy can be optional based on the needs and desires of people initiating treatment.²² [IMPAACT study 2017](#), More Options for Children and Adolescents (MOCHA), is currently evaluating the safety, tolerability, acceptability, and PK profile of IM CAB and RPV in adolescents weighing ≥ 35 kg and has reported acceptable PKs and safety for the single IM products administered monthly and good acceptability by both adolescents and their parents.^{23,24} However, MOCHA has not completed evaluation of the dual injectable regimen long-term, and clinical experience with IM CAB and RPV remains limited. See the [Cabotegravir](#) section for more information about this regimen.

Toxicity

In the PAINT study, the observed AEs were similar to those reported in adults (e.g., somnolence, nausea, vomiting, abdominal pain, dizziness, headache). The incidence of depressive disorders was 19.4% (7 of 36 participants) compared to 9% in the Phase 3 trials in adults. The incidence of Grade 3 and 4 depressive disorders was 5.6% (2 of 36 participants).³

Six out of 30 adolescents (20%) with a normal ACTH stimulation test at baseline developed an abnormal test during the trial. No serious AEs, deaths, or treatment discontinuations were attributed to adrenal insufficiency. The clinical significance of abnormal ACTH stimulation tests is not known, but this finding warrants further evaluation.³

Crushing Tablets for Enteral Administration

Some cases report DTG/RPV tablets' being crushed and successfully administered via an enteral tube.²⁵ If DTG/RPV is administered via enteral tube, care should be taken to disperse the tablets completely and flush the tube to avoid clogging.

References

1. Mehta R, Piscitelli J, Wolstenholme A, et al. The effect of moderate- and high-fat meals on the bioavailability of dolutegravir/rilpivirine fixed-dose combination tablet. *Clin Pharmacol.* 2020;12:49-52. Available at: <https://pubmed.ncbi.nlm.nih.gov/32607002>.
2. Foca M, Yoge R, Wiznia A, et al. Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults. *Pediatr Infect Dis J.* 2016;35(9):e271-274. Available at: <https://pubmed.ncbi.nlm.nih.gov/27187753>.
3. Rilpivirine (Edurant) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/202022s016lbl.pdf.
4. Lee MJ, Berry P, D'Errico F, et al. A case of rilpivirine drug-induced liver injury. *Sex Transm Infect.* 2020;96(8):618-619. Available at: <https://pubmed.ncbi.nlm.nih.gov/31974214>.
5. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. *Lancet.* 2011;378(9787):229-237. Available at: <https://pubmed.ncbi.nlm.nih.gov/21763935>.
6. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. *J Acquir Immune Defic Syndr.* 2012;60(1):33-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/22343174>.
7. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. *AIDS.* 2013;27(6):939-950. Available at: <https://pubmed.ncbi.nlm.nih.gov/23211772>.
8. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. *Lancet.* 2011;378(9787):238-246. Available at: <https://pubmed.ncbi.nlm.nih.gov/21763936>.
9. Lombaard J, Bunupuradah T, Flynn PM, et al. Rilpivirine as a treatment for HIV-infected antiretroviral-naive adolescents: week 48 safety, efficacy, virology and pharmacokinetics. *Pediatr Infect Dis J.* 2016;35(11):1215-1221. Available at: <https://pubmed.ncbi.nlm.nih.gov/27294305>.
10. Falcon-Neyra L, Palladino C, Navarro Gomez ML, et al. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: a multicenter study. *Medicine (Baltimore).* 2016;95(24):e3842. Available at: <https://pubmed.ncbi.nlm.nih.gov/27310962>.
11. Phongsamart W, Jantarabenjakul W, Chantaratin S, et al. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. *J Int AIDS Soc.* 2022;25(1):e25862. Available at: <https://pubmed.ncbi.nlm.nih.gov/35001501>.

12. Crauwels H, Hoogstoel A, Vanveggel S, et al. Rilpivirine pharmacokinetics in HIV-1-infected adolescents: a substudy of PAINT (Phase II trial). Presented at: Conference on Retroviruses and Opportunistic Infections. 2014. Boston, MA. Available at: <https://www.croiconference.org/sessions/rilpivirine-pharmacokinetics-hiv-1-infected-adolescents-substudy-paint-phase-ii-trial>.
13. Jantarabenjakul W, Anugulruengkitt S, Kasipong N, et al. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. *Antivir Ther.* 2018;23(3):259-265. Available at: <https://pubmed.ncbi.nlm.nih.gov/28994660>.
14. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet.* 2018;391(10123):839-849. Available at: <https://pubmed.ncbi.nlm.nih.gov/29310899>.
15. van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and -2 randomized clinical trials. *J Acquir Immune Defic Syndr.* 2020;85(3):325-330. Available at: <https://pubmed.ncbi.nlm.nih.gov/32675772>.
16. McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. *AIDS.* 2018;32(4):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239893>.
17. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf.
18. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. *Lancet.* 2017;390(10101):1499-1510. Available at: <https://pubmed.ncbi.nlm.nih.gov/28750935>.
19. Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. *Lancet HIV.* 2021;8(4):e185-e196. Available at: <https://pubmed.ncbi.nlm.nih.gov/33794181>.
20. Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. *AIDS.* 2022;36(2):185-194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34261093>.
21. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet.* 2021;396(10267):1994-2005. Available at: <https://pubmed.ncbi.nlm.nih.gov/33308425>.

22. Orkin C, Bernal Morell E, Tan DHS, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. *Lancet HIV*. 2021;8(11):e668-e678. Available at: <https://pubmed.ncbi.nlm.nih.gov/34656207>.
23. Lowenthal E, Chapman J, Calabrese K, et al. Adolescent and parent experiences with long-acting injectables in the MOCHA study. Presented at: Conference on Retroviruses and Opportunistic Infections. 2022. Virtual. Available at: https://www.natap.org/2022/CROI/croi_154.htm.
24. Moore CB, Capparelli E, Calabrese K, et al. Safety and PK of long-acting cabotegravir and rilpivirine in adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections. 2022. Virtual. Available at: <https://www.croiconference.org/abstract/safety-and-pk-of-long-acting-cabotegravir-and-rilpivirine-in-adolescents>.
25. Turley SL, Fulco PP. Enteral administration of twice-daily dolutegravir and rilpivirine as a part of a triple-therapy regimen in a critically ill patient with HIV. *J Int Assoc Provid AIDS Care*. 2017;16(2):117-119. Available at: <https://pubmed.ncbi.nlm.nih.gov/28198203>.

Appendix A: Pediatric Antiretroviral Drug Information

Protease Inhibitors

Atazanavir (ATV, Reyataz)

Darunavir (DRV, Prezista)

Lopinavir/Ritonavir (LPV/r, Kaletra)

Atazanavir (ATV, Reyataz)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | | | | | |
|--|--|-----------------|------------------------------|--|---|
| Powder Packet: 50 mg/packet | | | | | |
| Capsules: 150 mg, 200 mg, 300 mg | | | | | |
| Generic Formulations | | | | | |
| <ul style="list-style-type: none">150-mg, 200-mg, and 300-mg capsules | | | | | |
| Fixed-Dose Combination Tablets | | | | | |
| <ul style="list-style-type: none">[Evotaz] Atazanavir 300 mg/cobicistat 150 mg | | | | | |
| Capsules and powder packets are not interchangeable. | | | | | |
| For additional information, see Drugs@FDA: FDA-Approved Drugs or DailyMed . | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | |
| <p>Neonate Dose</p> <ul style="list-style-type: none">Atazanavir (ATV) is not approved for use in neonates and infants aged <3 months. ATV should not be administered to neonates because of risks associated with hyperbilirubinemia (e.g., bilirubin-induced neurologic dysfunction). <p>Infant and Child Dose</p> <p><i>Powder Formulation of ATV^a</i></p> <ul style="list-style-type: none">The powder formulation of ATV must be administered with ritonavir (RTV).The powder formulation is not approved for use in infants aged <3 months or weighing <5 kg. <p>ATV Powder Dosing Table for Infants and Children Aged ≥3 Months and Weighing ≥15 kg^a</p> <table border="1"><thead><tr><th>Weight</th><th>Once-Daily Dose</th></tr></thead><tbody><tr><td>15 kg to <25 kg^b</td><td>ATV 250 mg (five packets) plus RTV 100 mg (powder or tablet) with food</td></tr></tbody></table> <p><i>Capsule Formulation of ATV^a</i></p> <ul style="list-style-type: none">ATV capsules are not approved for use in children aged <6 years or weighing <15 kg. | Weight | Once-Daily Dose | 15 kg to <25 kg ^b | ATV 250 mg (five packets) plus RTV 100 mg (powder or tablet) with food | <ul style="list-style-type: none">Indirect hyperbilirubinemiaProlonged electrocardiogram PR interval, first-degree symptomatic atrioventricular block in some patientsNephrolithiasisIncreased serum transaminasesHyperlipidemia (occurs primarily with RTV boosting) |
| Weight | Once-Daily Dose | | | | |
| 15 kg to <25 kg ^b | ATV 250 mg (five packets) plus RTV 100 mg (powder or tablet) with food | | | | |
| Special Instructions | | | | | |
| <ul style="list-style-type: none">Administer ATV with food to enhance absorption.Capsules and powder packets are not interchangeable.Do not open capsules.Because ATV can prolong the PR interval of the electrocardiogram, use ATV with caution in patients with preexisting cardiac conduction system disease or with other drugs that are known to prolong the PR interval (e.g., calcium channel blockers, beta-blockers, digoxin, verapamil).ATV absorption is dependent on low gastric pH; therefore, when ATV is administered with medications that increase gastric pH, dosing adjustments may be indicated (see the Drug Interactions section in the ATV package insert). | | | | | |

Atazanavir/Ritonavir (ATV/r) Capsule Dosing Table for Children and Adolescents Aged ≥ 6 Years and Weighing ≥ 15 kg

| Weight | Once-Daily Dose |
|-----------------|--|
| <15 kg | Capsules not recommended |
| 15 kg to <35 kg | ATV/r 200 mg/100 mg, both with food ^c |
| ≥ 35 kg | ATV/r 300 mg/100 mg, both with food ^c |

ART-Naive Patients Who Are Unable to Tolerate RTV

Child and Adolescent (Aged ≥ 13 Years and Weighing ≥ 40 kg) and Adult Dose

- ATV 400 mg (capsule formulation only) once daily with food
- ATV powder is not an option because it must be administered with RTV.
- For the capsule formulation, the U.S. Food and Drug Administration (FDA) and the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) do not recommend the use of unboosted ATV in children aged <13 years.
- Although the FDA does allow for unboosted ATV in adolescents aged ≥ 13 years and weighing ≥ 40 kg if they are not concurrently taking tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), the Panel does not recommend the use of unboosted ATV in this population. Unboosted ATV is not recommended because adolescents may require doses of ATV that are higher than those recommended for use in adults to achieve target drug concentrations (see Pediatric Use below).

ART-Naive and ART-Experienced Patients

Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose

- ATV/r 300 mg/100 mg once daily with food^d
- Atazanavir/cobicistat (ATV/c) 300 mg/150 mg once daily with food, administered as single agents simultaneously or as the coformulated drug Evotaze
- Both ATV/r and ATV/c must be used in combination with other antiretroviral drugs.

[Evotaze] ATV/c

Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose

- One tablet once daily with food

- The plasma concentration and, therefore, the therapeutic effect of ATV can be expected to decrease substantially when ATV is coadministered with proton-pump inhibitors (PPIs). Antiretroviral therapy (ART)-naive patients who are receiving any PPI should receive a dose of that PPI that is equivalent to no more than a 20-mg dose of omeprazole. PPIs should be taken approximately 12 hours before taking boosted ATV. Coadministration of ATV with PPIs is not recommended in ART-experienced patients.

- Patients with hepatitis B or C virus infections and patients who have marked elevations in transaminase levels before treatment may have an increased risk of further elevations in transaminase levels or hepatic decompensation.

Powder Administration

- ATV oral powder contains phenylalanine, which can be harmful to patients with phenylketonuria. Each packet of oral powder contains 35 mg of phenylalanine.
- Mix ATV oral powder with at least 1 tablespoon of soft food (e.g., applesauce, yogurt). Oral powder mixed with a beverage (at least 30 mL of milk or water) may be used for older infants who can drink from a cup. For young infants (aged <6 months) who cannot eat solid food or drink from a cup, oral powder should be mixed with at least 10 mL of infant formula and administered using an oral dosing syringe.
- Administer RTV immediately following powder administration.
- Administer the entire dose of oral powder within 1 hour of preparation.

Metabolism/Elimination

- ATV is a substrate and inhibitor of cytochrome P450 (CYP) 3A4 and an inhibitor of CYP1A2, CYP2C9, and uridine diphosphate glucuronosyl transferase 1A1.

ATV Dosing in Patients with Hepatic Impairment

- ATV should be used with caution in patients with mild or moderate hepatic impairment. Consult the manufacturer's prescribing information for the dose adjustment in patients with moderate impairment.
- ATV should not be used in patients with severe hepatic impairment.

ATV Dosing in Patients with Renal Impairment

- No dose adjustment is required for patients with renal impairment.

| | |
|--|---|
| | <ul style="list-style-type: none"> • ATV should not be given to ART-experienced patients with end-stage renal disease who are on hemodialysis. |
|--|---|

^a mg/kg dosing is higher for the ATV powder packets than for the capsules. In P1020A, children of similar age and size who were taking ATV powder had lower exposures than those who were taking ATV capsules.

^b Children weighing ≥ 25 kg who cannot swallow ATV capsules may receive ATV 300-mg oral powder (six packets) plus RTV 100-mg oral solution, both administered once daily with food.

^c Either RTV capsules or RTV oral solution can be used.

^d Adult patients who cannot swallow capsules may take ATV oral powder once daily with food using the adult dose for the capsules. ATV oral powder should be administered with RTV.

^e See the [Cobicistat](#) section for important information about toxicity, drug interactions, and monitoring of patients who receive cobicistat (COBI) and the combination of COBI and TDF.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Atazanavir (ATV) is both a substrate and an inhibitor of the cytochrome P450 (CYP) 3A4 enzyme system and has significant interactions with drugs that are highly dependent on CYP3A4 for metabolism. ATV also competitively inhibits CYP1A2 and CYP2C9. ATV is a weak inhibitor of CYP2C8. ATV inhibits the glucuronidation enzyme uridine diphosphate glucuronosyl transferase (UGT1A1). Because of the potential for multiple drug interactions with ATV, a patient's medication profile should be carefully reviewed for potential drug interactions before administering ATV.
- **Nucleoside reverse transcriptase inhibitors (NRTIs):** Tenofovir disoproxil fumarate (TDF) decreases ATV plasma concentrations, and the effect of tenofovir alafenamide (TAF) on unboosted ATV is unknown. Thus, only atazanavir/ritonavir (ATV/r) or atazanavir/cobicistat (ATV/c) should be used in combination with TDF or TAF.
- **Non-nucleoside reverse transcriptase inhibitors:** Efavirenz (EFV), etravirine (ETR), and nevirapine (NVP) decrease ATV plasma concentrations significantly. NVP and ETR **should not be administered** to patients who are receiving ATV (with or without a booster). Although the combination of Efv and ATV/r is not commonly used in clinical practice, Efv may be used in combination with ritonavir (RTV)-boosted ATV 400 mg in antiretroviral therapy (ART)-naive patients. ATV/r should be taken with food, and Efv should be taken on an empty stomach, preferably at bedtime. Coadministering ATV/r and Efv in ART-experienced patients **is not recommended** because this combination is expected to result in suboptimal ATV exposure in these patients.
- **Integrase strand transfer inhibitors:** ATV is an inhibitor of UGT1A1 and may increase plasma concentrations of raltegravir (RAL). This interaction may not be clinically significant.
- **Absorption:** ATV absorption is dependent on low gastric pH. The dose for ATV should be adjusted when it is administered with medications that **increase** gastric pH. Guidelines for the appropriate doses of ATV to use with antacids, H2 receptor antagonists, and proton-pump inhibitors in adults are complex and can be found in the [package insert for ATV](#). No information is available on the appropriate doses of ATV to use in children when the drug is coadministered with medications that **increase** gastric pH.

- Coadministering cobicistat (COBI)—a CYP3A4 inhibitor—and medications that are metabolized by CYP3A4 may increase the plasma concentrations of these medications. This may increase the risk of clinically significant adverse reactions (including life-threatening or fatal reactions) that are associated with the concomitant medications. Coadministration of COBI, ATV, and CYP3A4 inducers may lead to lower exposures of COBI and ATV, a loss of efficacy of ATV, and possible development of resistance.¹ Coadministering COBI and ATV with some antiretroviral (ARV) agents (e.g., with ETR, with EFV in ART-experienced patients, or with another ARV drug that requires pharmacokinetic [PK] enhancement, such as another protease inhibitor [PI] or elvitegravir) may result in decreased plasma concentrations of that agent, leading to loss of therapeutic effect and the development of resistance.

Major Toxicities

- *More common:* Indirect hyperbilirubinemia that can result in jaundice or icterus but is not a marker of hepatic toxicity. Headache, fever, arthralgia, depression, insomnia, dizziness, nausea, vomiting, diarrhea, and paresthesia.
- *Less common:* Prolongation of the electrocardiogram PR interval. Abnormalities in atrioventricular (AV) conduction are generally limited to first-degree AV block, but second-degree AV block has been reported. Rash is generally mild or moderate, but in rare cases includes life-threatening Stevens-Johnson syndrome. Fat maldistribution and lipid abnormalities may be less common than with other PIs. The use of ATV/r is associated with lipid abnormalities, but to a lesser extent than with other boosted PIs.
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs, and elevation in serum transaminases. Chronic kidney disease, including biopsy-proven cases of granulomatous interstitial nephritis that were associated with the deposition of ATV drug crystals in the renal parenchyma have occurred. Nephrolithiasis and cholelithiasis have been reported. Hepatotoxicity (patients with hepatitis B virus or hepatitis C virus infections are at increased risk of hepatotoxicity).

Resistance

The International Antiviral Society–USA maintains a [list of updated resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

ATV is approved by the U.S. Food and Drug Administration (FDA) for use in infants (aged ≥ 3 months and weighing ≥ 5 kg), children, and adolescents. Because RTV oral solution is no longer commercially available, use of ATV/r is limited to children weighing ≥ 15 kg who can use the RTV 100 mg powder packet or 100 mg tablet. ATV coformulated with COBI (as Evotaz) has been approved by the FDA for use in pediatric patients weighing ≥ 35 kg.

Efficacy

Studies in ART-naïve adults have shown that ATV/r is as effective as EFV and lopinavir/ritonavir (LPV/r) when these drugs are administered with two NRTIs.²⁻⁵ In AIDS Clinical Trials Group (ACTG) A5257, ATV/r was compared to darunavir/ritonavir (DRV/r) or RAL, each administered with a TDF/emtricitabine backbone. Although all three regimens had equal virologic efficacy, the regimen that contained ATV/r was discontinued more frequently than the other regimens because of toxicity but most often because of hyperbilirubinemia or gastrointestinal complaints.⁶

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)/Pediatric AIDS Clinical Trials Group (PACTG) P1020 enrolled 195 ART-naïve and ART-experienced patients with HIV aged 3 months to 21 years. Capsule and powder formulations of ATV given with and without RTV boosting were investigated in this open-label study; area under the curve (AUC) targeting was used to direct dose finding. Of the 195 patients enrolled, 142 patients received ATV-based treatment at the final recommended dose. Among these patients, 58% were ART-naïve. At Week 48, 69.5% of the ART-naïve patients and 43.3% of the ART-experienced patients had HIV viral loads ≤ 400 copies/mL.^{7,8} (Kiser, Fletcher et al. 2008, Kiser, Rutstein et al. 2011)

Two open-label clinical trials in infants and children, PRINCE-1 and PRINCE-2, studied a powder formulation of ATV that was administered once daily and boosted with liquid RTV.⁹⁻¹¹ In total, 134 infants and children aged ≥ 3 months and weighing between 5 and 35 kg were evaluated. Using a modified intent-to-treat analysis, 28 of 52 ARV-naïve patients (54%) and 41 of 82 ART-experienced patients (50%) had HIV RNA < 50 copies/mL at Week 48. The median increase from baseline in absolute CD4 T lymphocyte cell count at 48 weeks of therapy was 215 cells/mm³ (a 6% increase) in ARV-naïve patients and 133 cells/mm³ (a 4% increase) in ARV-experienced patients.

Pharmacokinetics and Dosing

Oral Capsule

The results of the IMPAACT/PACTG 1020A trial in children and adolescents indicate that, in the absence of RTV boosting, ATV can achieve protocol-defined PK targets—but only when used at higher doses (on a mg per kg body weight or mg per m² of body surface area basis) than the doses that are currently recommended in adults. In IMPAACT/PACTG 1020A, children aged > 6 years to < 13 years required a dose of 520 mg per m² of body surface area per day of the ATV capsule formulation to achieve PK targets.⁸ Unboosted ATV at this dose was well tolerated in those aged < 13 years who were able to swallow capsules.¹² The approved dose for adults is ATV 400 mg once daily without RTV boosting; however, adolescents aged > 13 years required a dose of ATV 620 mg per m² of body surface area per day.⁸ In this study, the AUCs for the unboosted arms were similar to those seen in the ATV/r arms, but the maximum plasma concentration (C_{max}) was higher and the minimum plasma concentration (C_{min}) was lower in the unboosted arms. Median doses of ATV, both with and without RTV boosting, from IMPAACT/PACTG 1020A are outlined in [Table A](#) below. When administering unboosted ATV to pediatric patients, therapeutic drug monitoring is recommended to ensure that adequate ATV plasma concentrations have been achieved. A minimum target trough concentration for ATV is 150 ng/mL.¹³ Higher target trough concentrations may be required in PI-experienced patients. IMPAACT P1058, a study of unboosted ATV PK in ART-experienced children, concluded that once-daily ATV 400 mg provided suboptimal exposure and that

administering higher, unboosted doses or splitting the daily dose into twice-daily doses warranted investigation in ART-experienced children, adolescents, and young adults.¹⁴

Table A. Summary of Atazanavir Dosing Information Obtained from IMPAACT/PACTG 1020A

| Age Range | ATV Given with RTV | ATV Median Dose (mg/m ²) ^a | ATV Median Dose (mg) |
|------------|--------------------|---|----------------------|
| 6–13 years | No | 509 | 475 |
| 6–13 years | Yes | 206 | 200 |
| >13 years | No | 620 | 900 |
| >13 years | Yes | 195 | 350 |

^a These doses satisfied protocol-defined area under the curve/pharmacokinetic parameters and met all acceptable safety targets. These doses differ from those recommended by the manufacturer. Therapeutic drug monitoring was used to determine patient-specific dosing in this trial.

Source: Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS*. 2011;25(12):1489–96.

Key: ATV = atazanavir; RTV = ritonavir

In the report of the IMPAACT/PACTG P1020A data, ATV satisfied PK criteria at a dose of 205 mg per m² of body surface area in pediatric subjects when administered with RTV.¹² A study of a model-based approach that used ATV concentration-time data from three adult studies and one pediatric study (P1020A),¹⁵ along with subsequent additional adjusted modeling,¹⁶ informed the use of the following weight-based ATV/r doses that are listed in the current FDA-approved product label for children aged ≥6 to <18 years:

- Weighing 15 to <35 kg: ATV/r 200 mg/100 mg
- Weighing ≥35 kg: ATV/r 300 mg/100 mg

Cobicistat as a Pharmacokinetic Enhancer

COBI (as Tybost) is approved by the FDA at the 150-mg dose for use with ATV 300 mg in children and adolescents weighing ≥35 kg. A study of 14 adolescents, aged 12 to 18 years, showed that COBI is a safe and effective PK enhancer when used in combination with ATV and two NRTIs in adolescent patients.¹⁷ PK findings from this study are summarized in [Table B](#) below.

Table B. Pharmacokinetic Parameters for Atazanavir Administered with Cobicistat (as Tybost) in Pediatric Patients Aged 12 to 18 Years and Adults

| PK Parameters ^a | ATV | | COBI | |
|---|--------------------------------|----------------------------|--------------------------------|----------------------------|
| | Pediatric Patients (n = 12) | Adult Patients (n = 30) | Pediatric Patients (n = 12) | Adult Patients (n = 30) |
| AUC _{tau} $\mu\text{g}\cdot\text{h}/\text{mL}$ Geometric mean (CV%) | 49.48 (49.1) | 39.96 (52.1) | 12.11 (44.7) | 9.65 (41.8) |
| C _{max} $\mu\text{g}/\text{mL}$ Geometric mean (CV%) | 4.32 (49.9) | 3.54 (45.8) | 1.28 (31.7) | 1.28 (35.6) |
| C _{tau} $\mu\text{g}/\text{mL}$ Geometric mean (CV%) | 0.91 (96.4) | 0.58 (84.7) | 0.09 (156.2) | 0.04 (112.7) |

^a The information in this table comes from the Tybost package insert.¹⁰

Key: ATV = atazanavir; AUC_{tau} = area under the concentration-time curve over the dosing interval; C_{max} = maximum serum concentration; C_{tau} = trough serum concentration at the end of the dosing interval; COBI = cobicistat; CV = coefficient of variation; PK = pharmacokinetic

Oral Powder

The unboosted ATV powder arms in IMPAACT/PACTG P1020A were closed, because participants were unable to achieve target exposures. For the IMPAACT/PACTG P1020A trial, AUC targets (30,000 ng•hr/mL to 90,000 ng•hr/mL) were established based on exposures in adults in early studies of unboosted ATV. In IMPAACT/PACTG P1020A, children aged 3 months to 2 years who were in the boosted ATV powder cohorts and who received a daily dose of ATV 310 mg per m² of body surface area achieved average ATV exposures that approached, but did not meet, protocol targets. Variability in exposures was high, especially among the very young children of 3 months to 2 years in this study.⁸

Assessment of the PK, safety, tolerability, and virologic response of ATV oral powder for FDA approval was based on data from two open-label, multicenter clinical trials:

- PRINCE-1, which enrolled pediatric patients aged 3 months to <6 years⁹
- PRINCE-2, which enrolled pediatric patients aged 3 months to <11 years¹⁰

In total, 134 treated patients (weighing 5 to <35 kg) from both studies were evaluated during the FDA approval process. All patients in the PRINCE trials were treated with boosted ATV and two NRTIs. Children received an oral solution that contained ATV and RTV. Doses were assigned according to the child's weight:

- Weighing 5 to <10 kg: ATV 150 mg or ATV 200 mg and RTV 80 mg
- Weighing 10 to <15 kg: ATV 200 mg and RTV 80 mg
- Weighing 15 to <25 kg: ATV 250 mg and RTV 80 mg
- Weighing 25 to <35 kg: ATV 300 mg and RTV 100 mg

No new safety concerns were identified during these trials. [Table C](#) lists the PK parameters that were measured during the PRINCE trials, including mean AUC, for the weight ranges that correspond to the recommended doses.

Table C. Pharmacokinetic Parameters for Atazanavir Powder in Children (PRINCE-1 and PRINCE-2) versus Capsules in Young Adults and Adults

| PK Parameters | PRINCE Trial ^a ATV/r | | | | | Young Adult Study ^b | Adult Study |
|---|---|---|--|--|--|-------------------------------------|--------------------------|
| | Dose: 150 mg/ 80 mg Weighing: 5 kg to <10 kg | Dose: 200 mg/ 80 mg Weighing: 5 kg to <10 kg | Dose: 200 mg/ 80 mg Weighing: 10 kg to <15 kg | Dose: 250 mg/ 80 mg Weighing: 15 kg to <25 kg | Dose: 300 mg/ 100 mg Weighing: ≥25 kg to <35 kg | | |
| AUC ng·h/mL Mean ^c (CV% or 95% CI) | 32,503 (61) n = 20 | 39,519 (54) n = 10 | 50,305 (67) n = 18 | 55,687 (45) n = 31 | 44,329 (63) n = 8 | 35,971 (30,853–41,898) n = 22 | 46,073 (66) n = 10 |
| C _{24h} ng/mL Mean ^c (CV% or 95% CI) | 336 (76) n = 20 | 550 (60) n = 10 | 572 (111) n = 18 | 686 (68) n = 31 | 468 (104) n = 8 | 578 (474–704) n = 22 | 636 (97) n = 10 |

^a This information comes from the Reyataz package insert.¹⁰

^b The young adults also were receiving tenofovir disoproxil fumarate.⁷

^c Means are geometric means.

Note: RTV oral solution is no longer available. Use of ATV/r is now limited to children weighing ≥15 mg who can receive 100 mg RTV using powder or tablets.

Key: ATV/r = atazanavir/ritonavir; AUC = area under the curve; CI = confidence interval; CV = coefficient of variation; PK = pharmacokinetic

In these PK studies, although the PK targets were met in all patients using ATV powder except those who received ATV/r 150 mg/80 mg in the 5 to <10 kg weight band, the coefficients of variation were large, especially among the youngest patients.

Transitioning from Powder to Capsules

For children who reach a weight ≥25 kg while taking the powder, ATV 300 mg-powder (six packets) plus RTV 100-mg oral solution, both administered once daily with food, may be used. ATV capsules should be used for children who can swallow pills. Bioavailability is higher for the capsules than for the powder; therefore, a lower mg/kg dose is recommended when using capsules. Opened capsules have not been studied and should not be used.

Toxicity

In the IMPAACT/PACTG 1020A trial, 9% of patients enrolled had a total bilirubin ≥5.1 times the upper limit of normal,¹² whereas 9% of patients enrolled in the PRINCE studies had a total bilirubin ≥2.6 times the upper limit of normal.^{9,11} The most common laboratory abnormality during the

PRINCE trials was elevated amylase levels, which occurred in 33% of patients.¹⁰ Three children (2%) had treatment-related cardiac disorders during the PRINCE trials; one child discontinued therapy because of QT corrected for heart rate (QTc) prolongation, and two experienced first-degree AV block.^{9,11} In IMPAACT/PACTG P1020A, three children (3%) had QTc prolongations >470 msec; two of these children came off the study, and all were asymptomatic.

References

1. Cobicistat (Tybost) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203094s016lbl.pdf.
2. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. *J Acquir Immune Defic Syndr.* 2004;36(5):1011-1019. Available at: <https://pubmed.ncbi.nlm.nih.gov/15247553>.
3. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. *J Acquir Immune Defic Syndr.* 2008;47(2):161-167. Available at: <https://pubmed.ncbi.nlm.nih.gov/17971713>.
4. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet.* 2008;372(9639):646-655. Available at: <https://pubmed.ncbi.nlm.nih.gov/18722869>.
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr.* 2010;53(3):323-332. Available at: <https://pubmed.ncbi.nlm.nih.gov/20032785>.
6. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med.* 2014;161(7):461-471. Available at: <https://pubmed.ncbi.nlm.nih.gov/25285539>.
7. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother.* 2008;52(2):631-637. Available at: <https://pubmed.ncbi.nlm.nih.gov/18025112>.
8. Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS.* 2011;25(12):1489-1496. Available at: <https://pubmed.ncbi.nlm.nih.gov/21610486>.
9. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged ≥ 3 months to <6 years. *J Int AIDS Soc.* 2015;18:19467. Available at: <https://pubmed.ncbi.nlm.nih.gov/26066346>.
10. Reyataz (Atazanavir) [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021567s048,206352s010lbl.pdf

11. Cotton MF, Liberty A, Torres-Escobar I, et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to <11 years of age: the PRINCE-2 study. *Pediatr Infect Dis J.* 2018;37(6):e149-e156. Available at: <https://pubmed.ncbi.nlm.nih.gov/29206747>.
12. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children, and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. *Pediatr Infect Dis J.* 2015;34(2):162-167. Available at: <https://pubmed.ncbi.nlm.nih.gov/25232777>.
13. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range. Abstract 60. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005. Quebec City, Canada. Available at: https://www.researchgate.net/profile/Maria_Grazia_Milia2/publication/267256045_Atazanavir_Ctrough_is_associated_with_efficacy_and_safety_definition_of_therapeutic_range/links/560106c808ae07629e52b5e1/Atazanavir-Ctrough-is-associated-with-efficacy-and-safety-definition-of-therapeutic-range.pdf?origin=publication_detail.
14. Cressey TR, Hazra R, Wiznia A, et al. Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults. *Pediatr Infect Dis J.* 2016;35(12):1333-1335. Available at: <https://pubmed.ncbi.nlm.nih.gov/27583590>.
15. Hong Y, Kowalski KG, Zhang J, et al. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. *Antimicrob Agents Chemother.* 2011;55(12):5746-5752. Available at: <https://pubmed.ncbi.nlm.nih.gov/21930880>.
16. Sevinsky H, Cirincione B, Raybon J. Challenges in developing a population PK model describing the PK of atazanavir and supporting dose selection in HIV infected pediatric subjects. Presented at: The Seventh American Conference on Pharmacometrics 2016. Bellevue, WA.
17. McFarland EJ, Heresi GP, Batra J, et al. Pharmacokinetics, safety, and efficacy of ATV or DRV with COBI in adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017. Seattle, WA. Available at: <https://www.croiconference.org/abstract/pharmacokinetics-safety-and-efficacy-atv-or-drv-cobi-adolescents>.

Darunavir (DRV, Prezista)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|--|
| <p>Oral Suspension: 100 mg/mL</p> <p>Tablets: 75 mg, 150 mg, 600 mg, 800 mg</p> <p>Fixed-Dose Combination (FDC) Tablets</p> <ul style="list-style-type: none">• [Prezcobix] Darunavir 800 mg/cobicistat 150 mg• [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg <p>When using FDC tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents.</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Note: Darunavir (DRV) should not be used without a pharmacokinetic enhancer (boosting agent). Ritonavir (RTV) may be used as the boosting agent in children and adults. Cobicistat (COBI) may be used as a boosting agent with DRV in children weighing ≥ 40 kg and in adults.</p> <p>Neonate/Infant Dose</p> <ul style="list-style-type: none">• DRV is not approved for use in neonates/infants. <p>Child Dose</p> <p>Aged <3 Years</p> <ul style="list-style-type: none">• Do not use DRV in children aged <3 years or weighing ≤ 10 kg. In juvenile rats, DRV caused convulsions and death; these events have been attributed to immaturity of the blood-brain barrier and liver metabolic pathways. <p>Aged ≥ 3 to <12 Years</p> <ul style="list-style-type: none">• Dosing recommendations in the table below are for children aged ≥ 3 to <12 years and weighing ≥ 20 kg who are antiretroviral therapy-naïve or treatment-experienced and with or without resistance testing results that demonstrate that they have at least one mutation that is associated with DRV resistance. | <ul style="list-style-type: none">• Skin rash, including Stevens-Johnson syndrome and erythema multiforme• Hepatotoxicity• Diarrhea, nausea• Headache• Hyperlipidemia, transaminase elevation, hyperglycemia• Fat maldistribution |
| Special Instructions | |
| <ul style="list-style-type: none">• Once-daily DRV is not generally recommended for use in children aged <12 years or weighing <40 kg. Dosing estimates for these patients were based on limited data, and limited clinical experience exists with this dosing schedule in this age group.• Once-daily DRV should not be used if any one of the following resistance-associated mutations is present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, or L89V.• DRV must be administered with food, which increases DRV plasma concentrations by about 30%.• DRV contains a sulfonamide moiety. Use DRV with caution in patients with known sulfonamide allergies. | |

| Twice-Daily DRV and RTV Doses for Children Aged 3 to <12 Years and Weighing \geq 20 kg | | <ul style="list-style-type: none"> Pediatric dosing requires coadministration of tablets of different strengths to achieve the recommended dose for each weight band. It is important to provide careful instructions to caregivers when recommending a combination of different-strength tablets. Store DRV tablets and oral suspension at room temperature (25° C or 77° F). The suspension must be shaken well before dosing. Screen patients for hepatitis B virus (HBV) infection before using FDC tablets that contain FTC or TAF. Severe acute exacerbation of HBV infection can occur when FTC or TAF are discontinued; therefore, liver function should be monitored for several months after patients with HBV infection stop taking FTC or TAF. |
|--|--|---|
| Weight | Dose (Twice Daily with Food) ^a | |
| 20 kg to <30 kg^b | DRV 375 mg (combination of tablets or 3.8 mL) ^d plus RTV 100 mg (tablet or powder)^c | |
| 30 kg to <40 kg^b | DRV 450 mg (combination of tablets or 4.6 mL) ^d plus RTV 100 mg (tablet or powder) | |
| \geq40 kg^b | DRV 600 mg (tablet or 6 mL) plus RTV 100 mg (tablet or powder) | |
| Child and Adolescent (Aged \geq12 Years and Weighing \geq30 to <40 kg) Dose for Treatment-Naive or Treatment-Experienced Patients with or without at Least One Mutation Associated with DRV Resistance | <ul style="list-style-type: none"> DRV 450 mg (using a combination of tablets) plus RTV 100 mg, both twice daily with food | <h3>Metabolism/Elimination</h3> <ul style="list-style-type: none"> Cytochrome P450 3A4 substrate and inhibitor |
| Child and Adolescent (Aged \geq12 years and Weighing \geq40 kg)^d and Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated with DRV Resistance | <ul style="list-style-type: none"> DRV 800 mg (using a tablet or combination of tablets) plus RTV 100 mg, both once daily with food | <h4>DRV Dosing in Patients with Hepatic Impairment</h4> <ul style="list-style-type: none"> DRV is primarily metabolized by the liver. Caution should be used when administering DRV to patients with hepatic impairment. DRV is not recommended in patients with severe hepatic impairment. |
| Child and Adolescent (Weighing \geq40 kg) and Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated with DRV Resistance | <ul style="list-style-type: none"> DRV 800 mg (tablet) plus COBI^e 150 mg (tablet) or the coformulation Prezcobix, once daily with food | <h4>DRV Dosing in Patients with Renal Impairment</h4> <ul style="list-style-type: none"> No DRV dose adjustment is required in patients with moderate renal impairment (creatinine clearance [CrCl] 30–60 mL/min). The FDC Syntuza is not recommended for use in patients with an estimated CrCl <30 mL/min. |
| Child and Adolescent (Weighing \geq40 kg) and Adult Dose for Treatment-Experienced Patients with at Least One Mutation Associated with DRV Resistance | <ul style="list-style-type: none"> DRV 600 mg plus RTV 100 mg, both twice daily with food The use of COBI is not recommended with DRV 600 mg twice daily. | |
| [Prezcobix] DRV/COBI | | |
| Child and Adolescent (Weighing \geq40 kg) and Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated with DRV Resistance | <ul style="list-style-type: none"> One tablet once daily with food | |
| [Syntuza] DRV/COBI/Emtricitabine (FTC)/ Tenofovir Alafenamide (TAF) | | |

| | |
|---|--|
| <i>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</i> <ul style="list-style-type: none"> • One tablet once daily with food in ARV-naive patients or in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no known mutations associated with resistance to DRV or tenofovir. | |
|---|--|

^a Once-daily dosing of DRV is approved by the U.S. Food and Drug Administration (FDA), but the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) does not generally recommend using this dosing schedule in children (see Frequency of Administration below).

^b RTV oral solution is no longer available. Use of DRV boosted with ritonavir (DRV/r) is now limited to children weighing ≥ 20 kg who can receive 100 mg RTV using powder or tablets.

^c The volumes for the 375-mg and 450-mg DRV doses are rounded for dosing convenience of suspension.

^d Some Panel members recommend using the FDA-approved dose of once-daily DRV 675 mg (administered using a combination of tablets) plus RTV 100 mg once daily for adolescents weighing ≥ 30 to <40 kg (see [Table B](#) below).

^e See [Cobicistat](#) for important information about toxicity, drug interactions, and monitoring in patients who receive COBI.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Darunavir (DRV) is primarily metabolized by cytochrome P450 (CYP) 3A4. Both ritonavir (RTV) and cobicistat (COBI) are inhibitors of CYP3A4, thereby increasing the plasma concentration of DRV. Coadministration of DRV plus RTV (DRV/r) or DRV plus COBI (DRV/c) with drugs that are highly dependent on CYP3A clearance creates potential for multiple drug–drug interactions and may be associated with suboptimal efficacy or serious and/or life-threatening events.
- Coadministration of several drugs, including other protease inhibitors and rifampin, is **contraindicated** with DRV/r and DRV/c. A study involving adults with HIV suggested that etravirine (ETR) may reduce serum DRV concentrations by induction of CYP3A5, which is more commonly expressed in individuals of African descent.¹ Before administering DRV with a pharmacokinetic (PK) enhancer (boosting agent), a patient’s medication profile should be carefully reviewed for potential drug interactions.
 - When twice-daily DRV/r was used in combination with tenofovir disoproxil fumarate (TDF) in 13 patients aged 13 to 16 years with HIV, both TDF and DRV exposures were lower than those found in adults treated with the same combination.² No dose adjustment is recommended when using DRV/r with TDF, but caution is advised and therapeutic drug monitoring (TDM) may be useful.³ Data from the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) protocol P1058A indicate that coadministering once-daily DRV/r with once-daily or twice-daily ETR in children, adolescents, and young adults aged 9 to <24 years did not have a significant effect on DRV plasma concentrations.⁴ When DRV/r was coadministered with ETR twice daily in pediatric patients, target concentrations for both DRV and ETR were achieved.⁵ DRV PKs were not affected when DRV was coadministered with rilpivirine (RPV) in a study of adolescents and young adults.⁶ DRV/r coadministration increased RPV exposure twofold to threefold; close monitoring for RPV-related adverse events is advisable.

Major Toxicities

- *More common:* Diarrhea, nausea, vomiting, abdominal pain, headache, and fatigue.
- *Less common:* Skin rash, including erythema multiforme and Stevens-Johnson syndrome ; fever and elevated levels of hepatic transaminases; lipid abnormalities; and crystalluria.
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in people with hemophilia, and hepatic dysfunction, particularly in patients with underlying risk factors, such as hepatitis B or hepatitis C virus coinfection.

Resistance

The International Antiviral Society–USA maintains a list of updated [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

DRV/r is approved by the U.S. Food and Drug Administration (FDA) as a component of antiretroviral (ARV) therapy in treatment-naive and treatment-experienced children aged ≥ 3 years. . Because RTV oral solution is no longer commercially available, use of DRV/r is limited to children weighing ≥ 20 kg who can use the RTV 100 mg powder packet or 100 mg tablet.

DRV is approved by the FDA to be administered with COBI (Tybost) boosting in pediatric patients weighing ≥ 40 kg. The fixed-dose combinations (FDCs) DRV/c (Prezcobix) and DRV/c/emtricitabine/tenofovir alafenamide (Symtuza) are also approved by the FDA for use in pediatric patients weighing ≥ 40 kg.

Efficacy in Clinical Trials

In an international, multisite clinical trial (TMC114-TiDP29-C228) that enrolled treatment-experienced children aged 3 to <6 years, 17 (81%) of 21 children who received DRV/r twice daily had viral loads <50 copies/mL at Week 48.⁷⁻⁹

A randomized, open-label, multicenter pediatric trial⁹ that evaluated twice-daily DRV/r among 80 treatment-experienced children aged 6 to <18 years reported that 66% of patients had plasma HIV RNA <400 copies/mL and 51% had HIV RNA <50 copies/mL at Week 24.

Once-daily DRV/r has been investigated in a small study involving 12 treatment-experienced children aged 6 to 12 years who had maintained HIV viral loads <50 copies/mL for at least 6 months.¹⁰ All but one child continued to have undetectable viral loads during a median of 11.6 months of follow-up (range 0.5–14.2 months). The remaining child had detectable viral load measurements between 20 copies/mL and 200 copies/mL on three occasions during a 3-month period before, again, becoming undetectable without a change in regimen.

In one study, 12 participants aged 12 to 17 years received DRV/r once daily.¹¹ After 48 weeks, all but one participant had viral loads <50 copies/mL.

Pharmacokinetics and Dosing

Pharmacokinetics in Children Aged 3 to <6 Years

Twenty-one children aged 3 to <6 years and weighing 10 to <20 kg received twice-daily DRV/r oral suspension. These children had experienced virologic failure on their previous ARV regimens and had fewer than three DRV resistance mutations, confirmed by genotypic testing.^{7,8,12} The DRV area under the curve from 0-12 hours (AUC_{0-12h}), measured as a percent of the adult AUC value,^{7,8,13} was 126% overall, 143% in children weighing 10 to <15 kg, and 121% in children weighing 15 to <20 kg.

Pharmacokinetics in Children Aged ≥ 6 Years

Initial pediatric PK evaluation of DRV tablets and RTV oral solution or tablets was based on a Phase 2 randomized, open-label, multicenter study that enrolled 80 treatment-experienced children and adolescents aged 6 to <18 years and weighing ≥ 20 kg.¹⁴ Part 1 of the trial used a weight-adjusted dose of DRV (9–15 mg/kg) and RTV (1.5–2.5 mg/kg) twice daily, approximating the standard adult dose of DRV/r 600 mg/100 mg twice daily on a per-weight basis. This dose resulted in inadequate drug exposure in the pediatric population studied, with a 24-hour AUC (AUC_{0-24h}) that was 81% of the AUC_{0-24h} observed in adults and a predose concentration (C_{0h}) that was 91% of the C_{0h} observed in adults. A pediatric dose that was 20% to 33% higher than the directly scaled adult dose was needed to achieve a drug exposure that was similar to that found in adults, and this was the dose selected for Part 2 of the study. The higher dose used for the safety and efficacy evaluation was DRV 11 to 19 mg/kg and RTV 1.5 to 2.5 mg/kg twice daily. This dose resulted in a DRV AUC_{0-24h} of 123.3 mcg•h/mL (range 71.9–201.5 mcg•h/mL) and a C_{0h} of 3,693 ng/mL (range 1,842–7,191 ng/mL), representing 102% and 114% of the respective values in adults. Doses were given twice daily and were stratified into body-weight bands of 20 to <30 kg and 30 to <40 kg. The current weight-band doses of twice-daily DRV/r for treatment-experienced pediatric patients weighing >20 to <40 kg were selected using the findings from the safety and efficacy portion of this study (see [Table A](#) below).

A small study that involved 12 treatment-experienced children aged 6 to 12 years examined the PK and efficacy of DRV/r once daily administered in combination with abacavir and lamivudine.¹⁰ All participants had maintained HIV plasma viral loads <50 copies/mL for at least 6 months prior to beginning this regimen. The weight-based doses used for once-daily DRV/r were based on a prior modeling study¹⁵: 600 mg/100 mg for patients weighing 15 to 30 kg, 675 mg/100 mg for patients weighing 30 to 40 kg, and 800 mg/100 mg for patients weighing >40 kg. The geometric mean AUC_{0-24h} was below the study target of 80% of the value seen in adults (63.1 mg•h/L vs. 71.8 mg•h/L), but the trough values that were observed at 23.1 hours to 25.1 hours after the previous dose exceeded the trough plasma concentration recommended for treatment-experienced adults (0.55 mg/L).¹⁶ One child developed neuropsychiatric symptoms (anxiety and hallucinations) and was removed from study. This child did not have an excessive exposure to DRV; the AUC_{0-24h} was 47.8 mg•h/L.

Table A. Darunavir Pharmacokinetics with Twice-Daily Administration with Ritonavir and Optimized Background Therapy in Children, Adolescents, and Adults

| Population | n | Dose of DRV/r | AUC _{12h} (mcg·h/mL) Median ^a | C _{0h} (ng/mL) Median ^a |
|---|-------------|---|---|--|
| Children Weighing 10 kg to <15 kg ^a | 13 | 20 mg/kg/3 mg/kg | 66.0 | 3,533 |
| Children Weighing 10 kg to <15 kg ^a | 4 | 25 mg/kg/3 mg/kg | 116.0 | 8,522 |
| Children Weighing 15 kg to <20 kg ^a | 11 | 20 mg/kg/3 mg/kg | 54.2 | 3,387 |
| Children Weighing 15 kg to <20 kg ^a | 14 | 25 mg/kg/3 mg/kg | 68.6 | 4,365 |
| Children Aged 6 to <12 Years ^b | 24 | Determined by weight bands ^b | 56.4 | 3,354 |
| Adolescents Aged 12 to <18 Years ^b | 50 | Determined by weight bands ^b | 66.4 | 4,059 |
| Adults Aged >18 Years ^c (Three Studies) | 285/278/119 | 600 mg/100 mg | 54.7–61.7 | 3,197–3,539 |

^a Source: U.S. Food and Drug Administration. FDA clinical pharmacologic review of darunavir. 2011. Available at: <https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM287674.pdf>.

^b DRV/r was administered at doses of 375 mg/50 mg twice daily for patients weighing 20 to <30 kg, 450 mg/60 mg twice daily for patients weighing 30 to <40 kg, and 600 mg/100 mg twice daily for patients weighing ≥40 kg. Data from the 2008 FDA pharmacokinetics review. Available at:

<https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm129567.pdf>.

^c Source: Darunavir [package insert]. Food and Drug Administration. 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021976s043,202895s017lbl.pdf.

Note: RTV oral solution is no longer available. Use of DRV/r is now limited to children weighing ≥20 kg who can receive 100 mg RTV using powder or tablets.

Key: AUC_{12h} = 12-hour area under the curve; C_{0h} = predose concentration; DRV/r = darunavir/ritonavir

Dosing

Pharmacokinetic Enhancers

DRV should not be used without a PK enhancer (boosting agent). RTV may be used as a boosting agent in children and adults. COBI may be used as a boosting agent in children weighing ≥40 kg and adults.

A study that enrolled 19 Thai children used the RTV 100-mg capsule twice daily as the boosting dose for twice-daily DRV 375 mg (in children weighing 20 to <30 kg), 450 mg (in children weighing 30–40 kg), and 600 mg (in children weighing ≥40 kg).¹⁷ The DRV exposures with RTV 100 mg twice daily were similar to those obtained in the studies with lower (<100 mg) doses of liquid RTV.^{14,17} The tolerability and PK data from this small study support the use of RTV 100 mg for boosting using either the powder or tablet formulation in children weighing ≥20 kg. No data are available on the safety and tolerability of using DRV with the RTV 100-mg tablet or powder formulation in children weighing <20 kg.

Data on the dosing of DRV/c are available primarily for adult patients.¹⁸ Data on once-daily use of the FDC tablet DRV/c 800 mg/150 mg (Prezcobix) showed bioavailability that was comparable to the bioavailability observed with the use of DRV/r 800 mg/100 mg once daily.¹⁶

In an open-label switch study, eight adolescent patients with a median age of 14 years (range 12–17 years) who received DRV/c had DRV exposures (area under the curve for the dosing interval [AUC_{tau}]) that were similar to those observed in adults, except for a lower trough concentration at the end of the dosing interval (C_{tau}). The median DRV C_{tau} (494 ng/mL) was above the protein binding-adjusted half-maximal inhibitory concentration for wild-type virus (55 ng/mL). Adolescent patients in this study received the adult dose of COBI 150 mg daily. DRV dosing was based on weight, with patients who weighed ≥ 40 kg receiving DRV 800 mg once daily and patients who weighed 30 to <40 kg receiving DRV 675 mg once daily. In this small sample, 95.5% of patients had HIV RNA <50 copies/mL at Week 12. COBI appeared to be well tolerated with no discontinuations due to adverse events.¹⁹

Frequency of Administration

In February 2013, the FDA approved the use of once-daily DRV for treatment-naïve children and for treatment-experienced children without DRV resistance-associated mutations (see [Table B](#) below). Population PK modeling and simulation were used to develop recommendations for once-daily dosing in younger pediatric subjects aged 3 to <12 years and weighing 10 to <40 kg.^{8,20} Currently, limited data exist on the efficacy of once-daily DRV/r dosing in treatment-naïve or treatment-experienced children aged <6 years. Therefore, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) generally recommends dosing DRV/r twice daily in children aged ≥ 3 to <12 years (see Once-Daily Administration in Children Aged <12 Years and Weighing <40 kg below). The Panel recommends that once-daily DRV/r be used only in treatment-naïve and treatment-experienced adolescents weighing ≥ 40 kg who do not have mutations that are associated with DRV resistance. If DRV and RTV are used once daily in children aged <12 years, the Panel recommends conducting a PK evaluation of plasma concentrations of DRV and closely monitoring viral load.

Table B. U.S. Food and Drug Administration–Approved Once-Daily Dosing for Pediatric Patients Aged ≥ 3 Years and Weighing >10 kg Who Are Treatment Naive or Treatment Experienced with No Darunavir Resistance–Associated Mutations

Note: The Panel generally recommends dosing DRV plus RTV twice daily in children aged ≥ 3 to <12 years.

| Weight | Dose (Once Daily with Food) |
|-------------------|---|
| 15 kg to <30 kg | DRV 600 mg (tablet, combination of tablets, or 6 mL) plus RTV 100 mg (tablet or powder) ^a |
| 30 kg to <40 kg | DRV 675 mg (combination of tablets or 6.8 mL) ^{b,c} plus RTV 100 mg (tablet or powder) ^a |
| ≥ 40 kg | DRV 800 mg (tablet, combination of tablets, or 8 mL) ^c plus RTV 100 mg (tablet or powder) ^a |

^a RTV oral solution is no longer available. Use of DRV/r is now limited to children weighing ≥ 20 kg who can receive 100 mg RTV using powder or tablets.

^b DRV 100 mg/mL oral suspension; the 675-mg once daily DRV dose is rounded for dosing convenience of suspension.

^c The 6.8-mL and 8-mL DRV doses can be taken as two administrations (3.4 mL and 4 mL, respectively) once daily by refilling the oral dosing syringe supplied by the manufacturer or as one administration once daily if a larger syringe is provided by a pharmacy or provider.

Key: DRV = darunavir; DRV/r = darunavir/ritonavir; RTV = ritonavir

Once-Daily Administration in Children Aged <12 Years and Weighing <40 kg

During the TMC114-C228 trial, the researchers investigated once-daily dosing of DRV for 2 weeks; DRV PK were evaluated in treatment-experienced children aged 3 to <12 years as part of a substudy. After the conclusion of the substudy, the participants switched back to a twice-daily regimen.^{16,20} The DRV/r dose for once-daily use, which was based on PK simulation and did not include a relative bioavailability factor, was DRV 40 mg/kg coadministered with approximately 7 mg/kg of RTV for children weighing <15 kg and DRV/r 600 mg/100 mg once daily for children weighing ≥ 15 kg.^{20,21} The PK data obtained from 10 children aged 3 to 6 years in this substudy (see Table C below) were included as part of the population PK modeling and simulation that was used to determine the FDA-approved dose for once-daily DRV/r in children aged 3 to <12 years.

In a small study in which DRV/r was administered once daily to 12 treatment-experienced children aged 6 to 12 years,¹⁰ the geometric mean AUC_{0-24h} achieved was below the study target of 80% of the value seen in adults (63.1 mg•h/L vs. 71.8 mg•h/L). Trough values exceeded the plasma concentration that is recommended for treatment-experienced patients (0.55 mg/L). Despite the FDA dosing guidelines, the Panel generally recommends dosing DRV/r twice daily in children aged ≥ 3 to <12 years. The Panel makes this recommendation because of the small data set used for once-daily DRV/r PK modeling and the limited amount of data on the use of once-daily DRV/r in children aged <12 years.

Table C. Pharmacokinetics of Once-Daily Darunavir in Children Aged 3 to 6 Years After 2 Weeks of Therapy with Ritonavir and Optimized Background Therapy

| PK Parameter | Children Aged 3 to 6 Years (n = 10) ^a | Adults (n = 335) |
|---|---|---------------------|
| DRV AUC _{0-24h} geometric mean, ng·h/mL (SD) | 115 (40.6) | 89.7 (27.0) |
| DRV C _{0h} geometric mean, ng/mL (SD) | 3,029 (1,715) | 2,027 (1,168) |

^aSource: Kakuda TN, Brochot A, van de Casteele T, et al. Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients. Presented at: 14th Clinical Pharmacology Workshop on HIV; 2013. Amsterdam, Netherlands. Available at: https://www.natap.org/2013/Pharm/Pharm_19.htm.

Key: AUC_{0-24h} = 24-hour area under the curve; C_{0h} = predose concentration; DRV = darunavir; PK = pharmacokinetic; SD = standard deviation

Once-Daily Administration in Adolescents Aged ≥12 Years and Weighing ≥40 kg

A substudy of once-daily dosing of DRV/r 800 mg/100 mg demonstrated that DRV exposures in 12 treatment-naïve adolescents (aged 12–17 years and weighing ≥40 kg) were similar to those seen in adults treated with once-daily DRV (see **Table D** below).¹¹ After 48 weeks, 83.3% of patients had viral loads <50 copies/mL and 91.7% had viral loads <400 copies/mL.¹¹ Interestingly, no relationship was observed between DRV AUC_{0-24h} and C_{0h} and virologic outcome (HIV RNA <50 copies/mL) in this study. DRV exposures were found to be similar to those observed in adults with once-daily dosing in another study in which a single dose of DRV/r 800 mg/100 mg was administered to 24 subjects with a median age of 19.5 years (range 14–23 years).²² However, DRV exposures were slightly below the lower target concentrations in adolescent patients aged 14 to 17 years (n = 7) within the cohort, suggesting that higher doses may be needed in younger adolescents. A single case report involving a highly treatment-experienced adolescent patient suggests that using an increased DRV dose with standard RTV boosting and employing TDM can lead to virologic suppression.

Table D. Darunavir Pharmacokinetics with Once-Daily Administration in Adolescents Aged ≥12 Years and Adults Aged >18 Years

| Population | n | Dose of DRV/r | AUC _{0-24h} ^a (mcg·h/L) Median | C _{0h} (ng/mL) Median |
|--|---------|---------------|--|-----------------------------------|
| Adolescents Aged 12–17 Years (Mean Age 14.6 years) ^b | 12 | 800 mg/100 mg | 86.7 | 2,141 |
| Adolescents and Adults Aged 14–23 Years (Mean Age 19.5 years) ^c | 24 | 800 mg/100 mg | 69.5 | 1,300 |
| Adults Aged >18 Years (Two Studies) ^a | 335/280 | 800 mg/100 mg | 87.8–87.9 | 1,896–2,041 |

^aSource: Darunavir [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021976Orig1s063lbl.pdf.

^bSource: Kakuda TN, Brochot A, van de Casteele T, et al. Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients. Presented at: 14th Clinical Pharmacology Workshop on HIV; 2013. Amsterdam, Netherlands. Available at: https://www.natap.org/2013/Pharm/Pharm_19.htm.

^c Source: Flynn P, Blanche S, Giaquinto C, et al. . 24-week efficacy, safety, tolerability and pharmacokinetics of darunavir/ritonavir once daily in treatment-naïve adolescents aged 12 to < 18 years in DIONE. Abstract # PP_2. Presented at: 3rd International Workshop on HIV Pediatrics; 2011. Rome, Italy. Available at: https://www.natap.org/2011/IAS/IAS_40.htm.

Key: AUC_{0-24h} = 24-hour area under the curve; C_{0h} = predose concentration; DRV/r = darunavir/ritonavir

The efficacy of once-daily DRV has been established within a limited number of studies in small cohorts of adolescents that reported long-term data on virologic and immunologic outcomes.^{11,23}

References

1. Belkhir L, Elens L, Zech F, et al. Interaction between darunavir and etravirine is partly mediated by CYP3A5 polymorphism. *PLoS One*. 2016;11(10):e0165631. Available at: <https://pubmed.ncbi.nlm.nih.gov/27788239>.
2. King JR, Yoge R, Jean-Philippe P, et al. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. *Antimicrob Agents Chemother*. 2011;55(9):4290-4294. Available at: <https://pubmed.ncbi.nlm.nih.gov/21670182>.
3. Mujuru A, Strehalu R, Rakhmanina N, et al. Six-month outcome of F/TAF Cobicistat-boosted Darunavir in children 14 to <25kg. Presented at: Conference on Retroviruses and Opportunistic Infections; 2023. Seattle, Washington. Available at: <https://www.croiconference.org/abstract/six-month-outcome-of-f-taf-cobicistat-boosted-darunavir-in-children-14-to-25kg>.
4. Larson KB, Cressey TR, Yoge R, et al. Pharmacokinetics of once-daily darunavir/ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults. *J Pediatric Infect Dis Soc*. 2016;5(2):131-137. Available at: <https://pubmed.ncbi.nlm.nih.gov/27199469>.
5. Cressey TR, Yoge R, Wiznia A, et al. Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults. *J Pediatric Infect Dis Soc*. 2017;6(3):294-296. Available at: <https://pubmed.ncbi.nlm.nih.gov/27103489>.
6. Foca M, Yoge R, Wiznia A, et al. Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults. *Pediatr Infect Dis J*. 2016;35(9):e271-274. Available at: <https://pubmed.ncbi.nlm.nih.gov/27187753>.
7. Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. *Pediatr Infect Dis J*. 2015;34(5):e132-137. Available at: <https://pubmed.ncbi.nlm.nih.gov/25719453>.
8. Darunavir (Prezista) [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021976s06s068,202895s0361bl.pdf
9. Darunavir/cobicistat (Prezcobix) [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205395s025lbl.pdf

10. Bastiaans DET, Geelen SPM, Visser EG, et al. Pharmacokinetics, short-term safety and efficacy of the approved once-daily darunavir/ritonavir dosing regimen in HIV-infected children. *Pediatr Infect Dis J.* 2018;37(10):1008-1010. Available at: <https://pubmed.ncbi.nlm.nih.gov/29474261>.
11. Flynn P, Komar S, Blanche S, et al. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naive, HIV-1-infected adolescents: results from a Phase 2 open-label trial (DIONE). *Pediatr Infect Dis J.* 2014;33(9):940-945. Available at: <https://pubmed.ncbi.nlm.nih.gov/25361024>.
12. Clinical pharmacology review of darunavir [package insert]. Food and Drug Administration. 2011. Available at: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM287674.pdf>
13. Food and Drug Administration. Clinical pharmacology review of darunavir. 2011. Available at: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM287674.pdf>
14. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. *AIDS.* 2009;23(15):2005-2013. Available at: <https://pubmed.ncbi.nlm.nih.gov/19724191>.
15. Brochot A, Kakuda TN, Van De Casteele T, et al. Model-based once-daily darunavir/ritonavir dosing recommendations in pediatric HIV-1-infected patients aged ≥ 3 to < 12 years. *CPT Pharmacometrics Syst Pharmacol.* 2015;4(7):406-414. Available at: <https://pubmed.ncbi.nlm.nih.gov/26312164>.
16. Kakuda TN, Brochot A, Tomaka FL, et al. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. *J Antimicrob Chemother.* 2014;69(10):2591-2605. Available at: <https://pubmed.ncbi.nlm.nih.gov/24951533>.
17. Chokephaibulkit K, Prasitsuebsai W, Wittawatmongkol O, et al. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥ 7 years. *Antivir Ther.* 2012;17(7):1263-1269. Available at: <https://pubmed.ncbi.nlm.nih.gov/22954687>.
18. Cobicistat (Tybost) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203094s016lbl.pdf.
19. McFarland E, Heresi G, Batra J, et al. Pharmacokinetics, safety, and efficacy of atv or drv with cobi in adolescents. Abstract 425. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017. Seattle, Washington. Available at: <http://www.croiconference.org/sessions/pharmacokinetics-safety-and-efficacy-atv-or-drv-cobi-adolescents>.

20. Prezista drug label. Clinical review of darunavir [package insert]. Food and Drug Administration. 2012. Available at: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM346671.pdf>.
21. Kakuda TN, Brochot A, van de Castele T, et al. Establishing darunavir dosing recommendations in treatment-naive and treatment-experienced pediatric patients. Presented at: 14th Clinical Pharmacology Workshop on HIV; 2013. Amsterdam, Netherlands. Available at: http://www.natap.org/2013/Pharm/Pharm_19.htm.
22. King J, Hazra R, et al. Pharmacokinetics of darunavir 800 mg with ritonavir 100mg once daily in HIV+ adolescents and young adults. Presented at: Conference on Retroviruses and Opportunistic Infections 2013. Atlanta, GA. Available at.
23. Chokephaibulkit K, Rungmaitree S, Phongsamart W, et al. Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children. *HIV Med.* 2014;15(8):511-512. Available at: <https://pubmed.ncbi.nlm.nih.gov/25138061>.

Lopinavir/Ritonavir (LPV/r, Kaletra)

Updated: June 27, 2024
Reviewed: June 27, 2024

| Formulations | |
|---|--|
| Oral Solution <ul style="list-style-type: none">• [Kaletra] Lopinavir 80 mg/mL and ritonavir 20 mg/mL (contains 42.4% alcohol by volume and 15.3% propylene glycol by weight/volume) | |
| Film-Coated Tablets <ul style="list-style-type: none">• [Kaletra] Lopinavir 100 mg/ritonavir 25 mg• [Kaletra] Lopinavir 200 mg/ritonavir 50 mg | |
| When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Neonate (Aged <14 Days) Dose</p> <ul style="list-style-type: none">• Lopinavir/ritonavir (LPV/r) is not approved by the U.S. Food and Drug Administration (FDA) for use in neonates before a postmenstrual age of 42 weeks and a postnatal age of at least 14 days. <p>Dosing for Individuals Who Are Not Receiving Concomitant Nevirapine (NVP), Efavirenz (EFV), Fosamprenavir (FPV), or Nelfinavir (NFV)</p> <p><i>Infant (Aged 14 Days to 12 Months) Dose</i></p> <ul style="list-style-type: none">• Once-daily dosing is not recommended.• LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily. This approximates LPV/r 16 mg/4 mg (both per kg body weight) twice daily. Use of this dose in infants aged <12 months is associated with lower lopinavir (LPV) trough levels than those found in adults; LPV dosing should be adjusted for growth at frequent intervals (see Pharmacokinetics and Dosing below). <p><i>Child and Adolescent (Aged >12 Months to 18 Years) Dose</i></p> <ul style="list-style-type: none">• Once-daily dosing is not recommended.• LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily (maximum dose LPV/r 400 mg/100 mg twice daily, except as noted below). For patients weighing <15 kg, this dose | <ul style="list-style-type: none">• Gastrointestinal (GI) intolerance, nausea, vomiting, diarrhea, alteration of taste• Hyperlipidemia, especially hypertriglyceridemia• Elevated transaminases• Hyperglycemia• PR interval prolongation• QT interval prolongation and Torsades de Pointes• Risk of toxicity—including life-threatening cardiotoxicity—is increased in premature infants (see Major Toxicities below). |
| Special Instructions | |
| | <ul style="list-style-type: none">• LPV/r tablets can be administered without regard to food; administration with or after meals may enhance GI tolerability.• LPV/r tablets must be swallowed whole. Do not crush or split tablets.• LPV/r oral solution should be administered with food because a high-fat meal increases absorption. |

| <p>approximates LPV/r 13 mg/3.25 mg (both per kg body weight) twice daily. For patients weighing ≥ 15 kg to 45 kg, this dose approximates LPV/r 11 mg/2.75 mg (both per kg body weight) twice daily. This dose is routinely used by many clinicians and is the preferred dose for antiretroviral therapy (ART)-experienced patients who could harbor virus with decreased LPV susceptibility (see Pharmacokinetics and Dosing below).</p> <ul style="list-style-type: none"> LPV/r 230 mg/57.5 mg per m² of body surface area per dose twice daily can be used in antiretroviral (ARV)-naïve patients aged >1 year. For patients weighing <15 kg, this dose approximates LPV/r 12 mg/3 mg per kg body weight given twice daily. For patients weighing ≥ 15 kg to 40 kg, this dose approximates LPV/r 10 mg/2.5 mg per kg body weight given twice daily. This lower dose should not be used in treatment-experienced patients who could harbor virus with decreased LPV susceptibility. <p>Weight-Band Dosing for LPV/r 100-mg/25-mg Pediatric Tablets in Children and Adolescents</p> <table border="1" data-bbox="204 813 856 1362"> <thead> <tr> <th colspan="3">Recommended Number of LPV/r 100-mg/25-mg Tablets Given Twice Daily</th> </tr> <tr> <th>Dosing target</th> <th>300 mg/m² per dose given twice daily</th> <th>230 mg/m² per dose given twice daily</th> </tr> </thead> <tbody> <tr> <th colspan="3">Body Weight</th> </tr> <tr> <td>15 kg to 20 kg</td> <td>2</td> <td>2</td> </tr> <tr> <td>>20 kg to 25 kg</td> <td>3</td> <td>2</td> </tr> <tr> <td>>25 kg to 30 kg</td> <td>3</td> <td>3</td> </tr> <tr> <td>>30 kg to 35 kg</td> <td>4^a</td> <td>3</td> </tr> <tr> <td>>35 kg to 45 kg</td> <td>4^a</td> <td>4^a</td> </tr> <tr> <td>>45 kg</td> <td>4^a or 5^b</td> <td>4^a</td> </tr> </tbody> </table> <p>^a Two tablets that each contain LPV/r 200 mg/50 mg can be substituted for the four LPV/r 100-mg/25-mg tablets in children who are capable of swallowing a larger tablet.</p> <p>^b In patients who weigh >45 kg and who are receiving concomitant NVP, EFV, FPV, or NFV, the FDA-approved adult dose is LPV/r 500 mg/125 mg twice daily, given as a combination of two tablets of LPV/r 200 mg/50 mg and one tablet of LPV/r 100 mg/25 mg. Alternatively, three tablets of LPV/r 200 mg/50 mg can be used for ease of dosing.</p> <p><i>Adult (Aged ≥ 18 Years) Dose</i></p> <ul style="list-style-type: none"> LPV/r 800 mg/200 mg once daily; or LPV/r 400 mg/100 mg twice daily | Recommended Number of LPV/r 100-mg/25-mg Tablets Given Twice Daily | | | Dosing target | 300 mg/m ² per dose given twice daily | 230 mg/m ² per dose given twice daily | Body Weight | | | 15 kg to 20 kg | 2 | 2 | >20 kg to 25 kg | 3 | 2 | >25 kg to 30 kg | 3 | 3 | >30 kg to 35 kg | 4 ^a | 3 | >35 kg to 45 kg | 4 ^a | 4 ^a | >45 kg | 4 ^a or 5 ^b | 4 ^a | <ul style="list-style-type: none"> The poor palatability of LPV/r oral solution is difficult to mask with flavorings or foods (see Formulations below). LPV/r oral solution can be kept at room temperature (up to 77°F or 25°C) if used within 2 months. If kept refrigerated (36°F to 46°F or 2°C to 8°C), LPV/r oral solution remains stable until the expiration date printed on the label. Children aged <18 years who receive once-daily dosing of LPV/r have shown considerable variability in plasma concentrations and have a higher incidence of diarrhea. Therefore, once-daily dosing is not recommended for this age group. Use of LPV/r once daily is contraindicated if three or more of the following LPV resistance-associated substitutions are present: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. This is because higher LPV trough concentrations may be required to suppress resistant virus. <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> Cytochrome P450 3A4 substrate and inhibitor. <p>LPV/r Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> LPV/r is eliminated primarily by hepatic metabolism. Use caution when administering LPV to patients with hepatic impairment. No dosing information is currently available for children or adults with hepatic insufficiency. In the coformulation of LPV/r, ritonavir acts as a pharmacokinetic enhancer, not as an ARV agent. Ritonavir inhibits the metabolism of LPV and increases LPV plasma concentrations. |
|---|--|--|--|---------------|--|--|-------------|--|--|----------------|---|---|-----------------|---|---|-----------------|---|---|-----------------|----------------|---|-----------------|----------------|----------------|--------|----------------------------------|----------------|--|
| Recommended Number of LPV/r 100-mg/25-mg Tablets Given Twice Daily | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dosing target | 300 mg/m ² per dose given twice daily | 230 mg/m ² per dose given twice daily | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Body Weight | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 kg to 20 kg | 2 | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >20 kg to 25 kg | 3 | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >25 kg to 30 kg | 3 | 3 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >30 kg to 35 kg | 4 ^a | 3 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >35 kg to 45 kg | 4 ^a | 4 ^a | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >45 kg | 4 ^a or 5 ^b | 4 ^a | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | |
|---|--|
| <ul style="list-style-type: none"> Do not use once-daily dosing in children; adolescents; patients receiving concomitant therapy with NVP, EFV, FPV, or NFV; or patients with three or more LPV-associated mutations (see Special Instructions for a list of mutations below). <p>Dosing for Individuals with Three or More LPV-Associated Mutations (See Special Instructions for List)</p> <ul style="list-style-type: none"> LPV/r 400 mg/100 mg twice daily <p>Dosing for Individuals Receiving Concomitant NVP or EFV</p> <ul style="list-style-type: none"> These drugs induce LPV metabolism and reduce LPV plasma levels. Increased LPV/r dosing is required with concomitant administration of these drugs. Once-daily dosing should not be used in these patients. <p><i>Child and Adolescent (Aged >12 Months to ≥18 Years) Dose</i></p> <ul style="list-style-type: none"> LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily. See the table above for weight-band dosing when using tablets. <p><i>Adult (Aged ≥18 Years) Dose</i></p> <ul style="list-style-type: none"> The FDA-approved dose is LPV/r 500 mg/125 mg twice daily, given as a combination of two tablets of LPV/r 200 mg/50 mg and one tablet of LPV/r 100 mg/25 mg. Alternatively, three tablets of LPV/r 200 mg/50 mg can be used for ease of dosing. Once-daily dosing should not be used. <p>LPV/r Used in Combination with Maraviroc</p> <ul style="list-style-type: none"> Maraviroc doses may need modification (see the Maraviroc section). | |
|---|--|

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Metabolism:** Lopinavir/ritonavir (LPV/r) is a cytochrome P450 (CYP) 3A4 substrate and inhibitor with the potential for multiple drug interactions. Coadministering LPV/r with drugs that induce CYP3A4 may decrease LPV plasma concentrations, whereas coadministering LPV/r with other CYP3A4 inhibitors may increase LPV plasma concentrations. Coadministering LPV/r with other CYP3A4 substrates may require dose adjustments and additional monitoring.

Before initiating therapy with LPV/r, a patient's medication profile should be carefully reviewed for potential drug interactions. In patients treated with LPV/r, fluticasone (a commonly used inhaled and intranasal steroid) should be avoided, and an alternative steroid should be used. Fluticasone is a CYP3A substrate and LPV/r significantly increases fluticasone exposures, potentially resulting in adverse systemic corticosteroid effects including Cushing's syndrome and adrenal suppression.¹ Drug interactions with antituberculous drugs are common. Coadministration of LPV/r with the antituberculosis drug rifampin—a strong CYP3A4 inducer—may lead to suboptimal LPV levels.²⁻⁴

Patients who are receiving both LPV/r and antituberculous drugs may need a dose adjustment for LPV/r, or they may need to switch to an antiretroviral (ARV) regimen that does not include LPV/r.

Major Toxicities

- *More common:* Diarrhea, headache, asthenia, nausea and vomiting, rash, insulin resistance,⁵ and hyperlipidemia, especially hypercholesterolemia and hypertriglyceridemia,⁶⁻⁸ which may be more pronounced in girls than in boys.⁹ LPV requires a higher dose of ritonavir than some other protease inhibitors (PIs); this higher dose may exacerbate these adverse events (AEs).
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, hemolytic anemia, spontaneous and/or increased bleeding in hemophiliacs, pancreatitis, elevation in serum transaminases, hepatitis (which has been life-threatening in rare cases). PR interval prolongation, QT interval prolongation, and Torsades de Pointes may occur¹⁰.
- *Special populations—neonates:* An increased risk of toxicity in premature infants has been reported, including cases of transient symptomatic adrenal insufficiency,^{11,12} life-threatening bradyarrhythmias and cardiac dysfunction (including complete atrioventricular block, bradycardia, and cardiomyopathy),¹³⁻¹⁵ lactic acidosis, acute renal failure, central nervous system depression, and respiratory depression. These toxicities may be caused by the drug itself and/or by the inactive ingredients in the oral solution,¹⁵ which include propylene glycol (15.3%) and ethanol (42.4%). Transient asymptomatic elevation in 17-hydroxyprogesterone levels also has been reported¹¹ in term newborns treated at birth with LPV/r. The pharmacokinetics (PK) and safety of LPV/r were studied in IMPAACT P1106, a Phase 4 prospective study evaluating the safety and PK of antiretroviral medications in low and normal birthweight infants <3 months old, in which one group received LPV/r as clinical care¹⁶. A total of 28 neonates with HIV were enrolled, with a median birth weight of 2,288 g (interquartile range [IQR] 1,360–3,320 g) and a median gestational age of 36 weeks (IQR 27–39 weeks). In 25 infants with available PK data, the median LPV dose was 418mg/m² twice daily (23.6 mg/kg). The median trough LPV levels was 5.14 (IQR 2.95–8.51) µg/mL, above the minimal effective target concentration of 1 µg/mL. Nearly half of infants initiated therapy prior to 42 weeks postmenstrual age with no observed safety or PK differences compared with infants who initiated LPV/r at or after 42 weeks postmenstrual age. No adverse events Grade 3 or higher were considered related to LPV/r treatment.¹⁶

Resistance

The International Antiviral Society—USA maintains a list of [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

LPV/r is approved by the U.S. Food and Drug Administration (FDA) for use in children, including neonates who have attained a postmenstrual age of 42 weeks and a postnatal age of at least 14 days. The potential benefit of using LPV/r in premature infants who have not met these age thresholds must be carefully balanced with the risk of metabolic and cardiac toxicity. In pediatric patients

receiving LPV/r at a dose of 300 mg/75 mg per m² twice daily, lower LPV exposure has been observed in infants aged <6 weeks relative to older children.¹⁷

Efficacy

Clinical trials involving antiretroviral therapy (ART)-naive adults have shown that regimens that contain LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) are comparable to a variety of other regimens, including regimens that contain atazanavir, darunavir (DRV), fosamprenavir (FPV), saquinavir/ritonavir, or efavirenz (EFV). Studies also have shown that regimens that contain LPV/r plus two NRTIs are superior to regimens that contain nelfinavir (NFV) and inferior to regimens that contain DRV.¹⁸⁻²⁶

LPV/r has been studied in both ART-naive and ART-experienced children and has demonstrated durable virologic activity and acceptable toxicity.²⁷⁻³⁵

Pharmacokinetics

General Considerations

Children have lower LPV/r exposure than adults when treated with doses that are directly scaled for body surface area. The directly scaled dose approximation of the adult dose in children is calculated by dividing the adult dose by the typical adult body surface area of 1.73 m². For the adult dose of LPV/r 400 mg/100 mg, the scaled pediatric dose would be approximately LPV/r 230 mg/57.5 mg per m² of body surface area. However, younger children have higher LPV clearance and need higher doses to achieve LPV exposures that are similar to those seen in adults treated with standard doses. To achieve a trough concentration (C_{trough}) similar to that observed in adults, the pediatric dose needs to be increased 30% greater than the dose that is directly scaled for body surface area. LPV exposures in infants^{17,29,34} are compared to those in older children²⁷ and adults³⁶ in [Table A](#) below.

Table A. Pharmacokinetics of Lopinavir/Ritonavir by Age

| PK Parameters | Adults (n = 19) ³⁶ | Children (n = 12) ²⁷ | Children (n = 15) ²⁷ | Infants ^a at 12 Months (n = 20) ³⁴ | Infants at 6 Weeks to 6 Months (n = 18) ²⁹ | Infants at 14 Days to <6 Weeks (n = 9) ¹⁷ |
|------------------------------------|----------------------------------|------------------------------------|------------------------------------|--|--|---|
| LPV Dose | 400 mg | 230 mg/m ² | 300 mg/m ² | 300 mg/m ² | 300 mg/m ² | 300 mg/m ² |
| AUC ₀₋₁₂ (mcg·hr/mL) | 92.6 | 72.6 | 116.0 | 101.0 | 74.5 | 43.4 |
| C _{max} (mcg/mL) | 9.8 | 8.2 | 12.5 | 12.1 | 9.4 | 5.2 |
| C _{trough} (mcg/mL) | 7.1 | 4.7 | 7.9 | 4.9 | 2.7 | 2.5 |
| C _{min} (mcg/mL) | 5.5 | 3.4 | 6.5 | 3.8 | 2.0 | 1.4 |

^a This column contains unreported data that were originally generated for a published study. The data were provided by Edmund Capparelli, Pharm.D., in a personal communication (April 18, 2012).

Note: Values are means, and PK parameters refer to the LPV component; all data come from studies wherein none of the participants received non-nucleoside reverse transcriptase inhibitors as part of their antiretroviral therapy.

Key: AUC_{0-12h} = area under the curve from time zero to 12 hours after drug administration; C_{max} = maximum plasma concentration; C_{min} = minimum plasma concentration; C_{trough} = trough concentration; LPV = lopinavir; m = meter; mcg = microgram; mg = milligram; mL = milliliter; PK = pharmacokinetic

Models suggest that diet, body weight, and postnatal age are important factors in LPV PKs, with higher bioavailability as dietary fat increases during the first year of life³⁷ and clearance slowing by age 2.3 years.³⁸ A study from the United Kingdom and Ireland compared outcomes of LPV/r treatment with either 230 mg per m^2 of body surface area per dose or 300 mg per m^2 of body surface area per dose in children aged 5.6 to 12.8 years at the time of LPV/r initiation. The findings suggested that the higher dose was associated with improved long-term viral load suppression.³⁹

Pharmacokinetics and Dosing

14 Days to 12 Months (Without Concurrent Nevirapine, Efavirenz, Fosamprenavir, or Nelfinavir)

The PKs of the oral solution at approximately LPV/r 300 mg/75 mg per m^2 of body surface area per dose twice daily were evaluated in infants aged <6 weeks¹⁷ and infants aged 6 weeks to 6 months.²⁹ Even at this higher dose, C_{trough} levels were highly variable, but they were lower in infants than in children aged >6 months. C_{trough} levels were lower in infants aged ≤6 weeks than in infants aged 6 weeks to 6 months. By age 12 months, LPV area under the curve (AUC) was similar to that found in older children.³⁴ Because infants grow rapidly in the first months of life, it is important to optimize LPV dosing by adjusting the dose at frequent intervals. Given the safety of doses as high as 400 mg per m^2 of body surface area in older children and adolescents,³⁰ some practitioners anticipate rapid infant growth and prescribe doses somewhat higher than the 300 mg per m^2 of body surface area dose to allow for projected growth between clinic appointments.

12 Months to 12 Years (Without Concurrent Nevirapine, Efavirenz, Fosamprenavir, or Nelfinavir)

Lower C_{trough} values have been observed in children receiving LPV/r 230 mg/57.5 mg per m^2 of body surface area per dose twice daily than in children receiving LPV/r 300 mg/75 mg per m^2 of body surface area per dose twice daily (see [Table A](#) above).²⁶ Therefore, some clinicians choose to initiate therapy in children aged 12 months to 12 years using LPV/r 300 mg/75 mg per m^2 of body surface area per dose twice daily (when LPV/r is given without nevirapine [NVP], EFV, FPV, or NFV), rather than the FDA-approved dose of LPV/r 230 mg/57.5 mg per m^2 of body surface area per dose twice daily.

For infants receiving LPV/r 300 mg/75 mg per m^2 of body surface area per dose twice daily, immediate dose reduction at age 12 months is **not recommended**; many practitioners would allow patients to “grow into” the dose of LPV/r 230 mg/57.5 mg per m^2 of body surface area per dose twice daily as they gain weight over time. Some practitioners would continue the infant dose (LPV/r 300 mg/75 mg per m^2 of body surface area per dose twice daily) while using the LPV/r liquid formulation.

Pharmacokinetics and Dosing with Concurrent Nevirapine, Efavirenz, Fosamprenavir, or Nelfinavir

In both children and adults, the LPV C_{trough} is reduced by concurrent treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or concomitant FPV or NFV. Higher doses of LPV are recommended when the drug is given in combination with NVP, EFV, FPV, or NFV. In 14 children who were treated with LPV/r 230 mg/57.5 mg per m² of body surface area per dose twice daily plus NVP,²⁷ the mean LPV C_{trough} was 3.77 ± 3.57 mcg/mL. Not only are these trough plasma concentrations lower than those found in adults treated with standard doses of LPV/r, but the variability in concentration is much higher in children than in adults.^{27,40} In a study of 15 children with HIV aged 5.7 to 16.3 years who were treated with LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily plus EFV 14 mg/kg body weight per dose once daily, there was a 34-fold interindividual variation in LPV C_{trough} values. Five of 15 children (33%) had LPV 12-hour C_{trough} values that were <1.0 mcg/mL, the plasma concentration needed to inhibit wild-type HIV.⁴¹ A PK study in 20 children aged 10 to 16 years who were treated with LPV/r 300 mg/75 mg per m² of body surface area twice daily plus EFV 350 mg per m² of body surface area once daily reported only one patient (6.6%) with subtherapeutic LPV C_{trough} values,⁴² perhaps because the trial used an EFV dose that was approximately 11 mg/kg body weight⁴² instead of the 14 mg/kg body weight dose used in the trial discussed above.⁴¹

Dosing

Once Daily

A single daily dose of LPV/r 800 mg/200 mg is approved by the FDA for treatment of HIV in treatment-naive adults aged >18 years. However, once-daily administration **cannot be recommended for use in children in the absence of therapeutic drug monitoring (TDM)**; once-daily administration may be successful in select, closely monitored children.⁴³ There is high interindividual variability in drug exposure for LPV/r, and trough plasma concentrations may fall below the therapeutic range for wild-type virus, as demonstrated in studies of ARV-naive children and adolescents.⁴⁴⁻⁴⁷ The currently available tablet formulation of LPV/r has lower variability in trough levels than the previously used soft-gel formulation.^{47,48} An international, randomized, open-label trial attempted to demonstrate that once-daily LPV/r dosing was non-inferior to twice-daily LPV/r dosing in children and adolescents with HIV. This trial was unsuccessful, because a greater number of children and adolescents who received once-daily doses had viral loads ≥50 copies/mL within 48 weeks.⁴⁹

Dosing and Its Relation to Efficacy

LPV/r is effective in treatment-experienced patients with severe immune suppression,^{50,51} although heavily pretreated patients may be slower to reach undetectable viral loads^{51,52} and may have less robust CD4 T lymphocyte cell (CD4) count percentage responses.⁵³

The relationship between LPV exposure and the susceptibility of the HIV-1 isolate is a key component of successful treatment. The ratio of C_{trough} to half maximal effective concentration (EC₅₀) is called the inhibitory quotient (IQ), and in both adults and children treated with LPV/r, viral load reduction is more closely associated with IQ than with either C_{trough} or EC₅₀ alone.⁵⁴⁻⁵⁶ One study investigated the use of the IQ as a guide for therapy by administering higher doses of LPV/r to children and adolescents until a target IQ of 15 was reached. This study showed that doses of LPV/r

400 mg/100 mg per m² of body surface area per dose twice daily (without FPV, NFV, NVP, or EFV) and LPV/r 480 mg/120 mg per m² of body surface area per dose twice daily (with NVP or EFV) were safe and tolerable.³⁰ Results of a modeling study suggest that standard doses of LPV/r may be inadequate for treatment-experienced children and indicate the potential utility of TDM when LPV/r is used in children who were previously treated with PIs.⁵⁷ An LPV plasma concentration of ≥ 1 mcg/mL is cited as a minimum target C_{trough},⁵⁸⁻⁶⁰ but this C_{trough} may not adequately control viremia in patients with multiple LPV resistance mutations.^{61,62}

Formulations

Palatability

The poor palatability of the LPV/r oral solution can be a significant challenge to medication adherence for some children and families. Numbing the taste buds with ice chips before or after administering the solution, masking the taste of the solution by administering it with sweet or tangy foods (e.g., chocolate syrup, peanut butter), or having the pharmacist flavor the solution prior to dispensing it are examples of interventions that may improve tolerability. Alternative pediatric formulations are currently being developed.⁶³⁻⁶⁵

Do Not Use Crushed Tablets

LPV/r tablets must be swallowed whole. Crushed tablets are slowly and erratically absorbed and result in significantly reduced AUC, maximum concentration (C_{max}), and C_{trough} compared with swallowing the whole tablet. The variability of the reduced exposure with the crushed tablets (5% to 75% reduction in AUC) means that a dose modification cannot be relied on to overcome the reduced absorption. Crushed tablets **cannot be recommended for use**.⁶⁶ In a PK study that used a generic adult formulation of LPV/r manufactured in Thailand, 21 of 54 children were administered cut (not crushed) pills and had adequate LPV C_{trough} measurements.⁴⁸

Toxicity

Children treated with LPV/r may have less robust weight gain and smaller increases in CD4 percentage than children treated with NNRTI-based regimens.^{32,67-71} However, one study did not observe this difference in the effect of LPV/r on CD4 count,⁷² and another study found that the difference did not persist after a year of therapy.³⁵ Some studies found no differences between the weight gain of children treated with LPV/r and those treated with EFV.^{70,73} Switching to an EFV-based regimen at or after age 3 years removed the risk of LPV-associated metabolic toxicity, with no loss of virologic control (see Table 16 in [Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy](#)).^{70,71} Bone mineral density improved when children were treated with EFV-containing regimens instead of regimens that contained LPV/r.⁷⁴ Among 212 children randomized to either remain on an LPV/r-based regimen or switch to an EFV-containing regimen, osteocalcin—a biochemical marker of bone turnover—was higher in the LPV/r group than the EFV group at both 8 weeks and 2 years post-randomization. Levels of C-telopeptide of type 1 collagen and procollagen type I N-terminal propeptide did not differ between the two groups.⁷⁵ In a separate study, among 220 children with HIV (mean age 6.38 years), lower bone mass was observed in children on LPV/r-based regimens than those with EFV-based regimens over 2 years of follow-up.⁷⁶

References

1. Flonase (Fluticasone propionate) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf.
2. Salerno SN, Capparelli EV, McIlleron H, et al. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. *Pharmacotherapy*. 2022. Available at: <https://pubmed.ncbi.nlm.nih.gov/35607886/>.
3. Chabala C, Turkova A, Kapasa M, et al. Inadequate lopinavir concentrations with modified 8-hourly lopinavir/ritonavir 4:1 dosing during rifampicin-based tuberculosis treatment in children living with HIV. *Pediatr Infect Dis J*. 2023;42(10):899-904. Available at: <https://pubmed.ncbi.nlm.nih.gov/37506295/>.
4. Jacobs TG, Mumbiro V, Chitsamatanga M, et al. Brief report: suboptimal lopinavir exposure in infants on rifampicin treatment receiving double-dosed or semisuperboosted lopinavir/ritonavir: time for a change. *J Acquir Immune Defic Syndr*. 2023;93(1):42-46. Available at: <https://pubmed.ncbi.nlm.nih.gov/36724434/>.
5. Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. *J Pediatr Endocrinol Metab*. 2014;27(5-6):403-412. Available at: <https://pubmed.ncbi.nlm.nih.gov/24259240/>.
6. Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on lopinavir or nevirapine-based antiretroviral therapy. *Arch Dis Child*. 2013;98(4):258-264. Available at: <https://pubmed.ncbi.nlm.nih.gov/23220209/>.
7. Ige OO, Yilgwan CS, Ebonyi AO, et al. Serum lipid and glucose profiles in HIV-positive Nigerian children. *J Virus Erad*. 2017;3(3):157-162. Available at: <https://pubmed.ncbi.nlm.nih.gov/28758024/>.
8. Patel K, Lindsey J, Angelidou K, et al. Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children. *AIDS*. 2018;32(16):2327-2336. Available at: <https://pubmed.ncbi.nlm.nih.gov/30102656/>.
9. Shiau S, Kuhn L, Strehlau R, et al. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. *BMC Pediatr*. 2014;14:39. Available at: <https://pubmed.ncbi.nlm.nih.gov/24521425/>.
10. Ridjab DA, Ivan I, Budiman F, Juliawati DJ. Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and

saquinavir: A systematic review. *Medicine (Baltimore)*. 2021;100(31):e26787. Available at: <https://pubmed.ncbi.nlm.nih.gov/34397829/>.

11. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. *JAMA*. 2011;306(1):70-78. Available at: <https://pubmed.ncbi.nlm.nih.gov/21730243/>.
12. Kariyawasam D, Peries M, Foissac F, et al. Lopinavir-ritonavir impairs adrenal function in infants. *Clin Infect Dis*. 2019;71(4):1030-1039. Available at: <https://pubmed.ncbi.nlm.nih.gov/31633158/>.
13. Lopriore E, Rozendaal L, Gelinck LB, et al. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. *AIDS*. 2007;21(18):2564-2565. Available at: <https://pubmed.ncbi.nlm.nih.gov/18025905/>.
14. McArthur MA, Kalu SU, Foulks AR, et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. *Pediatr Infect Dis J*. 2009;28(12):1127-1129. Available at: <https://pubmed.ncbi.nlm.nih.gov/19820426/>.
15. Food and Drug Administration. Serious health problems seen in premature babies given kletra (lopinavir/ ritonavir) oral solution. 2011. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm246002.htm>.
16. Bekker A, Yang J, Wang J, et al. Safety and pharmacokinetics of lopinavir/ritonavir oral solution in preterm and term infants starting before 3 months of age. *Pediatr Infect Dis J*. 2024;43(4):355-360. Available at: <https://pubmed.ncbi.nlm.nih.gov/38190642/>.
17. Chadwick EG, Pinto J, Yoge R, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. *Pediatr Infect Dis J*. 2009;28(3):215-219. Available at: <https://pubmed.ncbi.nlm.nih.gov/19209098/>.
18. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med*. 2002;346(26):2039-2046. Available at: <https://pubmed.ncbi.nlm.nih.gov/12087139/>.
19. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet*. 2006;368(9534):476-482. Available at: <https://pubmed.ncbi.nlm.nih.gov/16890834/>.
20. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week

efficacy and safety results of the CASTLE study. *Lancet*. 2008;372(9639):646-655. Available at: <https://pubmed.ncbi.nlm.nih.gov/18722869>.

21. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. *AIDS*. 2008;22(12):1389-1397. Available at: <https://pubmed.ncbi.nlm.nih.gov/18614861>.
22. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med*. 2008;358(20):2095-2106. Available at: <https://pubmed.ncbi.nlm.nih.gov/18480202>.
23. Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. *HIV Clin Trials*. 2009;10(2):76-87. Available at: <https://pubmed.ncbi.nlm.nih.gov/19487177>.
24. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr*. 2015;70(5):515-519. Available at: <https://pubmed.ncbi.nlm.nih.gov/26262777>.
25. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. *HIV Med*. 2013;14(1):49-59. Available at: <https://pubmed.ncbi.nlm.nih.gov/23088336>.
26. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr*. 2010;53(3):323-332. Available at: <https://pubmed.ncbi.nlm.nih.gov/20032785>.
27. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2003;22(3):216-224. Available at: <https://pubmed.ncbi.nlm.nih.gov/12634581>.
28. De Luca M, Miccinesi G, Chiappini E, et al. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. *Int J Immunopathol Pharmacol*. 2005;18(4):729-735. Available at: <https://pubmed.ncbi.nlm.nih.gov/16388722>.
29. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. *AIDS*. 2008;22(2):249-255. Available at: <https://pubmed.ncbi.nlm.nih.gov/18097227>.

30. Robbins BL, Capparelli EV, Chadwick EG, et al. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. *Antimicrob Agents Chemother*. 2008;52(9):3276-3283. Available at: <https://pubmed.ncbi.nlm.nih.gov/18625762>.
31. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med*. 2008;359(21):2233-2244. Available at: <https://pubmed.ncbi.nlm.nih.gov/19020325>.
32. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *N Engl J Med*. 2010;363(16):1510-1520. Available at: <https://pubmed.ncbi.nlm.nih.gov/20942667>.
33. Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. *J Infect Dis*. 2010;201(8):1121-1131. Available at: <https://pubmed.ncbi.nlm.nih.gov/20214476>.
34. Chadwick EG, Yogev R, Alvero CG, et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. *AIDS*. 2011;25(5):643-649. Available at: <https://pubmed.ncbi.nlm.nih.gov/21297419>.
35. Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. *Clin Infect Dis*. 2016;63(8):1113-1121. Available at: <https://pubmed.ncbi.nlm.nih.gov/27439527>.
36. Kaletra (lopinavir/ritonavir) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021251s059,021906s054lbl.pdf.
37. Nikanjam M, Chadwick EG, Robbins B, et al. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. *Clin Pharmacol Ther*. 2012;91(2):243-249. Available at: <https://pubmed.ncbi.nlm.nih.gov/22190064>.
38. Urien S, Firtion G, Anderson ST, et al. Lopinavir/ritonavir population pharmacokinetics in neonates and infants. *Br J Clin Pharmacol*. 2011;71(6):956-960. Available at: <https://pubmed.ncbi.nlm.nih.gov/21564164>.
39. Donegan K, Doerholt K, Judd A, et al. Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J*. 2013;32(1):45-50. Available at: <https://pubmed.ncbi.nlm.nih.gov/23076384>.

40. Verweel G, Burger DM, Sheehan NL, et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. *Antivir Ther.* 2007;12(4):453-458. Available at: <https://pubmed.ncbi.nlm.nih.gov/17668553>.
41. Bergshoeff AS, Fraaij PL, Ndagijimana J, et al. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. *J Acquir Immune Defic Syndr.* 2005;39(1):63-68. Available at: <https://pubmed.ncbi.nlm.nih.gov/15851915>.
42. King JR, Acosta EP, Yogev R, et al. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. *Pediatr Infect Dis J.* 2009;28(2):159-161. Available at: <https://pubmed.ncbi.nlm.nih.gov/19106779>.
43. Gondrie IPE, Bastiaans DET, Fraaij PLA, et al. Sustained viral suppression in HIV-infected children on once-daily lopinavir/ritonavir in clinical practice. *Pediatr Infect Dis J.* 2017;36(10):976-980. Available at: <https://pubmed.ncbi.nlm.nih.gov/28475554>.
44. Rosso R, Di Biagio A, Dentone C, et al. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. *J Antimicrob Chemother.* 2006;57(6):1168-1171. Available at: <https://pubmed.ncbi.nlm.nih.gov/16606636>.
45. van der Lee M, Verweel G, de Groot R, Burger D. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. *Antivir Ther.* 2006;11(4):439-445. Available at: <https://pubmed.ncbi.nlm.nih.gov/16856617>.
46. la Porte C, van Heeswijk R, Mitchell CD, et al. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. *Antivir Ther.* 2009;14(4):603-606. Available at: <https://pubmed.ncbi.nlm.nih.gov/19578247>.
47. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. *Antivir Ther.* 2008;13(8):1087-1090. Available at: <https://pubmed.ncbi.nlm.nih.gov/19195335>.
48. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, et al. Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets. *Pediatr Infect Dis J.* 2010;29(1):79-82. Available at: <https://pubmed.ncbi.nlm.nih.gov/19858772>.
49. Paediatric European Network for Treatment of AIDS. Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. *AIDS.* 2015;29(18):2447-2457. Available at: <https://pubmed.ncbi.nlm.nih.gov/26558544>.

50. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2004;23(10):923-930. Available at: <https://pubmed.ncbi.nlm.nih.gov/15602192>.
51. Resino S, Bellon JM, Munoz-Fernandez MA, Spanish Group of HIV Infection. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. *J Antimicrob Chemother*. 2006;57(3):579-582. Available at: <https://pubmed.ncbi.nlm.nih.gov/16446377>.
52. Resino S, Galan I, Perez A, et al. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. *AIDS Res Hum Retroviruses*. 2005;21(5):398-406. Available at: <https://pubmed.ncbi.nlm.nih.gov/15929702>.
53. Larru B, Resino S, Bellon JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. *J Antimicrob Chemother*. 2008;61(1):183-190. Available at: <https://pubmed.ncbi.nlm.nih.gov/18025025>.
54. Casado JL, Moreno A, Sabido R, et al. Individualizing salvage regimens: the inhibitory quotient (C_trough/IC₅₀) as predictor of virological response. *AIDS*. 2003;17(2):262-264. Available at: <https://pubmed.ncbi.nlm.nih.gov/12545089>.
55. Delaugerre C, Teglas JP, Treliuyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. *J Acquir Immune Defic Syndr*. 2004;37(2):1269-1275. Available at: <https://pubmed.ncbi.nlm.nih.gov/15385734>.
56. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother*. 2003;47(1):350-359. Available at: <https://pubmed.ncbi.nlm.nih.gov/12499212>.
57. Rakhmanina N, van den Anker J, Baghdassarian A, et al. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. *Antimicrob Agents Chemother*. 2009;53(6):2532-2538. Available at: <https://pubmed.ncbi.nlm.nih.gov/19258274>.
58. Moholisa RR, Schomaker M, Kuhn L, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. *Antivir Ther*. 2014;19(4):399-406. Available at: <https://pubmed.ncbi.nlm.nih.gov/24518130>.
59. Moholisa RR, Schomaker M, Kuhn L, et al. Effect of lopinavir and nevirapine concentrations on viral outcomes in protease inhibitor-experienced HIV-infected

- children. *Pediatr Infect Dis J.* 2016;35(12):e378-e383. Available at: <https://pubmed.ncbi.nlm.nih.gov/27583591>.
60. Aurpibul L, Teerananchai S, Prasitsuebsai W, et al. Therapeutic drug monitoring of lopinavir in HIV-infected children on second-line antiretroviral therapy in Asia. *Ther Drug Monit.* 2016;38(6):791-795. Available at: <https://pubmed.ncbi.nlm.nih.gov/27749514>.
61. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. *J Acquir Immune Defic Syndr.* 2011;56(4):333-339. Available at: <https://pubmed.ncbi.nlm.nih.gov/21239995>.
62. Court R, Gordon M, Cohen K, et al. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. *Int J Antimicrob Agents.* 2016;48(2):158-162. Available at: <https://pubmed.ncbi.nlm.nih.gov/27345268>.
63. Food and Drug Administration. NDA 205425 tentative approval 2015. 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205425Orig1s000TAltr.pdf.
64. Kekitiinwa A, Musiime V, Thomason MJ, et al. Acceptability of lopinavir/r pellets (minitablets), tablets and syrups in HIV-infected children. *Antivir Ther.* 2016;21(7):579-585. Available at: <https://pubmed.ncbi.nlm.nih.gov/27128199>.
65. Rotsaert A, Ogara C, Mwanga-Amumpaire J, et al. Acceptability of a new 4-in-1 abacavir/lamivudine/lopinavir/ritonavir paediatric fixed-dose combination: the caregiver-child dyads' perspective. *Ther Adv Infect Dis.* 2023;10:20499361231159993. Available at: <https://pubmed.ncbi.nlm.nih.gov/36968554>.
66. Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. *J Acquir Immune Defic Syndr.* 2011;58(4):385-391. Available at: <https://pubmed.ncbi.nlm.nih.gov/21876444>.
67. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA.* 2010;304(10):1082-1090. Available at: <https://pubmed.ncbi.nlm.nih.gov/20823434>.
68. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *N Engl J Med.* 2012;366(25):2380-2389. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716976>.
69. Lindsey JC, Hughes MD, Violari A, et al. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with

and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. *Pediatr Infect Dis J.* 2014;33(8):846-854. Available at: <https://pubmed.ncbi.nlm.nih.gov/25222305>.

70. Murnane PM, Strehlau R, Shiau S, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term outcomes of a randomized trial. *Clin Infect Dis.* 2017;65(3):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/28419200>.
71. Coovadia A, Abrams EJ, Strehlau R, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. *JAMA.* 2015;314(17):1808-1817. Available at: <https://pubmed.ncbi.nlm.nih.gov/26529159>.
72. Dahourou DL, Amorissani-Folquet M, Malatesta K, et al. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Cote d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. *BMC Med.* 2017;15(1):85. Available at: <https://pubmed.ncbi.nlm.nih.gov/28434406>.
73. Achan J, Kakuru A, Ikilezi G, et al. Growth recovery among HIV-infected children randomized to lopinavir/ritonavir or NNRTI-based antiretroviral therapy. *Pediatr Infect Dis J.* 2016;35(12):1329-1332. Available at: <https://pubmed.ncbi.nlm.nih.gov/27580060>.
74. Arpadi SM, Shiau S, Strehlau R, et al. Efavirenz is associated with higher bone mass in South African children with HIV. *AIDS.* 2016;30(16):2459-2467. Available at: <https://pubmed.ncbi.nlm.nih.gov/27427876>.
75. Shiau S, Yin MT, Strehlau R, et al. Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz. *Bone.* 2020;138:115500. Available at: <https://pubmed.ncbi.nlm.nih.gov/32590137>.
76. Shen Y, Shiau S, Strehlau R, et al. Persistently lower bone mass and bone turnover among South African children living with well-controlled HIV. *AIDS.* 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34127577>.

Appendix A: Pediatric Antiretroviral Drug Information

Entry and Fusion Inhibitors

Fostemsavir (FTR, Rukobia)

Ibalizumab (IBA, Trogarzo)

Maraviroc (MVC, Selzentry)

Fostemsavir (FTR, Rukobia)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|--|
| Extended-release tablet: 600 mg | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Child and Adolescent (Aged <18 Years) Dose</p> <ul style="list-style-type: none">The safety and efficacy of using fostemsavir (FTR) in children and adolescents aged <18 years have not been established. <p>Adult Dose</p> <ul style="list-style-type: none">One tablet twice daily | <ul style="list-style-type: none">QT corrected (QTc) interval prolongation with higher than recommended dosagesIncreased hepatic transaminases in patients with hepatitis B or hepatitis C coinfection |
| Special Instructions | |
| | <ul style="list-style-type: none">Can be taken with or without foodExtended-release tablet must be swallowed whole. Do not chew, crush, or split tablets.Should not be coadministered with strong cytochrome P450 (CYP) 3A4 inducers of metabolism, such as rifampin, carbamazepine, phenytoin, and phenobarbitalPotential for multiple drug interactions. Check concomitant medications before prescribing FTR.Tablets have a slight odor similar to vinegar. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">FTR tromethamine is a prodrug of temsavir (TMR), an HIV-1 glycoprotein 120 (gp-120)-directed attachment inhibitor.FTR is rapidly converted to TMR after oral administration. Metabolic pathways of TMR include hydrolysis (esterases) (36.1% of oral dose), oxidation (CYP3A4) (21.1% of oral dose), and uridine diphosphate glucotransferase (<1% of oral dose).TMR is a substrate of CYP3A, esterases, P-glycoprotein, and breast cancer resistance protein (BCRP).TMR is an inhibitor of organic anion transporter (OAT) P1B1 and OATP1B3; TMR and two of its metabolites are inhibitors of BCRP. |
| FTR Dosing in Patients with Hepatic Impairment | |
| | <ul style="list-style-type: none">No dose adjustment is required in patients with mild-to-severe hepatic impairment. |
| FTR Dosing in Patients with Renal Impairment | |
| | <ul style="list-style-type: none">No dose adjustment is required in patients with renal impairment or those on hemodialysis. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Metabolism:* Coadministration with strong cytochrome P450 3A inducers is contraindicated, because the plasma concentrations of the active metabolite, temsavir (TMR), are significantly reduced, which could result in loss of virologic efficacy.
- *Cardiac toxicity:* Caution is required when used in combination with drugs that are associated with prolongation of the QT corrected for heart rate (QTc) interval of the echocardiogram.
- *Oral contraceptives and gender-affirming hormonal therapy:* TMR may increase ethinyl estradiol concentrations and risk of thrombosis. Do not exceed 30 mcg ethinyl estradiol daily when fostemsavir is co-administered with estrogen-based therapies. For gender-affirming hormonal therapy, estrogen concentrations can be monitored with dose adjustments as needed.¹
- *3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins):* TMR may increase plasma concentrations of statins, including rosuvastatin, atorvastatin, fluvastatin, pitavastatin, and simvastatin. Use the lowest possible starting dose of statin, and monitor for statin-associated adverse effects.
- *Hepatitis C virus direct-acting antivirals:* TMR may increase plasma concentrations of grazoprevir and voxilaprevir due to organic anion transporting polypeptide (OATP) 1B1/3 inhibition.
- *Other antiretroviral (ARV) agents:* Drug interaction studies of fostemsavir (FTR) in combination with darunavir/cobicistat, darunavir/ritonavir, etravirine, and maraviroc have been conducted in healthy volunteers. FTR given in combination with these other ARVs was generally well tolerated, and no dose adjustments were required.^{2,3}

Major Toxicities

- *More common:* Nausea, fatigue, diarrhea (reported in ≥5% of patients)
- *Less common:* QTc prolongation with higher-than-recommended doses⁴; increased hepatic transaminases in patients with hepatitis B or hepatitis C coinfection

Resistance

The International AIDS Society–USA maintains a list of [HIV drug resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

TMR showed reduced antiviral activity against HIV subtype AE (the predominant subtype found in Southeast Asia but not commonly found elsewhere in the world). Treatment-emergent glycoprotein 120 (gp120) genotypic substitutions at four key sites—S375, M434, M426, and M475—have been found in evaluable participants with virologic failure in clinical trials. However, overall frequency of polymorphisms previously associated with the potential to reduce susceptibility to TMR is low and should not be a barrier to its usage in patients with multidrug resistance.⁵

Pediatric Use

FTR is an HIV-1 gp120-directed attachment inhibitor that is not approved for use in pediatric patients. FTR was approved by the U.S. Food and Drug Administration in 2020 for use in adults in combination with other ARV drugs, with approval limited to heavily treatment-experienced adults with multidrug-resistant HIV who are experiencing virologic failure on their current regimen due to resistance, intolerance, or safety considerations.⁶ A pharmacokinetic, safety, acceptability, and swallowability study of FTR in children and adolescents weighing ≥ 20 kg is open to enrollment (PENTA Foundation: NCT04648280). The dose selection of FTR for children and adolescents weighing ≥ 20 kg utilized a population pharmacokinetic model-based approach to achieve similar adult TMR exposures following FTR 600 mg twice daily dosing that was demonstrated to be safe and effective in the BRIGHTE study in heavily treatment-experienced patients.⁷

Efficacy in Clinical Trials

The safety and efficacy of FTR in heavily treatment-experienced adults with HIV were evaluated in the BRIGHTE trial, a Phase 3, double-blind placebo-controlled trial. A total of 371 participants were enrolled into two cohorts (randomized and nonrandomized), depending on remaining treatment options. The randomized cohort included 272 participants, with at least one fully active drug in at least one but no more than two ARV classes that could be added to FTR. Participants received either FTR or a placebo twice daily for 8 days, in addition to their failing ARV regimen. On Day 8, participants treated with FTR had a significantly greater decrease in levels of HIV-RNA than those taking the placebo (0.79 vs. $0.17 \log_{10}$ copies, respectively).⁸ After Day 8, all participants received FTR as part of an optimized regimen. In results reported through 48 weeks,⁸ 54% of participants had an HIV viral load of <40 copies/mL. At Week 96, 60% of participants^{6,9} had HIV viral loads of <40 copies/mL and a mean increase in CD4 T lymphocyte (CD4) cell counts of 205 cells/mm 3 . In 51% (27 out of 53) of evaluable participants with virologic failure, treatment-emergent gp120 genotypic substitutions were detected at four key sites—S375, M434, M426, and M475. In the randomized cohort, virologic response rates increased over time, between the 24-week and 96-week analyses. Response rates were associated with better susceptibility scores for new optimized treatment regimens.¹⁰ Patients with the lowest CD4 counts at baseline were more likely to experience serious adverse events or death.¹⁰

An additional nonrandomized cohort of 99 patients who had no active drugs as treatment options but had FTR added to an optimized ARV regimen was studied. Of these, 38% achieved an HIV viral load of <40 copies/mL at 48 weeks.⁸ For this cohort, at 96 weeks,⁶ 37% of participants had HIV viral loads of <40 copies/mL, and the mean increase in CD4 counts was 119 cells/mm 3 .

Improvements in patient-reported outcomes in health-related quality of life were observed among participants in both cohorts of the BRIGHTE trial at 48 weeks.¹¹

Mechanism of Action

FTR tromethamine is a prodrug of TMR, an HIV-1 gp120-directed attachment inhibitor. FTR is rapidly converted to TMR after oral administration. TMR binds directly to the HIV-1 gp120 and prevents viral attachment and subsequent entry of virus into host T cells. FTR has a novel mechanism of action and no *in vitro* cross-resistance with other ARVs, and it can be used regardless of HIV-1 tropism.⁵

Pharmacokinetics

FTR is pre-systemically metabolized to the active moiety TMR by alkaline phosphatase in the luminal surface of the small intestine, and then TMR is rapidly absorbed. In healthy adults, the estimated half-life is approximately 11 hours.¹²

References

1. Nwokolo N, Post E, Mageau AS, et al. Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration. *HIV Med.* 2023;24(5):580-587. Available at: <https://pubmed.ncbi.nlm.nih.gov/36372442>.
2. Moore K, Thakkar N, Magee M, et al. Pharmacokinetics of temsavir, the active moiety of the HIV-1 attachment inhibitor prodrug, fostemsavir, coadministered with cobicistat, etravirine, darunavir/cobicistat, or darunavir/ritonavir with or without etravirine in healthy participants. *Antimicrob Agents Chemother.* 2022;66(4):e0225121. Available at: <https://pubmed.ncbi.nlm.nih.gov/35315687>.
3. Wire MB, Magee M, Ackerman P, et al. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants. *HIV Res Clin Pract.* 2021;23(1):1-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/35285786>.
4. Lagishetty C, Moore K, Ackerman P, et al. Effects of temsavir, active moiety of antiretroviral agent fostemsavir, on QT interval: results from a Phase I study and an exposure-responses analysis. *Clin Transl Sci.* 2020;13(4):769-776. Available at: <https://pubmed.ncbi.nlm.nih.gov/32027457>.
5. Gartland M, Arnoult E, Foley BT, et al. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. *J Antimicrob Chemother.* 2021;76(11):2958-2964. Available at: <https://pubmed.ncbi.nlm.nih.gov/34297843>.
6. Fostemsavir (Rukobia) [package insert]. Food and Drug Administration. 2024. Available at: https://gskpro.com/content/dam/global/hcportal/en_US/Prescribing_Information/Rukobia/pdf/RUKOBIA-PI-PIL.PDF.
7. Thakkar N, Magee M, Goyal N, et al. Model-based dose selection of fostemsavir for pediatric populations with multidrug-resistant HIV-1 and relative bioavailability assessment in healthy adults. *Clin Pharmacol Drug Dev.* 2023;12(10):991-1000. Available at: <https://pubmed.ncbi.nlm.nih.gov/37329260>.
8. Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. *N Engl J Med.* 2020;382(13):1232-1243. Available at: <https://pubmed.ncbi.nlm.nih.gov/32212519>.
9. Gartland M, Cahn P, DeJesus E, et al. Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1. *Antimicrob Agents Chemother.* 2022;66(6):e0175121. Available at: <https://pubmed.ncbi.nlm.nih.gov/35502922>.

10. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. *AIDS*. 2021;35(7):1061-1072. Available at: <https://pubmed.ncbi.nlm.nih.gov/33946085>.
11. Anderson SJ, Murray M, Cella D, et al. Patient-reported outcomes in the phase III BRIGHTE trial of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals. *Patient*. 2021;15:131-143. Available at: <https://pubmed.ncbi.nlm.nih.gov/34180035>.
12. Magee M, Slater J, Mannino F, et al. Effect of renal and hepatic impairment on the pharmacokinetics of temsavir, the active moiety of fostemsavir. *J Clin Pharmacol*. 2021;61(7):939-953. Available at: <https://pubmed.ncbi.nlm.nih.gov/33368327>.

Ibalizumab (IBA, Trogarzo)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|---|
| <p>Single-Dose Vial for Intravenous Administration: 200 mg/1.33 mL (150 mg/mL) in a single-dose vial. Each single-dose vial contains the following inactive ingredients: L-histidine, polysorbate 80, sodium chloride, and sucrose.</p> | |
| <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Child and Adolescent Dose</p> <ul style="list-style-type: none">The safety and efficacy of using ibalizumab (IBA) in children and adolescents has not been established. <p>Adult Dose</p> <ul style="list-style-type: none">A single-loading dose infusion of IBA, 2,000 mg of diluted solution, is administered intravenously (IV) over 30 minutes.The maintenance dose of IBA is 800 mg given every 2 weeks. The maintenance dose can be given as 800 mg of diluted solution administered IV over 15 minutes or as 800 mg of undiluted solution given by IV push over 30 seconds.U.S. Food and Drug Administration approval of IBA is limited to heavily treatment-experienced adults with multidrug-resistant HIV infection who are experiencing treatment failure on their current regimen.IBA is used in combination with other antiretroviral drugs. | <ul style="list-style-type: none">Diarrhea, dizziness, nausea, rashImmune reconstitution inflammatory syndromeIn studies of cynomolgus macaque monkeys, IBA use during pregnancy was associated with reversible immunosuppression (CD4 T and B cell lymphopenia) in offspring with IBA exposure <i>in utero</i>. Whether this association exists for infants with potential <i>in utero</i> or intrapartum exposure to IBA is unknown. |
| Special Instructions | |
| | <ul style="list-style-type: none">For administration by IV infusion, the appropriate number of vials must be diluted in 250 mL of 0.9% sodium chloride injection.Using aseptic technique, withdraw 1.33 mL from each vial and transfer into a 250-mL bag of 0.9% sodium chloride for IV injection. Other IV diluents must not be used.Once diluted, the solution should be administered immediately. If not used immediately, the solution can be stored at room temperature for up to 4 hours or refrigerated for up to 24 hours. Refrigerated solution should be allowed to stand at room temperature for at least 30 minutes but no more than 4 hours prior to administration.Diluted solution is administered as an IV infusion, not as a bolus or IV push.Undiluted solution may be given by IV push over 30 seconds to administer the maintenance dose. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">Monoclonal antibodies are metabolized to peptides and amino acids. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Ibalizumab (IBA) is a humanized immunoglobulin G4 monoclonal antibody that blocks HIV entry into CD4 T lymphocyte (CD4) cells. Based on IBA's mechanism of action and target-

mediated drug disposition, drug–drug interactions are not expected. However, no drug interaction studies have been conducted.¹

Major Toxicities

- *More common:* Rash, diarrhea, headache, nausea, dizziness, depression^{1,2}
- *Less common (more severe):* Immune reconstitution inflammatory syndrome, hypersensitivity reaction¹

Resistance

HIV has shown reduced susceptibility to IBA, as defined by a decrease in maximum percent inhibition, when HIV loses N-linked glycosylation sites in the V5 loop of glycoprotein 120.¹⁻³

Phenotypic and genotypic test results showed no evidence of cross-resistance between IBA and any U.S. Food and Drug Administration (FDA)–approved classes of antiretroviral (ARV) drugs.⁴ IBA exhibits ARV activity against R5-tropic, X4-tropic, and dual-tropic HIV.⁴

Pediatric Use

Approval

IBA is not approved by the FDA for use in pediatric patients. IBA was approved by the FDA in 2018 for use in adults in combination with other ARV drugs, with approval limited to heavily treatment-experienced adults with multidrug-resistant HIV who are experiencing treatment failure on their current regimen.⁵ IBA has an orphan drug designation exempting the requirement for pediatric studies under federal law. The FDA requested that the company (i.e., Theratechnologies) create a registry to collect prospective data in individuals exposed to IBA during pregnancy to monitor maternal and pregnancy outcomes, including adverse effects on the developing fetus, neonate, and infant. Health care providers are encouraged to report these adverse events to Theratechnologies by calling 1-833-23-THERA (1-833-23-4372).

Efficacy in Clinical Trials

A TaiMed Biologics trial, TMB-301, was conducted in 40 adults aged 23 to 65 years who had body weights ranging from 50 kg to 130 kg, had resistance to ARV drugs from three classes, had been treated for at least 6 months on stable ARV regimens, had viral loads >1,000 copies/mL, and had viral sensitivity to at least one ARV drug.^{3,5} Participants continued their current ARV regimens and received a 2,000-mg loading dose of IBA on Day 7 of the study. One week after the loading dose, participants optimized their ARV regimens. Participants received IBA 800 mg on Day 21 and every 2 weeks thereafter. At Week 25, 43% of participants achieved suppressed viral loads^{1,3} of <50 copies/mL. At Week 48 of an open-label extension study, 24 participants were taking IBA and their optimized ARV regimen. Sixteen of 27 participants (59%) had viral loads <50 copies/mL at 48 weeks.^{6,7}

Mechanism of Action

IBA is a recombinant humanized monoclonal antibody that blocks HIV from infecting CD4 cells. It does this by binding to domain 2 of the CD4 receptor, which interferes with the post-attachment steps that allow HIV virus particles to enter host cells and prevent the viral transmission that occurs via cell-cell fusion.^{1,7} IBA does not interfere with CD4-mediated immune functions because it binds to a conformational epitope located primarily in domain 2 of the extracellular portion of the CD4 receptor, away from major histocompatibility complex II molecule binding sites.

Embryo-Fetal Toxicity

In an enhanced prenatal and postnatal development study, pregnant cynomolgus monkeys were administered intravenous doses of IBA, and significant changes in infant monkey immune cell levels were found (CD4 T cell and B cell lymphocytopenia) that were attributed to *in utero* IBA exposure.¹ The lymphocyte changes correlated with infant monkey IBA serum concentrations and appeared to return to near-normal levels when IBA concentrations were nearly undetectable. One treatment-group infant monkey died from a systemic viral infection with secondary superficial bacterial infection that was acquired during the postnatal period. Despite the low incidence of death (1 of 20 infant monkeys), the death may be related to IBA-induced immunosuppression.¹

Based on these animal data, IBA may cause reversible immunosuppression (CD4 T cell and B cell lymphocytopenia) in infants with potential *in utero* or intrapartum exposure to IBA. Immune phenotyping of the peripheral blood and expert consultation are recommended to provide guidance regarding monitoring and management of exposed infants based on the degree of immunosuppression observed. Furthermore, the safety of administering live or live-attenuated vaccines to infants with *in utero* IBA exposure and abnormal lymphocyte levels is unknown.

References

1. Ibalizumab-uiyk (Trogarzo) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761065s013lbl.pdf.
2. Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. *Front Microbiol.* 2017;8:2323. Available at: <https://pubmed.ncbi.nlm.nih.gov/29230203>.
3. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. *N Engl J Med.* 2018;379(7):645-654. Available at: <https://pubmed.ncbi.nlm.nih.gov/30110589>.
4. Weinheimer S, Cohen Z, Marsolais C, Lewis S. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals. Abstract 561. Presented at: Conference on Retroviruses and Opportunistic Infections 2018. Boston, MA. Available at: <http://www.croiconference.org/sessions/ibalizumab-susceptibility-patient-hiv-isolates-resistant-antiretrovirals>.
5. Food and Drug Administration. FDA clinical pharmacology biopharmaceutics reviews. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/TROGARZO_761065_TOC.cfm.
6. Emu B, Fessel J, Schrader S, et al. Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1. *Open Forum Infect Dis.* 2017;4(Suppl 1):S38-S39. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632088>.
7. Gulick RM. Investigational antiretroviral drugs: what is coming down the pipeline. *Top Antivir Med.* 2018;25(4):127-132. Available at: <https://pubmed.ncbi.nlm.nih.gov/29689540>.

Maraviroc (MVC, Selzentry)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--------------------|--------------------------|---|-------------------------|--------------------|--------------------------|---------|---------------|-------|--------|-----|---------------|-------|------|-----|----------------|--------|------|---------------------------------------|----------------|--------|--------|-------------------|-----------------|--------|-------|---|-----------------|--------|-------|-------------------|--------------|--------|-------|-------------------|--|
| Oral Solution: 20 mg/mL Tablets: 25 mg, 75 mg, 150 mg, 300 mg For additional information, see Drugs@FDA or DailyMed . | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dosing Recommendations | | | | Selected Adverse Events | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none">Maraviroc (MVC) is approved by the U.S. Food and Drug Administration (FDA) for use, in combination with other antiretroviral (ARV) agents, for the treatment of CCR5-tropic HIV-1 infection in infants born full term and weighing ≥ 2 kg, children, adolescents, and adults. <p>Recommended MVC Dose for Full-Term Infants and Treatment-Experienced Children and Adolescents Weighing ≥ 2 kg: Tablets or Oral Solution</p> <table border="1"><thead><tr><th>Weight Band</th><th>Twice-Daily Dosing</th><th>Oral Solution (20 mg/mL)</th><th>Tablets</th></tr></thead><tbody><tr><td>2 kg to <4 kg</td><td>30 mg</td><td>1.5 mL</td><td>N/A</td></tr><tr><td>4 kg to <6 kg</td><td>40 mg</td><td>2 mL</td><td>N/A</td></tr><tr><td>6 kg to <10 kg</td><td>100 mg</td><td>5 mL</td><td>One 25-mg tablet and one 75-mg tablet</td></tr><tr><td>10 kg to 14 kg</td><td>150 mg</td><td>7.5 mL</td><td>One 150-mg tablet</td></tr><tr><td>14 kg to <30 kg</td><td>200 mg</td><td>10 mL</td><td>One 150-mg tablet and two 25-mg tablets</td></tr><tr><td>30 kg to <40 kg</td><td>300 mg</td><td>15 mL</td><td>One 300-mg tablet</td></tr><tr><td>≥ 40 kg</td><td>300 mg</td><td>15 mL</td><td>One 300-mg tablet</td></tr></tbody></table> <p>Recommended doses when MVC is given with noninteracting drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), nevirapine (NVP), enfuvirtide (T-20), and raltegravir (RAL)</p> | | | | Weight Band | Twice-Daily Dosing | Oral Solution (20 mg/mL) | Tablets | 2 kg to <4 kg | 30 mg | 1.5 mL | N/A | 4 kg to <6 kg | 40 mg | 2 mL | N/A | 6 kg to <10 kg | 100 mg | 5 mL | One 25-mg tablet and one 75-mg tablet | 10 kg to 14 kg | 150 mg | 7.5 mL | One 150-mg tablet | 14 kg to <30 kg | 200 mg | 10 mL | One 150-mg tablet and two 25-mg tablets | 30 kg to <40 kg | 300 mg | 15 mL | One 300-mg tablet | ≥ 40 kg | 300 mg | 15 mL | One 300-mg tablet | <ul style="list-style-type: none">Nausea, vomitingAbdominal pain, diarrheaCoughUpper respiratory tract infectionsFeverRashHepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)Postural hypotension (generally seen in patients with severe renal insufficiency)Dizziness |
| Weight Band | Twice-Daily Dosing | Oral Solution (20 mg/mL) | Tablets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 kg to <4 kg | 30 mg | 1.5 mL | N/A | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 kg to <6 kg | 40 mg | 2 mL | N/A | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 kg to <10 kg | 100 mg | 5 mL | One 25-mg tablet and one 75-mg tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 kg to 14 kg | 150 mg | 7.5 mL | One 150-mg tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 kg to <30 kg | 200 mg | 10 mL | One 150-mg tablet and two 25-mg tablets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 30 kg to <40 kg | 300 mg | 15 mL | One 300-mg tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ≥ 40 kg | 300 mg | 15 mL | One 300-mg tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Special Instructions | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none">MVC is recommended for use in patients who have only CCR5-tropic HIV-1. Before using MVC, conduct testing with an HIV tropism assay (see Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines) to exclude the presence of CXCR4-tropic or mixed/dual-tropic HIV. Do not use MVC if CXCR4-tropic or mixed/dual-tropic HIV is present.MVC can be given without regard to food.Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.Use caution when administering MVC to patients with underlying cardiac disease. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Recommended doses when MVC is given with potent cytochrome P450 (CYP) 3A inhibitors (with or without a potent CYP3A inducer), including all protease inhibitors (PIs) | | | | Metabolism/Elimination |
|---|---|--------|---------------------------------------|---|
| 2 kg to <10 kg Not recommended. Data are insufficient to make dosing recommendations for infants weighing <10 kg and receiving a potent P450 CYP3A inhibitor. | | | | <ul style="list-style-type: none"> MVC is a substrate of CYP3A4. If a patient is receiving ARV agents or other medications that act as CYP3A inducers or inhibitors, the dose of MVC should be adjusted accordingly. <p>MVC Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> Use caution when administering MVC to patients with hepatic impairment; MVC concentrations may be increased in these patients. <p>MVC Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> No data recommend specific doses of MVC for pediatric patients with mild or moderate renal impairment. MVC is contraindicated for pediatric patients with severe renal impairment or end-stage renal disease who are on regular hemodialysis and who are receiving potent CYP3A inhibitors. Refer to the manufacturer's prescribing information for the appropriate doses to use in adolescent and adult patients with renal impairment. |
| 10 kg to <20 kg | 50 mg | 2.5 mL | Two 25-mg tablets | |
| 20 kg to <30 kg | 75 mg | 4 mL | One 75-mg tablet | |
| 30 kg to <40 kg | 100 mg | 5 mL | One 25-mg tablet and one 75-mg tablet | |
| ≥40 kg | 150 mg | 7.5 mL | One 150-mg tablet | |
| Recommended doses when MVC is given with potent CYP3A inducers (without a potent CYP3A inhibitor), including efavirenz (EFV) and etravirine (ETR) | | | | |
| Infants and children and adolescents in all weight bands | Not recommended. Data are insufficient to make dosing recommendations. | | | |

Recommended MVC Dose for Adults: Tablets

| When Coadministered with | Dose |
|---|--------------------|
| Noninteracting concomitant medications, including NRTIs, T-20, NVP, and RAL | 300 mg twice daily |
| Potent CYP3A inhibitors (with or without a potent CYP3A inducer), including all PIs | 150 mg twice daily |
| Potent CYP3A inducers (without a potent CYP3A inhibitor), including Efv and ETR | 600 mg twice daily |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Absorption:** Absorption of maraviroc (MVC) is slightly reduced with ingestion of a high-fat meal. Food restrictions were not part of either the adult trials (which used the tablet formulation) or the pediatric trial (which used both the tablet and oral solution formulations) that demonstrated the efficacy, antiviral activity, and safety of MVC. Therefore, MVC can be given with or without food.

- **Metabolism:** MVC is a cytochrome P450 (CYP) 3A and p-glycoprotein (P-gp) substrate and requires dose adjustments when administered with medications that modulate CYP3A or P-gp. A patient's medication profile should be carefully reviewed for potential drug interactions before MVC is administered; recommended MVC doses are based on concomitant medications and their anticipated effect on MVC metabolism.

Major Toxicities

- **More common:** Cough, fever, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain, vomiting, diarrhea, and headache. Dizziness occurred in 12.2% of adults but only 3.2% of children when MVC was administered twice daily.
- **Less common (more severe):** Hepatotoxicity has been reported; some cases were preceded by evidence of a systemic allergic reaction (including pruritic rash, eosinophilia, or elevated levels of immunoglobulin). Serious adverse events (AEs) occurred in <2% of MVC-treated adult patients and included cardiovascular abnormalities (e.g., angina, heart failure, myocardial infarction), hepatic cirrhosis or failure, cholestatic jaundice, viral meningitis, pneumonia, myositis, osteonecrosis, and rhabdomyolysis.

Mechanism of Action

MVC is a CCR5 receptor antagonist that selectively binds to the human chemokine receptor CCR5 on the cell membrane, preventing interaction between HIV-1 glycoprotein 120 and CCR5 tropic HIV-1, inhibiting viral entry into the cell.

Resistance

An HIV tropism assay should be performed before MVC is administered to a patient. Clinical failure may also represent the outgrowth of CXCR4-using (naturally resistant) HIV variants. However, in circumstances when MVC is needed for presumptive HIV therapy for full-term neonates at high risk of perinatal HIV transmission, initiation of MVC should not be deferred until assay results are available, and consultation with an HIV expert is recommended.

Pediatric Use

Approval

MVC is approved by the U.S. Food and Drug Administration (FDA) for treatment of CCR5-tropic HIV virus, when used in conjunction with other antiretroviral drugs, in full-term infants weighing ≥ 2 kg, children, adolescents, and adults.^{1,2}

Pharmacokinetics and Efficacy

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT 2007) study evaluated the pharmacokinetics (PK) and safety of MVC added to a 6-week prophylactic antiretroviral regimen to prevent perinatal HIV transmission of HIV among infants born to mothers with HIV.² Analyses were stratified by exposure to efavirenz (EFV), either *in utero* or through breastmilk, versus non-EFV exposure. The MVC exposure target was average plasma concentration (C_{avg}) ≥ 75 ng/mL, as determined by adult treatment studies. MVC oral solution was

dosed at 8 mg/kg twice daily for the first 6 weeks of life. Among 25 infants with evaluable PK data, 12 of whom were EFV-exposed, 67% of the EFV-exposed infants achieved a $C_{avg} \geq 75$ ng/mL at Week 1, whereas 77% of the EFV-unexposed infants had a $C_{avg} \geq 75$ ng/mL. At Week 4, the proportion of infants achieving a $C_{avg} \geq 75$ ng/mL declined to 42% among EFV-exposed infants and 31% among EFV-unexposed infants. No infants in the study met safety endpoints or discontinued MVC during the study, and no infants acquired HIV. The FDA recommendation for MVC dosing among children >6 weeks of life but younger than 2 years of age is based on modeling using PK data from the IMPAACT 2007 study. A population PK model, which included assessment of age and maturational changes, was developed from IMPAACT 2007 data to describe MVC disposition within the first 6 weeks of life.³ Simulations with FDA-approved weight-band dosing resulted in the majority of simulated patients (84.3%) achieving an average concentration of ≥ 75 ng/mL. When considering the use of MVC for neonates and infants, a pediatric HIV specialist should be consulted.

PK, safety, and efficacy of MVC for treatment-experienced children ages 2 years to <18 years and weighing ≥ 10 kg, and who had plasma HIV RNA $>1,000$ copies/mL were examined in an international dose-finding and efficacy study (A4001031). Of the 103 children who participated in the study, 51% had HIV-1 subtype C, 25% had subtype B, and 23% had other subtypes.

In this trial, the MVC dose was based on body surface area and the composition of the patient's optimized background therapy. Most participants (90 of 103 participants [87%]) received MVC in combination with potent CYP3A inhibitors; 10 participants received MVC with noninteracting medications; and only 3 participants received MVC with CYP3A inducers (without CYP3A inhibitors). The key pharmacologic target (geometric mean $C_{avg} >100$ ng/mL) was achieved with both the tablet and oral solution formulation of MVC.⁴

From a mean baseline plasma HIV RNA concentration of $4.4 \log_{10}$ copies/mL, a decrease of $\geq 1.5 \log_{10}$ occurred in all four age-based cohorts. Only two participants discontinued the study due to AEs. The most common MVC-related AEs through 48 weeks were diarrhea (which occurred in 20.3% of participants), vomiting (19.8%), and upper respiratory infections (16.2%). At Week 48, 48% of participants had HIV RNA <48 copies/mL.⁴ The absolute CD4 T lymphocyte cell count and percentage increased in all four subgroups of the study, with overall median increases of 192 cells/mm³ (interquartile range [IQR] 92–352 cells/mm³) and 4% (IQR 1% to 8%), respectively.

References

1. Maraviroc (Selezentry) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022128Orig1s019,208984Orig1s002lbl.pdf.
2. Rosebush JC, Best BM, Chadwick EG, et al. Pharmacokinetics and safety of maraviroc in neonates. *AIDS*. 2021;35(3):419-427. Available at: <https://pubmed.ncbi.nlm.nih.gov/33252481>.
3. Liyanage M, Nikanjam M, McFadyen L, et al. Maraviroc population pharmacokinetics within the first 6 weeks of life. *Pediatr Infect Dis J*. 2022;41(11):885-890. Available at: <https://pubmed.ncbi.nlm.nih.gov/35980827>.
4. Giaquinto C, Mawela MP, Chokephaibulkit K, et al. Pharmacokinetics, safety and efficacy of maraviroc in treatment-experienced pediatric patients infected with CCR5-tropic HIV-1. *Pediatr Infect Dis J*. 2018;37(5):459-465. Available at: <https://pubmed.ncbi.nlm.nih.gov/29023357>.

Appendix A: Pediatric Antiretroviral Drug Information

Capsid Inhibitors

Lenacapavir (LEN, Sunlenca)

Lenacapavir (LEN, Sunlenca)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|--|
| <p>Tablet: 300 mg</p> <p>Single-Use Vial for Subcutaneous Injection: 463.5 mg/1.5 mL suspension</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Child and Adolescent Dose</p> <ul style="list-style-type: none">The safety and efficacy of using lenacapavir (LEN) in children and adolescents has not been established. <p>Adult Dose</p> <ul style="list-style-type: none">Approved for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection who are experiencing virologic failure on their current antiretroviral (ARV) regimen due to resistance, intolerance, or safety considerations. LEN is used in combination with an optimized background regimen. | <ul style="list-style-type: none">Injection site reactionNauseaHeadache |
| Special Instructions | |
| | <ul style="list-style-type: none">If LEN is discontinued, initiate an alternative, fully suppressive ARV regimen ≤ 28 weeks after the final injection of LEN to avoid virologic resistance. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">Minor metabolism by cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1Major route of elimination is unchanged drug in feces. |
| Dosing in Patients with Hepatic Impairment | |
| | <ul style="list-style-type: none">No dosage adjustment reported. Data on use in patients with severe hepatic impairment are insufficient. |
| Dosing in Patients with Renal Impairment | |
| | <ul style="list-style-type: none">Creatinine clearance (CrCl) ≥ 15 mL/minute: No dosage adjustment is required.CrCl < 15 mL/minute: No dosage adjustments are provided in the manufacturer's prescribing information (i.e., not studied).Dialysis: No dosage adjustments are required. Not expected to be significantly removed by dialysis due to high protein binding. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Concomitant administration of lenacapavir (LEN) (a moderate cytochrome P450 [CYP] 3A inhibitor) with moderate or strong CYP3A inducers may significantly decrease LEN plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to LEN. Concomitant administration with strong inducers is contraindicated and with moderate inducers **is not recommended.**
- Combined P-glycoprotein, uridine diphosphate glucuronosyltransferase 1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of LEN. Concomitant administration of LEN with these inhibitors **is not recommended.**
- LEN is a moderate inhibitor of CYP3A. Due to the long half-life of LEN following subcutaneous (SQ) administration, LEN may increase the exposure of drugs primarily metabolized by CYP3A.
- Drug interactions may occur up to 9 months after the last SQ dose of LEN.

Major Toxicities

- **More common (incidence >10%):** Injection site reactions (62% to 65%)—including pain (19% to 31%), swelling (23% to 36%), erythema (25% to 31%), induration (15%), or the development of a nodule (14% to 25%)—were reported. Most injection site reactions resolve within days; however, nodules may persist for long periods of time consistent with their depot formulation.¹⁻³ Nausea (12% to 14%), headache (8% to 13%),^{2,3} constipation (11% to 13%),^{1,2} and diarrhea (8% to 14%)¹⁻³ have been reported. No Grade 3 or 4 laboratory abnormalities were deemed clinically significant; the most frequent was abnormal creatinine clearance (CrCl) (13%). Low levels of CrCl or estimated glomerular filtration rate or high creatinine levels were transient or unconfirmed abnormalities.²
- **Less common (more severe):** Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy (ART).

Resistance

Resistance to LEN was noted in 8 of 72 patients in the CAPELLA trial (mainly in those with M66I mutations). Resistance largely occurred early in the trial, and half of these patients had low adherence to their optimized background therapy as indicated by plasma drug concentrations.² After 26 weeks, only one patient developed LEN resistance.¹

The reported prevalence of LEN-resistance mutations is low (0.14%) among drug-naïve individuals.⁴

The International Antiviral Society–USA maintains a list of updated [HIV Drug Resistance Mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

LEN is not approved by the U.S. Food and Drug Administration (FDA) for use in pediatric patients. LEN was approved by the FDA in 2022 in combination with other antiretroviral(s) (ARVs) and is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug

resistant HIV-1 infection who are experiencing virologic failure on their current ARV regimen due to resistance, intolerance, or safety considerations. LEN is given alongside two other fully active agents in the treatment of HIV if at least one agent has a high barrier to resistance; otherwise, three fully active agents are recommended in addition to LEN.⁵

There are limited data on the efficacy and safety of LEN in people with HIV who are initiating ART.

LEN is in Phase 3 development for HIV prevention in adults and adolescents.⁶

LEN has not been studied in pregnancy, and it is unknown if LEN is excreted in breast milk.⁷

Efficacy and Pharmacokinetics in Clinical Trials

Clinical Trials in Adults

A randomized, placebo-controlled, double-blind, multicenter trial (CAPELLA) evaluated LEN in combination with an optimized background ART regimen in 72 patients with multidrug resistant HIV-1.² Because CAPELLA was a clinical trial, the optimized background ART regimen did not include experimental agents. CAPELLA enrolled participants 23 to 78 years of age (enrollment criteria included those ≥ 12 years of age) who were experiencing virologic failure on their current regimen and with documented resistance to at least two ARV medications from at least three of the four main classes (nucleoside reverse transcriptase inhibitors, non–nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors) and to no more than two fully active ARV drugs from the four main classes that could be effectively combined. Patients were enrolled in two cohorts according to change in plasma HIV-1 RNA level between the screening and cohort-selection visits. In cohort 1, patients were first randomly assigned in a 2:1 ratio to receive oral LEN or placebo in addition to their failing therapy for 14 days. During the maintenance period, starting on Day 15, patients in the LEN group received SQ LEN once every 6 months, and those in the placebo group received oral LEN, followed by SQ LEN. Both groups also received optimized background therapy. In cohort 2, all the patients received open-label oral LEN with optimized background therapy on Days 1 through 14, and then SQ LEN was administered once every 6 months starting on Day 15. The primary endpoint was defined by the percentage of patients in the first cohort who had a decrease of at least $0.5 \log_{10}$ copies/mL viral load from baseline to Day 15. The secondary endpoint was a viral load of <50 copies/mL at Week 26. The results showed that 21 of 24 (88%) patients in the LEN group met the primary endpoint, as compared to 2 of 12 (17%) patients in the placebo group ($P < 0.001$); 81% of patients met the secondary endpoint.⁸ None of the patients developed serious adverse events that were considered related to LEN. At 52-week follow-up in CAPELLA, nine participants had emergent LEN resistance, four of whom resuppressed to <50 copies/mL. A high rate of virological suppression was achieved in this treatment-experienced cohort, with 83% (95% confidence interval [CI], 67% to 94%) achieving suppression to <50 copies/mL and 86% (95% CI, 71% to 95%) achieving suppression to <200 copies/mL.¹ LEN added to an optimized background regimen led to high efficacy in highly treatment-experienced participants with multidrug resistance but could select for resistance when used unintentionally as functional monotherapy (e.g., when patients have poor adherence to a self-administered optimized background regimen).⁸

CALIBRATE is a Phase 2, ongoing, randomized, open-label trial that enrolled 183 treatment-naïve patients with HIV ≥ 18 years of age to evaluate the efficacy of LEN in various combinations versus bictegravir (BIC)/tenofovir alafenamide/emtricitabine combination pill. At Week 54, virologic

suppression was greater for the BIC-containing combination pill group (92%) compared to various combinations with LEN (85% to 90%). This ongoing study will follow participants through 80 weeks of therapy.³

Pharmacokinetics

The elimination half-life of LEN is about 10 to 12 days (oral formulation) and 8 to 12 weeks (SQ formulation). Residual concentrations of LEN long-acting injection may remain in the systemic circulation of patients for \geq 12 months. To minimize the potential risk of resistance development, an alternative, fully suppressive ARV regimen should be initiated no later than 28 weeks after the final LEN injection when possible.

References

1. Ogbuagu O, Segal-Maurer S, Ratanasawan W, et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a Phase 2/3 trial. *Lancet HIV*. 2023;10(8):e497-e505. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37451297>.
2. Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. *N Engl J Med*. 2022;386(19):1793-1803. Available at: <https://pubmed.ncbi.nlm.nih.gov/35544387>.
3. Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, Phase 2 trial. *Lancet HIV*. 2023;10(1):e15-e23. Available at: <https://pubmed.ncbi.nlm.nih.gov/36566079>.
4. Nka AD, Bouba Y, Teto G, et al. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals. *J Antimicrob Chemother*. 2022;78(1):272-275. Available at: <https://pubmed.ncbi.nlm.nih.gov/36411257>.
5. Mushtaq A, Kazi F. Lenacapavir: a new treatment of resistant HIV-1 infections. *Lancet Infect Dis*. 2023;23(3):286. Available at: <https://pubmed.ncbi.nlm.nih.gov/36841248>.
6. ClinicalInfo Drug Database. Drug database: lenacapavir (HIV prevention). 2023. Available at: <https://clinicalinfo.hiv.gov/en/drugs/lenacapavir-hiv-prevention/health-professional#:~:text=Metabolism%2Felimination,of%20the%20total%20radioactive%20dose>.
7. Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. *Expert Rev Anti Infect Ther*. 2023;21(6):565-570. Available at: <https://pubmed.ncbi.nlm.nih.gov/37067160>.
8. Margot NA, Naik V, VanderVeen L, et al. Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir. *J Infect Dis*. 2022;226(11):1985-1991. Available at: <https://pubmed.ncbi.nlm.nih.gov/36082606>.

Appendix A: Pediatric Antiretroviral Drug Information

Integrase Inhibitors

Bictegravir (BIC)

Cabotegravir (CAB, Vocabria)

Dolutegravir (DTG, Tivicay)

Elvitegravir (EVG)

Raltegravir (RAL, Isentress)

Bictegravir (BIC)

Updated: June 27, 2024

Reviewed: June 27, 2024

Formulations

Bictegravir is available only in a fixed-dose combination (FDC) tablet.

FDC Tablet

- [Biktarvy]
 - Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg
 - Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg

When using FDC tablets, refer to other sections of [Appendix A. Pediatric Antiretroviral Drug Information](#) for information about the individual components of the FDC. See also [Appendix A. Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#).

For additional information, see [Drugs@FDA](#) or [DailyMed](#).

| Dosing Recommendations | Selected Adverse Events | | | | | | |
|--|--------------------------------|------|---------------|--------------------------------|--------|--------------------------------|--|
| <p>[Biktarvy] Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)</p> <p><i>Neonate or Child Aged <2 Years and Weighing <14 kg</i></p> <ul style="list-style-type: none">• No data currently are available on the appropriate dose of Biktarvy in children aged <2 years and weighing <14 kg. Studies are being conducted to develop an age-appropriate formulation and identify the appropriate dose for this age and weight group. <p><i>Child (Aged ≥2 Years), Adolescent, and Adult Dose</i></p> <ul style="list-style-type: none">• One tablet once daily with or without food <table border="1"><thead><tr><th>Body Weight</th><th>Dose</th></tr></thead><tbody><tr><td>≥14 to <25 kg</td><td>BIC 30 mg/FTC 120 mg/TAF 15 mg</td></tr><tr><td>≥25 kg</td><td>BIC 50 mg/FTC 200 mg/TAF 25 mg</td></tr></tbody></table> <ul style="list-style-type: none">• The U.S. Food and Drug Administration approved Biktarvy for use in only antiretroviral therapy-naïve patients or to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen and who have no history of treatment failure and no known mutations associated with resistance to the individual components of Biktarvy. Some members on the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommend the use of Biktarvy in patients with prior treatment failure and who have virus containing the M184V mutation but no other known mutations associated with resistance to the individual components of Biktarvy (see the Efficacy in Clinical Trials in Adults section below). | Body Weight | Dose | ≥14 to <25 kg | BIC 30 mg/FTC 120 mg/TAF 15 mg | ≥25 kg | BIC 50 mg/FTC 200 mg/TAF 25 mg | <ul style="list-style-type: none">• Diarrhea, nausea, headache <p>Special Instructions</p> <ul style="list-style-type: none">• Administer Biktarvy with or without food. See the Drug Interactions section below for guidance when administering Biktarvy with antacids or iron or calcium supplements.• For children who are unable to swallow a whole tablet, the tablet can be split and each part taken separately, as long as all parts are swallowed within approximately 10 minutes. Dissolving tablets may be an alternative, but crushing tablets is not recommended.• Screen patients for hepatitis B virus (HBV) infection before using FTC or TAF. Severe acute exacerbation of HBV can occur when discontinuing FTC or TAF; therefore, monitor hepatic function for several months after halting therapy with FTC or TAF. <p>Metabolism/Elimination</p> <ul style="list-style-type: none">• BIC is metabolized by cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1. |
| Body Weight | Dose | | | | | | |
| ≥14 to <25 kg | BIC 30 mg/FTC 120 mg/TAF 15 mg | | | | | | |
| ≥25 kg | BIC 50 mg/FTC 200 mg/TAF 25 mg | | | | | | |
| | | | | | | | |

| | |
|--|--|
| | <p>Biktarvy Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> Biktarvy is not recommended for use in patients with severe hepatic impairment. <p>Biktarvy Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> Biktarvy is not recommended for use in pediatric patients with estimated creatinine clearance <30 mL/min. See the Biktarvy product label for use in adult patients on dialysis. |
|--|--|

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Metabolism:** Bictegravir (BIC) is a substrate of cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A1. Tenofovir alafenamide (TAF) is a substrate of P-glycoprotein and UGT1A1. Coadministration of the fixed-dose combination (FDC) tablet bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF [Biktarvy]) and rifampin is **contraindicated**.^{1,2}
- Renal effects:** BIC is an inhibitor of organic cation transporter 2 and multidrug and toxin extrusion protein 1, so it decreases tubular secretion of creatinine. This increases serum creatinine and reduces estimated glomerular filtration rate (eGFR) with no change in glomerular function. Drugs that decrease renal function could reduce clearance of emtricitabine (FTC).
- Absorption:** Administering BIC concurrently with antacids lowers the plasma concentrations of BIC. This phenomenon occurs because of the formation of complexes in the gastrointestinal tract and not because of changes in gastric pH. Chelation by high concentrations of divalent cations, such as iron, decreases absorption of integrase strand transfer inhibitors (INSTIs), including elvitegravir and BIC. For this reason, Biktarvy should be administered at least 2 hours before or 6 hours after antacids and supplements or multivitamins that contain iron, calcium, aluminum, magnesium, and/or zinc³ when Biktarvy is given on an empty stomach. Biktarvy and antacids or supplements that contain calcium or iron can be taken together with food.

Major Toxicities

- More common:** Diarrhea, nausea, headache. In two clinical trials, total bilirubin increased by up to 2.5 times the upper limit of normal in 12% of patients who received Biktarvy. In general, however, bilirubin increase was mild and did not lead to drug discontinuations in these trials.² BIC may cause an increase in creatine kinase concentration. One patient out of 201 in a postmarketing observational study in adults experienced thrombocytopenia,⁴ and 1 participant out of 100 in a prospective cohort study in children and adolescents experienced insomnia/anxiety⁵ leading to drug discontinuation. Other neuropsychiatric and central nervous system manifestations have been reported in adults (see [Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity](#)). Weight gain has been reported in adults who were receiving Biktarvy,^{6,7} with an associated increased risk of cardiometabolic complications,⁸ but preliminary pediatric data regarding weight

gain appear to be inconsistent^{9,10} (see [Table 17h. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain](#)).

- *Less common (more severe):* Severe immune reconstitution inflammatory syndrome may be more common with INSTIs than with other antiretroviral (ARV) agents. Drug reaction with eosinophilia and systemic symptoms, or DRESS, syndrome has been reported in an adult starting a BIC-containing regimen.¹¹ Additionally, two cases of drug-induced liver injury—one leading to death—have been reported in adult women with HIV who were switched to a BIC-containing regimen.^{12,13}

Resistance

The International Antiviral Society—USA maintains a list of [HIV drug resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

BIC—available as part of the FDC tablet Biktarvy, which contains BIC 50 mg/FTC 200 mg/TAF 25 mg—was approved by the U.S. Food and Drug Administration (FDA) in 2018 for use in adults and in 2019 for use in children or adolescents weighing ≥ 25 kg. Biktarvy, containing BIC 30 mg/FTC 120 mg/TAF 15 mg, was approved by the FDA in 2021 for use in children aged ≥ 2 years and weighing ≥ 14 to <25 kg. Biktarvy is FDA-approved for patients who have no ARV treatment history or to replace current ARV regimens in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 3 months with no history of treatment failure and no known mutations associated with resistance to the individual components of the FDC.² However, some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommend the use of Biktarvy in patients with prior treatment failure and who have virus containing the M184V mutation but no other known mutations associated with resistance to the individual components of Biktarvy (see the Efficacy in Clinical Trials in Adults section below).

Clinical Efficacy in Adults

In a short-term Phase 1 study, BIC monotherapy at doses of BIC 50 mg or BIC 100 mg was well tolerated. Three out of eight participants in both of these dosing groups achieved HIV RNA <50 copies/mL within 11 days.¹⁴ The efficacy (defined as viral load suppression to HIV RNA <50 copies/mL) and safety (as measured by the incidence of study drug discontinuation or death) of Biktarvy were similar to the efficacy and safety of comparator regimens in two Phase 3 randomized trials in treatment-naïve adults. Viral load suppression occurred in 89% of participants who received coformulated BIC 50 mg/FTC 200 mg/TAF 25 mg ($n = 320$) and in 93% of participants who received a regimen of dolutegravir (DTG) 50 mg plus FTC 200 mg plus TAF 25 mg ($n = 325$). Study drug discontinuation occurred in 1% of participants in both groups.

In a separate trial, viral load suppression occurred in 92% of participants who received BIC/FTC/TAF ($n = 314$) and in 93% of participants who received coformulated abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg (ABC/DTG/3TC) ($n = 315$). Study drug discontinuation was not reported for any of the participants who received BIC/FTC/TAF, although it

did occur in 1% of participants who received ABC/DTG/3TC.^{2,15} Studies that randomized virologically suppressed patients who were on stable ARV regimens to either continue their current regimens or switch to coformulated BIC/FTC/TAF have shown that BIC/FTC/TAF has similar safety and efficacy to existing regimens. Viral load suppression occurred in 94% of participants who were randomized to switch to BIC/FTC/TAF (n = 282) and in 95% of participants who continued taking ABC/DTG/3TC (n = 281). Study drug discontinuation was reported in 2% of participants who received BIC/FTC/TAF and 1% of participants who received ABC/DTG/3TC. Ninety-two percent of participants who were randomized to switch to BIC/FTC/TAF (n = 290) achieved viral load suppression, whereas 89% of participants who continued receiving atazanavir-based or darunavir-based combination ARV regimens (n = 287) achieved viral load suppression. Study drug discontinuation occurred in 1% of participants in both groups.² In an open-label extension following two randomized trials, 98.6% (426 of 432) (95% confidence interval [CI], 97.0% to 99.5%) of participants with available viral load data at week 240 maintained HIV RNA <50 copies/mL; in an analysis counting missing viral loads as failures, 67.2% (426 of 634) (95% CI, 63.4% to 70.8%) met viral suppression criteria. No treatment-emergent resistance to BIC/FTC/TAF was detected, and adverse events led to drug discontinuation in 1.6% of participants.⁶ Similar BIC/FTC/TAF efficacy has been demonstrated in historically underrepresented populations, including Black and female populations with HIV.^{16,17}

Initial studies in participants switching to BIC/FTC/TAF from stable antiretroviral therapy (ART) required undetectable viral load for 3 or 6 months and no proven or presumed preexisting resistance to any of the components of BIC/FTC/TAF.^{2,18,19} Further analysis of data from these studies used proviral genotyping and showed presence of M184V/I mutation in 54 (10%) of 543 BIC/FTC/TAF-treated participants. Presence of this mutation did not affect viral load suppression, with Week 48 HIV RNA <50 copies/mL in 52 (96%) of 54 participants with archived M184V/I mutations compared with Week 48 HIV RNA <50 copies/mL in 561 (98%) of 570 participants without the mutation.²⁰ A study to measure the effect of preexisting nucleoside reverse transcriptase inhibitor (NRTI) mutations on virologic outcome in participants switching from a stable regimen to BIC/FTC/TAF showed Week 48 HIV RNA <50 copies/mL in 223 (94%) of 237 participants without M184V/I resistance and in 42 (89%) of 47 participants with M184V/I mutations at baseline.^{21,22} At Week 48, HIV RNA <50 copies/mL was maintained in 199 (93%) of 213 participants with no NRTI resistance mutation and in 66 (93%) of 71 participants with any NRTI resistance mutation, including K65R/E/N, any number of thymidine analogue mutations (M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/R/N), T69 insertions, T69D, K70E/G/M/Q/S/T, L74I/V, V75A/S/M/T, Y115F, Q151M, or M184V/I.²¹ That study required pre-enrollment virologic suppression for 6 months in those with suspected NRTI resistance and 3 months for those without suspected NRTI resistance.²¹ In an analysis of participant data pooled from six clinical trials switching virologically suppressed adults with HIV to BIC/FTC/TAF, 98% (179 of 182) of participants with pre-existing M184V/I and 99% (2,012 of 2,034) of all participants (with or without M184V/I) had an HIV-1 RNA viral load <50 copies/mL at their last on-treatment visit, with no treatment-emergent resistance to BIC/FTC/TAF.^{21,23-25} In a retrospective review at a single center in Spain involving 506 treatment-experienced adults with HIV who started BIC/FTC/TAF with a viral load <50 copies/mL, 69 (13.6%) had documented preexisting NRTI resistance mutations (11.2% M184V/I and 5.9% tenofovir mutations). In the intention-to-treat analysis, the proportion with a viral load <50 copies/mL was 88.4% (61/69) in those with NRTI resistance mutations versus 82.2% (359 of 437) in those without NRTI resistance mutations. In the per-protocol analysis, the proportions were 93.8% (61 of 65) in those with NRTI resistance mutations versus 94.4% (359 of 380) in those without NRTI mutations.²⁶ In another analysis from an HIV program in Canada using electronic health records from 50 adults with major NRTI resistance mutations prior to starting BIC/FTC/TAF, 49 had a viral load

<100 copies/mL at a mean of 18.6 months after starting the regimen, with the remaining patient having questionable adherence.²⁷ In practice, Panel members have used BIC/FTC/TAF even in patients with detectable viral load, prior ARV failure, or virus containing the M184V mutation but no other known mutations associated with resistance to the individual components of Biktarvy. This practice is based on the premise that the ability to simplify multi-pill or multi-dose regimens to a single small pill, once daily, can overcome potential resistance barriers with definite adherence benefits.²⁸

Pharmacokinetics

Pharmacokinetic (PK) studies of Biktarvy containing BIC 50 mg have been performed in adults, adolescents aged 12 years to <18 years who weigh ≥35 kg, and children aged 6 years to <12 years who weigh ≥25 kg. PK studies of “low-dose” Biktarvy, which contains BIC 30 mg, have been performed in children aged ≥2 years weighing 14 to <25 kg.²⁹ These studies show a higher BIC maximum serum concentration (C_{max}) in the younger cohorts than in the older cohorts, perhaps because the administered dose is higher on a mg/kg basis (see [Table A](#) below). The lower trough serum concentration (C_{tau}) and higher C_{max} in the younger age/lower body weight cohorts suggest more rapid clearance in children and adolescents than in adults. In the cohorts with body weight²⁹ ≥14 to <25 kg and body weight⁵ ≥35 kg, there is a lower geometric mean ratio when C_{tau} is compared to adult values, and the lower 90% CI suggests that some patients have quite rapid clearance (see [Table B](#) below). These PK observations raise the concern that some of the patients in the youngest age/lowest body weight cohorts may experience suboptimal trough concentrations, which may lead to less “pharmacologic forgiveness” in people with lower adherence (see [Table B](#) below).³⁰

Table A. Bictegravir Pharmacokinetics in Children, Adolescents, and Adults with HIV

| PK Parameters | Children Aged ≥2 Years and Weighing ≥14 to <25 kg | Children Aged 6 Years to <12 Years and Weighing ≥25 kg | Adolescents Aged 12 Years to <18 Years and Weighing ≥35 kg | Adults |
|---|--|---|---|-------------------|
| Dose (mg) | 30 | 50 | 50 | 50 |
| Dose for Lowest Weight in the Cohort (mg/kg) | 2.14 | 2 | 1.43 | 1.25 ^a |
| AUC _{tau} ng·h/mL Mean (CV%) | 109,000 (24) | 128,000 (28) | 89,100 (31) | 102,000 (26.9) |
| C _{max} ng/mL Mean (CV%) | 10,100 (21) | 9,460 (24) | 6,240 (27) | 6,150 (22.9) |
| C _{tau} ng/mL Mean (CV%) | 2,000 (78) | 2,360 (39) | 1,780 (44) | 2,610 (35.2) |

^a This dose was calculated using 40 kg as the lowest weight for adults.

Key: AUC_{tau} = area under the concentration time curve over the dosing interval; C_{max} = maximum serum concentration; C_{tau} = trough serum concentration at the end of the dosing interval; CV = coefficient of variation; PK = pharmacokinetic

Sources: Majeed S, German P, West SK, et al. B/F/TAF low-dose tablet relative bioavailability in HVs and PK in children with HIV. Abstract #841. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, MA. Available at: https://www.natap.org/2020/CROI/croi_111.htm

Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, Phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760/>.

Food and Drug Administration. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) [package insert]. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210251s015lbl.pdf.

Table B. Bictegravir Pharmacokinetics in Children and Adolescents with HIV

| Cohort Characteristics | Dose (mg) | Dose for Lowest Weight in Cohort (mg/kg) | GMR% (90% CI) Compared to Adult Values ^a | | |
|--|-----------|--|---|------------------|------------------|
| | | | AUC _{tau} | C _{max} | C _{tau} |
| Aged ≥2 Years and Weighing ≥14 to <25 kg²⁹ | 30 | 2.14 | 109 (96.7–122) | 166 (149–184) | 67.7 (49.6–92.4) |
| Aged 6 Years to <12 Years and Weighing ≥25 kg⁵ | 50 | 2 | 125 (117–134) | 153 (143–163) | 88.9 (80.6–98.0) |
| Aged 12 Years to <18 Years and Weighing ≥35 kg⁵ | 50 | 1.43 | 86 (80–93) | 100 (94–107) | 65.4 (58.3–73.3) |

^a In this table, child and adolescent pharmacokinetic (PK) values are compared with the PK values of adults who received bictegravir 50 mg. The dose for the lowest weight in the adult cohort was 1.25 mg/kg; this was calculated using 40 kg as the lowest weight for adults.

Key: AUC_{tau} = area under the concentration time curve over the dosing interval; C_{max} = maximum serum concentration; C_{tau} = trough serum concentration at the end of the dosing interval; CI = confidence interval; GMR = geometric mean ratio

Use of Biktarvy in Children and Adolescents Weighing ≥25 kg

BIC 50 mg/FTC 200 mg/TAF 25 mg (Biktarvy) was administered to adolescents aged 12 years to <18 years who weighed ≥35 kg (maximum body weight 56.1 kg) and who had maintained viral loads of <50 copies/mL for ≥6 months on their previous ARV regimens. The drug was well tolerated and was associated with a fall in eGFR similar to that seen in adults. This decrease in eGFR was considered to be from changes in tubular secretion of creatinine and was not a true change in glomerular function. In comparing cohorts of children (body weight ≥14 to <25 kg) and adolescents (body weight ≥35 kg) with adult cohorts, the geometric mean ratio of C_{tau} was noted to be lower (see Tables A and B above). All 50 participants in the study had viral loads <50 copies/mL at Week 24, and 49 of 50 had viral loads <50 copies/mL at week 48.⁵

BIC 50 mg/FTC 200 mg/TAF 25 mg was administered to children aged 6 years to <12 years who weighed ≥25 kg and who had had viral loads <50 copies/mL for ≥6 months on their current ARV regimens.⁵ Despite a high area under the curve (AUC) and C_{max} (see [Table A](#) above), the drug combination was well tolerated, with a fall in eGFR similar to that seen in adult studies. One participant stopped the study drug because of insomnia and anxiety. The geometric mean ratio of C_{tau} compared with adult values (see Table B above) showed trough concentrations similar to those seen in adults.⁵ All 50 participants in the study had viral loads <50 copies/mL at Week 24, and 49 of 50 had viral loads <50 copies/mL at Week 48.⁵

Use of Biktarvy in Children Weighing ≥14 to <25 kg

Biktarvy tablets consisting of BIC 30 mg/FTC 120 mg/TAF15 mg were administered to children aged ≥2 years weighing ≥14 to <25 kg and who had viral loads <50 copies/mL on stable ART. PK evaluation showed high AUC and C_{max}, similar to those in patients aged 6 years to <12 years who weighed ≥25 kg, a similarly low C_{tau} (see [Table A](#) above), and a lower geometric mean ratio when C_{tau} was compared with adult values (see [Table B](#) above).²⁹ In general, the low-dose tablet was well tolerated over 55 weeks in the 22 children studied.³¹ Adverse events considered related to the study

drug included transient neutropenia ($n = 2$) and abdominal pain ($n = 3$).³¹ At 24 weeks, the median change in CD4 cell count was a decrease of 100 cells/ μ L, and the change in CD4 percentage was an increase of 0.5%. HIV RNA at <50 copies/mL was maintained in 20 of 22 participants at 24 weeks.³¹

Dosing: Splitting, Dissolving, or Crushing Biktarvy Tablets

The product label states that for children who are unable to swallow a whole tablet, the tablet can be split and each part taken separately, as long as all parts are ingested within approximately 10 minutes.² Dissolving BIC/FTC/TAF tablets may be an alternative method of administration, but crushing tablets **is not recommended.**

In a Phase 1 open-label, single-dose, three-period crossover randomized trial of 18 adult participants without HIV, the bioavailability of Biktarvy (BIC 50 mg/FTC 200 mg/TAF 25 mg) was evaluated in fasting participants who received Biktarvy dissolved in water, crushed in applesauce, or as a solid tablet. Dissolved tablet plasma concentration AUC was considered bioequivalent for all ARV components. Although the dissolved tablet C_{max} was considered bioequivalent for BIC and FTC, the TAF C_{max} 90% lower confidence limit was not (dissolved vs. solid ratio, 96% [90% CI, 74% to 124%]). For crushed tablets mixed with applesauce, the BIC component was considered bioequivalent for AUC and C_{max} . However, crushed FTC and TAF AUC and C_{max} were lower than that of solid tablets, with FTC C_{max} (crushed vs. solid ratio, 70% [90% CI, 63% to 78%]), TAF AUC (84% [90% CI, 69% to 103%]), and TAF C_{max} (66% [90% CI, 51% to 85%]) failing to meet bioequivalence criteria. Crushing Biktarvy tablets may lead to suboptimal FTC and TAF exposures.³²

In the clinical literature, case reports in adults with HIV receiving crushed BIC/FTC/TAF describe inconsistent virological and resistance outcomes.^{24,33-36} These cases varied in underlying comorbidities, baseline viral loads, adherence, method of crushing and dissolving tablets, administration (i.e., orally vs. via a tube), and instructions about polyvalent cation and food administration.

References

1. Custodio J, West SK, Collins S, et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Presented at: Conference on Retroviruses and Opportunistic Infections. 2018. Boston, MA. Available at: <https://www.croiconference.org/sessions/pharmacokinetics-bictegravir-administered-twice-daily-combination-rifampin>.
2. Food and Drug Administration. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) [package insert]. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210251s015lbl.pdf.
3. Rock AE, DeMarais PL, Vergara-Rodriguez PT, Max BE. HIV-1 virologic rebound due to coadministration of divalent cations and bictegravir. *Infect Dis Ther.* 2020;9(3):691-696. Available at: <https://pubmed.ncbi.nlm.nih.gov/32623580>.
4. Hayes E, Derrick C, Smalls D, Smith H, Kremer N, Weissman S. Short-term adverse events with BIC/FTC/TAF: postmarketing study. *Open Forum Infect Dis.* 2020;7(9):ofaa285. Available at: <https://pubmed.ncbi.nlm.nih.gov/32908943>
5. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, Phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://pubmed.ncbi.nlm.nih.gov/34302760>.
6. Sax PE, Arribas JR, Orkin C, et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. *EClinicalMedicine.* 2023;59:101991. Available at: <https://pubmed.ncbi.nlm.nih.gov/37200995>.
7. Emond B, Rossi C, Cote-Sergent A, et al. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. *Curr Med Res Opin.* 2022;38(2):287-298. Available at: <https://pubmed.ncbi.nlm.nih.gov/34812097>.
8. Rebeiro PF, Emond B, Rossi C, et al. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States. *J Int AIDS Soc.* 2023;26(6):e26123. Available at: <https://pubmed.ncbi.nlm.nih.gov/37306118>.
9. Fernandez G, Stevens B, Jang J, Khaitan A. Bictegravir-containing ART regimens and weight gain in children with perinatal HIV. Presented at: International Workshop on HIV and Pediatrics 2022. July 27, 2022–July 28, 2022. Montreal, Canada. Available at: <https://academicmedicaleducation.com/hiv-pediatrics-2022>.
10. Patel K, Karalius B, Yao T, et al. Weight changes after initiation of an integrase strand transfer inhibitor among adolescents and young adults with perinatal HIV in the United States: a descriptive cohort study. Presented at: International Workshop on HIV and

Pediatrics 2022. July 27, 2022–July 28, 2022. Montreal, Canada. Available at: <https://academicmedicaleducation.com/hiv-pediatrics-2022>.

11. DiLorenzo MA, Medrano N, Chen JN, et al. Bictegravir-induced drug reaction with eosinophilia and systemic symptoms in a patient with acute human immunodeficiency virus. *Open Forum Infect Dis.* 2023;10(3):ofad066. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36879628>.
12. Heil EL, Pandit NS, Taylor GH. Probable hepatotoxicity from two second-generation integrase strand transfer inhibitors. *AIDS.* 2021;35(13):2232-2233. Available at: <https://pubmed.ncbi.nlm.nih.gov/34602594>.
13. Sanchez JL, Khiella M, Khoury M, Aryal BB, Verda L. A fatal case of bictegravir-induced fulminant hepatic failure. *Clin Drug Investig.* 2023;43(3):205-208. Available at: <https://pubmed.ncbi.nlm.nih.gov/36856947>.
14. Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. *J Acquir Immune Defic Syndr.* 2017;75(1):61-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/28196003>.
15. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial. *Lancet.* 2017;390(10107):2063-2072. Available at: <https://pubmed.ncbi.nlm.nih.gov/28867497>.
16. Hagins D, Kumar P, Saag M, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized Phase 3b, multicenter, open-label study. *J Acquir Immune Defic Syndr.* 2021;88(1):86-95. Available at: <https://pubmed.ncbi.nlm.nih.gov/34397746>.
17. Orkin C, Ajana F, Kityo C, et al. Brief Report: Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in females living with HIV: an integrated analysis of 5 trials. *J Acquir Immune Defic Syndr.* 2021;88(4):393-398. Available at: <https://pubmed.ncbi.nlm.nih.gov/34506342>.
18. Daar ES. Virology and immunology of acute HIV type 1 infection. *AIDS Res Hum Retroviruses.* 1998;14 Suppl 3:S229-234. Available at: <https://pubmed.ncbi.nlm.nih.gov/9814948>.
19. Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, Phase 3, non-inferiority trial. *Lancet HIV.* 2018;5(7):e357-e365. Available at: <https://pubmed.ncbi.nlm.nih.gov/29925489>.
20. Andreatta K, Willkom M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. *J Antimicrob Chemother.* 2019;74(12):3555-3564. Available at: <https://pubmed.ncbi.nlm.nih.gov/31430369>.

21. Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. *Clin Infect Dis*. 2021;73(2):e485-e493. Available at: <https://pubmed.ncbi.nlm.nih.gov/32668455>.
22. Acosta RK, Willkom M, Andreatta K, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. *J Acquir Immune Defic Syndr*. 2020;85(3):363-371. Available at: <https://pubmed.ncbi.nlm.nih.gov/32701823>.
23. Chamberlain N, Mena L, Brock JB. Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy. *Open Forum Infect Dis*. 2021;8(6):ofab297. Available at: <https://pubmed.ncbi.nlm.nih.gov/34189182>.
24. Rowe SM, Clary JC, Drummond M, Derrick C, Sanasi K, Bookstaver PB. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: a case report and review of the literature. *Am J Health Syst Pharm*. 2022;79(16):1330-1336. Available at: <https://pubmed.ncbi.nlm.nih.gov/35511892>.
25. Sax PE, Andreatta K, Molina JM, et al. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. *AIDS*. 2022;36(11):1511-1520. Available at: <https://pubmed.ncbi.nlm.nih.gov/35466963>.
26. Mican R, de Gea Grela A, Cadinanos J, et al. Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients. *AIDS*. 2022;36(14):1941-1947. Available at: <https://pubmed.ncbi.nlm.nih.gov/35848506>.
27. Shafran SD, Hughes CA. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance. *HIV Med*. 2023;24(3):361-365. Available at: <https://pubmed.ncbi.nlm.nih.gov/35973753>.
28. Levy ME, Griffith C, Ellenberger N, et al. Outcomes of integrase inhibitor-based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents and young adults with HIV infection. *Pediatr Infect Dis J*. 2020;39(5):421-428. Available at: <https://pubmed.ncbi.nlm.nih.gov/32176183>.
29. Majeed S, German P, West SK, et al. B/F/TAF low-dose tablet relative bioavailability in HVs and PK in children with HIV. Abstract #841. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, MA. Available at: https://www.natap.org/2020/CROI/croi_111.htm
30. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. *J Antimicrob Chemother*. 2008;61(4):769-773. Available at: <https://pubmed.ncbi.nlm.nih.gov/18256112>.
31. Natukunda E, Rodriguez C, McGrath E, et al. B/F/TAF in virologically suppressed adolescents and children: two-year outcomes in 6 to <18 year olds and six-month outcomes in toddlers. Presented at: 13th International Workshop on HIV Pediatrics. 2021. Virtual. https://www.natap.org/2021/IAS/IAS_80.htm.

32. Hocqueloux L, Lefevre S, Bois J, et al. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. *J Antimicrob Chemother.* 2022;78(1):161-168. Available at: <https://pubmed.ncbi.nlm.nih.gov/36322475>.
33. Ferrandez JS, Garcia AL, Alonso-Vega GG, Gonzalez AO, Garcia TM. Successful bictegravir/emtricitabine/tenofovir alafenamide treatment in a HIV patient with swallowing difficulties. *Ann Pharmacother.* 2021;55(4):556-557. Available at: <https://pubmed.ncbi.nlm.nih.gov/32862660>.
34. Fulco PP. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. *Am J Health Syst Pharm.* 2020;77(7):509-510. Available at: <https://pubmed.ncbi.nlm.nih.gov/32207818>.
35. Lozano AB, Chueca N, de Salazar A, et al. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. *Antiviral Res.* 2020;179:104717. Available at: <https://pubmed.ncbi.nlm.nih.gov/31982483>.
36. Roa PE, Bazzi R. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer. *Int J STD AIDS.* 2022;33(1):97-98. Available at: <https://pubmed.ncbi.nlm.nih.gov/34787026>.

Cabotegravir

Updated: June 27, 2024

Reviewed: June 27, 2024

Cabotegravir (CAB, Vocabria)

Cabotegravir for Intramuscular Injection (CAB, Apretude)

Cabotegravir and Rilpivirine for Intramuscular Injections (Long-Acting Injectable CAB and RPV, Cabenuva)

| Formulations | |
|--|---|
| <p>Tablet</p> <ul style="list-style-type: none">[Vocabria] Cabotegravir: 30 mg <p>Single-Dose Vial for Intramuscular Injection</p> <ul style="list-style-type: none">[Apretude] Cabotegravir 600-mg/3-mL (200-mg/mL) suspension for intramuscular injection for use as HIV pre-exposure prophylaxis only <p>Co-packaged Formulations</p> <ul style="list-style-type: none">[Cabenuva Kit] Cabotegravir 400-mg/2-mL (200-mg/mL) and rilpivirine 600-mg/2-mL (300-mg/mL) suspension for intramuscular injection (each drug packaged in a separate syringe)[Cabenuva Kit] Cabotegravir 600-mg/3-mL (200-mg/mL) and rilpivirine 900-mg/3-mL (300-mg/mL) suspension for intramuscular injection (each drug packaged in a separate syringe) | |
| <p>When using the co-packaged formulation, refer to the Rilpivirine section for additional information.</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>[Apretude] Cabotegravir (CAB) for Intramuscular Injection</p> <ul style="list-style-type: none">CAB 600 mg/3 mL for intramuscular (IM) injection is approved by the U.S. Food and Drug Administration (FDA) for use as HIV pre-exposure prophylaxis (PrEP) in adults and adolescents weighing ≥ 35 kg; an oral dosing lead-in period of approximately 1 month is optional. See package insert for additional information about dosing and administration of CAB as PrEP; this indication is not addressed in the Pediatric Antiretroviral Guidelines. <p>[Cabenuva] CAB and Rilpivirine (RPV) for IM Injection (Long-Acting Injectable CAB and RPV)</p> <p><i>Pediatric Dose</i></p> <ul style="list-style-type: none">CAB tablets and co-packaged long-acting injectable CAB and RPV are not FDA approved for the treatment of HIV in children aged <12 years. | <ul style="list-style-type: none">DepressionInsomniaHeadacheRash (can be severe and include drug reaction with eosinophilia and systemic symptoms) or hypersensitivityHepatotoxicityAltered adrenocorticotropic hormone stimulation test of uncertain clinical significanceInjection site reactionsCreatine phosphokinase elevation following IM injectionWeight gain |

| <i>Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose</i> | Special Instructions |
|--|--|
| <ul style="list-style-type: none"> • CAB and RPV is a two-drug co-packaged product for IM injection that is FDA approved as a complete regimen for the treatment of HIV-1 in patients with HIV RNA levels <50 copies/mL on a stable antiretroviral (ARV) regimen with no history of treatment failure and no known or suspected resistance to CAB or RPV. • Oral lead-in dosing with CAB and RPV for at least 28 days can be used to assess tolerability prior to initiating long-acting injectable CAB and RPV injections, or patients can proceed directly to long-acting injectable CAB and RPV on the last day of their current ARV regimen. • Refer to the package insert for instructions about changing the frequency of IM injections, i.e., from monthly to every-2-month dosing or from every-2-month to monthly dosing. <p>Oral Lead-in Dosing</p> <ul style="list-style-type: none"> ○ CAB 30 mg orally and RPV 25 mg orally once daily with a meal for at least 28 days. <p>Dosing for Monthly Administration of Long-Acting Injectable CAB and RPV</p> <ul style="list-style-type: none"> ○ On the last day of oral lead-in therapy or the current oral ARV regimen, a loading dose of CAB 600 mg (3 mL) and RPV 900 mg (3 mL) should be given as two separate IM injections in separate ventrogluteal sites. ○ Continuation therapy of CAB 400 mg (2 mL) and RPV 600 mg (2 mL) IM is given 1 month after the loading dose and once a month thereafter, with allowance for a ±7-day administration window. <p>Dosing for Every-2-Month Administration of Long-Acting Injectable CAB and RPV</p> <ul style="list-style-type: none"> ○ To initiate every-2-month dosing, CAB 600 mg (3 mL) and RPV 900 mg (3 mL) should be given as two separate IM injections in separate ventrogluteal sites on the last day of oral lead-in or the current oral ARV regimen and 1 month after the initial injections. ○ After these two initiation injections 1 month apart for 2 months, continuation therapy with IM CAB 600 mg (3 mL) and RPV 900 mg (3 mL) is administered every 2 months, with allowance for a ±7-day administration window. <p>Patients should be monitored for approximately 10 minutes for post-injection reactions. A 23-gauge, 1.5-inch IM needle is recommended for the injection and is provided in the packaging. Longer, 2-inch needles (not included with packaging) should be used in patients with a body mass index >30 kg/m². The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends that providers review instructions available</p> | <ul style="list-style-type: none"> • Coadministering oral RPV with drugs that increase gastric pH may decrease plasma concentrations of RPV. Refer to the RPV package insert for specific instructions regarding use of these products during the oral lead-in dosing. • If monthly injections are missed or delayed by more than 7 days and oral therapy has not been taken, clinically reassess the patient to determine if resumption of injection dosing remains appropriate. Refer to the package insert for information about managing planned and unplanned missed doses. • Long-acting injectable CAB and RPV is a complete regimen. Coadministration with other ARV drugs is not recommended. • When long-acting injectable CAB and RPV injections are stopped, residual concentrations may remain measurable for up to 12 months or longer. It is essential to initiate an alternative, fully suppressive ARV regimen no later than 1 month after the final injections of long-acting injectable CAB and RPV. • Use CAB and RPV with caution when coadministering with a drug that has a known risk of prolonging the QT corrected for heart rate interval or causing Torsades de Pointes (for more information, see CredibleMeds). |
| | <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> • CAB is metabolized by uridine diphosphate-glucuronosyl transferase 1A1. • RPV is a cytochrome P450 3A substrate. <p>Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • No dose adjustment of CAB or long-acting injectable CAB and RPV is necessary in patients with mild or moderate hepatic impairment. <p>Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • RPV decreases tubular secretion of creatinine and slightly increases measured serum creatinine, but it does not affect glomerular filtration. • No dose adjustment of CAB or long-acting injectable CAB and RPV is necessary in patients with mild or moderate renal impairment. However, long-acting injectable CAB and RPV should be used with caution in patients with severe renal impairment or end-stage renal disease. These patients should be monitored more frequently for adverse events. |

with the package insert prior to beginning IM administration of long-acting injectable CAB and RPV. [Additional clinical resources](#), including injection education, are available from the manufacturer, ViiV.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Metabolism:* Cabotegravir (CAB) is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). CAB is contraindicated in patients receiving strong inducers of UGT1A1 because such inducers decrease CAB plasma concentrations which may result in a loss of virologic response.
- Rilpivirine (RPV) is a cytochrome P450 (CYP) 3A substrate, and RPV concentrations may be affected when administered with CYP3A-modulating medications.
- A patient's medication profile should be carefully reviewed for potential drug interactions before CAB plus RPV is administered.
- CAB and RPV are both highly protein bound and unlikely to be removed by hemodialysis.
- Coadministering oral RPV with drugs that increase gastric pH may decrease plasma concentrations of RPV.
 - Antacids should not be taken 2 hours before or 4 hours after oral RPV.
 - H₂ receptor antagonists should not be administered 12 hours before or 4 hours after oral RPV.
 - Oral RPV is contraindicated with proton pump inhibitors.
- Rifamycin drugs significantly reduce CAB and RPV plasma concentrations. For patients who are concomitantly receiving rifabutin and oral RPV, the dose of RPV should be doubled to 50 mg once daily and taken with a meal. Coadministration of the following drugs is contraindicated:
 - Rifampin and oral RPV
 - Rifampin or rifapentine and CAB
 - Rifabutin and long-acting injectable CAB and RPV

Major Toxicities

- *More common:* Injection site reactions, insomnia, headache, rash, elevated creatine phosphokinase serum concentrations
- *More common:* In studies of adults, 7.3% of patients who were treated with RPV showed a change in adrenal function characterized by an abnormal 250-microgram adrenocorticotropic hormone stimulation test (peak cortisol level <18.1 micrograms/dL). In a study of adolescents, 6 of 30 patients (20%) developed this abnormality.¹ The clinical significance of these results is unknown.
- *Less common (more severe):* Depression or mood changes, suicidal ideation

- *Rare*: Hepatotoxicity and post-injection reactions, including dyspnea, agitation, abdominal cramping, flushing, sweating, oral numbness, and changes in blood pressure
- *Rare*: RPV drug-induced liver injury has been reported.²

Resistance

The International Antiviral Society–USA maintains a list of updated [HIV Drug Resistance Mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

CAB oral tablets (Vocabria) and co-packaged long-acting injectable CAB and RPV (Cabenuva) are approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in children or adolescents aged ≥ 12 years and weighing ≥ 35 kg (2022) and adults (2021). They are not approved for use in children aged <12 years. CAB tablets were approved by the FDA in 2021 for use in adults as part of the oral lead-in prior to beginning long-acting injectable CAB and RPV or as an oral interim treatment when patients miss planned injections.^{1,3} CAB and RPV co-packaged extended-release injectable suspensions for IM use are approved for use in patients (monthly or every 2 months) who are virologically suppressed on a stable antiretroviral (ARV) regimen with no history of virologic failure or known resistance affecting either of the component drugs.¹

In December 2021, the FDA approved CAB IM (Apretude) for HIV pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35 kg; an oral lead-in period of approximately 1 month may be used to assess safety and tolerability but is optional. Refer to the package insert for additional information about dosing and administration,⁴ and see the Centers for Disease Control and Prevention [Guidelines for Pre-Exposure Prophylaxis for the Prevention of HIV in the United States](#) for further information about the use of CAB for PrEP.

Efficacy and Pharmacokinetics in Clinical Trials

Clinical Trials in Pediatric Patients 12 Years to <18 Years

The safety and efficacy of CAB, an HIV-1 integrase inhibitor, given in combination with RPV, a non-nucleoside reverse transcriptase inhibitor (NNRTI), has been characterized in a series of clinical trials conducted in adults, which form the basis for approval.

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Study 2017, More Options for Children and Adolescents (MOCHA), is currently in progress to evaluate the safety, tolerability, acceptability, and pharmacokinetics of this injectable regimen in adolescents ([MOCHA Trial](#)) and has reported initial results leading to FDA approval in this age group. MOCHA evaluated 23 virologically suppressed adolescents on stable therapy who received either a 4-week lead-in of oral CAB followed by IM CAB 600 mg at Week 4 and 400 mg at Weeks 8 and 12 (n = 8) or a lead-in of oral RPV followed by IM RPV 900 mg at Week 4 and 600 mg at Weeks 8 and 12 (n = 13). Injection site reactions were observed but did not lead to treatment discontinuations. Two adolescents experienced Grade 3 adverse events, one due to insomnia (CAB arm) and one due to hypersensitivity

reaction to oral RPV, which led to discontinuation.⁵ In a concurrent assessment of adolescent and parental experiences with IM treatment in MOCHA, overall perceptions of the injectable treatment were favorable. Of the 21 adolescents who received all three study injections, >90% “definitely” or “probably” wanted to continue IM treatment.⁶ It should be noted, however, that none of the MOCHA participants received both monthly IM CAB and monthly IM RPV as a dual complete regimen, and clinical experience with this product remains limited. Intermittent viremias have been reported in young adults transitioned to long-acting injectable CAB and RPV with oral lead-in.⁷ The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV notes that significant questions remain regarding the use of long-acting injectable CAB and RPV in pediatric patients, including whether an oral lead-in is beneficial in the adolescent population, whether there are additional adverse effects specific to the pediatric population, whether the use of a two-drug nucleoside-sparing regimen for children with significant ARV treatment history is appropriate, and what potential implementation challenges might exist.

Clinical Trials in Adults

The Phase 3 Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study randomized stable, virologically suppressed adults to receive either CAB and RPV ($n = 308$) or continue their oral antiretroviral therapy (ART) ($n = 308$). Patients assigned to CAB and RPV initiated therapy with an oral regimen for 4 weeks prior to beginning monthly IM injections. The initial assessment at 48 weeks demonstrated that switching to monthly long-acting injectable CAB and RPV was noninferior to continuing a three-drug oral therapy. After 48 weeks, participants were allowed to transition to injections every 2 months in a follow-up study (ATLAS-2M, see below); 52 patients remaining on the original ATLAS study were included in the 96-week analysis. Adverse events were more common among patients receiving injectable ART; injection site reactions were common, but only 1% withdrew from the study because of these events.⁸ The ATLAS-2M trial randomized participants to monthly IM CAB 400 mg and RPV 600 mg ($n = 523$) or every-2-month injections of CAB 600 mg and RPV 900 mg ($n = 522$); it enrolled both new patients and those continuing from the ATLAS trial. After 96 weeks, the every-2-month injections were noninferior to monthly injections, with 11 (2%) confirmed virologic failures in the every-2-month injection group and 6 (1%) in the monthly injection group. No new safety signals were identified, and the rate of injection site reactions—the most common adverse event—was similar across treatment arms. Of those failing the every-2-month injection regimen, a majority had NNRTI resistance-associated mutations.⁹

The First Long-Acting Injectable Regimen (FLAIR) study enrolled 631 treatment-naïve adults and initiated treatment with a standard oral ARV regimen consisting of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) for 20 weeks. Those patients with documented HIV-1 RNA <50 copies/mL after 16 weeks were randomized to either continue oral DTG/ABC/3TC ($n = 283$) or switch to oral CAB and RPV for 4 weeks, followed by monthly injections of CAB and RPV ($n = 283$). After 96 weeks of randomized therapy, nine participants (3.2%) in each arm had HIV RNA >50 copies/mL. Adverse events were common in both treatment groups, but adverse events leading to withdrawal from the study were observed in only 14 (5%) participants in the long-acting injectable CAB and RPV group and 4 (1%) in the oral standard care group. Injection site reactions were the most common adverse events, reported by 245 (88%) participants in the long-acting injectable CAB and RPV group, and lasted a median of 3 days.¹⁰ The FLAIR study was extended to include an assessment of switching those participants remaining in the oral ARV arm after 120 weeks to long-acting injectable CAB and RPV either with or without the initial oral lead-in phase. There were no differences between the lead-in group and the direct-to-injection group in terms of safety, tolerability, or efficacy through an additional 24 weeks on the study.¹¹

These studies demonstrated noninferiority of switching to monthly long-acting injectable CAB and RPV compared to continuing oral ART. In all studies, adult patients expressed a high degree of treatment satisfaction and preference for the long-acting injectable CAB and RPV regimen. Although documented virologic failure with the long-acting injectable CAB and RPV regimen has been rare to date, investigators have attempted to assess the baseline factors associated with treatment failure. In a multivariate analysis of the adult long-acting injectable CAB and RPV Phase 3 trials, presence of at least two baseline factors of RPV resistance-associated mutations, HIV-1 subtype A6/A1, and body mass index $>30\text{kg/m}^2$ was associated with increased risk of virologic failure at 48 weeks.¹²

Pharmacokinetics

The pharmacokinetics (PK) of IM CAB are driven by slow absorption from the injection site. IM CAB reaches its maximum plasma concentration in adults in about 7 days and has a mean half-life of 5.6 to 11.5 weeks. Measurable levels of CAB can be detected in plasma for up to a year or longer. Due to this prolonged drug exposure, it is essential to initiate an alternative, fully suppressive ARV regimen no later than 1 month after the final injections of CAB and RPV to minimize the potential risk of developing viral resistance.¹ The PK profiles observed in adolescents enrolled in MOCHA were comparable to those observed in adults receiving monthly long-acting injectable CAB and RPV in the ATLAS and FLAIR studies described above.⁵

References

1. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf.
2. Lee MJ, Berry P, D'Errico F, et al. A case of rilpivirine drug-induced liver injury. *Sex Transm Infect.* 2020;96(8):618-619. Available at: <https://pubmed.ncbi.nlm.nih.gov/31974214>.
3. Vocabria (cabotegravir) tablets,for oral use [package insert]. Food and Drug Administration. 2023. Available at: https://gskpro.com/content/dam/global/hcpportal/en_us/prescribing_information/vocabria/pdf/vocabria-pi-pil.pdf
4. Apretude (cabotegravir extended-release injectable suspension), for intramuscular use [package insert]. Food and Drug Administration. 2023. Available at: https://gskpro.com/content/dam/global/hcpportal/en_us/prescribing_information/apretude/pdf/apretude-pi-pil-ifu.pdf
5. Moore CB, Capparelli E, Calabrese K, et al. Safety and PK of long-acting cabotegravir and rilpivirine in adolescents. Presented at: Conference on Retroviruses and Opportunistic Infections 2022. Virtual. Available at: <https://www.croiconference.org/abstract/safety-and-pk-of-long-acting-cabotegravir-and-rilpivirine-in-adolescents/>.
6. Lowenthal E, Chapman J, Calabrese K, et al. Adolescent and parent experiences with long-acting injectables in the MOCHA study. Presented at: Conference on Retroviruses and Opportunistic Infections; 2022. Virtual. Available at: https://www.natap.org/2022/CROI/croi_154.htm.
7. Rakhmanina N, Richards K, Adeline Koay WL. Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: considerations for dosing schedule and monitoring. *J Acquir Immune Defic Syndr.* 2023;92(3):e14-e17. Available at: <https://pubmed.ncbi.nlm.nih.gov/36480701>.
8. Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. *AIDS.* 2022;36(2):185-194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34261093>.
9. Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, Phase 3b, non-inferiority study. *Lancet HIV.* 2021;8(11):e679-e689. Available at: <https://pubmed.ncbi.nlm.nih.gov/34648734>.
10. Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, Phase 3 FLAIR

- study. *Lancet HIV*. 2021;8(4):e185-e196. Available at: <https://pubmed.ncbi.nlm.nih.gov/33794181>.
11. Orkin C, Bernal Morell E, Tan DHS, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label Phase 3 FLAIR study. *Lancet HIV*. 2021;8(11):e668-e678. Available at: <https://pubmed.ncbi.nlm.nih.gov/34656207>.
 12. Cutrell AG, Schapiro JM, Perno CF, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. *AIDS*. 2021;35(9):1333-1342. Available at: <https://pubmed.ncbi.nlm.nih.gov/33730748>.

Dolutegravir (DTG, Tivicay, Tivicay PD)

Updated: August 05, 2025

Reviewed: December 04, 2024

| Formulations | |
|--|---|
| Tablets | |
| <ul style="list-style-type: none">• Dispersible tablets for oral suspension [Tivicay PD] 5 mg• Film-coated tablets [Tivicay] 50 mg | |
| Fixed-Dose Combination (FDC) Tablets | |
| <ul style="list-style-type: none">• [Dovato] Dolutegravir 50 mg/lamivudine 300 mg• [Juluca] Dolutegravir 50 mg/rilpivirine 25 mg• [Triumeq] Abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg• [Triumeq PD] Abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg | |
| When using FDC tablets, refer to other sections of Appendix A: Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| All formulations and FDCs of dolutegravir (DTG) are U.S. Food and Drug Administration (FDA)-approved for use in treatment-naïve or treatment-experienced pediatric, adolescent, and adult patients naïve to the integrase strand transfer inhibitor (INSTI) drug class. The Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV endorses the use of DTG as appropriate for some children with prior INSTI use (see Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy and Recognizing and Managing Antiretroviral Treatment Failure in Management of Children Receiving Antiretroviral Therapy). | <ul style="list-style-type: none">• Insomnia• Headache• Neuropsychiatric symptoms (i.e., depression and/or suicidal thoughts or actions), especially in patients with a history of psychiatric illness• Rare cases of hypersensitivity reactions (HSRs), including rash and DRESS (drug reaction [or rash] with eosinophilia and systemic symptoms), constitutional symptoms, and organ dysfunction (including liver injury) |
| Special Instructions | |
| Neonate Dose | <ul style="list-style-type: none">• DTG is not approved by the FDA for use in neonates. |
| | <ul style="list-style-type: none">• DTG may be taken with or without food.• DTG should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral iron supplements, oral calcium supplements, or buffered medications. |

[Tivicay PD] DTG Dispersible Tablets

Infant (Aged ≥4 Weeks and Weighing ≥3 kg), Child, and Adolescent Dose

| Pediatric Body Weight | Recommended Dose ^a of DTG Dispersible Tablets | Number of 5-mg Tablets |
|-----------------------|--|------------------------|
| 3 kg to <6 kg | 5 mg once daily | 1 |
| 6 kg to <10 kg | 15 mg once daily | 3 |
| 10 kg to <14 kg | 20 mg once daily | 4 |
| 14 kg to <20 kg | 25 mg once daily | 5 |
| ≥20 kg | 30 mg once daily | 6 |

^a If certain drugs that induce uridine diphosphate glucuronyl transferase (UGT) 1A or cytochrome P450 (CYP) 3A are coadministered, administer DTG dispersible tablets twice daily (see the Drug Interactions section below).

[Tivicay] DTG Film-Coated Tablets

Child and Adolescent (Weighing ≥14 kg) Dose

- DTG film-coated tablets and DTG dispersible tablets are not bioequivalent and are not interchangeable on a milligram-per-milligram basis. Each formulation has different doses.

Dosing of Film-Coated Tablets for Pediatric Patients Weighing ≥14 kg Who Can Swallow Tablets

| Pediatric Body Weight | Recommended Dose ^a of DTG Film-Coated Tablets | Number of Tablets |
|-----------------------|--|------------------------|
| 14 kg to <20 kg | 40 mg once daily | 4 x 10 mg ^b |
| ≥20 kg | 50 mg once daily | 1 x 50 mg |

^a If certain drugs that induce UGT1A or CYP3A are coadministered, administer DTG tablets twice daily (see the Drug Interactions section below).

^b 10-mg tablets are no longer commercially available. Dosing from the package insert remains in the table above.

Some infants may have received raltegravir as presumptive HIV therapy prior to diagnosis. These infants and other infants and children with HIV who have received INSTIs are candidates to switch to once-daily DTG if they are virologically suppressed or have no mutations associated with resistance to INSTIs.

- For DTG dispersible tablets, fully disperse the dispersible tablets in 5 mL of drinking water (if using one or three tablets) or in 10 mL of drinking water (if using four, five, or six tablets) in the supplied cup; swirl the suspension so that no lumps remain. After full dispersion and within 30 minutes of mixing, administer the oral suspension. Rinse the dosing cup with a small amount of water and give this additional water to the child to ensure the child takes the full dose and no medication remains in the dosing cup.

- DTG dispersible tablets may be swallowed whole. If more than one tablet is required, swallow one tablet at a time to reduce the risk of choking. DTG dispersible tablets should not be chewed or crushed.

- For ABC/DTG/3TC dispersible tablets, tablets should be fully dispersed in the appropriate volume of drinking water in the supplied cup and the suspension should be swirled so that no lumps remain. After full dispersion and within 30 minutes of mixing, administer the oral suspension. Rinse the dosing cup with a small amount of water and give this additional water to the child to ensure the child takes the full dose and no medication remains in the dosing cup.

- ABC/DTG/3TC dispersible tablets should not be swallowed whole, chewed, or crushed.

- No data exist regarding dispersion in breast milk or any vehicles other than water.

- In patients who have difficulty swallowing the film-coated tablets whole, 50-mg tablets may be either split into halves followed by immediate ingestion of **both halves** of the tablet or crushed and added to a small amount of semisolid food or liquid, all of which should be consumed **immediately**.¹

- The efficacy of DTG is reduced in patients with certain combinations of INSTI-resistance mutations. DTG dosing strategies in pediatric patients with first-generation INSTI mutations differ from those in adults (see [Table A](#) and the Resistance section below). Screen patients for hepatitis B virus (HBV) infection before using FDC tablets that contain 3TC. Severe acute exacerbations of HBV can occur after discontinuation of 3TC. Patients with HBV/HIV coinfection who receive Dovato will require additional treatment for chronic HBV infection.

| <p>Adult Dose</p> <ul style="list-style-type: none"> One 50-mg DTG film-coated tablet once daily If certain drugs that induce UGT1A or CYP3A are coadministered, administer DTG 50 mg twice daily (see the Drug Interactions section below). Adults who are INSTI-experienced with certain INSTI-associated resistance mutations or clinically suspected INSTI resistance should receive 50 mg DTG twice daily. | <ul style="list-style-type: none"> For any FDC tablets containing ABC, test patients for the HLA-B*5701 allele before starting therapy to predict the risk of HSRs. Patients who test positive for the HLA-B*5701 allele should not be given an ABC-containing FDC. Patients with no prior HLA-B*5701 testing who are tolerating an ABC-containing regimen do not need to be tested. See the Abacavir section. | | | | | | | | | | | | | | | | | | |
|--|--|------------------------------|------------------------------|----------------|----------------------------------|---|-----------------|-----------------------------------|---|-----------------|-----------------------------------|---|-----------------|-----------------------------------|---|--------|-------------------------|--|--|
| <p>[Dovato] DTG/Lamivudine (3TC)</p> | <p>Metabolism/Elimination</p> | | | | | | | | | | | | | | | | | | |
| <p><i>Adolescents Aged ≥12 Years and Weighing ≥25 kg and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with or without food as a complete regimen in antiretroviral (ARV)-naive adolescents with no known mutations associated with resistance to the individual components of Dovato | <ul style="list-style-type: none"> Substrate for UGT1A1 and CYP3A. Also, a substrate of UGT1A3, UGT1A9, breast cancer resistance protein (BCRP), and P-glycoprotein (P-gp) <i>in vitro</i>. Drugs that induce these enzymes and transporters may decrease plasma concentrations of DTG. Drugs that inhibit these enzymes or transporters may increase DTG plasma concentrations. | | | | | | | | | | | | | | | | | | |
| <p>[Juluca] DTG/Rilpivirine</p> | <p>DTG Dosing in Patients With Hepatic Impairment</p> | | | | | | | | | | | | | | | | | | |
| <p>Adult Dose</p> <ul style="list-style-type: none"> One tablet once daily with a meal as a complete regimen to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months, with no history of treatment failure, and no known mutations associated with resistance to the individual components of Juluca | <ul style="list-style-type: none"> No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Due to the lack of data, DTG is not recommended for use in patients with severe hepatic impairment. FDC tablets containing ABC or 3TC should not be used in patients with impaired hepatic function. | | | | | | | | | | | | | | | | | | |
| <p>[Triumeq PD] Abacavir (ABC)/DTG/3TC</p> | <p>DTG Dosing in Patients With Renal Impairment</p> | | | | | | | | | | | | | | | | | | |
| <p><i>Children Aged ≥3 Months and Weighing ≥6 kg to <25 kg</i></p> <ul style="list-style-type: none"> Dispersible Triumeq PD tablets are FDA approved for children weighing ≥6 kg to <25 kg. They are not recommended for children weighing ≥25 kg. Administer the appropriate number of tablets for a child's weight once daily. Tablets should be dispersed in 15 mL of water if using three tablets or 20 mL of water if using four to six tablets (see Special Instructions). | <ul style="list-style-type: none"> DTG decreases tubular secretion of creatinine and increases measured serum creatinine without affecting glomerular filtration. No dose adjustment is required in INSTI-naive patients with mild, moderate, or severe renal impairment, or in INSTI-experienced patients with mild or moderate renal impairment. Use DTG with caution in INSTI-experienced patients with severe renal impairment (creatinine clearance [CrCl] <30 mL/min), because DTG concentrations will be decreased. The cause of this decrease is unknown. FDC tablets containing 3TC (Dovato, Triumeq PD, and Triumeq) should not be used in patients who have CrCl <30 mL/min or patients who are on dialysis because the doses of 3TC cannot be adjusted. Data about the FDC DTG/3TC (Dovato) suggest that patients with a sustained creatinine clearance 30–49 mL/min may experience a higher 3TC exposure and should be monitored for hematologic toxicities and potential FDC discontinuation and subsequent adjustment of the treatment regimen. See package inserts for additional information. | | | | | | | | | | | | | | | | | | |
| <p>Weight-Band Dosing of Triumeq PD Tablets for Children Aged ≥3 Months and Weighing ≥6 kg</p> | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Weight</th> <th>Recommended Daily Dose</th> <th>Number of Triumeq PD Tablets</th> </tr> </thead> <tbody> <tr> <td>6 kg to <10 kg</td> <td>ABC 180 mg, DTG 15 mg, 3TC 90 mg</td> <td>3</td> </tr> <tr> <td>10 kg to <14 kg</td> <td>ABC 240 mg, DTG 20 mg, 3TC 120 mg</td> <td>4</td> </tr> <tr> <td>14 kg to <20 kg</td> <td>ABC 300 mg, DTG 25 mg, 3TC 150 mg</td> <td>5</td> </tr> <tr> <td>20 kg to <25 kg</td> <td>ABC 360 mg, DTG 30 mg, 3TC 180 mg</td> <td>6</td> </tr> <tr> <td>≥25 kg</td> <td>Use Triumeq. See below.</td> <td></td> </tr> </tbody> </table> | Weight | Recommended Daily Dose | Number of Triumeq PD Tablets | 6 kg to <10 kg | ABC 180 mg, DTG 15 mg, 3TC 90 mg | 3 | 10 kg to <14 kg | ABC 240 mg, DTG 20 mg, 3TC 120 mg | 4 | 14 kg to <20 kg | ABC 300 mg, DTG 25 mg, 3TC 150 mg | 5 | 20 kg to <25 kg | ABC 360 mg, DTG 30 mg, 3TC 180 mg | 6 | ≥25 kg | Use Triumeq. See below. | | |
| Weight | Recommended Daily Dose | Number of Triumeq PD Tablets | | | | | | | | | | | | | | | | | |
| 6 kg to <10 kg | ABC 180 mg, DTG 15 mg, 3TC 90 mg | 3 | | | | | | | | | | | | | | | | | |
| 10 kg to <14 kg | ABC 240 mg, DTG 20 mg, 3TC 120 mg | 4 | | | | | | | | | | | | | | | | | |
| 14 kg to <20 kg | ABC 300 mg, DTG 25 mg, 3TC 150 mg | 5 | | | | | | | | | | | | | | | | | |
| 20 kg to <25 kg | ABC 360 mg, DTG 30 mg, 3TC 180 mg | 6 | | | | | | | | | | | | | | | | | |
| ≥25 kg | Use Triumeq. See below. | | | | | | | | | | | | | | | | | | |

- For use in patients who are ARV naive or ARV experienced (but INSTI naive) and who are not being treated with UGT1A1 or CYP3A inducers
- See the [Abacavir](#) section for special instructions about testing for ABC hypersensitivity.

[Triumeq] ABC/DTG/3TC

Child and Adolescent (Weighing ≥25 kg) and Adult Dose

- One tablet once daily with or without food
- For use in patients who are ARV naive or ARV experienced (but INSTI naive) and who are not being treated with UGT1A1 or CYP3A inducers
- See the [Abacavir](#) section for special instructions about testing for ABC hypersensitivity.

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Metabolism:* Dolutegravir (DTG) is a uridine diphosphate glucuronosyltransferase (UGT) 1A and cytochrome P450 (CYP) 3A substrate and may require dose adjustments when administered with UGT1A-modulating or CYP3A-modulating medications. DTG dosing should be adjusted to twice daily (i.e., twice the usual dose) when coadministered with drugs such as efavirenz and rifampin.²⁻⁴ Because etravirine (ETR) significantly reduces plasma DTG concentrations, DTG **should not be administered** with ETR without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir, which counteract this effect on DTG concentrations. DTG **should not be administered** with nevirapine because of insufficient data on interactions between these drugs. See the product label for a full listing of significant drug–drug interactions.
- Atazanavir (ATV) is an inhibitor of UGT1A1. In a pharmacologic survey of adult patients who were receiving DTG, patients who also received ATV had plasma concentrations of DTG that were twofold to fourfold higher than those of patients who received other antiretroviral (ARV) drugs.⁵
- Before administering DTG, clinicians should carefully review a patient’s medication profile for potential drug interactions.

Major Toxicities

- *More common:* Insomnia and headache. Excessive weight gain and increased body mass index (BMI) have been reported in adults who received DTG in clinical trials and in some pediatric and adolescent cohorts (see [Table 17h. Lipodystrophies and Weight Gain](#)),⁶⁻⁹ whereas other cohort studies have not identified an association with excessive weight gain.¹⁰

- *Less common (more severe)*: Hypersensitivity reactions characterized by rash, constitutional symptoms, and sometimes organ dysfunction; neuropsychiatric symptoms, especially in patients with a history of psychiatric illness. Multiple postmarketing reports note that neuropsychiatric adverse events (AEs) have occurred following the initiation of DTG-based therapy in adults.^{11,12}
- *Immune reconstitution inflammatory syndrome (IRIS)*: In retrospective observational studies, severe cases of IRIS that required hospitalization appeared to be more frequent in patients who presented with advanced HIV disease and who initiated treatment with integrase strand transfer inhibitors (INSTIs), particularly DTG.^{13,14} This phenomenon is presumed to be linked to the rapid decline in HIV RNA observed in patients receiving INSTI-based therapy.
- *Rare*: Hepatotoxicity has been reported; two cases of liver injury were presumed to be related to the use of DTG. One of these cases required liver transplantation.^{15,16}
- *Rare*: A single case of drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS) has been reported.¹⁷

Resistance

The International Antiviral Society–USA maintains a [list of updated resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation. For additional considerations on the impact of nucleoside reverse transcriptase inhibitor (NRTI) resistance and the use of DTG-containing fixed-dose combinations (FDCs), see [Recognizing and Managing Antiretroviral Treatment Failure](#).

The efficacy of DTG is reduced in patients with the INSTI-resistance Q148 substitution plus two or more additional INSTI-resistance mutations, and this reduced efficacy cannot be completely overcome with increased DTG dosing.^{18,19}

For INSTI-experienced adults with certain INSTI-resistance mutations or clinically suspected INSTI resistance, the [Tivicay package insert](#) recommends giving the standard 50-mg dose twice daily rather than once daily. However, modeling and simulation of this potential strategy with the dispersible tablet formulation of DTG in children suggested elevated maximum plasma concentrations (C_{max}) in comparison to historical data in adults, adolescents, and children would result. Thus, a different dosing strategy was needed for children with certain or clinically suspected INSTI-resistance mutations. The proposed dosing schedule in [Table A](#) below was based on simulations with the goal of achieving geometric mean concentration at 12 hours postdose $>1.97 \mu\text{g}/\text{mL}$ and area under the curve (AUC) through 12 hours postdose $>32.2 \mu\text{g}\cdot\text{h}/\text{mL}$ while avoiding elevated C_{max} values.²⁰ Additionally, the coformulated dispersible tablet containing abacavir (ABC)/DTG/lamivudine (3TC) cannot be used in combination with a separate dose of single-agent dispersible release DTG because the dosing of the separate formulation is not double the regular dose and the modified dosing strategy would result in underdosing the ABC and 3TC components.

Table A. Weight-Band Dosing of Dolutegravir Dispersible Tablets for Pediatric Patients Weighing \geq 3 kg and Aged \geq 3 Months With First-Generation Integrase Strand Transfer Inhibitors—Resistance Mutations

| Weight | Recommended Twice-Daily Dose | Number of Tablets per Dose |
|-----------------|------------------------------|----------------------------|
| 3 kg to <6 kg | 5 mg | 1 |
| 6 kg to <10 kg | 10 mg | 2 |
| 10 kg to <14 kg | 15 mg | 3 |
| 14 kg to <20 kg | 15 mg | 3 |
| 20 kg to <30 kg | 20 mg | 4 |
| 30 kg to <40 kg | 20 mg | 4 |

Pediatric Use

Approval

DTG is approved by the U.S. Food and Drug Administration (FDA) for use, in combination with other ARV drugs, in pediatric patients aged at least 4 weeks and weighing \geq 3 kg who are treatment naive or treatment experienced but INSTI naive (see [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)). DTG dispersible tablets and film-coated tablets in either the single-entity or FDC form can be administered with or without food.^{21,22} Pediatric patients weighing \geq 20 kg may take the DTG 50-mg film-coated tablets if they are able to swallow tablets.

The combination tablet ABC/DTG/3TC (Triumeq) is approved by the FDA for use in children and adolescents weighing \geq 25 kg. Dispersible ABC/DTG/3TC tablets (Triumeq PD) are FDA approved for use in children weighing \geq 6 kg to <25 kg.

The combination tablet DTG/3TC (Dovato) is approved by the FDA for adolescents weighing \geq 25 kg and aged \geq 12 years but is not approved for use in children aged <12 years.

The combination tablet DTG/rilpivirine (RPV) (Juluca) is not approved by the FDA for use in children or adolescents. However, the doses of the component drugs that make up this FDC tablet are approved for use in adolescents and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (the Panel) generally endorses the use of adult formulations for drugs that have been approved for use in children and adolescents. The FDC tablet may be appropriate for use in certain adolescents. See [Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy](#) for additional considerations on the use of this combination.

Formulation Differences: Film-Coated Tablet Compared to Dispersible Tablet

DTG is currently available as either film-coated tablets or dispersible tablets (tablets for oral suspension). The dispersible tablet has 60% to 80% greater bioavailability in adults than the film-coated tablet,²³ so recommended doses using the dispersible tablet cannot be directly compared to

those using the film-coated tablets. The drug exposure provided by the 50-mg film-coated tablet is approximately equal to that of DTG 30 mg administered as dispersible tablets.

Efficacy and Pharmacokinetics

Pediatric Patients Aged 4 Weeks to <18 Years

Single-Entity Dolutegravir

[IMPAACT P1093](#) is a multinational, open-label trial of DTG in children with HIV. Data from IMPAACT P1093 Cohort 1 (aged 12 years to <18 years) and Cohort 2 (aged 6 years to <12 years) provided support for use of DTG film-coated tablets in pediatric patients weighing ≥14 kg; Cohort 3 (aged 2 to <6 years), Cohort 4 (aged 6 months to <2 years), and Cohort 5 (aged 4 weeks to <6 months) provided evidence supporting the use of DTG 5-mg dispersible tablets. Dosing recommendations that previously included the 25-mg film-coated tablets have been replaced with other formulations.

Results of pharmacokinetic (PK), safety, and efficacy assessments have been reported sequentially for different age and weight cohorts as data became available; similarly, dosing recommendations have been revised sequentially.²⁴⁻²⁶ A total of 181 participants were enrolled across these cohorts, of which 96 received dispersible DTG tablets and 85 received nondispersible formulations.²⁶ Seventy-five participants received the recommended doses of the film-coated or dispersible tablets based on their weight and age, of which 80% were treatment-experienced and all were INSTI-naive.²⁷ At Week 48, of the 42 participants with available data, 69% achieved HIV RNA <50 copies/mL and 79% achieved HIV RNA <400 copies/mL. The effectiveness observed in the trial was comparable to that of treatment-experienced adult participants.²⁷ The median CD4 T lymphocyte cell (CD4) count (percent) increased from baseline to Week 48 by 141 cells/mm³ (7%). Overall, the safety profile in P1093 participants was comparable to that observed in adults, and both formulations were well tolerated.²⁷ Follow-up data among 16 adolescents in Cohort 1 through 144 weeks showed 43% and 35% of participants achieving and maintaining HIV RNA levels <400 copies/mL and <50 copies/mL, respectively.²⁸ Genotypic testing was available at the time of treatment failure for 6 of the 13 participants; one of these adolescents developed DTG resistance.^{26,28}

The Once-daily DTG-based ART in Young people vS Standard thErapY (ODYSSEY) trial, conducted by the Pediatric European Network for the Treatment of AIDS (PENTA), enrolled both treatment-naïve and treatment-experienced pediatric patients from the European Union, Thailand, and several African countries; this trial initially evaluated doses approved by the European Medicines Agency at the time the trial started. A total of 707 children aged <18 years were enrolled; 311 children started DTG as first-line therapy, and 396 started DTG as second-line therapy.²⁹ DTG-based antiretroviral therapy (ART) as both first-line therapy and second-line therapy in children was superior to standard care through 96 weeks of treatment.³⁰ Results from the younger ODYSSEY cohort of children weighing between 3 kg and 14 kg showed superiority of DTG-based ART compared with other regimens, of which over 70% were protease inhibitor (PI)-based regimens.³⁰⁻³² Follow-up data through 192 weeks continued to demonstrate the superiority of DTG-containing ART for virologic suppression compared with first- and second-line ART.³³

Nested PK substudies within ODYSSEY also evaluated simplified pediatric dosing that aligned with World Health Organization (WHO)-recommended weight bands. PK data are available from a cohort of children weighing >25 kg who switched to the DTG 50-mg film-coated tablet, 20 kg to <25 kg

who received either the DTG 50-mg film-coated tablet or DTG 30 mg administered as six 5-mg dispersible tablets,^{34,35} 14 kg to <20 kg who received 25 mg, 3 kg to <6 kg and younger than 6 months received 5 mg DTG, 3 kg to <6 kg and older than 6 months who received 10 mg, 6 kg to <10 kg who received 15 mg, and 10 kg to <14 kg who received 20 mg.³⁵ A total of 19 children weighing <20 kg experienced Grade 3 or higher AEs, including two deaths (one kwashiorkor and one accidental trauma) assessed as unrelated to the study drug. Eleven participants experienced serious AEs, 69% of which were due to infectious diseases.

Combined PK data from P1093 and ODYSSEY across all age/weight cohorts form the basis for the current FDA dose recommendations and are summarized in [Table B](#) below. Generally speaking, the AUC and C_{max} values were comparable or higher than adult values, whereas troughs were slightly lower and more variable, but exposures still fell within acceptable exposure ranges across weight bands. These data support the administration of either DTG 30 mg as dispersible tablets or DTG 50 mg as a film-coated tablet in patients weighing ≥20 kg. In addition, modeling and simulations that included UGT1A1 maturation in infants were used to support the dose of DTG in infants at least 4 weeks of age and weighing at least 3 kg. Dosing in neonates is under investigation.

Separate PK studies and population PK models have continued to support adequate DTG exposures among children and adolescents at the currently recommended doses.^{21,36-40} Exploratory investigations also have identified that genetic variants in ATP-binding cassette subfamily G member 2 (ABCG2), nuclear receptor subfamily 1 group I member 2, and UGT1A1 may affect DTG PK in infants and children, which may explain some of the additional variability observed in this population.⁴¹ Genetic variants in ABCG2 and UGT1A1 that were associated with higher DTG exposures showed a trend toward sustained virologic suppression.

Table B. Summary of Pharmacokinetic Parameters in Pediatric Participants With HIV-1 (Pooled Analyses for IMPAACT P1093 and ODYSSEY Trials)

| Weight Band ^a | Dose ^b of DTG FCT or DTG DT | n | Pharmacokinetic Parameter Geometric Mean (% CV) | | |
|--------------------------|--|----|---|---------------------------------|--------------------------|
| | | | C _{max} (mcg/mL) | AUC _{0-24h} (mcg·h/mL) | C _{24h} (ng/mL) |
| 3 kg to <6 kg | DTG DT 5 mg once daily | 8 | 3.80 (34) | 49.37 (49) | 962 (98) |
| 6 kg to <10 kg | DTG DT 15 mg once daily | 17 | 5.27 (50) | 57.17 (76) | 706 (177) |
| 10 kg to <14 kg | DTG DT 20 mg once daily | 13 | 5.99 (33) | 68.75 (48) | 977 (100) |
| 14 kg to <20 kg | DTG DT 25 mg once daily | 19 | 5.97 (42) | 58.97 (44) | 725 (75) |
| 20 kg to <25 kg | DTG DT 30 mg once daily | 9 | 7.16 (26) | 71.53 (26) | 759 (73) |
| ≥20 kg | DTG FCT 50 mg once daily | 49 | 4.92 (40) | 54.98 (43) | 778 (62) |

Table B: Summary of Pharmacokinetic Parameters in Pediatric Participants With HIV-1 (Pooled Analyses for IMPAACT P1093 and ODYSSEY Trials)

| | | | | | |
|---------------------|------------------------------|-----|-----------|-----------|------------|
| Adults ^c | DTG FCT 50 mg once daily | N/A | 3.67 (20) | 53.6 (27) | 1,110 (46) |
| Adults ^c | DTG FCT 50 mg twice daily | N/A | 4.15 (29) | 75.1 (35) | 2,120 (47) |

^a Data are from two weight-band-based pharmacokinetic substudies in the ODYSSEY trial.

^b The bioavailability of DTG tablets for oral suspension is approximately 1.6-fold that of DTG film-coated tablets.

^c Adult pharmacokinetic data are based on population pharmacokinetic analyses from clinical trials.²⁷

Key: AUC_{0-24h} = 24-hour area under the curve; C_{24h} = concentration at 24 hours postdose; C_{max} = maximum plasma concentration; CV = coefficient of variation; DT = dispersible tablets; DTG = dolutegravir; FCT = film-coated tablets

Dolutegravir/Abacavir/Lamivudine

The PK, safety, tolerability, and efficacy of dispersible and immediate-release ABC/DTG/3TC FDC tablet formulations were investigated in 57 children weighing 6 kg to <40 kg and aged <12 years among those enrolled in the IMPAACT 2019 study.⁴² Children were dosed across five weight bands in alignment with the WHO ARV dosing recommendations for each component. Children weighing 6 kg to <25 kg received dispersible FDC tablets containing ABC 60 mg/DTG 5 mg/3TC 30 mg (Triumeq PD), and those weighing 25 kg to <40 kg received the immediate-release FDC tablet containing ABC 600 mg/DTG 50 mg/3TC 300 mg (Triumeq). Drug exposures for all three components were comparable to previous studies in children and adults with HIV, including DTG exposures from IMPAACT P1093 and ODYSSEY. Dosing was confirmed based on PK and safety criteria across all weight bands. No Grade 3 or 4 AEs related to the drug components were identified through 24 weeks of treatment, and none of the participants discontinued the study drug because of AEs. At Week 24, 54 of 57 (95%) participants were suppressed to HIV-1 RNA <200 copies/mL, 52 of 57 (91%) were suppressed to HIV-1 RNA <50 copies/mL, and all treatment-experienced patients who switched to ABC/DTG/3TC maintained suppression. Both formulations were also well tolerated, and 10 of 11 participants in the highest weight band were able to swallow the larger immediate-release tablet whole and intact (see [Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents](#)). This finding contrasted a separate cohort of 12 adolescents in Spain, where half needed to crush or split the immediate-release tablet because of its size.⁴³ Analyses of safety and efficacy data through 48 weeks in IMPAACT 2019 are ongoing.

Population PK modeling of IMPAACT 2019 data through 48 weeks further demonstrated alignment of PK data collected within this study with existing population PK models for the individual components, further supporting dose confirmation of the dispersible FDC.⁴⁰ These models were then modified with maturation functions specific to each component to evaluate whether a single ABC 60 mg/DTG 5 mg/3TC 30 mg tablet in infants weighing ≥3 kg to <6 kg (aged ≥4 weeks) could achieve comparable drug exposures observed in older children and adults based on dosing simulations, and thus provide comparable safety and efficacy observed in older children and adults.⁴⁴ These models used data from young children across weight bands from IMPAACT 2019 (≥6 kg), P1093 (≥3 kg), ODYSSEY (≥3 kg) clinical trials for DTG, and the PETITE clinical trial for ABC and 3TC.^{26,35,40,42,45,46} Review of the ABC/3TC data from the PETITE study in neonates^{45,46} and available ABC, 3TC, and DTG safety data in infants aged <3 months (see below under Pediatric Postmarketing Safety Studies) were used to interpolate safety for infants aged ≥4 weeks to <3 months and suggested no safety concerns for coadministration of ABC/3TC/DTG in young infants. Notably, the doses in the safety evaluation were mostly in alignment with the WHO weight-band dose.

recommendations of fixed-dose formulations of ABC 120 mg/3TC 60 mg, which were higher than those under evaluation in this modeling and simulation. Based on these findings, the Panel supports the use of the single ABC/3TC/DTG FDC dispersible tablet as an alternative to the separate formulations of ABC, 3TC, and DTG in infants weighing ≥ 3 kg to <6 kg and aged ≥ 4 weeks to facilitate treatment adherence.

Retrospective Cohort Studies

Efficacy and safety of DTG-based regimens have been evaluated in multiple observational pediatric cohorts.⁴⁷⁻⁵¹ These studies have included a variety of populations, including children, adolescents, and young adults who were ART experienced but INSTI naive and either virologically suppressed or viremic at baseline. Virologic suppression rates between about 80% to 93% have been reported following at least 6 months to 24 months of DTG-containing therapy.⁴⁸⁻⁵³ Discontinuation rates due to toxicity have generally been low (<1%).⁴⁸ Factors associated with a higher likelihood of virologic suppression following the switch included suppressed viral loads at baseline,^{47-49,51,52} use of once-daily TDF/3TC/DTG as a single-tablet regimen (compared with ABC/3TC/DTG or ZDV/3TC/DTG),⁴⁸ and good medication adherence. Factors associated with lower odds of virologic suppression included age increases and poorer adherence.^{48,50,51} Given the retrospective nature of these analyses, many of which were performed following national rollout programs, direct comparisons among participants who were not suppressed and did not switch to a DTG-containing regimen could not always be performed.⁴⁸

Although observational studies have shown high virologic suppression rates, emerging INSTI mutations specific to DTG have been reported among children being monitored in national treatment programs.⁵³ Thus, continued assessments of sustained long-term virologic suppression (i.e., >24 months) and the development of resistance will be important.^{54,55} Additionally, one study noted⁵² more than one-third of children experienced at least two regimen changes during the follow-up period from 2019 to 2021, some of which involved switching from DTG to either a PI or non-nucleoside reverse transcriptase inhibitor (NNRTI). These changes were attributable, in part, to drug shortage, illustrating the importance of continued access and supply of DTG to support rollout initiatives.⁴³

Pediatric Postmarketing Safety Studies

Several studies continue to investigate longer-term safety outcomes in pediatric populations with the expanded use of DTG. Notable outcomes of interest include neuropsychiatric outcomes and growth, weight gain, and metabolic effects over time based on findings in adults.

ODYSSEY reported a small number of neuropsychiatric AEs among 707 children and adolescents randomized to DTG, which was not significantly different from those reported in study participants receiving standard care. However, participants receiving DTG were more likely to have suicidal ideation than those receiving standard care; however, these symptoms were described as transient and did not lead to changes in ART.³¹ A separate systematic review of INSTI use in 3,448 children with perinatal HIV infection identified rates of neuropsychiatric effects from 1% to 16% among those receiving DTG.⁵⁶

Reports of weight gain among adults enrolled in clinical trials prompted similar studies to investigate the metabolic effects of DTG in adolescents. Some studies have identified increases in weight-for-age z-score and BMI-for-age z-score,^{7,9,32} as well as trunk fat and trunk/total body fat ratios.⁶

However, others have not identified significant changes^{8,10,57} or lower rates of change among those with baseline BMI \geq 50th percentile.⁵⁸ Lipid changes also have been evaluated, with one study detailing decreases in total cholesterol and low-density lipoproteins, while serum triglycerides decreased early in the study and subsequently increased.⁶ In another study, adolescents who switched to DTG (n = 30) demonstrated reduced hepatic steatosis and lower total cholesterol and triglycerides compared to those who remained on their initial ART regimens (84% PI-based).⁵⁷ Based on these collective data, weight gain may be observed in adolescents receiving DTG, as observed in adults; the long-term clinical significance of these changes is unclear, and further studies are needed in adolescents and children receiving DTG. See the [What to Start](#) section for additional considerations.

Simplification of Treatment

Dolutegravir With Rilpivirine

Two trials in adults (Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults [SWORD-1 and SWORD-2]) supported the approval of a DTG 50-mg/RPV 25-mg FDC tablet as a complete regimen for treatment simplification or maintenance therapy in selected patients. The two identical SWORD trials enrolled 1,024 virologically suppressed patients who had been on stable ART for at least 6 months and who had no history of treatment failure or evidence of resistance mutations. The participants were randomized either to receive DTG/RPV or to continue their suppressive ARV regimen. After 48 weeks of treatment, 95% of patients in both arms maintained HIV RNA levels <50 copies/mL.⁵⁹ After 52 weeks, the participants who had been randomized to continue their suppressive ARV regimen were switched to DTG/RPV. At 148 weeks, 84% of the early-switch patients and 90% of the late-switch patients remained virologically suppressed, and only 11 patients receiving dual therapy met virologic failure criteria. No INSTI-resistance was identified.⁶⁰ During the comparative randomized phase of the study, more AEs were reported and led to discontinuation in the DTG/RPV arm. In a subgroup of the SWORD study, small but statistically significant increases in hip and spine bone mineral density and bone turnover markers were observed in patients whose original ARV regimen contained TDF.⁶¹

Although Juluca is not approved by the FDA for use in adolescents, the doses of the component drugs that make up this FDC tablet are approved for use in adolescents. The Panel generally endorses the use of adult formulations for drugs that have been approved for use in children and adolescents, and these products may be appropriate for use in certain adolescents. The use of DTG/RPV regimens could be useful in patients in whom there is concern for toxicity from NRTIs. However, the Panel notes that adolescents may have difficulties adhering to therapy and suggests considering close monitoring with viral load testing (see the Treatment Simplification section of [Management of Children Receiving Antiretroviral Therapy](#)).

Dolutegravir With Lamivudine

The approval of DTG 50 mg/3TC 300 mg as a complete regimen in adults was supported by data from two randomized, double-blind, controlled trials (Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naive HIV Infected Subjects [GEMINI-1 and GEMINI-2]). GEMINI-1 and GEMINI-2 were identical 148-week trials that enrolled a total of 1,433 adults with HIV who had plasma HIV RNA levels between 1,000 copies/mL and \leq 500,000 copies/mL at screening and no evidence of major resistance mutations or hepatitis B virus infection. Participants were randomized to receive

either DTG plus 3TC or DTG plus 3TC/TDF. During 96 weeks of treatment, 86% of patients who received DTG plus 3TC and 89.5% of patients who received DTG plus 3TC/TDF achieved HIV RNA levels <50 copies/mL. Patients who received DTG plus 3TC had a lower rate of adverse drug reactions (19.6%) than those who received DTG plus 3TC/TDF (25%).⁶²

The combination of DTG/3TC was evaluated as initial ART in adolescents weighing ≥ 25 kg and aged ≥ 12 years to <18 years with baseline HIV-1 RNA between 100 copies/mL and $\leq 500,000$ copies/mL through the DANCE study. A total of 32 participants were enrolled, of which 81% and 69% achieved HIV RNA levels <50 copies/mL at Weeks 48 and 96, respectively.⁶³ These results included individuals with missing data due to site closures; thus, sensitivity analyses were performed with the participants excluded. Virologic suppression rates in the sensitivity analyses were 87% (26 of 30) at Week 48 and 88% (22 of 25) at Week 96. Drug exposures for both components were also comparable to historical data in adults and the combination was overall safe and well tolerated.

Both film-coated tablet and dispersible tablet formulations of DTG/3TC are also under active investigation in children aged 2 years to <15 years of age and weighing 6 kg to <40 kg through the D3/Penta21 study.⁶⁴ The doses under evaluation include DTG 15 mg/3TC 90 mg for 6 kg to <10 kg, DTG 20 mg/3TC 120 mg for 10 kg to <14 kg, DTG 25 mg/3TC 150 mg for 14 kg to <20 kg, DTG 30 mg/3TC 180 mg or DTG 50 mg/3TC 300 mg film-coated tablet for 20 kg to <25 kg, and DTG 50 mg/3TC 300 mg for ≥ 25 kg, with DTG 50 mg/3TC 300 mg as the only film-coated formulation. These doses were largely aligned with the WHO weight-band dosing recommendations, except for the DTG 50 mg/3TC 300 mg FCT option in those weighing 20 kg to <25 kg, which is 1.3 times higher than the currently recommended dose from that weight band. Preliminary PK data from nested substudies in 53 children weighing 10 kg to <40 kg demonstrated that all participants achieved DTG trough concentrations (C_{trough}) above the *in vitro* protein-adjusted 90% maximal inhibitory concentration (IC_{90}) of 0.064 mg/L and 50 of 53 children exceeded the 90% effective concentration (EC_{90}) of 0.32 mg/L.⁶⁵ Exposures for DTG and 3TC were generally comparable to historical data from ODYSSEY and IMPAACT 2019, respectively.

Dolutegravir With Darunavir/Ritonavir

The combination of once-daily darunavir/ritonavir (DRV/r) with an INSTI is being investigated in a randomized non-inferiority trial among virologically suppressed children aged 6 years to <18 years through the SMILE Penta-17-ANRS 152 clinical trial.⁶⁶ Participants were randomized to either once-daily DRV/r with an INSTI or continuing their standard-of-care regimen consisting of a boosted PI or NNRTI with a NRTI backbone. A total of 318 participants were enrolled between 2016 and 2019, of which 158 were randomized to DRV/r with an INSTI (97% DTG, 3% elvitegravir). DRV/r with an INSTI was non-inferior to standard of care at Week 48 (HIV viral load ≥ 50 copies/mL in 5% for DRV/r with an INSTI vs. 7.6% in the standard-of-care arm; difference -2.5% [95% CI, -7.6% and 2.5%]). Secondary analyses comparing DRV/r with an INSTI versus standard of care revealed decreases in CD4 counts (-48.3 cells/mm³ [95% CI, -93.4 and -3.2; $P = 0.036$]) and mean high-density lipoprotein change from baseline (-4.1 mg/dL [95% CI, -6.7 and -1.4; $P = 0.003$]), and increases in weight and BMI (+1.97 kg [95% CI, 1.1 and 2.9; $P < 0.001$] and +0.66 kg/m² [95% CI, 0.3 and 1.0; $P < 0.001$], respectively). A nested PK substudy in 153 adolescents aged ≥ 12 years to <18 years from SMILE also demonstrated that total and unbound DTG concentrations were adequate and well above the protein-adjusted IC_{90} for DTG.⁶⁷ DTG C_{trough} were also comparable to those measured in adults receiving 50 mg once daily. Apparent clearance of the unbound drug was influenced by total bilirubin concentrations and Asian ethnicity.

Crushing Film-Coated Tablets for Administration

Dispersible tablets are now considered the preferred formulation for pediatric patients weighing <20 kg, and film-coated tablets should not be used in children weighing <14 kg. In children weighing >14 kg who have difficulty swallowing whole tablets, when the preferred dispersible tablets are not available, the 50-mg tablets either may be split into halves followed by immediate ingestion of **both halves** of the tablet or crushed and added to a small amount of semisolid food or liquid, all of which must be consumed **immediately**.¹ In healthy adults, the use of crushed tablets resulted in slightly higher exposures than the use of whole tablets.⁶⁸ No information exists on the impact of splitting or crushing film-coated tablets on palatability. Some case reports describe DTG-containing film-coated tablets being crushed and successfully administered via orogastric tube⁶⁹ or nasogastric tube.⁷⁰ If DTG is administered via enteral tube, care should be taken to disperse the tablets completely and flush the tube to avoid clogging.

References

1. Duggan JM, Akpanudo B, Shukla V, et al. Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. *Am J Health Syst Pharm.* 2015;72(18):1555-1565. Available at: <https://pubmed.ncbi.nlm.nih.gov/26346211>.
2. Jacobs TG, Mumbiro V, Cassia U, et al. Twice-daily dosing of dolutegravir in infants on rifampicin treatment: a pharmacokinetic substudy of the EMPIRICAL trial. *Clin Infect Dis.* 2024;78(3):702-710. Available at: <https://pubmed.ncbi.nlm.nih.gov/37882611>.
3. Naidoo A, Naidoo K, Cromhout G, et al. Twice daily 50 mg dolutegravir in tuberculosis-HIV coinfect children 20-35kg. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Seattle, WA. Available at: <https://www.croiconference.org/abstract/twice-daily-50-mg-dolutegravir-in-tuberculosis-hiv-coinfected-children-20-35-kg>.
4. Turkova A, Waalewijn H, Chan MK, et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. *Lancet HIV.* 2022;9(9):e627-e637. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35868341>.
5. Cattaneo D, Minisci D, Cozzi V, et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? *Antivir Ther.* 2017;22(4):353-356. Available at: <https://pubmed.ncbi.nlm.nih.gov/28008867>.
6. Giacomet V, Lazzarin S, Manzo A, et al. Body fat distribution and metabolic changes in a cohort of adolescents living with HIV switched to an antiretroviral regimen containing dolutegravir. *Pediatr Infect Dis J.* 2021;40(5):457-459. Available at: <https://pubmed.ncbi.nlm.nih.gov/33847293>.
7. Thivalapill N, Simelane T, Mthethwa N, et al. Transition to dolutegravir is associated with an increase in the rate of body mass index change in a cohort of virally suppressed adolescents. *Clin Infect Dis.* 2021;73(3):e580-e586. Available at: <https://pubmed.ncbi.nlm.nih.gov/33119739>.
8. Yeoh DK, Campbell AJ, Bowen AC. Increase in body mass index in children with HIV, switched to tenofovir alafenamide fumarate or dolutegravir containing antiretroviral regimens. *Pediatr Infect Dis J.* 2021;40(5):e215-e216. Available at: <https://pubmed.ncbi.nlm.nih.gov/33847305>.
9. Koay WLA, Dirajlal-Fargo S, Levy ME, et al. Integrase strand transfer inhibitors and weight gain in children and youth with perinatal human immunodeficiency virus in the DC Cohort. *Open Forum Infect Dis.* 2021;8(7):ofab308. Available at: <https://pubmed.ncbi.nlm.nih.gov/34295943>.

10. Belfrage E, Soeria-Atmadja S, Naver L. Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir. *BMC Pediatr.* 2023;23(1):339. Available at: <https://pubmed.ncbi.nlm.nih.gov/37403042>.
11. Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. *AIDS.* 2017;31(13):1853-1858. Available at: <https://pubmed.ncbi.nlm.nih.gov/28692533>.
12. Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. *J Acquir Immune Defic Syndr.* 2017;74(4):423-431. Available at: <https://pubmed.ncbi.nlm.nih.gov/27984559>.
13. Dutertre M, Cuzin L, Demonchy E, et al. Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization. *J Acquir Immune Defic Syndr.* 2017;76(1):e23-e26. Available at: <https://pubmed.ncbi.nlm.nih.gov/28418992>.
14. Wijting IEA, Wit F, Rokx C, et al. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. *EClinicalMedicine.* 2019;17:100210. Available at: <https://pubmed.ncbi.nlm.nih.gov/31891143>.
15. Wang B, Abbott L, Childs K, et al. Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. *Int J STD AIDS.* 2018;29(4):414-417. Available at: <https://pubmed.ncbi.nlm.nih.gov/29059031>.
16. Christensen ES, Jain R, Roxby AC. Abacavir/dolutegravir/lamivudine (trumeq)-induced liver toxicity in a human immunodeficiency virus-infected patient. *Open Forum Infect Dis.* 2017;4(3):ofx122. Available at: <https://pubmed.ncbi.nlm.nih.gov/28748198>.
17. Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? *Int J STD AIDS.* 2018;29(10):1036-1038. Available at: <https://pubmed.ncbi.nlm.nih.gov/29621952>.
18. Rhee SY, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. *J Antimicrob Chemother.* 2019;74(11):3135-3149. Available at: <https://pubmed.ncbi.nlm.nih.gov/31280314>.
19. Santoro MM, Fornabaio C, Malena M, et al. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. *Int J Antimicrob Agents.* 2020;56(1):106027. Available at: <https://pubmed.ncbi.nlm.nih.gov/32450199>.
20. Chandasana H, Buchanan A, McKenna M, et al. Model-informed dolutegravir dose selection in pediatrics with first generation INSTI-r. Presented at: Conference of Retroviruses and Opportunistic Infections. 2023. Seattle, WA. Available at: <https://www.croiconference.org/abstract/model-informed-dolutegravir-dose-selection-in-peds-with-1st-generation-insti-r>.

21. Bevers LAH, Waalewijn H, Szubert AJ, et al. Pharmacokinetic data of dolutegravir in second-line treatment of children with human immunodeficiency virus: results from the CHAPAS4 trial. *Clin Infect Dis*. 2023;77(9):1312-1317. Available at: <https://pubmed.ncbi.nlm.nih.gov/37280040>.
22. Chandasana H, Marnoch R, McKenna M, et al. Effect of food on the pediatric dispersible tablet formulations of TRIUMEQ and DOVATO in healthy adult participants. *Pharmaceutics*. 2023;15(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/37242711>.
23. Parasrampuria R, Adkison K, Wolstenholme A, et al. Comparison of relative bioavailability of TIVICAY immediate release and dispersible pediatric tablets to immediate release TIVICAY adult tablets. Presented at: 19th International Workshop on Clinical Pharmacology of Antiviral Therapy. 2018. Baltimore, MD. Available at: https://www.natap.org/2018/Pharm/Pharm_19.htm.
24. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *Pediatr Infect Dis J*. 2015;34(11):1207-1213. Available at: <https://pubmed.ncbi.nlm.nih.gov/26244832>.
25. Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results. Presented at: Conference on Retroviruses and Opportunistic Infections. 2016. Boston, MA. <https://www.croiconference.org/abstract/impaact-1093-dolutegravir-6-12-year-old-hiv-infected-children-48-week-results-0/>
26. Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. *Lancet HIV*. 2022;9(5):e332-e340. Available at: <https://pubmed.ncbi.nlm.nih.gov/35489377>.
27. TIVICAY and TIVICAY PD (dolutegravir) [package insert]. Food and Drug Administration. 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204790s031,213983s004lbl.pdf.
28. Viani RM, Ruel T, Alvero C, et al. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study. *J Pediatric Infect Dis Soc*. 2020;9(2):159-165. Available at: <https://pubmed.ncbi.nlm.nih.gov/30951600>.
29. Moore CL, Turkova A, Mujuru H, et al. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. *BMC Infect Dis*. 2021;21(1):5. Available at: <https://pubmed.ncbi.nlm.nih.gov/33446115>.

30. Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022;9(9):e638-e648. Available at: <https://pubmed.ncbi.nlm.nih.gov/36055295>.
31. Turkova A, White E, Kekitiinwa AR, et al. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. *Lancet Child Adolesc Health*. 2023;7(10):718-727. Available at: <https://pubmed.ncbi.nlm.nih.gov/37562418>.
32. Turkova A, Kityo C, Mujuru HA, et al. Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial. Abstract PEB202. Presented at: 11th International AIDS Society Conference on HIV Science. 2021. Virtual Conference. Available at: <https://theprogramme.ias2021.org/Abstract/Abstract/1311>.
33. Mujuru A, White EM, Kekitiinwa A, et al. ODYSSEY 192-week follow-up evidences superior efficacy of DTG for children on first/second-line ART. Presented at: Conference on Retroviruses and Opportunistic Infections. 2024. Denver, CO. Available at: <https://www.croiconference.org/abstract/odyssey-192-week-follow-up-evidences-superior-efficacy-of-dtg-for-children-on-first-second-line-art>.
34. Bollen PDJ, Moore CL, Mujuru HA, et al. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. *Lancet HIV*. 2020;7(8):e533-e544. Available at: <https://pubmed.ncbi.nlm.nih.gov/32763217>.
35. Waalewijn H, Chan MK, Bollen PDJ, et al. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. *Lancet HIV*. 2022;9(5):e341-e352. Available at: <https://pubmed.ncbi.nlm.nih.gov/35189082>.
36. Waalewijn H, Stol K, van der Knaap L, et al. Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Saharan Africa. *AIDS*. 2022;36(14):2077-2079. Available at: <https://pubmed.ncbi.nlm.nih.gov/36111542>.
37. Martyn-Dickens C, Ojewale O, Sly-Moore E, et al. Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg. *AIDS*. 2023;37(9):1409-1417. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37070558>.
38. Rungsappaiboon A, Wacharachaisurapol N, Anugulruengkitt S, et al. Pharmacokinetics of generic pediatric dolutegravir dispersible tablet in Thai young children living with HIV weighing below twenty kilograms. *Pediatr Infect Dis J*. 2024;43(8):789-794. Available at: <https://pubmed.ncbi.nlm.nih.gov/39018516>.

39. Chandasana H, Thapar M, Hayes S, et al. Population pharmacokinetic modeling of dolutegravir to optimize pediatric dosing in HIV-1-infected infants, children, and adolescents. *Clin Pharmacokinet*. 2023;62(10):1445-1459. Available at: <https://pubmed.ncbi.nlm.nih.gov/37603217>.
40. Chandasana H, van Dijkman SC, Mehta R, et al. Population pharmacokinetic modeling of abacavir/dolutegravir/lamivudine to support a fixed-dose combination in children with HIV-1. *Infect Dis Ther*. 2024;13(8):1877-1891. Available at: <https://pubmed.ncbi.nlm.nih.gov/38961048>.
41. Spector SA, Brummel SS, Chang A, et al. Impact of genetic variants in ABCG2, NR1I2, and UGT1A1 on the pharmacokinetics of dolutegravir in children. *J Acquir Immune Defic Syndr*. 2024;95(3):297-303. Available at: <https://pubmed.ncbi.nlm.nih.gov/38180896>.
42. Brooks KM, Kiser JJ, Ziembra L, et al. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. *Lancet HIV*. 2023;10(8):e506-e517. Available at: <https://pubmed.ncbi.nlm.nih.gov/37541705>.
43. Bossacoma Busquets F, Noguera-Julian A, Sanchez E, Fortuny C. Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters. *J Antimicrob Chemother*. 2017;72(10):2958-2960. Available at: <https://pubmed.ncbi.nlm.nih.gov/29091219>.
44. Chandasana H, Brooks KM, Buchanan A, et al. A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Denver, CO. Available at: <https://www.croiconference.org/abstract/a-single-once-daily-abc-dtg-3tc-tablet-predicts-safe-and-effective-exposures-in-children-3-to>.
45. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV*. 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.
46. Bekker A, Salvadori N, Rabie H, et al. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial. *Lancet HIV*. 2024;11(2):e86-e95. Available at: <https://pubmed.ncbi.nlm.nih.gov/38296364>.
47. Frange P, Blanche S, Veber F, Avettand-Fenoel V. Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance. *HIV Med*. 2021;22(10):958-964. Available at: <https://pubmed.ncbi.nlm.nih.gov/34369051>.

48. Bacha JM, Dlamini S, Anabwani F, et al. Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in eastern and southern Africa. *Pediatr Infect Dis J.* 2023;42(7):576-581. Available at: <https://pubmed.ncbi.nlm.nih.gov/36795586>.
49. Devendra A, Kohler M, Letsika M, et al. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study. *AIDS.* 2024;38(7):1013-1023. Available at: <https://pubmed.ncbi.nlm.nih.gov/38381717>.
50. Ezenwosu IL, Onu JU, Chukwuma UV, et al. Effect of dolutegravir-based drug combinations on the level of medication adherence and viral load among adolescents living with HIV in resource-limited setting: a pre-post design. *Int J Adolesc Med Health.* 2023;35(6):457-465. Available at: <https://pubmed.ncbi.nlm.nih.gov/38059505>.
51. Makonokaya L, Maida A, Kalitera LU, et al. Early effects of scaling up dolutegravir-based ARV regimens among children living with HIV in Malawi. *AIDS Behav.* 2024;28(6):2148-2155. Available at: <https://pubmed.ncbi.nlm.nih.gov/38615099>.
52. Gill MM, Herrera N, Guilaze R, et al. Virologic outcomes and ARV switch profiles 2 years after national rollout of dolutegravir to children less than 15 years in southern Mozambique. *Pediatr Infect Dis J.* 2023;42(10):893-898. Available at: <https://pubmed.ncbi.nlm.nih.gov/37409808>.
53. Konu YR, Takassi E, Peytavin G, et al. Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo. *Clin Infect Dis.* 2024. Available at: <https://pubmed.ncbi.nlm.nih.gov/38748464>.
54. Kamori D, Barabona G, Rugemalila J, et al. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey. *J Antimicrob Chemother.* 2023;78(3):779-787. Available at: <https://pubmed.ncbi.nlm.nih.gov/36680436>.
55. Malinga S, Khan A, Archary M. Breaking the unbreakable: a paediatric case of dolutegravir resistance from KwaZulu-Natal. *South Afr J HIV Med.* 2023;24(1):1458. Available at: <https://pubmed.ncbi.nlm.nih.gov/37293603>.
56. Failla M, Pasquali E, Galli L, Chiappini E. Integrase strand transfer inhibitor use in children with perinatal HIV-1 infection: a narrative review. *AIDS Res Hum Retroviruses.* 2023;39(6):263-284. Available at: <https://pubmed.ncbi.nlm.nih.gov/36352827>.
57. Rose PC, De la Rey Nel E, Cotton MF, et al. Decreased hepatic steatosis in South African adolescents with perinatal HIV switching to dolutegravir-containing regimens. *Pediatr Infect Dis J.* 2023;42(7):564-572. Available at: <https://pubmed.ncbi.nlm.nih.gov/36917035>.
58. Frange P, Avettand-Fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort. *HIV Med.* 2022;23(9):1019-1024. Available at: <https://pubmed.ncbi.nlm.nih.gov/35306718>.

59. Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Presented at: Conference on Retroviruses and Opportunistic Infections. 2017. Seattle, WA. Available at: https://www.natap.org/2017/CROI/croi_11.htm.
60. van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and -2 randomized clinical trials. *J Acquir Immune Defic Syndr.* 2020;85(3):325-330. Available at: <https://pubmed.ncbi.nlm.nih.gov/32675772>.
61. McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. *AIDS.* 2018;32(4):477-485. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239893>.
62. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr.* 2020;83(3):310-318. Available at: <https://pubmed.ncbi.nlm.nih.gov/31834000>.
63. Puthanakit T, Aurpibul L, Lopez M, et al. Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naive adolescents living with HIV-1: DANCE study week 96 results. Presented at: International AIDS Conference. 2023. Available at: https://www.natap.org/2023/IAS/IAS_75.htm.
64. Turkova A, Chan MK, Kityo C, et al. D3/Penta 21 clinical trial design: a randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years. *Contemp Clin Trials.* 2024;142:107540. Available at: <https://pubmed.ncbi.nlm.nih.gov/38636725>.
65. Bevers L, Chan MK, Bbuye D, et al. Pharmacokinetics of once-daily DTG/3TC FDC in children living with HIV: D3/PENTA21 sub-study. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Denver, CO. Available at: <https://www.croiconference.org/abstract/pharmacokinetics-of-once-daily-dtg-3tc-fdc-in-children-living-with-hiv-d3-penta21-sub-study>.
66. Compagnucci A, Chan MK, Saidi Y, et al. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV—week 48 results of the DA SMILE Penta-17-ANRS 152 clinical trial. *EClinicalMedicine.* 2023;60:102025. Available at: <https://pubmed.ncbi.nlm.nih.gov/37304494>.
67. Abdalla S, Compagnucci A, Zheng Y, et al. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial. *J Antimicrob Chemother.* 2023;78(4):1041-1049. Available at: <https://pubmed.ncbi.nlm.nih.gov/36869720>.

68. Roskam-Kwint M, Bollen P, Colbers A, et al. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure. *J Antimicrob Chemother.* 2018;73(9):2430-2434. Available at: <https://pubmed.ncbi.nlm.nih.gov/29796595>.
69. Turley SL, Fulco PP. Enteral administration of twice-daily dolutegravir and rilpivirine as a part of a triple-therapy regimen in a critically ill patient with HIV. *J Int Assoc Provid AIDS Care.* 2017;16(2):117-119. Available at: <https://pubmed.ncbi.nlm.nih.gov/28198203>.
70. Chrdle A, Jerhotova Z, Vacik M, et al. Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression. *Int J STD AIDS.* 2019;30(1):94-98. Available at: <https://pubmed.ncbi.nlm.nih.gov/30231834>.

Elvitegravir (EVG)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|--|--|
| Tablet: Elvitegravir is available only in fixed-dose combination (FDC) tablets. | |
| Dosing Recommendations | Selected Adverse Events |
| <p>[Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg</p> <p>[Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg</p> <p>When using FDC tablets, refer to other sections of the Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents.</p> <p>For additional information, see Drugs@FDA or DailyMed.</p> | <p>Genvoya- and Stribild-Associated Adverse Events</p> <ul style="list-style-type: none">NauseaDiarrheaFatigueHeadache <p>TAF-Specific Adverse Events</p> <ul style="list-style-type: none">Increased levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and total cholesterolGlomerular and proximal renal tubular dysfunction (less common when compared to TDF) <p>TDF-Specific Adverse Events</p> <ul style="list-style-type: none">Glomerular and proximal renal tubular dysfunctionDecreased bone mineral densityFlatulence <p>COBI-Specific Adverse Events</p> <ul style="list-style-type: none">Benign increases in serum creatinine levels (reductions in estimated glomerular filtration) due to inhibition of tubular secretion of creatinine |

| | Special Instructions |
|--|---|
| | <ul style="list-style-type: none"> Administer both Genvoya and Stribild with food. Genvoya and Stribild should be administered at least 4 hours before or after antacids and supplements or multivitamins that contain iron, calcium, aluminum, and/or magnesium. When using Genvoya or Stribild, monitor estimated creatinine clearance (CrCl), urine glucose, and urine protein at baseline and every 3 to 6 months while on therapy. In patients who are at risk of renal impairment, also monitor serum phosphate. Patients with an increase in serum creatinine levels >0.4 mg/dL should be closely monitored for renal safety. Screen patients for hepatitis B virus (HBV) infection before initiating FTC, TDF, or TAF. Severe acute exacerbation of HBV can occur when FTC, TDF, or TAF are discontinued. In patients with HBV, monitor hepatic function for several months after stopping therapy with FTC, TDF, or TAF. For information on crushing and cutting tablets, see the Information on Crushing and Liquid Drug Formulations table from Toronto General Hospital. |
| | <h4>Metabolism/Elimination</h4> <ul style="list-style-type: none"> EVG is metabolized by cytochrome P450 (CYP) 3A4 and is a modest inducer of CYP2C9. EVG is available only in combination with the pharmacokinetic enhancer (boosting agent) cobicistat in Stribild or Genvoya. Refer to the COBI, TDF, and TAF sections for further details on the metabolism of these drugs. <p>EVG Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> Stribild and Genvoya should not be used in patients with severe hepatic impairment. <p>EVG Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> Stribild should not be initiated in patients with estimated CrCl <70 mL/min, and it should be discontinued in patients with estimated CrCl <50 mL/min. FTC and TDF require dose adjustments in these patients, and these adjustments cannot be achieved with an FDC tablet. Genvoya is not recommended in patients with estimated CrCl 15 to <30 mL/min or in patients with estimated CrCl <15 mL/min who are not receiving chronic hemodialysis. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Absorption:* Elvitegravir (EVG) plasma concentrations are lower with concurrent administration of divalent cations due to the formation of complexes in the gastrointestinal tract and not due to changes in gastric pH. Therefore, Stribild and Genvoya should be administered at least 4 hours before or after administering antacids and supplements or multivitamins that contain iron, calcium, aluminum, and/or magnesium.¹
- *Metabolism:* Stribild and Genvoya contain EVG and cobicistat (COBI). COBI itself does not have antiretroviral (ARV) activity, but it is a cytochrome P450 (CYP) 3A4 inhibitor that acts as a pharmacokinetic (PK) enhancer, similar to ritonavir (RTV).² EVG is metabolized predominantly by CYP3A4, secondarily by uridine diphosphate glucuronosyltransferase 1A1/3, and by oxidative metabolism pathways. EVG is a moderate inducer of CYP2C9. COBI is a strong inhibitor of CYP3A4 and a weak inhibitor of CYP2D6. In addition, COBI inhibits the adenosine triphosphate-dependent transporters, P-glycoprotein and the breast cancer resistance protein, and the organic anion-transporting (OAT) polypeptides OATP1B1 and OATP1B3. See the [Cobicistat](#) section for a more detailed summary of drug interactions. Multiple drug interactions are possible when using both EVG and COBI. Neither Stribild nor Genvoya should be administered concurrently with products or regimens that contain RTV because of the similar effects of COBI and RTV on CYP3A4 metabolism. Coadministration of medications that induce or inhibit CYP3A4 may respectively decrease or increase exposures of EVG and COBI. Coadministration of medications that are CYP3A4 substrates may result in clinically significant adverse reactions that are severe, life-threatening, or fatal, or may result in loss of therapeutic effect if dependent on conversion to an active metabolite due to CYP3A4 inhibition by COBI.
- *Renal elimination:* Drugs that decrease renal function or compete for active tubular secretion could reduce clearance of tenofovir, in the form of tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC). Concomitant use of nephrotoxic drugs should be avoided when using Genvoya or Stribild. COBI inhibits MATE1, which increases serum creatinine levels up to 0.4 mg/dL from baseline in adults. Creatinine-based calculations of estimated glomerular filtration rate (GFR) will be altered, but the actual GFR might be only minimally changed.³ Significant increases in serum creatinine levels >0.4 mg/dL from baseline may represent renal toxicity and should be evaluated. People who experience a confirmed increase in serum creatinine levels should be closely monitored for renal toxicity; clinicians should monitor creatinine levels for further increases and perform a urinalysis to look for evidence of proteinuria or glycosuria.⁴

Major Toxicities

- *More common:* Nausea, diarrhea, fatigue, headache, flatulence
- *Less common (more severe):* Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported in patients receiving nucleoside reverse transcriptase inhibitors, including TDF and FTC. TDF caused bone toxicity (osteomalacia and reduced bone mineral density [BMD]) in animals when given in high doses. Decreases in BMD have been reported in both adults and children who were taking TDF; the clinical significance of these changes is not yet known. Evidence of renal toxicity has been observed in patients taking TAF or TDF,

including a higher incidence of glycosuria, proteinuria, phosphaturia, and/or calciuria; increases in the levels of serum creatinine and blood urea nitrogen; and decreases in serum phosphate levels. Numerous case reports of renal tubular dysfunction have been reported in patients receiving TAF or TDF; patients at increased risk of renal dysfunction should be closely monitored if they are being treated with Genvoya or Stribild. This nephrotoxicity may be more pronounced in patients with preexisting renal disease.⁴ Although postmarketing cases of renal impairment have been reported with TAF, Genvoya, which contains TAF, has an improved bone and renal safety profile in children and adults when compared to Stribild, which contains TDF.^{5,6} However, Genvoya is associated with greater increases in lipid levels than Stribild, according to findings from large-scale clinical trials in adults.

Resistance

The International Antiviral Society–USA maintains [a list of updated HIV drug resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation. There is phenotypic cross-resistance between EVG and raltegravir (RAL).⁷

Pediatric Use

Approval

Genvoya (EVG/c/FTC/TAF) is approved by the U.S. Food and Drug Administration (FDA) for use in ARV-naive children and adolescents with HIV weighing ≥ 25 kg. It also can be used to replace the current ARV regimen in those who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Genvoya.

Stribild (EVG/c/FTC/TDF) is approved by the FDA as a complete regimen for use in children and adolescents aged ≥ 12 years and weighing ≥ 35 kg. It can also be used to replace the current ARV regimen in those who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Stribild.⁸

Efficacy

EVG/c/FTC/TDF was found to be non-inferior to efavirenz/emtricitabine/TDF (EFV/FTC/TDF)⁹⁻¹¹ and atazanavir/ritonavir plus FTC/TDF in adults through 144 weeks of treatment.¹²⁻¹⁴

Studies of EVG/c/FTC/TDF and EVG/c/FTC/TAF in children with HIV aged ≥ 12 years and weighing ≥ 35 kg have demonstrated 90% efficacy (as measured by virological suppression) similar to that seen in adults through 24 weeks and 48 weeks of study, respectively.^{15,16}

EVG/c/FTC/TAF is FDA approved to treat children weighing ≥ 25 kg based on 24 weeks of data in 23 children.¹⁷ In this study, all children who had been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months were switched from their current regimens to EVG/c/FTC/TAF and all participants maintained virological suppression (HIV-1 RNA <50 copies/mL) at Week 24.

A retrospective analysis of integrase strand transfer inhibitor (INSTI) use in children and adolescents showed that 83.7% (61/73) of patients on an elvitegravir/cobicistat (EVG/c)-containing therapy

continued their prescribed regimen through the end of the study follow-up period (median [interquartile range (IQR)] 2.0 [1.4–2.7] years of exposure). Treatment interruption due to virologic occurred in 4.1% (3/73) of those on EVG/c, which was comparable to that of dolutegravir (DTG)-based regimens (3.7% [5 of 134 participants]) and lower than RAL-based regimens (17.3% [19 of 110 participants]). Two of the participants who experienced virologic failures with EVG had major INSTI drug-resistance mutations, but both attained virologic suppression after switching to regimens containing darunavir (DRV) or DRV with DTG.¹⁸

In a PK, safety, and efficacy study with a low-dose tablet in children aged ≥ 2 years and weighing ≥ 14 kg to < 25 kg, children had to be virologically suppressed (HIV RNA < 50 copies/mL) for at least 6 months prior to entry.¹⁹ In the most recent analysis, virologic suppression was maintained²⁰ in 27 (100%) of 27 children at Week 16, 26 (96%) of 27 children at Week 24, and 26 (96%) of 27 children at Week 48. No participant discontinued the study drug because of adverse events or met the criteria for resistance analyses through Week 48. At least 90% of children reported that swallowing the low-dose tablet was “easy” or “super easy” and perceived the tablet size when swallowing as “okay” at baseline, Week 4, and Week 24.¹⁹

Pharmacokinetics

EVG/c/FTC/TDF (Stribild)

The PK of EVG 150 mg/c 150 mg/FTC 200 mg/TDF 300 mg tablet were evaluated in 14 treatment-naive adolescents with HIV who were between 12 and < 18 years of age and weighing ≥ 35 kg. EVG area under the plasma concentration versus time curve over the dosing interval (AUC_{tau}) and peak concentrations (C_{max}) were 30% higher (90% confidence interval [CI], 105% to 162%) and 42% higher (90% CI, 116% to 173%), respectively, in comparison to historical data in adults. EVG concentrations at the end of the dosing interval (C_{tau}) were 6% higher (90% CI, 70% to 160%) than in adults, and approximately ninefold higher than the protein-adjusted 95% inhibitory concentration (PA-IC₉₅) of 44.5 ng/mL for EVG. COBI, FTC, and TFV exposures were comparable to those measured in adults.¹⁶

EVG/c/FTC/TAF (Genvoya)

The PK of EVG 150 mg/c 150 mg/FTC 200 mg/TAF 10 mg tablet have been evaluated in adolescents 12 to < 18 years of age weighing ≥ 35 kg and children 6 to < 12 years of age weighing ≥ 25 kg.¹⁷ AUC_{tau} , C_{max} , and C_{tau} for EVG, COBI, FTC, TAF, and TFV were comparable to or higher than those measured in adults with HIV in both cohorts (see Tables A and B below).

The PK of a low-dose FDC tablet containing EVG 90 mg/c 90 mg/FTC 120 mg/TAF 6 mg were evaluated in 27 children with HIV weighing ≥ 14 kg and < 25 kg.¹⁹ EVG and TAF AUC_{tau} were higher in comparison to historical data in adults receiving full-strength Genvoya (see Tables A and B below). EVG C_{tau} was 21% lower (90% CI [53.1% to 117%]) in children versus adults but was approximately 4.4-fold higher and ninefold higher than the PA-IC₉₅ and protein-adjusted 50% inhibitory concentration (PA-IC₅₀) for wild-type virus, respectively. However, EVG C_{tau} measured in this cohort was lower than those previously measured in children and adolescents weighing ≥ 25 kg on EVG at the 150-mg dose. COBI, FTC, and TFV exposures were all comparable to or higher than historical data in adults.

Table A. Pharmacokinetics of EVG, COBI, FTC, TAF, and TFV (Genvoya) in Children and Adolescents with HIV Between 2 to <18 Years of Age and Weighing ≥14 kg

| Component | Parameter | Children Aged ≥2 Years and Weighing ≥14 to <25 kg ¹⁹ | | Children Aged 6 to <12 Years and Weighing ≥25 kg ¹⁷ | | Adolescents Aged 12 to <18 Years and Weighing ≥35 kg ¹⁵ | | Adults ^{a15,17} | |
|----------------|--|--|--------|---|---------------|---|---------------|--------------------------|---------------|
| | | n | GLSM | n | Mean (%CV) | n | Mean (%CV) | n | Mean (%CV) |
| EVG | AUC _{tau} (ng·h/mL) | 27 | 29,900 | 22 | 33,814 (58%) | 24 | 23,840 (26%) | 19 | 22,800 (35%) |
| | C _{max} (ng/mL) | 27 | 2,850 | 23 | 3,055 (39%) | 24 | 2,230 (19%) | 19 | 2,100 (34%) |
| | C _{tau} (ng/mL) | 27 | 195 | 23 | 370 (119%) | 24 | 301 (81%) | 19 | 290 (62%) |
| COBI | AUC _{tau} (ng·h/mL) | 27 | 12,300 | 20 | 15,891 (52%) | 23 | 8,241 (36%) | 19 | 9,500 (34%) |
| | C _{max} (ng/mL) | 27 | 1,270 | 23 | 2,079 (47%) | 24 | 1,202 (35%) | 19 | 1,500 (28%) |
| | C _{tau} (ng/mL) | 27 | 16.6 | 23 | 96 (169%) | 15 | 25 (180%) | 19 | 20 (85%) |
| FTC | AUC _{tau} (ng·h/mL) | 27 | 18,600 | 22 | 20,629 (19%) | 24 | 14,424 (24%) | 19 | 11,714 (17%) |
| | C _{max} (ng/mL) | 27 | 2,810 | 23 | 3,397 (27%) | 24 | 2,265 (23%) | 19 | 2,056 (20%) |
| | C _{tau} (ng/mL) | 27 | 77.4 | 23 | 115 (24%) | 23 | 102 (39%) | 19 | 95 (47%) |
| TAF | AUC _{tau} (ng·h/mL) | 27 | 344 | 23 | 333 (45%) | 24 | 189 (56%) | 539 | 206 (72%) |
| | C _{max} (ng/mL) | 27 | 218 | 23 | 313 (61%) | 24 | 167 (64%) | 539 | 162 (51%) |
| TFV | AUC _{tau} (ng·h/mL) | 27 | 327 | 23 | 440 (21%) | 23 | 288 (19%) | 841 | 293 (27%) |
| | C _{max} (ng/mL) | 27 | 19.1 | 23 | 26 (21%) | 23 | 18 (24%) | 841 | 15 (26%) |
| | C _{tau} (ng/mL) | 27 | 11.1 | 23 | 15 (25%) | 23 | 10 (21%) | 841 | 11 (29%) |
| TFV-DP in PBMC | C _{0h} (fmol/10 ⁶ cells) | — | — | — | — | 12 | 222 (94%) | 21 | 121 (91%) |

^a Adult pharmacokinetic parameters for elvitegravir, cobicistat, and emtricitabine were derived from intensive pharmacokinetic analysis from a Phase 2 study GS 102; data for tenofovir alafenamide and tenofovir were from population pharmacokinetic analyses in Phase 3 GS studies 104 and 111.

Key: AUC_{tau} = area under the plasma concentration versus time curve over the dosing interval; C_{0h} = concentration at time 0 (pre-dose); C_{max} = maximum observed plasma concentration of drug; C_{tau} = observed drug concentration at the end of the dosing interval; COBI = cobicistat; CV = coefficient of variation; EVG = elvitegravir; fmol = femtomole; FTC = emtricitabine; GLSM = geometric least squares mean; kg = kilogram; mL = milliliter; ng = nanogram; PBMC = peripheral blood mononuclear cell; TAF = tenofovir alafenamide; TFV = tenofovir; TFV-DP = tenofovir-diphosphate

Table B. Comparisons of EVG, COBI, FTC, TAF, and TFV (Genvoya) Pharmacokinetics in Children and Adolescents with HIV Between 2 and <18 Years of Age and Weighing ≥14 kg to Adult Values

| Component | Parameter | % GLSM (90% CI) Compared with Adult Values ^a | | | |
|-----------|------------------------------|---|---|-----------|--|
| | | Dose (mg) | Children Aged ≥2 Years and Weighing ≥14 to <25 kg ¹⁷ | Dose (mg) | Children Aged 6 to <12 Years and Weighing ≥25 kg ¹⁹ |
| EVG | AUC _{tau} (ng·h/mL) | 90 | 139 (112,172) | 150 | 134 (104,173) |
| | C _{max} (ng/mL) | | 143 (113,180) | | 141 (115,173) |
| | C _{tau} (ng/mL) | | 79 (53,117) | | 86 (55,133) |
| COBI | AUC _{tau} (ng·h/mL) | 90 | — | 150 | 158 (126,198) |
| | C _{max} (ng/mL) | | — | | 127 (98,165) |
| | C _{tau} (ng/mL) | | — | | 171 (95,310) |
| FTC | AUC _{tau} (ng·h/mL) | 120 | — | 200 | 175 (160,192) |
| | C _{max} (ng/mL) | | — | | 164 (145,184) |
| | C _{tau} (ng/mL) | | — | | 125 (107,146) |
| TAF | AUC _{tau} (ng·h/mL) | 6 | 193 (166,224) | 10 | 171 (147,199) |
| | C _{max} (ng/mL) | | 150 (116,195) | | 182 (146,225) |
| TFV | AUC _{tau} (ng·h/mL) | 6 | — | 10 | 152 (142,163) |
| | C _{max} (ng/mL) | | — | | 173 (161,186) |
| | C _{tau} (ng/mL) | | — | | 143 (132,155) |

^aAdult pharmacokinetic parameters for elvitegravir, cobicistat, and emtricitabine were derived from intensive pharmacokinetic analysis from Phase 2 study 102; data for tenofovir alafenamide and tenofovir were from population pharmacokinetic analyses in Phase 3 studies 104 and 111.

Key: AUC_{tau} = area under the plasma concentration versus time curve over the dosing interval; C_{max} = maximum observed plasma concentration of drug; COBI = cobicistat; C_{tau} = observed drug concentration at the end of the dosing interval; CI = confidence interval; EVG = elvitegravir; FTC = emtricitabine; GLSM = geometric least squares mean; kg = kilogram; mL = milliliter; mg = milligram; ng = nanogram; TAF = tenofovir alafenamide; TFV = tenofovir

Coadministration of Elvitegravir, Cobicistat, and Darunavir

The combination of Stribild or Genvoya plus DRV may provide a low-pill-burden regimen for treatment-experienced individuals. However, an unfavorable drug interaction between EVG/c and DRV is possible, and the available data on the significance of the interaction and efficacy are conflicting.^{21–24} The most rigorous drug interaction study in HIV-seronegative adults found 21% lower DRV trough concentrations (C_{trough}) and 52% lower EVG C_{trough} in combination with DRV 800 mg plus EVG/c 150 mg/150 mg once daily compared to the administration of either DRV/c 800 mg/150 mg once daily or EVG/c 150 mg/150 mg once daily alone.²⁵ Despite the findings of the aforementioned drug interaction study in HIV-seronegative adults, the most rigorous efficacy evaluation found that among 89 treatment-experienced adults who were on five-tablet ARV regimens, 96.6% achieved virologic suppression (HIV RNA <50 copies/mL) 24 weeks after simplifying their regimens to a two-tablet regimen of Genvoya plus DRV 800 mg once daily.²³ Given

the uncertainty around the true magnitude of the drug interaction and the absence of pediatric data, viral load should be closely monitored in children taking this combination.

Toxicity

In studies comparing EVG/c/FTC/TDF or EVG/c/FTC/TAF over 48 weeks in 1,733 adults, those receiving EVG/c/FTC/TAF had significantly smaller mean serum creatinine increases (0.08 vs. 0.12 mg/dL; $P < 0.0001$), significantly less proteinuria (median percent change in protein -3% vs. $+20\%$; $P < 0.0001$), and a significantly smaller decrease in BMD at the spine (mean percent change -1.30% vs. -2.86% ; $P < 0.0001$) and hip (-0.66% vs. -2.95% ; $P < 0.0001$).⁶ Larger increases in fasting lipid levels were observed with EVG/c/FTC/TAF than with EVG/c/FTC/TDF; the median increases in levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides were all higher in patients who received EVG/c/FTC/TAF.

In children and adolescents, EVG/c/FTC/TAF is generally preferred over EVG/c/FTC/TDF because of the lower risk of renal and bone toxicity with EVG/c/FTC/TAF compared to EVG/c/FTC/TDF (see the [Tenofovir Alafenamide](#) section). Long-term bone safety data through 96 weeks with EVG/c/FTC/TAF in adolescents weighing ≥ 35 kg revealed no concerns for toxicity²⁶ in this age group on the basis of BMD (median change from baseline spine BMD height-age [HA] z-score $+0.14$ and total body less head [TBLH] HA z-score of -0.07) and serum biomarkers of bone formation and resorption.²⁷

In the approval study of EVG/c/FTC/TAF in children weighing ≥ 25 kg, no study discontinuations occurred due to medication toxicity. Long-term bone safety data with EVG/c/FTC/TAF through 96 weeks revealed no concerns for toxicity in this cohort on the basis of BMD (median change from baseline spine BMD HA z-score of -0.2 and TBLH HA z-score of -0.32) and serum biomarkers of bone formation and resorption.²⁰ A concerning decline in CD4 T lymphocyte (CD4) cell counts was observed in all 23 children over the first 24 weeks of EVG/c/FTC/TAF treatment.¹⁷ CD4 counts declined by a median of 130 cells/mm³ (with a range of -472 cells/mm³ to 266 cells/mm³) from baseline. However, after enrolling additional children (for a total of 52 participants),²⁸ the median CD4 count decline at 48 weeks was 25 cells/mm³ and at 96 weeks was 45 cells/mm³. Additionally, the CD4 percentage did not significantly change across Weeks 24, 48, and 96.²⁰ The mechanism for the reduction in CD4 count is unclear, and this reduction has only been reported in this study. Plasma exposures of all four drugs were higher in these children than the plasma exposures seen in historical data from adults, but no association was identified between plasma exposures of the four components of EVG/c/FTC/TAF and CD4 counts.²⁹

In an ongoing PK, safety, and efficacy study with a low-dose EVG/c/FTC/TAF tablet in children aged ≥ 2 years and weighing ≥ 14 kg to < 25 kg,¹⁹ long-term bone safety data with the low-dose formulation through 48 weeks revealed no concerns for bone safety in this cohort on the basis of BMD (median change from baseline in spine BMD HA z-score $+0.14$ and TBLH HA z-score of -0.06) and serum biomarkers of bone formation and resorption.²⁷ CD4 counts decreased²⁰ by a mean of 187 cells/mm³ between baseline and Week 48, although the CD4 percentage did not differ (mean [standard deviation] change of 0.0 [< 5.0]). In a cumulative analysis of two pediatric cohorts (Cohort 2 aged 6 to < 12 years and weighing ≥ 25 kg and Cohort 3 aged ≥ 2 years and weighing ≥ 14 kg to < 25 kg) on EVG/c/FTC/TAF once daily for at least 48 weeks, the absolute lymphocyte counts and absolute CD4 counts decreased from baseline to Week 48 in both cohorts, with larger decreases in the younger cohort.³⁰ Median (IQR) absolute lymphocyte counts ($\times 10^3$ per μ L) at baseline in Cohort 2

and Cohort 3 were 2.31 (range, 1.92–2.78) and 2.96 (range, 2.39–3.82), respectively. The absolute lymphocyte counts decreased during treatment (particularly in Cohort 3), with changes of −0.04 (range, −0.67 to 0.29) and −0.52 (range, −1.16 to 0.05) in Cohorts 2 and 3, respectively, at Week 48. Small decreases were seen in median (IQR) absolute CD4 counts (cells/ μ L), with changes of −33 (−194 to 80) and −187 (−370 to 44) in Cohorts 2 and 3, respectively, at Week 48. However, the relative proportion of CD4 cells and the CD4:CD8 ratio remained stable during treatment. Overall, the decline in absolute CD4 counts mirrored known physiological fluctuations in young children and was mainly observed in those aged <6 years.³⁰

References

1. Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. *J Acquir Immune Defic Syndr.* 2013;64(1):45-50. Available at: https://journals.lww.com/jaids/Fulltext/2013/09010/Pharmacokinetics_of_Once_Daily_Boosted.8.aspx.
2. Tybost (cobicistat) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203094s015lbl.pdf.
3. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr.* 2012;61(1):32-40. Available at: <https://pubmed.ncbi.nlm.nih.gov/22732469>.
4. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203100s035lbl.pdf.
5. Sharma S, Gupta S, Majeed S, et al. Exposure-safety of tenofovir in pediatric HIV-infected participants: comparison of tenofovir alafenamide & tenofovir disoproxil fumarate. Abstract 23. Presented at: 10th International Workshop on HIV Pediatrics 2018. Amsterdam, The Netherlands. Available at: https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2018/slideset/32wsharma?check_logged_in=1.
6. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. *Lancet.* 2015;385(9987):2606-2615. Available at: <https://pubmed.ncbi.nlm.nih.gov/25890673>.
7. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. *Antimicrob Agents Chemother.* 2012;56(6):2873-2878. Available at: <https://pubmed.ncbi.nlm.nih.gov/22450969>.
8. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203100s036lbl.pdf.
9. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet.* 2012;379(9835):2439-2448. Available at: <https://pubmed.ncbi.nlm.nih.gov/22748591>.

10. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. *J Acquir Immune Defic Syndr.* 2013;63(1):96-100. Available at: <https://pubmed.ncbi.nlm.nih.gov/23392460>.
11. Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr.* 2014;65(3):e118-120. Available at: <https://pubmed.ncbi.nlm.nih.gov/24256630>.
12. Rockstroh JK, Dejesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. *J Acquir Immune Defic Syndr.* 2013;62(5):483-486. Available at: <https://pubmed.ncbi.nlm.nih.gov/23337366>.
13. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3, non-inferiority trial. *Lancet.* 2012;379(9835):2429-2438. Available at: <https://pubmed.ncbi.nlm.nih.gov/22748590>.
14. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr.* 2014;65(3):e121-124. Available at: <https://pubmed.ncbi.nlm.nih.gov/24346640>.
15. Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. *Lancet HIV.* 2016;3(12):e561-e568. Available at: <https://pubmed.ncbi.nlm.nih.gov/27765666>.
16. Gaur A, Fourle J, et al. Pharmacokinetics, efficacy and safety of an integrase inhibitor STR in HIV-infected adoelscents. Presented at: 21st Conference on Retroviruses and Opportunistic Infections; 2014. Boston, MA. Available at: https://www.natap.org/2014/CROI/croi_176.htm.
17. Natukunda E, Gaur A, Kosalaraksa P, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. *Lancet Child Adolescent Health.* 2017;1(1):27-34. Available at: <http://www.sciencedirect.com/science/article/pii/S2352464217300093?via%3Dihub>.

18. Torres-Fernandez D, Jimenez de Ory S, Fortuny C, et al. Integrase inhibitors in children and adolescents: clinical use and resistance. *J Antimicrob Chemother*. 2022;77(10):2784-2792. Available at: <https://pubmed.ncbi.nlm.nih.gov/35971971>.
19. Natukunda E, Liberty A, Strehlau R, et al. Safety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children ≥ 2 years old living with HIV. Abstract OALB0101. Presented at: International AIDS Conference; 2020. Virtual Meeting. Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2020/abstract/safety-pharmacokinetics-and-efficacy>.
20. Anugulruengkitt S, A. Gaur, P. Kosalaraksa, A. Liberty, Y. Shao, et al. . Long-term safety & efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (E/C/F/TAF) single-tablet regimen in children and adolescents living with HIV. Abstract 4 Presented at: International Workshop on HIV Pediatrics 2021 2021. Virtual Meeting. Available at: https://www.natap.org/2021/IAS/IAS_79.htm.
21. Gutierrez-Valencia A, Benmarzouk-Hidalgo OJ, Llaves S, et al. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients. *J Antimicrob Chemother*. 2017;72(3):816-819. Available at: <https://pubmed.ncbi.nlm.nih.gov/27999051>.
22. Harris M, Ganase B, Watson B, et al. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. *AIDS Res Ther*. 2017;14(1):59. Available at: <https://pubmed.ncbi.nlm.nih.gov/29096670>.
23. Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. *J Acquir Immune Defic Syndr*. 2017;74(2):193-200. Available at: <https://pubmed.ncbi.nlm.nih.gov/27753684>.
24. Naccarato MJ, Yoong DM, Fong IW, et al. Combination therapy with tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat plus darunavir once daily in antiretroviral-naive and treatment-experienced patients: a retrospective review. *J Int Assoc Provid AIDS Care*. 2018;17:2325957417752260. Available at: <https://pubmed.ncbi.nlm.nih.gov/29385867>.
25. Ramanathan S, Wang H, Szwarcberg J, Kearney BP. Safety/tolerability, pharmacokinetics, and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir. Abstract P-08. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Barcelona, Spain. Available at: http://www.natap.org/2012/pharm/Pharm_28.htm.
26. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207561s029lbl.pdf.

27. Rakhmanina N, Gordon CN, E., Kosalaraksa PA, S. Shao, Y., et al. Effects of Long-term Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (E/C/F/TAF) on Bone Safety Parameters in Children and Adolescents Living with HIV [Abstract 64]. Presented at: International Workshop on HIV Pediatrics 2021; 2021. Virtual Meeting. Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2021/abstract>.
28. Rakhmanina N, Natukunda E, Kosalaraksa P, et al. Safety and efficacy of E/C/F/TAF in virologically suppressed, HIV-infected children through 96 weeks. Abstract 22. Presented at: 11th International Workshop on HIV Pediatrics; 2019. Mexico City, Mexico. Available at: <https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2019/abstract/safety-and-efficacy-ecftaf>.
29. Bell T, Baylor M, Rhee S, et al. FDA analysis of CD4+ cell count declines observed in HIV-infected children treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. *Open Forum Infect Dis.* 2018;5. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253452/>.
30. Rakhmanina N, Natukunda E, Strehalu R, et al. Longitudinal lymphocyte dynamics in virologically suppressed children with HIV initiating single-tablet elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide Presented at: IAS Conference on HIV Science; 2023. Brisbane, Australia. Available at: https://www.natap.org/2023/IAS/IAS_93.htm.

Raltegravir (RAL, Isentress)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | | | | | | | | | | | | | | | | | |
|---|--|--|---|----------------------------------|---------------|--------------------------|---------------|--------------------------|---------------|--------------------------|---|---------------------------------------|---------------|---------------------------|---------------|--------------------------|--|
| Tablet: 400 mg (film-coated poloxamer tablet) | | | | | | | | | | | | | | | | | |
| High-Dose (HD) Tablet: 600 mg (film-coated poloxamer tablet) | | | | | | | | | | | | | | | | | |
| Chewable Tablets: 100 mg (scored) and 25 mg | | | | | | | | | | | | | | | | | |
| Granules for Oral Suspension: Single-use packet of 100 mg of raltegravir, suspended in 10 mL of water for a final concentration of 10 mg/mL | | | | | | | | | | | | | | | | | |
| <i>Film-coated tablets, chewable tablets, and oral suspension are not interchangeable.</i> | | | | | | | | | | | | | | | | | |
| For additional information, see Drugs@FDA or DailyMed . | | | | | | | | | | | | | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | | | | | | | | | | | | | |
| <p>Note: No dosing information is available for preterm infants or infants weighing <2 kg at birth. See Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With In Utero or Intrapartum Exposure to HIV for information about using raltegravir (RAL) for the prevention of perinatal HIV transmission.</p> <p>Neonate (Weighing ≥2 kg) Dose^{a,b}</p> <p>RAL Oral Suspension Dosing Table for Full-Term Neonates from Birth to Age 4 Weeks</p> <p>Neonates Aged ≥37 Weeks and Weighing ≥2 kg</p> <table border="1"><thead><tr><th>Weight</th><th>Volume (Dose) of Suspension^b</th></tr></thead><tbody><tr><td>Birth to 1 Week of Age: Once-Daily Dosing</td><td>Approximately 1.5 mg/kg per Dose</td></tr><tr><td>2 kg to <3 kg</td><td>0.4 mL (4 mg) once daily</td></tr><tr><td>3 kg to <4 kg</td><td>0.5 mL (5 mg) once daily</td></tr><tr><td>4 kg to <5 kg</td><td>0.7 mL (7 mg) once daily</td></tr><tr><td>1–4 Weeks of Age: Twice-Daily Dosing</td><td>Approximately 3 mg/kg per Dose</td></tr><tr><td>2 kg to <3 kg</td><td>0.8 mL (8 mg) twice daily</td></tr><tr><td>3 kg to <4 kg</td><td>1 mL (10 mg) twice daily</td></tr></tbody></table> | Weight | Volume (Dose) of Suspension ^b | Birth to 1 Week of Age: Once-Daily Dosing | Approximately 1.5 mg/kg per Dose | 2 kg to <3 kg | 0.4 mL (4 mg) once daily | 3 kg to <4 kg | 0.5 mL (5 mg) once daily | 4 kg to <5 kg | 0.7 mL (7 mg) once daily | 1–4 Weeks of Age: Twice-Daily Dosing | Approximately 3 mg/kg per Dose | 2 kg to <3 kg | 0.8 mL (8 mg) twice daily | 3 kg to <4 kg | 1 mL (10 mg) twice daily | <ul style="list-style-type: none">Rash, including Stevens-Johnson syndrome, hypersensitivity reaction, and toxic epidermal necrolysisNausea, diarrheaHeadache, dizziness, fatigueInsomniaFeverCreatine phosphokinase elevation, muscle weakness, and rhabdomyolysis |
| Weight | Volume (Dose) of Suspension ^b | | | | | | | | | | | | | | | | |
| Birth to 1 Week of Age: Once-Daily Dosing | Approximately 1.5 mg/kg per Dose | | | | | | | | | | | | | | | | |
| 2 kg to <3 kg | 0.4 mL (4 mg) once daily | | | | | | | | | | | | | | | | |
| 3 kg to <4 kg | 0.5 mL (5 mg) once daily | | | | | | | | | | | | | | | | |
| 4 kg to <5 kg | 0.7 mL (7 mg) once daily | | | | | | | | | | | | | | | | |
| 1–4 Weeks of Age: Twice-Daily Dosing | Approximately 3 mg/kg per Dose | | | | | | | | | | | | | | | | |
| 2 kg to <3 kg | 0.8 mL (8 mg) twice daily | | | | | | | | | | | | | | | | |
| 3 kg to <4 kg | 1 mL (10 mg) twice daily | | | | | | | | | | | | | | | | |
| Special Instructions | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none">RAL can be given without regard to food.Coadministration or staggered administration of aluminum-containing and magnesium-containing antacids is not recommended with any RAL formulations.Significant drug interactions are more likely to occur when the RAL HD formulation is used once daily. The following drugs should not be coadministered with once-daily RAL HD dosing: calcium carbonate antacids, rifampin, tipranavir/ritonavir, and etravirine.Chewable tablets can be chewed, crushed (before administration), or swallowed whole.Film-coated tablets, including HD tablets, must be swallowed whole. | | | | | | | | | | | | | | | | | |

| 4 kg to <5 kg | 1.5 mL (15 mg) twice daily | | | | | | | | | | | | | | | |
|--|--|--|--------|--|---------------|----------------------------|---------------|--------------------------|---------------|--------------------------|----------------|--------------------------|-----------------|--------------------------|-----------------|----------------------------|
| ^a RAL is metabolized by uridine diphosphate glucuronyl transferase (UGT) 1A1, and enzyme activity is low at birth; enzyme activity increases rapidly during the next 4 to 6 weeks of life. | | | | | | | | | | | | | | | | |
| ^b For neonates, most of the prepared oral suspension will be discarded. The volume for the required dose is much smaller than the 10 mL suspension that is prepared. | | | | | | | | | | | | | | | | |
| Note: If the birthing parent has taken RAL 2 to 24 hours prior to delivery, the neonate's first dose may be delayed until 24 to 48 hours after birth. | | | | | | | | | | | | | | | | |
| Infant >4 Weeks of Age and Child (Weighing ≥3 kg to <20 kg) Dose | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> For children weighing 3 to 20 kg, either oral suspension or chewable tablets can be used. | | | | | | | | | | | | | | | | |
| RAL Oral Suspension Dosing Table for Patients Aged >4 Weeks^a | | | | | | | | | | | | | | | | |
| Note: The maximum dose of oral suspension is 10 mL (RAL 100 mg) twice daily. | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Weight</th><th>Twice-Daily Volume (Dose) of Suspension^b</th></tr> </thead> <tbody> <tr> <td>3 kg to <4 kg</td><td>2.5 mL (25 mg) twice daily</td></tr> <tr> <td>4 kg to <6 kg</td><td>3 mL (30 mg) twice daily</td></tr> <tr> <td>6 kg to <8 kg</td><td>4 mL (40 mg) twice daily</td></tr> <tr> <td>8 kg to <10 kg</td><td>6 mL (60 mg) twice daily</td></tr> <tr> <td>10 kg to <14 kg</td><td>8 mL (80 mg) twice daily</td></tr> <tr> <td>14 kg to <20 kg</td><td>10 mL (100 mg) twice daily</td></tr> </tbody> </table> | | | Weight | Twice-Daily Volume (Dose) of Suspension ^b | 3 kg to <4 kg | 2.5 mL (25 mg) twice daily | 4 kg to <6 kg | 3 mL (30 mg) twice daily | 6 kg to <8 kg | 4 mL (40 mg) twice daily | 8 kg to <10 kg | 6 mL (60 mg) twice daily | 10 kg to <14 kg | 8 mL (80 mg) twice daily | 14 kg to <20 kg | 10 mL (100 mg) twice daily |
| Weight | Twice-Daily Volume (Dose) of Suspension ^b | | | | | | | | | | | | | | | |
| 3 kg to <4 kg | 2.5 mL (25 mg) twice daily | | | | | | | | | | | | | | | |
| 4 kg to <6 kg | 3 mL (30 mg) twice daily | | | | | | | | | | | | | | | |
| 6 kg to <8 kg | 4 mL (40 mg) twice daily | | | | | | | | | | | | | | | |
| 8 kg to <10 kg | 6 mL (60 mg) twice daily | | | | | | | | | | | | | | | |
| 10 kg to <14 kg | 8 mL (80 mg) twice daily | | | | | | | | | | | | | | | |
| 14 kg to <20 kg | 10 mL (100 mg) twice daily | | | | | | | | | | | | | | | |
| ^a The weight-based dose recommendation for the oral suspension is based on a dose of approximately RAL 6 mg/kg per dose twice daily. | | | | | | | | | | | | | | | | |
| ^b For neonates, most of the prepared oral suspension will be discarded, because the volume for the required dose is much smaller than 10 mL. | | | | | | | | | | | | | | | | |
| Child and Adolescent Dose for Chewable Tablets, Film-Coated Tablets, and HD Tablets | | | | | | | | | | | | | | | | |
| Children Weighing ≥3 kg | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> Weighing <25 kg <ul style="list-style-type: none"> Chewable tablets twice daily. See the table below for chewable tablet doses. Weighing ≥25 kg | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> The chewable tablets and oral suspension have better bioavailability than the film-coated tablets. Because the formulations are not interchangeable, do not substitute chewable tablets or oral suspension for film-coated tablets. See specific recommendations for proper dosing of different formulations. The chewable tablets should be stored in the original package with a desiccant to protect them from moisture. Instructions for preparing and administering the chewable tablet as a crushed tablet are as follows: Place the tablet(s) in a small, clean cup. For each tablet, add a teaspoon (~5 mL) of liquid (e.g., water, juice, or breast milk). Within 2 minutes, the tablet(s) will absorb the liquid and fall apart. Using a spoon, crush any remaining pieces of the tablet(s). Immediately administer the entire dose orally. If any portion of the dose is left in the cup, add another teaspoon (~5 mL) of liquid, swirl, and administer immediately. The chewable tablets contain phenylalanine, a component of aspartame. Phenylalanine can be harmful to patients with phenylketonuria, and the necessary dietary adjustments should be made in consultation with a metabolic specialist. The oral suspension comes in a kit that includes instructions for use, mixing cups, oral dosing syringes, and 60 foil packets. Detailed instructions for preparation are provided in the Instructions for Use document.¹ Each single-use foil packet contains 100 mg of RAL, which will be suspended in 10 mL of water for a final concentration of RAL 10 mg/mL. Gently swirl the mixing cup for 45 seconds in a circular motion to mix the powder into a uniform suspension. Do not shake the oral suspension. Dose should be administered within 30 minutes of mixing; unused solution should be discarded as directed in the Instructions for Use document. For neonates, most of the prepared oral suspension will be discarded, because the volume for the required dose is much smaller than 10 mL. | | | | | | | | | | | | | | | | |
| Metabolism/Elimination | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> UGT1A1-mediated glucuronidation | | | | | | | | | | | | | | | | |
| RAL Dosing in Patients with Hepatic Impairment | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> No dose adjustment is necessary for patients with mild-to-moderate hepatic insufficiency who are receiving RAL twice daily. | | | | | | | | | | | | | | | | |

| <ul style="list-style-type: none"> ○ RAL 400-mg, film-coated tablets twice daily or chewable tablets twice daily. See the table below for chewable tablet doses. <p><i>Children and Adolescents Weighing ≥40 kg</i></p> <ul style="list-style-type: none"> ● Two RAL 600-mg HD tablets (1,200 mg) once daily ● This dose is for antiretroviral therapy-naïve or virologically suppressed patients who are on an initial dose of RAL 400 mg twice daily. <p>Chewable Tablet Dosing Table^a</p> <p>Note: The maximum dose of chewable tablets is RAL 300 mg twice daily.</p> <table border="1"> <thead> <tr> <th>Weight</th><th>Twice-Daily Dose</th><th>Number of Chewable Tablets</th></tr> </thead> <tbody> <tr> <td>3 kg to <6 kg</td><td>RAL 25 mg</td><td>1 tablet (25 mg)</td></tr> <tr> <td>6 kg to <10 kg</td><td>RAL 50 mg</td><td>2 tablets (25 mg)</td></tr> <tr> <td>10 kg to <14 kg</td><td>RAL 75 mg</td><td>3 tablets (25 mg)</td></tr> <tr> <td>14 kg to <20 kg</td><td>RAL 100 mg</td><td>1 tablet (100 mg)</td></tr> <tr> <td>20 kg to <28 kg</td><td>RAL 150 mg</td><td>1½ tablets^b (100 mg)</td></tr> <tr> <td>28 kg to <40 kg</td><td>RAL 200 mg</td><td>2 tablets (100 mg)</td></tr> <tr> <td>≥40 kg</td><td>RAL 300 mg</td><td>3 tablets (100 mg)</td></tr> </tbody> </table> <p>^aThe weight-based dose recommendation for the chewable tablet is based on a dose of approximately RAL 6 mg/kg per dose twice daily.</p> <p>^bThe RAL 100-mg chewable tablet can be divided into equal halves.</p> | Weight | Twice-Daily Dose | Number of Chewable Tablets | 3 kg to <6 kg | RAL 25 mg | 1 tablet (25 mg) | 6 kg to <10 kg | RAL 50 mg | 2 tablets (25 mg) | 10 kg to <14 kg | RAL 75 mg | 3 tablets (25 mg) | 14 kg to <20 kg | RAL 100 mg | 1 tablet (100 mg) | 20 kg to <28 kg | RAL 150 mg | 1½ tablets ^b (100 mg) | 28 kg to <40 kg | RAL 200 mg | 2 tablets (100 mg) | ≥40 kg | RAL 300 mg | 3 tablets (100 mg) | <ul style="list-style-type: none"> ● No studies have been conducted on the use of RAL HD in patients with hepatic impairment. Therefore, administering RAL HD is not recommended in patients with hepatic impairment. ● The effect of severe hepatic impairment on RAL pharmacokinetics has not been studied. <p>RAL Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> ● No dose adjustment is necessary in patients with any degree of renal impairment. |
|---|------------------|----------------------------------|----------------------------|---------------|-----------|------------------|----------------|-----------|-------------------|-----------------|-----------|-------------------|-----------------|------------|-------------------|-----------------|------------|----------------------------------|-----------------|------------|--------------------|--------|------------|--------------------|--|
| Weight | Twice-Daily Dose | Number of Chewable Tablets | | | | | | | | | | | | | | | | | | | | | | | |
| 3 kg to <6 kg | RAL 25 mg | 1 tablet (25 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| 6 kg to <10 kg | RAL 50 mg | 2 tablets (25 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| 10 kg to <14 kg | RAL 75 mg | 3 tablets (25 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| 14 kg to <20 kg | RAL 100 mg | 1 tablet (100 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| 20 kg to <28 kg | RAL 150 mg | 1½ tablets ^b (100 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| 28 kg to <40 kg | RAL 200 mg | 2 tablets (100 mg) | | | | | | | | | | | | | | | | | | | | | | | |
| ≥40 kg | RAL 300 mg | 3 tablets (100 mg) | | | | | | | | | | | | | | | | | | | | | | | |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** The major route of raltegravir (RAL) elimination is mediated through glucuronidation by uridine diphosphate glucuronyl transferase (UGT) 1A1.
- Coadministering RAL with inducers of UGT1A1—such as rifampin and tipranavir—may result in reduced plasma concentrations of RAL. Inhibitors of UGT1A1—such as atazanavir—may increase plasma concentrations of RAL. No dosing modifications are recommended when RAL is coadministered with atazanavir/ritonavir (ATV/r) or tipranavir/ritonavir (TPV/r). However, RAL high-dose (HD) tablets **should not be coadministered** with TPV/r.
- In adults, an increased dose of RAL is recommended when it is coadministered with rifampin. For adults receiving rifampin, the recommended RAL dose is 800 mg twice daily. **Do not coadminister** rifampin with once-daily RAL HD tablets. In children aged 4 weeks to <12 years who had tuberculosis (TB)/HIV coinfection and were taking rifampin, RAL 12 mg/kg per dose

twice daily of the chewable tablet formulation safely achieved pharmacokinetic (PK) targets.^{2,3} In a single case report of a 6-month-old infant receiving RAL oral granules for suspension and rifampicin for TB prophylaxis, three to four times the currently recommended dose of 12 mg/kg twice daily was needed⁴ to achieve target trough concentrations (C_{trough}) >0.022 mg/L.

- Aluminum-containing antacids and magnesium-containing antacids may reduce RAL plasma concentrations and **should not be coadministered** with RAL.
- Significant drug interactions may be more likely to occur with RAL HD once daily. C_{trough} in adults is approximately 30% lower with RAL HD 1,200 mg once daily than with RAL 400 mg twice daily. A lower C_{trough} increases the potential for clinically significant drug interactions with interfering drugs that decrease RAL exposure and further lower C_{trough} . In addition to aluminum-containing and magnesium-containing antacids, the following drugs **should not be coadministered** with the RAL HD formulation: calcium carbonate antacids, rifampin, TPV/r, and etravirine. The impact of other strong inducers of drug-metabolizing enzymes on RAL is unknown; coadministration with phenytoin, phenobarbital, and carbamazepine **is not recommended**.
- Before administering RAL, clinicians should carefully review a patient's medication profile for potential drug interactions with RAL.

Major Toxicities

- *More common:* Nausea, headache, dizziness, diarrhea, fatigue, itching, insomnia.
- *Less common:* Abdominal pain, vomiting. Patients with chronic active hepatitis B virus infection and/or hepatitis C virus infection are more likely to experience a worsening adverse events (AEs) grade from baseline for laboratory abnormalities of aspartate aminotransferase, alanine aminotransferase, or total bilirubin than patients who are not coinfected.
- *Rare:* Moderate-to-severe increase in creatine phosphokinase levels. Use RAL with caution in patients who are receiving medications that are associated with myopathy and rhabdomyolysis. Anxiety, depression, and paranoia, especially in those with a history of these conditions. Rash (including Stevens-Johnson syndrome), hypersensitivity reaction, **DRESS (drug reaction with eosinophilia and systemic symptoms),^{5,6}** and toxic epidermal necrolysis. Thrombocytopenia. Cerebellar ataxia. Hepatic failure (with and without associated hypersensitivity) in patients with underlying liver disease and/or concomitant medications.

Resistance

The International AIDS Society–USA maintains a [list of updated HIV resistance mutations](#), and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

RAL is an integrase strand transfer inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for use in combination with other antiretroviral (ARV) drugs for the treatment of HIV in pediatric patients weighing ≥ 2 kg. The current pediatric FDA approval and dose recommendations are based on evaluations of 122 patients aged ≥ 4 weeks to 18 years who

participated in [IMPAACT P1066](#) and 42 full-term neonates who were treated for ≤ 6 weeks starting from birth and followed for a total of 24 weeks during [IMPAACT P1110](#).⁷

The FDA has approved RAL HD, which allows once-daily dosing, for use in children and adolescents weighing ≥ 40 kg.

Efficacy in Clinical Trials

RAL has been evaluated in adults in three large randomized clinical trials: STARTMRK, SPRING-2, and AIDS Clinical Trials Group (ACTG) A5257. STARTMRK compared the safety and efficacy of a RAL-containing regimen and an efavirenz (EFV)-containing regimen. At 48 weeks, RAL was non-inferior to EFK. However, more patients discontinued EFK during the longer follow-up periods of 4 and 5 years, and RAL was found to be virologically and immunologically superior to EFK.⁸⁻¹⁰ Results from the SPRING-2 study in treatment-naïve adults showed that RAL and dolutegravir (DTG) were equally effective and had similar safety profiles.¹¹ ACTG A5257 compared RAL to ATV/r and darunavir/ritonavir; all regimens had equivalent virologic efficacy, but RAL had better tolerability.¹² The ONCEMRK study compared RAL 1,200 mg once daily (taken as two 600-mg RAL HD tablets) to RAL 400 mg twice daily in treatment-naïve adults. Once-daily dosing with RAL 1,200 mg (taken as two 600-mg HD tablets) was found to be as effective as dosing with RAL 400 mg twice daily. Discontinuation rates due to AEs were not different between the two groups.¹³ Once-daily dosing of RAL using the HD tablets was approved by the FDA for adults and children weighing ≥ 40 kg who are either treatment naïve or virologically suppressed on a twice-daily RAL regimen.

RAL was studied in infants, children, and adolescents in IMPAACT P1066, an open-label trial that evaluated PK, safety, tolerability, and efficacy. In 96 participants aged 2 to 18 years who were mostly antiretroviral therapy (ART) experienced, 79.1% of the patients achieved a favorable viral load response (i.e., viral loads <400 copies/mL or ≥ 1 log₁₀ decline in viral load) while receiving the currently recommended dose of RAL. Infants and toddlers aged ≥ 4 weeks to <2 years also were enrolled in IMPAACT P1066 and received treatment with RAL oral suspension. At Weeks 24 and 48, 61% of the participants (14 of 23 infants and toddlers) had HIV viral loads¹⁴⁻¹⁶ <400 copies/mL.

A systematic review of observational and clinical trials published on the effectiveness and safety of RAL and DTG for treating children and adolescents with HIV was conducted by the World Health Organization. The authors concluded that both medications are safe and effective as preferred regimens.¹⁷

Efficacy and Pharmacokinetics of Once-Daily Dosing in Children and Adults

RAL PK exhibit considerable intrasubject and intersubject variability.^{18,19} Current PK targets are based on results from a clinical trial in adults (QDMRK) in which treatment-naïve patients with HIV were randomized to receive RAL 800 mg once daily or RAL 400 mg twice daily. After 48 weeks of treatment, the percent of patients who achieved HIV RNA viral loads <50 copies/mL was 83% in the once-daily group, compared with 89% in the twice-daily group. Patients in the once-daily arm with C_{trough} concentrations <45 nM (20 ng/mL) were at greater risk of experiencing treatment failure.^{18,19} Overall drug exposures were similar in both groups, but the association between higher risk of treatment failure and lower C_{trough} concentrations suggests that maintaining RAL trough plasma concentrations >45 nM (20 ng/mL) is important for efficacy.^{18,19}

The highest concentration (C_{max}) is approximately six times higher in patients receiving RAL 1,200 mg once daily than in those receiving RAL 400 mg twice daily, with a twofold higher area under the curve (AUC). Although modeling and simulations for pediatric patients indicate that PK targets are met using the once-daily RAL 1,200-mg dose, no clinical data exist on the use of this dose in children weighing <50 kg. Six children in IMPAACT P1066 had drug exposures that were similar to those observed in ONCEMRK, but all six children weighed >50 kg. Dose-related central nervous system toxicities—such as insomnia or hyperactivity—may occur in children who are exposed to very high concentrations of RAL.⁷

Efficacy and Pharmacokinetics in Children

IMPAACT P1066 evaluated the PK, safety, and efficacy of RAL in treatment-experienced children aged 4 weeks to 18 years. A summary of RAL steady-state PK parameters, following administration of the recommended twice-daily doses (approximately 6 mg/kg twice daily), can be found in Table A below.^{15,16}

Table A. Raltegravir Steady-State Pharmacokinetic Parameters in Pediatric Patients Following Administration of Recommended Twice-Daily Doses: IMPAACT P1066

| Body Weight | Formulation | Dose | N ^a | Geometric Mean (% CV ^b) AUC_{0-12h} ($\mu M \cdot h$) ^{c,d} | Geometric Mean (% CV ^b) C_{12h} (nM) ^{c,d} |
|-----------------|--------------------|----------------------------------|----------------|---|--|
| ≥25 kg | Film-coated tablet | 400 mg twice daily | 18 | 14.1 (121%) | 233 (157%) |
| ≥25 kg | Chewable tablet | Weight-based dosing ^e | 9 | 22.1 (36%) | 113 (80%) |
| 11 kg to <25 kg | Chewable tablet | Weight-based dosing ^e | 13 | 18.6 (68%) | 82 (123%) |
| 3 kg to <20 kg | Oral suspension | Weight-based dosing ^e | 19 | 24.5 (43%) | 113 (69%) |

^a Number of patients with intensive PK results at the final recommended dose

^b Geometric coefficient of variation

^c Pharmacokinetic targets for film-coated tablets and chewable tablets: AUC_{0-12h} 14–25 $\mu M \cdot h$ (6–11 mg·h/L); C_{12h} nM ≥33 nM (14.7 ng/mL)

^d Pharmacokinetic targets for oral suspension: AUC_{0-12h} 14–45 $\mu M \cdot h$ (6–20 mg·h/L); C_{12h} nM ≥75 nM (33.3 ng/mL)

^e To approximate 6 mg/kg twice daily

Key: AUC = area under the curve; AUC_{0-12h} = AUC from time zero to 12 hours after drug administration; C_{12h} = concentration at 12 hours (trough); CV = coefficient of variation

Children Aged 2 Years to 18 Years

IMPAACT P1066 was a Phase 1/2 open-label, multicenter study that evaluated the PK profile, safety, tolerability, and efficacy of various formulations of RAL in ART-experienced children and adolescents with HIV aged 2 to 18 years. RAL was administered in combination with an optimized background ARV regimen.^{16,20} Participants received either the RAL 400-mg, film-coated tablet formulation twice daily (patients aged 6–18 years and weighing ≥25 kg) or the chewable tablet formulation at a dose of RAL 6 mg/kg twice daily (patients aged 2 years to <12 years). In IMPAACT P1066, the initial dose-finding stage included an intensive PK evaluation in various age cohorts (Cohort 1: 12 years to <19 years; Cohort 2: 6 years to <12 years; Cohort 3: 2 years to <6 years). Doses were selected with the aim of achieving target PK parameters that were similar to those seen in

adults: PK targets were a geometric mean (GM) AUC from time zero to 12 hours after drug administration (AUC_{0-12h}) of $14 \mu\text{M}\cdot\text{h}$ to $25 \mu\text{M}\cdot\text{h}$ and a GM 12-hour concentration (C_{12h}) $>33 \text{ nM}$. Additional participants were then enrolled in each age cohort to evaluate the long-term efficacy, tolerability, and safety of RAL.

A total of 126 treatment-experienced participants were enrolled, with 96 participants receiving the final recommended dose of RAL. Only treatment-experienced patients were eligible to enroll, and the optimized regimen was determined by the site investigators. Adolescents tended to be more treatment experienced and have more advanced disease than those in the younger cohorts, with 75% having the Centers for Disease Control and Prevention Category B or C classification of HIV infection. Ninety-six participants completed 48 weeks of treatment. Seventy-nine percent of participants achieved HIV RNA <400 copies/mL, and 57% of participants achieved HIV RNA <50 copies/mL, with a mean CD4 T lymphocyte (CD4) cell count increase¹⁶ of 156 cells/mm^3 (4.6%). Among 36 participants who experienced virologic failure, the development of drug resistance and/or poor adherence were contributing factors. Genotypic resistance data were available for 34 patients who experienced virologic failure, and RAL-associated mutations were detected in 12 out of 34 of those patients. The frequency, type, and severity of AEs through Week 48 were comparable to those observed in adult studies. AEs were commonly reported, but few serious AEs were considered to be drug related. Patients with AEs that were considered to be drug related included one patient with Grade 3 psychomotor hyperactivity, abnormal behavior, and insomnia, as well as one patient with a Grade 2 allergic rash on Day 17 and Grade 3 ALT and Grade 4 AST laboratory elevations after Day 122. There were no discontinuations due to AEs and no drug-related deaths.¹⁶ Overall, RAL was well tolerated when administered as a film-coated tablet twice daily in participants aged 6 years to <19 years and as chewable tablets at a dose of approximately 6 mg/kg twice daily in participants aged 2 years to <12 years, with favorable virologic and immunologic responses.²¹

Children Aged ≥ 4 Weeks to <2 Years

IMPAACT P1066 studied 26 infants and toddlers aged 4 weeks to <2 years who were administered the granules for RAL oral suspension in combination with an optimized background ARV regimen. All participants had previously received ARV drugs to prevent perinatal transmission and/or treat HIV, and 69% had baseline plasma HIV RNA exceeding 100,000 copies/mL. PK targets for Cohort IV (6 months to <2 years) and Cohort V (4 weeks to <6 months) were modified to a GM AUC_{0-12h} of $14 \mu\text{M}\cdot\text{h}$ to $45 \mu\text{M}\cdot\text{h}$ and a GM $C_{12h} \geq 75 \text{ nM}$ (33.3 ng/mL). These targets were modified so that an estimated $>90\%$ of patients would have C_{12h} above the 45 nM threshold. By Week 48, two participants experienced AEs that were thought to be related to the study drug: one patient experienced a serious erythematous rash that resulted in permanent discontinuation of RAL, and one patient experienced immune reconstitution inflammatory syndrome. Virologic success, defined as $\geq 1 \log_{10}$ decline in HIV RNA or <400 copies/mL at 48 weeks, was achieved in $>87\%$ of participants. At 48 weeks of follow up, 45.5% of participants had HIV RNA <50 copies/mL and mean CD4 count increases of 527.6 cells/mm^3 (7.3%). Four participants in Cohort 4 experienced virologic failure by Week 48, and one participant had a RAL-associated resistance mutation. Overall, the granules for oral suspension, at a dose of approximately RAL 6 mg/kg twice daily, were well tolerated and had good efficacy.¹⁵

Long-Term Follow Up in Children

The IMPAACT P1066 study team reported results regarding the safety and efficacy of different RAL formulations at 240 weeks in children enrolled in this multicenter trial.²² Eligible participants were

children aged 4 weeks to 18 years who had previously been treated with ART and who were experiencing virologic failure at the time of enrollment. RAL was added to an optimized ARV regimen in all participants. RAL was well tolerated, and few serious clinical or laboratory safety events were noted during the study.²²

The proportion of participants who achieved virologic success at 240 weeks varied by the RAL formulation used: 19 of 43 children (44.2%) who received RAL 400-mg tablets; 24 of 31 children (77.4%) who received chewable tablets; and 13 of 15 children (86.7%) who received the oral granules for suspension. RAL resistance was documented in 19 of 50 patients (38%) who experienced virologic rebound after initial suppression. These results suggest that younger children with less treatment experience are more likely to have sustained virologic suppression, whereas older children with an extensive treatment history are more likely to experience treatment failure and develop resistance to RAL. Poor adherence among adolescents may have contributed to the lower efficacy observed in older children who received the RAL 400-mg tablets.²²

Neonates Aged <4 Weeks

RAL is metabolized by UGT1A1, the same enzyme that is responsible for the elimination of bilirubin. UGT enzyme activity is low at birth, and RAL elimination is prolonged in neonates. Washout PKs of RAL in neonates born to pregnant women with HIV were studied in [IMPAACT P1097](#).²³ The neonatal plasma half-life of RAL was highly variable, ranging from 9.3 to 184 hours. This suggests that neonatal development may impact UGT1A1 enzyme activity, redistribution, and/or enterohepatic recirculation of RAL. RAL competes with unconjugated bilirubin for albumin binding sites. When RAL plasma concentrations are extremely high, unconjugated bilirubin may be displaced from albumin by RAL and cross the blood–brain barrier, leading to bilirubin-induced neurologic dysfunction. The effect of RAL on neonatal bilirubin binding is unlikely to be clinically significant, unless concentrations that are 50-fold to 100-fold higher than typical peak concentrations are reached (approximately 5,000 ng/mL).²⁴

IMPAACT P1110 was a Phase 1 multicenter trial that enrolled full-term neonates with or without *in utero* RAL exposure at risk of acquiring HIV. RAL-exposed neonates were those whose mothers received RAL within 2 to 24 hours of delivery. For RAL-exposed neonates, the initial dose of RAL was delayed until 12 to 60 hours after delivery. The study design included two cohorts: Cohort 1 infants received two RAL doses that were administered 1 week apart, and Cohort 2 infants received daily RAL doses for the first 6 weeks of life. PK data from Cohort 1 and from older infants and children were combined in a population PK model, and simulations were used to select the following RAL dosing regimen for evaluation in infants in Cohort 2: RAL 1.5 mg/kg daily, starting within 48 hours of life and continuing through Day 7; RAL 3 mg/kg twice daily on Days 8 to 28 of life; and RAL 6 mg/kg twice daily after 4 weeks of age.²⁵ Protocol exposure targets for each participant were AUC from time zero to 24 hours after drug administration ($AUC_{0-24\text{hr}}$) 12 mg·h/L to 40 mg·h/L, $AUC_{0-12\text{hr}}$ 6 mg·h/L to 20 mg·h/L, and $C_{12\text{h}}$ or $C_{24\text{h}} > 33$ ng/mL. Safety was assessed using clinical and laboratory evaluations.^{23,26,27}

Twenty-six RAL-naïve infants and 10 RAL-exposed infants were enrolled in Cohort 2; 25 RAL-naïve infants and 10 RAL-exposed infants had evaluable PK results and safety data. Results for the RAL-naïve infants and RAL-exposed infants who were enrolled in Cohort 2 are contained in Table B below.²⁷

Table B. Raltegravir Pharmacokinetic Parameters for Raltegravir-Naive and Raltegravir-Exposed Neonates

| PK Parameter | Initial Dose: RAL 1.5 mg/kg Once Daily RAL-Naive (n = 25) ^d | Initial Dose: RAL 1.5 mg/kg Once Daily RAL-Exposed (n = 10) | Days 15–18: RAL 3.0 mg/kg Twice Daily RAL-Naive (n = 24) ^e | Days 15–18: RAL 3.0 mg/kg Twice Daily RAL-Exposed (n = 10) ^f |
|--|---|--|--|--|
| | GM (CV%) | GM (CV%) | GM (CV%) | GM (CV%) |
| AUC _{0–24h} (mg·h/L) ^a | 38.2 (42.0%) | 42.9 (25.3%) | — | — |
| AUC _{0–12h} (mg·h/L) | — | — | 14.3 (49.5%) | 18.3 (62.8%) |
| C _{trough} (ng/mL) ^b | 948 (84.0%) | 946 (74.0%) | 176 (162.1%) | 274 (176.4%) |
| C _{max} (ng/mL) ^c | 2,350 (36.5%) | 2,565 (23.1%) | 2,849 (47.5%) | 3,667 (46.3%) |
| T _{max} (hours) | 5.4 (71.5%) | 3.8 (88.8%) | 2.3 (77.1%) | 1.9 (52.3%) |
| T _{1/2} (hours) | 15.8 (101.4%) | 14.4 (69.5%) | 2.5 (34.1%) | 2.9 (20.7%) |

^a AUC targets: AUC_{0–24h} 12–40 mg·h/L and AUC_{0–12h} 6–20 mg·h/L.

^b C_{trough} concentration >33 ng/mL. For initial dose, the last measurable plasma concentration collected at 24 hours was used. For Days 15–18, C_{12h} was estimated when the 12-hours-post-dose sample was collected earlier than 12 hours after dosing (the protocol specified a sample collection time of 8–12 hours postdose).

^c C_{max} <8,724 ng/mL

^d AUC_{0–24h} could not be estimated for one infant.

^e AUC_{0–12h} and C_{trough} could not be estimated for one infant with delayed absorption.

^f AUC_{0–12h} and C_{max} could not be estimated for one infant with incomplete sample collection.

Key: AUC = area under the curve; AUC_{0–12h} = AUC from time zero to 12 hours after drug administration; AUC_{0–24h} = AUC from time zero to 24 hours after drug administration; C_{max} = maximum concentration; C_{trough} = trough concentration; CV = coefficient of variation; GM = geometric mean; PK = pharmacokinetic; RAL = raltegravir; T_{1/2} = half-life; T_{max} = time to reach maximum concentration

Daily RAL was safe and well tolerated during the first 6 weeks of life. Infants were treated for up to 6 weeks from birth and followed for a total of 24 weeks. All GM protocol exposure targets were met. In some infants, AUC_{0–24h} following the initial dose was slightly above the target range, but this is considered acceptable given the rapid increase in RAL metabolism during the first week of life. The PK targets and the safety guidelines were met for both RAL-naive and RAL-exposed infants in Cohort 2 using the specified dosing regimen. No drug-related clinical AEs were observed. Three laboratory AEs were reported among the RAL-naive infants: Grade 4 transient neutropenia occurred in one infant who received a zidovudine-containing regimen; two bilirubin elevations (one Grade 1 and one Grade 2) were considered nonserious and did not require specific therapy.⁷ Among the RAL-exposed infants, four infants exhibited Grade 3 or 4 toxicities: anemia in one infant, neutropenia in one infant, and hyperbilirubinemia in two infants. No specific therapy was required to treat these toxicities, and no infants required phototherapy or exchange transfusion for hyperbilirubinemia.

Results from IMPAACT P1110 confirmed the PK modeling and simulation submitted for FDA approval and labeling. Neonates born to mothers who received RAL 2 to 24 hours prior to delivery

should have their first dose of RAL delayed until 24 to 48 hours after birth.^{26,27} The timing of administration of the initial dose of RAL to infants born to patients receiving DTG- or bictegravir-containing regimens has not been studied. In a single case report of a neonate born to a mother receiving an intensified regimen of DTG 50 mg twice daily for viremia close to the time of delivery, prolonged neonatal DTG concentrations were observed.²⁸ These findings suggest that a similar delay in the first dose of RAL until 24 to 48 hours after birth may be indicated in neonates born to patients receiving an INSTI-containing oral regimen to avoid potential toxicity. Results of ongoing studies [IMPAACT 2023](#) (DTG neonatal PK and safety study) and [IMPAACT 2026](#) (washout PK in infants born to mothers receiving bictegravir) may provide PK data that can inform future recommendations.

The current RAL dosing regimen with two dose changes in the first month of life may be challenging for some families. To simplify medication teaching and minimize dosing changes, some experts increase to the 3 mg/kg twice-daily dose on Day 4 or 5 of life. Because many infants receiving RAL as part of presumptive HIV therapy will have a longer hospital stay following birth by cesarean section, this dosing change can generally be made at the time of hospital discharge.

RAL can be safely administered to full-term infants using the daily dosing regimen that was studied in IMPAACT P1110. This regimen **is not recommended** for use in preterm infants. RAL elimination kinetics in preterm and low-birth-weight neonates after maternal dosing was studied in IMPAACT P1097.²⁹ Sixteen mothers and their 18 low-birth-weight neonates (<2.5 kg) were enrolled. Median (range) RAL elimination half-life was 24.4 hours (10.1–83) hours (n = 17). A PK model incorporating slower clearance in preterm neonates demonstrated that a reduction in RAL dosing is required in this population.²⁹

Two case reports of preterm infants who received RAL to prevent perinatal transmission have been published.^{30,31} These case reports involved one infant born at a gestational age of 24 weeks and 6 days who weighed 800 g and another infant born at 33 weeks gestation who weighed 1,910 g. In both infants, intermittent dosing of RAL was done using real-time therapeutic drug monitoring in the neonatal intensive care unit.^{30,31} Less-frequent dosing was required because RAL elimination was significantly delayed in these preterm infants. RAL PKs and safety must be studied in preterm infants before RAL can be safely used without real-time PK monitoring in this population.

Formulations

The PK of RAL in adult patients with HIV who swallowed intact 400-mg tablets were compared with those observed in patients who chewed the 400-mg, film-coated tablets because of swallowing difficulties. Drug absorption was significantly higher among patients who chewed the tablets, although the palatability was rated as poor.³² In adult volunteers, the PK of RAL 800 mg taken once daily by chewing was compared with the PK of two doses of RAL 400 mg taken every 12 hours by swallowing. Participants who took RAL by chewing had significantly higher drug exposure and reduced PK variability than those who swallowed whole tablets according to current recommendations.³³ According to the manufacturer, the film-coated tablets must be swallowed whole.

The RAL chewable tablet and oral suspension have higher oral bioavailability than the 400-mg, film-coated tablet, according to a comparative study in healthy adult volunteers.³⁴ Compared with the RAL 400-mg tablet formulation, the RAL 600-mg tablet has higher relative bioavailability.^{7,35} Interpatient and intrapatient variability for PK parameters of RAL are considerable, especially with the film-coated tablets.^{7,36} Because of differences in the bioavailability of various formulations, the

dosing recommendations for each formulation differ, and the formulations **are not interchangeable**. When prescribing RAL, clinicians should refer to the appropriate dosing table for the chosen formulation. The use of RAL chewable tablets as dispersible tablets in children aged <2 years has been studied in [IMPAACT P1101](#) for infants and toddlers with TB/HIV coinfection who received rifampin as part of their TB treatment. The use of RAL chewable tablets dispersed in water at a dose of RAL 12 mg/kg per dose twice daily safely achieved PK targets.^{2,37} The RAL chewable tablets are now approved for use in infants and young children 4 weeks of age and older and weighing at least 2 kg.³⁸ An *in vitro* evaluation demonstrated that the chewable tablets are stable in various liquids, including water, apple juice, and breast milk.³⁸ The chewable tablets may be crushed and mixed with a small amount of liquid to facilitate administration (see Special Instructions above).

Palatability was evaluated as part of IMPAACT P1066. Both chewable tablets and oral granules for suspension were thought to have acceptable palatability. Seventy-three percent of those surveyed reported no problems with chewable tablets; 82.6% reported no problems with administering the oral granules.^{15,16} The acceptability and feasibility of administering RAL granules for oral suspension in a low-resource setting has been studied in clinics in South Africa and Zimbabwe. With proper training by health care personnel, caregivers were able to prepare the suspension safely and accurately.^{39,40}

References

1. Mills A, Myers L, Raudenbush C, et al. A health literate patient-focused approach to the redesign of the raltegravir (ISENTRESS) pediatric kit and instructions for use. *Pediatr Infect Dis J.* 2022;41(1):51-56. Available at: <https://pubmed.ncbi.nlm.nih.gov/34694252>.
2. Meyers T, Samson P, Acosta EP, et al. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2–12 years on rifampicin for tuberculosis. *AIDS.* 2019;33(14):2197-2203. Available at: <https://pubmed.ncbi.nlm.nih.gov/31689263>.
3. Krogstad P, Samson P, Acosta EP, et al. Pharmacokinetics and safety of a raltegravir-containing regimen in children aged 4 weeks to 2 years living with human immunodeficiency virus and receiving rifampin for tuberculosis. *J Pediatric Infect Dis Soc.* 2021;10(2):201-204. Available at: <https://pubmed.ncbi.nlm.nih.gov/32448902>.
4. van der Veer MA, Jacobs TG, Bukkems LH, et al. Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report. *Antivir Ther.* 2022;27(4):13596535221119932. Available at: <https://pubmed.ncbi.nlm.nih.gov/36062614>.
5. Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. *Clin Infect Dis.* 2017;64(9):1198-1203. Available at: <https://pubmed.ncbi.nlm.nih.gov/28369189>.
6. Thomas SJ, Kilgore JT, Becken BA, et al. Raltegravir-associated drug-reaction with eosinophilia and systemic symptoms syndrome in a pediatric patient without characteristic human leukocyte antigen B*57:01 or B*53:01 alleles. *J Pediatric Infect Dis Soc.* 2021;10(3):363-366. Available at: <https://pubmed.ncbi.nlm.nih.gov/32766769>.
7. Raltegravir (Isentress) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022145s044,203045s017,205786s009lbl.pdf.
8. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet.* 2009;374(9692):796-806. Available at: <https://pubmed.ncbi.nlm.nih.gov/19647866>.
9. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. *HIV Clin Trials.* 2012;13(4):228-232. Available at: <https://pubmed.ncbi.nlm.nih.gov/22849964>.
10. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. *J Acquir Immune Defic Syndr.* 2013;63(1):77-85. Available at: <https://pubmed.ncbi.nlm.nih.gov/23412015>.

11. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis.* 2013;13(11):927-935. Available at: <https://pubmed.ncbi.nlm.nih.gov/24074642>.
12. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med.* 2014;161(7):461-471. Available at: <https://pubmed.ncbi.nlm.nih.gov/25285539>.
13. Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg once daily vs. 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial. *J Acquir Immune Defic Syndr.* 2018;78(5):589-598. Available at: <https://pubmed.ncbi.nlm.nih.gov/29771789>.
14. Briz V, Leon-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. *Pediatr Infect Dis J.* 2012;31(3):273-277. Available at: <https://pubmed.ncbi.nlm.nih.gov/22330165>.
15. Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. *J Pediatric Infect Dis Soc.* 2015;4(4):e76-83. Available at: <https://pubmed.ncbi.nlm.nih.gov/26582887>.
16. Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. *Clin Infect Dis.* 2014;58(3):413-422. Available at: <https://pubmed.ncbi.nlm.nih.gov/24145879>.
17. Townsend CL, O'Rourke J, Milanzi E, et al. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. *J Int AIDS Soc.* 2022;25(11):e25970. Available at: <https://pubmed.ncbi.nlm.nih.gov/36377082>.
18. Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. *Antimicrob Agents Chemother.* 2012;56(6):3101-3106. Available at: <https://pubmed.ncbi.nlm.nih.gov/22430964>.
19. Rizk ML, Du L, Bennetto-Hood C, et al. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. *J Clin Pharmacol.* 2015;55(7):748-756. Available at: <https://pubmed.ncbi.nlm.nih.gov/25753401>.
20. Larson KB, King JR, Acosta EP. Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics. *Adolesc Health Med Ther.* 2013;4:79-87. Available at: <https://pubmed.ncbi.nlm.nih.gov/24600298>.
21. Tuluc F, Spitsin S, Tustin NB, et al. Decreased PD-1 expression on CD8 lymphocyte subsets and increase in CD8 Tscm cells in children with HIV receiving raltegravir. *AIDS Res Hum Retroviruses.* 2016;33:133-142. Available at: <https://pubmed.ncbi.nlm.nih.gov/27615375>.

22. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at: <https://pubmed.ncbi.nlm.nih.gov/30527329>.
23. Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. *J Acquir Immune Defic Syndr*. 2014;67(3):310-315. Available at: <https://pubmed.ncbi.nlm.nih.gov/25162819>.
24. Clarke DF, Wong RJ, Wenning L, et al. Raltegravir in vitro effect on bilirubin binding. *Pediatr Infect Dis J*. 2013;32(9):978-980. Available at: <https://pubmed.ncbi.nlm.nih.gov/23470680>.
25. Clarke DF, Mirochnick M, Acosta EP, et al. Use of modeling and simulations to determine raltegravir dosing in neonates: a model for safely and efficiently determining appropriate neonatal dosing regimens: IMPAACT P1110. *J Acquir Immune Defic Syndr*. 2019;82(4):392-398. Available at: <https://pubmed.ncbi.nlm.nih.gov/31658182>.
26. Lommerse J, Clarke D, Kerbusch T, et al. Maternal-neonatal raltegravir population pharmacokinetics modeling: implications for initial neonatal dosing. *CPT Pharmacometrics Syst Pharmacol*. 2019;8(9):643-653. Available at: <https://pubmed.ncbi.nlm.nih.gov/31215170>.
27. Clarke DF, Acosta EP, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection (IMPAACT P1110). *J Acquir Immune Defic Syndr*. 2020;84(1):70-77. Available at: <https://pubmed.ncbi.nlm.nih.gov/31913995>.
28. Jacobs TG, Schouwenburg S, Penazzato M, et al. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. *Lancet HIV*. 2022;9(9):e649-e657. Available at: <https://pubmed.ncbi.nlm.nih.gov/35863363>.
29. Clarke DF, Lommerse J, Acosta EP, et al. Impact of low birth weight and prematurity on neonatal raltegravir pharmacokinetics: IMPAACT P1097. *J Acquir Immune Defic Syndr*. 2020;85:626-634. Available at: <https://pubmed.ncbi.nlm.nih.gov/32925360>.
30. Trahan MJ, Lamarre V, Metras ME, Kakkar F. Use of triple combination antiretroviral therapy with raltegravir as empiric HIV therapy in the high-risk HIV-exposed newborn. *Pediatr Infect Dis J*. 2018;38(4):410-412. Available at: <https://pubmed.ncbi.nlm.nih.gov/30882734>.
31. Kreutzwiser D, Sheehan N, Dayneka N, et al. Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV. *Antivir Ther*. 2017;22(6):545-549. Available at: <https://pubmed.ncbi.nlm.nih.gov/28198351>.
32. Cattaneo D, Baldelli S, Cerea M, et al. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. *Antimicrob Agents Chemother*. 2012;56(12):6132-6136. Available at: <https://pubmed.ncbi.nlm.nih.gov/22964253>.

33. Cattaneo D, Cossu MV, Fucile S, et al. Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. *Ther Drug Monit.* 2015;37(1):119-125. Available at: <https://pubmed.ncbi.nlm.nih.gov/2498438>.
34. Brainard D, Gendrano N, Jin B, et al. A pharmacokinetic comparison of adult and pediatric formulations of RAL in healthy adults. Presented at: Conference on Retroviruses and Opportunistic Infections. 2010. San Francisco, CA. Available at: https://www.natap.org/2010/CROI/croi_118.htm
35. Krishna R, Rizk ML, Larson P, et al. Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. *Clin Pharmacol Drug Dev.* 2018;7(2):196-206. Available at: <https://pubmed.ncbi.nlm.nih.gov/28419778>.
36. Siccardi M, D'Avolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. *Ther Drug Monit.* 2012;34(2):232-235. Available at: <https://pubmed.ncbi.nlm.nih.gov/22406652>.
37. Krogstad P, Samson P, Acosta E, et al. Pharmacokinetics of raltegravir in HIV/TB cotreated infants and young children. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, MA.
38. Teppler H, Thompson K, Chain A, et al. Crushing of raltegravir (RAL) chewable tablets for administration in infants and young children. Presented at: International Workshop on HIV Pediatrics. 2017. Paris, France.
39. Archary M, Zanoni BC, Lallemand M, et al. Acceptability and feasibility of using raltegravir oral granules for suspension for the treatment of neonates in a low resource setting. *Pediatr Infect Dis J.* 2020;39(1):57-60. Available at: <https://pubmed.ncbi.nlm.nih.gov/31815839>.
40. Katirayi L, Stecker C, Andifasi P, et al. Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers' and caregivers' perspectives. *BMJ Paediatr Open.* 2022;6(1). Available at: <https://pubmed.ncbi.nlm.nih.gov/36053612>.

Appendix A: Pediatric Antiretroviral Drug Information

Pharmacokinetic Enhancers

Cobicistat (COBI, Tybost)

Ritonavir (RTV, Norvir)

Cobicistat (COBI, Tybost)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|--|---|
| Tablet: 150 mg | |
| Fixed-Dose Combination (FDC) Tablets | |
| <ul style="list-style-type: none">• [Evotaz] Atazanavir 300 mg/cobicistat 150 mg• [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg• [Prezcobix] Darunavir 800 mg/cobicistat 150 mg• [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg• [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/ tenofovir alafenamide 10 mg | |
| When using FDC tablets, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Cobicistat (COBI) Is a Pharmacokinetic Enhancer</p> <ul style="list-style-type: none">• The only use of COBI is as a pharmacokinetic (PK) enhancer (boosting agent) for certain protease inhibitors (PIs) and integrase strand transfer inhibitors. COBI is not interchangeable with ritonavir (RTV) and has no antiviral activity. <p>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</p> <ul style="list-style-type: none">• COBI 150 mg with atazanavir (ATV) 300 mg administered at the same time with food <p>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</p> <ul style="list-style-type: none">• COBI 150 mg with darunavir (DRV) 800 mg administered at the same time with food <p>[Evotaz] ATV/COBI</p> <p><i>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none">• One tablet once daily with food• Use in combination with other antiretroviral (ARV) drugs. | <ul style="list-style-type: none">• COBI is an inhibitor of renal tubular transporters of creatinine. This increases serum creatinine and reduces the estimated glomerular filtration rate, with no change in glomerular function. <p>Special Instructions</p> <ul style="list-style-type: none">• COBI 150 mg is not interchangeable with RTV, but it has a PK-boosting effect that is comparable to RTV 100 mg.• Drug interactions may differ between RTV and COBI, because COBI is a stronger P-glycoprotein inhibitor and lacks some of the induction effects of RTV.• Do not administer COBI with RTV or with FDC tablets that contain COBI.• COBI is not recommended for use with more than one ARV drug that requires PK enhancement (e.g., EVG used in combination with a PI).• Using COBI with PIs other than once-daily ATV 300 mg or DRV 800 mg is not recommended. |

| | |
|--|--|
| <p>[Genvoya] Elvitegravir (EVG)/COBI/Emtricitabine (FTC)/Tenofovir Alafenamide (TAF)</p> <p><i>Child (Weighing ≥ 14 to < 25 kg)</i></p> <ul style="list-style-type: none"> Limited data currently exist on the appropriate dose of Genvoya in children weighing ≥ 14 kg to < 25 kg. Studies are currently being conducted to assess the safety and efficacy of a low-dose tablet with EVG 90 mg/COBI 90 mg/FTC 120 mg/TAF 6 mg. <p><i>Child and Adolescent (Weighing ≥ 25 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food <p>[Prezcobix] DRV/COBI</p> <p><i>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food Use in combination with other ARV drugs. <p>[Stribild] EVG/COBI/FTC/Tenofovir Disoproxil Fumarate (TDF)</p> <p><i>Child and Adolescent (Weighing ≥ 35 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends using Stribild only in patients with sexual maturity ratings of 4 or 5. <p>[Symtuza] DRV/COBI/FTC/TAF</p> <p><i>Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose</i></p> <ul style="list-style-type: none"> One tablet once daily with food | <ul style="list-style-type: none"> Patients with a confirmed increase in serum creatinine >0.4 mg/dL from baseline should be closely monitored for renal safety. When using COBI in combination with TDF, monitor serum creatinine, urine protein, and urine glucose at baseline and every 3 to 6 months while the patient is receiving therapy (see Table 17i. Nephrotoxic Effects). In patients who are at risk of renal impairment, serum phosphate also should be monitored. For information on crushing and cutting tablets, see Information on Crushing and Liquid Drug Formulations from Toronto General Hospital. <h3>Metabolism/Elimination</h3> <ul style="list-style-type: none"> COBI is a strong inhibitor of cytochrome P450 (CYP) 3A4 and a weak inhibitor of CYP2D6. <p>COBI Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> COBI does not require dose adjustment in patients with mild-to-moderate hepatic impairment. No data are available in patients with severe hepatic impairment. Dosing recommendations for medications that are coadministered with COBI should be followed. Genvoya, Prezcobix, Stribild, and Symtuza are not recommended in patients with severe hepatic impairment. Evotaz is not recommended in patients with any degree of hepatic impairment. <p>COBI Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> COBI does not require a dose adjustment in patients with renal impairment, including those with severe renal impairment. Dosing recommendations for medications that are coadministered with COBI should be followed. The use of COBI plus TDF is not recommended in patients with creatinine clearance (CrCl) <70 mL/min. Dose adjustments for TDF are required for patients with CrCl <50 mL/min, and the necessary dose adjustments for TDF when this drug is used with COBI have not been established in this group of patients. Genvoya is not recommended in patients with estimated CrCl 15 to <30 mL/min, or in patients with estimated CrCl <15 mL/min who are not receiving chronic hemodialysis. |
|--|--|

| | |
|--|---|
| | <ul style="list-style-type: none"> • Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min. The dose adjustments required for FTC and TDF in these patients cannot be achieved with an FDC tablet. • Symtuza is not recommended in patients with estimated CrCl <30 mL/min. |
|--|---|

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Metabolism of cobicistat (COBI) is mainly via cytochrome P450 (CYP) 3A4 and, to a lesser degree, CYP2D6. COBI is a strong inhibitor of CYP3A4 and a weak inhibitor of CYP2D6. COBI also inhibits breast cancer resistance protein, P-glycoprotein (P-gp), the organic anion transporting polypeptides OATP1B1 and OATP1B3, and multidrug and toxin extrusion 1. Unlike ritonavir, COBI does not demonstrate any enzyme-inducing effects. The potential exists for multiple drug interactions when using COBI. Before COBI is administered, a patient's medication profile should be carefully reviewed for potential interactions and overlapping toxicities with other drugs. Coadministration of medications that induce or inhibit CYP3A4 may respectively decrease or increase exposures of COBI and coformulated antiretroviral (ARV) medications. Coadministration of medications that are CYP3A4 substrates may result in clinically significant adverse reactions that are severe, life-threatening, or fatal, or may result in loss of therapeutic effect if dependent on conversion to an active metabolite due to CYP3A4 inhibition by COBI.¹
- **Nucleoside reverse transcriptase inhibitors:** COBI is a strong P-gp inhibitor; thus, a dose of tenofovir alafenamide (TAF) 10 mg combined with COBI produces tenofovir (TFV) exposures that are similar to those produced by TAF 25 mg without COBI.² COBI increases plasma TFV exposures by 23% when it is coadministered with TDF; thus, renal safety should be monitored in patients who are receiving this combination.^{1,3}
- **Non-nucleoside reverse transcriptase inhibitors:** Efavirenz, etravirine, and nevirapine **should not be used** with COBI.
- **Protease inhibitors:** Using COBI as a dual booster for elvitegravir (EVG) and darunavir (DRV) has been studied in people with and without HIV, and the evidence is conflicting. When EVG plus COBI plus DRV was administered to people without HIV, the trough concentration (C_{trough}) of EVG was 50% lower than the C_{trough} seen in people who received elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) without DRV.⁴ When EVG/c/FTC/TAF was administered with DRV to patients with HIV, both DRV and EVG concentrations were comparable to those seen in historic controls.⁵
- **Integrase inhibitors:** In one small study, dolutegravir (DTG) C_{trough} was 107% higher when DTG was administered with darunavir/cobicistat (DRV/c) than when it was administered with darunavir/ritonavir.⁶ Bictegravir (BIC) area under the curve increases 74% when BIC is administered with DRV/c.⁷

- **Corticosteroids:** Increased serum concentrations of corticosteroids can occur when corticosteroids and COBI are coadministered; this can lead to clinically significant adrenal suppression. Adrenal suppression occurs regardless of whether the corticosteroids are administered orally or by some other route (e.g., intranasal, inhaled, interlaminar, intraarticular) and regardless of whether the corticosteroids are administered routinely or intermittently. A possible exception is beclomethasone, which appears to be a relatively safe option with inhaled or intranasal administration.^{8,9}

Major Toxicities

- *More common:* Nausea, vomiting, diarrhea, abdominal pain, anorexia
- *Less common (more severe):* New onset renal impairment or worsening of renal impairment when used with TAF or TDF, rhabdomyolysis, increased amylase and lipase levels

Resistance

Not applicable because COBI has no antiviral activity.

Pediatric Use

Approval

COBI is a pharmacokinetic (PK) enhancer of ARV drugs that is available as a single agent or a component of fixed-dose combination products. COBI, as a component of Stribild, is approved by the U.S. Food and Drug Administration (FDA) at the adult dose for use in children and adolescents aged ≥ 12 years and weighing ≥ 35 kg.¹⁰ The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends limiting the use of Stribild to those with a sexual maturity rating of 4 or 5. COBI, as a component of Genvoya, is approved by the FDA at the adult dose for use in children weighing ≥ 25 kg.¹¹ The FDA has not approved COBI as a component of Genvoya for use in children weighing < 25 kg, but an ongoing PK, safety, and efficacy study is underway with a low-dose tablet in children weighing ≥ 14 kg to < 25 kg (see the [Elvitegravir](#) section). COBI alone (as Tybost) is approved by the FDA at the adult dose for use in children weighing ≥ 35 kg when used in combination with ATV, and in children weighing ≥ 40 kg when used in combination with DRV.¹ COBI, coformulated with ATV (as Evotaz),¹² is approved by the FDA at the adult dose for use in children and adolescents weighing ≥ 35 kg. COBI, coformulated with DRV (as Prezcobix)¹³ and as a component of Syntuzza,¹⁴ is approved by the FDA at the adult dose in children and adolescents weighing ≥ 40 kg.

References

1. Cobicistat (Tybost) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203094s016lbl.pdf.
2. Ramanathan S, Wei X, Custudio J, et al. Pharmacokinetics of a novel EVG/COBI/FTC/GS-7340 single tablet regimen. Abstract O-13. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Barcelona, Spain. Available at: http://www.natap.org/2012/pharm/Pharm_24.htm.
3. Custodio J, Garner W, Jin F, et al. Evaluation of the drug interaction potential between the pharmacokinetic enhancer and tenofovir disoproxil fumarate in healthy subjects. Presented at: 14th International Workshop on Clinical Pharmacology of HIV Therapy; 2013. Amsterdam, The Netherlands. Available at: https://www.natap.org/2013/Pharm/Pharm_15.htm.
4. Ramanathan S, Wang H, Szwarcberg J, Kearney BP. Safety/tolerability, pharmacokinetics, and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir. Abstract P-08. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012. Barcelona, Spain. Available at: http://www.natap.org/2012/pharm/Pharm_28.htm.
5. Gutierrez-Valencia A, Trujillo-Rodriguez M, Fernandez-Magdaleno T, et al. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations. *J Int AIDS Soc.* 2018;21(2). Available at: <https://pubmed.ncbi.nlm.nih.gov/29430854>.
6. Gervasoni C, Riva A, Cozzi V, et al. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. *J Antimicrob Chemother.* 2017;72(6):1842-1844. Available at: <https://pubmed.ncbi.nlm.nih.gov/28333266>.
7. Zhang H, Custudio J, Wei X, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Presented at: Conference on Retroviruses and Opportunistic Infections; 2017. Seattle, WA. Available at: <http://www.croiconference.org/sessions/clinical-pharmacology-hiv-integrase-strand-transfer-inhibitor-bictegravir>.
8. Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. *HIV Med.* 2013;14(9):519-529. Available at: <https://pubmed.ncbi.nlm.nih.gov/23590676>.
9. Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. *J Acquir Immune Defic Syndr.* 2013;63(3):355-361. Available at: <https://pubmed.ncbi.nlm.nih.gov/23535292>.

10. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [package insert]. Food and Drug Administration. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203100s036lbl.pdf.
11. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207561s029lbl.pdf.
12. Evotaz (atazanavir/cobicistat) [package insert]. Food and drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206353s007lbl.pdf.
13. Prezcobix (darunavir/cobicistat) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205395s024lbl.pdf.
14. Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210455s022lbl.pdf.

Ritonavir (RTV, Norvir)

Updated: June 27, 2024

Reviewed: June 27, 2024

| Formulations | |
|---|--|
| Oral Powder: 100 mg per packet | |
| Tablet: 100 mg | |
| Generic Formulation | |
| <ul style="list-style-type: none">• 100-mg tablet | |
| Fixed-Dose Combination (FDC) Solution | |
| <ul style="list-style-type: none">• [Kaletra] Lopinavir 80 mg/ritonavir 20 mg/mL. Oral solution contains 42.4% (v/v) ethanol and 15.3% (w/v) propylene glycol. | |
| FDC Tablets | |
| <ul style="list-style-type: none">• [Kaletra] Lopinavir 100 mg/ritonavir 25 mg• [Kaletra] Lopinavir 200 mg/ritonavir 50 mg | |
| When using FDC tablets or solution, refer to other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents . | |
| For additional information, see Drugs@FDA or DailyMed . | |
| Dosing Recommendations | Selected Adverse Events |
| Ritonavir (RTV) as a Pharmacokinetic Enhancer <ul style="list-style-type: none">• RTV is used as a pharmacokinetic (PK) enhancer of other protease inhibitors (PIs). The recommended dose of RTV varies and is specific to the drug combination selected. See other sections of Appendix A. Pediatric Antiretroviral Drug Information for information about the recommended doses of RTV to use with specific PIs. RTV has antiviral activity, but it is not used as an antiviral agent; instead, it is used as a PK enhancer of other PIs. | <ul style="list-style-type: none">• Gastrointestinal (GI) intolerance, nausea, vomiting, diarrhea• Hyperlipidemia, especially hypertriglyceridemia• Hepatitis• Hyperglycemia• Fat maldistribution |
| Formulation Considerations | Special Instructions |
| <ul style="list-style-type: none">• RTV oral powder should be used only for dosing increments of 100 mg and cannot be used for doses <100 mg. | <ul style="list-style-type: none">• Administer RTV with food to increase absorption and reduce the likelihood and severity of GI adverse events.• Do not administer RTV with cobicistat (COBI) or drugs that contain COBI (e.g., Stribild, Genvoya, Prezcobix, Evotaz).• RTV oral powder should be mixed with a soft food (e.g., applesauce, vanilla pudding) or a liquid (e.g., water, chocolate milk, infant formula) to help |
| [Kaletra] Lopinavir/Ritonavir | |
| Infant, Child, Adolescent, and Adult Dose <ul style="list-style-type: none">• See the Lopinavir/Ritonavir section of Appendix A. Pediatric Antiretroviral Drug Information for information. | |

| | |
|--|--|
| | <p>mitigate the bitter taste. Administer or discard the mixture within 2 hours of mixing.</p> <p>To Increase Tolerability of RTV Oral Powder in Children</p> <ul style="list-style-type: none"> • Mix the powder with milk, chocolate milk, ice cream, or vanilla or chocolate pudding. • Before administering RTV, give a child ice chips, an ice pop, or spoonfuls of partially frozen orange or grape juice concentrate to dull the taste buds. Another option is to give a nonallergic child peanut butter or hazelnut chocolate spread to coat the mouth.¹ • After administration, give foods with strong tastes (e.g., maple syrup, cheese). • Check a child's food allergy history before making these recommendations. • Counsel caregivers or patients that the bad taste will not be completely masked. |
| | <p>Metabolism/Elimination</p> <ul style="list-style-type: none"> • Cytochrome P450 (CYP) 3A and CYP2D6 inhibitor; CYP1A2, CYP2B6, CYP2C9, CYP2C19, and glucuronidation inducer. RTV inhibits the intestinal transporter P-glycoprotein. <p>RTV Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • RTV is primarily metabolized by the liver. • No dose adjustment is necessary in patients with mild or moderate hepatic impairment. • No data exist on RTV dosing for adult or pediatric patients with severe hepatic impairment. Use caution when administering RTV to patients with moderate-to-severe hepatic impairment. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Antiretroviral Guidelines](#) and the [HIV Drug Interaction Checker](#).

- **Metabolism:** Ritonavir (RTV) is extensively metabolized by (and is one of the most potent inhibitors of) hepatic cytochrome P450 (CYP) 3A. Also, RTV is a CYP2D6 inhibitor and a CYP1A2, CYP2B6, CYP2C9, CYP2C19, and glucuronidation inducer. RTV inhibits the intestinal transporter P-glycoprotein. There is potential for multiple drug interactions with RTV.
- Before RTV is administered, a patient's medication profile should be reviewed carefully for potential interactions with RTV and overlapping toxicities with other drugs.

- RTV and cobicistat **are not interchangeable**. The potential drug interactions for these drugs are different.²
- Avoid concomitant use of corticosteroids, including intranasal or inhaled fluticasone or inhaled budesonide. Reduced elimination of steroids can increase steroid effects, leading to adrenal insufficiency.^{3,4} Use caution when prescribing RTV with other inhaled steroids. Limited data suggest that beclomethasone may be a suitable alternative to fluticasone when a patient who is taking RTV requires an inhaled or intranasal corticosteroid.^{5,6} Iatrogenic Cushing's syndrome and suppression of the hypothalamic-pituitary axis secondary to the drug interaction between RTV and local injection of triamcinolone has occurred.^{7,8} See [Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) for additional information.

Major Toxicities

- *More common:* Nausea, vomiting, diarrhea, headache, abdominal pain, anorexia, circumoral paresthesia, abnormal lipid levels
- *Less common (more severe):* Exacerbation of chronic liver disease, fat maldistribution
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs, pancreatitis. Cases of hepatitis, including life-threatening cases, have been reported. Allergic reactions, including bronchospasm, urticaria, and angioedema have occurred. Toxic epidermal necrolysis and Stevens-Johnson syndrome have occurred.⁹

Resistance

Resistance to RTV is not clinically relevant when the drug is used as a pharmacokinetic (PK) enhancer of other antiretroviral (ARV) medications.

Pediatric Use

Approval

RTV has been approved by the U.S. Food and Drug Administration for use in the pediatric population.

Effectiveness in Practice

Use of RTV as the sole protease inhibitor (PI) in ARV therapy in children **is not recommended**. In both children and adults, RTV is recommended as a PK enhancer for use with other PIs. RTV is a CYP3A inhibitor and functions as a PK enhancer by slowing the metabolism of the PI.

Dosing

Dosing regimens for RTV-boosted darunavir and atazanavir and coformulated lopinavir/ritonavir (LPV/r) are available for pediatric patients. For more information about individual PIs, see other sections of [Appendix A: Pediatric Antiretroviral Drug Information](#).

Toxicity

Full-dose RTV has been shown to prolong the PR interval in a study of healthy adults who were given RTV 400 mg twice daily.⁹ Potentially life-threatening arrhythmias have been reported in premature infants who were treated with LPV/r; therefore, the use of LPV/r is generally not recommended before a gestational age of 42 weeks (see the [Lopinavir/Ritonavir](#) section).^{10,11} Coadministration of RTV with other drugs that prolong the PR interval (e.g., macrolides, quinolones, methadone) should be undertaken with caution because it is unknown how coadministering any of these drugs with RTV will affect the PR interval. In addition, RTV should be used with caution in patients who may be at increased risk of developing cardiac conduction abnormalities, such as patients who have underlying structural heart disease, conduction system abnormalities, ischemic heart disease, or cardiomyopathy.

References

1. Morris JB, Tisi DA, Tan DCT, Worthington JH. Development and palatability assessment of norvir (ritonavir) 100 mg powder for pediatric population. *Int J Mol Sci.* 2019;20(7):1718. Available at: <https://pubmed.ncbi.nlm.nih.gov/30959935>.
2. Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. *J Antimicrob Chemother.* 2016;71(7):1755-1758. Available at: <https://pubmed.ncbi.nlm.nih.gov/26945713>.
3. Bernecker C, West TB, Mansmann G, Scherbaum WA, Willenberg HS. Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature. *Exp Clin Endocrinol Diabetes.* 2012;120(3):125-127. Available at: <https://pubmed.ncbi.nlm.nih.gov/22328106>.
4. Peyro-Saint-Paul L, Besnier P, Demessine L, et al. Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance Database. *J Antimicrob Chemother.* 2019;74(11):3291-3294. Available at: <https://pubmed.ncbi.nlm.nih.gov/31369085>.
5. Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. *J Acquir Immune Defic Syndr.* 2013;63(3):355-361. Available at: <https://pubmed.ncbi.nlm.nih.gov/23535292>.
6. Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. *HIV Med.* 2013;14(9):519-529. Available at: <https://pubmed.ncbi.nlm.nih.gov/23590676>.
7. Dubrocq G, Estrada A, Kelly S, Rakhmanina N. Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy. *Endocrinol Diabetes Metab Case Rep.* 2017;2017:17-0076. Available at: <https://pubmed.ncbi.nlm.nih.gov/29118985>.
8. Noe S, Jaeger H, Heldwein S. Adrenal insufficiency due to ritonavir-triamcinolone drug-drug interaction without preceding Cushing's syndrome. *Int J STD AIDS.* 2018;29(11):1136-1139. Available at: <https://pubmed.ncbi.nlm.nih.gov/29749880>.
9. Changes to Norvir labeling. *AIDS Patient Care STDS.* 2008;22(10):834-835. Available at: <https://pubmed.ncbi.nlm.nih.gov/18924248>.
10. Lopriore E, Rozendaal L, Gelinck LB, Bokenkamp R, Boelen CC, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. *AIDS.* 2007;21(18):2564-2565. Available at: <https://pubmed.ncbi.nlm.nih.gov/18025905>.

11. McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, Patel JA. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. *Pediatr Infect Dis J*. 2009;28(12):1127-1129. Available at: <https://pubmed.ncbi.nlm.nih.gov/19820426>.

Appendix A: Pediatric Antiretroviral Drug Information

Fixed-Dose Combinations

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

Updated: June 27, 2024

Reviewed: June 27, 2024

| Brand Name | NRTIs | | | | | | NNRTIs | | | INSTIs | | | | PIs | | | PK Enhancers | |
|-------------------|-------|-----|-----|-----|-----|------------------|--------|-----|------------------|------------------|------------------|-----|------------------|-----|-----|------------------|--------------|-----|
| | ABC | 3TC | ZDV | FTC | TDF | TAF ^a | DOR | EFV | RPV ^b | BIC ^a | CAB ^b | DTG | EVG ^a | ATV | DRV | LPV ^c | COBI | RTV |
| NRTI | | | | | | | | | | | | | | | | | | |
| Cimduo | | X | | | X | | | | | | | | | | | | | |
| Combivir | | X | X | | | | | | | | | | | | | | | |
| Descovy | | | | X | | X | | | | | | | | | | | | |
| Epzicom | X | X | | | | | | | | | | | | | | | | |
| Temixys | | X | | | X | | | | | | | | | | | | | |
| Truvada | | | | X | X | | | | | | | | | | | | | |
| NRTI/NNRTI | | | | | | | | | | | | | | | | | | |
| Atripla | | | | X | X | | | X | | | | | | | | | | |
| Complera | | | | X | X | | | | | X | | | | | | | | |
| Delstrigo | | X | | | X | | X | | | | | | | | | | | |
| Odefsey | | | | X | | X | | | X | | | | | | | | | |
| Symfi or Symfi Lo | | X | | | X | | | X | | | | | | | | | | |
| NRTI/INSTI | | | | | | | | | | | | | | | | | | |
| Biktarvy | | | | X | | X | | | | X | | | | | | | | |
| Dovato | | X | | | | | | | | | | X | | | | | | |

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

| Brand Name | NRTIs | | | | | | NNRTIs | | | INSTIs | | | | PIs | | | PK Enhancers | |
|------------------------|-------|-----|-----|-----|-----|------------------|--------|-----|------------------|------------------|------------------|-----|------------------|-----|-----|------------------|--------------|-----|
| | ABC | 3TC | ZDV | FTC | TDF | TAF ^a | DOR | EFV | RPV ^b | BIC ^a | CAB ^b | DTG | EVG ^a | ATV | DRV | LPV ^c | COBI | RTV |
| Triumeq | X | X | | | | | | | | | | | X | | | | | |
| Triumeq PD | X | X | | | | | | | | | | | X | | | | | |
| NNRTI/INSTI | | | | | | | | | | | | | | | | | | |
| Juluca | | | | | | | | | | X | | | X | | | | | |
| Cabenuva | | | | | | | | | | X | | X | | | | | | |
| NRTI/INSTI/COBI | | | | | | | | | | | | | | | | | | |
| Genvoya | | | | X | | X | | | | | | | X | | | | X | |
| Stribild | | | | X | X | | | | | | | | X | | | | X | |
| NRTI/PI/COBI | | | | | | | | | | | | | | | | | | |
| Syntuzta | | | | X | | X | | | | | | | | | X | | X | |
| PI/COBI | | | | | | | | | | | | | | | | | | |
| Evotaz | | | | | | | | | | | | | X | | | | X | |
| Prezcobix | | | | | | | | | | | | | | X | | | X | |
| PI/RTV | | | | | | | | | | | | | | | | | | |
| Kaletra | | | | | | | | | | | | | | | X | | | X |

^a TAF, BIC, and EVG are only available in FDC tablets. However, TAF 25 mg tablets (Vemlidy) are FDA approved for treatment of HBV. In select circumstances, TAF might be used as one component of a combination ARV regimen, with dosing recommendations similar to those for Descovy.

^b CAB and RPV for intramuscular injection are available as a co-packaged product (Cabenuva); oral formulations of CAB and RPV for initial lead-in dosing must be prescribed separately; see [Cabotegravir and Rilpivirine](#).

^c LPV is only available in FDC tablets or solution.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; CAB = cabotegravir; COBI = cobicistat; DOR = doravirine; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = U.S. Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; HBV = hepatitis B virus;

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

INSTI = integrase strand transfer inhibitor; LPV = lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside and nucleotide reverse transcriptase inhibitor; PI = protease inhibitor; PK = pharmacokinetic; RPV = rilpivirine; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

Updated: June 27, 2024

Reviewed: June 27, 2024

General Considerations When Using Fixed-Dose Combination Products

Please see the individual drug sections under [Appendix A. Pediatric Antiretroviral Drug Information](#) for the recommended dosing of individual fixed-dose combination (FDC) products.

FDC tablets and individual ARV drugs also can be looked up by drug name (brand name and generic) at [DailyMed](#). Size is listed under the Ingredients and Appearance section.

For images of most of the FDC tablets listed in this table, see the [Antiretroviral Medications](#) section of the National HIV Curriculum. In addition, a resource from the United Kingdom illustrates the relative sizes of FDC tablets and individual ARV drugs (see the [ARV Chart](#) at [HIV i-BASE](#)). Although most of the drugs listed in the chart are the same as those in the United States, there are several differences: some formulations available in the United States are not included; a few of the brand names are not the same as those listed in Appendix A, Table 2; and the chart includes a formulation that is not available in the United States.

Integrase Strand Transfer Inhibitors

- Bictegravir (BIC) and dolutegravir (DTG), second-generation **integrase strand transfer inhibitors** (INSTIs), have a higher barrier to resistance than the first-generation INSTIs, elvitegravir (EVG) and raltegravir (RAL).
- For children weighing ≥ 6 kg **and aged ≥ 3 months**, DTG is available in once-daily FDC formulations of abacavir (ABC)/ DTG/lamivudine (3TC). If ABC/DTG/3TC is not an option, then single-entity DTG can be used in combination with other FDC tablets. Refer to [Dolutegravir](#) for dosing information.
 - ABC/DTG/3TC is available in two different formulations, with the appropriate formulation depending on weight. For children weighing ≥ 6 kg to <25 kg **and aged ≥ 3 months**, ABC/DTG/3TC is available in a dispersible tablet, once-daily regimen (Triumeq PD); the number of tablets per dose depends on the child's weight. For children and adolescents weighing ≥ 25 kg, ABC/DTG/3TC is available as a once-daily single-tablet regimen (Triumeq).
 - Whether considering DTG in FDC or single-entity form, **the film-coated tablets and dispersible tablets are not bioequivalent and, thus, are not interchangeable on a milligram-per-milligram basis**.

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

- For children weighing ≥ 14 kg, BIC is available as the single-tablet, once-daily regimen BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF) (Biktarvy). There are two dosage strengths for pediatric use: one for use in children weighing ≥ 14 to < 25 kg and another for children and adolescents weighing ≥ 25 kg and adults. Refer to [Bictegravir](#) for dosing information.
- For children weighing ≥ 25 kg, EVG is available as the single-tablet, once-daily regimen EVG/cobicistat (c)/FTC/TAF (Genvoya). EVG/c/FTC/TAF (Genvoya) has more drug–drug interactions than ABC/DTG/3TC (Triumeq or Triumeq PD) or BIC/FTC/TAF (Biktarvy). Refer to [Elvitegravir](#) for dosing information.
- The two-drug, co-packaged regimen of long-acting injectable cabotegravir (CAB) and rilpivirine (RPV) (Cabenuva) is approved by the U.S. Food and Drug Administration (FDA) for use in children and adolescents aged ≥ 12 years and weighing ≥ 35 kg. CAB and RPV are administered by intramuscular injection on a monthly or every-2-months schedule after an optional oral dose lead-in. See [Cabotegravir](#) and [Rilpivirine](#) for instructions about dosing and administration.

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

- ABC or TAF in combination with 3TC or FTC are favored over zidovudine (ZDV)/3TC because of the lower risk of nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)–associated mitochondrial toxicity.
- Tenofovir disoproxil fumarate (TDF) is more potent than ABC at high viral loads ($> 100,000$ copies/mL) when used in regimens that do not contain an INSTI.
- TAF is favored over TDF because of the lower risk of TDF-associated bone and renal toxicity. TDF is not recommended for children with sexual maturity ratings (SMRs) of 1 to 3 because of TDF-associated bone toxicity.
- For children weighing ≥ 14 kg who can swallow pills, FTC/TAF (Descovy) offers a once-daily alternative to twice-daily ZDV plus 3TC or ABC plus 3TC.
- For children weighing ≥ 14 kg and ≤ 35 kg, FTC/TAF (Descovy) can be used in combination with an INSTI or non-nucleoside reverse transcriptase inhibitor (NNRTI), but not with a protease inhibitor; this restriction does not apply to regimens containing ZDV or ABC.

Non-Nucleoside Reverse Transcriptase Inhibitors

- The FDC tablet doravirine (DOR)/3TC/TDF is approved by the FDA for children and adolescents weighing ≥ 35 kg who are antiretroviral (ARV) naive or virologically suppressed on a stable ARV regimen (see the [Doravirine](#) section).
- RPV has low potency at high viral loads ($> 100,000$ copies/mL) and requires a high-fat meal for optimal absorption, so efavirenz (EFV) or an INSTI are favored over RPV.

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

Fixed-Dose Combinations Available for Children and Adolescents

| FDC by Class Brand name and generic ^a products, when available | FDC Components | Minimum Body Weight or Weight Range (kg) or Age ^b | Pill Size (mm × mm) or Largest Dimension (mm) ^c | Food Requirements |
|---|---------------------------------------|---|---|--------------------------------|
| NRTI | | | | |
| Cimduo | 3TC 300 mg/TDF 300 mg | 35 kg | 19 | Take with or without food. |
| Combivir and Generic 3TC/ZDV | 3TC 150 mg/ZDV 300 mg (scored tablet) | 30 kg | 18 × 7 | Take with or without food. |
| Descovy | FTC 120 mg/TAF 15 mg | With an INSTI or NNRTI • 14 to < 25 kg | N/A | Take with or without food. |
| | FTC 200 mg/TAF 25 mg | With an INSTI or NNRTI With a Boosted PI • 25 kg • 35 kg | 12.5 × 6.4 | Take with or without food. |
| Epzicom and Generic ABC/3TC | ABC 600 mg/3TC 300 mg | 25 kg | 21 × 9 | Take with or without food. |
| Temixys | 3TC 300 mg/TDF 300 mg | 35 kg | N/A | Take with or without food. |
| Truvada | FTC 100 mg/TDF 150 mg | 17 to < 22 kg | 14 | Take with or without food. |
| | FTC 133 mg/TDF 200 mg | 22 to < 28 kg | 16 | Take with or without food. |
| | FTC 167 mg/TDF 250 mg | 28 to < 35 kg | 18 | Take with or without food. |
| | FTC 200 mg/TDF 300 mg | 35 kg | 19 × 8.5 | Take with or without food. |
| NRTI/NNRTI | | | | |
| Atripla | EFV 600 mg/FTC 200 mg/TDF 300 mg | 40 kg | 20 | Take on an empty stomach. |
| Complera | FTC 200 mg/RPV 25 mg/TDF 300 mg | 35 kg and aged ≥ 12 years | 19 | Take with a meal. ^d |

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

| FDC by Class Brand name and generic ^a products, when available | FDC Components | Minimum Body Weight or Weight Range (kg) or Age ^b | Pill Size (mm × mm) or Largest Dimension (mm) ^c | Food Requirements |
|---|---|--|---|--|
| Delstrigo | DOR 100 mg/3TC 300 mg/TDF 300 mg | 35 kg | 19 | Take with or without food. |
| Odefsey | FTC 200 mg/RPV 25 mg/TAF 25 mg | 35 kg and aged ≥12 years | 15 | Take with a meal. ^d |
| Symfi | EFV 600 mg/3TC 300 mg/TDF 300 mg (scored tablet) | 40 kg | 23 | Take on an empty stomach. |
| Symfi Lo | EFV 400 mg/3TC 300 mg/TDF 300 mg | 35 kg ^e | 21 | Take on an empty stomach. |
| NRTI/INSTI | | | | |
| Biktarvy | BIC 30 mg/FTC 120 mg/TAF 15 mg | 14 to <25 kg | N/A | Take with or without food. |
| | BIC 50 mg/FTC 200 mg/TAF 25 mg | 25 kg | 15 × 8 | Take with or without food. |
| Dovato | DTG 50 mg/3TC 300 mg | 25 kg | 19 | Take with or without food. |
| Triumeq | ABC 600 mg/DTG 50 mg/3TC 300 mg | 25 kg | 22 × 11 | Take with or without food. |
| Triumeq PD | ABC 60 mg/DTG 5 mg/3TC 30 mg | 6 to <25 kg and aged ≥3 months ^g | N/A (dispersible) | Take with or without food. |
| NNRTI/INSTI | | | | |
| Cabenuva ^h | Cabenuva 400 mg/600 mg kit contains CAB 400 mg/2 mL vial and RPV 600 mg/2 mL vial | 35 kg and aged ≥12 years | N/A | See Cabotegravir for instructions about dosing and administration. |
| | Cabenuva 600 mg/900 mg kit contains CAB 600 mg/3 mL vial and RPV 900 mg/3 mL vial | 35 kg and aged ≥12 years | N/A | See Cabotegravir for instructions about dosing and administration. |
| Juluca | DTG 50 mg/RPV 25 mg | Adults ^f | 14 | Take with a meal. ^d |
| NRTI/INSTI/COBI | | | | |
| Genvoya | EVG 150 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg | 25 kg | 19 × 8.5 | Take with food. |
| Stribild | EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg | 35 kg and SMR of 4 or 5 ⁱ | 20 | Take with food. |

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

| FDC by Class Brand name and generic ^a products, when available | FDC Components | Minimum Body Weight or Weight Range (kg) or Age ^b | Pill Size (mm × mm) or Largest Dimension (mm) ^c | Food Requirements |
|---|--|---|---|----------------------------|
| NRTI/PI/COBI | | | | |
| Syntuz | DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg | 40 kg | 22 | Take with food. |
| PI/COBI | | | | |
| Evotaz | ATV 300 mg/COBI 150 mg | 35 kg | 19 | Take with food. |
| Prezcobix | DRV 800 mg/COBI 150 mg | 40 kg | 23 | Take with food. |
| PI/RTV | | | | |
| Kaletra | LPV/r Oral Solution <ul style="list-style-type: none"> • LPV 80 mg/mL and RTV 20 mg/mL Tablets <ul style="list-style-type: none"> • LPV 200 mg/RTV 50 mg • LPV 100 mg/RTV 25 mg | Post-Menstrual Age of 42 Weeks and a Postnatal Age of ≥14 Days <ul style="list-style-type: none"> • No minimum weight | 19 | Take with or without food. |

^a The possibility of planned and unplanned pregnancy should be considered when selecting an antiretroviral therapy (ART) regimen for an adolescent. When discussing ART options with adolescents and their caregivers, it is important to consider childbearing potential and the benefits and risks of all ARV drugs and to provide the information and counseling needed to support informed decision-making (see [Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive](#) and [Appendix C: Antiretroviral Counseling Guide for Health Care Providers](#)).

^b Minimum body weight and age are those recommended by the FDA, unless otherwise noted.

^c Sizes or largest dimensions of generic drugs are not listed because they may vary by manufacturer; this information is available by looking up one of the drug components using [DailyMed](#).

^d Patients must be able to take oral RPV with a meal of at least 500 calories on a regular schedule (a protein drink alone does not constitute a meal).

^e Because of pharmacokinetic concerns, the Panel recommends caution when using Symfi Lo in children and adolescents who have SMRs of 1 to 3 and weigh ≥ 40 kg (see the [Efavirenz](#) section).

^f The Panel does not currently recommend using DTG/RPV (Juluca) as a complete two-drug regimen in adolescents and children. These FDC tablets could be used as part of a three-drug regimen in children who meet the minimum body weight requirements for each component drug.

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets and Co-packaged Formulations: Minimum Body Weights and Considerations for Use in Children and Adolescents

^g ABC/DTG/3TC is available in dispersible tablets (Triumeq PD) for children weighing ≥ 6 kg to <25 kg and aged ≥ 3 months with the dosage and number of tablets based on weight. Refer to the [Dolutegravir](#) section for exact dosage and instructions for administration. Dispersible tablets (Triumeq PD) are not recommended for children and adolescents weighing ≥ 25 kg.

^h Long-acting [injectable](#) CAB and RPV for intramuscular administration are available as a co-packaged product (Cabenuva); oral formulations of CAB and RPV for the optional initial lead-in dosing or bridging between injections >7 days from the target injection window must be prescribed separately (see the [Cabotegravir](#) and [Rilpivirine](#) sections).

ⁱ Although Stribild is approved by the FDA for use in children and adolescents weighing ≥ 35 kg and age ≥ 12 years, the Panel does not recommend its use in children with SMRs of 1 to 3 given the availability of other INSTI-containing FDCs.

Key: 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; BIC = bictegravir; CAB = cabotegravir; COBI = cobicistat; DOR = doravirine; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; FDA = U.S. Food and Drug Administration; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; kg = kilogram; LPV = lopinavir; LPV/r = lopinavir/ritonavir; mg = milligram; mL = milliliter; mm = millimeter; N/A = information not available or not applicable; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; the Panel = Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; PI = protease inhibitor; RPV = rilpivirine; RTV = ritonavir; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

Appendix A: Pediatric Antiretroviral Drug Information

Archived Drugs

The Archived Drugs section of Appendix A: Pediatric Antiretroviral Drug Information provides access to the last updated versions of drug sections that are no longer being reviewed by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel). Archived Drugs includes older antiretroviral drugs that the Panel does not recommend for use in children because they have unacceptable toxicities, inferior virologic efficacy, a high pill burden, pharmacologic concerns, and/or a limited amount of pediatric data.

[Didanosine \(ddl, Videx\)](#)

[Enfuvirtide \(T-20, Fuzeon\)](#)

[Fosamprenavir \(FPV, Lexiva\)](#)

[Indinavir \(IDV, Crixivan\)](#)

[Nelfinavir \(NFV, Viracept\)](#)

[Saquinavir \(SQV, Invirase\)](#)

[Stavudine \(d4t, Zerit\)](#)

[Tipranavir \(TPV, Aptivus\)](#)

Didanosine (ddI, Videx)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | | | | | | | | | |
|--|-------------------------|------|-----------------|-------------------|-----------------|-------------------|--------|-------------------|--|
| <p>Pediatric Oral Solution: 10 mg/mL</p> <p>Enteric-Coated (EC) Delayed-Release Capsules (EC Beadlets): 125 mg, 200 mg, 250 mg, and 400 mg</p> | | | | | | | | | |
| <p>Generic Formulations</p> <p>Delayed-Release Capsules: 125 mg, 200 mg, 250 mg, and 400 mg</p> | | | | | | | | | |
| <p>For additional information, see Drugs@FDA.</p> | | | | | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | | | | | |
| <p>Note: Didanosine is no longer recommended by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV for use in children due to higher rates of adverse effects than other NRTIs.</p> <p>Neonate/Infant Dose (Aged 2 Weeks to <3 Months)</p> <ul style="list-style-type: none">• 50 mg/m² of body surface area every 12 hours. See dosing section below for justification of this dose. <p>Infant Dose (Aged ≥3 Months to 8 Months)</p> <ul style="list-style-type: none">• 100 mg/m² of body surface area every 12 hours <p>Pediatric Dose of Oral Solution (Aged >8 Months)</p> <ul style="list-style-type: none">• 120 mg/m² of body surface area every 12 hours• Dose range: 90–150 mg/m² of body surface area every 12 hours. Do not exceed maximum adult dose; see table below.• In treatment-naïve children aged 3 years to 21 years, 240 mg/m² of body surface area once daily (oral solution or capsules) has resulted in viral suppression. <p>Pediatric Dose of Videx EC or Generic Capsules (Aged 6–18 Years and Weighing ≥20 kg)</p> <table border="1"><thead><tr><th>Body Weight</th><th>Dose</th></tr></thead><tbody><tr><td>20 kg to <25 kg</td><td>200 mg once daily</td></tr><tr><td>25 kg to <60 kg</td><td>250 mg once daily</td></tr><tr><td>≥60 kg</td><td>400 mg once daily</td></tr></tbody></table> | Body Weight | Dose | 20 kg to <25 kg | 200 mg once daily | 25 kg to <60 kg | 250 mg once daily | ≥60 kg | 400 mg once daily | <ul style="list-style-type: none">• Peripheral neuropathy• Diarrhea, abdominal pain, nausea, vomiting• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported (the risk is increased when didanosine is used in combination with stavudine).• Pancreatitis (less common in children than in adults, more common when didanosine is used in combination with tenofovir disoproxil fumarate or stavudine)• Non-cirrhotic portal hypertension• Retinal changes, optic neuritis• Insulin resistance/diabetes mellitus |
| Body Weight | Dose | | | | | | | | |
| 20 kg to <25 kg | 200 mg once daily | | | | | | | | |
| 25 kg to <60 kg | 250 mg once daily | | | | | | | | |
| ≥60 kg | 400 mg once daily | | | | | | | | |
| Special Instructions | | | | | | | | | |
| <ul style="list-style-type: none">• Administer didanosine on an empty stomach (30 minutes before or 2 hours after a meal). To improve adherence, some practitioners administer didanosine without regard to timing of meals (see text below).• Didanosine powder for oral solution contains antacids that may interfere with the absorption of other medications, including protease inhibitors (PIs). See individual PI for instructions on timing of administration.• Shake didanosine oral solution well before use. Keep refrigerated; solution is stable for 30 days. | | | | | | | | | |

| Adolescent and Adult Dose | | Metabolism/Elimination |
|---|-------------------|------------------------|
| Body Weight | Dose | |
| <60 kg | 250 mg once daily | |
| ≥60 kg | 400 mg once daily | |
| Pediatric and Adolescent Dose of Didanosine when Combined with Tenofovir Disoproxil Fumarate | | |
| <ul style="list-style-type: none"> This combination should be avoided because of enhanced didanosine toxicity, reports of immunologic nonresponse, high rates of early virologic failure, and rapid selection of resistance mutations (see the Adult and Adolescent Guidelines). | | |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Absorption:** Antacids in didanosine oral solution can decrease the absorption of a number of medications if given at the same time. Avoid giving other medications concurrently with didanosine oral solution.
- Mechanism unknown:** Didanosine serum concentrations are increased when didanosine is co-administered with tenofovir disoproxil fumarate (TDF). This combination should be avoided.
- Renal elimination:** Drugs that decrease renal function can decrease didanosine clearance.
- Overlapping toxicities:** The combination of stavudine with didanosine may result in enhanced toxicity. This combination should be avoided (see the Major Toxicities section below).

Major Toxicities

- More common:** Diarrhea, abdominal pain, nausea, vomiting
- Less common (more severe):** Peripheral neuropathy, electrolyte abnormalities, and hyperuricemia. Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported, and are more common when didanosine is used in combination with stavudine. Pancreatitis (less common in children than in adults, more common when didanosine is used in combination with TDF or stavudine) can occur. Increased liver enzymes, retinal depigmentation, and optic neuritis have been reported. Decreases in CD4 T lymphocyte counts have been reported when didanosine is used in combination with TDF.
- Rare:** Non-cirrhotic portal hypertension, presenting clinically with hematemesis, esophageal varices, ascites, and splenomegaly, and associated with increased transaminases, increased alkaline phosphatase, and thrombocytopenia, has been associated with long-term didanosine use.¹
- Possible risk of cancer after in-utero exposure:** In a study of 15,163 children without HIV infection who were exposed to at least one nucleoside reverse transcriptase inhibitor (NRTI) *in utero*, 21 cancers were identified. Didanosine accounted for only 10% of prescriptions but was associated with one-third of identified cancers, and, in multivariate analysis, didanosine was

associated with a 5.5-fold (95% CI, 2.1–14.4) increased risk of cancer with first-trimester exposure.² During adolescence, disanosine use while pregnant or at risk of becoming pregnant should prompt health care professionals to caution about this cancer risk.

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Although didanosine is a Food and Drug Administration (FDA)-approved NRTI for use in children as part of antiretroviral therapy, it **is not recommended** for in children due to its significant toxicity and the availability of safer agents.

Dosing

Standard Dose in Children Aged >8 Months

The standard dose of didanosine oral solution in children aged >8 months is 120 mg/m² of body surface area twice daily.^{3,4} Doses higher than 180 mg/m² of body surface area twice daily are associated with increased toxicity.⁵

Special Considerations for Children Aged 2 Weeks to <8 Months

For infants aged 2 weeks to 8 months, the FDA recommends 100 mg/m² of body surface area per dose twice daily. However, because pharmacokinetic (PK) differences in younger infants (aged 2 weeks–3 months) compared with older children raise concerns for increased toxicity in this younger age group, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV recommends a dose of 50 mg/m² of body surface area twice daily for infants aged 2 weeks to 3 months, with an increase to 100 mg/m² of body surface area per dose twice daily at 3 months, and finally increasing to 120 mg/m² of body surface area per dose twice daily at age 8 months (as discussed above).

Frequency of Administration (Once Daily or Twice Daily)

In those aged >3 years, a once-daily dosing regimen may be preferable to promote adherence, and multiple studies support the favorable PKs and efficacy of once-daily dosing of 240 mg/m² of body surface area.⁶

Food Restrictions

Although the prescribing information recommends taking didanosine on an empty stomach, this is impractical for infants who must be fed frequently, and it may decrease medication adherence by increasing regimen complexity. A comparison showed that systemic exposure measured by area under the curve was similar whether didanosine oral solution was given to children with or without food; absorption of didanosine administered with food was slower and elimination more prolonged.⁷

To improve adherence, some practitioners administer didanosine without regard to timing of meals. Studies in adults suggest that didanosine can be given without regard to food.^{8,9} A European study dosed didanosine oral solution as part of a four-drug regimen either 1 hour before or 1 hour after meals, but allowed the extended-release formulation to be given without food restriction. The study showed good virologic outcome with up to 96 weeks of follow-up.¹⁰

References

1. Scherbier HJ, Terpstra V, Pajkrt D, et al. Noncirrhotic portal hypertension in perinatally HIV-infected adolescents treated with didanosine-containing antiretroviral regimens in childhood. *Pediatr Infect Dis J.* 2016. Available at <http://www.ncbi.nlm.nih.gov/pubmed/27167116>.
2. Hleyhel M, Goujon S, Delteil C, et al. Risk of cancer in children exposed to didanosine *in utero*. *AIDS.* 2016;30(8):1245-1256. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26854809>.
3. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. *Antimicrob Agents Chemother.* 2000;44(4):1029-1034. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10722507>.
4. Nacro B, Zoure E, Hien H, et al. Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. *Bull World Health Organ.* 2011;89(6):451-458. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21673861>.
5. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. *N Engl J Med.* 1991;324(3):137-144. Available at <http://www.ncbi.nlm.nih.gov/pubmed/1670591>.
6. King JR, Nachman S, Yoge R, et al. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. *Antivir Ther.* 2002;7(4):267-270. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12553481>.
7. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. *AIDS Res Hum Retroviruses.* 2000;16(5):415-421. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10772527>.
8. Sanchez-Conde M, Palacios R, Sanz J, et al. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. *AIDS Res Hum Retroviruses.* 2007;23(10):1237-1241. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17961110>.
9. Hernandez-Novoa B, Antela A, Gutierrez C, et al. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study. *HIV Med.* 2008;9(4):187-191. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18298579>.
10. Scherbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. *Pediatrics.* 2007;119(3):e705-715. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17308244>.

Enfuvirtide (T-20, Fuzeon)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|--|--|
| <p>Lyophilized Powder for Injection: 108-mg vial of enfuvirtide. Reconstitution with 1.1 mL sterile water will deliver 90 mg/mL.</p> <p>Convenience Kit: 60 single-use vials of enfuvirtide (108-mg vial reconstituted as 90 mg/mL), 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 administration syringes (1 mL), alcohol wipes</p> <p>For additional information, see Drugs@FDA.</p> | |
| | |
| Dosage Recommendations | Selected Adverse Events |
| <p>Pediatric and Adolescent Dose (Aged 6–16 Years)</p> <p><i>Children Aged <6 Years</i></p> <ul style="list-style-type: none">Not approved for use in children aged <6 years <p><i>Children Aged ≥6 Years</i></p> <ul style="list-style-type: none">2 mg/kg (maximum dose 90 mg [1 mL]) twice daily injected subcutaneously (SQ) into the upper arm, anterior thigh, or abdomen <p>Adolescent (Aged >16 Years) and Adult Dose</p> <ul style="list-style-type: none">90 mg (1 mL) twice daily injected SQ into the upper arm, anterior thigh, or abdomen | <ul style="list-style-type: none">Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in up to 98% of patients.Increased rate of bacterial pneumonia (unclear association).Hypersensitivity reaction (HSR)—symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Rechallenge is not recommended. |
| Special Instructions | |
| | <ul style="list-style-type: none">Carefully instruct patient or caregiver in proper technique for drug reconstitution and administration of SQ injections. Enfuvirtide injection instructions are provided with convenience kits.Allow reconstituted vial to stand until the powder goes completely into solution, which could take up to 45 minutes. Do not shake.Once reconstituted, inject enfuvirtide immediately or keep refrigerated in the original vial until use. Reconstituted enfuvirtide must be used within 24 hours.Enfuvirtide must be given SQ; severity of reactions increases if given intramuscularly.Give each injection at a site different from the preceding injection site; do not inject into moles, scar tissue, bruises, or the navel. Both the patient/caregiver and health care provider should carefully monitor for signs and symptoms of local infection or cellulitis.To minimize local reactions, apply ice or heat after injection or gently massage injection site to better disperse the dose. There are reports of injection-associated neuralgia and paresthesia when alternative delivery systems, such as needle-free injection devices, are used. |

| | |
|-------------------------------|---|
| | <ul style="list-style-type: none"> Advise patients/caregivers of the possibility of a HSR; instruct them to discontinue treatment and seek immediate medical attention if a patient develops signs and symptoms consistent with a HSR. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none"> Catabolism to constituent amino acids. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

There are no known significant drug interactions with enfuvirtide.

Major Toxicities

- More common:** Almost all patients (87% to 98%) experience local injection site reactions including pain and discomfort, induration, erythema, nodules and cysts, pruritus, and ecchymosis. Reactions are usually mild to moderate in severity but can be more severe. Average duration of local injection site reaction is 3 to 7 days but was >7 days in 24% of patients.
- Less common (more severe):** Increased rate of bacterial pneumonia (unclear association).¹ Pediatric studies have lacked the statistical power to answer questions concerning enfuvirtide use and increased risk of pneumonia.
- Rare:** Hypersensitivity reactions (HSRs) (<1%) including fever, nausea and vomiting, chills, rigors, hypotension, and elevated liver transaminases; immune-mediated reactions including primary immune complex reaction, respiratory distress, glomerulonephritis, and Guillain-Barre syndrome. Patients experiencing HSRs should seek immediate medical attention. Therapy should not be restarted in patients with signs and symptoms consistent with HSRs.
- Pediatric specific:** Local site cellulitis requiring antimicrobial therapy (up to 11% in certain subgroups of patients in pediatric studies).²

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Resistance testing must be ordered specifically for fusion inhibitors, as it is not performed on routine genotypic or phenotypic assays.

Pediatric Use

Approval

Although enfuvirtide is Food and Drug Administration (FDA)-approved for use in children, it is not commonly used because of its high cost, need for twice-daily subcutaneous (SQ) injections, and high

rate of injection site reactions. Use in deep salvage regimens³ has also declined with the availability of integrase inhibitors and other entry inhibitors (such as maraviroc).

Pharmacokinetics

A single-dose pharmacokinetic evaluation study of enfuvirtide, given SQ to 14 children with HIV aged 4 years to 12 years (PACTG 1005), identified that enfuvirtide 60 mg/m² of body surface area per dose resulted in a target trough concentration that approximated the equivalent of a 90-mg dose delivered SQ to an adult (1000 mg/mL).⁴ In a second pediatric study of 25 children aged 5 years to 16 years, a 2-mg/kg dose (maximum 90 mg) of enfuvirtide given twice daily yielded drug concentrations similar to 60 mg/m² of body surface area dose independent of age group, body weight, body surface area, and sexual maturation.⁵ The FDA-recommended dose of enfuvirtide for children aged 6 to 16 years is 2 mg/kg (maximum 90 mg) administered SQ twice daily. Further data are needed for dosing in children aged <6 years.

Efficacy

The safety and antiretroviral (ARV) activity of twice-daily SQ enfuvirtide administration at 60 mg/m² per dose plus optimized background therapy (OBT) was evaluated over 96 weeks in 14 children aged 4 to 12 years who had failed to achieve viral suppression on multiple prior ARV regimens (PACTG 1005). At 24 weeks 71% of the children had a >1.0_{log} reduction in viral load; 43% and 21% had HIV RNA levels suppressed to <400 copies/mL and <50 copies/mL, respectively. However, only 36% of children maintained virologic suppression (>1.0_{log} decrease in HIV RNA) at Week 96. Most children had local injection site reactions.⁶ Significant improvements in CD4 T lymphocyte (CD4) cell percentages and height *z* scores were observed in children receiving enfuvirtide for 48 and 96 weeks.

T20-310, a Phase 1/2 study of enfuvirtide (2.0 mg/kg SQ, maximum 90 mg, twice daily) plus OBT, enrolled 52 treatment-experienced children aged 3 to 16 years for 48 weeks. Only 64% of the children completed 48 weeks of therapy. The median decrease in HIV RNA was -1.17 log₁₀ copies/mL (n = 32) and increase in CD4 cell count was 106 cells/mm³ (n = 25). At Week 8, treatment responses as measured by several plasma HIV RNA parameters were superior in younger children (aged <11 years) compared with adolescents. Median increases in CD4 cell count were 257 cells/mm³ in children and 84 cells/mm³ in adolescents. Local skin reactions were common in all age groups (87% of study participants). The observed differential responses between children and adolescents probably reflect unique challenges to adherence with the prescribed regimen.²

References

1. Kousignian I, Launay O, Mayaud C, et al. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? *J Antimicrob Chemother.* 2010;65(1):138-144. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19903719>.
2. Wiznia A, Church J, Emmanuel P, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. *Pediatr Infect Dis J.* 2007;26(9):799-805. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17721374>.
3. Feiterna-Sperling C, Walter H, Wahn V, Kleinkauf N. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide. *Eur J Med Res.* 2009;14(1):44-46. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19258211>.
4. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. *Pediatr Infect Dis J.* 2002;21(7):653-659. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12237598>.
5. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. *Pediatr Infect Dis J.* 2004;23(12):1137-1141. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15626952>.
6. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. *Pediatr Infect Dis J.* 2004;23(8):713-718. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15295220>.

Fosamprenavir (FPV, Lexiva)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | | | | | | | | | | | |
|---|--|---|--------|---|-----------------|---|-----------------|---|--------------|---|--|
| <p>Tablets: 700 mg</p> <p>Oral Suspension: 50 mg/mL</p> <p>For additional information, see Drugs@FDA.</p> | | | | | | | | | | | |
| Dosing Recommendations | Selected Adverse Events | | | | | | | | | | |
| <p>Pediatric Dose (Aged >6 Months to 18 Years)</p> <ul style="list-style-type: none">Unboosted fosamprenavir (without ritonavir) is Food and Drug Administration (FDA)-approved for antiretroviral (ARV)-naive children aged 2 to 5 years, but not recommended by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) because of low exposures (see text below).Boosted fosamprenavir (with ritonavir) is FDA-approved for ARV-naive infants ≥ 4 weeks and for treatment-experienced infants ≥ 6 months; however, the Panel does not recommend use in infants aged <6 months because of similarly low exposures (see text below). If used in infants as young as 4 weeks, it should only be administered to infants born at 38 weeks' gestation or greater. <p>Note: Once-daily dosing is not recommended for any pediatric patient.</p> <p>Pediatric Dose (Aged ≥ 6 Months to 18 Years)</p> <p>Twice-Daily Dose Regimens by Weight for Pediatric Patients ≥ 6 Months Using Fosamprenavir Oral Suspension with Ritonavir</p> <table border="1"><thead><tr><th>Weight</th><th>Dose (Both Drugs Twice Daily^a with Food)</th></tr></thead><tbody><tr><td><11 kg</td><td>Fosamprenavir 45 mg/kg/dose plus ritonavir 7 mg/kg/dose</td></tr><tr><td>11 kg to <15 kg</td><td>Fosamprenavir 30 mg/kg/dose plus ritonavir 3 mg/kg/dose</td></tr><tr><td>15 kg to <20 kg</td><td>Fosamprenavir 23 mg/kg/dose plus ritonavir 3 mg/kg/dose</td></tr><tr><td>≥ 20 kg</td><td>Fosamprenavir 18 mg/kg/dose plus ritonavir 3 mg/kg/dose</td></tr></tbody></table> | Weight | Dose (Both Drugs Twice Daily ^a with Food) | <11 kg | Fosamprenavir 45 mg/kg/dose plus ritonavir 7 mg/kg/dose | 11 kg to <15 kg | Fosamprenavir 30 mg/kg/dose plus ritonavir 3 mg/kg/dose | 15 kg to <20 kg | Fosamprenavir 23 mg/kg/dose plus ritonavir 3 mg/kg/dose | ≥ 20 kg | Fosamprenavir 18 mg/kg/dose plus ritonavir 3 mg/kg/dose | <ul style="list-style-type: none">Diarrhea, nausea, vomitingSkin rash (fosamprenavir has a sulfonamide moiety. Stevens-Johnson syndrome and erythema multiforme have been reported.)HeadacheHyperlipidemia, hyperglycemiaNephrolithiasisTransaminase elevationFat maldistributionPossible increased bleeding episodes in patients with hemophilia |
| Weight | Dose (Both Drugs Twice Daily ^a with Food) | | | | | | | | | | |
| <11 kg | Fosamprenavir 45 mg/kg/dose plus ritonavir 7 mg/kg/dose | | | | | | | | | | |
| 11 kg to <15 kg | Fosamprenavir 30 mg/kg/dose plus ritonavir 3 mg/kg/dose | | | | | | | | | | |
| 15 kg to <20 kg | Fosamprenavir 23 mg/kg/dose plus ritonavir 3 mg/kg/dose | | | | | | | | | | |
| ≥ 20 kg | Fosamprenavir 18 mg/kg/dose plus ritonavir 3 mg/kg/dose | | | | | | | | | | |
| Special Instructions | | | | | | | | | | | |
| | <ul style="list-style-type: none">Fosamprenavir tablets with ritonavir should be taken with food. Children should take the suspension with food.Patients taking antacids should take fosamprenavir at least 1 hour before or after antacid use.Fosamprenavir contains a sulfonamide moiety. The potential for cross sensitivity between fosamprenavir and other drugs in the sulfonamide class is unknown. Fosamprenavir should be used with caution in patients with sulfonamide allergy.Shake oral suspension well before use. Refrigeration is not required. | | | | | | | | | | |

| <p>^a Not to exceed the adult dose of fosamprenavir 700 mg plus ritonavir 100 mg twice daily.</p> <p>Note: When administered with ritonavir, the adult regimen of 700 mg fosamprenavir tablets plus 100 mg ritonavir, both given twice daily, can be used in patients weighing ≥39 kg. Ritonavir tablets can be used in patients weighing ≥33 kg.</p> | <h3 style="text-align: center;">Metabolism/Elimination</h3> |
|---|---|
| <p>Adolescent and Adult Dose</p> <ul style="list-style-type: none"> Dosing regimen depends on whether the patient is ARV-naive or ARV-experienced. <p><i>ARV-Naive Patients</i></p> <ul style="list-style-type: none"> Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily Fosamprenavir 1400 mg plus ritonavir 100–200 mg, both once daily <p><i>Protease-Inhibitor-Experienced Patients</i></p> <ul style="list-style-type: none"> Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily. <p>Note: Once-daily administration of fosamprenavir plus ritonavir is not recommended.</p> | <ul style="list-style-type: none"> The prodrug fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir by cellular phosphatases in the gut as it is absorbed. Amprenavir is a cytochrome P (CYP) 450 3A4 inhibitor, inducer, and substrate. <p>Fosamprenavir Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> Specific dose adjustments are recommended for adults with mild, moderate, and severe hepatic impairment. However, there are no data to support dosing recommendations for pediatric patients with hepatic impairment. Please refer to the package insert. <p>Fosamprenavir Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> No dose adjustment is required in patients with renal impairment. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Fosamprenavir may interact with a number of other drugs, and using ritonavir as a boosting agent increases the potential for drug interactions. Before administration, a patient's medication profile should be carefully reviewed for potential drug interactions with fosamprenavir.

Major Toxicities

- More common:* Vomiting, nausea, diarrhea, perioral paresthesia, headache, rash, lipid abnormalities
- Less common (more severe):* Life-threatening rash, including Stevens-Johnson syndrome, in <1% of patients. Fat maldistribution, neutropenia, and elevated serum creatinine kinase levels.
- Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs, hemolytic anemia, elevation in serum transaminases, angioedema, and nephrolithiasis.
- Pediatric-specific:* Vomiting was more frequent in children than in adults during clinical trials of fosamprenavir with ritonavir (20% to 36% vs. 10%, respectively) and in trials of fosamprenavir without ritonavir (60% vs. 16%, respectively). Neutropenia was also more common in children across all the trials (15% vs. 3%, respectively).¹

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Fosamprenavir is Food and Drug Administration (FDA)-approved for use in children as young as age 4 weeks, but the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends use only in children aged ≥ 6 months. Although unboosted fosamprenavir has been approved by the FDA for antiretroviral-naive children aged 2 to 5 years, the Panel **does not recommend** unboosted fosamprenavir for this—or any other—age group because of low exposures and also because unboosted fosamprenavir may select for mutations associated with resistance to darunavir.²

Efficacy and Pharmacokinetics

Dosing recommendations for fosamprenavir are based on three pediatric studies that enrolled more than 200 children aged 4 weeks to 18 years. In two, open-label trials in both treatment-experienced and treatment-naive children aged 2 to 18 years,^{3,4} fosamprenavir was well-tolerated and effective in suppressing viral load and increasing CD4 T lymphocyte count. However, data were insufficient to support a once-daily dosing regimen of fosamprenavir/ritonavir in children; therefore, once-daily dosing **is not recommended** for pediatric patients.

Pharmacokinetics in Infants

In a study of infants, higher doses of both fosamprenavir and ritonavir were used in treatment-naive infants as young as age 4 weeks and in treatment-experienced infants as young as age 6 months.^{1,5} Exposures in those aged < 6 months were much lower than those achieved in older children and adults and comparable to those seen with unboosted fosamprenavir (see table below). Given these low exposures, limited data, large dosing volumes, unpleasant taste, and the availability of alternatives for infants and young children, the Panel **does not recommend** fosamprenavir use in infants aged < 6 months.

Table A. Fosamprenavir Dose and Amprenavir Exposure by Age Group

| Population | Dose | AUC _{0-24h} (mcg*hr/mL) Except Where Noted | C _{min} (mcg/mL) |
|-----------------------------------|--|--|------------------------------|
| Infants Aged <6 Months | FPV 45 mg/kg plus RTV 10 mg/kg twice daily | 26.6 ^a | 0.86 |
| Children Aged 2 Years to <6 Years | FPV 30 mg/kg twice daily (no RTV) | 22.3 ^a | 0.513 |
| Children Weighing <11 kg | FPV 45 mg/kg plus RTV 7 mg/kg twice daily | 57.3 | 1.65 |
| Children Weighing 15 kg to <20 kg | FPV 23 mg/kg FPV plus RTV 3 mg/kg twice daily | 121.0 | 3.56 |
| Children Weighing \geq 20 kg | FPV 18 mg/kg plus RTV 3 mg/kg twice daily (maximum 700/100 mg) | 72.3–97.9 | 1.98–2.54 |
| Adults | FPV 1400 mg twice daily (no RTV) | 33 | 0.35 |
| Adults | FPV 1400 mg plus RTV 100–200 mg RTV once daily | 66.4–69.4 | 0.86–1.45 |
| Adults | FPV 700 mg plus RTV 100 mg twice daily | 79.2 | 2.12 |

^a AUC₀₋₁₂ (mcg*hr/mL)

Key: AUC_{0-24h} = area under the curve for 24 hours post-dose; C_{min} = minimum plasma concentration; FPV = fosamprenavir; RTV = ritonavir

Note: Dose for those weighing 11 kg to <15 kg is based on population pharmacokinetic studies; therefore, AUC and C_{min} are not available.

References

1. Fosamprenavir [package insert]. Food and Drug Administration. 2016. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022116s023_21548-s39lbl.pdf.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2022. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/AdultandAdolescentGL0034_12.pdf.
3. Chadwick E, Borkowsky W, Fortuny C, et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected pediatric subjects ages 2 to 18 years (48-week interim data, study apv20003). Presented at: 14th Conference on Retroviruses and Opportunistic Infections. 2007. Los Angeles, CA.
4. Fortuny C, Duiculescu D, Cheng K, et al. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. *Pediatr Infect Dis J*. 2014;33(1):50-56. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23811744>.
5. Cotton M, Cassim H, Pavia-Ruz N, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. *Pediatr Infect Dis J*. 2014;33(1):57-62. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23811743>.

Indinavir (IDV, Crixivan)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|---|--|
| <p>Capsules: 100 mg, 200 mg, and 400 mg</p> <p>For additional information, see Drugs@FDA.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Neonate and Infant Dose</p> <ul style="list-style-type: none">Not approved for use in neonates/infantsShould not be administered to neonates because of the risks associated with hyperbilirubinemia (kernicterus) <p>Pediatric Dose</p> <ul style="list-style-type: none">Not approved for use in childrenA range of indinavir doses (234–500 mg/m² body surface area) boosted with low-dose ritonavir has been studied in children (see text below). <p>Adolescent and Adult Dose</p> <ul style="list-style-type: none">800 mg indinavir plus 100 or 200 mg ritonavir every 12 hoursThe Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV does not recommend the use of indinavir in adolescents. | <ul style="list-style-type: none">NephrolithiasisGastrointestinal intolerance, nauseaHepatitisIndirect hyperbilirubinemiaHyperlipidemiaHyperglycemiaFat maldistributionPossible increased bleeding episodes in patients with hemophilia |
| Special Instructions | |
| | <ul style="list-style-type: none">When indinavir is given in combination with ritonavir, meal restrictions are not necessary.Adequate hydration is required to minimize risk of nephrolithiasis (≥ 48 oz of fluid daily in adult patients).Indinavir capsules are sensitive to moisture; store at room temperature (59–86°F) in original container with desiccant. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">Cytochrome P450 3A4 (CYP3A4) inhibitor and substrate <p>Indinavir Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none">Dose should be decreased in patients with mild-to-moderate hepatic impairment (recommended dose for adults is 600 mg indinavir every 8 hours). No dosing information is available for children with any degree of hepatic impairment or for adults with severe hepatic impairment. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Metabolism:* Cytochrome P450 3A4 (CYP3A4) is the major enzyme responsible for metabolism. There is potential for multiple drug interactions with indinavir.
- Avoid other drugs that cause hyperbilirubinemia, such as atazanavir.
- Before administration, a patient's medication profile should be carefully reviewed for potential drug interactions with indinavir.

Major Toxicities

- *More common:* Nephrolithiasis/urolithiasis with indinavir crystal deposit is reported more frequently in children (29%) than in adults (12.4%).¹ Interstitial nephritis and urothelial inflammation has been commonly reported in adults.² Nausea, abdominal pain, headache, metallic taste, dizziness, asymptomatic hyperbilirubinemia (10%), lipid abnormalities, pruritus, and rash.
- *Less common (more severe):* Fat maldistribution.
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs, acute hemolytic anemia, and hepatitis (life-threatening in rare cases).

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Indinavir has not been approved by the Food and Drug Administration for use in the pediatric population. Although indinavir was one of the first protease inhibitors to be studied in children, its use in pediatrics has never been common and is currently very rare.³ Indinavir is **not recommended** by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV for use in children and adolescents because of its unfavorable toxicity profile, limited efficacy data, and uncertain pharmacokinetics.

Efficacy and Pharmacokinetics

Both unboosted and ritonavir-boosted indinavir have been studied in children with HIV. In children, an unboosted indinavir dose of 500 to 600 mg/m² body surface area given every 8 hours results in peak blood concentrations and area under the curve that are slightly higher than those in adults, but trough concentrations are considerably lower. A significant proportion of children have trough indinavir concentrations less than the 0.1 mg/L value associated with virologic efficacy in adults.⁴⁻⁷

Studies that investigated a range of indinavir/ritonavir doses in small groups of children have shown that indinavir 500 mg/m² body surface area plus ritonavir 100 mg/m² body surface area twice daily is probably too high,⁸ that indinavir 234 to 250 mg/m² body surface area plus low-dose ritonavir twice daily is too low,^{9,10} and that indinavir 400 mg/m² body surface area plus ritonavir 100 to 125 mg/m² body surface area twice daily results in exposures approximating those seen with indinavir 800 mg plus ritonavir 100 mg twice daily in adults, albeit with considerable inter-individual variability and high rates of toxicity.¹⁰⁻¹²

References

1. Indinavir [package insert]. Food and Drug Administration. 2015. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020685s077lbl.pdf.
2. Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. *Clin Infect Dis.* 2002;34(8):1122-1128. Available at <https://www.ncbi.nlm.nih.gov/pubmed/11915002>.
3. Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. *J Acquir Immune Defic Syndr.* 2011;57(2):165-173. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21407086>.
4. Burger DM, van Rossum AM, Hugen PW, et al. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. *Antimicrob Agents Chemother.* 2001;45(3):701-705. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11181346>.
5. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. *Antimicrob Agents Chemother.* 2000;44(4):1029-1034. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10722507>.
6. Gatti G, Vigano A, Sala N, et al. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection. *Antimicrob Agents Chemother.* 2000;44(3):752-755. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10681350>.
7. Mueller BU, Sleasman J, Nelson RP, Jr., et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. *Pediatrics.* 1998;102(1 Pt 1):101-109. Available at <http://www.ncbi.nlm.nih.gov/pubmed/9651421>.
8. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. *Pediatrics.* 2002;110(2 Pt 1):e19. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12165618>.
9. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. *Pediatr Infect Dis J.* 2007;26(1):86-88. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17195716>.
10. Curras V, Hocht C, Mangano A, et al. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. *Pharmacology.* 2009;83(1):59-66. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19052483>.
11. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. *Antimicrob Agents Chemother.* 2004;48(5):1904-1907. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15105157>.

12. Fraaij PL, Bergshoeff AS, van Rossum AM, Hartwig NG, Burger DM, de Groot R. Changes in indinavir exposure over time: a case study in six HIV-1-infected children. *J Antimicrob Chemother.* 2003;52(4):727-730. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12917234>.

Nelfinavir (NFV, Viracept)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|--|---|
| Tablets: 250 mg and 625 mg For additional information, see Drugs@FDA . | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Note: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV no longer recommends nelfinavir-based regimens for use in children due to inferior potency compared to other regimens.</p> <p>Neonate and Infant Dose</p> <ul style="list-style-type: none">Nelfinavir should not be used for treatment in children aged <2 years. <p>Pediatric Dose (Aged ≥2 Years)</p> <ul style="list-style-type: none">45–55 mg/kg twice daily <p>Adolescent and Adult Dose</p> <ul style="list-style-type: none">1,250 mg (five 250-mg tablets or two 625-mg tablets) twice daily | <ul style="list-style-type: none">DiarrheaHyperlipidemiaHyperglycemiaFat maldistributionSerum transaminase elevations |
| Special Instructions | |
| | <ul style="list-style-type: none">Administer nelfinavir with meal or light snack.If co-administered with didanosine, administer nelfinavir 2 hours before or 1 hour after didanosine.Patients unable to swallow nelfinavir tablets can dissolve the tablets in a small amount of water. Once tablets are dissolved, mix the cloudy mixture well and consume it immediately. The glass should be rinsed with water and the rinse swallowed to ensure that the entire dose is consumed. Tablets can also be crushed and administered with pudding or other nonacidic foods. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">Cytochrome P (CYP) 2C19 and 3A4 substrateMetabolized to active M8 metaboliteCYP3A4 inhibitor |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Metabolism:** Cytochrome P (CYP) 2C19 and 3A4 substrate and CYP3A4 inhibitor. Ritonavir boosting does not significantly increase nelfinavir concentrations, and co-administration of nelfinavir with ritonavir is **not recommended**.

- There is potential for multiple drug interactions with nelfinavir. Before administering nelfinavir, carefully review a patient's medication profile for potential drug interactions.

Major Toxicities

- *More common:* Diarrhea (most common), asthenia, abdominal pain, rash, lipid abnormalities
- *Less common (more severe):* Fat redistribution, exacerbation of chronic liver disease
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of pre-existing diabetes mellitus, spontaneous bleeding in patients with hemophilia, elevations in transaminases

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Nelfinavir is approved by the Food and Drug Administration (FDA) for use in children aged ≥ 2 years. Given the higher variability of nelfinavir plasma concentrations in infants and younger children,^{1,2} nelfinavir is not approved for children aged < 2 years. Despite being FDA-approved for pediatric use, nelfinavir **is not recommended** for use in children and adolescents by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, due to its limited efficacy and uncertain pharmacokinetics (PK).

Efficacy in Pediatric Clinical Trials

Nelfinavir used in combination with other antiretroviral (ARV) drugs has been extensively studied in children with HIV infection.^{3–10} In randomized trials of children aged 2 to 13 years receiving nelfinavir as part of triple combination therapy, the proportion of patients with HIV RNA < 400 copies/mL through 48 weeks of therapy has been quite variable, ranging from 26% to 69%. The antiviral response to nelfinavir is significantly less in children aged < 2 years than in older children.^{8,10,11} In clinical studies, virologic and immunologic response to nelfinavir-based therapy has varied according to the patient's age or prior treatment history, the number of drugs included in the combination regimen, and the dose of nelfinavir used.

Pharmacokinetics: Exposure-Response Relationships

Nelfinavir's relatively poor ability to control plasma viremia in infants and children in clinical trials may be related to its lower potency when compared with other ARV drugs, as well as highly variable drug exposure, metabolism, and poor palatability.^{12–14} The bioavailability of dissolved nelfinavir tablets is comparable to that of tablets swallowed whole.^{3,15}

Administration of nelfinavir with food increases nelfinavir exposure (area under the curve increases by up to fivefold) and decreases PK variability when compared to the fasted state. Nelfinavir plasma exposure may be even more unpredictable in pediatric patients than in adults due to the increased

clearance of nelfinavir observed in children and difficulties in taking nelfinavir with sufficient food to improve bioavailability.

Nelfinavir is metabolized by multiple CYP450 enzymes, including CYP3A4 and CYP2C19. The variability of drug exposure at any given dose is much higher for children than for adults,¹⁶ which has been attributed—at least in part—to differences in the diets of children and adults. Two population PK studies of nelfinavir and its active metabolite, M8, describe the large intersubject variability observed in children.^{17,18} Furthermore, CYP2C19 genotype has been shown to affect nelfinavir PK and the virologic responses in children with HIV.¹²

Several studies have demonstrated a correlation between nelfinavir trough concentrations and virologic response. In both children and adults, an increased risk of virologic failure was associated with low nelfinavir drug exposure, particularly with a nelfinavir minimum plasma concentration (C_{min}) <1.0 mcg/mL.¹⁹⁻²¹

In a study of 32 children treated with a high dose of nelfinavir (a twofold increase of the recommended dose), 80% of children with morning trough nelfinavir plasma concentration >0.8 mcg/mL had HIV RNA concentrations <50 copies/mL at Week 48, compared with only 29% of those with morning trough <0.8 mcg/mL.²² Children in the group with $C_{trough} < 0.8$ mcg/mL were younger than the children in the group with $C_{trough} > 0.8$ mcg/mL (median ages in these groups were 3.8 years and 8.3 years, respectively).²² Therapeutic drug monitoring of nelfinavir plasma concentrations, with appropriate adjustments for low drug exposure, has been shown to improve virologic response in adults and children.^{18,19,23,24} Pediatric and adolescent patients may require doses higher than those recommended in adults to achieve higher plasma nelfinavir exposure.

References

1. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. *Pediatr Infect Dis J.* 2001;20(8):746-751. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11734735>.
2. Mirochnick M, Stek A, Acevedo M, et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. *J Acquir Immune Defic Syndr.* 2005;39(2):189-194. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15905735>.
3. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. *AIDS.* 2004;18(2):237-245. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15075541>.
4. King JR, Nachman S, Yoge R, et al. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. *Pediatr Infect Dis J.* 2005;24(10):880-885. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16220085>.
5. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. *Clin Infect Dis.* 2002;34(7):991-1001. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11880966>.
6. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. *Clin Infect Dis.* 1999;28(5):1109-1118. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10452644>.
7. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. *N Engl J Med.* 2004;350(24):2471-2480. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15190139>.
8. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet.* 2002;359(9308):733-740. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11888583&query_hl=42.
9. Resino S, Larru B, Maria Bellon J, et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. *BMC Infect Dis.* 2006;6:107. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16834769>.
10. Scherbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. *Pediatrics.* 2006;117(3):e528-536. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16481448>.

11. Nelfinavir [package insert]. Food and Drug Administration. 2011. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf.
12. Saitoh A, Capparelli E, Aweeka F, et al. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2010;54(3):285-289. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19890215>.
13. Wu H, Lathey J, Ruan P, et al. Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12–22 years) infected through high-risk behavior. *J Infect Dis.* 2004;189(4):593-601. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14767811&query_hl=31.
14. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med.* 2002;346(26):2039-2046. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12087139>.
15. Regazzi MB, Seminari E, Villani P, et al. Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile. *J Chemother.* 2001;13(5):569-574. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11760223>.
16. Gatti G, Castelli-Gattinara G, Cruciani M, et al. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. *Clin Infect Dis.* 2003;36(11):1476-1482. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12766843>.
17. Hirt D, Urien S, Jullien V, et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. *Antimicrob Agents Chemother.* 2006;50(3):910-916. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16495250>.
18. Crommentuyn KM, Scherbier HJ, Kuijpers TW, Mathot RA, Huitema AD, Beijnen JH. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. *Pediatr Infect Dis J.* 2006;25(6):538-543. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16732153>.
19. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. *Ther Drug Monit.* 2003;25(1):73-80. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12548148&query_hl=15.
20. Gonzalez de Requena D, Nunez M, de Mendoza C, Jimenez-Nacher I, Soriano V. Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. *AIDS.* 2003;17(3):442-444. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12556700>.

21. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). *AIDS*. 2002;16(10):1331-1340. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12131209>.
22. Burger DM, Bergshoeff AS, De Groot R, et al. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. *J Pediatr*. 2004;145(3):403-405. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15343199>.
23. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. *AIDS*. 2003;17(8):1157-1165. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12819517>.
24. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. *Clin Pharmacol Ther*. 2008;83(2):300-306. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17609682>.

Saquinavir (SQV, Invirase)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|--|---|
| Capsules: 200 mg Tablets: 500 mg For additional information, see Drugs@FDA . | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Pediatric Dose</p> <ul style="list-style-type: none">Not approved for use in infants, children, and adolescents aged <16 years. <p>Adolescent and Adult Dose</p> <ul style="list-style-type: none">Saquinavir should only be used in combination with ritonavir.Saquinavir 1000 mg plus ritonavir 100 mg twice daily | <ul style="list-style-type: none">Gastrointestinal intolerance, nausea, diarrheaElevated transaminasesHyperlipidemiaHyperglycemiaFat maldistributionPR interval prolongation, QT interval prolongation, and ventricular tachycardia (Torsades de Pointes) |
| Special Instructions | |
| | <ul style="list-style-type: none">Administer within 2 hours after a full meal.Sun exposure can cause photosensitivity reactions; advise patients to use sunscreen or protective clothing.Pre-therapy electrocardiogram is recommended; saquinavir is contraindicated in patients with a prolonged QT interval. |
| Metabolism/Elimination | |
| | <ul style="list-style-type: none">Cytochrome P450 3A4 (CYP3A4) substrate and inhibitor90% metabolized in the liverUse saquinavir with caution in patients who have hepatic impairment; no dose adjustment recommended. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Saquinavir is both a substrate and inhibitor of the cytochrome P 450 3A4 (CYP3A4) system. Potential exists for multiple drug interactions. Saquinavir **should not be coadministered** with

drugs that are highly dependent on CYP3A clearance, especially in cases where elevated plasma concentrations of the coadministered drug can cause serious or life-threatening events.

- Before administration, a patient's medication profile should be carefully reviewed for potential drug interactions.

Major Toxicities

- *More common:* Diarrhea, abdominal discomfort, headache, nausea, paresthesia, skin rash, lipid abnormalities
- *Less common (more severe):* Exacerbation of chronic liver disease, lipodystrophy
- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of pre-existing diabetes mellitus, spontaneous bleeding in patients with hemophilia, pancreatitis, and elevation in serum transaminases. Saquinavir administered with ritonavir can lead to prolonged QT and/or PR intervals with potential for heart block and ventricular tachycardia (Torsades de Pointes).

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Saquinavir is not approved for use in children or adolescents aged <16 years.¹

Efficacy

Saquinavir has been studied with nucleoside reverse transcriptase inhibitors and other protease inhibitors in children with HIV.^{2–9} Saquinavir/ritonavir (SQV/r) and a dual-protease inhibitor saquinavir/lopinavir/ritonavir regimen were considered for salvage therapy in children prior to the emergence of the new classes of antiretroviral medications; these regimens **are no longer recommended**.

Pharmacokinetics

Pharmacokinetic (PK) data from children who received SQV/r showed prohibitively low exposure in children younger than 2 years.¹⁰ In children aged ≥2 years, a dose of saquinavir 50 mg/kg twice daily in combination with ritonavir and lopinavir/ritonavir resulted in steady-state plasma trough concentrations (C_{trough}) similar to those seen adults.^{9,11} No clinical trials have collected data on the efficacy of saquinavir doses <50 mg/kg in children.

Toxicity

In healthy adult volunteers, SQV/r dose and exposure were associated with increases in both QT and PR intervals.^{1,12} Rare cases of Torsades de Pointes and complete heart block have been reported in postmarketing surveillance. SQV/r **is not recommended** for adolescent and adult patients with any

of the following conditions: documented congenital or acquired QT prolongation, pretreatment QT interval of >450 milliseconds, refractory hypokalemia or hypomagnesemia, complete atrioventricular block without implanted pacemakers, at risk of complete atrioventricular block, or the use of other drugs that prolong QT interval. An electrocardiogram (EKG) is recommended before initiation of therapy with saquinavir and repeat EKGs should be considered during therapy.

Steady-state saquinavir exposures observed in one pediatric trial (NV20911) were substantially higher than those seen in historical data from adults with QT and PR prolongation.^{1,12} Although no EKG abnormalities have been reported among the small number of subjects in pediatric trials, pediatric PK/pharmacodynamics modeling suggests that reducing the saquinavir dose in order to minimize the risk of QT prolongation would decrease saquinavir efficacy in children. Pediatric saquinavir dose recommendations that were both reliably effective and below the thresholds of concern for QT and PR prolongation were not determined.

References

1. Saquinavir [package insert]. Food and Drug Administration. 2015. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020628s43-021785s19lbl.pdf.
2. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. *Pediatr Infect Dis J.* 2005;24(10):874-879. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16220084>.
3. De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. *Int J Immunopathol Pharmacol.* 2005;18(4):729-735. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16388722>.
4. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. *Clin Pharmacol Ther.* 2002;71(3):122-130. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11907486>.
5. Hoffmann F, Notheis G, Wintergerst U, Eberle J, Gurtler L, Belohradsky BH. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. *Pediatr Infect Dis J.* 2000;19(1):47-51. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10643850>.
6. Kline MW, Brundage RC, Fletcher CV, et al. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. *Pediatr Infect Dis J.* 2001;20(7):666-671. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11465838>.
7. Palacios GC, Palafox VL, Alvarez-Munoz MT, et al. Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children. *Scandinavian journal of infectious diseases.* 2002;34(1):41-44. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11874163>.
8. Robbins BL, Capparelli EV, Chadwick EG, et al. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. *Antimicrob Agents Chemother.* 2008;52(9):3276-3283. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18625762>.
9. Bunupuradah T, van der Lught J, Kosalaraksa P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. *Antivir Ther.* 2009;14(2):241-248. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19430099>.
10. Haznedar J, Zhang A, Labriola-Tompkins E, et al. A pharmacokinetic study of ritonavir-boosted saquinavir in HIV-infected children 4 months to <6 years old. Presented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI); February 16–19, 2010; San Francisco, CA.

11. Kosalaraksa P, Bunupuradah T, Engchamil C, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. *Pediatr Infect Dis J.* 2008;27(7):623-628. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18520443>.
12. Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. *J Clin Pharmacol.* 2012;52(4):520-529. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21558456>.

Stavudine (d4T, Zerit)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|---|---|
| <p>Powder for Oral Solution: 1 mg/mL</p> <p>Capsules: 15 mg, 20 mg, 30 mg, and 40 mg</p> | |
| <p>Generic Formulations</p> <p>Powder for Oral Solution: 1 mg/mL</p> <p>Capsules: 15 mg, 20 mg, 30 mg, and 40 mg</p> | |
| <p>For additional information, see Drugs@FDA.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Note: Stavudine is no longer recommended for use in children by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, because it causes higher rates of adverse effects than other nucleoside reverse transcriptase inhibitors (NRTIs).</p> <p>Pediatric (Aged ≥14 Days and Weighing <30 kg) Dose</p> <ul style="list-style-type: none">• 1 mg/kg per dose twice daily <p>Adolescent (Weighing ≥30 kg) and Adult Dose</p> <ul style="list-style-type: none">• 30 mg per dose twice daily | <ul style="list-style-type: none">• Associated with a higher risk of mitochondrial toxicity than other NRTI drugs• Peripheral neuropathy is dose-related and occurs more frequently in patients who have advanced HIV disease or a prior history of peripheral neuropathy, and in patients receiving other drugs associated with neuropathy.• Facial/peripheral lipoatrophy• Pancreatitis• Lactic acidosis/severe hepatomegaly with hepatic steatosis (higher incidence than with other NRTIs). The risk increases when stavudine is used in combination with didanosine.• Dyslipidemia• Insulin resistance, asymptomatic hyperglycemia• Rapidly progressive ascending neuromuscular weakness (rare) |
| Special Instructions | <ul style="list-style-type: none">• Stavudine can be given without regard to food.• Shake stavudine oral solution well before use. Keep refrigerated; the solution is stable for 30 days. |
| Metabolism/Elimination | <ul style="list-style-type: none">• Renal excretion 50%. Decrease dose in patients with renal dysfunction.• Stavudine is phosphorylated intracellularly to the active metabolite stavudine triphosphate. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- *Renal elimination:* Drugs that decrease renal function could decrease stavudine clearance.
- *Other nucleoside reverse transcriptase inhibitors (NRTIs):* Stavudine **should not be administered** in combination with zidovudine because of virologic antagonism.
- *Overlapping toxicities:* The combination of stavudine and didanosine **is not recommended** because of overlapping toxicities. Reported toxicities occur more frequently in adults and include serious, even fatal, cases of lactic acidosis with hepatic steatosis with or without pancreatitis in pregnant women.
- *Ribavirin and interferon:* Hepatic decompensation (sometimes fatal) has occurred in patients with HIV/hepatitis C virus co-infection who are receiving antiretroviral therapy (ART), interferon, and ribavirin.
- *Doxorubicin:* Simultaneous use of doxorubicin and stavudine should be avoided. Doxorubicin may inhibit the phosphorylation of stavudine to its active form.

Major Toxicities

- *More common:* Headache, gastrointestinal disturbances, skin rashes, hyperlipidemia, fat maldistribution
- *Less common (more severe):* Peripheral sensory neuropathy is dose-related. It occurs more frequently in patients with advanced HIV disease, a prior history of peripheral neuropathy, and in patients receiving other drugs associated with neuropathy. Pancreatitis. Lactic acidosis and severe hepatomegaly with hepatic steatosis, including fatal cases, have been reported.¹⁻³ The combination of stavudine and didanosine may result in enhanced toxicity (increased risk of fatal and nonfatal cases of lactic acidosis, pancreatitis, peripheral neuropathy, and hepatotoxicity), particularly in adults, including pregnant persons—**this combination should not be used.** Risk factors found to be associated with lactic acidosis in adults include female sex, obesity, and prolonged nucleoside exposure.⁴
- *Rare:* Increased liver enzymes and hepatic toxicity, which may be severe or fatal. Neurologic symptoms, including rapidly progressive ascending neuromuscular weakness, are most often seen in the setting of lactic acidosis. Noncirrhotic portal hypertension with prolonged exposure.

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval

Although stavudine is Food and Drug Administration (FDA)-approved for use in infants aged ≥14 days and children, it **is no longer recommended** for use by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV because it carries a higher risk of adverse effects associated with mitochondrial toxicity and a higher incidence of lipoatrophy than other NRTIs.

Efficacy

Data from multiple pediatric studies of stavudine administered alone or in combination with other antiretroviral (ARV) agents demonstrate that stavudine is associated with clinical and virologic response.⁵⁻¹¹ In resource-limited countries, stavudine is frequently a component of initial ART in children, given with lamivudine and nevirapine. Stavudine is often a component of fixed-dose combinations that are not available in the United States. In this setting, reported outcomes from observational studies are good; data show substantial increases in the CD4 T lymphocyte (CD4) cell count and complete viral suppression in 50% to 80% of treatment-naïve children.¹²⁻¹⁵ In such a setting, where pediatric patients are already predisposed to anemia because of malnutrition, parasitic infestations, or sickle cell anemia, stavudine carries a lower risk of hematologic toxicity than zidovudine, especially in patients receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.¹⁶ Short-term use of stavudine in certain settings where access to other ARVs may be limited remains an important strategy for treating HIV in children.^{17,18}

Toxicity

Stavudine is associated with a higher rate of adverse events than zidovudine in adults and children receiving ART.^{19,20} In a large pediatric natural history study (PACTG 219C), stavudine-containing regimens had a modest—but significantly higher—rate of clinical and laboratory toxicities than regimens containing zidovudine, with pancreatitis, peripheral neuropathy, and lipodystrophy/lipoatrophy (fat maldistribution) associated more often with stavudine use.²⁰

Lipodystrophy and Metabolic Abnormalities

Lipodystrophy syndrome (LS), and specifically lipoatrophy (loss of subcutaneous fat), are toxicities associated with NRTIs, particularly stavudine, in adults and children.²¹⁻²⁴ Stavudine use has consistently been associated with a higher risk of lipodystrophy and other metabolic abnormalities (e.g., insulin resistance) in multiple pediatric studies involving children.²⁵⁻³³ Improvements in (or resolution of) lipodystrophy were reported in 22.9% to 73% of cases after discontinuation of stavudine in two separate studies.^{30,34}

Lactic acidosis with hepatic steatosis, including fatal cases, has been reported with use of nucleoside analogues, including stavudine, alone or in combination with didanosine.¹⁻³

Mechanism

Many of the stavudine-related adverse events are believed to be due to mitochondrial toxicity resulting from inhibition of mitochondrial DNA polymerase gamma, with depletion of mitochondrial

DNA in fat, muscle, peripheral blood mononuclear cells, and other tissues.^{1,35-37} In a recent analysis involving a large cohort of pediatric patients (PACTG protocols 219 and 219C), possible mitochondrial dysfunction was associated with NRTI use, especially in children receiving stavudine and/or lamivudine.³⁸

World Health Organization Recommendations

The World Health Organization (WHO) cautions against using doses of stavudine that exceed 30 mg twice daily. This is in contrast to the FDA-recommended dose of 40 mg twice daily in patients weighing 60 kg or more.^{39,40} Studies comparing the efficacy and toxicity of the two doses have consistently shown that both doses have similar efficacy. However, while the 30-mg dose shows lower toxicity than the 40-mg dose, the overall incidence of toxicity with the 30-mg dose is considered to be unacceptably high.⁴¹⁻⁴⁵ WHO recommends that stavudine be phased out of use in all patients because of concerns about unacceptable toxicity, even at the lower dose. Safer alternative agents can be prescribed.

Pharmacokinetics

Current pediatric dosing recommendations are based on early pharmacokinetic (PK) studies designed to achieve exposure (area under the curve) in children similar to that found in adults receiving a dose with proven efficacy.⁴⁶ Although WHO has recommended using a reduced dose in adults, a similar dose reduction has not been suggested in children. A reduced pediatric dose has been proposed based on PK modeling, but clinical data on intracellular concentrations of the active stavudine triphosphate are lacking.^{47,48} Intracellular stavudine triphosphate concentrations have not been measured in neonates.

Formulations

The pediatric formulation for stavudine oral solution requires refrigeration and has limited stability once reconstituted. As an alternative dosing method for children, capsules can be opened and dispersed in a small amount of water, with the appropriate dose drawn up into an oral syringe and administered immediately. Because plasma exposure of stavudine is equivalent whether the drug is administered in an intact or a dispersed capsule, dosing with the dispersal method can be used as an alternative to the oral solution.⁴⁹

References

1. Haugaard SB, Andersen O, Pedersen SB, et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. *J Med Virol.* 2005;77(1):29-38. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16032748>.
2. Koh MT. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors. *Int J Infect Dis.* 2007;11(1):85-86. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16581278>.
3. Hernandez Perez E, Dawood H. Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa. *J Int Assoc Physicians AIDS Care (Chic).* 2010;9(2):109-112. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20484736>.
4. Matthews LT, Giddy J, Ghebremichael M, et al. A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. *PLoS One.* 2011;6(4):e18736. Available at <http://www.ncbi.nlm.nih.gov/pubmed/21494566>.
5. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. *AIDS.* 2004;18(2):237-245. Available at <http://www.ncbi.nlm.nih.gov/pubmed/15075541>.
6. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. *Pediatrics.* 1995;96(2 Pt 1):247-252. Available at <http://www.ncbi.nlm.nih.gov/pubmed/7630678>.
7. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. *Pediatrics.* 1996;97(6 Pt 1):886-890. Available at <http://www.ncbi.nlm.nih.gov/pubmed/8657531>.
8. Kline MW, Van Dyke RB, Lindsey JC, et al. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. *Pediatrics.* 1999;103(5):e62. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10224206>.
9. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. *Clin Infect Dis.* 2002;34(7):991-1001. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11880966>.
10. Nachman SA, Stanley K, Yoge R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. *JAMA.* 2000;283(4):492-498. Available at <http://www.ncbi.nlm.nih.gov/pubmed/10659875>.

11. Yoge R, Lee S, Wiznia A, et al. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. *Pediatr Infect Dis J.* 2002;21(2):119-125. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11840078>.
12. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. *JAMA.* 2007;298(16):1888-1899. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17954540>.
13. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. *Pediatrics.* 2007;120(5):e1134-1140. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17954553>.
14. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2007;46(2):187-193. Available at <http://www.ncbi.nlm.nih.gov/pubmed/17693883>.
15. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. *J Acquir Immune Defic Syndr.* 2007;46(5):594-598. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18043313>.
16. Okechukwu AA, Gambo D, Okechukwu IO. Prevalence of anaemia in HIV-infected children at the University of Abuja Teaching Hospital, Gwagwalada. *Niger J Med.* 2010;19(1):50-57. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20232757>.
17. Kenny J, Musiime V, Judd A, Gibb D. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. *Curr Opin HIV AIDS.* 2012;7(4):305-316. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22678488>.
18. Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. *AIDS.* 2013;27(5):781-785. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23169331>.
19. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med.* 2003;349(24):2293-2303. Available at <http://www.ncbi.nlm.nih.gov/pubmed/14668455>.
20. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis.* 2008;198(11):1599-1608. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
21. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. *AIDS.* 2002;16(18):2447-2454. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12461419>.

22. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. *AIDS*. 2004;18(10):1443-1451. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15199321&query_hl=60.
23. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. *Eur J Pediatr*. 2007;166(1):13-21. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16896646>.
24. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS*. 2009;23(9):1109-1118. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19417580>.
25. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. *Am J Clin Nutr*. 2011;94(6):1485-1495. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22049166>.
26. Dapena M, Jimenez B, Noguera-Julian A, et al. Metabolic disorders in vertically HIV-infected children: future adults at risk for cardiovascular disease. *J Ped Endocrin Metab*. 2012;25(5-6):529-535. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22876550>.
27. Alam N, Cortina-Borja M, Goetghebuer T, et al. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. *J Acquir Immune Defic Syndr*. 2012;59(3):314-324. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22205436>.
28. Kinabo GD, Sprengers M, Msuya LJ, et al. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2013;32(1):39-44. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23038217>.
29. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. *J Int AIDS Soc*. 2012;15(2):17427. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22814353>.
30. Aurpibul L, Puthanakit T, Taejaroenkul S, et al. Improvement of lipodystrophy in children after substitution of stavudine with zidovudine in NNRTI-based antiretroviral therapy, Abstract #CDB437. Presented at: 6th IAS Conference on HIV Pathogenesis Treatment and Prevention. 2011. Rome, Italy.
31. Innes SEV, van Niekerk M, Rabie H, et al. Prevalence and risk factors for lipoatrophy among pre-pubertal African children on HAART, Abstract #CDB430. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2011. Rome, Italy.
32. Cohen S, Innes S, Geelen SP, et al. Long-term changes of subcutaneous fat mass in HIV-infected children on antiretroviral therapy: a retrospective analysis of longitudinal data from two pediatric HIV-cohorts. *PLoS One*. 2015;10(7):e0120927. Available at <http://www.ncbi.nlm.nih.gov/pubmed/26148119>.

33. Fortuin-de Smidt M, de Waal R, Cohen K, et al. First-line antiretroviral drug discontinuations in children. *PLoS One*. 2017;12(2):e0169762. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28192529>.
34. Sawawiboon N, Wittawatmongkol O, Phongsamart W, Prasitsuebsai W, Lapphra K, Chokephaibulkit K. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine. *Int J STD AIDS*. 2012;23(7):497-501. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22844004>.
35. Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings. *HIV Clin Trials*. 2003;4(1):11-19. Available at <http://www.ncbi.nlm.nih.gov/pubmed/12577192>.
36. Cherry CL, Gahan ME, McArthur JC, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. *J Acquir Immune Defic Syndr*. 2002;30(3):271-277. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12131563.
37. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. *HIV Clin Trials*. 2005;6(4):197-202. Available at <http://www.ncbi.nlm.nih.gov/pubmed/16214736>.
38. Crain MJ, Chernoff MC, Oleske JM, et al. Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. *J Infect Dis*. 2010;202(2):291-301. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20533872>.
39. World Health Organization. Toxicity of reduced and standard doses of d4T. 2009. Available at <https://iris.who.int/handle/10665/107280>.
40. World Health Organization. Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. 2009. Available at <https://iris.who.int/handle/10665/107280>.
41. Pahuja M, Glesby M, Grobler A, et al. Effects of a reduced dose of stavudine (d4T) on the incidence and severity of peripheral neuropathy in PLHIV in South Africa. Abstract #WEPE0149. Presented at: IAS-AIDS. 2010.
42. Hoffmann CJ, Charalambous S, Fielding KL, et al. HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. *AIDS*. 2009;23(13):1784-1786. Available at <http://www.ncbi.nlm.nih.gov/pubmed/19491652>.
43. Pujades-Rodriguez M, Dantony E, Pinoges L, et al. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. *PLoS One*. 2011;6(11):e28112. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22132226>.
44. Brennan A, Maskew M, Sanne I, Fox M. The effect of 30 vs. 40 mg of stavudine vs. tenofovir on treatment outcomes amongst HIV+ patients: Johannesburg, South Africa. Abstract # 1098. Presented at: Conference on Retroviruses and Opportunistic Infections. 2013. Atlanta, GA.

45. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. *J Int AIDS Soc.* 2012;15(1):13. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22410312>.
46. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection. *Antimicrob Agents Chemother.* 2001;45(3):758-763. Available at <http://www.ncbi.nlm.nih.gov/pubmed/11181356>.
47. Sy SK, Innes S, Derendorf H, Cotton MF, Rosenkranz B. Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily. *Antimicrob Agents Chemother.* 2014;58(2):1084-1091. Available at <http://www.ncbi.nlm.nih.gov/pubmed/24295968>.
48. Sy SK, Malmberg R, Matsushima A, et al. Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model. *Int J Antimicrob Agents.* 2015;45(4):413-419. Available at <http://www.ncbi.nlm.nih.gov/pubmed/25697412>.
49. Innes S, Norman J, Smith P, et al. Bioequivalence of dispersed stavudine: opened versus closed capsule dosing. *Antivir Ther.* 2011;16(7):1131-1134. Available at <http://www.ncbi.nlm.nih.gov/pubmed/22024529>.

Tipranavir (TPV, Aptivus)

Updated: May 22, 2018

Reviewed: May 22, 2018

| Formulations | |
|---|---|
| <p>Oral Solution: 100 mg tipranavir/mL with 116 International Units (IU) vitamin E/mL</p> <p>Capsules: 250 mg</p> <p>For additional information, see Drugs@FDA.</p> | |
| Dosing Recommendations | Selected Adverse Events |
| <p>Note: Tipranavir must be boosted with ritonavir. The ritonavir boosting dose used for tipranavir is higher than the doses used for other protease inhibitors.</p> <p>Pediatric (Aged <2 Years) Dose</p> <ul style="list-style-type: none">Not approved for use in children aged <2 years <p>Pediatric (Aged 2–18 Years) Dose</p> <p>Note: Not recommended for treatment-naïve patients</p> <p>Body Surface Area Dosing</p> <ul style="list-style-type: none">Tipranavir/ritonavir (TPV/r) 375 mg/m²/150 mg/m², both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily) <p>Weight-Based Dosing</p> <ul style="list-style-type: none">TPV/r 14 mg/kg/6 mg/kg, both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily) <p>Adult Dose</p> <ul style="list-style-type: none">TPV/r 500 mg (as two 250-mg capsules)/200 mg, both twice daily <p>Note: Not recommended for treatment-naïve patients</p> | <ul style="list-style-type: none">Rare cases of fatal and nonfatal intracranial hemorrhageSkin rash (more common in children than adults)Nausea, vomiting, diarrheaHepatotoxicity: elevated transaminases; clinical hepatitisHyperlipidemiaHyperglycemiaElevated creatine phosphokinase |

| | Metabolism/Elimination |
|--|---|
| | <ul style="list-style-type: none"> • Cytochrome P450 3A4 (CYP3A4) inducer and substrate • P-glycoprotein substrate <p>Tipranavir Dosing in Patients with Renal Impairment</p> <ul style="list-style-type: none"> • No dose adjustment is required. <p>Tipranavir Dosing in Patients with Hepatic Impairment</p> <ul style="list-style-type: none"> • No dose adjustment is required for mild hepatic impairment. • Use of tipranavir is contraindicated in patients with moderate-to-severe hepatic impairment. |

Drug Interactions

Additional information about drug interactions is available in the [Adult and Adolescent Guidelines](#) and the [HIV Drug Interaction Checker](#).

- Tipranavir has the potential for multiple drug interactions. Co-administration of tipranavir/ritonavir (TPV/r) with drugs that are highly dependent on cytochrome P (CYP) 3A for clearance or are potent CYP3A inducers is contraindicated.
- Before tipranavir is administered, a patient's medication profile should be carefully reviewed for potential drug interactions.
- TPV/r is a potent enzyme inducer and has the potential to decrease plasma concentrations of other antiretroviral drugs. TPV/r significantly decreases plasma concentrations of etravirine. Etravirine and TPV/r **should not be co-administered**.
- TPV/r has been shown to decrease raltegravir concentrations. TPV/r dose adjustment **is not currently recommended** when raltegravir is administered twice daily. However, TPV/r **should not be co-administered** with raltegravir HD once daily because significantly lower raltegravir concentrations are likely to occur.
- Tipranavir should be used with caution in patients who are receiving medications known to increase the risk of bleeding, such as antiplatelet agents, anticoagulants, or high doses of supplemental vitamin E.

Major Toxicities

- *More common:* Diarrhea, nausea, fatigue, headache, rash (which is more frequent in children than in adults), and vomiting. Elevated transaminases, cholesterol, and triglycerides. Elevated creatine phosphokinase.
- *Less common (more severe):* Lipodystrophy. Hepatotoxicity: clinical hepatitis and hepatic decompensation, including some fatalities. Patients with chronic hepatitis B or hepatitis C coinfection or elevations in transaminases are at increased risk of developing further transaminase elevations or hepatic decompensation (approximately 2.5-fold risk). Epistaxis, which is more common with oral solution than capsule formulation.

- *Rare:* New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs. Increased risk of intracranial hemorrhage. Tipranavir should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other medical conditions.

Resistance

The International AIDS Society–USA maintains a [list of updated resistance mutations](#) and the [Stanford University HIV Drug Resistance Database](#) offers a discussion of each mutation.

Pediatric Use

Approval and General Considerations

Tipranavir is approved for use in children aged as young as 2 years and is available in a liquid formulation.

Its indication is limited to those patients who are treatment-experienced and who have HIV strains that are resistant to more than one protease inhibitor (PI).¹ Tipranavir imposes a high pill burden on patients taking tipranavir capsules and requires a higher dose of boosting ritonavir than the doses used with other PIs. This increased dose of ritonavir is associated with a greater potential for drug interactions and increased toxicity. In addition, tipranavir is associated with serious adverse events (AEs) that limit its use to patients with few treatment options.

Efficacy

The Food and Drug Administration's approval of tipranavir was based on a multicenter, pediatric study of the safety, efficacy, and pharmacokinetics (PKs) of TPV/r in children with HIV (PACTG 1051/BI-1182.14).² This study enrolled 110 treatment-experienced children (with the exception of three treatment-naïve patients) aged 2 years to 18 years (with a median age of 11.7 years). Patients were randomized to receive two different dosing regimens. The higher dose of TPV/r (375 mg/150 mg/m² body surface area [BSA] twice daily) plus optimized background therapy was associated with better virologic responses at 48 weeks, particularly in the older, more heavily pretreated patients, when compared to the lower dose that was studied. A follow-up study of PACTG 1051 participants evaluated the long-term safety, efficacy, and tolerability of TPV/r in pediatric patients.³ At Week 288, most children were no longer receiving TPV/r. Reasons for discontinuation included AEs, virologic failure, and nonadherence. The youngest patients who were stable at Week 48 were more likely to still be on treatment after 5 years with continued efficacy.³

Pharmacokinetics

PK evaluation of the liquid formulation at steady state in children was assessed.⁴ In children aged 2 to <12 years, a dose of TPV/r 290 mg/115 mg/m² BSA achieved tipranavir trough concentrations that were consistent with those achieved in adults receiving standard TPV/r 500 mg/200 mg dosing. However, children aged 12 to 18 years required a higher dose (375 mg/150 mg/m² BSA, 30% higher than the directly scaled adult dose) to achieve drug exposure similar to that seen in adults receiving the standard TPV/r dose. Based on available data, a dose of TPV/r 375 mg/150 mg/m² BSA twice daily is recommended.

Toxicity

AEs were similar between treatment groups in the multicenter, pediatric study.² Twenty-five percent of children experienced a drug-related serious AE, and 9% of patients discontinued study drugs because of AEs. The most common AEs were gastrointestinal disturbances: 37% of participants had vomiting and 24% had diarrhea. The most common Grade 3 through 4 laboratory abnormalities were increases in the levels of creatine phosphokinase (11% of participants), alanine aminotransferase (6.5% of participants), and amylase (7.5% of participants). In the long-term follow-up report for PACTG 1051, incidence of AEs defined as drug-related was 55% to 65% regardless of age at entry, with higher discontinuation rates due to AEs in the older age groups.³

Vitamin E is an excipient in the tipranavir oral solution, with a concentration of 116 international units (IU) of vitamin E and 100 mg tipranavir per mL of solution. The recommended dose of tipranavir (14 mg/kg body weight) results in a vitamin E dose of 16 IU/kg body weight per day, significantly higher than the reference daily intake for vitamin E (which is 30 IU for adults and approximately 6–22 IU for children and adolescents, depending on age of the child or adolescent) and close to the upper limit of tolerability for children. In PACTG 1051, bleeding events were reported more commonly in children receiving tipranavir oral capsules (14.3%) than in children taking tipranavir oral solution (5.75%).² Overall, the incidence of bleeding episodes (primarily epistaxis) in pediatric patients observed in clinical trials was 7.5%.⁵

References

1. Courter JD, Teevan CJ, Li MH, Girotto JE, Salazar JC. Role of tipranavir in treatment of patients with multidrug-resistant HIV. *Ther Clin Risk Manag.* 2010;6:431-441. Available at <http://www.ncbi.nlm.nih.gov/pubmed/20957134>.
2. Salazar JC, Cahn P, Yoge R, et al. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. *AIDS.* 2008;22(14):1789-1798. Available at <http://www.ncbi.nlm.nih.gov/pubmed/18753862>.
3. Salazar JC, Cahn P, Della Negra M, et al. Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience. *Pediatr Infect Dis J.* 2014;33(4):396-400. Available at <http://www.ncbi.nlm.nih.gov/pubmed/23995585>.
4. Sabo J, Cahn P, Della Negra M, et al. Population pharmacokinetic (PK) assessment of systemic steady-state tipranavir (TPV) concentrations for HIV+ pediatric patients administered tipranavir/ritonavir (TPV/r) 290/115 mg/m² and 375/150 mg/m² BID (BI 1192.14 and PACTG 1051 study team). Presented at: 13th Conference on Retroviruses and Opportunistic Infections (CROI). 2006. Denver, CO.
5. Tipranavir [package insert]. Food and Drug Administration. 2015. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021814lbl.pdf.

Appendix B. Acronyms

Updated: June 27, 2024

Reviewed: June 27, 2024

Drug Name Abbreviations

| Abbreviation | Full Name |
|--------------|-----------------------------------|
| 3TC | lamivudine |
| ABC | abacavir |
| ATV | atazanavir |
| BIC | bictegravir |
| CAB | cabotegravir |
| COBI or /c | cobicistat |
| d4T | stavudine |
| ddl | didanosine |
| DMPA | depot medroxyprogesterone acetate |
| DOX | doravirine |
| DRV | darunavir |
| DTG | dolutegravir |
| EFV | efavirenz |
| ETR | etravirine |
| EVG | elvitegravir |
| FPV | fosamprenavir |
| FTC | emtricitabine |
| FTR | fostemsavir |
| IBA | ibalizumab |
| IDV | indinavir |
| LEN | lenacapavir |
| LPV | lopinavir |
| MVC | maraviroc |
| NFV | nelfinavir |
| NVP | nevirapine |
| RAL | raltegravir |
| RPV | rilpivirine |
| RTV or /r | ritonavir |

| | |
|---------|---|
| SQV | saquinavir |
| T-20 | enfuvirtide |
| TAF | tenofovir alafenamide |
| TDF | tenofovir disoproxil fumarate |
| TFV | tenofovir |
| TFV-DP | tenofovir diphosphate |
| THAM | tris (hydroxymethyl) aminomethane |
| TMP-SMX | trimethoprim sulfamethoxazole |
| TMR | temsavir |
| TPV | tipranavir |
| XTC | 3TC (lamivudine) or FTC (emtricitabine) |
| ZDV | zidovudine |

General Terms

| Acronym | Term |
|----------------------|--|
| ° C | degrees Celsius |
| ° F | degrees Fahrenheit |
| % v | volume |
| 25-OH-vitamin D | 25-hydroxy vitamin D |
| AAP | American Academy of Pediatrics |
| ACTH | adrenocorticotrophic hormone |
| AE | adverse effect or adverse event |
| AHR | adjusted hazard ratio |
| ALT | alanine aminotransferase |
| ANC | absolute neutrophil count |
| app | mobile application |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUC _{0-12h} | area under the curve from time 0 to 12 hours postdose |
| AUC _{12h} | 12-hour area under the curve |
| AUC _{24h} | 24-hour area under the curve |
| AUC _{tau} | area under the concentration time curve over the dosing interval |
| AV | atrioventricular |
| BCRP | breast cancer resistance protein |
| BHIVA | British HIV Association |
| BMD | bone mineral density |
| BMI | body mass index |
| BSA | body surface area |
| C _{0h} | pre-dose concentration |
| C _{12h} | concentration at 12 hours |
| C _{24h} | concentration at 24 hours |
| CAR | chimeric antigen receptor |
| C _{avg} | average plasma concentration |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CD8 | CD8 T lymphocyte |

| | |
|---------------------|--|
| CDC | Centers for Disease Control and Prevention |
| CEPAC | Cost-Effectiveness of Preventing AIDS Complications, a model |
| CI | confidence interval |
| CK | creatine kinase |
| C_{\max} | maximum plasma concentration |
| C_{\min} | minimum plasma concentration |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| COMB-R | cognitive behavioral therapy and medication management algorithm |
| Cr | creatinine |
| CRAFFT | Car, Relax, Alone, Forget, Friends, and Trouble |
| CrCl | creatinine clearance |
| CT | continuous therapy |
| C_{tau} | concentration at the end of a dosing interval |
| C_{trough} | trough concentration |
| CT _x | C-telopeptide of type 1 collagen |
| CV | coefficient of variation |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| CYP2B6 | cytochrome P450 family 2 subfamily B member 6 |
| DAIDS | Division of AIDS (NIAID) |
| DBS | dried blood spot |
| DM | diabetes mellitus |
| DOT | directly observed therapy |
| DRESS | drug reaction (or rash) with eosinophilia and systemic symptoms |
| DSG | delayed switch group |
| DT | dispersible tablet |
| DXA | dual energy X-ray absorptiometry |
| EBV | Epstein-Barr virus |
| EC | enteric-coated |
| EC_{50} | half maximal effective concentration |
| ECG | electrocardiogram |
| ECMO | extracorporeal membrane oxygenation |
| EEG | electroencephalogram |
| eGFR | estimated glomerular filtration rate |
| EM | erythema multiforme or extensive metabolizer |
| FCT | film-coated tablet |

| | |
|----------------------|--|
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| FLP | fasting lipid profile |
| FPG | fasting plasma glucose |
| g/dL | grams per deciliter |
| G6PD | glucose-6-phosphate dehydrogenase |
| GA | gestational age |
| GFR | glomerular filtration rate |
| GI | gastrointestinal |
| GLSM | geometric least squares mean |
| GM | geometric mean |
| GMR | geometric mean ratio |
| gp120 | glycoprotein 120 |
| HA | height age |
| HAV | hepatitis A virus |
| HBcAb | HBV core antibody |
| HBsAb | HBV surface antibody |
| HBsAg | HBV surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HD | high dose |
| HDL | high-density lipoprotein |
| HDL-C | high-density lipoprotein cholesterol |
| Hgb | hemoglobin |
| HgbA1c | glycosylated hemoglobin |
| HHS | U.S. Department of Health and Human Services |
| HIV RNA or HIV-1 RNA | viral load |
| HLA | human leukocyte antigen |
| HMG-CoA | 3-hydroxy-3-methylglutaryl coenzyme A |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HSV | herpes simplex virus |
| IAS–USA | International Antiviral Society–USA |
| IFPG | impaired fasting plasma glucose |
| IGT | impaired glucose tolerance |
| IM | intramuscular |
| INSTI | integrase strand transfer inhibitor |

| | |
|-------------|--|
| IQ | inhibitory quotient |
| IQR | interquartile range |
| IR | insulin resistance |
| IRIS | immune reconstitution inflammatory syndrome |
| ISG | immediate switch group |
| IU | international unit |
| IV | intravenous |
| IVIG | intravenous immune globulin |
| L | liter |
| LAI | long-acting injectable |
| LBW | low birth weight |
| LDL | low-density lipoprotein |
| LDL-C | low-density lipoprotein cholesterol |
| LFT | liver function test |
| \log_{10} | the logarithm to the base 10 |
| LS | lipodystrophy syndrome |
| LVH | left ventricular hypertrophy |
| MCV | mean cell volume |
| mDAART | modified directly administered ART |
| MEMS | medication event monitoring system |
| N/A | not available or not applicable |
| NASBA | nucleic acid sequence–based amplification |
| NAT | nucleic acid test |
| NHLBI | National Heart, Lung, and Blood Institute |
| NHSS | National HIV Surveillance System |
| NIH | National Institutes of Health |
| nM | nanometer |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside-reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OAT | organic anion transporter |
| OATP | organic anion transporter polypeptide |
| OBT | optimized background therapy |
| OGTT | oral glucose tolerance test |
| OI | opportunistic infection |
| OR | odds ratio |

| | |
|---------------------|--|
| PA-IC ₉₅ | protein-adjusted IC ₉₅ |
| The Panel | the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV |
| PBMC | peripheral blood mononuclear cell |
| PCP | <i>Pneumocystis jirovecii</i> pneumonia |
| PEPFAR | President's Emergency Plan for AIDS Relief |
| PCR | polymerase chain reaction |
| PEP | post-exposure prophylaxis |
| PG | plasma glucose |
| P-gp | P-glycoprotein |
| PHIV | perinatally acquired HIV |
| PK | pharmacokinetic |
| PI | protease inhibitor |
| POC | point of care |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| QTc | heart rate-corrected QT |
| RCT | randomized controlled trial |
| RPG | random plasma glucose |
| RR | relative risk |
| RT-PCR | reverse transcription polymerase chain reaction |
| SAM | severe acute malnutrition |
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SCT | short-cycle therapy |
| SD | standard deviation |
| SJS | Stevens-Johnson syndrome |
| SM | slow metabolizer |
| SMR | sexual maturity rating |
| SMS | short message service |
| SOC | standard of care |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| T _½ | half-life |
| TB | tuberculosis |
| TBLH | total body less head |
| TC | total cholesterol |

| | |
|-------------------------|--|
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrolysis |
| TG | triglyceride |
| TIC | trauma-informed care |
| TMA | transcription-mediated amplification |
| T _{max} | time to reach maximum concentration |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1A and UGT1A1 | uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex or uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex 1 |
| ULN | upper limit of normal |
| v/v | volume per volume |
| w | weight |
| w/v | weight per volume |
| WHO | World Health Organization |
| XR | extended release |

Study and Trial Names

| Acronym | Name |
|-----------|--|
| ACTG | AIDS Clinical Trials Group |
| AMP | Adolescent Master Protocol |
| ANRS | National Agency for AIDS Research (France) |
| ARROW | AntiRetroviral Research fOr Watoto |
| ATHENA | AIDS Therapy Evaluation in the Netherlands |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| BAN | Breastfeeding, Antiretrovirals, and Nutrition |
| CHAPAS | Children with HIV in Africa—Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens |
| CHER | Children with HIV Early Antiretroviral Therapy |
| DOLPHIN-2 | Dolutegravir in Pregnant HIV Mothers and Their Neonates |
| ECHO | Evidence for Contraceptive Options and HIV Outcomes |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| EPIICAL | Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies |
| EPPICC | European Pregnancy and Paediatric Infections Cohort Collaboration |
| FLAIR | First Long-Acting Injectable Regimen |
| HPTN | HIV Prevention Trials Network |
| IeDEA | International Epidemiology Databases to Evaluate AIDS |
| IMPAACT | International Maternal Pediatric Adolescent AIDS Clinical Trials |
| LATTITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| MOCHA | More Options for Children and Adolescents |
| NADIA | Nucleosides And Darunavir/Dolutegravir in Africa |
| NEVEREST | Nevirapine Resistance Study |
| ODYSSEY | Once-daily DTG based ART in Young people vS Standard thErApY |
| PACTG | Pediatric AIDS Clinical Trials Group |
| PAINT | Pediatric Study in Adolescents Investigating a New NNRTI TMC278 |
| PENPACT | Trial run in collaboration between PENTA and PACTG/IMPAACT |
| PENTA | Paediatric European Network for Treatment of AIDS |
| PHACS | Pediatric HIV/AIDS Cohort Study |
| PIANO | Paediatric study of Intelence As an NNRTI Option |
| PREDICT | Early Versus Deferred Antiretroviral Therapy for Children Older Than 1 Year Infected with HIV |
| PROMISE | Promoting Maternal and Infant Survival Everywhere Study |
| PROMOTE | PEPFAR PROMise Ongoing Treatment Evaluation |

| | |
|---------------------|--|
| SBIRT | Screening, Brief Intervention, and Referral to Treatment |
| SMILE | Strategy for Maintenance of HIV Suppression with Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children |
| START | Strategic Timing of AntiRetroviral Treatment |
| SWORD-1 and SWORD-2 | Regimen Switch to Dolutegravir + Rilpivirine from Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults |
| THRIVE | TMC278 against HIV, in a once-daily Regimen Versus Efavirenz |

Appendix C: CDC Pediatric HIV CD4 Cell Count/Percentage and HIV-Related Diseases Categorization

Updated: Apr.11, 2022

Reviewed: Apr.11, 2022

Table A. HIV Infection Stage Based on Age-Specific CD4 Count or Percentage

| Stage ^a | Aged <1 Year | | Aged 1 Year to <6 Years | | Aged ≥6 Years | |
|--------------------|-----------------------|-------|-------------------------|-------|-----------------------|-------|
| | Cells/mm ³ | % | Cells/mm ³ | % | Cells/mm ³ | % |
| 1 | ≥1,500 | ≥34 | ≥1,000 | ≥30 | ≥500 | ≥26 |
| 2 | 750–1,499 | 26–33 | 500–999 | 22–29 | 200–499 | 14–25 |
| 3 | <750 | <26 | <500 | <22 | <200 | <14 |

^a The stage is based primarily on the CD4 count; the CD4 count takes precedence over the CD4 percentage, and the percentage is considered only when the count is missing. If a Stage 3-defining condition has been diagnosed (see Table 6), then the stage is 3, regardless of CD4 test results.

Key: CD4 = CD4 T lymphocyte

Source: Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. MMWR 2014;63(No. RR-3):1-10.

Table B. HIV-Related Symptoms and Conditions

| Mildly Symptomatic |
|---|
| Children with two or more of the following conditions, but none of the conditions listed in the Moderately Symptomatic category, are considered mildly symptomatic: |
| <ul style="list-style-type: none"> • Lymphadenopathy (lymph nodes are ≥0.5 cm at more than two sites and/or bilateral at one site) • Hepatomegaly • Splenomegaly • Dermatitis • Parotitis • Recurrent or persistent upper respiratory tract infection, sinusitis, or otitis media |
| Moderately Symptomatic |
| <ul style="list-style-type: none"> • Anemia (hemoglobin <8 g/dL [<80 g/L]), neutropenia (white blood cell count <1,000 per µL [<1.0 × 10⁹ per L]), and/or thrombocytopenia (platelet count <100 × 10³ per µL [<100 × 10⁹ per L]) persisting for ≥30 days • Bacterial meningitis, pneumonia, or sepsis (single episode) |

- Candidiasis, oropharyngeal (thrush), persisting for >2 months in children aged >6 months
- Cardiomyopathy
- CMV infection, with onset before age 1 month
- Diarrhea, recurrent or chronic
- Hepatitis
- HSV stomatitis, recurrent (more than two episodes within 1 year)
- HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month
- Herpes zoster (shingles) involving at least two distinct episodes or more than one dermatome
- Leiomyosarcoma
- Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex
- Nephropathy
- Nocardiosis
- Persistent fever (lasting >1 month)
- Toxoplasmosis, onset before age 1 month
- Varicella, disseminated (complicated chickenpox)

AIDS-Defining Conditions

- Bacterial infections, multiple or recurrent^a
- Candidiasis of bronchi, trachea, or lungs
- Candidiasis of esophagus
- Cervical cancer, invasive
- Coccidioidomycosis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (>1-month duration)
- CMV disease (other than liver, spleen, or lymph nodes), onset at age >1 month
- CMV retinitis (with loss of vision)
- Encephalopathy attributed to HIV^b
- HSV: chronic ulcers (>1-month duration) or bronchitis, pneumonitis, or esophagitis (onset at age >1 month)
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (>1-month duration)
- Kaposi sarcoma
- Lymphoma, Burkitt (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary (of brain)
- *Mycobacterium avium* complex or *Mycobacterium kansasi*, disseminated or extrapulmonary

- *Mycobacterium* tuberculosis of any site, pulmonary, disseminated, or extrapulmonary
- *Mycobacterium*, other species or unidentified species, disseminated or extrapulmonary
- *Pneumocystis jirovecii* (previously known as *Pneumocystis carinii*) pneumonia
- Pneumonia, recurrent^c
- Progressive multifocal leukoencephalopathy
- *Salmonella* septicemia, recurrent
- Toxoplasmosis of brain, onset at age >1 month
- Wasting syndrome attributed to HIV^b

^a Only among children aged <6 years.

^b Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy and HIV wasting syndrome, are described in the following references:

Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).

Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR*. 1992;41(No. RR-17).

^c Only among adults, adolescents, and children aged ≥6 years.

Key: CMV = cytomegalovirus; HSV = herpes simplex virus

Modified from:

Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*. 1994;43(No. RR-12).

Centers for Disease Control and Prevention: Revised Surveillance Case Definition for HIV Infection—United States, 2014. *MMWR*. 2014;63(No. RR-3):1-10.

Appendix D: Supplemental Information

Updated: Apr.11, 2022

Reviewed: Apr.11, 2022

Table A. Likelihood of Developing AIDS or Death Within 12 Months, by Age and CD4 T-Cell Percentage or Log₁₀ HIV-1 RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy

| Age | CD4 Percentage | | | | Log ₁₀ HIV RNA Copy Number | | |
|--|----------------|------|------|------|---------------------------------------|------|------|
| | 10% | 20% | 25% | 30% | 6.0 | 5.0 | 4.0 |
| Percent Mortality (95% Confidence Interval) | | | | | | | |
| 6 Months | 28.7 | 12.4 | 8.5 | 6.4 | 9.7 | 4.1 | 2.7 |
| 1 Year | 19.5 | 6.8 | 4.5 | 3.3 | 8.8 | 3.1 | 1.7 |
| 2 Years | 11.7 | 3.1 | 2.0 | 1.5 | 8.2 | 2.5 | 1.1 |
| 5 Years | 4.9 | 0.9 | 0.6 | 0.5 | 7.8 | 2.1 | 0.7 |
| 10 Years | 2.1 | 0.3 | 0.2 | 0.2 | 7.7 | 2.0 | 0.6 |
| Percent Developing AIDS (95% Confidence Interval) | | | | | | | |
| 6 Months | 51.4 | 31.2 | 24.9 | 20.5 | 23.7 | 13.6 | 10.9 |
| 1 Year | 40.5 | 20.9 | 15.9 | 12.8 | 20.9 | 10.5 | 7.8 |
| 2 Years | 28.6 | 12.0 | 8.8 | 7.2 | 18.8 | 8.1 | 5.3 |
| 5 Years | 14.7 | 4.7 | 3.7 | 3.1 | 17.0 | 6.0 | 3.2 |
| 10 Years | 7.4 | 2.2 | 1.9 | 1.8 | 16.2 | 5.1 | 2.2 |

Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study Group. *Lancet.* 2003;362:1605-1611.

Table B. Death and AIDS/Death Rate per 100 Person-Years by Current Absolute CD4 Cell Count and Age in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy (HIV Paediatric Prognostic Markers Collaborative Study) and Adult Seroconverters (CASCADE Study)

| Age (Years) | Absolute CD4 Cell Count (cells/mm ³) | | | | | |
|--|--|-------|---------|---------|---------|------|
| | <50 | 50–99 | 100–199 | 200–349 | 350–499 | 500+ |
| Rate of Death Per 100 Patient-Years | | | | | | |
| 0–4 | 59.3 | 39.6 | 25.4 | 11.1 | 10.0 | 3.5 |
| 5–14 | 28.9 | 11.8 | 4.3 | 0.89 | 0.00 | 0.00 |
| 15–24 | 34.7 | 6.1 | 1.1 | 0.71 | 0.58 | 0.65 |
| 25–34 | 47.7 | 10.8 | 3.7 | 1.1 | 0.38 | 0.22 |
| 35–44 | 58.8 | 15.6 | 4.5 | 0.92 | 0.74 | 0.85 |
| 45–54 | 66.0 | 18.8 | 7.7 | 1.8 | 1.3 | 0.86 |
| 55+ | 91.3 | 21.4 | 17.6 | 3.8 | 2.5 | 0.91 |

| Rate of AIDS or Death per 100 Patient-Years | | | | | | |
|---|-------|------|------|------|------|------|
| 0-4 | 82.4 | 83.2 | 57.3 | 21.4 | 20.7 | 14.5 |
| 5-14 | 64.3 | 19.6 | 16.0 | 6.1 | 4.4 | 3.5 |
| 15-24 | 61.7 | 30.2 | 5.9 | 2.6 | 1.8 | 1.2 |
| 25-34 | 93.2 | 57.6 | 19.3 | 6.1 | 2.3 | 1.1 |
| 35-44 | 88.1 | 58.7 | 25.5 | 6.6 | 4.0 | 1.9 |
| 45-54 | 129.1 | 56.2 | 24.7 | 7.7 | 3.1 | 2.7 |
| 55+ | 157.9 | 42.5 | 30.0 | 10.0 | 5.1 | 1.8 |

Note: Table modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. *J Infect Dis.* 2008;197:398-404.

Table C. Association of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number and CD4T-Cell Percentage with Long-Term Risk of Death in HIV-Infected Children^a

| Baseline HIV RNA ^c (Copies/mL) Baseline CD4 Percentage | No. Patients ^d | Deaths ^b | |
|--|---------------------------|---------------------|------------|
| | | Number | Percentage |
| $\leq 100,000$ | | | |
| $\geq 15\%$ | 103 | 15 | (15%) |
| <15% | 24 | 15 | (63%) |
| $>100,000$ | | | |
| $\geq 15\%$ | 89 | 32 | (36%) |
| <15% | 36 | 29 | (81%) |

^a Data from the *Eunice Kennedy Shriver National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial*.

^b Mean follow-up: 5.1 years.

^c Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

^d Mean age: 3.4 years.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis*. 1997;175(5):1029–1038.

Figure A. Estimated Probability of AIDS Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611

Figure B. Estimated Probability of Death Within 12 Months by Age and CD4 Percentage in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611

Figure C. Death Rate per 100 Person-Years in HIV-Infected Children Aged 5 Years or Older in the HIV Paediatric Prognostic Marker Collaborative Study and HIV-Infected Seroconverting Adults from the CASCADE Study*




Figure modified from: HIV Paediatric Prognostic Markers Collaborative Study and the CASCADE Collaboration. *J Infect Dis.* 2008;197:398-404.

Figure D. Estimated Probability of AIDS Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611

Figure E. Estimated Probability of Death Within 12 Months of Age and HIV RNA Copy Number in HIV-Infected Children Receiving No Therapy or Zidovudine Monotherapy




Figure modified from *Lancet* 2003;362:1605-1611